Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7949501,AUIC,"AUIC values in the patients ranged from 6.0 to more than 7000, yet the AUIC value was highly predictive of time to bacterial eradication (p < 0.001).",Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7949501/),,6.0 to more than 7000,69,DB00537,Ciprofloxacin
>,7949501,AUIC,"At appropriate AUIC values (> 250) for ciprofloxacin, the median time to eradication was two days, while cefmenoxime (also at AUIC values > 250) required six days to achieve the same result.",Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7949501/),,250,70,DB00537,Ciprofloxacin
,7949501,time to eradication,"At appropriate AUIC values (> 250) for ciprofloxacin, the median time to eradication was two days, while cefmenoxime (also at AUIC values > 250) required six days to achieve the same result.",Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7949501/),d,two,71,DB00537,Ciprofloxacin
,33490134,Cmax/MIC90,Monte Carlo simulations targeting Cmax/MIC90 = 10 and AUC0-24/MIC90 =125 were also performed based on a set of MIC (minimum inhibitory concentration) values of bacterial strains that induce common clinical diseases in broiler chickens and that showed to be susceptible to ENR-HCl.,"Pharmacokinetics, Pharmacodynamic Efficacy Prediction Indexes and Monte Carlo Simulations of Enrofloxacin Hydrochloride Against Bacterial Strains That Induce Common Clinical Diseases in Broiler Chickens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33490134/),,10,312,DB00537,Ciprofloxacin
,33490134,AUC0-24/MIC90,Monte Carlo simulations targeting Cmax/MIC90 = 10 and AUC0-24/MIC90 =125 were also performed based on a set of MIC (minimum inhibitory concentration) values of bacterial strains that induce common clinical diseases in broiler chickens and that showed to be susceptible to ENR-HCl.,"Pharmacokinetics, Pharmacodynamic Efficacy Prediction Indexes and Monte Carlo Simulations of Enrofloxacin Hydrochloride Against Bacterial Strains That Induce Common Clinical Diseases in Broiler Chickens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33490134/),,125,313,DB00537,Ciprofloxacin
,33490134,Maximum plasma concentrations,"Maximum plasma concentrations of 1.35 ± 0.15 μg/mL for ENR-HCl and 0.09 ± 0.01 μg/mL for CIP were reached at 4.00 ± 0.00 h and 3.44 ± 1.01 h, respectively.","Pharmacokinetics, Pharmacodynamic Efficacy Prediction Indexes and Monte Carlo Simulations of Enrofloxacin Hydrochloride Against Bacterial Strains That Induce Common Clinical Diseases in Broiler Chickens. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33490134/),[μg] / [ml],1.35,314,DB00537,Ciprofloxacin
,33490134,Maximum plasma concentrations,"Maximum plasma concentrations of 1.35 ± 0.15 μg/mL for ENR-HCl and 0.09 ± 0.01 μg/mL for CIP were reached at 4.00 ± 0.00 h and 3.44 ± 1.01 h, respectively.","Pharmacokinetics, Pharmacodynamic Efficacy Prediction Indexes and Monte Carlo Simulations of Enrofloxacin Hydrochloride Against Bacterial Strains That Induce Common Clinical Diseases in Broiler Chickens. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33490134/),[μg] / [ml],0.09,315,DB00537,Ciprofloxacin
,33490134,Areas under the plasma vs. time concentration curve in 24 h (AUC0-24),"Areas under the plasma vs. time concentration curve in 24 h (AUC0-24) were 18.91 ± 1.91 h × μg/mL and 1.19 ± 0.12 h × μg/mL for ENR-HCl and CIP, respectively.","Pharmacokinetics, Pharmacodynamic Efficacy Prediction Indexes and Monte Carlo Simulations of Enrofloxacin Hydrochloride Against Bacterial Strains That Induce Common Clinical Diseases in Broiler Chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33490134/),[h·μg] / [ml],18.91,316,DB00537,Ciprofloxacin
,33490134,Areas under the plasma vs. time concentration curve in 24 h (AUC0-24),"Areas under the plasma vs. time concentration curve in 24 h (AUC0-24) were 18.91 ± 1.91 h × μg/mL and 1.19 ± 0.12 h × μg/mL for ENR-HCl and CIP, respectively.","Pharmacokinetics, Pharmacodynamic Efficacy Prediction Indexes and Monte Carlo Simulations of Enrofloxacin Hydrochloride Against Bacterial Strains That Induce Common Clinical Diseases in Broiler Chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33490134/),[h·μg] / [ml],1.19,317,DB00537,Ciprofloxacin
≤,33490134,MIC,"The PK/PD efficacy prediction indexes and Monte Carlo simulations indicated that the ENR-HCl oral dose used in this study is useful for bacterial infections in treating C. perfringens (Gram-positive), E. coli and S. ser. Enteritidis (Gram-negative) and M. gallisepticum bacteria responsible for systemic infections in poultry, predicting a success rate of 100% when MIC ≤ 0.06 μg/mL for E. coli and S. ser.","Pharmacokinetics, Pharmacodynamic Efficacy Prediction Indexes and Monte Carlo Simulations of Enrofloxacin Hydrochloride Against Bacterial Strains That Induce Common Clinical Diseases in Broiler Chickens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33490134/),[μg] / [ml],0.06,318,DB00537,Ciprofloxacin
≤,33490134,MIC,Enteritidis and MIC ≤ 0.1 μg/mL for M. gallisepticum.,"Pharmacokinetics, Pharmacodynamic Efficacy Prediction Indexes and Monte Carlo Simulations of Enrofloxacin Hydrochloride Against Bacterial Strains That Induce Common Clinical Diseases in Broiler Chickens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33490134/),[μg] / [ml],0.1,319,DB00537,Ciprofloxacin
≤,33490134,MIC,"For C. perfringens, the success rate was 98.26% for MIC ≤ 0.12.","Pharmacokinetics, Pharmacodynamic Efficacy Prediction Indexes and Monte Carlo Simulations of Enrofloxacin Hydrochloride Against Bacterial Strains That Induce Common Clinical Diseases in Broiler Chickens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33490134/),,0.12,320,DB00537,Ciprofloxacin
,2530933,MICs,"The MICs for 90% of strains tested were 4 micrograms/ml for clarithromycin, 64 micrograms/ml for erythromycin, 32 micrograms/ml for difloxacin, 8 micrograms/ml for temafloxacin, 4 micrograms/ml for ciprofloxacin, 4 micrograms/ml for rifampin, 32 micrograms/ml for amikacin, and 32 micrograms/ml for ethambutol.",In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],4,1008,DB00537,Ciprofloxacin
,2530933,MICs,"The MICs for 90% of strains tested were 4 micrograms/ml for clarithromycin, 64 micrograms/ml for erythromycin, 32 micrograms/ml for difloxacin, 8 micrograms/ml for temafloxacin, 4 micrograms/ml for ciprofloxacin, 4 micrograms/ml for rifampin, 32 micrograms/ml for amikacin, and 32 micrograms/ml for ethambutol.",In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],64,1009,DB00537,Ciprofloxacin
,2530933,MICs,"The MICs for 90% of strains tested were 4 micrograms/ml for clarithromycin, 64 micrograms/ml for erythromycin, 32 micrograms/ml for difloxacin, 8 micrograms/ml for temafloxacin, 4 micrograms/ml for ciprofloxacin, 4 micrograms/ml for rifampin, 32 micrograms/ml for amikacin, and 32 micrograms/ml for ethambutol.",In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],32,1010,DB00537,Ciprofloxacin
,2530933,MICs,"The MICs for 90% of strains tested were 4 micrograms/ml for clarithromycin, 64 micrograms/ml for erythromycin, 32 micrograms/ml for difloxacin, 8 micrograms/ml for temafloxacin, 4 micrograms/ml for ciprofloxacin, 4 micrograms/ml for rifampin, 32 micrograms/ml for amikacin, and 32 micrograms/ml for ethambutol.",In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],8,1011,DB00537,Ciprofloxacin
,2530933,peak concentration,The peak concentration in serum at which clarithromycin was active was approximately 1.0 microgram/ml.,In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],1.0,1012,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],9.9,1668,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],6.5,1669,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],0.7,1670,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],97.9,1671,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],36.7,1672,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],13.8,1673,DB00537,Ciprofloxacin
,11296178,concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],97.9,1674,DB00537,Ciprofloxacin
,11296178,concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],36.7,1675,DB00537,Ciprofloxacin
,11296178,concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],13.8,1676,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],22.1,1677,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],9.2,1678,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],1.5,1679,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],105.1,1680,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],36.2,1681,DB00537,Ciprofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],15.1,1682,DB00537,Ciprofloxacin
,31271466,half-life,The half-life was long (43-44 hr) and similar after both administrations.,Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in freshwater crocodiles (Crocodylus siamensis) after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31271466/),h,43-44,2336,DB00537,Ciprofloxacin
,31271466,absolute,The absolute i.m. bioavailability was 82.65% and the binding percentage of ENR to plasma protein ranged from 9% to 18% with an average of 10.6%.,Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in freshwater crocodiles (Crocodylus siamensis) after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31271466/),%,82.65,2337,DB00537,Ciprofloxacin
,31271466,bioavailability,The absolute i.m. bioavailability was 82.65% and the binding percentage of ENR to plasma protein ranged from 9% to 18% with an average of 10.6%.,Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in freshwater crocodiles (Crocodylus siamensis) after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31271466/),%,82.65,2338,DB00537,Ciprofloxacin
,31271466,binding percentage,The absolute i.m. bioavailability was 82.65% and the binding percentage of ENR to plasma protein ranged from 9% to 18% with an average of 10.6%.,Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in freshwater crocodiles (Crocodylus siamensis) after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31271466/),%,9,2339,DB00537,Ciprofloxacin
,31271466,binding percentage,The absolute i.m. bioavailability was 82.65% and the binding percentage of ENR to plasma protein ranged from 9% to 18% with an average of 10.6%.,Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in freshwater crocodiles (Crocodylus siamensis) after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31271466/),%,18,2340,DB00537,Ciprofloxacin
,31271466,binding percentage,The absolute i.m. bioavailability was 82.65% and the binding percentage of ENR to plasma protein ranged from 9% to 18% with an average of 10.6%.,Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in freshwater crocodiles (Crocodylus siamensis) after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31271466/),%,10.6,2341,DB00537,Ciprofloxacin
>,31271466,MIC,"Based on the pharmacokinetic data, susceptibility break point and PK-PD indexes, i.m. single administration of ENR at a dosage of 5 mg/kg b.w. might be appropriate for treatment of susceptible bacteria (MIC > 1 μg/mL) in freshwater crocodiles, C. siamensis.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in freshwater crocodiles (Crocodylus siamensis) after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31271466/),[μg] / [ml],1,2342,DB00537,Ciprofloxacin
,22685162,MIC,"From a wild-type (wt) Escherichia coli UTI isolate, three isogenic strains were constructed carrying low-level ciprofloxacin resistance genes qnrA1, qnrB19 or qnrS1 (ciprofloxacin MIC range: 0.19-0.38 mg/L).","Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22685162/),[mg] / [l],0.19-0.38,2560,DB00537,Ciprofloxacin
<,22685162,cfu counts,"None of the four strains infected the kidneys well, with median cfu counts of <1 log(10).","Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22685162/),log(10,1,2561,DB00537,Ciprofloxacin
>,7736911,area under the concentration-time curve ratio,"This evidence, together with the zwitterion characteristics of CIP, reaching a bile/medium area under the concentration-time curve ratio > 10, suggests that an active transport mechanism is involved in the drug's biliary excretion, as has been demonstrated for its renal elimination.",Disposition of ciprofloxacin in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736911/),,10,2682,DB00537,Ciprofloxacin
,12115015,time to peak plasma concentration,"There was no difference in time to peak plasma concentration of ciprofloxacin HCl in both groups (n = 5), which occurred at 1 hour.",In vivo evaluation of interaction between aqueous seed extract of Garcinia kola Heckel and ciprofloxacin hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115015/),h,1,3492,DB00537,Ciprofloxacin
,12115015,peak plasma concentration,"However, the peak plasma concentration of ciprofloxacin HCl was 46.90 +/- 9.50 microg/mL in the group that received ciprofloxacin HCl alone as against 35.80 +/- 9.30 microg/mL noted in the group that received both agents (difference of 22.24%).",In vivo evaluation of interaction between aqueous seed extract of Garcinia kola Heckel and ciprofloxacin hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115015/),[μg] / [ml],46.90,3493,DB00537,Ciprofloxacin
,12115015,peak plasma concentration,"However, the peak plasma concentration of ciprofloxacin HCl was 46.90 +/- 9.50 microg/mL in the group that received ciprofloxacin HCl alone as against 35.80 +/- 9.30 microg/mL noted in the group that received both agents (difference of 22.24%).",In vivo evaluation of interaction between aqueous seed extract of Garcinia kola Heckel and ciprofloxacin hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115015/),[μg] / [ml],35.80,3494,DB00537,Ciprofloxacin
,3555060,MICs,Ciprofloxacin MICs ranged from 0.008 to 1.0 microgram/ml.,Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555060/),[μg] / [ml],0.008 to 1.0,3973,DB00537,Ciprofloxacin
,3555060,peak serum concentrations,"The pharmacokinetics of ciprofloxacin in these patients varied with renal function, and average peak serum concentrations ranged from 1.7 to 4.9 micrograms/ml.",Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555060/),[μg] / [ml],1.7 to 4.9,3974,DB00537,Ciprofloxacin
less,3555060,MICs,Essentially all bacteria with MICs of less than 0.25 were eradicated.,Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555060/),,0.25,3975,DB00537,Ciprofloxacin
more,3555060,MICs,"Of the non-eradicated bacteria, most had either MICs of more than 0.25, or less than 100 percent time above the MIC.",Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555060/),,0.25,3976,DB00537,Ciprofloxacin
less,3555060,MICs,"It is concluded that 200 mg of intravenous ciprofloxacin every 12 hours is highly effective for bacteria with MICs less than 0.25 microgram/ml, but higher dosages may be required to eradicate organisms with higher MICs.",Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555060/),[μg] / [ml],0.25,3977,DB00537,Ciprofloxacin
>,22616681,AUC : MIC,The aim of this study was to determine the ciprofloxacin serum concentrations in hospitalized patients and to determine which percentage reached the efficacy target of AUC : MIC > 125.,The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616681/),,125,4005,DB00537,Ciprofloxacin
,22616681,clearance,"Mean (± SD) age was 66 (± 17) years, the mean clearance corrected for bodyweight was 0.24 l h(-1) kg(-1) and the mean AUC was 49 mg l(-1) h.",The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616681/),[l] / [h·kg],0.24,4006,DB00537,Ciprofloxacin
,22616681,AUC,"Mean (± SD) age was 66 (± 17) years, the mean clearance corrected for bodyweight was 0.24 l h(-1) kg(-1) and the mean AUC was 49 mg l(-1) h.",The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616681/),[h·mg] / [l],49,4007,DB00537,Ciprofloxacin
>,22616681,AUC : MIC,"Of all patients, 21% and 75% of the patients, did not reach the proposed ciprofloxacin AUC : MIC > 125 target with MICs of 0.25 and 0.5 mg l(-1), respectively.",The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616681/),target,125,4008,DB00537,Ciprofloxacin
,22616681,MICs,"Of all patients, 21% and 75% of the patients, did not reach the proposed ciprofloxacin AUC : MIC > 125 target with MICs of 0.25 and 0.5 mg l(-1), respectively.",The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616681/),[mg] / [l],0.25,4009,DB00537,Ciprofloxacin
,22616681,MICs,"Of all patients, 21% and 75% of the patients, did not reach the proposed ciprofloxacin AUC : MIC > 125 target with MICs of 0.25 and 0.5 mg l(-1), respectively.",The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616681/),[mg] / [l],0.5,4010,DB00537,Ciprofloxacin
>,22616681,AUC : MIC,"Taking into account the increasing resistance to ciprofloxacin worldwide, a ciprofloxacin dose of 1200 mg i.v. daily in patients with normal renal function is necessary to reach the targeted AUC : MIC > 125.",The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616681/),,125,4011,DB00537,Ciprofloxacin
,11069211,bioavailability,The bioavailability is approximately 50%.,Clinical pharmacokinetics of ropinirole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069211/),%,50,4089,DB00537,Ciprofloxacin
,11069211,half-life,"Ropinirole shows approximately linear pharmacokinetics when given as single or repeated doses, and is eliminated with a half-life of approximately 6 hours.",Clinical pharmacokinetics of ropinirole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069211/),h,6,4090,DB00537,Ciprofloxacin
,2499248,total body clearance,"As a consequence of a declining renal clearance but not nonrenal clearance, the total body clearance of fleroxacin declined with decreasing glomerular filtration rate from 1.41 +/- 0.23 ml/min per kg in subjects with normal renal function to 0.58 +/- 0.13 ml/min per kg in patients with end-stage renal disease (r = 0.84, P less than 0.001).",Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499248/),[ml] / [kg·min],1.41,5528,DB00537,Ciprofloxacin
,2499248,total body clearance,"As a consequence of a declining renal clearance but not nonrenal clearance, the total body clearance of fleroxacin declined with decreasing glomerular filtration rate from 1.41 +/- 0.23 ml/min per kg in subjects with normal renal function to 0.58 +/- 0.13 ml/min per kg in patients with end-stage renal disease (r = 0.84, P less than 0.001).",Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499248/),[ml] / [kg·min],0.58,5529,DB00537,Ciprofloxacin
,2499248,dialysate/plasma concentration ratio,"In patients on continuous ambulatory peritoneal dialysis the mean dialysate/plasma concentration ratio of fleroxacin increased from 0.52 +/- 0.11 to 0.71 +/- 0.13 (P less than 0.001) with increasing dwell time, resulting in a 7.8 +/- 3.6% recovery of unchanged fleroxacin in peritoneal dialysate.",Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499248/),,0.52,5530,DB00537,Ciprofloxacin
,2499248,dialysate/plasma concentration ratio,"In patients on continuous ambulatory peritoneal dialysis the mean dialysate/plasma concentration ratio of fleroxacin increased from 0.52 +/- 0.11 to 0.71 +/- 0.13 (P less than 0.001) with increasing dwell time, resulting in a 7.8 +/- 3.6% recovery of unchanged fleroxacin in peritoneal dialysate.",Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499248/),,0.71,5531,DB00537,Ciprofloxacin
,2729952,Total clearance,Total clearance of ciprofloxacin increased from 0.96 +/- 0.32 (standard deviation) to 1.57 +/- 0.63 liters/h per kg (P less than 0.05).,Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729952/),[l] / [h·kg],0.96,5721,DB00537,Ciprofloxacin
,2729952,Total clearance,Total clearance of ciprofloxacin increased from 0.96 +/- 0.32 (standard deviation) to 1.57 +/- 0.63 liters/h per kg (P less than 0.05).,Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729952/),[l] / [h·kg],1.57,5722,DB00537,Ciprofloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],2.11,5942,DB00537,Ciprofloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],2.45,5943,DB00537,Ciprofloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],9.21,5944,DB00537,Ciprofloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],8.86,5945,DB00537,Ciprofloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],0.67,5946,DB00537,Ciprofloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],0.45,5947,DB00537,Ciprofloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],6.09,5948,DB00537,Ciprofloxacin
,11711259,Peak levels,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[μg] / [ml],5.83,5949,DB00537,Ciprofloxacin
,11711259,T(1/2),"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),h,3.19,5950,DB00537,Ciprofloxacin
,11711259,T(1/2),"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),h,3.55,5951,DB00537,Ciprofloxacin
,11711259,T(1/2),"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),h,15.60,5952,DB00537,Ciprofloxacin
,11711259,T(1/2),"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),h,9.45,5953,DB00537,Ciprofloxacin
,11711259,AUC,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[mg] / [h·l],3.62,5954,DB00537,Ciprofloxacin
,11711259,AUC,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[mg] / [h·l],7.39,5955,DB00537,Ciprofloxacin
,11711259,AUC,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[mg] / [h·l],137.85,5956,DB00537,Ciprofloxacin
,11711259,AUC,"Peak levels of the 200 mg dose of ciprofloxacin, of the 300 mg dose of ciprofloxacin, of pefloxacin and of ofloxacin in serum were 2.11,2.45,9.21 and 8.86 microg/ml, respectively and in the ascitic fluid 0.67, 0.45, 6.09 and 5.83 microg/ml, respectively T(1/2) was 3.19+/-0.73, 3.55+/-1.68, 15.60+/-12.40 and 9.45+/-3.14 h, respectively with AUC of 3.62+/-4.02, 7.39+/-4.70, 137.85+/-63.96 and 119.8+/-16.83 mg/l h.",Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),[mg] / [h·l],119.8,5957,DB00537,Ciprofloxacin
,11711259,urinary excretion,Urinary excretion of ciprofloxacin and of ofloxacin was similar to healthy individuals but pefloxacin showed a mean urinary excretion of 30.11%.,Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711259/),%,30.11,5958,DB00537,Ciprofloxacin
,3053553,peak level,The mean peak level in pancreatic juice was 0.5 +/- 0.0 mg/l (+/- S.E.) for ciprofloxacin and occurred at 4 h after drug intake.,Penetration of ciprofloxacin and ofloxacin into human allograft pancreatic juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3053553/),[mg] / [l],0.5,6139,DB00537,Ciprofloxacin
,17970994,Sample collection time,Sample collection time was 15 s.,Pharmacokinetics of topically applied ciprofloxacin in equine tears. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970994/),s,15,6284,DB00537,Ciprofloxacin
,17970994,tear concentrations,"The mean tear concentrations of ciprofloxacin at 30 min and at 1, 2, 4 and 6 h were 66.6 +/- 56.0, 60.25 +/- 55.7, 42.25 +/- 30.9, 36.25 +/- 32.0, and 45.5 +/- 46.5 microg/g, respectively.",Pharmacokinetics of topically applied ciprofloxacin in equine tears. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970994/),[μg] / [g],66.6,6285,DB00537,Ciprofloxacin
,17970994,tear concentrations,"The mean tear concentrations of ciprofloxacin at 30 min and at 1, 2, 4 and 6 h were 66.6 +/- 56.0, 60.25 +/- 55.7, 42.25 +/- 30.9, 36.25 +/- 32.0, and 45.5 +/- 46.5 microg/g, respectively.",Pharmacokinetics of topically applied ciprofloxacin in equine tears. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970994/),[μg] / [g],60.25,6286,DB00537,Ciprofloxacin
,17970994,tear concentrations,"The mean tear concentrations of ciprofloxacin at 30 min and at 1, 2, 4 and 6 h were 66.6 +/- 56.0, 60.25 +/- 55.7, 42.25 +/- 30.9, 36.25 +/- 32.0, and 45.5 +/- 46.5 microg/g, respectively.",Pharmacokinetics of topically applied ciprofloxacin in equine tears. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970994/),[μg] / [g],42.25,6287,DB00537,Ciprofloxacin
,17970994,tear concentrations,"The mean tear concentrations of ciprofloxacin at 30 min and at 1, 2, 4 and 6 h were 66.6 +/- 56.0, 60.25 +/- 55.7, 42.25 +/- 30.9, 36.25 +/- 32.0, and 45.5 +/- 46.5 microg/g, respectively.",Pharmacokinetics of topically applied ciprofloxacin in equine tears. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970994/),[μg] / [g],36.25,6288,DB00537,Ciprofloxacin
,17970994,tear concentrations,"The mean tear concentrations of ciprofloxacin at 30 min and at 1, 2, 4 and 6 h were 66.6 +/- 56.0, 60.25 +/- 55.7, 42.25 +/- 30.9, 36.25 +/- 32.0, and 45.5 +/- 46.5 microg/g, respectively.",Pharmacokinetics of topically applied ciprofloxacin in equine tears. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970994/),[μg] / [g],45.5,6289,DB00537,Ciprofloxacin
,9736541,Peak ciprofloxacin concentrations,"Peak ciprofloxacin concentrations were as follows: D0, 6. 01 +/- 1.93 mg/liter; D2, 6.68 +/- 2.01 mg/liter; and D6 to D8 6.45 +/- 1.54 mg/liter.",Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736541/),[mg] / [l],6. 01,6551,DB00537,Ciprofloxacin
,9736541,Peak ciprofloxacin concentrations,"Peak ciprofloxacin concentrations were as follows: D0, 6. 01 +/- 1.93 mg/liter; D2, 6.68 +/- 2.01 mg/liter; and D6 to D8 6.45 +/- 1.54 mg/liter.",Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736541/),[mg] / [l],6.68,6552,DB00537,Ciprofloxacin
,9736541,Peak ciprofloxacin concentrations,"Peak ciprofloxacin concentrations were as follows: D0, 6. 01 +/- 1.93 mg/liter; D2, 6.68 +/- 2.01 mg/liter; and D6 to D8 6.45 +/- 1.54 mg/liter.",Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736541/),[mg] / [l],6.45,6553,DB00537,Ciprofloxacin
,9736541,Trough levels,"Trough levels were as follows: D0, 0.6 +/- 0.5 mg/liter; D2, 0.7 +/- 0.4 mg/liter; and D6 to D8 0.6 +/- 0.4 mg/liter.",Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736541/),[mg] / [l],0.6,6554,DB00537,Ciprofloxacin
,9736541,Trough levels,"Trough levels were as follows: D0, 0.6 +/- 0.5 mg/liter; D2, 0.7 +/- 0.4 mg/liter; and D6 to D8 0.6 +/- 0.4 mg/liter.",Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736541/),[mg] / [l],0.7,6555,DB00537,Ciprofloxacin
,9736541,Trough levels,"Trough levels were as follows: D0, 0.6 +/- 0.5 mg/liter; D2, 0.7 +/- 0.4 mg/liter; and D6 to D8 0.6 +/- 0.4 mg/liter.",Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736541/),[mg] / [l],0.6,6556,DB00537,Ciprofloxacin
,9736541,areas under the concentration curves,"The areas under the concentration curves (8 h) were as follows: D0, 13.3 +/- 3.8 mg .",Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736541/),mg,13.3,6557,DB00537,Ciprofloxacin
,9736541,D2,"h/liter; D2, 16.8 +/- 5.4 mg .",Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9736541/),mg,16.8,6558,DB00537,Ciprofloxacin
,9559797,MIC,"Trovafloxacin is a novel naphthyridone quinolone with promising activity against S. pneumoniae, including penicillin-resistant strains (MIC for 90% of the isolates tested, 0.25 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],0.25,6718,DB00537,Ciprofloxacin
,9559797,MIC,"Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 microg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 microg/ml) and a ciprofloxacin-resistant strain (MIC, 32 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],0.03,6719,DB00537,Ciprofloxacin
,9559797,MICs,"Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 microg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 microg/ml) and a ciprofloxacin-resistant strain (MIC, 32 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],4 to 8,6720,DB00537,Ciprofloxacin
,9559797,MIC,"Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 microg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 microg/ml) and a ciprofloxacin-resistant strain (MIC, 32 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],32,6721,DB00537,Ciprofloxacin
,3144533,elimination half-life,"The characteristics of this new trifluorinated quinolone are the long elimination half-life of approximately 10 h and the high plasma concentrations, which exceed 2 mg/l after an oral dose of 200 mg.",Single and multiple dose pharmacokinetics of fleroxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144533/),h,10,6873,DB00537,Ciprofloxacin
exceeded,3144533,volume of distribution (Vss),The volume of distribution (Vss) exceeded 1 l/kg and reflects the good tissue penetration.,Single and multiple dose pharmacokinetics of fleroxacin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144533/),[l] / [kg],1,6874,DB00537,Ciprofloxacin
,3144533,Renal clearance of unbound drug,Renal clearance of unbound drug was 104 ml/min and within three days 56% of the dose could be recovered from urine as unchanged drug.,Single and multiple dose pharmacokinetics of fleroxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144533/),[ml] / [min],104,6875,DB00537,Ciprofloxacin
,3144533,F,The administered tablets were completely bioavailable (F = 1.0) and a significant first pass metabolism can therefore be excluded.,Single and multiple dose pharmacokinetics of fleroxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144533/),,1.0,6876,DB00537,Ciprofloxacin
,33107624,elimination half-life,"The elimination half-life values of ENR were 38.7 and 50.4 hr at dose rates of 5 and 7.5 mg/kg b.w. after i.v. administration, whereas CIP was 33.6 and 22.6 hr, respectively.",Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107624/),h,38.7,6976,DB00537,Ciprofloxacin
,33107624,elimination half-life,"The elimination half-life values of ENR were 38.7 and 50.4 hr at dose rates of 5 and 7.5 mg/kg b.w. after i.v. administration, whereas CIP was 33.6 and 22.6 hr, respectively.",Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107624/),h,50.4,6977,DB00537,Ciprofloxacin
,33107624,CIP,"The elimination half-life values of ENR were 38.7 and 50.4 hr at dose rates of 5 and 7.5 mg/kg b.w. after i.v. administration, whereas CIP was 33.6 and 22.6 hr, respectively.",Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107624/),h,33.6,6978,DB00537,Ciprofloxacin
,33107624,CIP,"The elimination half-life values of ENR were 38.7 and 50.4 hr at dose rates of 5 and 7.5 mg/kg b.w. after i.v. administration, whereas CIP was 33.6 and 22.6 hr, respectively.",Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107624/),h,22.6,6979,DB00537,Ciprofloxacin
,33107624,maximum concentration (Cmax ),"The maximum concentration (Cmax ) values of ENR were 2.07 and 2.59 μg/ml at dose rates of 5 and 7.5 mg/kg b.w., respectively.",Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107624/),[μg] / [ml],2.07,6980,DB00537,Ciprofloxacin
,33107624,maximum concentration (Cmax ),"The maximum concentration (Cmax ) values of ENR were 2.07 and 2.59 μg/ml at dose rates of 5 and 7.5 mg/kg b.w., respectively.",Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107624/),[μg] / [ml],2.59,6981,DB00537,Ciprofloxacin
>,33107624,area under the curve from 0 to 24 hr (AUC0-24 )/minimum inhibitory concentration (MIC) ratio,"The value of area under the curve from 0 to 24 hr (AUC0-24 )/minimum inhibitory concentration (MIC) ratio of ENR was >125 for bacteria with MIC of 0.12 and 0.13 μg/ml after the administration of 5 mg/kg by i.m. and i.v. administration, respectively.",Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107624/),,125,6982,DB00537,Ciprofloxacin
,33107624,MIC,"The value of area under the curve from 0 to 24 hr (AUC0-24 )/minimum inhibitory concentration (MIC) ratio of ENR was >125 for bacteria with MIC of 0.12 and 0.13 μg/ml after the administration of 5 mg/kg by i.m. and i.v. administration, respectively.",Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107624/),[μg] / [ml],0.12,6983,DB00537,Ciprofloxacin
,33107624,MIC,"The value of area under the curve from 0 to 24 hr (AUC0-24 )/minimum inhibitory concentration (MIC) ratio of ENR was >125 for bacteria with MIC of 0.12 and 0.13 μg/ml after the administration of 5 mg/kg by i.m. and i.v. administration, respectively.",Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107624/),[μg] / [ml],0.13,6984,DB00537,Ciprofloxacin
,2360815,maximum observed concentration,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),[μg] / [ml],1.13,7265,DB00537,Ciprofloxacin
,2360815,maximum observed concentration,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),[μg] / [ml],1.95,7266,DB00537,Ciprofloxacin
,2360815,half-life,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),h,5.37,7267,DB00537,Ciprofloxacin
,2360815,half-life,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),h,4.47,7268,DB00537,Ciprofloxacin
,2360815,total plasma clearance,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),[ml] / [h·kg],259,7269,DB00537,Ciprofloxacin
,2360815,total plasma clearance,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),[ml] / [h·kg],199,7270,DB00537,Ciprofloxacin
,2360815,renal clearance,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),[ml] / [h·kg],113,7271,DB00537,Ciprofloxacin
,2360815,renal clearance,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),[ml] / [h·kg],86,7272,DB00537,Ciprofloxacin
,2360815,Varea/F,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),[l] / [kg],2.05,7273,DB00537,Ciprofloxacin
,2360815,Varea/F,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),[l] / [kg],1.28,7274,DB00537,Ciprofloxacin
,2360815,excreted,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),%,42.5,7275,DB00537,Ciprofloxacin
,2360815,excreted,"Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively.",Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360815/),%,42.8,7276,DB00537,Ciprofloxacin
,15862658,recovery,Sample preparation by SPE C18 (Supelclean) with recovery 72% was performed.,High-performance liquid chromatographic determination of ciprofloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15862658/),%,72,7654,DB00537,Ciprofloxacin
,8257131,total body clearance,"A significant (P < 0.05) decrease in total body clearance was observed during the SURG and POST phases (298 and 306 ml/min/1.73 m2, respectively) compared with that during the PRE phase (364 ml/min/1.73 m2).",Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257131/),[ml] / [1.73·m2·min],298,7839,DB00537,Ciprofloxacin
,8257131,total body clearance,"A significant (P < 0.05) decrease in total body clearance was observed during the SURG and POST phases (298 and 306 ml/min/1.73 m2, respectively) compared with that during the PRE phase (364 ml/min/1.73 m2).",Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257131/),[ml] / [1.73·m2·min],306,7840,DB00537,Ciprofloxacin
,8257131,total body clearance,"A significant (P < 0.05) decrease in total body clearance was observed during the SURG and POST phases (298 and 306 ml/min/1.73 m2, respectively) compared with that during the PRE phase (364 ml/min/1.73 m2).",Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257131/),[ml] / [1.73·m2·min],364,7841,DB00537,Ciprofloxacin
,8257131,apparent volume of distribution,"A nonsignificant decline occurred in the apparent volume of distribution, from mean values of 2.1 and 2.0 liters/kg during the PRE and POST phases, respectively, to 1.7 liters/kg during the SURG phase.",Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257131/),[l] / [kg],2.1,7842,DB00537,Ciprofloxacin
,8257131,apparent volume of distribution,"A nonsignificant decline occurred in the apparent volume of distribution, from mean values of 2.1 and 2.0 liters/kg during the PRE and POST phases, respectively, to 1.7 liters/kg during the SURG phase.",Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257131/),[l] / [kg],2.0,7843,DB00537,Ciprofloxacin
,8257131,apparent volume of distribution,"A nonsignificant decline occurred in the apparent volume of distribution, from mean values of 2.1 and 2.0 liters/kg during the PRE and POST phases, respectively, to 1.7 liters/kg during the SURG phase.",Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257131/),[l] / [kg],1.7,7844,DB00537,Ciprofloxacin
,2940518,peak level,"The geriatric subjects had higher serum levels throughout the sampling period, with a peak level of 3.24 +/- 0.79 versus 2.26 +/- 0.75 micrograms/ml for the younger group (p less than 0.005; one-way analysis of variance).",Pharmacokinetics of ciprofloxacin in elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940518/),[μg] / [ml],3.24,8033,DB00537,Ciprofloxacin
,2940518,peak level,"The geriatric subjects had higher serum levels throughout the sampling period, with a peak level of 3.24 +/- 0.79 versus 2.26 +/- 0.75 micrograms/ml for the younger group (p less than 0.005; one-way analysis of variance).",Pharmacokinetics of ciprofloxacin in elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940518/),[μg] / [ml],2.26,8034,DB00537,Ciprofloxacin
,2940518,renal clearance,"A twofold increase in the ciprofloxacin half-life may be partly explained by a decrease in the glomerular filtration rate, as shown by slower ciprofloxacin renal clearance (152.4 +/- 54.2 vs 395.6 +/- 139.0 for elderly and young subjects respectively; p less than 0.001).",Pharmacokinetics of ciprofloxacin in elderly subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940518/),,152.4,8035,DB00537,Ciprofloxacin
,2940518,renal clearance,"A twofold increase in the ciprofloxacin half-life may be partly explained by a decrease in the glomerular filtration rate, as shown by slower ciprofloxacin renal clearance (152.4 +/- 54.2 vs 395.6 +/- 139.0 for elderly and young subjects respectively; p less than 0.001).",Pharmacokinetics of ciprofloxacin in elderly subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940518/),,395.6,8036,DB00537,Ciprofloxacin
,11913498,effects,"At 10-times the MIC, the post-antibiotic effects of BMS-284756, levofloxacin, and ciprofloxacin were 1.6-2.6 h for the methicillin-susceptible Staphylococcus aureus strain and 1.5-1.9 h for the methicillin-resistant Staphylococcus aureus strain.","Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913498/),h,1.6-2.6,8340,DB00537,Ciprofloxacin
,11913498,effects,"At 10-times the MIC, the post-antibiotic effects of BMS-284756, levofloxacin, and ciprofloxacin were 1.6-2.6 h for the methicillin-susceptible Staphylococcus aureus strain and 1.5-1.9 h for the methicillin-resistant Staphylococcus aureus strain.","Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913498/),h,1.5-1.9,8341,DB00537,Ciprofloxacin
,11786657,minimum inhibitory concentrations (MICs),"The minimum inhibitory concentrations (MICs) of CPFX, IMP and CZOP were 1.0, 1.0 and 4.0 mg/l, respectively.",Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11786657/),[mg] / [l],1.0,8826,DB00537,Ciprofloxacin
,11786657,minimum inhibitory concentrations (MICs),"The minimum inhibitory concentrations (MICs) of CPFX, IMP and CZOP were 1.0, 1.0 and 4.0 mg/l, respectively.",Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11786657/),[mg] / [l],4.0,8827,DB00537,Ciprofloxacin
,9002120,peak serum concentrations,"After oral CIP mean +/- SD peak serum concentrations and peak times were 3.7 +/- 1.4 mg/l and 2.5 +/- 1.8 h, respectively, compared with 5.0 +/- 1.5 mg/l and 1.0 +/- 0.3 h after completion of the i.v. infusion.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),[mg] / [l],3.7,9240,DB00537,Ciprofloxacin
,9002120,peak serum concentrations,"After oral CIP mean +/- SD peak serum concentrations and peak times were 3.7 +/- 1.4 mg/l and 2.5 +/- 1.8 h, respectively, compared with 5.0 +/- 1.5 mg/l and 1.0 +/- 0.3 h after completion of the i.v. infusion.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),[mg] / [l],5.0,9241,DB00537,Ciprofloxacin
,9002120,peak times,"After oral CIP mean +/- SD peak serum concentrations and peak times were 3.7 +/- 1.4 mg/l and 2.5 +/- 1.8 h, respectively, compared with 5.0 +/- 1.5 mg/l and 1.0 +/- 0.3 h after completion of the i.v. infusion.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),h,2.5,9242,DB00537,Ciprofloxacin
,9002120,peak times,"After oral CIP mean +/- SD peak serum concentrations and peak times were 3.7 +/- 1.4 mg/l and 2.5 +/- 1.8 h, respectively, compared with 5.0 +/- 1.5 mg/l and 1.0 +/- 0.3 h after completion of the i.v. infusion.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),h,1.0,9243,DB00537,Ciprofloxacin
,9002120,Maximum concentrations,"Maximum concentrations, when normalized for dose, were 0.52 +/- 0.12 and 0.19 +/- 0.07 mg/l/kg after i.v. and oral dosing, respectively.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),[mg] / [kg·l],0.52,9244,DB00537,Ciprofloxacin
,9002120,Maximum concentrations,"Maximum concentrations, when normalized for dose, were 0.52 +/- 0.12 and 0.19 +/- 0.07 mg/l/kg after i.v. and oral dosing, respectively.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),[mg] / [kg·l],0.19,9245,DB00537,Ciprofloxacin
,9002120,bioavailability,"The mean bioavailability of oral CIP for all patients was 76%; younger patients appeared to absorb oral CIP less than older subjects, 68% vs. 95%, respectively.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),%,76,9246,DB00537,Ciprofloxacin
,9002120,bioavailability,"The mean bioavailability of oral CIP for all patients was 76%; younger patients appeared to absorb oral CIP less than older subjects, 68% vs. 95%, respectively.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),%,68,9247,DB00537,Ciprofloxacin
,9002120,bioavailability,"The mean bioavailability of oral CIP for all patients was 76%; younger patients appeared to absorb oral CIP less than older subjects, 68% vs. 95%, respectively.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),%,95,9248,DB00537,Ciprofloxacin
,9002120,elimination half-lives,"For all patients elimination half-lives were 2.6 +/- 0.6 and 3.4 +/- 0.7 h after i.v. and oral administration, respectively, and did not differ by age.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),h,2.6,9249,DB00537,Ciprofloxacin
,9002120,elimination half-lives,"For all patients elimination half-lives were 2.6 +/- 0.6 and 3.4 +/- 0.7 h after i.v. and oral administration, respectively, and did not differ by age.",Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),h,3.4,9250,DB00537,Ciprofloxacin
,9002120,Total clearance,Total clearance after i.v. administration was 19.5 +/- 10.9 liters/h.,Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002120/),[l] / [h],19.5,9251,DB00537,Ciprofloxacin
>,20063816,area under the curve from the time of dosing to 24 hr:minimal inhibitory concentration (MIC),"The integrated pharmacokinetic-pharmacodynamic (PK-PD) variables showed that optimal area under the curve from the time of dosing to 24 hr:minimal inhibitory concentration (MIC) (>125) and peak plasma concentrations:MIC (>8) ratios, as reported for concentration-dependent bactericidal antimicrobials like fluoroquinolones, were achievable with both a single i.v. or i.m. dose for susceptible microorganisms with MIC values of < or =0.5 microg/ml, while the relatively slow onset of peak time allowed an effective plasma drug level only on day 3.","Pharmacokinetic behavior of enrofloxacin in estuarine crocodile (Crocodylus porosus) after single intravenous, intramuscular, and oral doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063816/),,125,9635,DB00537,Ciprofloxacin
>,20063816,peak plasma concentrations:MIC,"The integrated pharmacokinetic-pharmacodynamic (PK-PD) variables showed that optimal area under the curve from the time of dosing to 24 hr:minimal inhibitory concentration (MIC) (>125) and peak plasma concentrations:MIC (>8) ratios, as reported for concentration-dependent bactericidal antimicrobials like fluoroquinolones, were achievable with both a single i.v. or i.m. dose for susceptible microorganisms with MIC values of < or =0.5 microg/ml, while the relatively slow onset of peak time allowed an effective plasma drug level only on day 3.","Pharmacokinetic behavior of enrofloxacin in estuarine crocodile (Crocodylus porosus) after single intravenous, intramuscular, and oral doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063816/),,8,9636,DB00537,Ciprofloxacin
<,20063816,MIC,"The integrated pharmacokinetic-pharmacodynamic (PK-PD) variables showed that optimal area under the curve from the time of dosing to 24 hr:minimal inhibitory concentration (MIC) (>125) and peak plasma concentrations:MIC (>8) ratios, as reported for concentration-dependent bactericidal antimicrobials like fluoroquinolones, were achievable with both a single i.v. or i.m. dose for susceptible microorganisms with MIC values of < or =0.5 microg/ml, while the relatively slow onset of peak time allowed an effective plasma drug level only on day 3.","Pharmacokinetic behavior of enrofloxacin in estuarine crocodile (Crocodylus porosus) after single intravenous, intramuscular, and oral doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063816/),[μg] / [ml],0.5,9637,DB00537,Ciprofloxacin
,1803788,area under the serum concentration-time curve (AUC),"In patients with nosocomial pneumonia, one of the model compounds studied was cefmenoxime, where a target six-hour area under the serum concentration-time curve (AUC) of 140 micrograms.h/mL above minimum inhibitory concentration (MIC) was previously associated with bacterial eradication in an average of four days.","Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803788/),[h·μg] / [ml],140,10374,DB00537,Ciprofloxacin
,1803788,AUC,The target AUC value of 140 micrograms.h/mL above MIC is unique to cefmenoxime.,"Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803788/),[h·μg] / [ml],140,10375,DB00537,Ciprofloxacin
,1803788,MIC,"For cefmenoxime, the target was 540 area units over MIC per 24 hours, tobramycin with 34 area units, and ciprofloxacin with 23 area units per 24 hours.","Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803788/),area·units,540,10376,DB00537,Ciprofloxacin
,1803788,MIC,"For cefmenoxime, the target was 540 area units over MIC per 24 hours, tobramycin with 34 area units, and ciprofloxacin with 23 area units per 24 hours.","Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803788/),[area·units] / [24·h],23,10377,DB00537,Ciprofloxacin
,7625786,peak concentrations in plasma (Cmax),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[μg] / [ml],2.88,10775,DB00537,Ciprofloxacin
,7625786,peak concentrations in plasma (Cmax),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[μg] / [ml],2.60,10776,DB00537,Ciprofloxacin
,7625786,areas under the curves (AUC),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[μg] / [ml],2.60,10777,DB00537,Ciprofloxacin
,7625786,areas under the curves (AUC),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[h·μg] / [ml],24.9,10778,DB00537,Ciprofloxacin
,7625786,areas under the curves (AUC),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[h·μg] / [ml],11.9,10779,DB00537,Ciprofloxacin
,7625786,half-life,"The Cmax of lomefloxacin was not significantly higher than that of ciprofloxacin, but lomefloxacin's AUC reached twice that of ciprofloxacin because of its significantly longer half-life in plasma (6.68 +/- 1.94 as against 4.15 +/- 0.92 h, respectively, P < or = 0.01).",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),h,6.68,10780,DB00537,Ciprofloxacin
,7625786,half-life,"The Cmax of lomefloxacin was not significantly higher than that of ciprofloxacin, but lomefloxacin's AUC reached twice that of ciprofloxacin because of its significantly longer half-life in plasma (6.68 +/- 1.94 as against 4.15 +/- 0.92 h, respectively, P < or = 0.01).",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),h,4.15,10781,DB00537,Ciprofloxacin
,16958780,LOD,The LOD and LOQ for both fluoroquinolones were 60 and 200 ng/mL for plasma.,Enrofloxacin assay validation and pharmacokinetics following a single oral dose in chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958780/),[ng] / [ml],60,10937,DB00537,Ciprofloxacin
,16958780,LOQ,The LOD and LOQ for both fluoroquinolones were 60 and 200 ng/mL for plasma.,Enrofloxacin assay validation and pharmacokinetics following a single oral dose in chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958780/),[ng] / [ml],200,10938,DB00537,Ciprofloxacin
,16958780,maximal plasma concentration,The maximal plasma concentration of 1.5 +/- 0.2 mg/mL was achieved at 9 +/- 2 h.,Enrofloxacin assay validation and pharmacokinetics following a single oral dose in chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958780/),[mg] / [ml],1.5,10939,DB00537,Ciprofloxacin
,16958780,elimination half-life,"The elimination half-life and the mean residence time of ENRO were 1.5 +/- 0.2 and 15.64 h, respectively.",Enrofloxacin assay validation and pharmacokinetics following a single oral dose in chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958780/),h,1.5,10940,DB00537,Ciprofloxacin
,16958780,mean residence time,"The elimination half-life and the mean residence time of ENRO were 1.5 +/- 0.2 and 15.64 h, respectively.",Enrofloxacin assay validation and pharmacokinetics following a single oral dose in chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958780/),h,15.64,10941,DB00537,Ciprofloxacin
,16958780,area under the concentration-time curve,The area under the concentration-time curve was calculated as 35 +/- 4 mgxh/mL.,Enrofloxacin assay validation and pharmacokinetics following a single oral dose in chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958780/),[h·mg] / [ml],35,10942,DB00537,Ciprofloxacin
,3789695,Peak levels,"Peak levels in serum ranged from 1.27 to 5.6 mg/liter (mean, 3.16 +/- 1.27), and absorption was rapid, the time to peak concentration ranging from 0.5 to 3.0 h (mean, 1.5 +/- 0.9).",Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789695/),[mg] / [l],3.16,11059,DB00537,Ciprofloxacin
,3789695,time to peak concentration,"Peak levels in serum ranged from 1.27 to 5.6 mg/liter (mean, 3.16 +/- 1.27), and absorption was rapid, the time to peak concentration ranging from 0.5 to 3.0 h (mean, 1.5 +/- 0.9).",Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789695/),h,1.5,11060,DB00537,Ciprofloxacin
,9507453,AM to plasma ratio,"Mean concentrations of both drugs in AM were greater than in plasma (AM to plasma ratio, 10.3 for enrofloxacin and 4.7 for ciprofloxacin).",Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9507453/),,10.3,11338,DB00537,Ciprofloxacin
,9507453,AM to plasma ratio,"Mean concentrations of both drugs in AM were greater than in plasma (AM to plasma ratio, 10.3 for enrofloxacin and 4.7 for ciprofloxacin).",Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9507453/),,4.7,11339,DB00537,Ciprofloxacin
,9507453,ELF to plasma ratio,"Mean concentrations of enrofloxacin, but not ciprofloxacin, in ELF were greater than in plasma (ELF to plasma ratio, 13.5 for enrofloxacin and 0.52 for ciprofloxacin).",Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9507453/),,13.5,11340,DB00537,Ciprofloxacin
,9507453,ELF to plasma ratio,"Mean concentrations of enrofloxacin, but not ciprofloxacin, in ELF were greater than in plasma (ELF to plasma ratio, 13.5 for enrofloxacin and 0.52 for ciprofloxacin).",Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9507453/),,0.52,11341,DB00537,Ciprofloxacin
,3158273,F,"Peak levels (+/- standard deviation) after the first and seventh doses averaged F (fasting): 1.35 +/- 0.17, B (breakfast): 1.02 +/- 0.28 micrograms/ml, and F: 1.41 +/- 0.32, B: 1.17 +/- 0.5 micrograms/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],1.35,11446,DB00537,Ciprofloxacin
,3158273,F,"Peak levels (+/- standard deviation) after the first and seventh doses averaged F (fasting): 1.35 +/- 0.17, B (breakfast): 1.02 +/- 0.28 micrograms/ml, and F: 1.41 +/- 0.32, B: 1.17 +/- 0.5 micrograms/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],1.02,11447,DB00537,Ciprofloxacin
,3158273,F,"Peak levels (+/- standard deviation) after the first and seventh doses averaged F (fasting): 1.35 +/- 0.17, B (breakfast): 1.02 +/- 0.28 micrograms/ml, and F: 1.41 +/- 0.32, B: 1.17 +/- 0.5 micrograms/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],1.41,11448,DB00537,Ciprofloxacin
,3158273,F,"Peak levels (+/- standard deviation) after the first and seventh doses averaged F (fasting): 1.35 +/- 0.17, B (breakfast): 1.02 +/- 0.28 micrograms/ml, and F: 1.41 +/- 0.32, B: 1.17 +/- 0.5 micrograms/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],1.17,11449,DB00537,Ciprofloxacin
,3158273,B,"Peak levels (+/- standard deviation) after the first and seventh doses averaged F (fasting): 1.35 +/- 0.17, B (breakfast): 1.02 +/- 0.28 micrograms/ml, and F: 1.41 +/- 0.32, B: 1.17 +/- 0.5 micrograms/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],1.17,11450,DB00537,Ciprofloxacin
,3158273,trough concentrations,"Mean trough concentrations after the first and seventh doses were F: 0.10 +/- 0.03, B: 0.14 +/- 0.03 micrograms/ml, and F: 0.16 +/- 0.05, B: 0.14 +/- 0.04 microgram/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],0.10,11451,DB00537,Ciprofloxacin
,3158273,trough concentrations,"Mean trough concentrations after the first and seventh doses were F: 0.10 +/- 0.03, B: 0.14 +/- 0.03 micrograms/ml, and F: 0.16 +/- 0.05, B: 0.14 +/- 0.04 microgram/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],0.14,11452,DB00537,Ciprofloxacin
,3158273,F,"Mean trough concentrations after the first and seventh doses were F: 0.10 +/- 0.03, B: 0.14 +/- 0.03 micrograms/ml, and F: 0.16 +/- 0.05, B: 0.14 +/- 0.04 microgram/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],0.10,11453,DB00537,Ciprofloxacin
,3158273,F,"Mean trough concentrations after the first and seventh doses were F: 0.10 +/- 0.03, B: 0.14 +/- 0.03 micrograms/ml, and F: 0.16 +/- 0.05, B: 0.14 +/- 0.04 microgram/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],0.14,11454,DB00537,Ciprofloxacin
,3158273,F,"Mean trough concentrations after the first and seventh doses were F: 0.10 +/- 0.03, B: 0.14 +/- 0.03 micrograms/ml, and F: 0.16 +/- 0.05, B: 0.14 +/- 0.04 microgram/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],0.16,11455,DB00537,Ciprofloxacin
,3158273,F,"Mean trough concentrations after the first and seventh doses were F: 0.10 +/- 0.03, B: 0.14 +/- 0.03 micrograms/ml, and F: 0.16 +/- 0.05, B: 0.14 +/- 0.04 microgram/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],0.14,11456,DB00537,Ciprofloxacin
,3158273,B,"Mean trough concentrations after the first and seventh doses were F: 0.10 +/- 0.03, B: 0.14 +/- 0.03 micrograms/ml, and F: 0.16 +/- 0.05, B: 0.14 +/- 0.04 microgram/ml, respectively.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),[μg] / [ml],0.14,11457,DB00537,Ciprofloxacin
,3158273,F,"Breakfast equally did not affect the terminal half-lives, which averaged F: 3.97 +/- 0.67, B: 4.35 +/- 0.88 h after the first dose and F: 4.64 +/- 0.91, B: 3.72 +/- 0.84 h after the seventh dose.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),h,3.97,11458,DB00537,Ciprofloxacin
,3158273,F,"Breakfast equally did not affect the terminal half-lives, which averaged F: 3.97 +/- 0.67, B: 4.35 +/- 0.88 h after the first dose and F: 4.64 +/- 0.91, B: 3.72 +/- 0.84 h after the seventh dose.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),h,4.35,11459,DB00537,Ciprofloxacin
,3158273,F,"Breakfast equally did not affect the terminal half-lives, which averaged F: 3.97 +/- 0.67, B: 4.35 +/- 0.88 h after the first dose and F: 4.64 +/- 0.91, B: 3.72 +/- 0.84 h after the seventh dose.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),h,4.64,11460,DB00537,Ciprofloxacin
,3158273,F,"Breakfast equally did not affect the terminal half-lives, which averaged F: 3.97 +/- 0.67, B: 4.35 +/- 0.88 h after the first dose and F: 4.64 +/- 0.91, B: 3.72 +/- 0.84 h after the seventh dose.",Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158273/),h,3.72,11461,DB00537,Ciprofloxacin
,15951472,f,"Tissue penetration in smuG (f =0.61 +/- 0.36) was slightly lower than in 1G (f =0.92 +/- 0.63); however, the difference was not significant.",Effect of simulated microgravity on the disposition and tissue penetration of ciprofloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951472/),,0.61,11564,DB00537,Ciprofloxacin
,15951472,f,"Tissue penetration in smuG (f =0.61 +/- 0.36) was slightly lower than in 1G (f =0.92 +/- 0.63); however, the difference was not significant.",Effect of simulated microgravity on the disposition and tissue penetration of ciprofloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951472/),,0.92,11565,DB00537,Ciprofloxacin
,17724088,half-life,"A slightly greater value of half-life for (R)-warfarin was observed when coadministered with ciprofloxacin PR compared with warfarin administered alone (52.6 vs 50.1 hours, P = .029).",Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724088/),h,52.6,11612,DB00537,Ciprofloxacin
,17724088,half-life,"A slightly greater value of half-life for (R)-warfarin was observed when coadministered with ciprofloxacin PR compared with warfarin administered alone (52.6 vs 50.1 hours, P = .029).",Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724088/),h,50.1,11613,DB00537,Ciprofloxacin
,8856215,Blood flow,Blood flow through the haemofilters was 100 ml/min resulting in an average ultrafiltrate flow rate (UFR) of 13.2 +/- 4.6 (range 3.2-22.1) ml/min.,Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856215/),[ml] / [min],100,12329,DB00537,Ciprofloxacin
,8856215,ultrafiltrate flow rate (UFR),Blood flow through the haemofilters was 100 ml/min resulting in an average ultrafiltrate flow rate (UFR) of 13.2 +/- 4.6 (range 3.2-22.1) ml/min.,Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856215/),[ml] / [min],13.2,12330,DB00537,Ciprofloxacin
,12118662,half-life,"Harmonic mean half-life for oral administration was 14.80, 10.80, and 13.07 hours, respectively, for the oral drench, crushed tablets in grain, and enrofloxacin solution in grain.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),h,14.80,12450,DB00537,Ciprofloxacin
,12118662,half-life,"Harmonic mean half-life for oral administration was 14.80, 10.80, and 13.07 hours, respectively, for the oral drench, crushed tablets in grain, and enrofloxacin solution in grain.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),h,10.80,12451,DB00537,Ciprofloxacin
,12118662,half-life,"Harmonic mean half-life for oral administration was 14.80, 10.80, and 13.07 hours, respectively, for the oral drench, crushed tablets in grain, and enrofloxacin solution in grain.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),h,13.07,12452,DB00537,Ciprofloxacin
,12118662,Oral bioavailability,"Oral bioavailability for the oral drench, crushed tablets in grain, and enrofloxacin in grain was 4789, 98.07, and 94.60%, respectively, and median maximum concentration (Cmax) was 1.61, 2.69, and 2.26 microg/ml, respectively.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),%,4789,12453,DB00537,Ciprofloxacin
,12118662,Oral bioavailability,"Oral bioavailability for the oral drench, crushed tablets in grain, and enrofloxacin in grain was 4789, 98.07, and 94.60%, respectively, and median maximum concentration (Cmax) was 1.61, 2.69, and 2.26 microg/ml, respectively.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),%,98.07,12454,DB00537,Ciprofloxacin
,12118662,Oral bioavailability,"Oral bioavailability for the oral drench, crushed tablets in grain, and enrofloxacin in grain was 4789, 98.07, and 94.60%, respectively, and median maximum concentration (Cmax) was 1.61, 2.69, and 2.26 microg/ml, respectively.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),%,94.60,12455,DB00537,Ciprofloxacin
,12118662,maximum concentration (Cmax),"Oral bioavailability for the oral drench, crushed tablets in grain, and enrofloxacin in grain was 4789, 98.07, and 94.60%, respectively, and median maximum concentration (Cmax) was 1.61, 2.69, and 2.26 microg/ml, respectively.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),[μg] / [ml],1.61,12456,DB00537,Ciprofloxacin
,12118662,maximum concentration (Cmax),"Oral bioavailability for the oral drench, crushed tablets in grain, and enrofloxacin in grain was 4789, 98.07, and 94.60%, respectively, and median maximum concentration (Cmax) was 1.61, 2.69, and 2.26 microg/ml, respectively.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),[μg] / [ml],2.69,12457,DB00537,Ciprofloxacin
,12118662,maximum concentration (Cmax),"Oral bioavailability for the oral drench, crushed tablets in grain, and enrofloxacin in grain was 4789, 98.07, and 94.60%, respectively, and median maximum concentration (Cmax) was 1.61, 2.69, and 2.26 microg/ml, respectively.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),[μg] / [ml],2.26,12458,DB00537,Ciprofloxacin
,12118662,Cmax,Median Cmax of the multiple-dose regimen was 2.99 microg/ml.,Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),[μg] / [ml],2.99,12459,DB00537,Ciprofloxacin
<,12118662,MIC,"Oral administration at 10 mg/kg, q 24 h, was sufficient to achieve a plasma concentration of 8 to 10 times the minimum inhibitory concentration (MIC) of any microorganism with an MIC < or = 0.29 microg/ml.",Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12118662/),[μg] / [ml],0.29,12460,DB00537,Ciprofloxacin
,9661000,total urinary recovery,The total urinary recovery of pefloxacin and the active metabolite norfloxacin was 34%.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),%,34,12488,DB00537,Ciprofloxacin
,9661000,MIC,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/ml the UBT was at least 1:4 for 48 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),[μg] / [ml],0.5,12489,DB00537,Ciprofloxacin
,9661000,UBT,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/ml the UBT was at least 1:4 for 48 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),,1,12490,DB00537,Ciprofloxacin
,9661000,UBTs,The UBTs of both drugs against Klebsiella pneumoniae were at least 1:16 for 72 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),,1:16,12491,DB00537,Ciprofloxacin
,9661000,MIC,"The UBTs for Staphylococcus aureus (the MIC for which was 16 micrograms/ml) of both antibiotics were low, and in some of the samples, no bactericidal titers were observed.",Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),[μg] / [ml],16,12492,DB00537,Ciprofloxacin
,2334162,maximum concentrations,"The maximum concentrations in serum (mean value +/- standard deviation, 11.1 +/- 7.8 mg/liter) during surgery were reached 30 min after ciprofloxacin was administered.",Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334162/),[mg] / [l],11.1,12833,DB00537,Ciprofloxacin
,26563280,elimination half-life (T(1/2β)),The elimination half-life (T(1/2β)) was estimated to be 22.58 h.,"Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563280/),h,22.58,13232,DB00537,Ciprofloxacin
,26563280,"volume of distribution, V(d(area))","The volume of distribution, V(d(area)), was estimated to be 5.95 L/kg, indicating good tissue penetration of sarafloxacin in the fish.","Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563280/),[l] / [kg],5.95,13233,DB00537,Ciprofloxacin
,26563280,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) and total body clearance of sarafloxacin were 56.86 µg·h/mL and 0.18 L/h/kg, respectively.","Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563280/),[h·μg] / [ml],56.86,13234,DB00537,Ciprofloxacin
,26563280,total body clearance,"Area under the concentration-time curve (AUC) and total body clearance of sarafloxacin were 56.86 µg·h/mL and 0.18 L/h/kg, respectively.","Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563280/),[l] / [h·kg],0.18,13235,DB00537,Ciprofloxacin
,26563280,maximum plasma concentration (C(max)),"Following p.o. administration, the maximum plasma concentration (C(max)), T(1/2β), and AUC of sarafloxacin were 0.79 µg/mL, 46.68 h, and 16.58 µg·h/mL, respectively.","Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563280/),[μg] / [ml],0.79,13236,DB00537,Ciprofloxacin
,26563280,T(1/2β),"Following p.o. administration, the maximum plasma concentration (C(max)), T(1/2β), and AUC of sarafloxacin were 0.79 µg/mL, 46.68 h, and 16.58 µg·h/mL, respectively.","Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563280/),h,46.68,13237,DB00537,Ciprofloxacin
,26563280,AUC,"Following p.o. administration, the maximum plasma concentration (C(max)), T(1/2β), and AUC of sarafloxacin were 0.79 µg/mL, 46.68 h, and 16.58 µg·h/mL, respectively.","Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563280/),[h·μg] / [ml],16.58,13238,DB00537,Ciprofloxacin
,26563280,bioavailability (F),Absorption of the drug was not good with a bioavailability (F) of 29.15%.,"Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563280/),%,29.15,13239,DB00537,Ciprofloxacin
,26563280,minimum inhibitory concentration (MIC),"Based on a minimum inhibitory concentration (MIC) of 0.00625 to 0.045 μg/mL for susceptible strains, sarafloxacin p.o. administration at a dose 10 mg/kg could be efficacious against common pathogenic bacteria of fish.","Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563280/),[μg] / [ml],0.00625 to 0.045,13240,DB00537,Ciprofloxacin
,8851610,inhibitory titers,Geometric mean inhibitory titers ranged between 1:2.4 and 1:6.3 and bactericidal titers ranged between 1:1.3 and 1:3.6 during a time period of 1 to 6 h after drug intake.,Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851610/),,1,14615,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),[mg] / [l],2.16,15272,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),[mg] / [l],1.42,15273,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),[mg] / [l],0.82,15274,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),[mg] / [l],0.56,15275,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),[mg] / [l],2.50,15276,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),[mg] / [l],1.04,15277,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),[mg] / [l],1.16,15278,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),mg,0.42,15279,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),[mg] / [l],0.27,15280,DB00537,Ciprofloxacin
,8098576,bone concentrations,"The mean bone concentrations in cancellous and cortical bone after ciprofloxacin administration were, respectively, 2.16 mg/l and 1.42 mg/l after 1 hour; 0.82 mg/l and 0.56 mg/l after 2 hours; 2.50 mg/l and 1.04 mg/l after 3 hours; 1.16 mg/l and 0.42 mg/1 after 4-5 hours; and 0.27 mg/l and 0.15 mg/l after 13-19 hours.",[Concentration of ciprofloxacin in bone tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098576/),[mg] / [l],0.15,15281,DB00537,Ciprofloxacin
,17563126,AUC(infinity),"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),[h·μg] / [ml],14.37,15640,DB00537,Ciprofloxacin
,17563126,AUC(infinity),"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),[h·μg] / [ml],16.71,15641,DB00537,Ciprofloxacin
,17563126,maximum plasma concentration (C(max)),"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),[μg] / [ml],2.52,15642,DB00537,Ciprofloxacin
,17563126,maximum plasma concentration (C(max)),"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),[μg] / [ml],2.61,15643,DB00537,Ciprofloxacin
,17563126,time to c,"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),h,1.5,15644,DB00537,Ciprofloxacin
,2229451,clearance,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[l] / [h],20.3,15994,DB00537,Ciprofloxacin
,2229451,clearance,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[l] / [h],20.1,15995,DB00537,Ciprofloxacin
,2229451,half-life,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,7.9,15996,DB00537,Ciprofloxacin
,2229451,half-life,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,7.8,15997,DB00537,Ciprofloxacin
,2229451,maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[mg] / [l],1.4,15998,DB00537,Ciprofloxacin
,2229451,maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[mg] / [l],1.5,15999,DB00537,Ciprofloxacin
,2229451,time to maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,1.5,16000,DB00537,Ciprofloxacin
,2229451,time to maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,1.5,16001,DB00537,Ciprofloxacin
,7577224,maximum level,The maximum level of antibiotic was noted on the first day (49.9 +/- 5.1 mg/l).,Pharmacokinetic study of fibrin clot-ciprofloxacin complex: an in vitro and in vivo experimental investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7577224/),[mg] / [l],49.9,16754,DB00537,Ciprofloxacin
,2369810,t1/2,"In group 1, ciprofloxacin administration resulted in a significant decrease in antipyrine elimination (t1/2, 9.45 +/- 3.74 vs. 14.92 +/- 3.32 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,9.45,16811,DB00537,Ciprofloxacin
,2369810,t1/2,"In group 1, ciprofloxacin administration resulted in a significant decrease in antipyrine elimination (t1/2, 9.45 +/- 3.74 vs. 14.92 +/- 3.32 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,14.92,16812,DB00537,Ciprofloxacin
,2369810,clearance,The average decrease in antipyrine clearance was 35% (0.85 +/- 0.45 vs. 0.52 +/- 0.24 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.85,16813,DB00537,Ciprofloxacin
,2369810,clearance,The average decrease in antipyrine clearance was 35% (0.85 +/- 0.45 vs. 0.52 +/- 0.24 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.52,16814,DB00537,Ciprofloxacin
,2369810,t1/2,"In group 2, the change in antipyrine kinetics was less pronounced (t1/2, 9.79 +/- 3.06 vs. 11.22 +/- 2.64 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,9.79,16815,DB00537,Ciprofloxacin
,2369810,t1/2,"In group 2, the change in antipyrine kinetics was less pronounced (t1/2, 9.79 +/- 3.06 vs. 11.22 +/- 2.64 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,11.22,16816,DB00537,Ciprofloxacin
,2369810,clearance,Antipyrine clearance was decreased by only 10% (0.77 +/- 0.13 vs. 0.70 +/- 0.14 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.77,16817,DB00537,Ciprofloxacin
,2369810,clearance,Antipyrine clearance was decreased by only 10% (0.77 +/- 0.13 vs. 0.70 +/- 0.14 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.70,16818,DB00537,Ciprofloxacin
,30203024,clearance,"Ciprofloxacin clearance (mean ± SD) was 0.81 ± 0.30 L/h/kg, increased allometrically with weight, decreased with increasing creatinine concentration, was 89% higher in SCD compared with non-SCD patients and increased by 0.95 L/h/kg per year of age.",Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30203024/),[l] / [h·kg],0.81,17051,DB00537,Ciprofloxacin
,30203024,volume of distribution,The volume of distribution was 6.9 L/kg and depended only on the weight.,Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30203024/),[l] / [kg],6.9,17052,DB00537,Ciprofloxacin
>,30203024,AUC/MIC ratio,"Monte Carlo simulations were performed separately in SCD and non-SCD patients to target an AUC/MIC ratio >125 at steady-state, required for antibacterial efficacy, and recommendations of dosing regimens were proposed.",Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30203024/),,125,17053,DB00537,Ciprofloxacin
not exceed,2599653,MICs,"Selection of mutants with decreased sensitivity to ciprofloxacin occurred during therapy, however, post-therapy MICs of ciprofloxacin did not exceed a level of 1 mg/l and rises of MICs did not detrimentally influence treatment outcome.","Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2599653/),[mg] / [l],1,17488,DB00537,Ciprofloxacin
,20444030,total clearance,"The total clearance of enrofloxacin (CLEN) and ciprofloxacin (CLCP) was 0.613 L/h and 1.15 L/h, respectively.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in chicken based on retrospective data, incorporating first-pass metabolism. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444030/),[l] / [h],0.613,18405,DB00537,Ciprofloxacin
,20444030,total clearance,"The total clearance of enrofloxacin (CLEN) and ciprofloxacin (CLCP) was 0.613 L/h and 1.15 L/h, respectively.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in chicken based on retrospective data, incorporating first-pass metabolism. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444030/),[l] / [h],1.15,18406,DB00537,Ciprofloxacin
,20444030,transformation rate,"After intravenous administration of enrofloxacin, the transformation rate of enrofloxacin to ciprofloxacin was 0.429 L/h.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in chicken based on retrospective data, incorporating first-pass metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444030/),[l] / [h],0.429,18407,DB00537,Ciprofloxacin
,20444030,bioavailability factor,"The bioavailability factor after oral administration was 0.926, and 12.6% of enrofloxacin after oral administration was transformed to ciprofloxacin via first-pass effect.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in chicken based on retrospective data, incorporating first-pass metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444030/),,0.926,18408,DB00537,Ciprofloxacin
,20444030,bioavailability factor,"The bioavailability factor after oral administration was 0.926, and 12.6% of enrofloxacin after oral administration was transformed to ciprofloxacin via first-pass effect.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in chicken based on retrospective data, incorporating first-pass metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444030/),%,12.6,18409,DB00537,Ciprofloxacin
,3468101,plasma half-life,The mean plasma half-life was 3.6 +/- 1.0 h and the mean plasma clearance was 8.42 +/- 2.5 ml/min/kg.,"Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468101/),h,3.6,18947,DB00537,Ciprofloxacin
,3468101,plasma clearance,The mean plasma half-life was 3.6 +/- 1.0 h and the mean plasma clearance was 8.42 +/- 2.5 ml/min/kg.,"Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468101/),[ml] / [kg·min],8.42,18948,DB00537,Ciprofloxacin
,8239590,MIC,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],0.78,19585,DB00537,Ciprofloxacin
,8239590,MIC90,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],0.78,19586,DB00537,Ciprofloxacin
,8239590,MIC50,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],0.39,19587,DB00537,Ciprofloxacin
,8239590,MB,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],3.13,19588,DB00537,Ciprofloxacin
,8239590,MBC90,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],3.13,19589,DB00537,Ciprofloxacin
,8239590,MBC50,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],0.78,19590,DB00537,Ciprofloxacin
,8239590,MBC50-to-MIC50 ratio,The MBC50-to-MIC50 ratio for Q-35 was 2.,"In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),,2,19591,DB00537,Ciprofloxacin
,30099019,half-life,Ciprofloxacin dosed in identical fashion displayed rapid clearance with a half-life of approximately 30 min.,Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30099019/),min,30,19760,DB00537,Ciprofloxacin
,24594453,MIC,The MIC range of DS-8587 against MDR A. baumannii was 0.25-2 mg/L.,Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24594453/),[mg] / [l],0.25-2,20401,DB00537,Ciprofloxacin
,24594453,AUC/MIC,"The total and free drug AUC/MIC value required for a static effect was 29.4 and 14.1, respectively.",Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24594453/),,29.4,20402,DB00537,Ciprofloxacin
,24594453,AUC/MIC,"The total and free drug AUC/MIC value required for a static effect was 29.4 and 14.1, respectively.",Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24594453/),,14.1,20403,DB00537,Ciprofloxacin
,8961058,maximum serum concentration,"After the initial dose, the maximum serum concentration ranged from 1.24-3.06 mg/L, and the area under the time curve from 0-12 h ranged from 3.2-19.65 mg.h/L.",Enteric absorption of ciprofloxacin during tube feeding in the critically ill. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8961058/),[mg] / [l],1.24-3.06,20729,DB00537,Ciprofloxacin
,8961058,area under the time curve from 0-12 h,"After the initial dose, the maximum serum concentration ranged from 1.24-3.06 mg/L, and the area under the time curve from 0-12 h ranged from 3.2-19.65 mg.h/L.",Enteric absorption of ciprofloxacin during tube feeding in the critically ill. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8961058/),[h·mg] / [l],3.2-19.65,20730,DB00537,Ciprofloxacin
,29311199,steady-state maximum serum concentration,"Mean steady-state maximum serum concentration and half-life were 4.4 ± 1.5 mg/L and 10.3 ± 2.6 hours, respectively.",Steady-State Pharmacokinetics of Oral Ciprofloxacin in Continuous Cycling Peritoneal Dialysis Patients: Brief Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29311199/),[mg] / [l],4.4,20841,DB00537,Ciprofloxacin
,29311199,half-life,"Mean steady-state maximum serum concentration and half-life were 4.4 ± 1.5 mg/L and 10.3 ± 2.6 hours, respectively.",Steady-State Pharmacokinetics of Oral Ciprofloxacin in Continuous Cycling Peritoneal Dialysis Patients: Brief Report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29311199/),h,10.3,20842,DB00537,Ciprofloxacin
,29311199,maximum dialysate concentration,"Mean maximum dialysate concentration in the daytime long dwell and overnight continuous cycling dwell were 7.4 ± 1.2 mg/L and 3.3 ± 1.2 mg/L, respectively.",Steady-State Pharmacokinetics of Oral Ciprofloxacin in Continuous Cycling Peritoneal Dialysis Patients: Brief Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29311199/),[mg] / [l],7.4,20843,DB00537,Ciprofloxacin
,29311199,maximum dialysate concentration,"Mean maximum dialysate concentration in the daytime long dwell and overnight continuous cycling dwell were 7.4 ± 1.2 mg/L and 3.3 ± 1.2 mg/L, respectively.",Steady-State Pharmacokinetics of Oral Ciprofloxacin in Continuous Cycling Peritoneal Dialysis Patients: Brief Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29311199/),[mg] / [l],3.3,20844,DB00537,Ciprofloxacin
,29486265,half-lives,"HPC-CIP conjugate 2 and HEC-CIP conjugate 6 exhibited half-lives of 10.87 and 11.71h, respectively with area under the curve values of 164 and 175hμgmL-1, respectively, indicating enhanced bioavailability and improved pharmacokinetic profiles in animal model.",Design of cellulose ether-based macromolecular prodrugs of ciprofloxacin for extended release and enhanced bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486265/),h,10.87,20928,DB00537,Ciprofloxacin
,29486265,half-lives,"HPC-CIP conjugate 2 and HEC-CIP conjugate 6 exhibited half-lives of 10.87 and 11.71h, respectively with area under the curve values of 164 and 175hμgmL-1, respectively, indicating enhanced bioavailability and improved pharmacokinetic profiles in animal model.",Design of cellulose ether-based macromolecular prodrugs of ciprofloxacin for extended release and enhanced bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486265/),h,11.71,20929,DB00537,Ciprofloxacin
,29486265,area under the curve,"HPC-CIP conjugate 2 and HEC-CIP conjugate 6 exhibited half-lives of 10.87 and 11.71h, respectively with area under the curve values of 164 and 175hμgmL-1, respectively, indicating enhanced bioavailability and improved pharmacokinetic profiles in animal model.",Design of cellulose ether-based macromolecular prodrugs of ciprofloxacin for extended release and enhanced bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486265/),1/[hμgml],164,20930,DB00537,Ciprofloxacin
,29486265,area under the curve,"HPC-CIP conjugate 2 and HEC-CIP conjugate 6 exhibited half-lives of 10.87 and 11.71h, respectively with area under the curve values of 164 and 175hμgmL-1, respectively, indicating enhanced bioavailability and improved pharmacokinetic profiles in animal model.",Design of cellulose ether-based macromolecular prodrugs of ciprofloxacin for extended release and enhanced bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486265/),1/[hμgml],175,20931,DB00537,Ciprofloxacin
,3322752,peak serum level,The peak serum level of ciprofloxacin at the oral dose of 20 mg/kg was 0.43 mg/l which was well above the MIC values for E. coli but not for Bact. fragilis.,Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3322752/),[mg] / [l],0.43,21332,DB00537,Ciprofloxacin
,12485362,time to peak concentration (tmax,"Results indicated that absorption rate was slow, peak concentration was higher (P < 0.05), and the time to peak concentration (tmax congruent with 1.5 h) was significantly longer (P < 0.05) for liposome-encapsulated enrofloxacin (LEE) when compared with free enrofloxacin.",Comparative pharmacokinetics of enrofloxacin and tissue concentrations of parent drug and ciprofloxacin after intramuscular administrations of free and liposome-encapsulated enrofloxacin in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485362/),h,1.5,21456,DB00537,Ciprofloxacin
,12485362,elimination half-life (t1/2beta,Values of elimination half-life (t1/2beta = 12.9 h) and mean residence time (MRT = 17.6 h) of liposome-encapsulated enrofloxacin were longer (P < 0.05) and total clearance (Cl = 0.43 l/h/kg) was lower than those of free form.,Comparative pharmacokinetics of enrofloxacin and tissue concentrations of parent drug and ciprofloxacin after intramuscular administrations of free and liposome-encapsulated enrofloxacin in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485362/),h,12.9,21457,DB00537,Ciprofloxacin
,12485362,mean residence time (MRT,Values of elimination half-life (t1/2beta = 12.9 h) and mean residence time (MRT = 17.6 h) of liposome-encapsulated enrofloxacin were longer (P < 0.05) and total clearance (Cl = 0.43 l/h/kg) was lower than those of free form.,Comparative pharmacokinetics of enrofloxacin and tissue concentrations of parent drug and ciprofloxacin after intramuscular administrations of free and liposome-encapsulated enrofloxacin in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485362/),h,17.6,21458,DB00537,Ciprofloxacin
,12485362,total clearance (Cl,Values of elimination half-life (t1/2beta = 12.9 h) and mean residence time (MRT = 17.6 h) of liposome-encapsulated enrofloxacin were longer (P < 0.05) and total clearance (Cl = 0.43 l/h/kg) was lower than those of free form.,Comparative pharmacokinetics of enrofloxacin and tissue concentrations of parent drug and ciprofloxacin after intramuscular administrations of free and liposome-encapsulated enrofloxacin in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485362/),[l] / [h·kg],0.43,21459,DB00537,Ciprofloxacin
,12485362,distribution volume at steady-state (Vd(ss),"Moreover, the distribution volume at steady-state (Vd(ss) = 14.4 l/kg) of enrofloxacin administered encapsulated into liposomes was significantly higher (P < 0.05) than that of free enrofloxacin (FE).",Comparative pharmacokinetics of enrofloxacin and tissue concentrations of parent drug and ciprofloxacin after intramuscular administrations of free and liposome-encapsulated enrofloxacin in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485362/),[l] / [kg],14.4,21460,DB00537,Ciprofloxacin
≤,30025351,MIC,The preliminary results indicated that all mono-isatin-ciprofloxacin hybrids exhibited excellent antibacterial activities with MIC ranging from ≤0.03 to 0.5 μg/mL against most of the tested strains.,"Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0,21477,DB00537,Ciprofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.10,21478,DB00537,Ciprofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.5,21479,DB00537,Ciprofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.78,21480,DB00537,Ciprofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.39,21481,DB00537,Ciprofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],2.0,21482,DB00537,Ciprofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],32,21483,DB00537,Ciprofloxacin
>,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],128,21484,DB00537,Ciprofloxacin
,30025351,CC50,"Both hybrid 3b and 3d with low cytotoxicity (CC50: 64 and 256 μg/mL) also showed acceptable metabolic stability and in vivo PK properties, could act as leads for further optimization.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],64,21485,DB00537,Ciprofloxacin
,30025351,CC50,"Both hybrid 3b and 3d with low cytotoxicity (CC50: 64 and 256 μg/mL) also showed acceptable metabolic stability and in vivo PK properties, could act as leads for further optimization.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],256,21486,DB00537,Ciprofloxacin
,8787870,elimination rates,"The elimination rates of ciprofloxacin were 0.126 +/- 0.084 micrograms.min-1.cm-2 in the cecum and 0.264 +/- 0.126, 0.11 +/- 0.07, and 0.21 +/- 0.141 micrograms.min-1.cm-2 in the proximal colon, distal colon, and sigmoid colon, respectively.",Excretion of ciprofloxacin into the large bowel of the rabbit. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787870/),[μg] / [(cm)^2·min],0.126,22582,DB00537,Ciprofloxacin
,8787870,elimination rates,"The elimination rates of ciprofloxacin were 0.126 +/- 0.084 micrograms.min-1.cm-2 in the cecum and 0.264 +/- 0.126, 0.11 +/- 0.07, and 0.21 +/- 0.141 micrograms.min-1.cm-2 in the proximal colon, distal colon, and sigmoid colon, respectively.",Excretion of ciprofloxacin into the large bowel of the rabbit. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787870/),[μg] / [(cm)^2·min],0.264,22583,DB00537,Ciprofloxacin
,8787870,elimination rates,"The elimination rates of ciprofloxacin were 0.126 +/- 0.084 micrograms.min-1.cm-2 in the cecum and 0.264 +/- 0.126, 0.11 +/- 0.07, and 0.21 +/- 0.141 micrograms.min-1.cm-2 in the proximal colon, distal colon, and sigmoid colon, respectively.",Excretion of ciprofloxacin into the large bowel of the rabbit. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787870/),[μg] / [(cm)^2·min],0.11,22584,DB00537,Ciprofloxacin
,8787870,elimination rates,"The elimination rates of ciprofloxacin were 0.126 +/- 0.084 micrograms.min-1.cm-2 in the cecum and 0.264 +/- 0.126, 0.11 +/- 0.07, and 0.21 +/- 0.141 micrograms.min-1.cm-2 in the proximal colon, distal colon, and sigmoid colon, respectively.",Excretion of ciprofloxacin into the large bowel of the rabbit. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787870/),[μg] / [(cm)^2·min],0.21,22585,DB00537,Ciprofloxacin
,2504591,absolute bioavailability,The absolute bioavailability of an oral dose was greater in the elderly than in the young subjects at both 250 mg (72 versus 58%; p less than 0.05) and 500 mg (79 versus 63%; p less than 0.05).,Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504591/),%,72,22766,DB00537,Ciprofloxacin
,2504591,absolute bioavailability,The absolute bioavailability of an oral dose was greater in the elderly than in the young subjects at both 250 mg (72 versus 58%; p less than 0.05) and 500 mg (79 versus 63%; p less than 0.05).,Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504591/),%,58,22767,DB00537,Ciprofloxacin
,2504591,absolute bioavailability,The absolute bioavailability of an oral dose was greater in the elderly than in the young subjects at both 250 mg (72 versus 58%; p less than 0.05) and 500 mg (79 versus 63%; p less than 0.05).,Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504591/),%,79,22768,DB00537,Ciprofloxacin
,2504591,absolute bioavailability,The absolute bioavailability of an oral dose was greater in the elderly than in the young subjects at both 250 mg (72 versus 58%; p less than 0.05) and 500 mg (79 versus 63%; p less than 0.05).,Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504591/),%,63,22769,DB00537,Ciprofloxacin
,19168412,elimination half-life,The elimination half-life of 3.00 +/- 0.21 and 3.28 +/- 0.11 h was calculated for both brands.,Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19168412/),h,3.00,23366,DB00537,Ciprofloxacin
,19168412,elimination half-life,The elimination half-life of 3.00 +/- 0.21 and 3.28 +/- 0.11 h was calculated for both brands.,Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19168412/),h,3.28,23367,DB00537,Ciprofloxacin
,19168412,peak plasma concentrations,The peak plasma concentrations of (3.59 +/-0.26 ug/mL) and (3.34 +/- 1.20 ug/mL) was attained in about 1.48 +/- 0.11 hour and 1.47+/-0.05 for both Test and Reference ciprofloxacin respectively.,Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19168412/),[ug] / [ml],3.59,23368,DB00537,Ciprofloxacin
,19168412,peak plasma concentrations,The peak plasma concentrations of (3.59 +/-0.26 ug/mL) and (3.34 +/- 1.20 ug/mL) was attained in about 1.48 +/- 0.11 hour and 1.47+/-0.05 for both Test and Reference ciprofloxacin respectively.,Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19168412/),[ug] / [ml],3.34,23369,DB00537,Ciprofloxacin
,19168412,peak plasma concentrations,The peak plasma concentrations of (3.59 +/-0.26 ug/mL) and (3.34 +/- 1.20 ug/mL) was attained in about 1.48 +/- 0.11 hour and 1.47+/-0.05 for both Test and Reference ciprofloxacin respectively.,Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19168412/),,1,23370,DB00537,Ciprofloxacin
,19168412,total area under the curve (AUC O-alpha),"The mean +/- SE values for total area under the curve (AUC O-alpha) were 26.15 +/- 1.35, and 24.95 +/- 0.93 hmg/1 for both test and reference tablets respectively.",Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19168412/),hmg,26.15,23371,DB00537,Ciprofloxacin
,19168412,total area under the curve (AUC O-alpha),"The mean +/- SE values for total area under the curve (AUC O-alpha) were 26.15 +/- 1.35, and 24.95 +/- 0.93 hmg/1 for both test and reference tablets respectively.",Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19168412/),hmg,24.95,23372,DB00537,Ciprofloxacin
,19168412,clearance,The mean +/- SE values of clearance were 24.83+/-1.63 and 24.73+/-1.11 1/h for both formulations respectively.,Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19168412/),[1] / [h],24.83,23373,DB00537,Ciprofloxacin
,19168412,clearance,The mean +/- SE values of clearance were 24.83+/-1.63 and 24.73+/-1.11 1/h for both formulations respectively.,Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19168412/),[1] / [h],24.73,23374,DB00537,Ciprofloxacin
,16669863,terminal half-life (t1/2),"Following i.v. administration, orbifloxacin had a terminal half-life (t1/2) of 5.08 h and a volume of distribution (V(d(SS))) of 1.58 L/kg.",The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669863/),h,5.08,24223,DB00537,Ciprofloxacin
,16669863,volume of distribution (V(d(SS))),"Following i.v. administration, orbifloxacin had a terminal half-life (t1/2) of 5.08 h and a volume of distribution (V(d(SS))) of 1.58 L/kg.",The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669863/),[l] / [kg],1.58,24224,DB00537,Ciprofloxacin
,16669863,maximum plasma concentration (Cmax),"Following oral administration, the average maximum plasma concentration (Cmax) was 1.25 microg/mL with a t1/2 of 3.42 h.",The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669863/),[μg] / [ml],1.25,24225,DB00537,Ciprofloxacin
,16669863,t1/2,"Following oral administration, the average maximum plasma concentration (Cmax) was 1.25 microg/mL with a t1/2 of 3.42 h.",The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669863/),h,3.42,24226,DB00537,Ciprofloxacin
,16669863,Systemic bioavailability,Systemic bioavailability was 68.35%. Plasma protein binding was 20.64%.,The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669863/),%,68.35,24227,DB00537,Ciprofloxacin
,16669863,Plasma protein binding,Systemic bioavailability was 68.35%. Plasma protein binding was 20.64%.,The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669863/),%,20.64,24228,DB00537,Ciprofloxacin
,16669863,octanol:water partition coefficient,The octanol:water partition coefficient (pH 7.4) was 0.2 +/- 0.11.,The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669863/),,0.2,24229,DB00537,Ciprofloxacin
,2756350,bioavailability,"After oral administration there is, furthermore, an increased AUC and Cmax, which are explained by a higher bioavailability of an oral dose in the elderly (72.4%) as compared to young volunteers (58.4%).",Influence of age on the pharmacokinetics of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2756350/),%,72.4,24684,DB00537,Ciprofloxacin
,2756350,bioavailability,"After oral administration there is, furthermore, an increased AUC and Cmax, which are explained by a higher bioavailability of an oral dose in the elderly (72.4%) as compared to young volunteers (58.4%).",Influence of age on the pharmacokinetics of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2756350/),%,58.4,24685,DB00537,Ciprofloxacin
,10606835,sputum to plasma ratios,The mean sputum to plasma ratios of both ciprofloxacin and fleroxacin were approximately 1 on both days 1 and 3.,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),,1,24771,DB00537,Ciprofloxacin
,10606835,accumulation index,Fleroxacin accumulated in plasma (accumulation index 1.52+/-0.07) and sputum (accumulation index 1.79+/-0.39) from day 1 to day 3.,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),,1.52,24772,DB00537,Ciprofloxacin
,10606835,accumulation index,Fleroxacin accumulated in plasma (accumulation index 1.52+/-0.07) and sputum (accumulation index 1.79+/-0.39) from day 1 to day 3.,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),,1.79,24773,DB00537,Ciprofloxacin
,10606835,half life,Accumulation did not occur for ciprofloxacin because the dose interval (12 h) was considerable longer than its half life (3-4 h).,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),h,3-4,24774,DB00537,Ciprofloxacin
,10606835,sputum to plasma ratio,The sputum to plasma ratio of ciprofloxacin and fleroxacin is approximately 1.,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),,1,24775,DB00537,Ciprofloxacin
,31061152,time to culture conversion,"New-generation fluoroquinolones showed a faster time to culture conversion (median 16 versus 40 weeks, P = 0.012).",Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31061152/),weeks,16,25010,DB00537,Ciprofloxacin
,31061152,time to culture conversion,"New-generation fluoroquinolones showed a faster time to culture conversion (median 16 versus 40 weeks, P = 0.012).",Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31061152/),weeks,40,25011,DB00537,Ciprofloxacin
,26779495,MIC,The 101 E. coli strains with MIC closest to the MIC50 (0.05 μg/mL) were submitted for serotype identification.,Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),[μg] / [ml],0.05,25485,DB00537,Ciprofloxacin
,26779495,MIC50,The 101 E. coli strains with MIC closest to the MIC50 (0.05 μg/mL) were submitted for serotype identification.,Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),[μg] / [ml],0.05,25486,DB00537,Ciprofloxacin
,26779495,peak concentration (C max),"For intestinal contents after oral administration, the peak concentration (C max), the time when the maximum concentration reached (T max), and the area under the concentration-time curve (AUC) were 21.69-31.69 μg/mL, 1.13-1.23 h, and 228.97-444.86 μg h/mL, respectively.",Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),[μg] / [ml],21.69-31.69,25487,DB00537,Ciprofloxacin
,26779495,time when the maximum concentration reached (T max),"For intestinal contents after oral administration, the peak concentration (C max), the time when the maximum concentration reached (T max), and the area under the concentration-time curve (AUC) were 21.69-31.69 μg/mL, 1.13-1.23 h, and 228.97-444.86 μg h/mL, respectively.",Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),h,1.13-1.23,25488,DB00537,Ciprofloxacin
,26779495,area under the concentration-time curve (AUC),"For intestinal contents after oral administration, the peak concentration (C max), the time when the maximum concentration reached (T max), and the area under the concentration-time curve (AUC) were 21.69-31.69 μg/mL, 1.13-1.23 h, and 228.97-444.86 μg h/mL, respectively.",Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),[h·μg] / [ml],228.97-444.86,25489,DB00537,Ciprofloxacin
,26779495,MIC,"The MIC and minimal bactericidal concentration (MBC) of enrofloxacin against E. coli (Anhui 112) in Mueller-Hinton (MH) broth and intestinal contents were determined to be similar, 0.25 and 0.5 μg/mL respectively.",Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),[μg] / [ml],0.25,25490,DB00537,Ciprofloxacin
,26779495,minimal bactericidal concentration (MBC),"The MIC and minimal bactericidal concentration (MBC) of enrofloxacin against E. coli (Anhui 112) in Mueller-Hinton (MH) broth and intestinal contents were determined to be similar, 0.25 and 0.5 μg/mL respectively.",Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),[μg] / [ml],0.5,25491,DB00537,Ciprofloxacin
,26779495,area under concentration-time curve/MIC ratios (AUC0-24 h/MIC),"The ex vivo growth inhibition data were fitted to the sigmoid E max (Hill) equation to provide values for intestinal contents of 24 h area under concentration-time curve/MIC ratios (AUC0-24 h/MIC) producing, bacteriostasis (624.94 h), bactericidal activity (1065.93 h) and bacterial eradication (1343.81 h).",Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),h,624.94,25492,DB00537,Ciprofloxacin
,26779495,area under concentration-time curve/MIC ratios (AUC0-24 h/MIC),"The ex vivo growth inhibition data were fitted to the sigmoid E max (Hill) equation to provide values for intestinal contents of 24 h area under concentration-time curve/MIC ratios (AUC0-24 h/MIC) producing, bacteriostasis (624.94 h), bactericidal activity (1065.93 h) and bacterial eradication (1343.81 h).",Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),h,1065.93,25493,DB00537,Ciprofloxacin
,26779495,area under concentration-time curve/MIC ratios (AUC0-24 h/MIC),"The ex vivo growth inhibition data were fitted to the sigmoid E max (Hill) equation to provide values for intestinal contents of 24 h area under concentration-time curve/MIC ratios (AUC0-24 h/MIC) producing, bacteriostasis (624.94 h), bactericidal activity (1065.93 h) and bacterial eradication (1343.81 h).",Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779495/),h,1343.81,25494,DB00537,Ciprofloxacin
less,2109576,excretion ratios,"In dogs, on the other hand, the excretion ratios were less than unity (0.608 and 0.456) both without and with probenecid, and so were not affected by probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,0.608,26050,DB00537,Ciprofloxacin
,2109576,excretion ratios,"In dogs, on the other hand, the excretion ratios were less than unity (0.608 and 0.456) both without and with probenecid, and so were not affected by probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,0.456,26051,DB00537,Ciprofloxacin
,2109576,excretion ratio,"The excretion ratio without probenecid was 1.13, which was significantly decreased to 0.750 with probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,1.13,26052,DB00537,Ciprofloxacin
,2109576,excretion ratio,"The excretion ratio without probenecid was 1.13, which was significantly decreased to 0.750 with probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,0.750,26053,DB00537,Ciprofloxacin
,21816053,ultrafiltration rate,CVVHDF was performed at prescribed dialysate rates of 1 or 2 L/hr and ultrafiltration rate of 2 L/hr.,An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),[l] / [h],2,26385,DB00537,Ciprofloxacin
,21816053,blood flow rate,"The blood flow rate was 200 ml/min, achieved using a Gambro blood pump and Hospal AN69HF haemofilter.",An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),[ml] / [min],200,26386,DB00537,Ciprofloxacin
,21816053,t1/2,"CVVHDF resulted in a median ciprofloxacin t1/2 of 13.8 (range 5.15-39.4) hr, median TBC of 9.90 (range 3.10-13.2) L/hr, a median Vdss of 125 (range 79.5-554) L, a CVVHDF clearance of 2.47+/-0.29 L/hr and a clearance of creatinine (Clcr) of 2.66+/-0.25 L/hr.",An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),h,13.8,26387,DB00537,Ciprofloxacin
,21816053,TBC,"CVVHDF resulted in a median ciprofloxacin t1/2 of 13.8 (range 5.15-39.4) hr, median TBC of 9.90 (range 3.10-13.2) L/hr, a median Vdss of 125 (range 79.5-554) L, a CVVHDF clearance of 2.47+/-0.29 L/hr and a clearance of creatinine (Clcr) of 2.66+/-0.25 L/hr.",An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),[l] / [h],9.90,26388,DB00537,Ciprofloxacin
,21816053,Vdss,"CVVHDF resulted in a median ciprofloxacin t1/2 of 13.8 (range 5.15-39.4) hr, median TBC of 9.90 (range 3.10-13.2) L/hr, a median Vdss of 125 (range 79.5-554) L, a CVVHDF clearance of 2.47+/-0.29 L/hr and a clearance of creatinine (Clcr) of 2.66+/-0.25 L/hr.",An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),l,125,26389,DB00537,Ciprofloxacin
,21816053,clearance,"CVVHDF resulted in a median ciprofloxacin t1/2 of 13.8 (range 5.15-39.4) hr, median TBC of 9.90 (range 3.10-13.2) L/hr, a median Vdss of 125 (range 79.5-554) L, a CVVHDF clearance of 2.47+/-0.29 L/hr and a clearance of creatinine (Clcr) of 2.66+/-0.25 L/hr.",An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),[l] / [h],2.47,26390,DB00537,Ciprofloxacin
,21816053,flow rate,"Thus CVVHDF, at an average flow rate of ~3.5 L/hr, was responsible for removing 26% of ciprofloxacin cleared.",An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),[l] / [h],3.5,26391,DB00537,Ciprofloxacin
,21816053,Cpmax/MIC,"At the dose rate of 400 mg every 12 hr, the median estimated Cpmax/MIC and AUC0-24/MIC ratios were 10.3 and 161 respectively (for a MIC of 0.5 mg/L) and exceed the proposed criteria of >10 for Cpmax/MIC and > 100 for AUC0-24/MIC.",An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),,10.3,26392,DB00537,Ciprofloxacin
,21816053,AUC0-24/MIC ratios,"At the dose rate of 400 mg every 12 hr, the median estimated Cpmax/MIC and AUC0-24/MIC ratios were 10.3 and 161 respectively (for a MIC of 0.5 mg/L) and exceed the proposed criteria of >10 for Cpmax/MIC and > 100 for AUC0-24/MIC.",An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),,161,26393,DB00537,Ciprofloxacin
,21816053,MIC,"At the dose rate of 400 mg every 12 hr, the median estimated Cpmax/MIC and AUC0-24/MIC ratios were 10.3 and 161 respectively (for a MIC of 0.5 mg/L) and exceed the proposed criteria of >10 for Cpmax/MIC and > 100 for AUC0-24/MIC.",An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21816053/),[mg] / [l],0.5,26394,DB00537,Ciprofloxacin
,16962551,concentrations,"The highest average concentrations of enrofloxacin in liver, muscle, gill, and hemolymph were 3.93, 12.42, 16.73, and 11.04 microg/g (ml), respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[g·μg] / [ml],3.93,28138,DB00537,Ciprofloxacin
,16962551,concentrations,"The highest average concentrations of enrofloxacin in liver, muscle, gill, and hemolymph were 3.93, 12.42, 16.73, and 11.04 microg/g (ml), respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[g·μg] / [ml],12.42,28139,DB00537,Ciprofloxacin
,16962551,concentrations,"The highest average concentrations of enrofloxacin in liver, muscle, gill, and hemolymph were 3.93, 12.42, 16.73, and 11.04 microg/g (ml), respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[g·μg] / [ml],16.73,28140,DB00537,Ciprofloxacin
,16962551,concentrations,"The highest average concentrations of enrofloxacin in liver, muscle, gill, and hemolymph were 3.93, 12.42, 16.73, and 11.04 microg/g (ml), respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[g·μg] / [ml],11.04,28141,DB00537,Ciprofloxacin
,16962551,elimination half-lives (t(1/2beta)),"The elimination half-lives (t(1/2beta)) for enrofloxacin were 92.42, 64.86, 38.80, and 52.39 h, respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),h,92.42,28142,DB00537,Ciprofloxacin
,16962551,elimination half-lives (t(1/2beta)),"The elimination half-lives (t(1/2beta)) for enrofloxacin were 92.42, 64.86, 38.80, and 52.39 h, respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),h,64.86,28143,DB00537,Ciprofloxacin
,16962551,elimination half-lives (t(1/2beta)),"The elimination half-lives (t(1/2beta)) for enrofloxacin were 92.42, 64.86, 38.80, and 52.39 h, respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),h,38.80,28144,DB00537,Ciprofloxacin
,16962551,elimination half-lives (t(1/2beta)),"The elimination half-lives (t(1/2beta)) for enrofloxacin were 92.42, 64.86, 38.80, and 52.39 h, respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),h,52.39,28145,DB00537,Ciprofloxacin
,16962551,AUC(0-infinity),"The AUC(0-infinity) values for enrofloxacin were 304.80, 260.74, 288.30, and 269.24 microg h/ml, respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[h·μg] / [ml],304.80,28146,DB00537,Ciprofloxacin
,16962551,AUC(0-infinity),"The AUC(0-infinity) values for enrofloxacin were 304.80, 260.74, 288.30, and 269.24 microg h/ml, respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[h·μg] / [ml],260.74,28147,DB00537,Ciprofloxacin
,16962551,AUC(0-infinity),"The AUC(0-infinity) values for enrofloxacin were 304.80, 260.74, 288.30, and 269.24 microg h/ml, respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[h·μg] / [ml],288.30,28148,DB00537,Ciprofloxacin
,16962551,AUC(0-infinity),"The AUC(0-infinity) values for enrofloxacin were 304.80, 260.74, 288.30, and 269.24 microg h/ml, respectively.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[h·μg] / [ml],269.24,28149,DB00537,Ciprofloxacin
,16962551,Cmax,"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[g·μg] / [ml],0.52,28150,DB00537,Ciprofloxacin
,16962551,t(1/2beta),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),h,38.38,28151,DB00537,Ciprofloxacin
,16962551,t(1/2beta),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),h,65.36,28152,DB00537,Ciprofloxacin
,16962551,t(1/2beta),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),h,112.88,28153,DB00537,Ciprofloxacin
,16962551,t(1/2beta),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[g·μg] / [ml],0.30,28154,DB00537,Ciprofloxacin
,16962551,t(1/2beta),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),h,93.33,28155,DB00537,Ciprofloxacin
,16962551,AUC(0-infinity),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[h·μg] / [ml],35.06,28156,DB00537,Ciprofloxacin
,16962551,AUC(0-infinity),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[h·μg] / [ml],11.57,28157,DB00537,Ciprofloxacin
,16962551,AUC(0-infinity),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[g·μg] / [ml],0.30,28158,DB00537,Ciprofloxacin
,16962551,AUC(0-infinity),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),h,93.33,28159,DB00537,Ciprofloxacin
,16962551,AUC(0-infinity),"The respective values of main pharmacokinetics parameters Cmax, t(1/2beta), and AUC(0-infinity) were 0.52 microg/g (ml), 38.38 h, and 35.06 microg h/ml for liver; 0.24 microg/g (ml), 65.36 h, and 25.64 microg h/ml for muscle; 0.10 microg/g (ml), 112.88 h, and 11.57 microg h/ml for gill; and 0.30 microg/g (ml), 93.33 h, and 39.99 microg h/ml for hemolymph.","Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962551/),[h·μg] / [ml],39.99,28160,DB00537,Ciprofloxacin
,2218417,bioavailability,"Following oral administration, norfloxacin and ciprofloxacin are well absorbed and the bioavailability of ofloxacin is almost 100%.","The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2218417/),%,100,28613,DB00537,Ciprofloxacin
,2218417,Half-lives,Half-lives of the drugs are 3-6 hours and they may therefore be administrated twice daily.,"The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2218417/),h,3-6,28614,DB00537,Ciprofloxacin
,15523125,Peak values,"Peak values on days 1, 3 and 7 were [mean +/- SEM] 2.3 +/- 0.39 microg/mL, 3.0 +/- 0.44 microg/mL and 2.7 +/- 0.39 microg/mL respectively (P >0.05).",Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523125/),[μg] / [ml],2.3,29044,DB00537,Ciprofloxacin
,15523125,Peak values,"Peak values on days 1, 3 and 7 were [mean +/- SEM] 2.3 +/- 0.39 microg/mL, 3.0 +/- 0.44 microg/mL and 2.7 +/- 0.39 microg/mL respectively (P >0.05).",Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523125/),[μg] / [ml],3.0,29045,DB00537,Ciprofloxacin
,15523125,Peak values,"Peak values on days 1, 3 and 7 were [mean +/- SEM] 2.3 +/- 0.39 microg/mL, 3.0 +/- 0.44 microg/mL and 2.7 +/- 0.39 microg/mL respectively (P >0.05).",Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523125/),[μg] / [ml],2.7,29046,DB00537,Ciprofloxacin
,15523125,Trough,Trough values on these days were 0.7 +/- 0.14 microg/mL 0.8 +/- 0.14 microg/mL and 1.0 +/- 0.21 microg/mL respectively (P > 0.05).,Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523125/),[μg] / [ml],0.7,29047,DB00537,Ciprofloxacin
,15523125,Trough,Trough values on these days were 0.7 +/- 0.14 microg/mL 0.8 +/- 0.14 microg/mL and 1.0 +/- 0.21 microg/mL respectively (P > 0.05).,Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523125/),[μg] / [ml],0.8,29048,DB00537,Ciprofloxacin
,15523125,Trough,Trough values on these days were 0.7 +/- 0.14 microg/mL 0.8 +/- 0.14 microg/mL and 1.0 +/- 0.21 microg/mL respectively (P > 0.05).,Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523125/),[μg] / [ml],1.0,29049,DB00537,Ciprofloxacin
,18603456,distribution half-life (t(1/2alpha)),"Following a single IV injection, the plasma difloxacin concentration-time curve was best described by a two-compartment open model, with a distribution half-life (t(1/2alpha)) of 0.22+/-0.02h and an elimination half-life (t(1/2beta)) of 2.97+/-0.31h.",Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),h,0.22,29495,DB00537,Ciprofloxacin
,18603456,elimination half-life (t(1/2beta)),"Following a single IV injection, the plasma difloxacin concentration-time curve was best described by a two-compartment open model, with a distribution half-life (t(1/2alpha)) of 0.22+/-0.02h and an elimination half-life (t(1/2beta)) of 2.97+/-0.31h.",Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),h,2.97,29496,DB00537,Ciprofloxacin
,18603456,Steady-state volume of distribution (V(dss)),"Steady-state volume of distribution (V(dss)) and total body clearance (Cl(tot)) were 1.02+/-0.21L/kg and 0.24+/-0.07L/kg/h, respectively.",Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),[l] / [kg],1.02,29497,DB00537,Ciprofloxacin
,18603456,total body clearance (Cl(tot)),"Steady-state volume of distribution (V(dss)) and total body clearance (Cl(tot)) were 1.02+/-0.21L/kg and 0.24+/-0.07L/kg/h, respectively.",Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),[l] / [h·kg],0.24,29498,DB00537,Ciprofloxacin
,18603456,absorption half-life (t(1)(/)(2ab)),"Following IM administration, the absorption half-life (t(1)(/)(2ab)) and the mean absorption time (MAT) were 0.44+/-0.03h and 1.53+/-0.22h, respectively.",Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),h,0.44,29499,DB00537,Ciprofloxacin
,18603456,mean absorption time (MAT),"Following IM administration, the absorption half-life (t(1)(/)(2ab)) and the mean absorption time (MAT) were 0.44+/-0.03h and 1.53+/-0.22h, respectively.",Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),h,1.53,29500,DB00537,Ciprofloxacin
,18603456,peak plasma concentration (C(max)),The peak plasma concentration (C(max)) of 2.84+/-0.34microg/mL was achieved at 1.42+/-0.21h.,Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),[μg] / [ml],2.84,29501,DB00537,Ciprofloxacin
,18603456,elimination half-life (t(1/2el)),"The elimination half-life (t(1/2el)) and the mean residence time (MRT) was 3.46+/-0.42h and 5.61+/-0.23h, respectively.",Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),h,3.46,29502,DB00537,Ciprofloxacin
,18603456,mean residence time (MRT),"The elimination half-life (t(1/2el)) and the mean residence time (MRT) was 3.46+/-0.42h and 5.61+/-0.23h, respectively.",Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),h,5.61,29503,DB00537,Ciprofloxacin
,18603456,plasma protein binding,The in vitro plasma protein binding of difloxacin ranged from 28-43% and the absolute bioavailability following IM administration was 93.51+/-11.63%.,Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),%,28-43,29504,DB00537,Ciprofloxacin
,18603456,absolute bioavailability,The in vitro plasma protein binding of difloxacin ranged from 28-43% and the absolute bioavailability following IM administration was 93.51+/-11.63%.,Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603456/),%,93.51,29505,DB00537,Ciprofloxacin
,9210675,peak concentration of drug in serum (Cmax),"Mean values (+/- standard deviations [SD]) for p.o. ciprofloxacin were as follows: peak concentration of drug in serum (Cmax), 2.94 +/- 0.51 microg/ml; time to Cmax, 1.38 +/- 0.43 h; area under the concentration-time curve from 0 to 12 h (AUC(0-12)), 12.13 +/- 3.21 microg x h/ml; and half-life (t(1/2)), 3.86 +/- 0.48 h.",Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210675/),[μg] / [ml],2.94,31048,DB00537,Ciprofloxacin
,9210675,time to Cmax,"Mean values (+/- standard deviations [SD]) for p.o. ciprofloxacin were as follows: peak concentration of drug in serum (Cmax), 2.94 +/- 0.51 microg/ml; time to Cmax, 1.38 +/- 0.43 h; area under the concentration-time curve from 0 to 12 h (AUC(0-12)), 12.13 +/- 3.21 microg x h/ml; and half-life (t(1/2)), 3.86 +/- 0.48 h.",Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210675/),h,1.38,31049,DB00537,Ciprofloxacin
,9210675,area under the concentration-time curve from 0 to 12 h (AUC(0-12)),"Mean values (+/- standard deviations [SD]) for p.o. ciprofloxacin were as follows: peak concentration of drug in serum (Cmax), 2.94 +/- 0.51 microg/ml; time to Cmax, 1.38 +/- 0.43 h; area under the concentration-time curve from 0 to 12 h (AUC(0-12)), 12.13 +/- 3.21 microg x h/ml; and half-life (t(1/2)), 3.86 +/- 0.48 h.",Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210675/),[h·μg] / [ml],12.13,31050,DB00537,Ciprofloxacin
,9210675,half-life (t(1/2)),"Mean values (+/- standard deviations [SD]) for p.o. ciprofloxacin were as follows: peak concentration of drug in serum (Cmax), 2.94 +/- 0.51 microg/ml; time to Cmax, 1.38 +/- 0.43 h; area under the concentration-time curve from 0 to 12 h (AUC(0-12)), 12.13 +/- 3.21 microg x h/ml; and half-life (t(1/2)), 3.86 +/- 0.48 h.",Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210675/),h,3.86,31051,DB00537,Ciprofloxacin
,9210675,Cmax,"Mean values (+/- SD) for i.v. ciprofloxacin were as follows: Cmax, 3.61 +/- 0.82 microg/ml; time to Cmax, 1.0 h; AUC(0-12), 11.92 +/- 2.92 microg x h/ml; and t(1/2), 3.98 +/- 0.94 h.",Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210675/),[μg] / [ml],3.61,31052,DB00537,Ciprofloxacin
,9210675,time to Cmax,"Mean values (+/- SD) for i.v. ciprofloxacin were as follows: Cmax, 3.61 +/- 0.82 microg/ml; time to Cmax, 1.0 h; AUC(0-12), 11.92 +/- 2.92 microg x h/ml; and t(1/2), 3.98 +/- 0.94 h.",Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210675/),h,1.0,31053,DB00537,Ciprofloxacin
,9210675,AUC(0-12),"Mean values (+/- SD) for i.v. ciprofloxacin were as follows: Cmax, 3.61 +/- 0.82 microg/ml; time to Cmax, 1.0 h; AUC(0-12), 11.92 +/- 2.92 microg x h/ml; and t(1/2), 3.98 +/- 0.94 h.",Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210675/),[h·μg] / [ml],11.92,31054,DB00537,Ciprofloxacin
,9210675,t(1/2),"Mean values (+/- SD) for i.v. ciprofloxacin were as follows: Cmax, 3.61 +/- 0.82 microg/ml; time to Cmax, 1.0 h; AUC(0-12), 11.92 +/- 2.92 microg x h/ml; and t(1/2), 3.98 +/- 0.94 h.",Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210675/),h,3.98,31055,DB00537,Ciprofloxacin
,9210675,percent absolute bioavailability,"The mean percent absolute bioavailability for ciprofloxacin was calculated to be 82% +/- 13%, similar to the value for healthy volunteers.",Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210675/),%,82,31056,DB00537,Ciprofloxacin
,12016861,recoveries,"The mean recoveries were 74.76% in plasma and 82.43% in cerebrospinal fluid, with the lowest detectable limits of 10 micrograms.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),%,74.76,31685,DB00537,Ciprofloxacin
,12016861,recoveries,"The mean recoveries were 74.76% in plasma and 82.43% in cerebrospinal fluid, with the lowest detectable limits of 10 micrograms.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),%,82.43,31686,DB00537,Ciprofloxacin
,12016861,blood Ke,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),1/[h],0.12,31687,DB00537,Ciprofloxacin
,12016861,T1/2,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),h,6.05,31688,DB00537,Ciprofloxacin
,12016861,Tmax,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),h,1.05,31689,DB00537,Ciprofloxacin
,12016861,Cmax,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[mg] / [l],3.67,31690,DB00537,Ciprofloxacin
,12016861,AUC,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),mg,33.43,31691,DB00537,Ciprofloxacin
,12016861,CLs,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[l] / [h],9.46,31692,DB00537,Ciprofloxacin
,12016861,Vd,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),l,77.49,31693,DB00537,Ciprofloxacin
,12016861,Ke,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),1/[h],0.11,31694,DB00537,Ciprofloxacin
,12016861,T1/2,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),h,6.95,31695,DB00537,Ciprofloxacin
,12016861,Tmax,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),h,3.56,31696,DB00537,Ciprofloxacin
,12016861,Cmax,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[mg] / [l],1.68,31697,DB00537,Ciprofloxacin
,12016861,AUC,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[h·mg] / [l],23.70,31698,DB00537,Ciprofloxacin
,12016861,CLs,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[l] / [h],13.70,31699,DB00537,Ciprofloxacin
,12016861,Vd,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),l,126.61,31700,DB00537,Ciprofloxacin
,26596287,bioavailability,"The s.c. bioavailability of ER was 52.36 ± 4.24% and 72.12 ± 5.39% at doses of 5.0 and 7.5 mg/kg BW, respectively.",Dispositions of enrofloxacin and its major metabolite ciprofloxacin in Thai swamp buffaloes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26596287/),%,52.36,31853,DB00537,Ciprofloxacin
,26596287,bioavailability,"The s.c. bioavailability of ER was 52.36 ± 4.24% and 72.12 ± 5.39% at doses of 5.0 and 7.5 mg/kg BW, respectively.",Dispositions of enrofloxacin and its major metabolite ciprofloxacin in Thai swamp buffaloes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26596287/),%,72.12,31854,DB00537,Ciprofloxacin
,15257070,terminal elimination half-life,The terminal elimination half-life of the compound was (mean +/- SD) 5.0 +/- 2.8 hours.,A population pharmacokinetic-metabolism model for individualizing ciprofloxacin therapy in ophthalmology. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257070/),h,5.0,32239,DB00537,Ciprofloxacin
,15257070,apparent volume of distribution (Vss/F),The apparent volume of distribution (Vss/F) was calculated to be 122.1 +/- 39.7 L.,A population pharmacokinetic-metabolism model for individualizing ciprofloxacin therapy in ophthalmology. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257070/),l,122.1,32240,DB00537,Ciprofloxacin
,10447832,Vd(ss),"Both antimicrobials were widely distributed in chickens throughout the body with a mean Vd(ss) of 1.98+/-0.18 L/kg for EFX, and 4.04+/-0.69 L/kg for CFX.",Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447832/),[l] / [kg],1.98,32977,DB00537,Ciprofloxacin
,10447832,Vd(ss),"Both antimicrobials were widely distributed in chickens throughout the body with a mean Vd(ss) of 1.98+/-0.18 L/kg for EFX, and 4.04+/-0.69 L/kg for CFX.",Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447832/),[l] / [kg],4.04,32978,DB00537,Ciprofloxacin
,2937812,Peak serum concentrations,"Peak serum concentrations averaged 2.8, 4.5, and 4.6 micrograms/mL respectively at the three doses, well above the mean inhibitory concentrations of most isolates of Pseudomonas aeruginosa.",Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2937812/),[μg] / [ml],2.8,33735,DB00537,Ciprofloxacin
,2937812,Peak serum concentrations,"Peak serum concentrations averaged 2.8, 4.5, and 4.6 micrograms/mL respectively at the three doses, well above the mean inhibitory concentrations of most isolates of Pseudomonas aeruginosa.",Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2937812/),[μg] / [ml],4.5,33736,DB00537,Ciprofloxacin
,2937812,Peak serum concentrations,"Peak serum concentrations averaged 2.8, 4.5, and 4.6 micrograms/mL respectively at the three doses, well above the mean inhibitory concentrations of most isolates of Pseudomonas aeruginosa.",Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2937812/),[μg] / [ml],4.6,33737,DB00537,Ciprofloxacin
,2937812,sputum levels,The range of sputum levels in three patients was 1.1-2.1 micrograms/mL at four hours after the three doses.,Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2937812/),,1.1-2.1,33738,DB00537,Ciprofloxacin
,2937812,serum elimination half-life,The serum elimination half-life was 3.7 hours and was independent of dose.,Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2937812/),h,3.7,33739,DB00537,Ciprofloxacin
,2937812,Urinary recovery,Urinary recovery was 26%; greater than 90% of urinary excretion occurred within the first 12 hours.,Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2937812/),%,26,33740,DB00537,Ciprofloxacin
greater,23772453,volume of distribution,"The volume of distribution was high, greater than 1 in all cases, and highest for danofloxacin, followed by enrofloxacin, then marbofloxacin.","Comparative pharmacokinetics of enrofloxacin, danofloxacin, and marbofloxacin after intravenous and oral administration in Japanese quail (Coturnix coturnix japonica). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23772453/),,1,33887,DB00537,Ciprofloxacin
,2941278,apparent time lag before absorption,As the oral dose increased a slight increase was observed in the apparent time lag before absorption from 0.34 h after 100 mg to 0.53 h after 1000 mg.,Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941278/),h,0.34,34030,DB00537,Ciprofloxacin
,2941278,apparent time lag before absorption,As the oral dose increased a slight increase was observed in the apparent time lag before absorption from 0.34 h after 100 mg to 0.53 h after 1000 mg.,Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941278/),h,0.53,34031,DB00537,Ciprofloxacin
,2941278,serum half-life,The serum half-life after the intravenous dose was 3.2 h.,Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941278/),h,3.2,34032,DB00537,Ciprofloxacin
,2941278,elimination phase distribution volume,The intravenous dose showed an elimination phase distribution volume of 2.76 l/kg and total body clearance of 40.7 l/h.,Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941278/),[l] / [kg],2.76,34033,DB00537,Ciprofloxacin
,2941278,total body clearance,The intravenous dose showed an elimination phase distribution volume of 2.76 l/kg and total body clearance of 40.7 l/h.,Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941278/),[l] / [h],40.7,34034,DB00537,Ciprofloxacin
,2941278,total urinary excretion,The total urinary excretion was 42.2 +/- 15.6% of the dose after the intravenous dose; the figure was lower after the oral doses.,Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941278/),%,42.2,34035,DB00537,Ciprofloxacin
,2941278,bioavailability,The bioavailability of the 100 mg oral dose was 83.7% as calculated from the value of the total area under the serum curve after the same oral and intravenous dose in all 12 subjects.,Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941278/),%,83.7,34036,DB00537,Ciprofloxacin
,2509411,Peak fleroxacin,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],14.6,36167,DB00537,Ciprofloxacin
,2509411,concentrations,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],13,36168,DB00537,Ciprofloxacin
,2509411,peak fleroxacin,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],12.3,36169,DB00537,Ciprofloxacin
,2509411,abscess fluid concentrations,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],8.9,36170,DB00537,Ciprofloxacin
,2509411,abscess fluid concentrations,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),,85,36171,DB00537,Ciprofloxacin
,2509411,Abscess fluid concentrations,Abscess fluid concentrations at 96 h were: fleroxacin 4.7 +/- 2.6 mg/l and pefloxacin 4.5 +/- 1.7 mg/l.,The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],4.7,36172,DB00537,Ciprofloxacin
,2509411,Abscess fluid concentrations,Abscess fluid concentrations at 96 h were: fleroxacin 4.7 +/- 2.6 mg/l and pefloxacin 4.5 +/- 1.7 mg/l.,The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],4.5,36173,DB00537,Ciprofloxacin
,12019073,peak/dose,"Pharmacokinetic studies revealed peak/dose values of 0.23 to 0.32, area under the concentration-time curve (AUC)/dose values of 0.47 to 0.62, and half-lives of 0.6 to 1.1 h.",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,0.23 to 0.32,36323,DB00537,Ciprofloxacin
,12019073,area under the concentration-time curve (AUC)/dose,"Pharmacokinetic studies revealed peak/dose values of 0.23 to 0.32, area under the concentration-time curve (AUC)/dose values of 0.47 to 0.62, and half-lives of 0.6 to 1.1 h.",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,0.47 to 0.62,36324,DB00537,Ciprofloxacin
,12019073,half-lives,"Pharmacokinetic studies revealed peak/dose values of 0.23 to 0.32, area under the concentration-time curve (AUC)/dose values of 0.47 to 0.62, and half-lives of 0.6 to 1.1 h.",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),h,0.6 to 1.1,36325,DB00537,Ciprofloxacin
,12019073,PAEs,Gatifloxacin produced in vivo PAEs of 0.2 to 3.1 h for S. pneumoniae and 0.4 to 2.3 h for S. aureus.,Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),h,0.2 to 3.1,36326,DB00537,Ciprofloxacin
,12019073,PAEs,Gatifloxacin produced in vivo PAEs of 0.2 to 3.1 h for S. pneumoniae and 0.4 to 2.3 h for S. aureus.,Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),h,0.4 to 2.3,36327,DB00537,Ciprofloxacin
,12019073,MICs,MICs ranged from 0.015 to 8 microg/ml.,Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),[μg] / [ml],0.015 to 8,36328,DB00537,Ciprofloxacin
,12019073,AUC/MICs,The 24-h AUC/MICs for each static dose (1.7 to 592) varied from 16 to 72.,Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,16 to 72,36329,DB00537,Ciprofloxacin
,12019073,24,"Mean +/- standard deviation 24-h AUC/MICs for isolates of the family Enterobacteriaceae, S. pneumoniae, and S. aureus were 41 +/- 21, 52 +/- 20, and 36 +/- 9, respectively.",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,41,36330,DB00537,Ciprofloxacin
,12019073,AUC/MICs,"Mean +/- standard deviation 24-h AUC/MICs for isolates of the family Enterobacteriaceae, S. pneumoniae, and S. aureus were 41 +/- 21, 52 +/- 20, and 36 +/- 9, respectively.",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,41,36331,DB00537,Ciprofloxacin
,12019073,AUC/MICs,"Mean +/- standard deviation 24-h AUC/MICs for isolates of the family Enterobacteriaceae, S. pneumoniae, and S. aureus were 41 +/- 21, 52 +/- 20, and 36 +/- 9, respectively.",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,52,36332,DB00537,Ciprofloxacin
,12019073,AUC/MICs,"Mean +/- standard deviation 24-h AUC/MICs for isolates of the family Enterobacteriaceae, S. pneumoniae, and S. aureus were 41 +/- 21, 52 +/- 20, and 36 +/- 9, respectively.",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,36,36333,DB00537,Ciprofloxacin
,12019073,AUC/MICs,"The 24-h AUC/MICs required to achieve bacteriostatic effects against K. pneumoniae were quite similar in the thigh and lung (70 versus 56 in neutropenic mice and 32 versus 43 in nonneutropenic mice, respectively).",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,70,36334,DB00537,Ciprofloxacin
,12019073,AUC/MICs,"The 24-h AUC/MICs required to achieve bacteriostatic effects against K. pneumoniae were quite similar in the thigh and lung (70 versus 56 in neutropenic mice and 32 versus 43 in nonneutropenic mice, respectively).",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,56,36335,DB00537,Ciprofloxacin
,12019073,AUC/MICs,"The 24-h AUC/MICs required to achieve bacteriostatic effects against K. pneumoniae were quite similar in the thigh and lung (70 versus 56 in neutropenic mice and 32 versus 43 in nonneutropenic mice, respectively).",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,32,36336,DB00537,Ciprofloxacin
,12019073,AUC/MICs,"The 24-h AUC/MICs required to achieve bacteriostatic effects against K. pneumoniae were quite similar in the thigh and lung (70 versus 56 in neutropenic mice and 32 versus 43 in nonneutropenic mice, respectively).",Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019073/),,43,36337,DB00537,Ciprofloxacin
,27490210,CmaxCF/CmaxEF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,4.41,36577,DB00537,Ciprofloxacin
,27490210,CmaxCF/CmaxEF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,0,36578,DB00537,Ciprofloxacin
,27490210,AUC0-t-CF/AUC0-t-EF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,3.69,36579,DB00537,Ciprofloxacin
,27490210,AUC0-t-CF/AUC0-t-EF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,1.84,36580,DB00537,Ciprofloxacin
,27490210,AUC0-t-CF/AUC0-t-EF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,1.76,36581,DB00537,Ciprofloxacin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,26.57,36582,DB00537,Ciprofloxacin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,27.45,36583,DB00537,Ciprofloxacin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,30.88,36584,DB00537,Ciprofloxacin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,5.79,36585,DB00537,Ciprofloxacin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,35.18,36586,DB00537,Ciprofloxacin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,38.11,36587,DB00537,Ciprofloxacin
≥,21831986,AUC(0-24)/MIC ratio,Monte Carlo simulations investigated dosage regimens to achieve a target AUC(0-24)/MIC ratio of ≥125.,Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831986/),,125,37118,DB00537,Ciprofloxacin
,21831986,C(max),Absorption was generally rapid but variable; C(max) ranged from 0.6 to 4.5 mg/L.,Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831986/),[mg] / [l],0.6 to 4.5,37119,DB00537,Ciprofloxacin
,21831986,CL,The parameters were CL (L/h) = 42.7 (L/h/70 kg) × [weight (kg)/70](0.75) × [1 + 0.0368 (Na(+) - 136)] × [1 - 0.283 (high risk)] and V (L) = 372 × (L/70 kg) × [1 + 0.0291 (Na(+) - 136)].,Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831986/),[l] / [70·h·kg],42.7,37120,DB00537,Ciprofloxacin
,21831986,V (L),The parameters were CL (L/h) = 42.7 (L/h/70 kg) × [weight (kg)/70](0.75) × [1 + 0.0368 (Na(+) - 136)] × [1 - 0.283 (high risk)] and V (L) = 372 × (L/70 kg) × [1 + 0.0291 (Na(+) - 136)].,Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831986/),,372,37121,DB00537,Ciprofloxacin
,21831986,AUC(0-24),Estimates of AUC(0-24) ranged from 8 to 61 mg·h/L.,Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831986/),[h·mg] / [l],8 to 61,37122,DB00537,Ciprofloxacin
,26651022,AUC,Drug exposure of ciprofloxacin was highly variable (AUC 5.52-22.47 h μg/mL) compared to enrofloxacin (AUC 3.86-7.50 h μg/mL).,Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),[h·μg] / [ml],5.52-22.47,38212,DB00537,Ciprofloxacin
,26651022,AUC,Drug exposure of ciprofloxacin was highly variable (AUC 5.52-22.47 h μg/mL) compared to enrofloxacin (AUC 3.86-7.50 h μg/mL).,Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),[h·μg] / [ml],3.86-7.50,38213,DB00537,Ciprofloxacin
,26651022,relative bioavailability,The mean relative bioavailability for ciprofloxacin and concurrent sucralfate was 48% (range 8-143%) compared to ciprofloxacin alone.,Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),%,48,38214,DB00537,Ciprofloxacin
,26651022,Relative bioavailability,Relative bioavailability of ciprofloxacin improved to 87% (range 37-333%) when sucralfate was delayed by 2 hours.,Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),%,87,38215,DB00537,Ciprofloxacin
,26651022,relative bioavailability,"By contrast, relative bioavailability for enrofloxacin and concurrent sucralfate was 104% (94-115%).",Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),%,104,38216,DB00537,Ciprofloxacin
,2088195,peak titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,1,38429,DB00537,Ciprofloxacin
,2088195,peak titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,2.1,38430,DB00537,Ciprofloxacin
,2088195,peak titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,3.1,38431,DB00537,Ciprofloxacin
,2088195,trough titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,1,38432,DB00537,Ciprofloxacin
,2088195,trough titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,2.0,38433,DB00537,Ciprofloxacin
,2088195,trough titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,2.9,38434,DB00537,Ciprofloxacin
,23231925,elimination half-life (t(1/2β)),"Following a single intravenous injection, an elimination half-life (t(1/2β)) of 8.31±0.102h.",Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),h,8.31,38574,DB00537,Ciprofloxacin
,23231925,Steady-state,"Steady-state volume of distribution (Vd(ss)) and total body clearance (Cl(B)) were 3.09±0.282L/kg and 0.158±0.006L/kg/h, respectively.",Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),[l] / [kg],3.09,38575,DB00537,Ciprofloxacin
,23231925,volume of distribution (Vd(ss)),"Steady-state volume of distribution (Vd(ss)) and total body clearance (Cl(B)) were 3.09±0.282L/kg and 0.158±0.006L/kg/h, respectively.",Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),[l] / [kg],3.09,38576,DB00537,Ciprofloxacin
,23231925,total body clearance (Cl(B)),"Steady-state volume of distribution (Vd(ss)) and total body clearance (Cl(B)) were 3.09±0.282L/kg and 0.158±0.006L/kg/h, respectively.",Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),[l] / [h·kg],0.158,38577,DB00537,Ciprofloxacin
,23231925,elimination rate constant (β),"Following intramuscular administration, an elimination rate constant (β), the area under the curve from zero to infinity (AUC(0-∞)) and the mean absorption time (MAT) were 0.015±0.001h(-1), 23.49±1.722μg·h/mL and 7.50±0.58h, respectively.",Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),1/[h],0.015,38578,DB00537,Ciprofloxacin
,23231925,area under the curve from zero to infinity (AUC(0-∞)),"Following intramuscular administration, an elimination rate constant (β), the area under the curve from zero to infinity (AUC(0-∞)) and the mean absorption time (MAT) were 0.015±0.001h(-1), 23.49±1.722μg·h/mL and 7.50±0.58h, respectively.",Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),[h·μg] / [ml],23.49,38579,DB00537,Ciprofloxacin
,23231925,mean absorption time (MAT),"Following intramuscular administration, an elimination rate constant (β), the area under the curve from zero to infinity (AUC(0-∞)) and the mean absorption time (MAT) were 0.015±0.001h(-1), 23.49±1.722μg·h/mL and 7.50±0.58h, respectively.",Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),h,7.50,38580,DB00537,Ciprofloxacin
,23231925,peak plasma concentration (C(max)),The peak plasma concentration (C(max)) of 1.81±0.005µg/mL was achieved at 1.00±0.00h.,Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),[μg] / [ml],1.81,38581,DB00537,Ciprofloxacin
,23231925,mean residence time (MRT),"The mean residence time (MRT) was 26.25±1.083h and the absolute bioavailability was 150.8±12.35%, respectively.",Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),h,26.25,38582,DB00537,Ciprofloxacin
,23231925,absolute bioavailability,"The mean residence time (MRT) was 26.25±1.083h and the absolute bioavailability was 150.8±12.35%, respectively.",Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23231925/),%,150.8,38583,DB00537,Ciprofloxacin
,16423485,recoveries,"The recoveries of levofloxacin and ciprofloxacin were 55.2% and 77.3%, respectively.",Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levofloxacin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423485/),%,55.2,38834,DB00537,Ciprofloxacin
,16423485,recoveries,"The recoveries of levofloxacin and ciprofloxacin were 55.2% and 77.3%, respectively.",Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levofloxacin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423485/),%,77.3,38835,DB00537,Ciprofloxacin
,9145377,systemic clearance,"In the three doses examined, systemic clearance and steady-state volume of distribution of DW-116, calculated by model-independent methods, were in the range 0.17 approximately 0.23 L/h/kg and 2.90 approximately 4.44 L/kg, respectively.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),[l] / [h·kg],0.17 approximately 0.23,38861,DB00537,Ciprofloxacin
,9145377,steady-state volume of distribution,"In the three doses examined, systemic clearance and steady-state volume of distribution of DW-116, calculated by model-independent methods, were in the range 0.17 approximately 0.23 L/h/kg and 2.90 approximately 4.44 L/kg, respectively.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),[l] / [kg],2.90 approximately 4.44,38862,DB00537,Ciprofloxacin
,9145377,percent bioavailability,"When DW-116 was given orally at doses of 4, 20, or 200 mg/kg, the AUC values were nearly identical to those following iv administration, indicating an almost complete absorption (i.e., the percent bioavailability was 90.0 for 4 mg/kg, 99.0 for 20 mg/kg, and 98.3 for 200 mg/kg) in the dose range examined.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),,90.0,38863,DB00537,Ciprofloxacin
,9145377,percent bioavailability,"When DW-116 was given orally at doses of 4, 20, or 200 mg/kg, the AUC values were nearly identical to those following iv administration, indicating an almost complete absorption (i.e., the percent bioavailability was 90.0 for 4 mg/kg, 99.0 for 20 mg/kg, and 98.3 for 200 mg/kg) in the dose range examined.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),,99.0,38864,DB00537,Ciprofloxacin
,9145377,percent bioavailability,"When DW-116 was given orally at doses of 4, 20, or 200 mg/kg, the AUC values were nearly identical to those following iv administration, indicating an almost complete absorption (i.e., the percent bioavailability was 90.0 for 4 mg/kg, 99.0 for 20 mg/kg, and 98.3 for 200 mg/kg) in the dose range examined.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),,98.3,38865,DB00537,Ciprofloxacin
,9145377,Absolute percent bioavailabilities,Absolute percent bioavailabilities of ciprofloxacin (69.9%) and rufloxacin (84.9%) were smaller than that obtained for DW-116 (99.0%).,"Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),%,69.9,38866,DB00537,Ciprofloxacin
,9145377,Absolute percent bioavailabilities,Absolute percent bioavailabilities of ciprofloxacin (69.9%) and rufloxacin (84.9%) were smaller than that obtained for DW-116 (99.0%).,"Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),%,84.9,38867,DB00537,Ciprofloxacin
,9145377,Absolute percent bioavailabilities,Absolute percent bioavailabilities of ciprofloxacin (69.9%) and rufloxacin (84.9%) were smaller than that obtained for DW-116 (99.0%).,"Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),%,99.0,38868,DB00537,Ciprofloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.2,39031,DB00537,Ciprofloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.71,39032,DB00537,Ciprofloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.17,39033,DB00537,Ciprofloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.48,39034,DB00537,Ciprofloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],4.6,39035,DB00537,Ciprofloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],15,39036,DB00537,Ciprofloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],17.9,39037,DB00537,Ciprofloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],19.7,39038,DB00537,Ciprofloxacin
,24995312,bioavailability,The lowest bioavailability was determined to be for product A (93.24%) while the highest bioavailability was determined to be for product E (108.01%).,In vitro dissolution and in vivo bioavailability of six brands of ciprofloxacin tablets administered in rabbits and their pharmacokinetic modeling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24995312/),%,93.24,39695,DB00537,Ciprofloxacin
,24995312,bioavailability,The lowest bioavailability was determined to be for product A (93.24%) while the highest bioavailability was determined to be for product E (108.01%).,In vitro dissolution and in vivo bioavailability of six brands of ciprofloxacin tablets administered in rabbits and their pharmacokinetic modeling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24995312/),%,108.01,39696,DB00537,Ciprofloxacin
,19301941,maximum plasma concentration (C(max)),The maximum plasma concentration (C(max)) of ciprofloxacin increased from 2.48 +/- 0.33 microg/mL when administered alone to 3.91 +/- 0.8 microg/mL with co-administration of diclofenac.,"Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301941/),[μg] / [ml],2.48,39915,DB00537,Ciprofloxacin
,19301941,maximum plasma concentration (C(max)),The maximum plasma concentration (C(max)) of ciprofloxacin increased from 2.48 +/- 0.33 microg/mL when administered alone to 3.91 +/- 0.8 microg/mL with co-administration of diclofenac.,"Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301941/),[μg] / [ml],3.91,39916,DB00537,Ciprofloxacin
,19301941,Time to reach C(max) (t(max)),Time to reach C(max) (t(max)) with ciprofloxacin reduced from 2.02 +/- 0.3 hours when administered alone to 1.49 +/- 0.2 h with co-administration of diclofenac.,"Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301941/),h,2.02,39917,DB00537,Ciprofloxacin
,19301941,Time to reach C(max) (t(max)),Time to reach C(max) (t(max)) with ciprofloxacin reduced from 2.02 +/- 0.3 hours when administered alone to 1.49 +/- 0.2 h with co-administration of diclofenac.,"Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301941/),h,1.49,39918,DB00537,Ciprofloxacin
,17242152,Postantibiotic effects (PAEs),"Postantibiotic effects (PAEs) of 2.0 and 1.7 h for methicillin-susceptible S. aureus and MRSA strains, respectively, were observed, and these were similar to those seen with moxifloxacin at 10x MIC.",In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17242152/),h,2.0,40835,DB00537,Ciprofloxacin
,17242152,Postantibiotic effects (PAEs),"Postantibiotic effects (PAEs) of 2.0 and 1.7 h for methicillin-susceptible S. aureus and MRSA strains, respectively, were observed, and these were similar to those seen with moxifloxacin at 10x MIC.",In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17242152/),h,1.7,40836,DB00537,Ciprofloxacin
,1601962,limit of detection,Determination was possible for ofloxacin over the concentration range 50-2000 ng/ml; the limit of detection was 20 ng/ml.,Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1601962/),[ng] / [ml],20,41000,DB00537,Ciprofloxacin
,1601962,recovery,The recovery of ofloxacin added to serum was 88.8-101.7% with a coefficient of variation of less than 5.2%.,Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1601962/),%,88.8-101.7,41001,DB00537,Ciprofloxacin
,3481328,peak serum concentration,"After an oral dose of ofloxacin 400mg, the mean peak serum concentration in 10 elderly patients was 5.5 mg/L and mean renal excretion during 24 hours was 41%.","In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481328/),[mg] / [l],5.5,41593,DB00537,Ciprofloxacin
,3481328,renal excretion during 24 hours,"After an oral dose of ofloxacin 400mg, the mean peak serum concentration in 10 elderly patients was 5.5 mg/L and mean renal excretion during 24 hours was 41%.","In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481328/),%,41,41594,DB00537,Ciprofloxacin
,8092817,maximum concentration,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[mg] / [l],6.4,41616,DB00537,Ciprofloxacin
,8092817,maximum concentration,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[mg] / [l],6.7,41617,DB00537,Ciprofloxacin
,8092817,minimum concentration of drug,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[mg] / [l],3.0,41618,DB00537,Ciprofloxacin
,8092817,minimum concentration of drug,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[mg] / [l],2.5,41619,DB00537,Ciprofloxacin
,8092817,time to the maximum concentration,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),h,2.3,41620,DB00537,Ciprofloxacin
,8092817,time to the maximum concentration,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),h,2.0,41621,DB00537,Ciprofloxacin
,8092817,elimination half-life,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),h,19.7,41622,DB00537,Ciprofloxacin
,8092817,elimination half-life,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),h,17.9,41623,DB00537,Ciprofloxacin
,8092817,oral clearance,"Oral clearance of fleroxacin (CL = CL/F, where F is bioavailability was slightly, but not significantly, reduced during the bacteremic phase (oral clearance, 43.8+/- 23.5 versus 48.5 +/- 17.5 ml/min.).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[ml] / [min],43.8,41624,DB00537,Ciprofloxacin
,8092817,oral clearance,"Oral clearance of fleroxacin (CL = CL/F, where F is bioavailability was slightly, but not significantly, reduced during the bacteremic phase (oral clearance, 43.8+/- 23.5 versus 48.5 +/- 17.5 ml/min.).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[ml] / [min],48.5,41625,DB00537,Ciprofloxacin
,21108984,elimination half-lives (t(½)β),Mean (± SD) elimination half-lives (t(½)β) of difloxacin were 9.53±1.00 and 12.23±1.81 h after IV and oral administration.,"Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21108984/),h,9.53,41708,DB00537,Ciprofloxacin
,21108984,elimination half-lives (t(½)β),Mean (± SD) elimination half-lives (t(½)β) of difloxacin were 9.53±1.00 and 12.23±1.81 h after IV and oral administration.,"Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21108984/),h,12.23,41709,DB00537,Ciprofloxacin
,21108984,Maximum plasma concentration,Maximum plasma concentration was 2.34±0.50 μg/ml and interval from oral administration until maximal concentration was 1.34±0.03 h.,"Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21108984/),[μg] / [ml],2.34,41710,DB00537,Ciprofloxacin
,21108984,interval from oral administration until maximal concentration,Maximum plasma concentration was 2.34±0.50 μg/ml and interval from oral administration until maximal concentration was 1.34±0.03 h.,"Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21108984/),h,1.34,41711,DB00537,Ciprofloxacin
,21108984,Oral bioavailability,Oral bioavailability was found to be 68.89±15.21%.,"Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21108984/),%,68.89,41712,DB00537,Ciprofloxacin
,21108984,concentrations,"After multiple oral dose (10mg difloxacin/kg BW, daily for 5 days), mean kidney, liver, muscle and skin + fat tissue concentrations of difloxacin and sarafloxacin ranging between 604.8±132.5 and 368.1±52.5 μg/kg and 136.4±18.3 and 10.4±1.2 μg/kg, respectively, were measured 1 day after administration of the final dose of difloxacin.","Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21108984/),[μg] / [kg],604.8,41713,DB00537,Ciprofloxacin
,21108984,concentrations,"After multiple oral dose (10mg difloxacin/kg BW, daily for 5 days), mean kidney, liver, muscle and skin + fat tissue concentrations of difloxacin and sarafloxacin ranging between 604.8±132.5 and 368.1±52.5 μg/kg and 136.4±18.3 and 10.4±1.2 μg/kg, respectively, were measured 1 day after administration of the final dose of difloxacin.","Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21108984/),[μg] / [kg],368.1,41714,DB00537,Ciprofloxacin
,21108984,concentrations,"After multiple oral dose (10mg difloxacin/kg BW, daily for 5 days), mean kidney, liver, muscle and skin + fat tissue concentrations of difloxacin and sarafloxacin ranging between 604.8±132.5 and 368.1±52.5 μg/kg and 136.4±18.3 and 10.4±1.2 μg/kg, respectively, were measured 1 day after administration of the final dose of difloxacin.","Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21108984/),[μg] / [kg],136.4,41715,DB00537,Ciprofloxacin
,21108984,concentrations,"After multiple oral dose (10mg difloxacin/kg BW, daily for 5 days), mean kidney, liver, muscle and skin + fat tissue concentrations of difloxacin and sarafloxacin ranging between 604.8±132.5 and 368.1±52.5 μg/kg and 136.4±18.3 and 10.4±1.2 μg/kg, respectively, were measured 1 day after administration of the final dose of difloxacin.","Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21108984/),[μg] / [kg],10.4,41716,DB00537,Ciprofloxacin
,11914204,peak concentration,A peak concentration of 1.6 microg/ml (or mg/l) was measured between 2.5 and 4 hours post-dose.,Vitreous penetration of levofloxacin in the uninflamed phakic human eye. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914204/),[μg] / [ml],1.6,42472,DB00537,Ciprofloxacin
,3662471,clearance,"These studies revealed that clearance of ciprofloxacin was reduced significantly after multiple doses (7.42 +/- 0.85 [standard deviation] versus 6.09 +/- 0.71 liters/h, P less than 0.01).",Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662471/),[l] / [h],7.42,42918,DB00537,Ciprofloxacin
,3662471,clearance,"These studies revealed that clearance of ciprofloxacin was reduced significantly after multiple doses (7.42 +/- 0.85 [standard deviation] versus 6.09 +/- 0.71 liters/h, P less than 0.01).",Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662471/),[l] / [h],6.09,42919,DB00537,Ciprofloxacin
,3662471,Half-life,"Half-life, clearance, and volume of distribution changed from 1.27 +/- 0.2 to 1.60 +/- 0.21 h (P less than 0.05), 0.54 +/- 0.05 to 0.39 +/- 0.04 liters/h (P less than 0.01), and 0.37 +/- 0.04 to 0.31 +/- 0.03 liters/kg (P less than 0.05), respectively.",Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662471/),h,1.27,42920,DB00537,Ciprofloxacin
,3662471,clearance,"Half-life, clearance, and volume of distribution changed from 1.27 +/- 0.2 to 1.60 +/- 0.21 h (P less than 0.05), 0.54 +/- 0.05 to 0.39 +/- 0.04 liters/h (P less than 0.01), and 0.37 +/- 0.04 to 0.31 +/- 0.03 liters/kg (P less than 0.05), respectively.",Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662471/),h,1.60,42921,DB00537,Ciprofloxacin
,3662471,clearance,"Half-life, clearance, and volume of distribution changed from 1.27 +/- 0.2 to 1.60 +/- 0.21 h (P less than 0.05), 0.54 +/- 0.05 to 0.39 +/- 0.04 liters/h (P less than 0.01), and 0.37 +/- 0.04 to 0.31 +/- 0.03 liters/kg (P less than 0.05), respectively.",Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662471/),[l] / [h],0.54,42922,DB00537,Ciprofloxacin
,3662471,volume of distribution,"Half-life, clearance, and volume of distribution changed from 1.27 +/- 0.2 to 1.60 +/- 0.21 h (P less than 0.05), 0.54 +/- 0.05 to 0.39 +/- 0.04 liters/h (P less than 0.01), and 0.37 +/- 0.04 to 0.31 +/- 0.03 liters/kg (P less than 0.05), respectively.",Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662471/),[l] / [h],0.39,42923,DB00537,Ciprofloxacin
,3662471,volume of distribution,"Half-life, clearance, and volume of distribution changed from 1.27 +/- 0.2 to 1.60 +/- 0.21 h (P less than 0.05), 0.54 +/- 0.05 to 0.39 +/- 0.04 liters/h (P less than 0.01), and 0.37 +/- 0.04 to 0.31 +/- 0.03 liters/kg (P less than 0.05), respectively.",Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662471/),[l] / [kg],0.37,42924,DB00537,Ciprofloxacin
,3662471,volume of distribution,"Half-life, clearance, and volume of distribution changed from 1.27 +/- 0.2 to 1.60 +/- 0.21 h (P less than 0.05), 0.54 +/- 0.05 to 0.39 +/- 0.04 liters/h (P less than 0.01), and 0.37 +/- 0.04 to 0.31 +/- 0.03 liters/kg (P less than 0.05), respectively.",Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662471/),[l] / [kg],0.31,42925,DB00537,Ciprofloxacin
,3194878,percentage penetration,Of the nine patients who took amoxycillin 500 mg thrice daily the mean (SD) percentage penetration was 75.,Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3194878/),,75,43253,DB00537,Ciprofloxacin
,3194878,percentage penetration,This was significantly lower than the mean percentage penetration of 147 in 29 patients who took ciprofloxacin 500 mg twice daily.,Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3194878/),,147,43254,DB00537,Ciprofloxacin
,3194878,percentage penetration,Ten patients were given a single intravenous dose of ciprofloxacin 200 mg one hour before bronchoscopy and the mean percentage penetration was 231.,Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3194878/),,231,43255,DB00537,Ciprofloxacin
,2836821,MIC90s,"It is the most active quinolone against Pseudomonas aeruginosa, with MIC90s on the order of 0.5 micrograms/ml.","Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2836821/),[μg] / [ml],0.5,43390,DB00537,Ciprofloxacin
,2836821,bioavailability,"When given orally, ciprofloxacin exhibited 70% bioavailability and attained peak serum levels ranging between 1.5 and 2.9 micrograms/ml after a single 500-mg dose.","Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2836821/),%,70,43391,DB00537,Ciprofloxacin
,2836821,peak serum levels,"When given orally, ciprofloxacin exhibited 70% bioavailability and attained peak serum levels ranging between 1.5 and 2.9 micrograms/ml after a single 500-mg dose.","Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2836821/),[μg] / [ml],1.5 and 2.9,43392,DB00537,Ciprofloxacin
,3142338,peak levels,The peak levels of fleroxacin in plasma were significantly higher after multiple dosing of 800 mg (14.3 versus 8.2 micrograms/ml; P less than 0.01) but not after the last 400-mg dose (6.7 versus 5.0 micrograms/ml).,Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],14.3,43436,DB00537,Ciprofloxacin
,3142338,peak levels,The peak levels of fleroxacin in plasma were significantly higher after multiple dosing of 800 mg (14.3 versus 8.2 micrograms/ml; P less than 0.01) but not after the last 400-mg dose (6.7 versus 5.0 micrograms/ml).,Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],8.2,43437,DB00537,Ciprofloxacin
,3142338,peak levels,The peak levels of fleroxacin in plasma were significantly higher after multiple dosing of 800 mg (14.3 versus 8.2 micrograms/ml; P less than 0.01) but not after the last 400-mg dose (6.7 versus 5.0 micrograms/ml).,Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],6.7,43438,DB00537,Ciprofloxacin
,3142338,peak levels,The peak levels of fleroxacin in plasma were significantly higher after multiple dosing of 800 mg (14.3 versus 8.2 micrograms/ml; P less than 0.01) but not after the last 400-mg dose (6.7 versus 5.0 micrograms/ml).,Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],5.0,43439,DB00537,Ciprofloxacin
,3142338,elimination half-life,"Increased elimination half-life occurred after multiple dosing of 800 mg, from 13.45 +/- 2.94 to 15.60 +/- 3.16 h (P less than 0.05).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),h,13.45,43440,DB00537,Ciprofloxacin
,3142338,elimination half-life,"Increased elimination half-life occurred after multiple dosing of 800 mg, from 13.45 +/- 2.94 to 15.60 +/- 3.16 h (P less than 0.05).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),h,15.60,43441,DB00537,Ciprofloxacin
,3142338,peak concentrations,"Mean peak concentrations in blister fluid were significantly different when the first (3.7 +/- 0.8 and 7.7 +/- 1.8 micrograms/ml for 400 and 800 mg, respectively) and last (5.7 +/- 0.9 and 12.3 +/- 2.1 micrograms/ml for 400 and 800 mg, respectively) doses were compared (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],3.7,43442,DB00537,Ciprofloxacin
,3142338,peak concentrations,"Mean peak concentrations in blister fluid were significantly different when the first (3.7 +/- 0.8 and 7.7 +/- 1.8 micrograms/ml for 400 and 800 mg, respectively) and last (5.7 +/- 0.9 and 12.3 +/- 2.1 micrograms/ml for 400 and 800 mg, respectively) doses were compared (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],7.7,43443,DB00537,Ciprofloxacin
,3142338,peak concentrations,"Mean peak concentrations in blister fluid were significantly different when the first (3.7 +/- 0.8 and 7.7 +/- 1.8 micrograms/ml for 400 and 800 mg, respectively) and last (5.7 +/- 0.9 and 12.3 +/- 2.1 micrograms/ml for 400 and 800 mg, respectively) doses were compared (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],5.7,43444,DB00537,Ciprofloxacin
,3142338,peak concentrations,"Mean peak concentrations in blister fluid were significantly different when the first (3.7 +/- 0.8 and 7.7 +/- 1.8 micrograms/ml for 400 and 800 mg, respectively) and last (5.7 +/- 0.9 and 12.3 +/- 2.1 micrograms/ml for 400 and 800 mg, respectively) doses were compared (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],12.3,43445,DB00537,Ciprofloxacin
,3142338,cleared,"After multiple administration of 800 mg, fleroxacin was cleared from the body more slowly: from 98.80 ml/min after a single dose to 77.72 ml/min following 800 mg every 24 h (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[ml] / [min],98.80,43446,DB00537,Ciprofloxacin
,3142338,cleared,"After multiple administration of 800 mg, fleroxacin was cleared from the body more slowly: from 98.80 ml/min after a single dose to 77.72 ml/min following 800 mg every 24 h (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[ml] / [min],77.72,43447,DB00537,Ciprofloxacin
,2589390,total clearance,"The mean parameter estimates for total clearance, renal clearance, non-renal clearance, and volume of distribution were 30.08 liters/hour/1.73 m2, 16.62 liters/hour/1.73 m2, 13.46 liters/hour/1.73 m2, and 2.10 liters/kg.",Ciprofloxacin pharmacokinetics in critically ill trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589390/),[l] / [1.73·h·m2],30.08,43910,DB00537,Ciprofloxacin
,2589390,renal clearance,"The mean parameter estimates for total clearance, renal clearance, non-renal clearance, and volume of distribution were 30.08 liters/hour/1.73 m2, 16.62 liters/hour/1.73 m2, 13.46 liters/hour/1.73 m2, and 2.10 liters/kg.",Ciprofloxacin pharmacokinetics in critically ill trauma patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589390/),[l] / [1.73·h·m2],16.62,43911,DB00537,Ciprofloxacin
,2589390,renal clearance,"The mean parameter estimates for total clearance, renal clearance, non-renal clearance, and volume of distribution were 30.08 liters/hour/1.73 m2, 16.62 liters/hour/1.73 m2, 13.46 liters/hour/1.73 m2, and 2.10 liters/kg.",Ciprofloxacin pharmacokinetics in critically ill trauma patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589390/),[l] / [1.73·h·m2],13.46,43912,DB00537,Ciprofloxacin
,2589390,non-renal clearance,"The mean parameter estimates for total clearance, renal clearance, non-renal clearance, and volume of distribution were 30.08 liters/hour/1.73 m2, 16.62 liters/hour/1.73 m2, 13.46 liters/hour/1.73 m2, and 2.10 liters/kg.",Ciprofloxacin pharmacokinetics in critically ill trauma patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589390/),[l] / [1.73·h·m2],16.62,43913,DB00537,Ciprofloxacin
,2589390,non-renal clearance,"The mean parameter estimates for total clearance, renal clearance, non-renal clearance, and volume of distribution were 30.08 liters/hour/1.73 m2, 16.62 liters/hour/1.73 m2, 13.46 liters/hour/1.73 m2, and 2.10 liters/kg.",Ciprofloxacin pharmacokinetics in critically ill trauma patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589390/),[l] / [1.73·h·m2],13.46,43914,DB00537,Ciprofloxacin
,2589390,volume of distribution,"The mean parameter estimates for total clearance, renal clearance, non-renal clearance, and volume of distribution were 30.08 liters/hour/1.73 m2, 16.62 liters/hour/1.73 m2, 13.46 liters/hour/1.73 m2, and 2.10 liters/kg.",Ciprofloxacin pharmacokinetics in critically ill trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589390/),[l] / [kg],2.10,43915,DB00537,Ciprofloxacin
,1510426,oral bioavailability,The oral bioavailability was 78.0%.,Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510426/),%,78.0,44147,DB00537,Ciprofloxacin
,1510426,steady-state volume of distribution,"The steady-state volume of distribution averaged 178 liters, and the terminal half-life in serum after i.v. dosing was approximately 4.3 h.",Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510426/),l,178,44148,DB00537,Ciprofloxacin
,1510426,terminal half-life,"The steady-state volume of distribution averaged 178 liters, and the terminal half-life in serum after i.v. dosing was approximately 4.3 h.",Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510426/),h,4.3,44149,DB00537,Ciprofloxacin
,10817727,half-lives,"Population pharmacokinetic software, P-Pharm, was used to calculate the mean half-lives of the loss of ciprofloxacin from aqueous and vitreous, which were 3.5 and 5.3 h, respectively.",Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817727/),h,3.5,44873,DB00537,Ciprofloxacin
,10817727,half-lives,"Population pharmacokinetic software, P-Pharm, was used to calculate the mean half-lives of the loss of ciprofloxacin from aqueous and vitreous, which were 3.5 and 5.3 h, respectively.",Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817727/),h,5.3,44874,DB00537,Ciprofloxacin
,10817727,MICs,"After the administration of one or two doses of 750 mg of ciprofloxacin, the concentrations in both aqueous and vitreous in a number of patients were lower than the MICs at which 90% of isolates are inhibited (0.5 mg/liter) for common intraocular bacterial pathogens.",Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817727/),[mg] / [l],0.5,44875,DB00537,Ciprofloxacin
,11400196,limit of detection (LOD),The limit of detection (LOD) for the method was 500 pg/mL based on a signal-to-noise ratio of 3.,Determination of gatifloxacin in human plasma by liquid chromatography/electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11400196/),[pg] / [ml],500,45096,DB00537,Ciprofloxacin
,11400196,signal-to-noise ratio,The limit of detection (LOD) for the method was 500 pg/mL based on a signal-to-noise ratio of 3.,Determination of gatifloxacin in human plasma by liquid chromatography/electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11400196/),,3,45097,DB00537,Ciprofloxacin
>,32298468,minimum inhibitory concentration (MIC) (AUC/MIC),A dose of 400 mg every 12 hours was sufficient to reach the preestablished target of area under the curve (AUC) in relation to the minimum inhibitory concentration (MIC) (AUC/MIC) > 125 in patients with an estimated glomerular filtration rate (eGFR) < 130 mL/min and an infection caused by a pathogen with an MIC ≤ 0.125 mg/L.,Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32298468/),,125,45269,DB00537,Ciprofloxacin
≤,32298468,MIC,A dose of 400 mg every 12 hours was sufficient to reach the preestablished target of area under the curve (AUC) in relation to the minimum inhibitory concentration (MIC) (AUC/MIC) > 125 in patients with an estimated glomerular filtration rate (eGFR) < 130 mL/min and an infection caused by a pathogen with an MIC ≤ 0.125 mg/L.,Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32298468/),[mg] / [l],0.125,45270,DB00537,Ciprofloxacin
≥,32298468,MIC,"For patients with infections caused by pathogens with an MIC ≥ 0.5 mg/L and eGFR> 100 mL/min, doses up to 600 mg four times daily or more were estimated to be required.",Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32298468/),[mg] / [l],0.5,45271,DB00537,Ciprofloxacin
,7784342,steady-state plasma concentrations,"The effects of norfloxacin (NOR), at steady-state plasma concentrations of 0-32 mg.l-1, on the plasma clearance of a 6 mg.",Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784342/),[mg] / [l],0-32,45925,DB00537,Ciprofloxacin
,7784342,Ki,"The effects were characterised by a Ki value (Ki = 12 microM), which was comparable with Ki values obtained previously under identical conditions for ciprofloxacin, but higher than that obtained for enoxacin.",Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784342/),μM,12,45926,DB00537,Ciprofloxacin
,2504254,er,"The erythrocyte sedimentation rate fell from a mean pretherapy value of 81 mm/h (range, 41 to 138 mm/h) to 18 mm/h (range, 3 to 45 mm/h) after the completion of antibiotic therapy.",Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504254/),[mm] / [h],81,46599,DB00537,Ciprofloxacin
,3216035,t1/2,"Ciprofloxacin t1/2, VSSF, CLF, and CLR in the matched CF subjects averaged 4.5 hours, 2.8 L/kg, 2.73 mL/min/kg and 5.7 mL/min/kg, respectively.",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),h,4.5,46981,DB00537,Ciprofloxacin
,3216035,VSSF,"Ciprofloxacin t1/2, VSSF, CLF, and CLR in the matched CF subjects averaged 4.5 hours, 2.8 L/kg, 2.73 mL/min/kg and 5.7 mL/min/kg, respectively.",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),[l] / [kg],2.8,46982,DB00537,Ciprofloxacin
,3216035,VSSF,"Ciprofloxacin t1/2, VSSF, CLF, and CLR in the matched CF subjects averaged 4.5 hours, 2.8 L/kg, 2.73 mL/min/kg and 5.7 mL/min/kg, respectively.",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),[ml] / [kg·min],2.73,46983,DB00537,Ciprofloxacin
,3216035,CLF,"Ciprofloxacin t1/2, VSSF, CLF, and CLR in the matched CF subjects averaged 4.5 hours, 2.8 L/kg, 2.73 mL/min/kg and 5.7 mL/min/kg, respectively.",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),[l] / [kg],2.8,46984,DB00537,Ciprofloxacin
,3216035,CLF,"Ciprofloxacin t1/2, VSSF, CLF, and CLR in the matched CF subjects averaged 4.5 hours, 2.8 L/kg, 2.73 mL/min/kg and 5.7 mL/min/kg, respectively.",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),[ml] / [kg·min],2.73,46985,DB00537,Ciprofloxacin
,3216035,CLR,"Ciprofloxacin t1/2, VSSF, CLF, and CLR in the matched CF subjects averaged 4.5 hours, 2.8 L/kg, 2.73 mL/min/kg and 5.7 mL/min/kg, respectively.",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),[ml] / [kg·min],5.7,46986,DB00537,Ciprofloxacin
,3216035,tmax,"In contrast, CF subjects demonstrated a prolonged tmax (2.3 versus 1.3 hours P less than .05) though ciprofloxacin Cmax was similar (4.7 versus 3.8 mg/L, NS).",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),h,2.3,46987,DB00537,Ciprofloxacin
,3216035,tmax,"In contrast, CF subjects demonstrated a prolonged tmax (2.3 versus 1.3 hours P less than .05) though ciprofloxacin Cmax was similar (4.7 versus 3.8 mg/L, NS).",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),h,1.3,46988,DB00537,Ciprofloxacin
,3216035,Cmax,"In contrast, CF subjects demonstrated a prolonged tmax (2.3 versus 1.3 hours P less than .05) though ciprofloxacin Cmax was similar (4.7 versus 3.8 mg/L, NS).",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),[mg] / [l],4.7,46989,DB00537,Ciprofloxacin
,3216035,Cmax,"In contrast, CF subjects demonstrated a prolonged tmax (2.3 versus 1.3 hours P less than .05) though ciprofloxacin Cmax was similar (4.7 versus 3.8 mg/L, NS).",Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216035/),[mg] / [l],3.8,46990,DB00537,Ciprofloxacin
,3691576,Cmax,The results were found to be comparable for the concentrations in serum (mean Cmax = 0.97 +/- 0.17 microgram/ml by HPLC and 1.08 +/- 0.19 microgram/ml by bioassay) and in urine (0.6 h: 267 +/- 74 micrograms/ml and 241 +/- 58 micrograms/ml respectively).,Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691576/),[μg] / [ml],0.97,47943,DB00537,Ciprofloxacin
,3691576,Cmax,The results were found to be comparable for the concentrations in serum (mean Cmax = 0.97 +/- 0.17 microgram/ml by HPLC and 1.08 +/- 0.19 microgram/ml by bioassay) and in urine (0.6 h: 267 +/- 74 micrograms/ml and 241 +/- 58 micrograms/ml respectively).,Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691576/),[μg] / [ml],1.08,47944,DB00537,Ciprofloxacin
,3691576,Cmax,The results were found to be comparable for the concentrations in serum (mean Cmax = 0.97 +/- 0.17 microgram/ml by HPLC and 1.08 +/- 0.19 microgram/ml by bioassay) and in urine (0.6 h: 267 +/- 74 micrograms/ml and 241 +/- 58 micrograms/ml respectively).,Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691576/),[μg] / [ml],267,47945,DB00537,Ciprofloxacin
,3691576,Cmax,The results were found to be comparable for the concentrations in serum (mean Cmax = 0.97 +/- 0.17 microgram/ml by HPLC and 1.08 +/- 0.19 microgram/ml by bioassay) and in urine (0.6 h: 267 +/- 74 micrograms/ml and 241 +/- 58 micrograms/ml respectively).,Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691576/),[μg] / [ml],241,47946,DB00537,Ciprofloxacin
,3691576,peak concentration,Higher concentrations were found in bile when measured by bioassay compared with HPLC (peak concentration = 10.3 +/- 3.4 micrograms/ml and 7.5 +/- 2.8 micrograms/ml respectively; p less than 0.02).,Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691576/),[μg] / [ml],10.3,47947,DB00537,Ciprofloxacin
,3691576,peak concentration,Higher concentrations were found in bile when measured by bioassay compared with HPLC (peak concentration = 10.3 +/- 3.4 micrograms/ml and 7.5 +/- 2.8 micrograms/ml respectively; p less than 0.02).,Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691576/),[μg] / [ml],7.5,47948,DB00537,Ciprofloxacin
,3691576,total biliary elimination,The total biliary elimination was also significantly higher according to bioassay data (2167 +/- 288 micrograms/ml versus 1587 +/- 222 micrograms/ml; p less than 0.01).,Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691576/),[μg] / [ml],2167,47949,DB00537,Ciprofloxacin
,3691576,total biliary elimination,The total biliary elimination was also significantly higher according to bioassay data (2167 +/- 288 micrograms/ml versus 1587 +/- 222 micrograms/ml; p less than 0.01).,Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691576/),[μg] / [ml],1587,47950,DB00537,Ciprofloxacin
,2940965,peak serum concentrations,"There was no accumulation during the course of 5 days with peak serum concentrations identical (2.8 and 2.3 mg/liter) after the first and final doses, and the areas under the serum curves were similar (9.6 mg/liter).",Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940965/),[mg] / [l],2.8,48038,DB00537,Ciprofloxacin
,2940965,peak serum concentrations,"There was no accumulation during the course of 5 days with peak serum concentrations identical (2.8 and 2.3 mg/liter) after the first and final doses, and the areas under the serum curves were similar (9.6 mg/liter).",Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940965/),[mg] / [l],2.3,48039,DB00537,Ciprofloxacin
,2940965,areas under the serum curves,"There was no accumulation during the course of 5 days with peak serum concentrations identical (2.8 and 2.3 mg/liter) after the first and final doses, and the areas under the serum curves were similar (9.6 mg/liter).",Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940965/),[mg] / [l],9.6,48040,DB00537,Ciprofloxacin
,2940965,serum half-life,The serum half-life was 2.5 h on both days.,Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940965/),h,2.5,48041,DB00537,Ciprofloxacin
above,2940965,MICs,No new colonization of ciprofloxacin-resistant bacteria for which MICs were above 1.0 mg/liter was observed.,Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940965/),[mg] / [l],1.0,48042,DB00537,Ciprofloxacin
,20359917,Plasma,"Plasma and milk elimination half-lives after P407-CMC dosing were 35.19 h and 33.93 h, respectively.",Pharmacokinetic and milk penetration of a difloxacin long-acting poloxamer gel formulation with carboxy-methylcellulose in lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359917/),h,35.19,48145,DB00537,Ciprofloxacin
,20359917,milk elimination half-lives,"Plasma and milk elimination half-lives after P407-CMC dosing were 35.19 h and 33.93 h, respectively.",Pharmacokinetic and milk penetration of a difloxacin long-acting poloxamer gel formulation with carboxy-methylcellulose in lactating goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359917/),h,33.93,48146,DB00537,Ciprofloxacin
,20359917,maximum plasma concentrations,"With this formulation, difloxacin achieved maximum plasma concentrations of 2.67±0.34 mg/L at 2.92±1.20 h and maximum milk concentrations of 2.31±0.35 mg/L at 4.00±0.00 h.",Pharmacokinetic and milk penetration of a difloxacin long-acting poloxamer gel formulation with carboxy-methylcellulose in lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359917/),[mg] / [l],2.67,48147,DB00537,Ciprofloxacin
,20359917,maximum milk concentrations,"With this formulation, difloxacin achieved maximum plasma concentrations of 2.67±0.34 mg/L at 2.92±1.20 h and maximum milk concentrations of 2.31±0.35 mg/L at 4.00±0.00 h.",Pharmacokinetic and milk penetration of a difloxacin long-acting poloxamer gel formulation with carboxy-methylcellulose in lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359917/),[mg] / [l],2.31,48148,DB00537,Ciprofloxacin
,20359917,area under the curve (AUC) ratio AUC,The area under the curve (AUC) ratio AUC(milk)/AUC(plasma) was 0.89 after P407-CMC administration.,Pharmacokinetic and milk penetration of a difloxacin long-acting poloxamer gel formulation with carboxy-methylcellulose in lactating goats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359917/),,0.89,48149,DB00537,Ciprofloxacin
≤,20359917,minimum inhibitory concentration (MIC),It was concluded that a 15 mg/kg dose of difloxacin within P407-CMC would be effective against mastitis pathogens with a minimum inhibitory concentration (MIC)≤0.12 mg/L.,Pharmacokinetic and milk penetration of a difloxacin long-acting poloxamer gel formulation with carboxy-methylcellulose in lactating goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359917/),[mg] / [l],0.12,48150,DB00537,Ciprofloxacin
,30545255,flow rate,"Various anti-infective drugs (β-lactams, quinolones, aminoglycosides, glycopeptides, azole antimycotics) were prepared in normal saline 0.9% and human albumin 5%, and pumped through a cytokine cartridge (CytoSorb®; CytoSorbents Corporation, Monmouth Junction, NJ, USA) at a flow rate of 1.2 L/h for 1.5 h.",In vitro removal of anti-infective agents by a novel cytokine adsorbent system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30545255/),[l] / [h],1.2,48406,DB00537,Ciprofloxacin
,30545255,flow rate,"In addition, meropenem and ciprofloxacin were dissolved in reconstituted blood and run through a CytoSorb cartridge, which was integrated into a continuous renal replacement therapy circuit with a flow rate of 2 L/h for 18 h.",In vitro removal of anti-infective agents by a novel cytokine adsorbent system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30545255/),[l] / [h],2,48407,DB00537,Ciprofloxacin
,30545255,clearance,Observed mean clearance of the drugs in normal saline was 1.22 ± 0.07 L/h.,In vitro removal of anti-infective agents by a novel cytokine adsorbent system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30545255/),[l] / [h],1.22,48408,DB00537,Ciprofloxacin
,30545255,clearance,"In human albumin, clearance was 1.29 ± 0.08 L/h.",In vitro removal of anti-infective agents by a novel cytokine adsorbent system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30545255/),[l] / [h],1.29,48409,DB00537,Ciprofloxacin
,30545255,clearance,"In reconstituted blood, clearance of meropenem decreased from 5.4 to 1.4 L/h and for ciprofloxacin from 6.3 to 4.3 L/h within the first 1.5 h because of early drug adsorption.",In vitro removal of anti-infective agents by a novel cytokine adsorbent system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30545255/),[l] / [h],5.4 to 1.4,48410,DB00537,Ciprofloxacin
,30545255,clearance,"In reconstituted blood, clearance of meropenem decreased from 5.4 to 1.4 L/h and for ciprofloxacin from 6.3 to 4.3 L/h within the first 1.5 h because of early drug adsorption.",In vitro removal of anti-infective agents by a novel cytokine adsorbent system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30545255/),[l] / [h],6.3 to 4.3,48411,DB00537,Ciprofloxacin
,30545255,clearance,"Continuous renal replacement therapy clearance measured without CytoSorb was stable at 2 and 1.7 L/h, respectively.",In vitro removal of anti-infective agents by a novel cytokine adsorbent system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30545255/),[l] / [h],2,48412,DB00537,Ciprofloxacin
,30545255,clearance,"Continuous renal replacement therapy clearance measured without CytoSorb was stable at 2 and 1.7 L/h, respectively.",In vitro removal of anti-infective agents by a novel cytokine adsorbent system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30545255/),[l] / [h],1.7,48413,DB00537,Ciprofloxacin
,2327763,peak levels,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),[μg] / [ml],0.25,48765,DB00537,Ciprofloxacin
,2327763,peak levels,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),[μg] / [ml],0.50,48766,DB00537,Ciprofloxacin
,2327763,peak levels,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),[μg] / [ml],1.14,48767,DB00537,Ciprofloxacin
,2327763,peak levels,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),[μg] / [ml],0.49,48768,DB00537,Ciprofloxacin
,2327763,elimination half-lives,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),h,5.0,48769,DB00537,Ciprofloxacin
,2327763,elimination half-lives,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),h,3.8,48770,DB00537,Ciprofloxacin
,2327763,elimination half-lives,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),h,8.0,48771,DB00537,Ciprofloxacin
,2327763,elimination half-lives,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),h,11.7,48772,DB00537,Ciprofloxacin
,2327763,oral bioavailability,The oral bioavailability of AT-4140 calculated from the ratio of the areas under the concentration-time curve after oral and intravenous administration was 77% in dogs.,"Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,77,48773,DB00537,Ciprofloxacin
,2327763,biliary recovery,The mean 24-h biliary recovery of AT-4140 in rats was 5.6% of the dose and became 21.3% after beta-glucuronidase treatment.,"Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),,5,48774,DB00537,Ciprofloxacin
,2327763,biliary recovery,The mean 24-h biliary recovery of AT-4140 in rats was 5.6% of the dose and became 21.3% after beta-glucuronidase treatment.,"Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,21.3,48775,DB00537,Ciprofloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,6.7,48776,DB00537,Ciprofloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,12.9,48777,DB00537,Ciprofloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,8.6,48778,DB00537,Ciprofloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,12.7,48779,DB00537,Ciprofloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,7.8,48780,DB00537,Ciprofloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,16.3,48781,DB00537,Ciprofloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,8.9,48782,DB00537,Ciprofloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,18.9,48783,DB00537,Ciprofloxacin
,8226402,Cmax,"Mean (range) pharmacokinetic parameters before chemotherapy were: Cmax, 6.1 (2.7-9.1) mg/L; AUC0-2, 7.5 (1.9-11.6) mg.h/L.",Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226402/),[mg] / [l],6.1,49135,DB00537,Ciprofloxacin
,8226402,AUC0-2,"Mean (range) pharmacokinetic parameters before chemotherapy were: Cmax, 6.1 (2.7-9.1) mg/L; AUC0-2, 7.5 (1.9-11.6) mg.h/L.",Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226402/),[h·mg] / [l],7.5,49136,DB00537,Ciprofloxacin
,8226402,Cmax,"On days 2-3 post-chemotherapy the values were reduced to: Cmax, 5.0 (3.6-7.3) mg/L; AUC0-2, 5.8 (1.9-7.8) mg.h/L.",Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226402/),[mg] / [l],5.0,49137,DB00537,Ciprofloxacin
,8226402,AUC0-2,"On days 2-3 post-chemotherapy the values were reduced to: Cmax, 5.0 (3.6-7.3) mg/L; AUC0-2, 5.8 (1.9-7.8) mg.h/L.",Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226402/),[h·mg] / [l],5.8,49138,DB00537,Ciprofloxacin
,8226402,Cmax,"On days 5-7 the values were: Cmax, 6.1 (4.0-10.4) mg/L; AUC0-2, 8.5 (0.8-16.8) mg.h/L, and by days 8-10 the values were: Cmax, 6.4 (3.3-12.5) mg/L; AUC0-2, 8.6 (0.8-23.1) mg.h/L.",Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226402/),[mg] / [l],6.1,49139,DB00537,Ciprofloxacin
,8226402,AUC0-2,"On days 5-7 the values were: Cmax, 6.1 (4.0-10.4) mg/L; AUC0-2, 8.5 (0.8-16.8) mg.h/L, and by days 8-10 the values were: Cmax, 6.4 (3.3-12.5) mg/L; AUC0-2, 8.6 (0.8-23.1) mg.h/L.",Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226402/),[h·mg] / [l],8.5,49140,DB00537,Ciprofloxacin
,8226402,Cmax,"On days 5-7 the values were: Cmax, 6.1 (4.0-10.4) mg/L; AUC0-2, 8.5 (0.8-16.8) mg.h/L, and by days 8-10 the values were: Cmax, 6.4 (3.3-12.5) mg/L; AUC0-2, 8.6 (0.8-23.1) mg.h/L.",Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226402/),[mg] / [l],6.4,49141,DB00537,Ciprofloxacin
,8226402,AUC0-2,"On days 5-7 the values were: Cmax, 6.1 (4.0-10.4) mg/L; AUC0-2, 8.5 (0.8-16.8) mg.h/L, and by days 8-10 the values were: Cmax, 6.4 (3.3-12.5) mg/L; AUC0-2, 8.6 (0.8-23.1) mg.h/L.",Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226402/),[h·mg] / [l],8.6,49142,DB00537,Ciprofloxacin
,12376030,MICs,Levofloxacin MICs ranged from 1.4 to 3.2 micro g/ml.,Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],1.4 to 3.2,49205,DB00537,Ciprofloxacin
,12376030,MICs,"Against strains with levofloxacin MICs of 1.4 and 1.8 micro g/ml, the 500 mg dose exhibited pharmacodynamics similar to the 750 mg dose.",Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],1.4,49206,DB00537,Ciprofloxacin
,12376030,MICs,"Against strains with levofloxacin MICs of 1.4 and 1.8 micro g/ml, the 500 mg dose exhibited pharmacodynamics similar to the 750 mg dose.",Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],1.8,49207,DB00537,Ciprofloxacin
,12376030,MICs,"In contrast, against strains with levofloxacin MICs of 2.6 and 3.2 micro g/ml, viable counts never fell below 10(4) cfu/ml.",Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],2.6,49208,DB00537,Ciprofloxacin
,12376030,MICs,"In contrast, against strains with levofloxacin MICs of 2.6 and 3.2 micro g/ml, viable counts never fell below 10(4) cfu/ml.",Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],3.2,49209,DB00537,Ciprofloxacin
,2941277,peak concentrations,Mean peak concentrations between 0.37 +/- 0.49 mg/l (100 mg dose) and 1.97 +/- 0.50 (750 mg dose) were measured 60-75 min after oral administration.,Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),[mg] / [l],0.37,49514,DB00537,Ciprofloxacin
,2941277,peak concentrations,Mean peak concentrations between 0.37 +/- 0.49 mg/l (100 mg dose) and 1.97 +/- 0.50 (750 mg dose) were measured 60-75 min after oral administration.,Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),,1.97,49515,DB00537,Ciprofloxacin
,2941277,serum concentrations,"Twelve hours after 750 mg ciprofloxacin, serum concentrations were 0.15 +/- 0.05 mg/l.",Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),mg,0.15,49516,DB00537,Ciprofloxacin
,2941277,initial serum concentrations,"After 200 mg i.v. (20 min infusion period), initial serum concentrations of 4.0 +/- 1.2 mg/l were observed which declined 12 h later to 0.070 +/- 0.025 mg/l.",Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),[mg] / [l],4.0,49517,DB00537,Ciprofloxacin
,2941277,initial serum concentrations,"After 200 mg i.v. (20 min infusion period), initial serum concentrations of 4.0 +/- 1.2 mg/l were observed which declined 12 h later to 0.070 +/- 0.025 mg/l.",Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),[mg] / [l],0.070,49518,DB00537,Ciprofloxacin
,2941277,cumulated recovery,Mean cumulated recovery of ciprofloxacin from urine over 24 h varied between 25.5% and 33.6% of oral doses and between 53.2% and 57.4% of intravenous doses.,Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),%,25.5,49519,DB00537,Ciprofloxacin
,2941277,cumulated recovery,Mean cumulated recovery of ciprofloxacin from urine over 24 h varied between 25.5% and 33.6% of oral doses and between 53.2% and 57.4% of intravenous doses.,Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),%,33.6,49520,DB00537,Ciprofloxacin
,2941277,cumulated recovery,Mean cumulated recovery of ciprofloxacin from urine over 24 h varied between 25.5% and 33.6% of oral doses and between 53.2% and 57.4% of intravenous doses.,Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),%,53.2,49521,DB00537,Ciprofloxacin
,2941277,cumulated recovery,Mean cumulated recovery of ciprofloxacin from urine over 24 h varied between 25.5% and 33.6% of oral doses and between 53.2% and 57.4% of intravenous doses.,Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),%,57.4,49522,DB00537,Ciprofloxacin
,2941277,Cumulated renal excretion,Cumulated renal excretion after an oral 250 mg dose was 1.2 +/- 0.4% of M1 and 5.5 +/- 1.6% of M3.(ABSTRACT TRUNCATED AT 250 WORDS),Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),%,1.2,49523,DB00537,Ciprofloxacin
,2941277,Cumulated renal excretion,Cumulated renal excretion after an oral 250 mg dose was 1.2 +/- 0.4% of M1 and 5.5 +/- 1.6% of M3.(ABSTRACT TRUNCATED AT 250 WORDS),Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941277/),%,5.5,49524,DB00537,Ciprofloxacin
,9527774,renal clearance (CLR),"After parenteral administration, only renal clearance (CLR) was reduced in nephrectomized rats (5.3+/-1.4 versus 17.8+/-4.7 ml/min/kg, P < 0.01, nephrectomized versus control rats).",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[ml] / [kg·min],5.3,50078,DB00537,Ciprofloxacin
,9527774,renal clearance (CLR),"After parenteral administration, only renal clearance (CLR) was reduced in nephrectomized rats (5.3+/-1.4 versus 17.8+/-4.7 ml/min/kg, P < 0.01, nephrectomized versus control rats).",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[ml] / [kg·min],17.8,50079,DB00537,Ciprofloxacin
,9527774,nonrenal clearance,"However, nonrenal clearance was increased in nephrectomized rats (32+/-4 versus 15+/-5 ml/min/kg, P < 0.01, nephrectomized versus control rats), suggesting compensatory mechanisms for reduced renal function.",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[ml] / [kg·min],32,50080,DB00537,Ciprofloxacin
,9527774,nonrenal clearance,"However, nonrenal clearance was increased in nephrectomized rats (32+/-4 versus 15+/-5 ml/min/kg, P < 0.01, nephrectomized versus control rats), suggesting compensatory mechanisms for reduced renal function.",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[ml] / [kg·min],15,50081,DB00537,Ciprofloxacin
,9527774,apparent total clearance,"After oral administration, apparent total clearance and CLR were reduced (P < 0.01) in nephrectomized rats (117+/-25 and 6.8+/-4.4 ml/min/kg, respectively) compared with the values for control rats (185+/-9 and 22.6+/-5.3 ml/min/kg, respectively) and the area under the concentration-time curve was higher (P < 0.01) for nephrectomized rats (436.3+/-90.5 mg. min/liter) than for control rats (271.3+/-14.3 mg.min/liter).",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[ml] / [kg·min],117,50082,DB00537,Ciprofloxacin
,9527774,apparent total clearance,"After oral administration, apparent total clearance and CLR were reduced (P < 0.01) in nephrectomized rats (117+/-25 and 6.8+/-4.4 ml/min/kg, respectively) compared with the values for control rats (185+/-9 and 22.6+/-5.3 ml/min/kg, respectively) and the area under the concentration-time curve was higher (P < 0.01) for nephrectomized rats (436.3+/-90.5 mg. min/liter) than for control rats (271.3+/-14.3 mg.min/liter).",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[ml] / [kg·min],6.8,50083,DB00537,Ciprofloxacin
,9527774,apparent total clearance,"After oral administration, apparent total clearance and CLR were reduced (P < 0.01) in nephrectomized rats (117+/-25 and 6.8+/-4.4 ml/min/kg, respectively) compared with the values for control rats (185+/-9 and 22.6+/-5.3 ml/min/kg, respectively) and the area under the concentration-time curve was higher (P < 0.01) for nephrectomized rats (436.3+/-90.5 mg. min/liter) than for control rats (271.3+/-14.3 mg.min/liter).",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[ml] / [kg·min],185,50084,DB00537,Ciprofloxacin
,9527774,CLR,"After oral administration, apparent total clearance and CLR were reduced (P < 0.01) in nephrectomized rats (117+/-25 and 6.8+/-4.4 ml/min/kg, respectively) compared with the values for control rats (185+/-9 and 22.6+/-5.3 ml/min/kg, respectively) and the area under the concentration-time curve was higher (P < 0.01) for nephrectomized rats (436.3+/-90.5 mg. min/liter) than for control rats (271.3+/-14.3 mg.min/liter).",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[ml] / [kg·min],6.8,50085,DB00537,Ciprofloxacin
,9527774,CLR,"After oral administration, apparent total clearance and CLR were reduced (P < 0.01) in nephrectomized rats (117+/-25 and 6.8+/-4.4 ml/min/kg, respectively) compared with the values for control rats (185+/-9 and 22.6+/-5.3 ml/min/kg, respectively) and the area under the concentration-time curve was higher (P < 0.01) for nephrectomized rats (436.3+/-90.5 mg. min/liter) than for control rats (271.3+/-14.3 mg.min/liter).",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[ml] / [kg·min],22.6,50086,DB00537,Ciprofloxacin
,9527774,area under the concentration-time curve,"After oral administration, apparent total clearance and CLR were reduced (P < 0.01) in nephrectomized rats (117+/-25 and 6.8+/-4.4 ml/min/kg, respectively) compared with the values for control rats (185+/-9 and 22.6+/-5.3 ml/min/kg, respectively) and the area under the concentration-time curve was higher (P < 0.01) for nephrectomized rats (436.3+/-90.5 mg. min/liter) than for control rats (271.3+/-14.3 mg.min/liter).",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[mg·min] / [l],436.3,50087,DB00537,Ciprofloxacin
,9527774,area under the concentration-time curve,"After oral administration, apparent total clearance and CLR were reduced (P < 0.01) in nephrectomized rats (117+/-25 and 6.8+/-4.4 ml/min/kg, respectively) compared with the values for control rats (185+/-9 and 22.6+/-5.3 ml/min/kg, respectively) and the area under the concentration-time curve was higher (P < 0.01) for nephrectomized rats (436.3+/-90.5 mg. min/liter) than for control rats (271.3+/-14.3 mg.min/liter).",Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527774/),[mg·min] / [l],271.3,50088,DB00537,Ciprofloxacin
,22186313,detection limits (LOD),"The detection limits (LOD) were 0.02μg/ml and 0.1μg/ml, for both methods respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[μg] / [ml],0.02,50327,DB00537,Ciprofloxacin
,22186313,detection limits (LOD),"The detection limits (LOD) were 0.02μg/ml and 0.1μg/ml, for both methods respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[μg] / [ml],0.1,50328,DB00537,Ciprofloxacin
,22186313,maximum concentration,The Comparison of means maximum concentration 2.68 μg/ml at 1.5 hr for test and 2.43 μg/ml are attain in HPLC method of Reference at 2hrs respectively.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[μg] / [ml],2.68,50329,DB00537,Ciprofloxacin
,22186313,maximum concentration,The Comparison of means maximum concentration 2.68 μg/ml at 1.5 hr for test and 2.43 μg/ml are attain in HPLC method of Reference at 2hrs respectively.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[μg] / [ml],2.43,50330,DB00537,Ciprofloxacin
,22186313,plasma concentrations,The plasma concentrations measured by microbiological assay of reference tablet are 3.95μg/ml (mean ± SE) at 1 hour and 3.80μg/ml (mean ± SE) at 1 hour.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[μg] / [ml],3.95,50331,DB00537,Ciprofloxacin
,22186313,plasma concentrations,The plasma concentrations measured by microbiological assay of reference tablet are 3.95μg/ml (mean ± SE) at 1 hour and 3.80μg/ml (mean ± SE) at 1 hour.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[μg] / [ml],3.80,50332,DB00537,Ciprofloxacin
,22186313,total area under the curve (AUC 0-oo),"The mean ± SE values of pharmacokinetic parameters calculated by HPLC method, for total area under the curve (AUC 0-oo) were 13.11, and 11.91 h.mg/l for both test and reference tablets respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[h·mg] / [l],13.11,50333,DB00537,Ciprofloxacin
,22186313,total area under the curve (AUC 0-oo),"The mean ± SE values of pharmacokinetic parameters calculated by HPLC method, for total area under the curve (AUC 0-oo) were 13.11, and 11.91 h.mg/l for both test and reference tablets respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[h·mg] / [l],11.91,50334,DB00537,Ciprofloxacin
,22186313,clearance,The mean ± SE values of clearance measured in l/h were 44.91 and 48.42 respectively.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[l] / [h],44.91,50335,DB00537,Ciprofloxacin
,22186313,clearance,The mean ± SE values of clearance measured in l/h were 44.91 and 48.42 respectively.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[l] / [h],48.42,50336,DB00537,Ciprofloxacin
,22186313,elimination rate constant Kel,"The elimination rate constant Kel [l/h] showed 0.17 l/h for test and 0.15 l/h reference tablets and likewise, absorption half-life expressed in hours shown 0.67 h for test and 1.04 h for reference respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[l] / [h],0.17,50337,DB00537,Ciprofloxacin
,22186313,elimination rate constant Kel,"The elimination rate constant Kel [l/h] showed 0.17 l/h for test and 0.15 l/h reference tablets and likewise, absorption half-life expressed in hours shown 0.67 h for test and 1.04 h for reference respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[l] / [h],0.15,50338,DB00537,Ciprofloxacin
,22186313,absorption half-life,"The elimination rate constant Kel [l/h] showed 0.17 l/h for test and 0.15 l/h reference tablets and likewise, absorption half-life expressed in hours shown 0.67 h for test and 1.04 h for reference respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),h,0.67,50339,DB00537,Ciprofloxacin
,22186313,absorption half-life,"The elimination rate constant Kel [l/h] showed 0.17 l/h for test and 0.15 l/h reference tablets and likewise, absorption half-life expressed in hours shown 0.67 h for test and 1.04 h for reference respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),h,1.04,50340,DB00537,Ciprofloxacin
,22186313,Mean Residence Time,The Mean Residence Time for test is 5.48 h and 5.49 h for reference.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),h,5.48,50341,DB00537,Ciprofloxacin
,22186313,Mean Residence Time,The Mean Residence Time for test is 5.48 h and 5.49 h for reference.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),h,5.49,50342,DB00537,Ciprofloxacin
,22186313,total area under the curve (AUC 0-oo),The mean ± SE values of pharmacokinetic parameters (Microbiological assay) for total area under the curve (AUC 0-oo) were 22.11 and 19.33 h.mg/l for both test and reference tablets respectively.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[h·mg] / [l],22.11,50343,DB00537,Ciprofloxacin
,22186313,total area under the curve (AUC 0-oo),The mean ± SE values of pharmacokinetic parameters (Microbiological assay) for total area under the curve (AUC 0-oo) were 22.11 and 19.33 h.mg/l for both test and reference tablets respectively.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[h·mg] / [l],19.33,50344,DB00537,Ciprofloxacin
,22186313,clearance,The mean ± SE values of clearance measured in l/h were 29.02 and 31.63 respectively.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[l] / [h],29.02,50345,DB00537,Ciprofloxacin
,22186313,clearance,The mean ± SE values of clearance measured in l/h were 29.02 and 31.63 respectively.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[l] / [h],31.63,50346,DB00537,Ciprofloxacin
,22186313,elimination rate constant Kel,"The elimination rate constant Kel [l/h] showed 0.21 l/h for test and 0.20 l/h reference tablets and likewise, absorption half-life expressed in hours shown 0.86h for test and 0.56 h for reference respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[l] / [h],0.21,50347,DB00537,Ciprofloxacin
,22186313,elimination rate constant Kel,"The elimination rate constant Kel [l/h] showed 0.21 l/h for test and 0.20 l/h reference tablets and likewise, absorption half-life expressed in hours shown 0.86h for test and 0.56 h for reference respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),[l] / [h],0.20,50348,DB00537,Ciprofloxacin
,22186313,absorption half-life,"The elimination rate constant Kel [l/h] showed 0.21 l/h for test and 0.20 l/h reference tablets and likewise, absorption half-life expressed in hours shown 0.86h for test and 0.56 h for reference respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),h,0.86,50349,DB00537,Ciprofloxacin
,22186313,absorption half-life,"The elimination rate constant Kel [l/h] showed 0.21 l/h for test and 0.20 l/h reference tablets and likewise, absorption half-life expressed in hours shown 0.86h for test and 0.56 h for reference respectively.",Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),h,0.56,50350,DB00537,Ciprofloxacin
,22186313,Mean Residence Time,The Mean Residence Time for test is 5.27 h and 4.67 h for reference.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),h,5.27,50351,DB00537,Ciprofloxacin
,22186313,Mean Residence Time,The Mean Residence Time for test is 5.27 h and 4.67 h for reference.,Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186313/),h,4.67,50352,DB00537,Ciprofloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,12,50495,DB00537,Ciprofloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,7,50496,DB00537,Ciprofloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,6.8,50497,DB00537,Ciprofloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,4,50498,DB00537,Ciprofloxacin
,12709329,ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC,"The respective ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC varied from 13 to 244 h, and the starting inoculum was 10(8) CFU/ml (6 x 10(9) CFU per 60-ml central compartment).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,13 to 244,50499,DB00537,Ciprofloxacin
,12709329,ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC,"The respective ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC varied from 13 to 244 h, and the starting inoculum was 10(8) CFU/ml (6 x 10(9) CFU per 60-ml central compartment).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),,6,50500,DB00537,Ciprofloxacin
,12709329,AUC(24)/MIC,"With all four quinolones, the greatest increases in MIC were observed at those AUC(24)/MIC values (from 24 to 62 h) that corresponded to quinolone concentrations within the MSW over most of the dosing interval (>20%).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,24,50501,DB00537,Ciprofloxacin
,12709329,AUC(24)/MIC,"With all four quinolones, the greatest increases in MIC were observed at those AUC(24)/MIC values (from 24 to 62 h) that corresponded to quinolone concentrations within the MSW over most of the dosing interval (>20%).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,62,50502,DB00537,Ciprofloxacin
,12709329,AUC(24)/MIC,"Less-pronounced increases in MIC were associated with the smallest simulated AUC(24)/MIC values (15 to 16 h) of GAT and CIP, whose C(max) exceeded the MICs.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,15 to 16,50503,DB00537,Ciprofloxacin
,12709329,AUC(24)/MIC,"No such increases were observed with the smallest AUC(24)/MIC values (13 to 17 h) of MOX and LEV, whose C(max) were close to the MICs.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,13 to 17,50504,DB00537,Ciprofloxacin
,12709329,AUC(24)/MIC,"Also, less pronounced but significant increases in MIC occurred at AUC(24)/MIC values (107 to 123 h) that correspond to quinolone concentrations partly overlapping the MIC-to-MPC range.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,107 to 123,50505,DB00537,Ciprofloxacin
,12709329,AUC(24)/MIC,"With all four drugs, no change in MIC was seen at the highest AUC(24)/MIC values (201 to 244 h), where quinolone concentrations exceeded the MPC over most of the dosing interval.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,201 to 244,50506,DB00537,Ciprofloxacin
,12385699,half-life,"Monoexponentially decreasing concentrations of gemifloxacin (single dose, half-life 7.4 h) and ciprofloxacin (two 12-h doses, half-life 4 h) were simulated in an in vitro dynamic model over 8-fold ranges of the area under the curve (AUC)-to-MIC ratio: from 56 to 466 and 112-932 h, respectively.",Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385699/),h,7.4,50546,DB00537,Ciprofloxacin
,12385699,half-life,"Monoexponentially decreasing concentrations of gemifloxacin (single dose, half-life 7.4 h) and ciprofloxacin (two 12-h doses, half-life 4 h) were simulated in an in vitro dynamic model over 8-fold ranges of the area under the curve (AUC)-to-MIC ratio: from 56 to 466 and 112-932 h, respectively.",Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385699/),h,4,50547,DB00537,Ciprofloxacin
,12385699,area under the curve (AUC)-to-MIC ratio,"Monoexponentially decreasing concentrations of gemifloxacin (single dose, half-life 7.4 h) and ciprofloxacin (two 12-h doses, half-life 4 h) were simulated in an in vitro dynamic model over 8-fold ranges of the area under the curve (AUC)-to-MIC ratio: from 56 to 466 and 112-932 h, respectively.",Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385699/),h,56 to 466,50548,DB00537,Ciprofloxacin
,12385699,area under the curve (AUC)-to-MIC ratio,"Monoexponentially decreasing concentrations of gemifloxacin (single dose, half-life 7.4 h) and ciprofloxacin (two 12-h doses, half-life 4 h) were simulated in an in vitro dynamic model over 8-fold ranges of the area under the curve (AUC)-to-MIC ratio: from 56 to 466 and 112-932 h, respectively.",Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385699/),h,112-932,50549,DB00537,Ciprofloxacin
,12385699,AUC/MIC(90)s,"Based on these predictions, the AUC/MIC(90)s of 320 mg gemifloxacin (800 h with H. influenzae and 400 h with M. catarrhalis) may be 31-34% more efficient than those of 2 x 500 mg ciprofloxacin (730 and 365 h, respectively).",Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385699/),h,800,50550,DB00537,Ciprofloxacin
,12385699,AUC/MIC(90)s,"Based on these predictions, the AUC/MIC(90)s of 320 mg gemifloxacin (800 h with H. influenzae and 400 h with M. catarrhalis) may be 31-34% more efficient than those of 2 x 500 mg ciprofloxacin (730 and 365 h, respectively).",Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385699/),h,400,50551,DB00537,Ciprofloxacin
,12385699,AUC/MIC(90)s,"Based on these predictions, the AUC/MIC(90)s of 320 mg gemifloxacin (800 h with H. influenzae and 400 h with M. catarrhalis) may be 31-34% more efficient than those of 2 x 500 mg ciprofloxacin (730 and 365 h, respectively).",Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385699/),h,730,50552,DB00537,Ciprofloxacin
,12385699,AUC/MIC(90)s,"Based on these predictions, the AUC/MIC(90)s of 320 mg gemifloxacin (800 h with H. influenzae and 400 h with M. catarrhalis) may be 31-34% more efficient than those of 2 x 500 mg ciprofloxacin (730 and 365 h, respectively).",Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385699/),h,365,50553,DB00537,Ciprofloxacin
,11777179,Minimum Inhibitory Concentration (MIC90),"After administration of a single topical dose of ciprofloxacin (0.3%/30 microL), corneal levels greater than the Minimum Inhibitory Concentration (MIC90) (0.5 microg/g) were observed through eight hours.",Ocular bioavailability of ciprofloxacin in sustained release formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777179/),[μg] / [g],0.5,50691,DB00537,Ciprofloxacin
,11777179,Maximum ciprofloxacin concentrations,Maximum ciprofloxacin concentrations in the aqueous humor (0.5-0.7 microg/mL) were attained between one and two hours after dosing.,Ocular bioavailability of ciprofloxacin in sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777179/),[μg] / [ml],0.5-0.7,50692,DB00537,Ciprofloxacin
,25567298,volume of distribution,Values of volume of distribution were respectively 4.63 l/kg and 3.67 l/kg for enrofloxacin and 1.56 l/kg and 1.43 l/kg for marbofloxacin.,Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567298/),[l] / [kg],4.63,52383,DB00537,Ciprofloxacin
,25567298,volume of distribution,Values of volume of distribution were respectively 4.63 l/kg and 3.67 l/kg for enrofloxacin and 1.56 l/kg and 1.43 l/kg for marbofloxacin.,Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567298/),[l] / [kg],3.67,52384,DB00537,Ciprofloxacin
,25567298,volume of distribution,Values of volume of distribution were respectively 4.63 l/kg and 3.67 l/kg for enrofloxacin and 1.56 l/kg and 1.43 l/kg for marbofloxacin.,Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567298/),[l] / [kg],1.56,52385,DB00537,Ciprofloxacin
,25567298,volume of distribution,Values of volume of distribution were respectively 4.63 l/kg and 3.67 l/kg for enrofloxacin and 1.56 l/kg and 1.43 l/kg for marbofloxacin.,Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567298/),[l] / [kg],1.43,52386,DB00537,Ciprofloxacin
,25567298,bioavailability,Higher bioavailability was observed for marbofloxacin (118%).,Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567298/),%,118,52387,DB00537,Ciprofloxacin
,25567298,bioavailability,"Relatively low bioavailability was established in quails for enrofloxacin (26.4%), accompanied by extensive conversion to ciprofloxacin.",Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567298/),%,26.4,52388,DB00537,Ciprofloxacin
more,1511632,recovery,This method yielded a high recovery of more than 85%.,Penetration of fleroxacin into human and animal tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1511632/),%,85,52447,DB00537,Ciprofloxacin
,1511632,peak concentrations,"Following oral administration of the recommended therapeutic dose of 400 mg, once daily, peak concentrations of 5-6 mg/l were reached in human plasma at steady state.",Penetration of fleroxacin into human and animal tissues. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1511632/),[mg] / [l],5-6,52448,DB00537,Ciprofloxacin
,7840567,maximum concentrations,"OPC-17116 showed a high degree of distribution in the lung tissues of both species, with maximum concentrations of 29.6 and 32.0 micrograms/g, respectively.",Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840567/),[μg] / [g],29.6,53129,DB00537,Ciprofloxacin
,7840567,maximum concentrations,"OPC-17116 showed a high degree of distribution in the lung tissues of both species, with maximum concentrations of 29.6 and 32.0 micrograms/g, respectively.",Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840567/),[μg] / [g],32.0,53130,DB00537,Ciprofloxacin
<,7840567,MICs,The MICs of this compound for 90% of these organisms except methicillin-resistant S. aureus and P. aeruginosa ranged from < or = 0.006 to 0.78 microgram/ml.,Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840567/),[μg] / [ml],0,53131,DB00537,Ciprofloxacin
,23065257,half-life,"The half-life and mean residence time of ENR (12.08 hours and 17.85 hours) after intramuscular route were significantly longer compared with intravenous administration (9.54 hours and 7.46 hours, respectively) and these were associated with a flip-flop phenomenon.",Plasma disposition of enrofloxacin following intravenous and intramuscular administration in donkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23065257/),h,12.08,53576,DB00537,Ciprofloxacin
,23065257,half-life,"The half-life and mean residence time of ENR (12.08 hours and 17.85 hours) after intramuscular route were significantly longer compared with intravenous administration (9.54 hours and 7.46 hours, respectively) and these were associated with a flip-flop phenomenon.",Plasma disposition of enrofloxacin following intravenous and intramuscular administration in donkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23065257/),h,9.54,53577,DB00537,Ciprofloxacin
,23065257,mean residence time,"The half-life and mean residence time of ENR (12.08 hours and 17.85 hours) after intramuscular route were significantly longer compared with intravenous administration (9.54 hours and 7.46 hours, respectively) and these were associated with a flip-flop phenomenon.",Plasma disposition of enrofloxacin following intravenous and intramuscular administration in donkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23065257/),h,17.85,53578,DB00537,Ciprofloxacin
,23065257,mean residence time,"The half-life and mean residence time of ENR (12.08 hours and 17.85 hours) after intramuscular route were significantly longer compared with intravenous administration (9.54 hours and 7.46 hours, respectively) and these were associated with a flip-flop phenomenon.",Plasma disposition of enrofloxacin following intravenous and intramuscular administration in donkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23065257/),h,7.46,53579,DB00537,Ciprofloxacin
,23065257,Mean absorption time,"Mean absorption time was relatively long (10.39 hours), and the bioavailability of ENR was 76.56 per cent after intramuscular route in the donkeys.",Plasma disposition of enrofloxacin following intravenous and intramuscular administration in donkeys. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23065257/),h,10.39,53580,DB00537,Ciprofloxacin
,23065257,bioavailability,"Mean absorption time was relatively long (10.39 hours), and the bioavailability of ENR was 76.56 per cent after intramuscular route in the donkeys.",Plasma disposition of enrofloxacin following intravenous and intramuscular administration in donkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23065257/),%,76.56,53581,DB00537,Ciprofloxacin
,10224340,peak lung concentration,"A pharmacokinetic study in infected mice revealed good oral absorption and lung tissue penetration of levofloxacin (peak lung concentration: 5.95 microg/g of lung), low oral absorption of ciprofloxacin in spite of a good penetration into lung tissue (1.10 microg/g of lung), and low lung tissue penetration of ampicillin despite rather good oral absorption (1.71 microg/g of lung).","Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224340/),[μg] / [g],5.95,53608,DB00537,Ciprofloxacin
,10224340,penetration into lung,"A pharmacokinetic study in infected mice revealed good oral absorption and lung tissue penetration of levofloxacin (peak lung concentration: 5.95 microg/g of lung), low oral absorption of ciprofloxacin in spite of a good penetration into lung tissue (1.10 microg/g of lung), and low lung tissue penetration of ampicillin despite rather good oral absorption (1.71 microg/g of lung).","Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224340/),[μg] / [g],1.10,53609,DB00537,Ciprofloxacin
,10224340,oral absorption,"A pharmacokinetic study in infected mice revealed good oral absorption and lung tissue penetration of levofloxacin (peak lung concentration: 5.95 microg/g of lung), low oral absorption of ciprofloxacin in spite of a good penetration into lung tissue (1.10 microg/g of lung), and low lung tissue penetration of ampicillin despite rather good oral absorption (1.71 microg/g of lung).","Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224340/),[μg] / [g],1.71,53610,DB00537,Ciprofloxacin
,10499235,elimination half-life (t1/2,"Pharmacokinetic parameter values for both application routes calculated by noncompartmental methods were similar for danofloxacin compared to enrofloxacin with respect to elimination half-life (t1/2: approximately 6-7 h), mean residence time (MRT; 6-9 h) and mean absorption time (MAT; 1.44 vs. 1.20 h).",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),h,6-7,53922,DB00537,Ciprofloxacin
,10499235,mean residence time (MRT,"Pharmacokinetic parameter values for both application routes calculated by noncompartmental methods were similar for danofloxacin compared to enrofloxacin with respect to elimination half-life (t1/2: approximately 6-7 h), mean residence time (MRT; 6-9 h) and mean absorption time (MAT; 1.44 vs. 1.20 h).",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),h,6-9,53923,DB00537,Ciprofloxacin
,10499235,mean absorption time (MAT,"Pharmacokinetic parameter values for both application routes calculated by noncompartmental methods were similar for danofloxacin compared to enrofloxacin with respect to elimination half-life (t1/2: approximately 6-7 h), mean residence time (MRT; 6-9 h) and mean absorption time (MAT; 1.44 vs. 1.20 h).",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),h,1.44,53924,DB00537,Ciprofloxacin
,10499235,mean absorption time (MAT,"Pharmacokinetic parameter values for both application routes calculated by noncompartmental methods were similar for danofloxacin compared to enrofloxacin with respect to elimination half-life (t1/2: approximately 6-7 h), mean residence time (MRT; 6-9 h) and mean absorption time (MAT; 1.44 vs. 1.20 h).",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),h,1.20,53925,DB00537,Ciprofloxacin
,10499235,body clearance (ClB,"However, values were twofold higher for body clearance (ClB; 24 vs. 10 mL/min.",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[ml] / [min],24,53926,DB00537,Ciprofloxacin
,10499235,body clearance (ClB,"However, values were twofold higher for body clearance (ClB; 24 vs. 10 mL/min.",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[ml] / [min],10,53927,DB00537,Ciprofloxacin
,10499235,volume of distribution at steady state (VdSS,kg) and volume of distribution at steady state (VdSS; 10 vs. 4 L/kg).,Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[l] / [kg],10,53928,DB00537,Ciprofloxacin
,10499235,volume of distribution at steady state (VdSS,kg) and volume of distribution at steady state (VdSS; 10 vs. 4 L/kg).,Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[l] / [kg],4,53929,DB00537,Ciprofloxacin
,10499235,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) after oral administration was 0.5 and 1.9 micrograms/mL for danofloxacin and enrofloxacin, respectively, occurring at 1.5 h for both drugs.",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[μg] / [ml],0.5,53930,DB00537,Ciprofloxacin
,10499235,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) after oral administration was 0.5 and 1.9 micrograms/mL for danofloxacin and enrofloxacin, respectively, occurring at 1.5 h for both drugs.",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[μg] / [ml],1.9,53931,DB00537,Ciprofloxacin
,10499235,Bioavailability (F),Bioavailability (F) was high: 99% for danofloxacin and 89% for enrofloxacin.,Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),%,99,53932,DB00537,Ciprofloxacin
,10499235,Bioavailability (F),Bioavailability (F) was high: 99% for danofloxacin and 89% for enrofloxacin.,Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),%,89,53933,DB00537,Ciprofloxacin
,10499235,Steady-state plasma concentrations,Steady-state plasma concentrations (mean +/- SD) following administration via the drinking water were fourfold higher for enrofloxacin (0.52 +/- 0.16 microgram/mL) compared to danofloxacin (0.12 +/- 0.01 microgram/mL).,Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[μg] / [ml],0.52,53934,DB00537,Ciprofloxacin
,10499235,Steady-state plasma concentrations,Steady-state plasma concentrations (mean +/- SD) following administration via the drinking water were fourfold higher for enrofloxacin (0.52 +/- 0.16 microgram/mL) compared to danofloxacin (0.12 +/- 0.01 microgram/mL).,Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[μg] / [ml],0.12,53935,DB00537,Ciprofloxacin
,10499235,steady-state AUC0-24 h,"The steady-state AUC0-24 h values of 12.48 and 2.88 micrograms.h/mL, respectively, derived from these plasma concentrations are comparable with corresponding area under the plasma concentration-time curve (AUC) values after single oral administration.",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[h·μg] / [ml],12.48,53936,DB00537,Ciprofloxacin
,10499235,steady-state AUC0-24 h,"The steady-state AUC0-24 h values of 12.48 and 2.88 micrograms.h/mL, respectively, derived from these plasma concentrations are comparable with corresponding area under the plasma concentration-time curve (AUC) values after single oral administration.",Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499235/),[h·μg] / [ml],2.88,53937,DB00537,Ciprofloxacin
,2653697,t1/2,"The t1/2 for enoxacin ranges from 4 to 6 hours, which allows effective twice-daily administration without significant accumulation.",Enoxacin absorption and elimination characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653697/),h,4 to 6,54494,DB00537,Ciprofloxacin
,11721591,maximum serum concentration (Cmax),The maximum serum concentration (Cmax) after intramuscular and oral administration were 1.03 and 0.55 mu/ml for danofloxacin and 2.92 and 1.24 mu/ml for ciprofloxacin attained at 0.8 and 2.43 and 0.55 and 1.27 hours for danofloxacin and ciprofloxacin respectively.,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),[mu] / [ml],1.03,54639,DB00537,Ciprofloxacin
,11721591,maximum serum concentration (Cmax),The maximum serum concentration (Cmax) after intramuscular and oral administration were 1.03 and 0.55 mu/ml for danofloxacin and 2.92 and 1.24 mu/ml for ciprofloxacin attained at 0.8 and 2.43 and 0.55 and 1.27 hours for danofloxacin and ciprofloxacin respectively.,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),[mu] / [ml],0.55,54640,DB00537,Ciprofloxacin
,11721591,maximum serum concentration (Cmax),The maximum serum concentration (Cmax) after intramuscular and oral administration were 1.03 and 0.55 mu/ml for danofloxacin and 2.92 and 1.24 mu/ml for ciprofloxacin attained at 0.8 and 2.43 and 0.55 and 1.27 hours for danofloxacin and ciprofloxacin respectively.,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),[mu] / [ml],2.92,54641,DB00537,Ciprofloxacin
,11721591,maximum serum concentration (Cmax),The maximum serum concentration (Cmax) after intramuscular and oral administration were 1.03 and 0.55 mu/ml for danofloxacin and 2.92 and 1.24 mu/ml for ciprofloxacin attained at 0.8 and 2.43 and 0.55 and 1.27 hours for danofloxacin and ciprofloxacin respectively.,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),[mu] / [ml],1.24,54642,DB00537,Ciprofloxacin
,11721591,Vdss,The volume of distribution and systemic bioavailability were higher for danofloxacin (Vdss 2.21 L/kg and F% 96.56 and 81.4%) as compared with ciprofloxacin (Vdss 1.41 L/kg and F% 75.5 and 29.4%).,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),[l] / [kg],2.21,54643,DB00537,Ciprofloxacin
,11721591,F%,The volume of distribution and systemic bioavailability were higher for danofloxacin (Vdss 2.21 L/kg and F% 96.56 and 81.4%) as compared with ciprofloxacin (Vdss 1.41 L/kg and F% 75.5 and 29.4%).,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),%,96.56,54644,DB00537,Ciprofloxacin
,11721591,F%,The volume of distribution and systemic bioavailability were higher for danofloxacin (Vdss 2.21 L/kg and F% 96.56 and 81.4%) as compared with ciprofloxacin (Vdss 1.41 L/kg and F% 75.5 and 29.4%).,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),%,81.4,54645,DB00537,Ciprofloxacin
,11721591,Vdss,The volume of distribution and systemic bioavailability were higher for danofloxacin (Vdss 2.21 L/kg and F% 96.56 and 81.4%) as compared with ciprofloxacin (Vdss 1.41 L/kg and F% 75.5 and 29.4%).,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),[l] / [kg],1.41,54646,DB00537,Ciprofloxacin
,11721591,F%,The volume of distribution and systemic bioavailability were higher for danofloxacin (Vdss 2.21 L/kg and F% 96.56 and 81.4%) as compared with ciprofloxacin (Vdss 1.41 L/kg and F% 75.5 and 29.4%).,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),%,75.5,54647,DB00537,Ciprofloxacin
,11721591,F%,The volume of distribution and systemic bioavailability were higher for danofloxacin (Vdss 2.21 L/kg and F% 96.56 and 81.4%) as compared with ciprofloxacin (Vdss 1.41 L/kg and F% 75.5 and 29.4%).,Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721591/),%,29.4,54648,DB00537,Ciprofloxacin
,7867438,area under the curve of serum concentration versus time,"For the former group, the area under the curve of serum concentration versus time was tripled (42.22 +/- 12.48 vs. 14.55 +/- 6.66 mg.h-1.ml-1, the renal clearance of ciprofloxacin was reduced to one-tenth (22.43 +/- 12.08 vs. 193.13 +/- 65.14 ml/min), and the elimination half-life was prolonged twofold (9.28 +/- 2.42 vs. 4.72 +/- 1.35 h).",[The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees]. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867438/),[mg] / [h·ml],42.22,55399,DB00537,Ciprofloxacin
,7867438,area under the curve of serum concentration versus time,"For the former group, the area under the curve of serum concentration versus time was tripled (42.22 +/- 12.48 vs. 14.55 +/- 6.66 mg.h-1.ml-1, the renal clearance of ciprofloxacin was reduced to one-tenth (22.43 +/- 12.08 vs. 193.13 +/- 65.14 ml/min), and the elimination half-life was prolonged twofold (9.28 +/- 2.42 vs. 4.72 +/- 1.35 h).",[The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees]. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867438/),[mg] / [h·ml],14.55,55400,DB00537,Ciprofloxacin
,7867438,renal clearance,"For the former group, the area under the curve of serum concentration versus time was tripled (42.22 +/- 12.48 vs. 14.55 +/- 6.66 mg.h-1.ml-1, the renal clearance of ciprofloxacin was reduced to one-tenth (22.43 +/- 12.08 vs. 193.13 +/- 65.14 ml/min), and the elimination half-life was prolonged twofold (9.28 +/- 2.42 vs. 4.72 +/- 1.35 h).",[The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867438/),[ml] / [min],22.43,55401,DB00537,Ciprofloxacin
,7867438,renal clearance,"For the former group, the area under the curve of serum concentration versus time was tripled (42.22 +/- 12.48 vs. 14.55 +/- 6.66 mg.h-1.ml-1, the renal clearance of ciprofloxacin was reduced to one-tenth (22.43 +/- 12.08 vs. 193.13 +/- 65.14 ml/min), and the elimination half-life was prolonged twofold (9.28 +/- 2.42 vs. 4.72 +/- 1.35 h).",[The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867438/),[ml] / [min],193.13,55402,DB00537,Ciprofloxacin
,7867438,elimination half-life,"For the former group, the area under the curve of serum concentration versus time was tripled (42.22 +/- 12.48 vs. 14.55 +/- 6.66 mg.h-1.ml-1, the renal clearance of ciprofloxacin was reduced to one-tenth (22.43 +/- 12.08 vs. 193.13 +/- 65.14 ml/min), and the elimination half-life was prolonged twofold (9.28 +/- 2.42 vs. 4.72 +/- 1.35 h).",[The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867438/),h,9.28,55403,DB00537,Ciprofloxacin
,7867438,elimination half-life,"For the former group, the area under the curve of serum concentration versus time was tripled (42.22 +/- 12.48 vs. 14.55 +/- 6.66 mg.h-1.ml-1, the renal clearance of ciprofloxacin was reduced to one-tenth (22.43 +/- 12.08 vs. 193.13 +/- 65.14 ml/min), and the elimination half-life was prolonged twofold (9.28 +/- 2.42 vs. 4.72 +/- 1.35 h).",[The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867438/),h,4.72,55404,DB00537,Ciprofloxacin
,1512936,Maximal serum concentrations,Maximal serum concentrations in these patients were 0.88-1.29 micrograms/ml (mean = 1.08 micrograms/ml).,[Pharmacokinetics and clinical efficacy of ciprofloxacin in aged patients with chronic respiratory diseases]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512936/),[μg] / [ml],0.88-1.29,55506,DB00537,Ciprofloxacin
,1512936,Maximal serum concentrations,Maximal serum concentrations in these patients were 0.88-1.29 micrograms/ml (mean = 1.08 micrograms/ml).,[Pharmacokinetics and clinical efficacy of ciprofloxacin in aged patients with chronic respiratory diseases]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512936/),[μg] / [ml],1.08,55507,DB00537,Ciprofloxacin
,1512936,peak sputum levels,"However, peak sputum levels of CPFX following oral administration of 200 mg CPFX ranged from 0.53 to 1.47 micrograms/ml at 1-4 hours.",[Pharmacokinetics and clinical efficacy of ciprofloxacin in aged patients with chronic respiratory diseases]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512936/),[μg] / [ml],0.53 to 1.47,55508,DB00537,Ciprofloxacin
,11398692,urea clearance,"The CVVHDF displayed a urea clearance of 42 +/- 3 ml/min, and removed ciprofloxacin with a clearance of 37 +/- 7 ml/min.",Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11398692/),[ml] / [min],42,55759,DB00537,Ciprofloxacin
,11398692,clearance,"The CVVHDF displayed a urea clearance of 42 +/- 3 ml/min, and removed ciprofloxacin with a clearance of 37 +/- 7 ml/min.",Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11398692/),[ml] / [min],37,55760,DB00537,Ciprofloxacin
,11398692,total body clearance,The total body clearance of ciprofloxacin was 12.2 +/- 4.3 l/h.,Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11398692/),[l] / [h],12.2,55761,DB00537,Ciprofloxacin
,11398692,trough concentration,The trough concentration following the initial dose was 0.7 +/- 0.3 mg/l.,Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11398692/),[mg] / [l],0.7,55762,DB00537,Ciprofloxacin
,11398692,area under the plasma concentration time curves,The area under the plasma concentration time curves over a 24-h period ranged from 21 to 55 mg.h l-1.,Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11398692/),[h·mg] / [l],21 to 55,55763,DB00537,Ciprofloxacin
,8843294,volume of distribution of the central compartment,"The final median values of the population parameters were follows: the volume of distribution of the central compartment was equal to 0.249 liter/kg, the volume of distribution of the peripheral compartment was equal to 0.173 liter/kg, the distributional clearance between the central and peripheral compartments was equal to 0.2251 liter/h/kg, the slope of the total clearance (CL) versus the creatinine clearance (CLCR) was equal to 0.000736 liter/h/kg of CL/1 ml/min/1.73 m2 of CLCR, and nonrenal clearance was equal to + 0.00527 liter/h/kg.","Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843294/),[l] / [kg],0.249,56066,DB00537,Ciprofloxacin
,8843294,volume of distribution of the peripheral compartment,"The final median values of the population parameters were follows: the volume of distribution of the central compartment was equal to 0.249 liter/kg, the volume of distribution of the peripheral compartment was equal to 0.173 liter/kg, the distributional clearance between the central and peripheral compartments was equal to 0.2251 liter/h/kg, the slope of the total clearance (CL) versus the creatinine clearance (CLCR) was equal to 0.000736 liter/h/kg of CL/1 ml/min/1.73 m2 of CLCR, and nonrenal clearance was equal to + 0.00527 liter/h/kg.","Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843294/),[l] / [kg],0.173,56067,DB00537,Ciprofloxacin
,8843294,distributional clearance between the central and peripheral compartments,"The final median values of the population parameters were follows: the volume of distribution of the central compartment was equal to 0.249 liter/kg, the volume of distribution of the peripheral compartment was equal to 0.173 liter/kg, the distributional clearance between the central and peripheral compartments was equal to 0.2251 liter/h/kg, the slope of the total clearance (CL) versus the creatinine clearance (CLCR) was equal to 0.000736 liter/h/kg of CL/1 ml/min/1.73 m2 of CLCR, and nonrenal clearance was equal to + 0.00527 liter/h/kg.","Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843294/),[l] / [h·kg],0.2251,56068,DB00537,Ciprofloxacin
up to,11958474,minimal inhibitory enrofloxacin concentrations,"Nevertheless, even after single injection, minimal inhibitory enrofloxacin concentrations of up to 0.5 microg ml or microg/g sample against most pathogens of osteomyelitis were exceeded.",Concentration of enrofloxacin and its metabolite ciprofloxacin in canine matrices of the locomotor system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11958474/),ml·μg,0.5,56534,DB00537,Ciprofloxacin
,9124826,AUCtissue/AUCserum ratios,"For cefodizime and cefpirome, the AUCtissue/AUCserum ratios were 0.12 to 0.35 and 1.20 to 1.79, respectively.",Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124826/),,0,56896,DB00537,Ciprofloxacin
,9124826,AUCtissue/AUCserum ratios,The AUCtissue/AUCserum ratios were 0.34 to 0.38 for fleroxacin and 0.42 to 0.49 for dirithromycin.,Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124826/),,0.34 to 0.38,56897,DB00537,Ciprofloxacin
,9124826,AUCtissue/AUCserum ratios,The AUCtissue/AUCserum ratios were 0.34 to 0.38 for fleroxacin and 0.42 to 0.49 for dirithromycin.,Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124826/),,0.42 to 0.49,56898,DB00537,Ciprofloxacin
,33026316,CL,"A one-compartment model was used for ciprofloxacin population pharma-cokinetik (popPK) analysis, and the values for ciprofloxacin CL and Vd in the final model were estimated at 19.8 L/h and 74.9 L, respectively.",Population pharmacokinetics of ciprofloxacin in Pakistani patients suffering from enteric fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33026316/),[l] / [h],19.8,56951,DB00537,Ciprofloxacin
,33026316,Vd,"A one-compartment model was used for ciprofloxacin population pharma-cokinetik (popPK) analysis, and the values for ciprofloxacin CL and Vd in the final model were estimated at 19.8 L/h and 74.9 L, respectively.",Population pharmacokinetics of ciprofloxacin in Pakistani patients suffering from enteric fever. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33026316/),l,74.9,56952,DB00537,Ciprofloxacin
,15155200,MICs,"The geometric mean plasma ciprofloxacin concentrations were applied to an in vitro pharmacokinetic-pharmacodynamic model exposing three different clinical strains of Escherichia coli (MICs, 0.03, 0.5, and 2.0 mg/liter) to 24 h of simulated concentrations in plasma.",Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15155200/),[mg] / [l],0.03,57856,DB00537,Ciprofloxacin
,15155200,MICs,"The geometric mean plasma ciprofloxacin concentrations were applied to an in vitro pharmacokinetic-pharmacodynamic model exposing three different clinical strains of Escherichia coli (MICs, 0.03, 0.5, and 2.0 mg/liter) to 24 h of simulated concentrations in plasma.",Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15155200/),[mg] / [l],0.5,57857,DB00537,Ciprofloxacin
,15155200,MICs,"The geometric mean plasma ciprofloxacin concentrations were applied to an in vitro pharmacokinetic-pharmacodynamic model exposing three different clinical strains of Escherichia coli (MICs, 0.03, 0.5, and 2.0 mg/liter) to 24 h of simulated concentrations in plasma.",Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15155200/),[mg] / [l],2.0,57858,DB00537,Ciprofloxacin
,15155200,MICs,"Comparing the two formulations at equivalent daily doses, the rates and extents of bacterial killing were similar with the IR and XR formulations at MICs of 0.03 and 2.0 mg/liter.",Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15155200/),[mg] / [l],0.03,57859,DB00537,Ciprofloxacin
,15155200,MICs,"Comparing the two formulations at equivalent daily doses, the rates and extents of bacterial killing were similar with the IR and XR formulations at MICs of 0.03 and 2.0 mg/liter.",Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15155200/),[mg] / [l],2.0,57860,DB00537,Ciprofloxacin
,15155200,MIC,"At an MIC of 0.5 mg/liter, however, the 1,000-mg/day XR formulation showed a moderate advantage in antibacterial effect: the area under the CFU-time curve was 45% higher for the IR regimen; the nadir log CFU and 24-h log CFU values for the IR regimen were 3.75 and 2.49, respectively; and those for XR were 4.54 and 3.13, respectively.",Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15155200/),[mg] / [l],0.5,57861,DB00537,Ciprofloxacin
,8540739,areas under the concentration-time curve from 0 h to infinity,"Pharmacokinetic parameters (means +/- standard deviations) for the p.o. and i.v. doses were as follows: areas under the concentration-time curve from 0 h to infinity, 9.74 +/- 2.59 and 11.78 +/- 3.18 micrograms.h/ml, respectively; maximum concentrations of drug in serum, 2.13 +/- 0.67 and 4.21 +/- 1.07 micrograms/ml, respectively; and half-lives, 4.03 +/- 0.58 and 4.20 +/- 0.58 h, respectively.",Absorption of ciprofloxacin in patients with diabetic gastroparesis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540739/),[h·μg] / [ml],9.74,57975,DB00537,Ciprofloxacin
,8540739,areas under the concentration-time curve from 0 h to infinity,"Pharmacokinetic parameters (means +/- standard deviations) for the p.o. and i.v. doses were as follows: areas under the concentration-time curve from 0 h to infinity, 9.74 +/- 2.59 and 11.78 +/- 3.18 micrograms.h/ml, respectively; maximum concentrations of drug in serum, 2.13 +/- 0.67 and 4.21 +/- 1.07 micrograms/ml, respectively; and half-lives, 4.03 +/- 0.58 and 4.20 +/- 0.58 h, respectively.",Absorption of ciprofloxacin in patients with diabetic gastroparesis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540739/),[h·μg] / [ml],11.78,57976,DB00537,Ciprofloxacin
,8540739,maximum concentrations of drug in serum,"Pharmacokinetic parameters (means +/- standard deviations) for the p.o. and i.v. doses were as follows: areas under the concentration-time curve from 0 h to infinity, 9.74 +/- 2.59 and 11.78 +/- 3.18 micrograms.h/ml, respectively; maximum concentrations of drug in serum, 2.13 +/- 0.67 and 4.21 +/- 1.07 micrograms/ml, respectively; and half-lives, 4.03 +/- 0.58 and 4.20 +/- 0.58 h, respectively.",Absorption of ciprofloxacin in patients with diabetic gastroparesis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540739/),[μg] / [ml],2.13,57977,DB00537,Ciprofloxacin
,8540739,maximum concentrations of drug in serum,"Pharmacokinetic parameters (means +/- standard deviations) for the p.o. and i.v. doses were as follows: areas under the concentration-time curve from 0 h to infinity, 9.74 +/- 2.59 and 11.78 +/- 3.18 micrograms.h/ml, respectively; maximum concentrations of drug in serum, 2.13 +/- 0.67 and 4.21 +/- 1.07 micrograms/ml, respectively; and half-lives, 4.03 +/- 0.58 and 4.20 +/- 0.58 h, respectively.",Absorption of ciprofloxacin in patients with diabetic gastroparesis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540739/),[μg] / [ml],4.21,57978,DB00537,Ciprofloxacin
,8540739,half-lives,"Pharmacokinetic parameters (means +/- standard deviations) for the p.o. and i.v. doses were as follows: areas under the concentration-time curve from 0 h to infinity, 9.74 +/- 2.59 and 11.78 +/- 3.18 micrograms.h/ml, respectively; maximum concentrations of drug in serum, 2.13 +/- 0.67 and 4.21 +/- 1.07 micrograms/ml, respectively; and half-lives, 4.03 +/- 0.58 and 4.20 +/- 0.58 h, respectively.",Absorption of ciprofloxacin in patients with diabetic gastroparesis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540739/),h,4.03,57979,DB00537,Ciprofloxacin
,8540739,half-lives,"Pharmacokinetic parameters (means +/- standard deviations) for the p.o. and i.v. doses were as follows: areas under the concentration-time curve from 0 h to infinity, 9.74 +/- 2.59 and 11.78 +/- 3.18 micrograms.h/ml, respectively; maximum concentrations of drug in serum, 2.13 +/- 0.67 and 4.21 +/- 1.07 micrograms/ml, respectively; and half-lives, 4.03 +/- 0.58 and 4.20 +/- 0.58 h, respectively.",Absorption of ciprofloxacin in patients with diabetic gastroparesis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540739/),h,4.20,57980,DB00537,Ciprofloxacin
,8540739,absolute bioavailability,"The ratio of the areas under the concentration-time curves from 0 h to infinity for the p.o. and i.v. doses was 0.84, with a 90% confidence interval of 0.68 to 0.98; the mean absolute bioavailability was calculated to be 67% (range, 43 to 82%).",Absorption of ciprofloxacin in patients with diabetic gastroparesis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540739/),%,67,57981,DB00537,Ciprofloxacin
,3144534,AUC-,The high AUC-value of 60.4 +/- 8.4 mg.h/l is the result of complete absorption and the long half-life of 10.8 +/- 1.6 h.,Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[h·mg] / [l],60.4,57999,DB00537,Ciprofloxacin
,3144534,half-life,The high AUC-value of 60.4 +/- 8.4 mg.h/l is the result of complete absorption and the long half-life of 10.8 +/- 1.6 h.,Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),h,10.8,58000,DB00537,Ciprofloxacin
,3144534,total,"The total, renal and non-renal clearance of fleroxacin were 107.9 +/- 15.1, 67.6 +/- 11.8 and 40.3 +/- 14.5 ml/min respectively.",Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[ml] / [min],107.9,58001,DB00537,Ciprofloxacin
,3144534,renal,"The total, renal and non-renal clearance of fleroxacin were 107.9 +/- 15.1, 67.6 +/- 11.8 and 40.3 +/- 14.5 ml/min respectively.",Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[ml] / [min],67.6,58002,DB00537,Ciprofloxacin
,3144534,non-renal clearance,"The total, renal and non-renal clearance of fleroxacin were 107.9 +/- 15.1, 67.6 +/- 11.8 and 40.3 +/- 14.5 ml/min respectively.",Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[ml] / [min],40.3,58003,DB00537,Ciprofloxacin
,3144534,volume of distribution Vd beta/F,The volume of distribution Vd beta/F was 101.4 +/- 21.9 or 1.32 +/- 0.28 l/kg.,Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[l] / [kg],101.4,58004,DB00537,Ciprofloxacin
,3144534,volume of distribution Vd beta/F,The volume of distribution Vd beta/F was 101.4 +/- 21.9 or 1.32 +/- 0.28 l/kg.,Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[l] / [kg],1.32,58005,DB00537,Ciprofloxacin
,25229385,distribution,"The distribution and elimination half-lives (t0.5α) and (t0.5el), respectively, were 0.10 ± 0.016 h and 3.7 ± 0.08 h in healthy chickens compared with 0.05 ± 0.005 h and 6.42 ± 0.71 h in E. coli-infected birds.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,0.10,58560,DB00537,Ciprofloxacin
,25229385,distribution,"The distribution and elimination half-lives (t0.5α) and (t0.5el), respectively, were 0.10 ± 0.016 h and 3.7 ± 0.08 h in healthy chickens compared with 0.05 ± 0.005 h and 6.42 ± 0.71 h in E. coli-infected birds.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,0.05,58561,DB00537,Ciprofloxacin
,25229385,elimination half-lives (t0.5α),"The distribution and elimination half-lives (t0.5α) and (t0.5el), respectively, were 0.10 ± 0.016 h and 3.7 ± 0.08 h in healthy chickens compared with 0.05 ± 0.005 h and 6.42 ± 0.71 h in E. coli-infected birds.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,0.10,58562,DB00537,Ciprofloxacin
,25229385,elimination half-lives (t0.5α),"The distribution and elimination half-lives (t0.5α) and (t0.5el), respectively, were 0.10 ± 0.016 h and 3.7 ± 0.08 h in healthy chickens compared with 0.05 ± 0.005 h and 6.42 ± 0.71 h in E. coli-infected birds.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,3.7,58563,DB00537,Ciprofloxacin
,25229385,elimination half-lives (t0.5α),"The distribution and elimination half-lives (t0.5α) and (t0.5el), respectively, were 0.10 ± 0.016 h and 3.7 ± 0.08 h in healthy chickens compared with 0.05 ± 0.005 h and 6.42 ± 0.71 h in E. coli-infected birds.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,0.05,58564,DB00537,Ciprofloxacin
,25229385,elimination half-lives (t0.5α),"The distribution and elimination half-lives (t0.5α) and (t0.5el), respectively, were 0.10 ± 0.016 h and 3.7 ± 0.08 h in healthy chickens compared with 0.05 ± 0.005 h and 6.42 ± 0.71 h in E. coli-infected birds.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,6.42,58565,DB00537,Ciprofloxacin
,25229385,(t0.5el),"The distribution and elimination half-lives (t0.5α) and (t0.5el), respectively, were 0.10 ± 0.016 h and 3.7 ± 0.08 h in healthy chickens compared with 0.05 ± 0.005 h and 6.42 ± 0.71 h in E. coli-infected birds.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,3.7,58566,DB00537,Ciprofloxacin
,25229385,(t0.5el),"The distribution and elimination half-lives (t0.5α) and (t0.5el), respectively, were 0.10 ± 0.016 h and 3.7 ± 0.08 h in healthy chickens compared with 0.05 ± 0.005 h and 6.42 ± 0.71 h in E. coli-infected birds.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,6.42,58567,DB00537,Ciprofloxacin
,25229385,volumes of distribution Vdss,"The volumes of distribution Vdss were 3.14 ± 0.11 and 9.25 ± 0.43 l/kg, with total body clearance (Cltot) of 0.65 ± 0.018 and 1.14 ± 0.1 ml/kg/h, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),[l] / [kg],3.14,58568,DB00537,Ciprofloxacin
,25229385,volumes of distribution Vdss,"The volumes of distribution Vdss were 3.14 ± 0.11 and 9.25 ± 0.43 l/kg, with total body clearance (Cltot) of 0.65 ± 0.018 and 1.14 ± 0.1 ml/kg/h, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),[l] / [kg],9.25,58569,DB00537,Ciprofloxacin
,25229385,total body clearance (Cltot),"The volumes of distribution Vdss were 3.14 ± 0.11 and 9.25 ± 0.43 l/kg, with total body clearance (Cltot) of 0.65 ± 0.018 and 1.14 ± 0.1 ml/kg/h, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),[ml] / [h·kg],0.65,58570,DB00537,Ciprofloxacin
,25229385,total body clearance (Cltot),"The volumes of distribution Vdss were 3.14 ± 0.11 and 9.25 ± 0.43 l/kg, with total body clearance (Cltot) of 0.65 ± 0.018 and 1.14 ± 0.1 ml/kg/h, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),[ml] / [h·kg],1.14,58571,DB00537,Ciprofloxacin
,25229385,t0.5(ab),"3. Following oral administration, difloxacin was absorbed with t0.5(ab) of 0.57 ± 0.06 and 0.77 ± 0.04 h and was eliminated with t0.5(el) of 4.7 ± 0.34 and 3.42 ± 0.19, respectively, in normal and infected chickens.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,0.57,58572,DB00537,Ciprofloxacin
,25229385,t0.5(ab),"3. Following oral administration, difloxacin was absorbed with t0.5(ab) of 0.57 ± 0.06 and 0.77 ± 0.04 h and was eliminated with t0.5(el) of 4.7 ± 0.34 and 3.42 ± 0.19, respectively, in normal and infected chickens.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,0.77,58573,DB00537,Ciprofloxacin
,25229385,t0.5(el),"3. Following oral administration, difloxacin was absorbed with t0.5(ab) of 0.57 ± 0.06 and 0.77 ± 0.04 h and was eliminated with t0.5(el) of 4.7 ± 0.34 and 3.42 ± 0.19, respectively, in normal and infected chickens.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),,4.7,58574,DB00537,Ciprofloxacin
,25229385,t0.5(el),"3. Following oral administration, difloxacin was absorbed with t0.5(ab) of 0.57 ± 0.06 and 0.77 ± 0.04 h and was eliminated with t0.5(el) of 4.7 ± 0.34 and 3.42 ± 0.19, respectively, in normal and infected chickens.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),,3.42,58575,DB00537,Ciprofloxacin
,25229385,peak serum concentrations,"The peak serum concentrations were 1.34 ± 0.09 and 1.05 ± 0.06 µg/ml and attained a Tmax of 2.27 ± 0.07 and 2.43 ± 0.06 h, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),[μg] / [ml],1.34,58576,DB00537,Ciprofloxacin
,25229385,peak serum concentrations,"The peak serum concentrations were 1.34 ± 0.09 and 1.05 ± 0.06 µg/ml and attained a Tmax of 2.27 ± 0.07 and 2.43 ± 0.06 h, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),[μg] / [ml],1.05,58577,DB00537,Ciprofloxacin
,25229385,Tmax,"The peak serum concentrations were 1.34 ± 0.09 and 1.05 ± 0.06 µg/ml and attained a Tmax of 2.27 ± 0.07 and 2.43 ± 0.06 h, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,2.27,58578,DB00537,Ciprofloxacin
,25229385,Tmax,"The peak serum concentrations were 1.34 ± 0.09 and 1.05 ± 0.06 µg/ml and attained a Tmax of 2.27 ± 0.07 and 2.43 ± 0.06 h, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),h,2.43,58579,DB00537,Ciprofloxacin
,25229385,systemic bioavailability,The systemic bioavailability of difloxacin following oral administration was 86.2% in healthy chickens and 90.6% in E. coli-infected birds.,Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),%,86.2,58580,DB00537,Ciprofloxacin
,25229385,systemic bioavailability,The systemic bioavailability of difloxacin following oral administration was 86.2% in healthy chickens and 90.6% in E. coli-infected birds.,Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),%,90.6,58581,DB00537,Ciprofloxacin
,25229385,minimum inhibitory concentration (MIC),"The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of difloxacin against the field strain of E. coli O78 in vitro were 0.02 µg and 0.04 µg/ml, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),μg,0.02,58582,DB00537,Ciprofloxacin
,25229385,minimum bactericidal concentration (MBC),"The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of difloxacin against the field strain of E. coli O78 in vitro were 0.02 µg and 0.04 µg/ml, respectively.",Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229385/),[μg] / [ml],0.04,58583,DB00537,Ciprofloxacin
,8452184,serum half-life,Its long serum half-life (8-12 hours) allows once-a-day dosing.,Overview of the pharmacokinetics of fleroxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452184/),h,8-12,58610,DB00537,Ciprofloxacin
,14638484,maximum concentration,"The mean maximum concentration of linezolid in plasma was 13.1 mg/liter, and that of ciprofloxacin was 2.46 mg/liter.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),[mg] / [l],13.1,58667,DB00537,Ciprofloxacin
,14638484,maximum concentration,"The mean maximum concentration of linezolid in plasma was 13.1 mg/liter, and that of ciprofloxacin was 2.46 mg/liter.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),[mg] / [l],2.46,58668,DB00537,Ciprofloxacin
,14638484,cumulative levels of renal excretion,"The median cumulative levels of renal excretion of the administered dose of the parent drug were 44% for linezolid (range, 28 to 47%; mean +/- standard deviation, 40% +/- 7.8%) and 43% for ciprofloxacin (range, 20 to 56%; mean +/- standard deviation, 40% +/- 9.3%).","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),%,44,58669,DB00537,Ciprofloxacin
,14638484,cumulative levels of renal excretion,"The median cumulative levels of renal excretion of the administered dose of the parent drug were 44% for linezolid (range, 28 to 47%; mean +/- standard deviation, 40% +/- 7.8%) and 43% for ciprofloxacin (range, 20 to 56%; mean +/- standard deviation, 40% +/- 9.3%).","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),%,43,58670,DB00537,Ciprofloxacin
,14638484,MICs,"The UBTs, i.e., the highest twofold dilution (with antibiotic-free urine used as the diluent) of urine that was still bactericidal, were determined for a reference strain and five gram-positive clinical uropathogens for which the MICs of linezolid and ciprofloxacin were as follows: Staphylococcus aureus ATCC 27278, 2 and 0.25 mg/liter, respectively; Staphylococcus aureus (methicillin susceptible), 1 and 16 mg/liter, respectively; Staphylococcus aureus (methicillin resistant), 2 and 64 mg/liter, respectively; Staphylococcus saprophyticus (methicillin susceptible), 1 and 0.25 mg/liter, respectively; Enterococcus faecalis, 2 and 1 mg/liter, respectively; and Enterococcus faecium, 2 and 1 mg/liter, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),[mg] / [l],2,58671,DB00537,Ciprofloxacin
,14638484,MICs,"The UBTs, i.e., the highest twofold dilution (with antibiotic-free urine used as the diluent) of urine that was still bactericidal, were determined for a reference strain and five gram-positive clinical uropathogens for which the MICs of linezolid and ciprofloxacin were as follows: Staphylococcus aureus ATCC 27278, 2 and 0.25 mg/liter, respectively; Staphylococcus aureus (methicillin susceptible), 1 and 16 mg/liter, respectively; Staphylococcus aureus (methicillin resistant), 2 and 64 mg/liter, respectively; Staphylococcus saprophyticus (methicillin susceptible), 1 and 0.25 mg/liter, respectively; Enterococcus faecalis, 2 and 1 mg/liter, respectively; and Enterococcus faecium, 2 and 1 mg/liter, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),[mg] / [l],0.25,58672,DB00537,Ciprofloxacin
,14638484,MICs,"The UBTs, i.e., the highest twofold dilution (with antibiotic-free urine used as the diluent) of urine that was still bactericidal, were determined for a reference strain and five gram-positive clinical uropathogens for which the MICs of linezolid and ciprofloxacin were as follows: Staphylococcus aureus ATCC 27278, 2 and 0.25 mg/liter, respectively; Staphylococcus aureus (methicillin susceptible), 1 and 16 mg/liter, respectively; Staphylococcus aureus (methicillin resistant), 2 and 64 mg/liter, respectively; Staphylococcus saprophyticus (methicillin susceptible), 1 and 0.25 mg/liter, respectively; Enterococcus faecalis, 2 and 1 mg/liter, respectively; and Enterococcus faecium, 2 and 1 mg/liter, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),[mg] / [l],1,58673,DB00537,Ciprofloxacin
,14638484,MICs,"The UBTs, i.e., the highest twofold dilution (with antibiotic-free urine used as the diluent) of urine that was still bactericidal, were determined for a reference strain and five gram-positive clinical uropathogens for which the MICs of linezolid and ciprofloxacin were as follows: Staphylococcus aureus ATCC 27278, 2 and 0.25 mg/liter, respectively; Staphylococcus aureus (methicillin susceptible), 1 and 16 mg/liter, respectively; Staphylococcus aureus (methicillin resistant), 2 and 64 mg/liter, respectively; Staphylococcus saprophyticus (methicillin susceptible), 1 and 0.25 mg/liter, respectively; Enterococcus faecalis, 2 and 1 mg/liter, respectively; and Enterococcus faecium, 2 and 1 mg/liter, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),[mg] / [l],16,58674,DB00537,Ciprofloxacin
,14638484,MICs,"The UBTs, i.e., the highest twofold dilution (with antibiotic-free urine used as the diluent) of urine that was still bactericidal, were determined for a reference strain and five gram-positive clinical uropathogens for which the MICs of linezolid and ciprofloxacin were as follows: Staphylococcus aureus ATCC 27278, 2 and 0.25 mg/liter, respectively; Staphylococcus aureus (methicillin susceptible), 1 and 16 mg/liter, respectively; Staphylococcus aureus (methicillin resistant), 2 and 64 mg/liter, respectively; Staphylococcus saprophyticus (methicillin susceptible), 1 and 0.25 mg/liter, respectively; Enterococcus faecalis, 2 and 1 mg/liter, respectively; and Enterococcus faecium, 2 and 1 mg/liter, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),[mg] / [l],64,58675,DB00537,Ciprofloxacin
,14638484,UBTs,The median UBTs of linezolid measured within the first 6 h were 1:96 for each of the two enterococcal strains and between 1:128 and 1:256 for the four staphylococcal strains.,"Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),,1:96,58676,DB00537,Ciprofloxacin
,14638484,UBTs,The median UBTs of linezolid measured within the first 6 h were 1:96 for each of the two enterococcal strains and between 1:128 and 1:256 for the four staphylococcal strains.,"Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),,1:128,58677,DB00537,Ciprofloxacin
,14638484,UBTs,The median UBTs of linezolid measured within the first 6 h were 1:96 for each of the two enterococcal strains and between 1:128 and 1:256 for the four staphylococcal strains.,"Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),,1:256,58678,DB00537,Ciprofloxacin
,14638484,UBTs,"The median UBTs of ciprofloxacin were 1:64 for the two enterococcal strains; between 1:384 and 1:512 for the two ciprofloxacin-susceptible strains; and 1 (bactericidal activity of undiluted urine only) and 1:2 for the two resistant staphylococcal strains, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),,1:64,58679,DB00537,Ciprofloxacin
,14638484,UBTs,"The median UBTs of ciprofloxacin were 1:64 for the two enterococcal strains; between 1:384 and 1:512 for the two ciprofloxacin-susceptible strains; and 1 (bactericidal activity of undiluted urine only) and 1:2 for the two resistant staphylococcal strains, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),,1:384,58680,DB00537,Ciprofloxacin
,14638484,UBTs,"The median UBTs of ciprofloxacin were 1:64 for the two enterococcal strains; between 1:384 and 1:512 for the two ciprofloxacin-susceptible strains; and 1 (bactericidal activity of undiluted urine only) and 1:2 for the two resistant staphylococcal strains, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),,1:512,58681,DB00537,Ciprofloxacin
,14638484,UBTs,"The median UBTs of ciprofloxacin were 1:64 for the two enterococcal strains; between 1:384 and 1:512 for the two ciprofloxacin-susceptible strains; and 1 (bactericidal activity of undiluted urine only) and 1:2 for the two resistant staphylococcal strains, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),,1,58682,DB00537,Ciprofloxacin
,14638484,UBTs,"The median UBTs of ciprofloxacin were 1:64 for the two enterococcal strains; between 1:384 and 1:512 for the two ciprofloxacin-susceptible strains; and 1 (bactericidal activity of undiluted urine only) and 1:2 for the two resistant staphylococcal strains, respectively.","Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638484/),,1:2,58683,DB00537,Ciprofloxacin
,9226619,maximal plasma concentration,A mean (+/- SD) maximal plasma concentration of 1.66 (+/- 0.42) micrograms/ml was measured at 5.75 hr postinjection.,Disposition of enrofloxacin and its metabolite ciprofloxacin after intramuscular injection in juvenile Burmese pythons (Python molurus bivittatus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226619/),[μg] / [ml],1.66,58700,DB00537,Ciprofloxacin
,9226619,half-life,The harmonic mean half-life was calculated to be 6.37 hr.,Disposition of enrofloxacin and its metabolite ciprofloxacin after intramuscular injection in juvenile Burmese pythons (Python molurus bivittatus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226619/),h,6.37,58701,DB00537,Ciprofloxacin
,25881576,Extra,Extracorporeal CL increased with higher-intensity CRRT but the increase was significant for vancomycin only (mean 28 versus 22 mL/minute; P = 0.0003).,A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881576/),[ml] / [min],28,59274,DB00537,Ciprofloxacin
,25881576,Extra,Extracorporeal CL increased with higher-intensity CRRT but the increase was significant for vancomycin only (mean 28 versus 22 mL/minute; P = 0.0003).,A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881576/),[ml] / [min],22,59275,DB00537,Ciprofloxacin
,9624541,peak concentration,"Enoxacin (250 mg/l) demonstrated the highest peak concentration (median) in the urine (0-6 h), followed by ciprofloxacin (237 mg/l) and norfloxacin (157 mg/l) as determined by the HPLC assay.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),[mg] / [l],237,59410,DB00537,Ciprofloxacin
,9624541,peak concentration,"Enoxacin (250 mg/l) demonstrated the highest peak concentration (median) in the urine (0-6 h), followed by ciprofloxacin (237 mg/l) and norfloxacin (157 mg/l) as determined by the HPLC assay.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),[mg] / [l],157,59411,DB00537,Ciprofloxacin
,9624541,total amount,"The total amount (mean) excreted by the kidneys as parent drugs were as follows: enoxacin 54% of dose, ciprofloxacin 33% of dose, and norfloxacin 22% of dose.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),,54,59412,DB00537,Ciprofloxacin
,9624541,total amount,"The total amount (mean) excreted by the kidneys as parent drugs were as follows: enoxacin 54% of dose, ciprofloxacin 33% of dose, and norfloxacin 22% of dose.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),,33,59413,DB00537,Ciprofloxacin
,9624541,plasma concentrations,"The mean plasma concentrations decreased from 1 to 4 h after administration for enoxacin from 1.9 to 1.4 mg/l, for ciprofloxacin from 2.0 to 0.8 mg/l and for norfloxacin from 1.3 to 0.5 mg/l.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),[mg] / [l],1.9 to 1.4,59414,DB00537,Ciprofloxacin
,3204076,peak concentrations,"With the lower dose, the peak concentrations in the bronchial secretions were (mean +/- S.D.) 0.40 +/- 0.29 mg/l after the first injection and 0.35 +/- 0.25 mg/l after the fourth injection.",Penetration of ciprofloxacin in bronchial secretions after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204076/),[mg] / [l],0.40,59602,DB00537,Ciprofloxacin
,3204076,peak concentrations,"With the lower dose, the peak concentrations in the bronchial secretions were (mean +/- S.D.) 0.40 +/- 0.29 mg/l after the first injection and 0.35 +/- 0.25 mg/l after the fourth injection.",Penetration of ciprofloxacin in bronchial secretions after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204076/),[mg] / [l],0.35,59603,DB00537,Ciprofloxacin
,3204076,peak bronchial concentrations,"With the higher dose, the corresponding mean peak bronchial concentrations were 0.84 +/- 0.58 and 1.16 +/- 0.86 mg/l respectively.",Penetration of ciprofloxacin in bronchial secretions after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204076/),[mg] / [l],0.84,59604,DB00537,Ciprofloxacin
,3204076,peak bronchial concentrations,"With the higher dose, the corresponding mean peak bronchial concentrations were 0.84 +/- 0.58 and 1.16 +/- 0.86 mg/l respectively.",Penetration of ciprofloxacin in bronchial secretions after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204076/),[mg] / [l],1.16,59605,DB00537,Ciprofloxacin
,3204076,half-lives,The half-lives of the drug in bronchial secretions ranged from 2.13 to 3.72 h.,Penetration of ciprofloxacin in bronchial secretions after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204076/),h,2.13 to 3.72,59606,DB00537,Ciprofloxacin
,9609412,bioavailability,The mean bioavailability of enteral dosing was 53.1% [95% confidence interval (CI) 43.5-62.8].,Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9609412/),%,53.1,60055,DB00537,Ciprofloxacin
,9609412,serum steady-state concentration,"In seven additional patients, the mean serum steady-state concentration at 2 h after enteral administration was 3.9 microg/ml (95% CI 1.9-5.9), not significantly different from that found in the crossover study (p = 0.4).",Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9609412/),[μg] / [ml],3.9,60056,DB00537,Ciprofloxacin
,3777908,Half-lives,"Half-lives (mean +/- standard deviation) for the intravenous and oral administration arms were 4.2 +/- 0.77 and 4.11 +/- 0.74 h, respectively.",Absolute oral bioavailability of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777908/),h,4.2,60234,DB00537,Ciprofloxacin
,3777908,Half-lives,"Half-lives (mean +/- standard deviation) for the intravenous and oral administration arms were 4.2 +/- 0.77 and 4.11 +/- 0.74 h, respectively.",Absolute oral bioavailability of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777908/),h,4.11,60235,DB00537,Ciprofloxacin
,3777908,serum clearance rate,The serum clearance rate averaged 28.5 +/- 4.7 liters/h per 1.73 m2 for the intravenous administration arm.,Absolute oral bioavailability of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777908/),[l] / [1.73·h·m2],28.5,60236,DB00537,Ciprofloxacin
,3777908,renal clearance rate,The renal clearance rate accounted for approximately 60% of the corresponding serum clearance rate and was 16.9 +/- 3.0 liters/h per 1.73 m2 for the intravenous arm and 17.0 +/- 2.86 liters/h per 1.73 m2 for the oral administration arm.,Absolute oral bioavailability of ciprofloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777908/),[l] / [1.73·h·m2],16.9,60237,DB00537,Ciprofloxacin
,3777908,renal clearance rate,The renal clearance rate accounted for approximately 60% of the corresponding serum clearance rate and was 16.9 +/- 3.0 liters/h per 1.73 m2 for the intravenous arm and 17.0 +/- 2.86 liters/h per 1.73 m2 for the oral administration arm.,Absolute oral bioavailability of ciprofloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777908/),[l] / [1.73·h·m2],17.0,60238,DB00537,Ciprofloxacin
,3777908,Bioavailability,"Bioavailability, defined as the ratio of the area under the curve from 0 h to infinity for the oral to the intravenous dose, was 69 +/- 7%.",Absolute oral bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777908/),%,69,60239,DB00537,Ciprofloxacin
,10963305,maximum serum concentration (Cmax),Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[mg] / [l],2.7,60409,DB00537,Ciprofloxacin
,10963305,maximum serum concentration (Cmax),Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[mg] / [l],0.99,60410,DB00537,Ciprofloxacin
,10963305,area under the blood level curve (AUC),Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[h·mg] / [l],8.82,60411,DB00537,Ciprofloxacin
,10963305,area under the blood level curve (AUC),Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[h·mg] / [l],8.52,60412,DB00537,Ciprofloxacin
,10963305,Cmax,"Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[mg] / [l],1.52,60413,DB00537,Ciprofloxacin
,10963305,Cmax,"Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[mg] / [l],0.57,60414,DB00537,Ciprofloxacin
,10963305,AUC,"Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[h·mg] / [l],9.87,60415,DB00537,Ciprofloxacin
,10963305,AUC,"Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[h·mg] / [l],7.55,60416,DB00537,Ciprofloxacin
,10963305,absolute BA,The absolute BA following oral administration was found to be 0.79+/-0.47 for ciprofloxacin and 1.01+/-0.78 for fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.79,60417,DB00537,Ciprofloxacin
,10963305,absolute BA,The absolute BA following oral administration was found to be 0.79+/-0.47 for ciprofloxacin and 1.01+/-0.78 for fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,1.01,60418,DB00537,Ciprofloxacin
,10963305,renal clearance [Cl(r)],"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.37,60419,DB00537,Ciprofloxacin
,10963305,renal clearance [Cl(r)],"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.53,60420,DB00537,Ciprofloxacin
,10963305,elimination half-life (t1/2),"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.31,60421,DB00537,Ciprofloxacin
,10963305,elimination half-life (t1/2),"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.53,60422,DB00537,Ciprofloxacin
,10963305,elimination half-life (t1/2),"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.99,60423,DB00537,Ciprofloxacin
,15951159,MIC90,"Gemifloxacin demonstrated excellent in vitro activity (minimum inhibitory concentration necessary to inhibit 90% of the strains tested, MIC90 = 0.03 mg/L (range 0.0019-0.03 mg/L)) against 199 strains of Streptococcus pneumoniae.",Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951159/),[mg] / [l],0.03,60457,DB00537,Ciprofloxacin
,15951159,Cmax/MIC90,"Gemifloxacin demonstrated excellent pharmacodynamic parameters, with a Cmax/MIC90 of 67 (where Cmax is the peak serum level) and an AUC/MIC90 of 297 (where AUC is the area under the curve).",Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951159/),,67,60458,DB00537,Ciprofloxacin
,15951159,AUC/MIC90,"Gemifloxacin demonstrated excellent pharmacodynamic parameters, with a Cmax/MIC90 of 67 (where Cmax is the peak serum level) and an AUC/MIC90 of 297 (where AUC is the area under the curve).",Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951159/),,297,60459,DB00537,Ciprofloxacin
,2941262,peak serum levels,Mean peak serum levels were 1.45 micrograms/ml and 2.5 micrograms/ml for 250 and 500 mg doses.,The pharmacology of orally administered ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),[μg] / [ml],1.45,60857,DB00537,Ciprofloxacin
,2941262,peak serum levels,Mean peak serum levels were 1.45 micrograms/ml and 2.5 micrograms/ml for 250 and 500 mg doses.,The pharmacology of orally administered ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),[μg] / [ml],2.5,60858,DB00537,Ciprofloxacin
,2941262,T1/2 alpha,T1/2 alpha values were 0.32 and 0.43 h; T1/2 beta was 4 h and Vd (area) values were 80L and 90L for the two doses respectively.,The pharmacology of orally administered ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),h,0.32,60859,DB00537,Ciprofloxacin
,2941262,T1/2 alpha,T1/2 alpha values were 0.32 and 0.43 h; T1/2 beta was 4 h and Vd (area) values were 80L and 90L for the two doses respectively.,The pharmacology of orally administered ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),h,0.43,60860,DB00537,Ciprofloxacin
,2941262,T1/2 beta,T1/2 alpha values were 0.32 and 0.43 h; T1/2 beta was 4 h and Vd (area) values were 80L and 90L for the two doses respectively.,The pharmacology of orally administered ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),h,4,60861,DB00537,Ciprofloxacin
,2941262,Vd (area),T1/2 alpha values were 0.32 and 0.43 h; T1/2 beta was 4 h and Vd (area) values were 80L and 90L for the two doses respectively.,The pharmacology of orally administered ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),l,80,60862,DB00537,Ciprofloxacin
,2941262,Vd (area),T1/2 alpha values were 0.32 and 0.43 h; T1/2 beta was 4 h and Vd (area) values were 80L and 90L for the two doses respectively.,The pharmacology of orally administered ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),l,90,60863,DB00537,Ciprofloxacin
,2941262,AUC,AUC was 5.65 h. micrograms/ml and 10.37 h. micrograms/ml.,The pharmacology of orally administered ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),[h·μg] / [ml],5.65,60864,DB00537,Ciprofloxacin
,2941262,AUC,AUC was 5.65 h. micrograms/ml and 10.37 h. micrograms/ml.,The pharmacology of orally administered ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),[h·μg] / [ml],10.37,60865,DB00537,Ciprofloxacin
,2941262,Serum clearance,Serum clearance was 23L for both doses.,The pharmacology of orally administered ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941262/),l,23,60866,DB00537,Ciprofloxacin
,11753269,area under concentration-time curve (AUC(0-300)),"Before angioplasty area under concentration-time curve (AUC(0-300)) values for ciprofloxacin were lower in ischemic tissue than in healthy tissue, with median values of 7.1 mg.h/L (range, 3.5-13.0) and 11.3 mg.h/L (range, 3.4-19.0), respectively (P =.03).",Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753269/),[h·mg] / [l],7.1,60940,DB00537,Ciprofloxacin
,11753269,area under concentration-time curve (AUC(0-300)),"Before angioplasty area under concentration-time curve (AUC(0-300)) values for ciprofloxacin were lower in ischemic tissue than in healthy tissue, with median values of 7.1 mg.h/L (range, 3.5-13.0) and 11.3 mg.h/L (range, 3.4-19.0), respectively (P =.03).",Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753269/),[h·mg] / [l],11.3,60941,DB00537,Ciprofloxacin
,11753269,AUC(0-300),"After angioplasty AUC(0-300) values were identical in ischemic and healthy adipose tissue; median AUC(0-300) values were 8.0 mg.h/L (range, 4.0-20.7) and 8.5 mg.h/L (range, 4.4-22.9), respectively (P =.7).",Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753269/),[h·mg] / [l],8.0,60942,DB00537,Ciprofloxacin
,11753269,AUC(0-300),"After angioplasty AUC(0-300) values were identical in ischemic and healthy adipose tissue; median AUC(0-300) values were 8.0 mg.h/L (range, 4.0-20.7) and 8.5 mg.h/L (range, 4.4-22.9), respectively (P =.7).",Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753269/),[h·mg] / [l],8.5,60943,DB00537,Ciprofloxacin
,18467248,mean sampling time,"The mean sampling time in the 1-hour group was 1.47 hours (range, 1.25-1.75 hours) and in the 3-hour group was 3.27 hours (range, 3.03-3.42 hours) after ciprofloxacin dosing.","Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467248/),h,1.47,62012,DB00537,Ciprofloxacin
,18467248,mean sampling time,"The mean sampling time in the 1-hour group was 1.47 hours (range, 1.25-1.75 hours) and in the 3-hour group was 3.27 hours (range, 3.03-3.42 hours) after ciprofloxacin dosing.","Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467248/),h,3.27,62013,DB00537,Ciprofloxacin
,18467248,pro,The mean prostate : serum ciprofloxacin concentration ratio was 1.9 : 1 for the 1-hour group and 1.6 : 1 for the 3-hour group.,"Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467248/),,1.9,62014,DB00537,Ciprofloxacin
,18467248,pro,The mean prostate : serum ciprofloxacin concentration ratio was 1.9 : 1 for the 1-hour group and 1.6 : 1 for the 3-hour group.,"Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467248/),,1.6,62015,DB00537,Ciprofloxacin
,18467248,concentration ratio,The mean prostate : serum ciprofloxacin concentration ratio was 1.9 : 1 for the 1-hour group and 1.6 : 1 for the 3-hour group.,"Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467248/),,1.9,62016,DB00537,Ciprofloxacin
,18467248,concentration ratio,The mean prostate : serum ciprofloxacin concentration ratio was 1.9 : 1 for the 1-hour group and 1.6 : 1 for the 3-hour group.,"Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467248/),,1.6,62017,DB00537,Ciprofloxacin
>,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],128,62027,DB00537,Ciprofloxacin
,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],16,62028,DB00537,Ciprofloxacin
,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],32,62029,DB00537,Ciprofloxacin
,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],0.25,62030,DB00537,Ciprofloxacin
,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],1,62031,DB00537,Ciprofloxacin
,9687379,peak,"The anticipated peak and trough levels of Y-688 were 4 and 1 mg/liter at 0.5 and 12 h, respectively.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],4,62032,DB00537,Ciprofloxacin
,9687379,trough levels,"The anticipated peak and trough levels of Y-688 were 4 and 1 mg/liter at 0.5 and 12 h, respectively.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],1,62033,DB00537,Ciprofloxacin
,1559306,bioavailability,"The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h.",Ofloxacin clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559306/),%,95 to 100,62035,DB00537,Ciprofloxacin
,1559306,peak serum concentrations,"The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h.",Ofloxacin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559306/),[mg] / [l],2 to 3,62036,DB00537,Ciprofloxacin
,1559306,half-life,"The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h.",Ofloxacin clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559306/),h,5 to 8,62037,DB00537,Ciprofloxacin
,31419586,Permeability,"Permeability of small molecules was 10-6-10-5 cm/s showing 13-15 fold range of outward and inward permeation, while permeability of bevacizumab was lower by 2-3 orders of magnitude.",Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419586/),[cm] / [s],10-6-10-5,62128,DB00537,Ciprofloxacin
,2708183,peak plasma concentration,"After administration of a single dose of 5 mg/kg, ciprofloxacin was rapidly absorbed, producing a peak plasma concentration of 1.9 +/- 0.6 mg/l after 3-4 h with an apparent bioavailability of 0.84.",Pharmacokinetics of intraperitoneal ciprofloxacin in patients on CAPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708183/),[mg] / [l],1.9,62215,DB00537,Ciprofloxacin
,2708183,apparent bioavailability,"After administration of a single dose of 5 mg/kg, ciprofloxacin was rapidly absorbed, producing a peak plasma concentration of 1.9 +/- 0.6 mg/l after 3-4 h with an apparent bioavailability of 0.84.",Pharmacokinetics of intraperitoneal ciprofloxacin in patients on CAPD. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708183/),,0.84,62216,DB00537,Ciprofloxacin
,2708183,mean plasma concentration,During the period of administration the mean plasma concentration was 0.5 +/- 0.2 mg/l.,Pharmacokinetics of intraperitoneal ciprofloxacin in patients on CAPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708183/),[mg] / [l],0.5,62217,DB00537,Ciprofloxacin
,2054264,Peak serum ciprofloxacin concentrations,"2. Peak serum ciprofloxacin concentrations and area under the curve (AUC) were significantly reduced when ciprofloxacin was administered with 300 mg ferrous sulphate (3.0 vs 2.0 mg l-1, P less than 0.05 and 12.3 vs 6.7 mg l-1 h, P less than 0.01, respectively).",Clinical and chemical interactions between iron preparations and ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054264/),[mg] / [l],3.0,62288,DB00537,Ciprofloxacin
,2054264,Peak serum ciprofloxacin concentrations,"2. Peak serum ciprofloxacin concentrations and area under the curve (AUC) were significantly reduced when ciprofloxacin was administered with 300 mg ferrous sulphate (3.0 vs 2.0 mg l-1, P less than 0.05 and 12.3 vs 6.7 mg l-1 h, P less than 0.01, respectively).",Clinical and chemical interactions between iron preparations and ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054264/),[mg] / [l],2.0,62289,DB00537,Ciprofloxacin
,2054264,area under the curve (AUC),"2. Peak serum ciprofloxacin concentrations and area under the curve (AUC) were significantly reduced when ciprofloxacin was administered with 300 mg ferrous sulphate (3.0 vs 2.0 mg l-1, P less than 0.05 and 12.3 vs 6.7 mg l-1 h, P less than 0.01, respectively).",Clinical and chemical interactions between iron preparations and ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054264/),[h·mg] / [l],12.3,62290,DB00537,Ciprofloxacin
,2054264,area under the curve (AUC),"2. Peak serum ciprofloxacin concentrations and area under the curve (AUC) were significantly reduced when ciprofloxacin was administered with 300 mg ferrous sulphate (3.0 vs 2.0 mg l-1, P less than 0.05 and 12.3 vs 6.7 mg l-1 h, P less than 0.01, respectively).",Clinical and chemical interactions between iron preparations and ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054264/),[h·mg] / [l],6.7,62291,DB00537,Ciprofloxacin
,2054264,t1/2,"3. When ferrous ion was mixed with ciprofloxacin, rapid spectral changes occurred (t1/2 = 1.9 min).",Clinical and chemical interactions between iron preparations and ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054264/),min,1.9,62292,DB00537,Ciprofloxacin
<,20047912,MIC,"Dalbavancin demonstrated potent in vitro activity against B. anthracis (MIC range, < or =0.03 to 0.5 mg/liter; MIC(50) and MIC(90), 0.06 and 0.25 mg/liter, respectively), which led us to test its efficacy in a murine inhalation anthrax model.",Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047912/),[mg] / [l],0.03 to 0.5,62629,DB00537,Ciprofloxacin
,20047912,MIC(50),"Dalbavancin demonstrated potent in vitro activity against B. anthracis (MIC range, < or =0.03 to 0.5 mg/liter; MIC(50) and MIC(90), 0.06 and 0.25 mg/liter, respectively), which led us to test its efficacy in a murine inhalation anthrax model.",Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047912/),[mg] / [l],0.06,62630,DB00537,Ciprofloxacin
,20047912,MIC(90),"Dalbavancin demonstrated potent in vitro activity against B. anthracis (MIC range, < or =0.03 to 0.5 mg/liter; MIC(50) and MIC(90), 0.06 and 0.25 mg/liter, respectively), which led us to test its efficacy in a murine inhalation anthrax model.",Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047912/),[mg] / [l],0.25,62631,DB00537,Ciprofloxacin
,20047912,peak concentrations,"The peak concentrations of dalbavancin in mouse plasma after the administration of single intraperitoneal doses of 5 and 20 mg/kg of body weight were 15 and 71 mg/kg, respectively.",Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047912/),[mg] / [kg],15,62632,DB00537,Ciprofloxacin
,20047912,peak concentrations,"The peak concentrations of dalbavancin in mouse plasma after the administration of single intraperitoneal doses of 5 and 20 mg/kg of body weight were 15 and 71 mg/kg, respectively.",Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047912/),[mg] / [kg],71,62633,DB00537,Ciprofloxacin
,20047912,terminal half-life,"At 20 mg/kg, the dalbavancin activity was detectable for 6 days after administration (terminal half-life, 53 h), indicating that long intervals between doses were feasible.",Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047912/),h,53,62634,DB00537,Ciprofloxacin
,28363047,peak plasma concentration (Cmax),"The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 μg/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr·μg/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively.",PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363047/),[μg] / [ml],5.25,62952,DB00537,Ciprofloxacin
,28363047,peak plasma concentration (Cmax),"The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 μg/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr·μg/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively.",PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363047/),[μg] / [ml],5.77,62953,DB00537,Ciprofloxacin
,28363047,time to peak plasma concentration (Tmax),"The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 μg/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr·μg/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively.",PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363047/),h,1.49,62954,DB00537,Ciprofloxacin
,28363047,time to peak plasma concentration (Tmax),"The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 μg/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr·μg/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively.",PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363047/),h,1.1,62955,DB00537,Ciprofloxacin
,28363047,area under the curve (AUC),"The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 μg/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr·μg/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively.",PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363047/),[h·μg] / [ml],49.9,62956,DB00537,Ciprofloxacin
,28363047,area under the curve (AUC),"The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 μg/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr·μg/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively.",PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363047/),[h·μg] / [ml],47.3,62957,DB00537,Ciprofloxacin
,28363047,terminal half-life (t1/2),"The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 μg/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr·μg/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively.",PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363047/),h,5.83,62958,DB00537,Ciprofloxacin
,28363047,terminal half-life (t1/2),"The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 μg/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr·μg/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively.",PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363047/),h,6.46,62959,DB00537,Ciprofloxacin
≤,28363047,minimal inhibitory concentration,"Based on the results of the present study, a dose of 15 mg/kg enrofloxacin delivered either orally or subcutaneously in the Caribbean flamingo every 24 hr is recommended for susceptible bacterial pathogens with a minimal inhibitory concentration ≤ 0.25 μg/ml.",PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363047/),[μg] / [ml],0.25,62960,DB00537,Ciprofloxacin
,18611695,C(max),"The mean values for C(max) were 2.45 +/- 0.77 and 2.31 +/- 1.26 microg/ml, for T(max) 1.48 +/- 0.75 and 2.48 +/- 1.46 h, AUC(0-->infinity) 10.91 +/- 3.64 and 11.05 +/- 4.41 microg/ml h, and T (1 2 ) 4.05 +/- 0.65 and 4.08 +/- 0.76 h, respectively, for the febrile and afebrile periods.",Absorption of ciprofloxacin in febrile and afebrile patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611695/),[μg] / [ml],2.45,63252,DB00537,Ciprofloxacin
,18611695,C(max),"The mean values for C(max) were 2.45 +/- 0.77 and 2.31 +/- 1.26 microg/ml, for T(max) 1.48 +/- 0.75 and 2.48 +/- 1.46 h, AUC(0-->infinity) 10.91 +/- 3.64 and 11.05 +/- 4.41 microg/ml h, and T (1 2 ) 4.05 +/- 0.65 and 4.08 +/- 0.76 h, respectively, for the febrile and afebrile periods.",Absorption of ciprofloxacin in febrile and afebrile patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611695/),[μg] / [ml],2.31,63253,DB00537,Ciprofloxacin
,18611695,T(max),"The mean values for C(max) were 2.45 +/- 0.77 and 2.31 +/- 1.26 microg/ml, for T(max) 1.48 +/- 0.75 and 2.48 +/- 1.46 h, AUC(0-->infinity) 10.91 +/- 3.64 and 11.05 +/- 4.41 microg/ml h, and T (1 2 ) 4.05 +/- 0.65 and 4.08 +/- 0.76 h, respectively, for the febrile and afebrile periods.",Absorption of ciprofloxacin in febrile and afebrile patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611695/),h,1.48,63254,DB00537,Ciprofloxacin
,18611695,T(max),"The mean values for C(max) were 2.45 +/- 0.77 and 2.31 +/- 1.26 microg/ml, for T(max) 1.48 +/- 0.75 and 2.48 +/- 1.46 h, AUC(0-->infinity) 10.91 +/- 3.64 and 11.05 +/- 4.41 microg/ml h, and T (1 2 ) 4.05 +/- 0.65 and 4.08 +/- 0.76 h, respectively, for the febrile and afebrile periods.",Absorption of ciprofloxacin in febrile and afebrile patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611695/),h,2.48,63255,DB00537,Ciprofloxacin
,18611695,AUC(0-->infinity),"The mean values for C(max) were 2.45 +/- 0.77 and 2.31 +/- 1.26 microg/ml, for T(max) 1.48 +/- 0.75 and 2.48 +/- 1.46 h, AUC(0-->infinity) 10.91 +/- 3.64 and 11.05 +/- 4.41 microg/ml h, and T (1 2 ) 4.05 +/- 0.65 and 4.08 +/- 0.76 h, respectively, for the febrile and afebrile periods.",Absorption of ciprofloxacin in febrile and afebrile patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611695/),[μg] / [h·ml],10.91,63256,DB00537,Ciprofloxacin
,18611695,AUC(0-->infinity),"The mean values for C(max) were 2.45 +/- 0.77 and 2.31 +/- 1.26 microg/ml, for T(max) 1.48 +/- 0.75 and 2.48 +/- 1.46 h, AUC(0-->infinity) 10.91 +/- 3.64 and 11.05 +/- 4.41 microg/ml h, and T (1 2 ) 4.05 +/- 0.65 and 4.08 +/- 0.76 h, respectively, for the febrile and afebrile periods.",Absorption of ciprofloxacin in febrile and afebrile patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611695/),[μg] / [h·ml],11.05,63257,DB00537,Ciprofloxacin
,18611695,T (1 2 ),"The mean values for C(max) were 2.45 +/- 0.77 and 2.31 +/- 1.26 microg/ml, for T(max) 1.48 +/- 0.75 and 2.48 +/- 1.46 h, AUC(0-->infinity) 10.91 +/- 3.64 and 11.05 +/- 4.41 microg/ml h, and T (1 2 ) 4.05 +/- 0.65 and 4.08 +/- 0.76 h, respectively, for the febrile and afebrile periods.",Absorption of ciprofloxacin in febrile and afebrile patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611695/),h,4.05,63258,DB00537,Ciprofloxacin
,18611695,T (1 2 ),"The mean values for C(max) were 2.45 +/- 0.77 and 2.31 +/- 1.26 microg/ml, for T(max) 1.48 +/- 0.75 and 2.48 +/- 1.46 h, AUC(0-->infinity) 10.91 +/- 3.64 and 11.05 +/- 4.41 microg/ml h, and T (1 2 ) 4.05 +/- 0.65 and 4.08 +/- 0.76 h, respectively, for the febrile and afebrile periods.",Absorption of ciprofloxacin in febrile and afebrile patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611695/),h,4.08,63259,DB00537,Ciprofloxacin
,6489326,elimination half-life,The elimination half-life was about 4 h and the renal clearance was 4.75 ml/min .,Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489326/),h,4,64091,DB00537,Ciprofloxacin
,6489326,renal clearance,The elimination half-life was about 4 h and the renal clearance was 4.75 ml/min .,Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489326/),[ml] / [min],4.75,64092,DB00537,Ciprofloxacin
,6489326,total clearance,The total clearance (9.62 ml/min . kg) was about twofold higher than the renal clearance.,Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489326/),[ml] / [kg·min],9.62,64093,DB00537,Ciprofloxacin
,6489326,volume of distribution of the central compartment,The volume of distribution of the central compartment was calculated to be 0.161 l/kg and the total volume at steady state was 2.0 l/kg.,Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489326/),[l] / [kg],0.161,64094,DB00537,Ciprofloxacin
,6489326,total volume at steady state,The volume of distribution of the central compartment was calculated to be 0.161 l/kg and the total volume at steady state was 2.0 l/kg.,Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489326/),[l] / [kg],2.0,64095,DB00537,Ciprofloxacin
,6489326,urinary recovery,"About 27% of the oral dose was excreted in urine, whereas the urinary recovery of the i.v. dose was 46%.",Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489326/),%,46,64096,DB00537,Ciprofloxacin
,6489326,absolute bioavailability,The absolute bioavailability of ciprofloxacin was found to be approximately 60%.,Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489326/),%,60,64097,DB00537,Ciprofloxacin
,34275813,Cmax,"The mean values of Cmax and Tmax were found to be 1.35±0.09µg/ml and 1.25±0.27h respectively while for other pharmacokinetic parameters including AUCo-t, AUC0-∞ were found to be 5.98±0.96 μg/ml×h and 6.34±1.07μg/ml×h.",Modification and validation of liquid chromatographic method for the quantification of ciprofloxacin in human plasma and its application to a bioavailability study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275813/),[μg] / [ml],1.35,64761,DB00537,Ciprofloxacin
,34275813,Tmax,"The mean values of Cmax and Tmax were found to be 1.35±0.09µg/ml and 1.25±0.27h respectively while for other pharmacokinetic parameters including AUCo-t, AUC0-∞ were found to be 5.98±0.96 μg/ml×h and 6.34±1.07μg/ml×h.",Modification and validation of liquid chromatographic method for the quantification of ciprofloxacin in human plasma and its application to a bioavailability study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275813/),h,1.25,64762,DB00537,Ciprofloxacin
,34275813,AUCo-t,"The mean values of Cmax and Tmax were found to be 1.35±0.09µg/ml and 1.25±0.27h respectively while for other pharmacokinetic parameters including AUCo-t, AUC0-∞ were found to be 5.98±0.96 μg/ml×h and 6.34±1.07μg/ml×h.",Modification and validation of liquid chromatographic method for the quantification of ciprofloxacin in human plasma and its application to a bioavailability study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275813/),[μg] / [h·ml],5.98,64763,DB00537,Ciprofloxacin
,34275813,AUC0-∞,"The mean values of Cmax and Tmax were found to be 1.35±0.09µg/ml and 1.25±0.27h respectively while for other pharmacokinetic parameters including AUCo-t, AUC0-∞ were found to be 5.98±0.96 μg/ml×h and 6.34±1.07μg/ml×h.",Modification and validation of liquid chromatographic method for the quantification of ciprofloxacin in human plasma and its application to a bioavailability study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275813/),[μg] / [h·ml],6.34,64764,DB00537,Ciprofloxacin
,34275813,half-life (t½),The drug exhibited half-life (t½) of 3.94±0.33h.,Modification and validation of liquid chromatographic method for the quantification of ciprofloxacin in human plasma and its application to a bioavailability study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275813/),h,3.94,64765,DB00537,Ciprofloxacin
,18614429,peak plasma concentrations,"The peak plasma concentrations of (2.28+/-0.04 mg/L) and (1.9+/-0.02 mg/L) was attained in about 1.71 hours and 2.00 hours for both Test and Reference ciprofloxacin, respectively.",Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18614429/),[mg] / [l],2.28,66593,DB00537,Ciprofloxacin
,18614429,peak plasma concentrations,"The peak plasma concentrations of (2.28+/-0.04 mg/L) and (1.9+/-0.02 mg/L) was attained in about 1.71 hours and 2.00 hours for both Test and Reference ciprofloxacin, respectively.",Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18614429/),[mg] / [l],1.9,66594,DB00537,Ciprofloxacin
,18614429,total area under the curve (AUC),The mean +/- SE values for total area under the curve (AUC) were 11.91+/-0.26 and 13.11+/-0.27 h.mg/L for both test and reference tablets respectively.,Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18614429/),[h·mg] / [l],11.91,66595,DB00537,Ciprofloxacin
,18614429,total area under the curve (AUC),The mean +/- SE values for total area under the curve (AUC) were 11.91+/-0.26 and 13.11+/-0.27 h.mg/L for both test and reference tablets respectively.,Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18614429/),[h·mg] / [l],13.11,66596,DB00537,Ciprofloxacin
,8157550,peak plasma concentration,Mean peak plasma concentration was 6.7 +/- 1.4 mg/L after i.v. and 3.9 +/- 1.7 mg/L after oral administration with mean elimination half-lives of 4.2 and 4.0 h respectively.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),[mg] / [l],6.7,67104,DB00537,Ciprofloxacin
,8157550,peak plasma concentration,Mean peak plasma concentration was 6.7 +/- 1.4 mg/L after i.v. and 3.9 +/- 1.7 mg/L after oral administration with mean elimination half-lives of 4.2 and 4.0 h respectively.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),[mg] / [l],3.9,67105,DB00537,Ciprofloxacin
,8157550,elimination half-lives,Mean peak plasma concentration was 6.7 +/- 1.4 mg/L after i.v. and 3.9 +/- 1.7 mg/L after oral administration with mean elimination half-lives of 4.2 and 4.0 h respectively.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),h,4.2,67106,DB00537,Ciprofloxacin
,8157550,elimination half-lives,Mean peak plasma concentration was 6.7 +/- 1.4 mg/L after i.v. and 3.9 +/- 1.7 mg/L after oral administration with mean elimination half-lives of 4.2 and 4.0 h respectively.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),h,4.0,67107,DB00537,Ciprofloxacin
,8157550,area under the concentration versus time curve (AUC),Mean area under the concentration versus time curve (AUC) was greater following oral administration (19.2 +/- 1.1 mg/L.h versus 14.2 +/- 1.1 mg/L.h).,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),[mg] / [h·l],19.2,67108,DB00537,Ciprofloxacin
,8157550,area under the concentration versus time curve (AUC),Mean area under the concentration versus time curve (AUC) was greater following oral administration (19.2 +/- 1.1 mg/L.h versus 14.2 +/- 1.1 mg/L.h).,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),[mg] / [h·l],14.2,67109,DB00537,Ciprofloxacin
,8157550,peak concentrations,Blister fluid peak concentrations following i.v. and oral administration were 2.6 +/- 1.3 mg/L and 2.28 +/- 1.2 mg/L respectively.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),[mg] / [l],2.6,67110,DB00537,Ciprofloxacin
,8157550,peak concentrations,Blister fluid peak concentrations following i.v. and oral administration were 2.6 +/- 1.3 mg/L and 2.28 +/- 1.2 mg/L respectively.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),[mg] / [l],2.28,67111,DB00537,Ciprofloxacin
,8157550,elimination half-life from blister fluid,The elimination half-life from blister fluid was 4.1 +/- 1.1 h and the AUC 13.8 +/- 1.1 mg/L.h following i.v. administration compared with 4.6 +/- 1.5 h and 20.3 +/- 1.3 mg/L.h for the oral dose.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),h,4.1,67112,DB00537,Ciprofloxacin
,8157550,elimination half-life from blister fluid,The elimination half-life from blister fluid was 4.1 +/- 1.1 h and the AUC 13.8 +/- 1.1 mg/L.h following i.v. administration compared with 4.6 +/- 1.5 h and 20.3 +/- 1.3 mg/L.h for the oral dose.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),h,4.6,67113,DB00537,Ciprofloxacin
,8157550,AUC,The elimination half-life from blister fluid was 4.1 +/- 1.1 h and the AUC 13.8 +/- 1.1 mg/L.h following i.v. administration compared with 4.6 +/- 1.5 h and 20.3 +/- 1.3 mg/L.h for the oral dose.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),[mg] / [h·l],13.8,67114,DB00537,Ciprofloxacin
,8157550,AUC,The elimination half-life from blister fluid was 4.1 +/- 1.1 h and the AUC 13.8 +/- 1.1 mg/L.h following i.v. administration compared with 4.6 +/- 1.5 h and 20.3 +/- 1.3 mg/L.h for the oral dose.,The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157550/),[mg] / [h·l],20.3,67115,DB00537,Ciprofloxacin
,3282749,bioavaila,"With the exception of norfloxacin, which is only 30 to 40% bioavailable from the oral route, the 4-quinolones are 80 to 100% bioavailable, absorption occurring within 1 to 3 hours.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,80 to 100,67687,DB00537,Ciprofloxacin
greater,3282749,volumes of distribution,"The 4-quinolones are widely distributed throughout the body, with volumes of distribution greater than 1.5 L/kg.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),[l] / [kg],1.5,67688,DB00537,Ciprofloxacin
less,3282749,Protein binding,Protein binding is less than 30% in most cases.,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,30,67689,DB00537,Ciprofloxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,3 and 5,67690,DB00537,Ciprofloxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,8 to 14,67691,DB00537,Ciprofloxacin
,1491053,limit of detection,The limit of detection of ciprofloxacin is 0.05 microgram/ml and that of its three metabolites is 0.25 microgram/ml.,Improved high-performance liquid chromatographic determination of ciprofloxacin and its metabolites in human specimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491053/),[μg] / [ml],0.05,67715,DB00537,Ciprofloxacin
,1491053,limit of detection,The limit of detection of ciprofloxacin is 0.05 microgram/ml and that of its three metabolites is 0.25 microgram/ml.,Improved high-performance liquid chromatographic determination of ciprofloxacin and its metabolites in human specimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491053/),[μg] / [ml],0.25,67716,DB00537,Ciprofloxacin
,11782909,Q(p),"The obtained Q(p) of 2.81 L/h/kg, F(a) of 32.6, F(h) of 68.1, and BA of 22.2% were found to be in good agreement with the reported values.",A recirculatory model for local absorption and disposition of ciprofloxacin by measuring portal and systemic blood concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782909/),[l] / [h·kg],2.81,68312,DB00537,Ciprofloxacin
,11782909,F(a),"The obtained Q(p) of 2.81 L/h/kg, F(a) of 32.6, F(h) of 68.1, and BA of 22.2% were found to be in good agreement with the reported values.",A recirculatory model for local absorption and disposition of ciprofloxacin by measuring portal and systemic blood concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782909/),,32.6,68313,DB00537,Ciprofloxacin
,11782909,F(h),"The obtained Q(p) of 2.81 L/h/kg, F(a) of 32.6, F(h) of 68.1, and BA of 22.2% were found to be in good agreement with the reported values.",A recirculatory model for local absorption and disposition of ciprofloxacin by measuring portal and systemic blood concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782909/),%,68.1,68314,DB00537,Ciprofloxacin
,11782909,BA,"The obtained Q(p) of 2.81 L/h/kg, F(a) of 32.6, F(h) of 68.1, and BA of 22.2% were found to be in good agreement with the reported values.",A recirculatory model for local absorption and disposition of ciprofloxacin by measuring portal and systemic blood concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782909/),%,22.2,68315,DB00537,Ciprofloxacin
,12238145,area under the plasma concentration-time curve (AUC0-->infinity),"The area under the plasma concentration-time curve (AUC0-->infinity) values, after the first dose was administered, for the 30 mg/kg groups given garenoxacin, ciprofloxacin and norfloxacin were 164, 68.1 and 65.7 micrograms.hr/mL, respectively.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],164,68460,DB00537,Ciprofloxacin
,12238145,area under the plasma concentration-time curve (AUC0-->infinity),"The area under the plasma concentration-time curve (AUC0-->infinity) values, after the first dose was administered, for the 30 mg/kg groups given garenoxacin, ciprofloxacin and norfloxacin were 164, 68.1 and 65.7 micrograms.hr/mL, respectively.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],68.1,68461,DB00537,Ciprofloxacin
,12238145,area under the plasma concentration-time curve (AUC0-->infinity),"The area under the plasma concentration-time curve (AUC0-->infinity) values, after the first dose was administered, for the 30 mg/kg groups given garenoxacin, ciprofloxacin and norfloxacin were 164, 68.1 and 65.7 micrograms.hr/mL, respectively.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],65.7,68462,DB00537,Ciprofloxacin
,12238145,AUC0-->infinity,"The AUC0-->infinity values, obtained after the 6th day of antimicrobial administration, were 202 and 173 micrograms.hr/mL for male and female dogs, respectively, from the 50 mg/kg garenoxacin group.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],202,68463,DB00537,Ciprofloxacin
,12238145,AUC0-->infinity,"The AUC0-->infinity values, obtained after the 6th day of antimicrobial administration, were 202 and 173 micrograms.hr/mL for male and female dogs, respectively, from the 50 mg/kg garenoxacin group.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],173,68464,DB00537,Ciprofloxacin
,29943470,Serum half-lives,Serum half-lives ranged from 64.56 to 72.68 hr.,Pharmacokinetic/pharmacodynamic relationship of enrofloxacin against Aeromonas hydrophila in crucian carp (Carassius auratus gibelio). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943470/),h,64.56 to 72.68,68785,DB00537,Ciprofloxacin
,29943470,AUC/minimum inhibitory concentration (MIC) ratio,"Dosing of 10 mg/kg resulted in an AUC/minimum inhibitory concentration (MIC) ratio of 368.92 hr and a Cmax /MIC ratio of 7.23, respectively, against A. hydrophila 147 (MIC = 0.48 μg/ml), indicating a likely high level of effectiveness in clinical infections caused by A. hydrophila with MIC value ≤ 0.48 μg/ml.",Pharmacokinetic/pharmacodynamic relationship of enrofloxacin against Aeromonas hydrophila in crucian carp (Carassius auratus gibelio). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943470/),h,368.92,68786,DB00537,Ciprofloxacin
,29943470,Cmax /MIC ratio,"Dosing of 10 mg/kg resulted in an AUC/minimum inhibitory concentration (MIC) ratio of 368.92 hr and a Cmax /MIC ratio of 7.23, respectively, against A. hydrophila 147 (MIC = 0.48 μg/ml), indicating a likely high level of effectiveness in clinical infections caused by A. hydrophila with MIC value ≤ 0.48 μg/ml.",Pharmacokinetic/pharmacodynamic relationship of enrofloxacin against Aeromonas hydrophila in crucian carp (Carassius auratus gibelio). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943470/),,7.23,68787,DB00537,Ciprofloxacin
,29943470,MIC,"Dosing of 10 mg/kg resulted in an AUC/minimum inhibitory concentration (MIC) ratio of 368.92 hr and a Cmax /MIC ratio of 7.23, respectively, against A. hydrophila 147 (MIC = 0.48 μg/ml), indicating a likely high level of effectiveness in clinical infections caused by A. hydrophila with MIC value ≤ 0.48 μg/ml.",Pharmacokinetic/pharmacodynamic relationship of enrofloxacin against Aeromonas hydrophila in crucian carp (Carassius auratus gibelio). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943470/),[μg] / [ml],0.48,68788,DB00537,Ciprofloxacin
≤,29943470,MIC,"Dosing of 10 mg/kg resulted in an AUC/minimum inhibitory concentration (MIC) ratio of 368.92 hr and a Cmax /MIC ratio of 7.23, respectively, against A. hydrophila 147 (MIC = 0.48 μg/ml), indicating a likely high level of effectiveness in clinical infections caused by A. hydrophila with MIC value ≤ 0.48 μg/ml.",Pharmacokinetic/pharmacodynamic relationship of enrofloxacin against Aeromonas hydrophila in crucian carp (Carassius auratus gibelio). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943470/),[μg] / [ml],0.48,68789,DB00537,Ciprofloxacin
,29943470,AUC24 hr /MIC,"Modeling of ex vivo growth inhibition data to the sigmoid Emax equation provided the values of AUC24 hr /MIC required to produce bacteriostasis, bactericidal activity, and elimination of bacteria, these values were 21.70, 53.01, and 125.21 hr, respectively.",Pharmacokinetic/pharmacodynamic relationship of enrofloxacin against Aeromonas hydrophila in crucian carp (Carassius auratus gibelio). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943470/),h,21.70,68790,DB00537,Ciprofloxacin
,29943470,AUC24 hr /MIC,"Modeling of ex vivo growth inhibition data to the sigmoid Emax equation provided the values of AUC24 hr /MIC required to produce bacteriostasis, bactericidal activity, and elimination of bacteria, these values were 21.70, 53.01, and 125.21 hr, respectively.",Pharmacokinetic/pharmacodynamic relationship of enrofloxacin against Aeromonas hydrophila in crucian carp (Carassius auratus gibelio). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943470/),h,53.01,68791,DB00537,Ciprofloxacin
,29943470,AUC24 hr /MIC,"Modeling of ex vivo growth inhibition data to the sigmoid Emax equation provided the values of AUC24 hr /MIC required to produce bacteriostasis, bactericidal activity, and elimination of bacteria, these values were 21.70, 53.01, and 125.21 hr, respectively.",Pharmacokinetic/pharmacodynamic relationship of enrofloxacin against Aeromonas hydrophila in crucian carp (Carassius auratus gibelio). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943470/),h,125.21,68792,DB00537,Ciprofloxacin
,1803994,intracellular/serum ratio,"High-performance liquid chromatographic determination of ciprofloxacin in serum and cells showed that the intracellular/serum ratio was 3.7 at 1.5 h (maximum concentration of drug in serum), 5.7 at 12 h, and 20 at 24 h.",In vitro and in vivo ciprofloxacin pharmacokinetics in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803994/),,3.7,69947,DB00537,Ciprofloxacin
,1803994,intracellular/serum ratio,"High-performance liquid chromatographic determination of ciprofloxacin in serum and cells showed that the intracellular/serum ratio was 3.7 at 1.5 h (maximum concentration of drug in serum), 5.7 at 12 h, and 20 at 24 h.",In vitro and in vivo ciprofloxacin pharmacokinetics in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803994/),,5.7,69948,DB00537,Ciprofloxacin
,1803994,area under the curve ratio,The area under the curve ratio was 3.73.,In vitro and in vivo ciprofloxacin pharmacokinetics in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803994/),,3.73,69949,DB00537,Ciprofloxacin
,1803994,elimination half-lives,"The mean elimination half-lives of ciprofloxacin were 3.7 and 6.2 h in serum and PMNs, respectively.",In vitro and in vivo ciprofloxacin pharmacokinetics in human neutrophils. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803994/),h,3.7,69950,DB00537,Ciprofloxacin
,1803994,elimination half-lives,"The mean elimination half-lives of ciprofloxacin were 3.7 and 6.2 h in serum and PMNs, respectively.",In vitro and in vivo ciprofloxacin pharmacokinetics in human neutrophils. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803994/),h,6.2,69951,DB00537,Ciprofloxacin
,15456526,maximum serum concentration (Cmax),"The maximum serum concentration (Cmax), the area under the plasma concentration-time curve (AUC(0-infinity)), and concentration in cartilage was 16.3 +/- 2.1 mg/L, 97.2 +/- 12.3 mg x h x L(-1), and 13.4 +/- 2.8 microg x g(-1) and 21.8 +/- 2.5 mg/L, 143.1 +/- 22.3 mg x h x L(-1), and 20.3 +/- 3.5 microg x g(-1) after oral administration of CPFX 800 or 1200 mg/kg on d 1, respectively.",In vivo and in vitro chondrotoxicity of ciprofloxacin in juvenile rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15456526/),[mg] / [l],16.3,70237,DB00537,Ciprofloxacin
,15456526,area under the plasma concentration-time curve (AUC(0-infinity)),"The maximum serum concentration (Cmax), the area under the plasma concentration-time curve (AUC(0-infinity)), and concentration in cartilage was 16.3 +/- 2.1 mg/L, 97.2 +/- 12.3 mg x h x L(-1), and 13.4 +/- 2.8 microg x g(-1) and 21.8 +/- 2.5 mg/L, 143.1 +/- 22.3 mg x h x L(-1), and 20.3 +/- 3.5 microg x g(-1) after oral administration of CPFX 800 or 1200 mg/kg on d 1, respectively.",In vivo and in vitro chondrotoxicity of ciprofloxacin in juvenile rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15456526/),[h·mg] / [l],97.2,70238,DB00537,Ciprofloxacin
,15456526,area under the plasma concentration-time curve (AUC(0-infinity)),"The maximum serum concentration (Cmax), the area under the plasma concentration-time curve (AUC(0-infinity)), and concentration in cartilage was 16.3 +/- 2.1 mg/L, 97.2 +/- 12.3 mg x h x L(-1), and 13.4 +/- 2.8 microg x g(-1) and 21.8 +/- 2.5 mg/L, 143.1 +/- 22.3 mg x h x L(-1), and 20.3 +/- 3.5 microg x g(-1) after oral administration of CPFX 800 or 1200 mg/kg on d 1, respectively.",In vivo and in vitro chondrotoxicity of ciprofloxacin in juvenile rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15456526/),[μg] / [g],13.4,70239,DB00537,Ciprofloxacin
,15456526,area under the plasma concentration-time curve (AUC(0-infinity)),"The maximum serum concentration (Cmax), the area under the plasma concentration-time curve (AUC(0-infinity)), and concentration in cartilage was 16.3 +/- 2.1 mg/L, 97.2 +/- 12.3 mg x h x L(-1), and 13.4 +/- 2.8 microg x g(-1) and 21.8 +/- 2.5 mg/L, 143.1 +/- 22.3 mg x h x L(-1), and 20.3 +/- 3.5 microg x g(-1) after oral administration of CPFX 800 or 1200 mg/kg on d 1, respectively.",In vivo and in vitro chondrotoxicity of ciprofloxacin in juvenile rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15456526/),[μg] / [g],20.3,70240,DB00537,Ciprofloxacin
,15456526,concentration,"The maximum serum concentration (Cmax), the area under the plasma concentration-time curve (AUC(0-infinity)), and concentration in cartilage was 16.3 +/- 2.1 mg/L, 97.2 +/- 12.3 mg x h x L(-1), and 13.4 +/- 2.8 microg x g(-1) and 21.8 +/- 2.5 mg/L, 143.1 +/- 22.3 mg x h x L(-1), and 20.3 +/- 3.5 microg x g(-1) after oral administration of CPFX 800 or 1200 mg/kg on d 1, respectively.",In vivo and in vitro chondrotoxicity of ciprofloxacin in juvenile rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15456526/),[μg] / [g],13.4,70241,DB00537,Ciprofloxacin
<,27121980,MIC,"Results suggest that E is able to reach blood concentrations high enough to kill susceptible bacteria (MIC < 0.9 μg/mL), but at the same time does not significantly affect intestinal bacteria.",Pharmacokinetic and pharmacodynamic evaluations of a 10 mg/kg enrofloxacin intramuscular administration in bearded dragons (Pogona vitticeps): a preliminary assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121980/),[μg] / [ml],0.9,70438,DB00537,Ciprofloxacin
,7802401,flow rate,"For each compound, the placenta in 5 rabbits was perfused for 200 minutes with Earle's enriched bicarbonate buffer at flow rate of 1.5 ml/min.",Placental transfer of enrofloxacin and ciprofloxacin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802401/),[ml] / [min],1.5,70987,DB00537,Ciprofloxacin
,7802401,Placental clearance,Placental clearance of the drugs was significantly (P < 0.01) different (0.88 +/- 0.13 ml/min for enrofloxacin and 0.06 +/- 0.02 ml/min for ciprofloxacin).,Placental transfer of enrofloxacin and ciprofloxacin in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802401/),[ml] / [min],0.88,70988,DB00537,Ciprofloxacin
,7802401,Placental clearance,Placental clearance of the drugs was significantly (P < 0.01) different (0.88 +/- 0.13 ml/min for enrofloxacin and 0.06 +/- 0.02 ml/min for ciprofloxacin).,Placental transfer of enrofloxacin and ciprofloxacin in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802401/),[ml] / [min],0.06,70989,DB00537,Ciprofloxacin
,3555029,absorption rate constant,"Mean values for compartmental rate constants (hours-1) were as follows: absorption rate constant = 1.15; intercompartmental rate constants, k12 = 0.48, and k21 = 0.58; elimination rate constant = 0.46; distribution rate constant = 1.31; and terminal elimination rate constant = 0.19.","Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),1/[h],1.15,71392,DB00537,Ciprofloxacin
,3555029,k21,"Mean values for compartmental rate constants (hours-1) were as follows: absorption rate constant = 1.15; intercompartmental rate constants, k12 = 0.48, and k21 = 0.58; elimination rate constant = 0.46; distribution rate constant = 1.31; and terminal elimination rate constant = 0.19.","Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),,0.58,71393,DB00537,Ciprofloxacin
,3555029,elimination rate constant,"Mean values for compartmental rate constants (hours-1) were as follows: absorption rate constant = 1.15; intercompartmental rate constants, k12 = 0.48, and k21 = 0.58; elimination rate constant = 0.46; distribution rate constant = 1.31; and terminal elimination rate constant = 0.19.","Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),,0.46,71394,DB00537,Ciprofloxacin
,3555029,distribution rate constant,"Mean values for compartmental rate constants (hours-1) were as follows: absorption rate constant = 1.15; intercompartmental rate constants, k12 = 0.48, and k21 = 0.58; elimination rate constant = 0.46; distribution rate constant = 1.31; and terminal elimination rate constant = 0.19.","Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),,1.31,71395,DB00537,Ciprofloxacin
,3555029,terminal elimination rate constant,"Mean values for compartmental rate constants (hours-1) were as follows: absorption rate constant = 1.15; intercompartmental rate constants, k12 = 0.48, and k21 = 0.58; elimination rate constant = 0.46; distribution rate constant = 1.31; and terminal elimination rate constant = 0.19.","Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),,0.19,71396,DB00537,Ciprofloxacin
,3555029,apparent volume of distribution at steady state/bioavailability,The apparent volume of distribution at steady state/bioavailability was 196 liters and total body clearance/bioavailability was 45.9 liters/hour.,"Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),l,196,71397,DB00537,Ciprofloxacin
,3555029,total body clearance/bioavailability,The apparent volume of distribution at steady state/bioavailability was 196 liters and total body clearance/bioavailability was 45.9 liters/hour.,"Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),[l] / [h],45.9,71398,DB00537,Ciprofloxacin
,3555029,time to peak concentration,The mean time to peak concentration was 1.3 hours.,"Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),h,1.3,71399,DB00537,Ciprofloxacin
,3555029,peak concentration,The mean peak concentration as determined by compartmental fitting (2.4 micrograms/ml) underestimated the observed peak (3.2 micrograms/ml) by 24.8 percent.,"Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),[μg] / [ml],2.4,71400,DB00537,Ciprofloxacin
,3555029,peak concentration,The mean peak concentration as determined by compartmental fitting (2.4 micrograms/ml) underestimated the observed peak (3.2 micrograms/ml) by 24.8 percent.,"Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),[μg] / [ml],3.2,71401,DB00537,Ciprofloxacin
,3555029,peak,The mean peak concentration as determined by compartmental fitting (2.4 micrograms/ml) underestimated the observed peak (3.2 micrograms/ml) by 24.8 percent.,"Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555029/),[μg] / [ml],3.2,71402,DB00537,Ciprofloxacin
less,21114393,area under the plasma concentration-time curve (AUC):minimum inhibitory concentration (MIC) ratio,Pharmacodynamic targets for ciprofloxacin were defined as a 24-hour area under the plasma concentration-time curve (AUC):minimum inhibitory concentration (MIC) ratio of less than 110 for resistance acquisition and greater than 125 for bacterial eradication.,Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21114393/),,110,73250,DB00537,Ciprofloxacin
greater,21114393,area under the plasma concentration-time curve (AUC):minimum inhibitory concentration (MIC) ratio,Pharmacodynamic targets for ciprofloxacin were defined as a 24-hour area under the plasma concentration-time curve (AUC):minimum inhibitory concentration (MIC) ratio of less than 110 for resistance acquisition and greater than 125 for bacterial eradication.,Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21114393/),,125,73251,DB00537,Ciprofloxacin
less,21114393,AUC:MIC ratio,"For a P. aeruginosa isolate with an MIC close to the clinical breakpoint, the probability of the AUC:MIC ratio to be less than 110 achieved values of 74-100%, depending on the model used, whereas the probability to achieve an AUC:MIC ratio greater than 125 decreased to 0-22%.",Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21114393/),,110,73252,DB00537,Ciprofloxacin
greater,21114393,AUC:MIC ratio,"For a P. aeruginosa isolate with an MIC close to the clinical breakpoint, the probability of the AUC:MIC ratio to be less than 110 achieved values of 74-100%, depending on the model used, whereas the probability to achieve an AUC:MIC ratio greater than 125 decreased to 0-22%.",Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21114393/),,125,73253,DB00537,Ciprofloxacin
,26056878,area under the concentration vs. time curve,A population pharmacokinetics model demonstrated that an oral ciprofloxacin dose of 10 mg/kg achieved an area under the concentration vs. time curve of 6.01 μg hr/ml.,PHARMACOKINETICS OF SINGLE-DOSE ORALLY ADMINISTERED CIPROFLOXACIN IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056878/),[h·μg] / [ml],6.01,74085,DB00537,Ciprofloxacin
,26056878,absorption half-life,"Absorption was rapid, with ciprofloxacin detectable in plasma 0.54 hr after drug administration; absorption half-life was 0.09 hr.",PHARMACOKINETICS OF SINGLE-DOSE ORALLY ADMINISTERED CIPROFLOXACIN IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS). ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056878/),h,0.09,74086,DB00537,Ciprofloxacin
,26056878,maximum plasma concentration,"A maximum plasma concentration of 1.21 μg/ml was observed at 1.01 hr, with an elimination half-life of 3.09 hr.",PHARMACOKINETICS OF SINGLE-DOSE ORALLY ADMINISTERED CIPROFLOXACIN IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056878/),[μg] / [ml],1.21,74087,DB00537,Ciprofloxacin
,26056878,elimination half-life,"A maximum plasma concentration of 1.21 μg/ml was observed at 1.01 hr, with an elimination half-life of 3.09 hr.",PHARMACOKINETICS OF SINGLE-DOSE ORALLY ADMINISTERED CIPROFLOXACIN IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056878/),h,3.09,74088,DB00537,Ciprofloxacin
,15757137,MICs,Danofloxacin and enrofloxacin had MICs of 0.03 microg/mL for the M. haemolytica challenge isolate.,Comparison of pharmacokinetics of danofloxacin and enrofloxacin in calves challenged with Mannheimia haemolytica. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757137/),[μg] / [ml],0.03,74825,DB00537,Ciprofloxacin
>,15757137,Cmax-to-MIC ratios,Danofloxacin and enrofloxacin achieved Cmax-to-MIC ratios >10 and AUC(12h)-to-MIC ratios >125 hours.,Comparison of pharmacokinetics of danofloxacin and enrofloxacin in calves challenged with Mannheimia haemolytica. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757137/),,10,74826,DB00537,Ciprofloxacin
>,15757137,AUC(12h)-to-MIC ratios,Danofloxacin and enrofloxacin achieved Cmax-to-MIC ratios >10 and AUC(12h)-to-MIC ratios >125 hours.,Comparison of pharmacokinetics of danofloxacin and enrofloxacin in calves challenged with Mannheimia haemolytica. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757137/),h,125,74827,DB00537,Ciprofloxacin
,29067175,Overall,Overall i.m. bioavailability of the parent compound with its metabolite was found to be 91%.,Pharmacokinetic-pharmacodynamic integration of enrofloxacin and its metabolite ciprofloxacin in buffalo calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067175/),%,91,75457,DB00537,Ciprofloxacin
,8257135,urinary output,The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h.,Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[μg] / [4·h],160.8,76179,DB00537,Ciprofloxacin
,8257135,urinary output,The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h.,Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[μg] / [4·h],544.8,76180,DB00537,Ciprofloxacin
,8257135,peak fleroxacin concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[mg] / [l],6.3,76181,DB00537,Ciprofloxacin
,8257135,peak fleroxacin concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[mg] / [l],6.2,76182,DB00537,Ciprofloxacin
,8257135,time to maximum concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,1.1,76183,DB00537,Ciprofloxacin
,8257135,time to maximum concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,1.3,76184,DB00537,Ciprofloxacin
,8257135,renal clearance,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],58.3,76185,DB00537,Ciprofloxacin
,8257135,renal clearance,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],61.9,76186,DB00537,Ciprofloxacin
,8257135,area under the curve AUC,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[h·mg] / [l],71.4,76187,DB00537,Ciprofloxacin
,8257135,area under the curve AUC,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[h·mg] / [l],62.2,76188,DB00537,Ciprofloxacin
,8257135,terminal half-life,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,11.4,76189,DB00537,Ciprofloxacin
,8257135,terminal half-life,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,9.2,76190,DB00537,Ciprofloxacin
,8257135,total plasma clearance,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],97.7,76191,DB00537,Ciprofloxacin
,8257135,total plasma clearance,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],112.3,76192,DB00537,Ciprofloxacin
,8257135,Metabolic clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],6.9,76193,DB00537,Ciprofloxacin
,8257135,Metabolic clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],12.5,76194,DB00537,Ciprofloxacin
,8257135,clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],5.8,76195,DB00537,Ciprofloxacin
,8257135,clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],5.8,76196,DB00537,Ciprofloxacin
,3583969,peak dialysate level,The mean peak dialysate level (2.17 +/- 1.63 mg/l) exceeded the MIC of ciprofloxacin for 32 of 34 bacterial strains responsible for peritonitis.,Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3583969/),[mg] / [l],2.17,76308,DB00537,Ciprofloxacin
,3468102,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax = 1.2 h) and enoxacin the least (Tmax = 1.9 h).,The comparative pharmacokinetics of five quinolones. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,1.2,77966,DB00537,Ciprofloxacin
,3468102,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax = 1.2 h) and enoxacin the least (Tmax = 1.9 h).,The comparative pharmacokinetics of five quinolones. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,1.9,77967,DB00537,Ciprofloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,3.75,77968,DB00537,Ciprofloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,3.9,77969,DB00537,Ciprofloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,4.0,77970,DB00537,Ciprofloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,7.0,77971,DB00537,Ciprofloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,6.2,77972,DB00537,Ciprofloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,5.1,77973,DB00537,Ciprofloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,10.5,77974,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,62,77975,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,46.4,77976,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,12.2,77977,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,27,77978,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,30.6,77979,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,75.7,77980,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,73,77981,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,4.9,77982,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,9.2,77983,DB00537,Ciprofloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,17.8,77984,DB00537,Ciprofloxacin
,1361781,dwell time,In a randomized cross-over setting ciprofloxacin was added either to a long dwell exchange (lastbag) or to four short dwell exchanges (dwell time 1.5 h).,Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),h,1.5,79023,DB00537,Ciprofloxacin
,1361781,"Cmax,D","In the subsequent last bag devoid of ciprofloxacin a dialysate Cmax,D of 1.38 mg/l was observed at 30 min.",Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),[mg] / [l],1.38,79024,DB00537,Ciprofloxacin
,1361781,"serum Cmax,S","Mean +/- SD serum Cmax,S was 0.59 +/- 0.29 mg/l after 5.4 h.",Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),[mg] / [l],0.59,79025,DB00537,Ciprofloxacin
,1361781,"Cmax,D","Instillation of 100 mg/l ciprofloxacin in the last-bag yielded Cmax,D of 99.1 mg/l, falling with a t1/2 of 3.3 h towards levels < 2 mg/l at 19.8 h.",Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),[mg] / [l],99.1,79026,DB00537,Ciprofloxacin
,1361781,t1/2,"Instillation of 100 mg/l ciprofloxacin in the last-bag yielded Cmax,D of 99.1 mg/l, falling with a t1/2 of 3.3 h towards levels < 2 mg/l at 19.8 h.",Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),h,3.3,79027,DB00537,Ciprofloxacin
,1361781,t1/2,"Instillation of 100 mg/l ciprofloxacin in the last-bag yielded Cmax,D of 99.1 mg/l, falling with a t1/2 of 3.3 h towards levels < 2 mg/l at 19.8 h.",Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),,2,79028,DB00537,Ciprofloxacin
,1361781,"serum Cmax,S","A mean +/- SD serum Cmax,S of 0.69 +/- 0.19 was reached after 4 h.",Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),,0.69,79029,DB00537,Ciprofloxacin
,1361781,"Cmax,D","Instillation of 25 mg/l ciprofloxacin in the last-bag yielded a Cmax,D of 21.7 mg/l, falling towards levels < 2 mg/l at 15 h with a t1/2 of 3.85 h.",Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),[mg] / [l],21.7,79030,DB00537,Ciprofloxacin
,1361781,t1/2,"Instillation of 25 mg/l ciprofloxacin in the last-bag yielded a Cmax,D of 21.7 mg/l, falling towards levels < 2 mg/l at 15 h with a t1/2 of 3.85 h.",Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),h,3.85,79031,DB00537,Ciprofloxacin
,1361781,"serum Cmax,S","A mean +/- SD serum Cmax,S of 0.26 +/- 0.03 was reached after 8 h.",Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361781/),,0.26,79032,DB00537,Ciprofloxacin
,16372380,oral bioavailability,"Its oral bioavailability is only 40% due to extensive presystemic elimination, mainly by CYP3A4.",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),%,40,79257,DB00537,Ciprofloxacin
,16372380,AUC,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],1407,79258,DB00537,Ciprofloxacin
,16372380,AUC,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],2986,79259,DB00537,Ciprofloxacin
,16372380,Cmax,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],287,79260,DB00537,Ciprofloxacin
,16372380,Cmax,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],623,79261,DB00537,Ciprofloxacin
,16372380,AUC,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],1407,79262,DB00537,Ciprofloxacin
,16372380,AUC,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],3209,79263,DB00537,Ciprofloxacin
,16372380,Cmax,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],287,79264,DB00537,Ciprofloxacin
,16372380,Cmax,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],694,79265,DB00537,Ciprofloxacin
,14982788,MICs,"Pharmacodynamics of these drugs was investigated against three quinolone-susceptible strains of Stenotrophomonas maltophilia (MICs of ciprofloxacin and moxifloxacin of 0.5 to 2 and 0.0625 to 0.5 microg/ml, respectively).",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[μg] / [ml],0.5 to 2,79902,DB00537,Ciprofloxacin
,14982788,MICs,"Pharmacodynamics of these drugs was investigated against three quinolone-susceptible strains of Stenotrophomonas maltophilia (MICs of ciprofloxacin and moxifloxacin of 0.5 to 2 and 0.0625 to 0.5 microg/ml, respectively).",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[μg] / [ml],0.0625 to 0.5,79903,DB00537,Ciprofloxacin
,14982788,area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48),"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],342.3 to 401.3,79904,DB00537,Ciprofloxacin
,14982788,area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48),"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],295.2 to 378.7,79905,DB00537,Ciprofloxacin
,14982788,area between the control growth curve and the killing and regrowth curve from 0 to 48 h (,"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],40.4 to 101.1,79906,DB00537,Ciprofloxacin
,14982788,area between the control growth curve and the killing and regrowth curve from 0 to 48 h (,"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],72.9 to 144.7,79907,DB00537,Ciprofloxacin
,14982788,ABBC(0-48),"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],40.4 to 101.1,79908,DB00537,Ciprofloxacin
,14982788,ABBC(0-48),"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],72.9 to 144.7,79909,DB00537,Ciprofloxacin
,7666121,peak,"Ciprofloxacin, having a shorter half-life, showed a peak of about 1 microgram/ml, 12 hours after administration (500 mg/12 hours/os).",Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666121/),[μg] / [ml],1,79970,DB00537,Ciprofloxacin
,12017373,C(max 500),The mean (range) serum steady-state concentration at 2 h after enteral administration was: C(max 500) = 2.6 (1.2-4.3) mg/L in group 1 and C(max 750) = 3.5 (1.5-5.9) mg/L in group 2.,Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12017373/),[mg] / [l],2.6,80165,DB00537,Ciprofloxacin
,12017373,C(max 750),The mean (range) serum steady-state concentration at 2 h after enteral administration was: C(max 500) = 2.6 (1.2-4.3) mg/L in group 1 and C(max 750) = 3.5 (1.5-5.9) mg/L in group 2.,Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12017373/),[mg] / [l],3.5,80166,DB00537,Ciprofloxacin
,12017373,AUC(0-12 (500)),The mean (range) calculated 12-h area under the serum concentration was high in both groups: AUC(0-12 (500)) = 24.7 (12.9-36.2) mg.h/L in group 1 and AUC(0-12 (750)) = 28.9 (18.3-47.5) mg.h/L in group 2.,Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12017373/),[h·mg] / [l],24.7,80167,DB00537,Ciprofloxacin
,12017373,AUC(0-12 (750)),The mean (range) calculated 12-h area under the serum concentration was high in both groups: AUC(0-12 (500)) = 24.7 (12.9-36.2) mg.h/L in group 1 and AUC(0-12 (750)) = 28.9 (18.3-47.5) mg.h/L in group 2.,Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12017373/),[h·mg] / [l],28.9,80168,DB00537,Ciprofloxacin
,9108186,Relative bioavailability,Relative bioavailability was 105% (tablet/capsule).,Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9108186/),%,105,80590,DB00537,Ciprofloxacin
,22415905,flow rate,"The chromatographic separation was achieved on a reversed-phase zwitterionic hydrophilic interaction liquid chromatographic ZIC®HILIC-C₁₈ (4.6 × 100 mm; 5 µm) column using acetonitrile-10 mM ammonium acetate (pH 3.5; 80:20, v/v) as a mobile phase in an isocratic elution mode at a flow rate 0.6 mL/min at 27 °C.",Determination of gemifloxacin on dried blood spots by hydrophilic interaction liquid chromatography with fluorescence detector: application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22415905/),[ml] / [min],0.6,80605,DB00537,Ciprofloxacin
>,22415905,recovery,The recovery of GFX from dried blood spots was >95.0% and its stability was excellent with no evidence of degradation during sample processing for at least 3 months storage in a freezer at -20 °C.,Determination of gemifloxacin on dried blood spots by hydrophilic interaction liquid chromatography with fluorescence detector: application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22415905/),%,95.0,80606,DB00537,Ciprofloxacin
,8807018,bioavailability,"When the same dose was administered IM, enrofloxacin was rapidly and almost completely absorbed, with bioavailability of 85%.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and intramuscular administrations in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807018/),%,85,81260,DB00537,Ciprofloxacin
,28685835,volume of distribution Vd(area),"The volume of distribution Vd(area) of EF was 3.84 L/kg, indicating that the distribution of EF was good.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),[l] / [kg],3.84,81416,DB00537,Ciprofloxacin
,28685835,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) of EF was 90.1 and 274.2 μg hr/ml in muscle and hepatopancreas, respectively, which was higher than 75.8 μg hr/ml in hemolymph.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),[h·μg] / [ml],90.1,81417,DB00537,Ciprofloxacin
,28685835,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) of EF was 90.1 and 274.2 μg hr/ml in muscle and hepatopancreas, respectively, which was higher than 75.8 μg hr/ml in hemolymph.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),[h·μg] / [ml],274.2,81418,DB00537,Ciprofloxacin
higher,28685835,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) of EF was 90.1 and 274.2 μg hr/ml in muscle and hepatopancreas, respectively, which was higher than 75.8 μg hr/ml in hemolymph.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),[h·μg] / [ml],75.8,81419,DB00537,Ciprofloxacin
,28685835,half-life (T1/2β ),"The EF elimination was slow in muscle and hepatopancreas with the half-life (T1/2β ) of 52.3 and 75.8 hr, respectively.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),h,52.3,81420,DB00537,Ciprofloxacin
,28685835,half-life (T1/2β ),"The EF elimination was slow in muscle and hepatopancreas with the half-life (T1/2β ) of 52.3 and 75.8 hr, respectively.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),h,75.8,81421,DB00537,Ciprofloxacin
,28685835,Cmax,"The Cmax was 0.030, 0.013 and 0.218 μg/ml, respectively.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),[μg] / [ml],0.030,81422,DB00537,Ciprofloxacin
,28685835,Cmax,"The Cmax was 0.030, 0.013 and 0.218 μg/ml, respectively.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),[μg] / [ml],0.013,81423,DB00537,Ciprofloxacin
,28685835,Cmax,"The Cmax was 0.030, 0.013 and 0.218 μg/ml, respectively.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),[μg] / [ml],0.218,81424,DB00537,Ciprofloxacin
,28685835,minimum inhibitory concentration (MIC),"Based on a minimum inhibitory concentration (MIC) of 0.006-0.032 μg/ml for susceptible strains, EF i.m. injected at a dose 10 mg/kg could be efficacious against common pathogenic bacteria of Pacific white shrimp.",Pharmacokinetics and tissue distribution of enrofloxacin after single intramuscular injection in Pacific white shrimp. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685835/),[μg] / [ml],0.006-0.032,81425,DB00537,Ciprofloxacin
,28221736,AUC,"Results A 14-fold variation in AUC for the 500 mg CIP (median 473.5 µg/ml × min), and a 30-fold variation in Cmax for CIP (median 2 µg/ml) was found.",Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28221736/),[μg] / [min·ml],473.5,81434,DB00537,Ciprofloxacin
,28221736,Cmax,"Results A 14-fold variation in AUC for the 500 mg CIP (median 473.5 µg/ml × min), and a 30-fold variation in Cmax for CIP (median 2 µg/ml) was found.",Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28221736/),[μg] / [ml],2,81435,DB00537,Ciprofloxacin
,20649056,AUC/MIC at MICs,"For the ciprofloxacin 400 mg intravenously every 8 h regimen, the 24-h AUC/MIC at MICs of 0.5 and 1 microg/ml were 218.63 +/- 78.75 and 109.31 +/- 39.37, respectively.",Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),[μg] / [ml],0.5,81721,DB00537,Ciprofloxacin
,20649056,AUC/MIC at MICs,"For the ciprofloxacin 400 mg intravenously every 8 h regimen, the 24-h AUC/MIC at MICs of 0.5 and 1 microg/ml were 218.63 +/- 78.75 and 109.31 +/- 39.37, respectively.",Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),[μg] / [ml],1,81722,DB00537,Ciprofloxacin
,20649056,AUC/MIC at MICs,"For the ciprofloxacin 400 mg intravenously every 8 h regimen, the 24-h AUC/MIC at MICs of 0.5 and 1 microg/ml were 218.63 +/- 78.75 and 109.31 +/- 39.37, respectively.",Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),[μg] / [ml],218.63,81723,DB00537,Ciprofloxacin
,20649056,AUC/MIC at MICs,"For the ciprofloxacin 400 mg intravenously every 8 h regimen, the 24-h AUC/MIC at MICs of 0.5 and 1 microg/ml were 218.63 +/- 78.75 and 109.31 +/- 39.37, respectively.",Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),[μg] / [ml],109.31,81724,DB00537,Ciprofloxacin
,20649056,AUC/MIC at MICs,"For the ciprofloxacin 400 mg intravenously every 12 h regimen, the 24-h AUC/MIC at MICs of 0.5 and +/- microg/ml were 144.07 +/- 57.02 and 72.03 +/- 28.51, respectively.",Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),,0.5,81725,DB00537,Ciprofloxacin
,20649056,AUC/MIC at MICs,"For the ciprofloxacin 400 mg intravenously every 12 h regimen, the 24-h AUC/MIC at MICs of 0.5 and +/- microg/ml were 144.07 +/- 57.02 and 72.03 +/- 28.51, respectively.",Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),,144.07,81726,DB00537,Ciprofloxacin
,20649056,AUC/MIC at MICs,"For the ciprofloxacin 400 mg intravenously every 12 h regimen, the 24-h AUC/MIC at MICs of 0.5 and +/- microg/ml were 144.07 +/- 57.02 and 72.03 +/- 28.51, respectively.",Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),,72.03,81727,DB00537,Ciprofloxacin
,20649056,MIC,Both ciprofloxacin 400 mg every 8 h and 400 mg every 12 h regimens can provide good coverage for pathogens with the susceptibility breakpoint of ciprofloxacin with an MIC of 0.5 microg/ml.,Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),[μg] / [ml],0.5,81728,DB00537,Ciprofloxacin
,20649056,MIC,"For pathogens with an MIC of 1.0 microg/ml, only ciprofloxacin 400 mg every 8 h regimen can provide a 24-h AUC/MIC ratio greater than 100.",Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),[μg] / [ml],1.0,81729,DB00537,Ciprofloxacin
greater,20649056,AUC/MIC ratio,"For pathogens with an MIC of 1.0 microg/ml, only ciprofloxacin 400 mg every 8 h regimen can provide a 24-h AUC/MIC ratio greater than 100.",Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649056/),,100,81730,DB00537,Ciprofloxacin
,22779234,plasma concentration,An i.v. administration of enrofloxacin resulted in an extrapolated mean plasma concentration of 7.86 microg/ml at time zero.,Pharmacokinetics of enrofloxacin after single dose oral and intravenous administration in the African penguin (Spheniscus demersus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779234/),[μg] / [ml],7.86,82438,DB00537,Ciprofloxacin
,22779234,Plasma volume of distribution,"Plasma volume of distribution for i.v. administration was 3.00 L/kg, with a mean elimination half-life of 13.67 hr and a mean total body clearance rate of 3.03 ml/min/kg.",Pharmacokinetics of enrofloxacin after single dose oral and intravenous administration in the African penguin (Spheniscus demersus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779234/),[l] / [kg],3.00,82439,DB00537,Ciprofloxacin
,22779234,elimination half-life,"Plasma volume of distribution for i.v. administration was 3.00 L/kg, with a mean elimination half-life of 13.67 hr and a mean total body clearance rate of 3.03 ml/min/kg.",Pharmacokinetics of enrofloxacin after single dose oral and intravenous administration in the African penguin (Spheniscus demersus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779234/),h,13.67,82440,DB00537,Ciprofloxacin
,22779234,total body clearance rate,"Plasma volume of distribution for i.v. administration was 3.00 L/kg, with a mean elimination half-life of 13.67 hr and a mean total body clearance rate of 3.03 ml/min/kg.",Pharmacokinetics of enrofloxacin after single dose oral and intravenous administration in the African penguin (Spheniscus demersus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779234/),[ml] / [kg·min],3.03,82441,DB00537,Ciprofloxacin
,22779234,maximum plasma concentration,"Oral administration of enrofloxacin achieved a mean maximum plasma concentration of4.38 microg/ml at 4.8 hr after administration when pilled, whereas mean maximum plasma concentration was 4.77 microg/ml at 1.59 hr after administration when given in fish.",Pharmacokinetics of enrofloxacin after single dose oral and intravenous administration in the African penguin (Spheniscus demersus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779234/),[μg] / [ml],4.38,82442,DB00537,Ciprofloxacin
,22779234,maximum plasma concentration,"Oral administration of enrofloxacin achieved a mean maximum plasma concentration of4.38 microg/ml at 4.8 hr after administration when pilled, whereas mean maximum plasma concentration was 4.77 microg/ml at 1.59 hr after administration when given in fish.",Pharmacokinetics of enrofloxacin after single dose oral and intravenous administration in the African penguin (Spheniscus demersus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779234/),[μg] / [ml],4.77,82443,DB00537,Ciprofloxacin
,22779234,terminal elimination half-life,Mean terminal elimination half-life was 13.79 hr pilled and 11.93 hr when given in fish.,Pharmacokinetics of enrofloxacin after single dose oral and intravenous administration in the African penguin (Spheniscus demersus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779234/),h,13.79,82444,DB00537,Ciprofloxacin
,22779234,terminal elimination half-life,Mean terminal elimination half-life was 13.79 hr pilled and 11.93 hr when given in fish.,Pharmacokinetics of enrofloxacin after single dose oral and intravenous administration in the African penguin (Spheniscus demersus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779234/),h,11.93,82445,DB00537,Ciprofloxacin
,22779234,minimum inhibitory concentration,"Enrofloxacin administered to African penguins at 15 mg/kg p.o.q. 24 hr, whether in fish or pilled, is expected to achieve the surrogate markers of efficacy for bacteria with a minimum inhibitory concentration of 0.5 microg/ml or less; however, clinical studies are needed to determine efficacy.",Pharmacokinetics of enrofloxacin after single dose oral and intravenous administration in the African penguin (Spheniscus demersus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779234/),[μg] / [ml],0.5,82446,DB00537,Ciprofloxacin
,3549940,peak serum concentration,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),[μg] / [ml],3.6,82726,DB00537,Ciprofloxacin
,3549940,peak serum concentrations,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),[μg] / [ml],9.2,82727,DB00537,Ciprofloxacin
,3549940,peak serum concentrations,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),[μg] / [ml],16.9,82728,DB00537,Ciprofloxacin
,3549940,half-lives for serum elimination,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),h,2,82729,DB00537,Ciprofloxacin
,1503446,relative bioavailability,The relative bioavailability of Cipro when given with calcium carbonate was approximately 60% of the control value.,Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503446/),%,60,82780,DB00537,Ciprofloxacin
,1503446,relative bioavailability,"When Cipro was given with aluminum hydroxide, the relative bioavailability was approximately 15%.",Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503446/),%,15,82781,DB00537,Ciprofloxacin
,34107961,MIC50,"The MIC values of 15 E. coli strains were found to be nearest to the MIC50 i.e., 0.25 μg/mL.",Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34107961/),[μg] / [ml],0.25,83430,DB00537,Ciprofloxacin
,34107961,peak drug concentration (Cmax),"The basic PK parameters of ENR for the peak drug concentration (Cmax) and the area under the concentration-time curve (AUC) values were found to be in the range of 0.27-1.97 μg/mL and 0.62-3.14 μg.h/mL, respectively.",Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34107961/),[μg] / [ml],0.27-1.97,83431,DB00537,Ciprofloxacin
,34107961,area under the concentration-time curve (AUC),"The basic PK parameters of ENR for the peak drug concentration (Cmax) and the area under the concentration-time curve (AUC) values were found to be in the range of 0.27-1.97 μg/mL and 0.62-3.14 μg.h/mL, respectively.",Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34107961/),[h·μg] / [ml],0.62-3.14,83432,DB00537,Ciprofloxacin
,17825693,AUC:MIC ratio,The probability of target attainment was determined for each regimen for an AUC:MIC ratio from 0 to 300.,Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,0 to 300,83660,DB00537,Ciprofloxacin
,17825693,AUC:MIC ratio,"For ciprofloxacin 400 mg TID and levofloxacin 750 mg QD, the AUC:MIC ratio at the corresponding 2002 Clinical Laboratory Standards Institute break points of 1 and 2 microg/mL were 33 and 34, respectively.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,33,83661,DB00537,Ciprofloxacin
,17825693,AUC:MIC ratio,"For ciprofloxacin 400 mg TID and levofloxacin 750 mg QD, the AUC:MIC ratio at the corresponding 2002 Clinical Laboratory Standards Institute break points of 1 and 2 microg/mL were 33 and 34, respectively.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,34,83662,DB00537,Ciprofloxacin
>,17825693,free,"The probabilities of target attainment for a free AUC:MIC ratio >90 (equivalent to a total AUC:MIC ratio > or =125) were 47% for ciprofloxacin 400 mg BID, 54% for ciprofloxacin 400 mg TID, and 48% for levofloxacin 750 mg QD.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,90,83663,DB00537,Ciprofloxacin
>,17825693,AUC:MIC ratio,"The probabilities of target attainment for a free AUC:MIC ratio >90 (equivalent to a total AUC:MIC ratio > or =125) were 47% for ciprofloxacin 400 mg BID, 54% for ciprofloxacin 400 mg TID, and 48% for levofloxacin 750 mg QD.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,90,83664,DB00537,Ciprofloxacin
>,17825693,total AUC:MIC ratio,"The probabilities of target attainment for a free AUC:MIC ratio >90 (equivalent to a total AUC:MIC ratio > or =125) were 47% for ciprofloxacin 400 mg BID, 54% for ciprofloxacin 400 mg TID, and 48% for levofloxacin 750 mg QD.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,125,83665,DB00537,Ciprofloxacin
,3619423,concentrations,"Mean concentrations in serum 5 min postinfusion were 3.08 and 2.14 micrograms/ml, and mean peak concentrations after oral dosing were 3.24 and 3.34 micrograms/ml in subjects with and without CF, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[μg] / [ml],3.08,84111,DB00537,Ciprofloxacin
,3619423,concentrations,"Mean concentrations in serum 5 min postinfusion were 3.08 and 2.14 micrograms/ml, and mean peak concentrations after oral dosing were 3.24 and 3.34 micrograms/ml in subjects with and without CF, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[μg] / [ml],2.14,84112,DB00537,Ciprofloxacin
,3619423,peak concentrations,"Mean concentrations in serum 5 min postinfusion were 3.08 and 2.14 micrograms/ml, and mean peak concentrations after oral dosing were 3.24 and 3.34 micrograms/ml in subjects with and without CF, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[μg] / [ml],3.24,84113,DB00537,Ciprofloxacin
,3619423,peak concentrations,"Mean concentrations in serum 5 min postinfusion were 3.08 and 2.14 micrograms/ml, and mean peak concentrations after oral dosing were 3.24 and 3.34 micrograms/ml in subjects with and without CF, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[μg] / [ml],3.34,84114,DB00537,Ciprofloxacin
,3619423,elimination half-life,"Mean values for elimination half-life in all subjects were 4.8 and 5.0 h after intravenous and oral administration, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),h,4.8,84115,DB00537,Ciprofloxacin
,3619423,elimination half-life,"Mean values for elimination half-life in all subjects were 4.8 and 5.0 h after intravenous and oral administration, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),h,5.0,84116,DB00537,Ciprofloxacin
,3619423,renal clearances,"The mean renal clearances in all subjects after intravenous and oral administration were 19.4 and 14.5 liters/h and accounted for 64 and 47% of the total clearance, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[l] / [h],19.4,84117,DB00537,Ciprofloxacin
,3619423,renal clearances,"The mean renal clearances in all subjects after intravenous and oral administration were 19.4 and 14.5 liters/h and accounted for 64 and 47% of the total clearance, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[l] / [h],14.5,84118,DB00537,Ciprofloxacin
,3619423,bioavailability,The mean bioavailability was 71.2% and did not differ between the groups.,Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),%,71.2,84119,DB00537,Ciprofloxacin
,2067414,initial mucosal peak,Cefuroxime showed a bimodal tissue concentration curve with an initial mucosal peak of 2.97 micrograms/g at 1 hour.,Pharmacokinetics of cefuroxime and ciprofloxacin in gastric mucosa: comparison to in vitro inhibitory concentrations against Helicobacter pylori. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2067414/),[μg] / [g],2.97,84584,DB00537,Ciprofloxacin
,2067414,mucosa/serum ratio,The corresponding mucosa/serum ratio was 36.75.,Pharmacokinetics of cefuroxime and ciprofloxacin in gastric mucosa: comparison to in vitro inhibitory concentrations against Helicobacter pylori. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2067414/),,36.75,84585,DB00537,Ciprofloxacin
,2067414,mucosa/serum ratio,The mucosa/serum ratio was highest (1.69) 4 hours post injection.,Pharmacokinetics of cefuroxime and ciprofloxacin in gastric mucosa: comparison to in vitro inhibitory concentrations against Helicobacter pylori. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2067414/),,1.69,84586,DB00537,Ciprofloxacin
,9306065,elimination half-life,"After i.v. administration, elimination half-life of enrofloxacin was 4.4 h and volume of distribution was 2.3 1/kg bwt.",Pharmacokinetics of enrofloxacin in horses after single intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9306065/),h,4.4,84635,DB00537,Ciprofloxacin
,9306065,volume of distribution,"After i.v. administration, elimination half-life of enrofloxacin was 4.4 h and volume of distribution was 2.3 1/kg bwt.",Pharmacokinetics of enrofloxacin in horses after single intravenous and intramuscular administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9306065/),[1] / [bwt·kg],2.3,84636,DB00537,Ciprofloxacin
,9306065,elimination half-life,"After i.m. administration, elimination half-life of enrofloxacin was longer (9.9 h) than after i.v. administration.",Pharmacokinetics of enrofloxacin in horses after single intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9306065/),h,9.9,84637,DB00537,Ciprofloxacin
,9306065,Mean absorption time,Mean absorption time of enrofloxacin was also long (9.9 h).,Pharmacokinetics of enrofloxacin in horses after single intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9306065/),h,9.9,84638,DB00537,Ciprofloxacin
,8712523,body clearances,"The time courses of ENR and CIP in plasma were similar in lactating adult rabbits (mean body clearances, 23.9 and 27.2 ml/min/kg of body weight, for ENR and CIP, respectively).","Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712523/),[ml] / [kg·min],23.9,85339,DB00537,Ciprofloxacin
,8712523,body clearances,"The time courses of ENR and CIP in plasma were similar in lactating adult rabbits (mean body clearances, 23.9 and 27.2 ml/min/kg of body weight, for ENR and CIP, respectively).","Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712523/),[ml] / [kg·min],27.2,85340,DB00537,Ciprofloxacin
,8712523,milk-to-plasma ratios (M/P),"Observed milk-to-plasma ratios (M/P) were determined, using the area under the milk and plasma concentration versus time profiles (ENR, 2.59; CIP, 3.61).","Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712523/),,2.59,85341,DB00537,Ciprofloxacin
,8712523,milk-to-plasma ratios (M/P),"Observed milk-to-plasma ratios (M/P) were determined, using the area under the milk and plasma concentration versus time profiles (ENR, 2.59; CIP, 3.61).","Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712523/),,3.61,85342,DB00537,Ciprofloxacin
,8712523,M/P,"Predicted M/P (ENR, 6.35; CIP, 3.04) were calculated from in vitro measurements.","Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712523/),,6.35,85343,DB00537,Ciprofloxacin
,8712523,M/P,"Predicted M/P (ENR, 6.35; CIP, 3.04) were calculated from in vitro measurements.","Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712523/),,3.04,85344,DB00537,Ciprofloxacin
,10501821,Trough concentrations,"Trough concentrations measured on day 3 (mean +/- SD) were above the minimum inhibitory concentration (MIC) for the organism responsible for infection; i.e., 2.0 +/- 1.2 microg.",Clinical pharmacokinetics of ciprofloxacin in patients with major burns. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501821/),μg,2.0,86160,DB00537,Ciprofloxacin
,10501821,minimum inhibitory concentration (MIC),"Trough concentrations measured on day 3 (mean +/- SD) were above the minimum inhibitory concentration (MIC) for the organism responsible for infection; i.e., 2.0 +/- 1.2 microg.",Clinical pharmacokinetics of ciprofloxacin in patients with major burns. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501821/),μg,2.0,86161,DB00537,Ciprofloxacin
,10501821,maximum concentrations,"ml(-1), and maximum concentrations were high 9. 9 +/- 3.4 microg.",Clinical pharmacokinetics of ciprofloxacin in patients with major burns. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501821/),μg,9. 9,86162,DB00537,Ciprofloxacin
above,10501821,area under the concentration-time curve (AUC)/MIC ratio,"An area under the concentration-time curve (AUC)/MIC ratio above 125 SIT(-1) (where SIT is the serum inhibitory titer), which has been strongly correlated with clinical response and time to bacterial eradication, was achieved in 11 patients with a MIC of 0.5 microg.",Clinical pharmacokinetics of ciprofloxacin in patients with major burns. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501821/),1/[sit],125,86163,DB00537,Ciprofloxacin
,10501821,MIC,"An area under the concentration-time curve (AUC)/MIC ratio above 125 SIT(-1) (where SIT is the serum inhibitory titer), which has been strongly correlated with clinical response and time to bacterial eradication, was achieved in 11 patients with a MIC of 0.5 microg.",Clinical pharmacokinetics of ciprofloxacin in patients with major burns. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501821/),μg,0.5,86164,DB00537,Ciprofloxacin
,3141343,Tmax,There were no significant differences in Tmax (0.9 vs. 1.3 h) and in plasma elimination half-life (11.9 vs.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),h,0.9,86368,DB00537,Ciprofloxacin
,3141343,Tmax,There were no significant differences in Tmax (0.9 vs. 1.3 h) and in plasma elimination half-life (11.9 vs.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),h,1.3,86369,DB00537,Ciprofloxacin
,3141343,plasma elimination half-life,There were no significant differences in Tmax (0.9 vs. 1.3 h) and in plasma elimination half-life (11.9 vs.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),,11.9,86370,DB00537,Ciprofloxacin
,3141343,Cmax,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [l],5.62,86371,DB00537,Ciprofloxacin
,3141343,Cmax,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [l],4.09,86372,DB00537,Ciprofloxacin
,3141343,AUC0-48,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],65.9,86373,DB00537,Ciprofloxacin
,3141343,AUC0-48,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],48.7,86374,DB00537,Ciprofloxacin
,3141343,AUC0-infinity,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],70.7,86375,DB00537,Ciprofloxacin
,3141343,AUC0-infinity,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],51.5,86376,DB00537,Ciprofloxacin
,3141343,Renal clearances,Renal clearances of fleroxacin and pefloxacin were 51.8 and 11.7 ml/min respectively.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[ml] / [min],51.8,86377,DB00537,Ciprofloxacin
,3141343,Renal clearances,Renal clearances of fleroxacin and pefloxacin were 51.8 and 11.7 ml/min respectively.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[ml] / [min],11.7,86378,DB00537,Ciprofloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,48.6,86379,DB00537,Ciprofloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,8.6,86380,DB00537,Ciprofloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,7.1,86381,DB00537,Ciprofloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,17.4,86382,DB00537,Ciprofloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,3.8,86383,DB00537,Ciprofloxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,16.6,86384,DB00537,Ciprofloxacin
,8115734,elimination half life,"In normal eyes, the elimination half life was 2.2 hours with a distribution volume of 1.2 ml.",Clearance and distribution of ciprofloxacin after intravitreal injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8115734/),h,2.2,86434,DB00537,Ciprofloxacin
,8115734,distribution volume,"In normal eyes, the elimination half life was 2.2 hours with a distribution volume of 1.2 ml.",Clearance and distribution of ciprofloxacin after intravitreal injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8115734/),ml,1.2,86435,DB00537,Ciprofloxacin
,8115734,half life,"In aphakic vitrectomized eyes, the half life was 1 hour and the distribution volume was 1.4 ml.",Clearance and distribution of ciprofloxacin after intravitreal injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8115734/),h,1,86436,DB00537,Ciprofloxacin
,8115734,distribution volume,"In aphakic vitrectomized eyes, the half life was 1 hour and the distribution volume was 1.4 ml.",Clearance and distribution of ciprofloxacin after intravitreal injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8115734/),ml,1.4,86437,DB00537,Ciprofloxacin
,8452360,maximum concentration,"At approximately 2 h after oral administration, a maximum concentration of 5.6 mg/liter was determined in plasma; the area under the plasma concentration-time curve (AUC) amounted to 70.3 mg.h/liter, and the elimination half-life in the postdistributive phase was 8 h.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[mg] / [l],5.6,87054,DB00537,Ciprofloxacin
,8452360,area under the plasma concentration-time curve (AUC),"At approximately 2 h after oral administration, a maximum concentration of 5.6 mg/liter was determined in plasma; the area under the plasma concentration-time curve (AUC) amounted to 70.3 mg.h/liter, and the elimination half-life in the postdistributive phase was 8 h.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[h·mg] / [l],70.3,87055,DB00537,Ciprofloxacin
,8452360,elimination half-life,"At approximately 2 h after oral administration, a maximum concentration of 5.6 mg/liter was determined in plasma; the area under the plasma concentration-time curve (AUC) amounted to 70.3 mg.h/liter, and the elimination half-life in the postdistributive phase was 8 h.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),h,8,87056,DB00537,Ciprofloxacin
,8452360,Total systemic clearance,"Total systemic clearance was 97.3 ml/min, and urinary excretion was 38% of the dose within 48 h.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[ml] / [min],97.3,87057,DB00537,Ciprofloxacin
,8452360,maximum concentration,"In breast milk, the mean maximum concentration was 3.5 mg/liter, which was reached 2.6 h after drug administration.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[mg] / [l],3.5,87058,DB00537,Ciprofloxacin
,8452360,AUC,"The elimination half-life of fleroxacin in milk was identical to that in plasma, and the AUC reached 43.3 mg.h/liter.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[h·mg] / [l],43.3,87059,DB00537,Ciprofloxacin
,8452360,cumulative excretion,The cumulative excretion in milk amounted to only 0.219 mg within 48 h.,Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),mg,0.219,87060,DB00537,Ciprofloxacin
,28603916,maximum plasma concentration (Cmax ),"After IM, PO and bath administration, the maximum plasma concentration (Cmax ) of 2.29, 3.24 and 0.36 μg/ml was obtained at 4.08, 0.68 and 0 hr, respectively; the elimination half-life (T1/2β ) was 80.95, 62.17 and 61.15 hr, respectively; the area under the concentration-time curve (AUC) values were 223.46, 162.72 and 14.91 μg hr/ml, respectively.","Pharmacokinetics of enrofloxacin after oral, intramuscular and bath administration in crucian carp (Carassius auratus gibelio). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603916/),[μg] / [ml],2.29,87200,DB00537,Ciprofloxacin
,28603916,maximum plasma concentration (Cmax ),"After IM, PO and bath administration, the maximum plasma concentration (Cmax ) of 2.29, 3.24 and 0.36 μg/ml was obtained at 4.08, 0.68 and 0 hr, respectively; the elimination half-life (T1/2β ) was 80.95, 62.17 and 61.15 hr, respectively; the area under the concentration-time curve (AUC) values were 223.46, 162.72 and 14.91 μg hr/ml, respectively.","Pharmacokinetics of enrofloxacin after oral, intramuscular and bath administration in crucian carp (Carassius auratus gibelio). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603916/),[μg] / [ml],3.24,87201,DB00537,Ciprofloxacin
,28603916,maximum plasma concentration (Cmax ),"After IM, PO and bath administration, the maximum plasma concentration (Cmax ) of 2.29, 3.24 and 0.36 μg/ml was obtained at 4.08, 0.68 and 0 hr, respectively; the elimination half-life (T1/2β ) was 80.95, 62.17 and 61.15 hr, respectively; the area under the concentration-time curve (AUC) values were 223.46, 162.72 and 14.91 μg hr/ml, respectively.","Pharmacokinetics of enrofloxacin after oral, intramuscular and bath administration in crucian carp (Carassius auratus gibelio). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603916/),[μg] / [ml],0.36,87202,DB00537,Ciprofloxacin
,28603916,elimination half-life (T1/2β ),"After IM, PO and bath administration, the maximum plasma concentration (Cmax ) of 2.29, 3.24 and 0.36 μg/ml was obtained at 4.08, 0.68 and 0 hr, respectively; the elimination half-life (T1/2β ) was 80.95, 62.17 and 61.15 hr, respectively; the area under the concentration-time curve (AUC) values were 223.46, 162.72 and 14.91 μg hr/ml, respectively.","Pharmacokinetics of enrofloxacin after oral, intramuscular and bath administration in crucian carp (Carassius auratus gibelio). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603916/),h,80.95,87203,DB00537,Ciprofloxacin
,28603916,elimination half-life (T1/2β ),"After IM, PO and bath administration, the maximum plasma concentration (Cmax ) of 2.29, 3.24 and 0.36 μg/ml was obtained at 4.08, 0.68 and 0 hr, respectively; the elimination half-life (T1/2β ) was 80.95, 62.17 and 61.15 hr, respectively; the area under the concentration-time curve (AUC) values were 223.46, 162.72 and 14.91 μg hr/ml, respectively.","Pharmacokinetics of enrofloxacin after oral, intramuscular and bath administration in crucian carp (Carassius auratus gibelio). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603916/),h,62.17,87204,DB00537,Ciprofloxacin
,28603916,elimination half-life (T1/2β ),"After IM, PO and bath administration, the maximum plasma concentration (Cmax ) of 2.29, 3.24 and 0.36 μg/ml was obtained at 4.08, 0.68 and 0 hr, respectively; the elimination half-life (T1/2β ) was 80.95, 62.17 and 61.15 hr, respectively; the area under the concentration-time curve (AUC) values were 223.46, 162.72 and 14.91 μg hr/ml, respectively.","Pharmacokinetics of enrofloxacin after oral, intramuscular and bath administration in crucian carp (Carassius auratus gibelio). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603916/),h,61.15,87205,DB00537,Ciprofloxacin
,28603916,area under the concentration-time curve (AUC),"After IM, PO and bath administration, the maximum plasma concentration (Cmax ) of 2.29, 3.24 and 0.36 μg/ml was obtained at 4.08, 0.68 and 0 hr, respectively; the elimination half-life (T1/2β ) was 80.95, 62.17 and 61.15 hr, respectively; the area under the concentration-time curve (AUC) values were 223.46, 162.72 and 14.91 μg hr/ml, respectively.","Pharmacokinetics of enrofloxacin after oral, intramuscular and bath administration in crucian carp (Carassius auratus gibelio). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603916/),[h·μg] / [ml],223.46,87206,DB00537,Ciprofloxacin
,28603916,area under the concentration-time curve (AUC),"After IM, PO and bath administration, the maximum plasma concentration (Cmax ) of 2.29, 3.24 and 0.36 μg/ml was obtained at 4.08, 0.68 and 0 hr, respectively; the elimination half-life (T1/2β ) was 80.95, 62.17 and 61.15 hr, respectively; the area under the concentration-time curve (AUC) values were 223.46, 162.72 and 14.91 μg hr/ml, respectively.","Pharmacokinetics of enrofloxacin after oral, intramuscular and bath administration in crucian carp (Carassius auratus gibelio). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603916/),[h·μg] / [ml],162.72,87207,DB00537,Ciprofloxacin
,28603916,area under the concentration-time curve (AUC),"After IM, PO and bath administration, the maximum plasma concentration (Cmax ) of 2.29, 3.24 and 0.36 μg/ml was obtained at 4.08, 0.68 and 0 hr, respectively; the elimination half-life (T1/2β ) was 80.95, 62.17 and 61.15 hr, respectively; the area under the concentration-time curve (AUC) values were 223.46, 162.72 and 14.91 μg hr/ml, respectively.","Pharmacokinetics of enrofloxacin after oral, intramuscular and bath administration in crucian carp (Carassius auratus gibelio). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603916/),[h·μg] / [ml],14.91,87208,DB00537,Ciprofloxacin
> or =,8193415,pleural/plasma ratio,Pleural fluid concentrations of ciprofloxacin equaled plasma concentrations 1.5 hours after 200 mg was given intravenously and the pleural/plasma ratio remained > or = 0.9 for 4 hours.,Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193415/),,0.9,87888,DB00537,Ciprofloxacin
,8193415,pleural fluid/plasma ratio,"After a single 750-mg oral dose, pleural ciprofloxacin concentrations rose from 0 to 1.4 micrograms/mL over 5 hours with the highest pleural fluid/plasma ratio (0.7) at 5 hours.",Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193415/),,0.7,87889,DB00537,Ciprofloxacin
,8193415,steady-state ciprofloxacin concentrations,"In empyemic pleural fluid at the same dosage, average steady-state ciprofloxacin concentrations ranged between 1.9 and 3.4 micrograms/mL with ratios between 1.0 and 2.0 over 5 hours.",Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193415/),[μg] / [ml],1.9 and 3.4,87890,DB00537,Ciprofloxacin
,3435126,Peak concentrations,"Peak concentrations in serum noted in the absence of antacids ranged from 2.9 to 6.4 micrograms/ml, and peak concentrations in dialysate in the absence of antacids ranged from 1.8 to 4.5 micrograms/ml.",Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435126/),[μg] / [ml],2.9 to 6.4,88327,DB00537,Ciprofloxacin
,3435126,peak concentrations,"Peak concentrations in serum noted in the absence of antacids ranged from 2.9 to 6.4 micrograms/ml, and peak concentrations in dialysate in the absence of antacids ranged from 1.8 to 4.5 micrograms/ml.",Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435126/),[μg] / [ml],1.8 to 4.5,88328,DB00537,Ciprofloxacin
,3435126,D/S,"At 4 h D/S was 0.57 +/- 0.07 (mean +/- standard error of the mean; n = 9), and at 8 h it was 0.75 +/- 0.04 (n = 26).",Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435126/),,0.57,88329,DB00537,Ciprofloxacin
,3435126,D/S,"At 4 h D/S was 0.57 +/- 0.07 (mean +/- standard error of the mean; n = 9), and at 8 h it was 0.75 +/- 0.04 (n = 26).",Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435126/),,0.75,88330,DB00537,Ciprofloxacin
,18471140,elimination half-lives (t(1/2beta)),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t(1/2beta)) were 17.14 +/- 4.14, 25.79 +/- 8.10, 16.67 +/- 4.04 (pigs) and 6.11 +/- 1.50, 5.64 +/- 0.74, 8.20 +/- 3.12 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),,17.14,88894,DB00537,Ciprofloxacin
,18471140,elimination half-lives (t(1/2beta)),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t(1/2beta)) were 17.14 +/- 4.14, 25.79 +/- 8.10, 16.67 +/- 4.04 (pigs) and 6.11 +/- 1.50, 5.64 +/- 0.74, 8.20 +/- 3.12 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),,25.79,88895,DB00537,Ciprofloxacin
,18471140,elimination half-lives (t(1/2beta)),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t(1/2beta)) were 17.14 +/- 4.14, 25.79 +/- 8.10, 16.67 +/- 4.04 (pigs) and 6.11 +/- 1.50, 5.64 +/- 0.74, 8.20 +/- 3.12 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),h,16.67,88896,DB00537,Ciprofloxacin
,18471140,elimination half-lives (t(1/2beta)),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t(1/2beta)) were 17.14 +/- 4.14, 25.79 +/- 8.10, 16.67 +/- 4.04 (pigs) and 6.11 +/- 1.50, 5.64 +/- 0.74, 8.20 +/- 3.12 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),h,6.11,88897,DB00537,Ciprofloxacin
,18471140,elimination half-lives (t(1/2beta)),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t(1/2beta)) were 17.14 +/- 4.14, 25.79 +/- 8.10, 16.67 +/- 4.04 (pigs) and 6.11 +/- 1.50, 5.64 +/- 0.74, 8.20 +/- 3.12 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),h,5.64,88898,DB00537,Ciprofloxacin
,18471140,elimination half-lives (t(1/2beta)),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t(1/2beta)) were 17.14 +/- 4.14, 25.79 +/- 8.10, 16.67 +/- 4.04 (pigs) and 6.11 +/- 1.50, 5.64 +/- 0.74, 8.20 +/- 3.12 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),h,8.20,88899,DB00537,Ciprofloxacin
,18471140,peak plasma concentrations (C(max)),"After single i.m. and p.o. administration, difloxacin was rapidly absorbed, with peak plasma concentrations (C(max)) of 1.77 +/- 0.66, 2.29 +/- 0.85 (pigs) and 2.51 +/- 0.36, 1.00 +/- 0.21 microg/mL (broilers) attained at t(max) of 1.29 +/- 0.26, 1.41 +/- 0.88 (pigs) and 0.86 +/- 0.4, 4.34 +/- 2.40 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[μg] / [ml],1.77,88900,DB00537,Ciprofloxacin
,18471140,peak plasma concentrations (C(max)),"After single i.m. and p.o. administration, difloxacin was rapidly absorbed, with peak plasma concentrations (C(max)) of 1.77 +/- 0.66, 2.29 +/- 0.85 (pigs) and 2.51 +/- 0.36, 1.00 +/- 0.21 microg/mL (broilers) attained at t(max) of 1.29 +/- 0.26, 1.41 +/- 0.88 (pigs) and 0.86 +/- 0.4, 4.34 +/- 2.40 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[μg] / [ml],2.29,88901,DB00537,Ciprofloxacin
,18471140,peak plasma concentrations (C(max)),"After single i.m. and p.o. administration, difloxacin was rapidly absorbed, with peak plasma concentrations (C(max)) of 1.77 +/- 0.66, 2.29 +/- 0.85 (pigs) and 2.51 +/- 0.36, 1.00 +/- 0.21 microg/mL (broilers) attained at t(max) of 1.29 +/- 0.26, 1.41 +/- 0.88 (pigs) and 0.86 +/- 0.4, 4.34 +/- 2.40 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[μg] / [ml],2.51,88902,DB00537,Ciprofloxacin
,18471140,peak plasma concentrations (C(max)),"After single i.m. and p.o. administration, difloxacin was rapidly absorbed, with peak plasma concentrations (C(max)) of 1.77 +/- 0.66, 2.29 +/- 0.85 (pigs) and 2.51 +/- 0.36, 1.00 +/- 0.21 microg/mL (broilers) attained at t(max) of 1.29 +/- 0.26, 1.41 +/- 0.88 (pigs) and 0.86 +/- 0.4, 4.34 +/- 2.40 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[μg] / [ml],1.00,88903,DB00537,Ciprofloxacin
,18471140,t(max),"After single i.m. and p.o. administration, difloxacin was rapidly absorbed, with peak plasma concentrations (C(max)) of 1.77 +/- 0.66, 2.29 +/- 0.85 (pigs) and 2.51 +/- 0.36, 1.00 +/- 0.21 microg/mL (broilers) attained at t(max) of 1.29 +/- 0.26, 1.41 +/- 0.88 (pigs) and 0.86 +/- 0.4, 4.34 +/- 2.40 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),h,1.29,88904,DB00537,Ciprofloxacin
,18471140,t(max),"After single i.m. and p.o. administration, difloxacin was rapidly absorbed, with peak plasma concentrations (C(max)) of 1.77 +/- 0.66, 2.29 +/- 0.85 (pigs) and 2.51 +/- 0.36, 1.00 +/- 0.21 microg/mL (broilers) attained at t(max) of 1.29 +/- 0.26, 1.41 +/- 0.88 (pigs) and 0.86 +/- 0.4, 4.34 +/- 2.40 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),h,1.41,88905,DB00537,Ciprofloxacin
,18471140,t(max),"After single i.m. and p.o. administration, difloxacin was rapidly absorbed, with peak plasma concentrations (C(max)) of 1.77 +/- 0.66, 2.29 +/- 0.85 (pigs) and 2.51 +/- 0.36, 1.00 +/- 0.21 microg/mL (broilers) attained at t(max) of 1.29 +/- 0.26, 1.41 +/- 0.88 (pigs) and 0.86 +/- 0.4, 4.34 +/- 2.40 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),h,0.86,88906,DB00537,Ciprofloxacin
,18471140,t(max),"After single i.m. and p.o. administration, difloxacin was rapidly absorbed, with peak plasma concentrations (C(max)) of 1.77 +/- 0.66, 2.29 +/- 0.85 (pigs) and 2.51 +/- 0.36, 1.00 +/- 0.21 microg/mL (broilers) attained at t(max) of 1.29 +/- 0.26, 1.41 +/- 0.88 (pigs) and 0.86 +/- 0.4, 4.34 +/- 2.40 h (broilers), respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),h,4.34,88907,DB00537,Ciprofloxacin
,18471140,Bioavailabilities (F),"Bioavailabilities (F) were (95.3 +/- 28.9)% and (105.7 +/- 37.1)% (pigs) and (77.0 +/- 11.8)% and (54.2 +/- 12.6)% (broilers) after i.m. and p.o. doses, respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),%,95.3,88908,DB00537,Ciprofloxacin
,18471140,Bioavailabilities (F),"Bioavailabilities (F) were (95.3 +/- 28.9)% and (105.7 +/- 37.1)% (pigs) and (77.0 +/- 11.8)% and (54.2 +/- 12.6)% (broilers) after i.m. and p.o. doses, respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),%,105.7,88909,DB00537,Ciprofloxacin
,18471140,Bioavailabilities (F),"Bioavailabilities (F) were (95.3 +/- 28.9)% and (105.7 +/- 37.1)% (pigs) and (77.0 +/- 11.8)% and (54.2 +/- 12.6)% (broilers) after i.m. and p.o. doses, respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),%,77.0,88910,DB00537,Ciprofloxacin
,18471140,Bioavailabilities (F),"Bioavailabilities (F) were (95.3 +/- 28.9)% and (105.7 +/- 37.1)% (pigs) and (77.0 +/- 11.8)% and (54.2 +/- 12.6)% (broilers) after i.m. and p.o. doses, respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),%,54.2,88911,DB00537,Ciprofloxacin
,18471140,Apparent distribution volumes(V(d(area))),"Apparent distribution volumes(V(d(area))) of 4.91 +/- 1.88 and 3.10 +/- 0.67 L/kg and total body clearances(Cl(B)) of 0.20 +/- 0.06 and 0.37 +/- 0.10 L/kg/h were determined in pigs and broilers, respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[l] / [kg],4.91,88912,DB00537,Ciprofloxacin
,18471140,Apparent distribution volumes(V(d(area))),"Apparent distribution volumes(V(d(area))) of 4.91 +/- 1.88 and 3.10 +/- 0.67 L/kg and total body clearances(Cl(B)) of 0.20 +/- 0.06 and 0.37 +/- 0.10 L/kg/h were determined in pigs and broilers, respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[l] / [kg],3.10,88913,DB00537,Ciprofloxacin
,18471140,total body clearances(Cl(B)),"Apparent distribution volumes(V(d(area))) of 4.91 +/- 1.88 and 3.10 +/- 0.67 L/kg and total body clearances(Cl(B)) of 0.20 +/- 0.06 and 0.37 +/- 0.10 L/kg/h were determined in pigs and broilers, respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[l] / [h·kg],0.20,88914,DB00537,Ciprofloxacin
,18471140,total body clearances(Cl(B)),"Apparent distribution volumes(V(d(area))) of 4.91 +/- 1.88 and 3.10 +/- 0.67 L/kg and total body clearances(Cl(B)) of 0.20 +/- 0.06 and 0.37 +/- 0.10 L/kg/h were determined in pigs and broilers, respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[l] / [h·kg],0.37,88915,DB00537,Ciprofloxacin
<,18471140,MIC(90),"Based on the single-dose pharmacokinetic parameters determined, multiple dosage regimens were recommended as: a dosage of 5 mg/kg given intramuscularly every 24 h in pigs, or administered orally every 24 h at the dosage of 10 mg/kg in broilers, can maintain effective plasma concentrations with bacteria infections, in which MIC(90) are <0.25 microg/mL and <0.1 microg/mL respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[μg] / [ml],0.25,88916,DB00537,Ciprofloxacin
<,18471140,MIC(90),"Based on the single-dose pharmacokinetic parameters determined, multiple dosage regimens were recommended as: a dosage of 5 mg/kg given intramuscularly every 24 h in pigs, or administered orally every 24 h at the dosage of 10 mg/kg in broilers, can maintain effective plasma concentrations with bacteria infections, in which MIC(90) are <0.25 microg/mL and <0.1 microg/mL respectively.","Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471140/),[μg] / [ml],0.1,88917,DB00537,Ciprofloxacin
,15618751,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma after the oral administration of GPFX were 5.69 +/- 1.00 and 352 +/- 57, respectively, which were several-fold greater than those of ciprofloxacin (CPFX).","Distribution characteristics of grepafloxacin, a fluoroquinolone antibiotic, in lung epithelial lining fluid and alveolar macrophage. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618751/),,5.69,89679,DB00537,Ciprofloxacin
,15618751,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma after the oral administration of GPFX were 5.69 +/- 1.00 and 352 +/- 57, respectively, which were several-fold greater than those of ciprofloxacin (CPFX).","Distribution characteristics of grepafloxacin, a fluoroquinolone antibiotic, in lung epithelial lining fluid and alveolar macrophage. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618751/),,352,89680,DB00537,Ciprofloxacin
,2557762,bioavailability,The oxazine ring of ofloxacin provides excellent oral absorption with virtually 95 percent bioavailability; this modification also has prevented metabolism and has provided a long half-life of seven to eight hours.,Chemical evolution of the fluoroquinolone antimicrobial agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2557762/),%,95,90487,DB00537,Ciprofloxacin
,2557762,half-life,The oxazine ring of ofloxacin provides excellent oral absorption with virtually 95 percent bioavailability; this modification also has prevented metabolism and has provided a long half-life of seven to eight hours.,Chemical evolution of the fluoroquinolone antimicrobial agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2557762/),h,seven to eight,90488,DB00537,Ciprofloxacin
,21530184,half-life (t(1/2)),"On Day 5 of a twice-daily dosing regimen of 17.5 mg/kg, the ciprofloxacin half-life (t(1/2)), maximum drug concentration (C(max)) and area under the concentration-time curve (AUC) in marmoset plasma were 1.9 h, 2.1 μg/mL and 7.9 μg/mL/h, respectively.",Post-exposure therapy of inhalational anthrax in the common marmoset. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21530184/),h,1.9,90810,DB00537,Ciprofloxacin
,21530184,maximum drug concentration (C(max)),"On Day 5 of a twice-daily dosing regimen of 17.5 mg/kg, the ciprofloxacin half-life (t(1/2)), maximum drug concentration (C(max)) and area under the concentration-time curve (AUC) in marmoset plasma were 1.9 h, 2.1 μg/mL and 7.9 μg/mL/h, respectively.",Post-exposure therapy of inhalational anthrax in the common marmoset. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21530184/),[μg] / [ml],2.1,90811,DB00537,Ciprofloxacin
,21530184,area under the concentration-time curve (AUC),"On Day 5 of a twice-daily dosing regimen of 17.5 mg/kg, the ciprofloxacin half-life (t(1/2)), maximum drug concentration (C(max)) and area under the concentration-time curve (AUC) in marmoset plasma were 1.9 h, 2.1 μg/mL and 7.9 μg/mL/h, respectively.",Post-exposure therapy of inhalational anthrax in the common marmoset. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21530184/),[μg] / [h·ml],7.9,90812,DB00537,Ciprofloxacin
,11118849,half-life (T(1/2)),"To compare the antimicrobial effects (AMEs) of gemifloxacin (GEM) and ciprofloxacin (CIP) on Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa, a series of pharmacokinetic profiles of GEM (a single dose with the half-life (T(1/2)) of 7.4 h and CIP (two 12 h doses with T(1/2) of 4 h) were simulated in vitro over eight-fold ranges of the AUC/MIC ratio.",Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118849/),h,7.4,93112,DB00537,Ciprofloxacin
,11118849,T(1/2),"To compare the antimicrobial effects (AMEs) of gemifloxacin (GEM) and ciprofloxacin (CIP) on Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa, a series of pharmacokinetic profiles of GEM (a single dose with the half-life (T(1/2)) of 7.4 h and CIP (two 12 h doses with T(1/2) of 4 h) were simulated in vitro over eight-fold ranges of the AUC/MIC ratio.",Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118849/),h,4,93113,DB00537,Ciprofloxacin
,11118849,AUC/MIC,The predicted ratio for GEM that might be equivalent to a clinically established breakpoint value of AUC/MIC=125 (mg h/l)/(mg/l) for CIP was estimated at 110 (mg h/l)/(mg/l).,Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118849/),[h·l·mg] / [l·mg],125,93114,DB00537,Ciprofloxacin
,11118849,AUC/MIC,The predicted ratio for GEM that might be equivalent to a clinically established breakpoint value of AUC/MIC=125 (mg h/l)/(mg/l) for CIP was estimated at 110 (mg h/l)/(mg/l).,Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118849/),[h·l·mg] / [l·mg],110,93115,DB00537,Ciprofloxacin
high,11118849,MICs=MIC(50)s,"It was calculated, that a daily dose of CIP that might provide the same AME as a clinical dose of GEM (320 mg) on a hypothetical strain of S. aureus with MICs=MIC(50)s would be as high as 2 x 3200 mg.",Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118849/),mg,2 x 3200,93116,DB00537,Ciprofloxacin
,18384536,half-life,Results indicate enrofloxacin half-life after intramuscular dosing is estimated to be 2.4 hours.,A pharmacokinetic study of enrofloxacin and its active metabolite ciprofloxacin after oral and intramuscular dosing of enrofloxacin in rhesus monkeys (Macaca mulatta). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384536/),h,2.4,93351,DB00537,Ciprofloxacin
,17991225,plasma half-life,"The mean +/- SD plasma half-life was 6.8 +/- 1.2 and 7.3 +/- 1 h for enrofloxacin and ciprofloxacin, respectively.",Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991225/),h,6.8,93677,DB00537,Ciprofloxacin
,17991225,plasma half-life,"The mean +/- SD plasma half-life was 6.8 +/- 1.2 and 7.3 +/- 1 h for enrofloxacin and ciprofloxacin, respectively.",Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991225/),h,7.3,93678,DB00537,Ciprofloxacin
,17991225,peak plasma concentration (Cmax),"The combined (ciprofloxacin + enrofloxacin) peak plasma concentration (Cmax) was 1.52 microg/mL, and the combined area under the curve (AUC) was 25.33 microg/mL.",Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991225/),[μg] / [ml],1.52,93679,DB00537,Ciprofloxacin
,17991225,area under the curve (AUC),"The combined (ciprofloxacin + enrofloxacin) peak plasma concentration (Cmax) was 1.52 microg/mL, and the combined area under the curve (AUC) was 25.33 microg/mL.",Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991225/),[μg] / [ml],25.33,93680,DB00537,Ciprofloxacin
,17991225,plasma free drug concentrations,"The plasma free drug concentrations were 54% and 81% for enrofloxacin and ciprofloxacin, respectively, and free drug concentration in the tissue fluid was higher than in plasma.",Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991225/),%,54,93681,DB00537,Ciprofloxacin
,17991225,plasma free drug concentrations,"The plasma free drug concentrations were 54% and 81% for enrofloxacin and ciprofloxacin, respectively, and free drug concentration in the tissue fluid was higher than in plasma.",Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991225/),%,81,93682,DB00537,Ciprofloxacin
,17991225,MIC,We concluded that Cmax/MIC and AUC/MIC ratios for free drug concentrations in plasma and ISF would meet suggested ratios for a targeted MIC of 0.06 microg/mL.,Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991225/),[μg] / [ml],0.06,93683,DB00537,Ciprofloxacin
<,21371548,lag times,The duration of floating times were predominantly >24 h and floating lag times <20 s.,Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: pharmacokinetic characterization in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371548/),s,20,93908,DB00537,Ciprofloxacin
,21371548,C(max),"C(max), T(max), and AUC(0-∞) of GT vs CT were 0.945±0.29 vs 2.1±0.46 μg/ml, 6.0±1.42 vs 1.42±0.59 h and 8.54±1.87 vs 9.45±2.12 μg/ml/h, respectively.",Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: pharmacokinetic characterization in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371548/),[μg] / [ml],0.945,93909,DB00537,Ciprofloxacin
,21371548,T(max),"C(max), T(max), and AUC(0-∞) of GT vs CT were 0.945±0.29 vs 2.1±0.46 μg/ml, 6.0±1.42 vs 1.42±0.59 h and 8.54±1.87 vs 9.45±2.12 μg/ml/h, respectively.",Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: pharmacokinetic characterization in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371548/),[μg] / [ml],2.1,93910,DB00537,Ciprofloxacin
,21371548,T(max),"C(max), T(max), and AUC(0-∞) of GT vs CT were 0.945±0.29 vs 2.1±0.46 μg/ml, 6.0±1.42 vs 1.42±0.59 h and 8.54±1.87 vs 9.45±2.12 μg/ml/h, respectively.",Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: pharmacokinetic characterization in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371548/),h,6.0,93911,DB00537,Ciprofloxacin
,21371548,T(max),"C(max), T(max), and AUC(0-∞) of GT vs CT were 0.945±0.29 vs 2.1±0.46 μg/ml, 6.0±1.42 vs 1.42±0.59 h and 8.54±1.87 vs 9.45±2.12 μg/ml/h, respectively.",Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: pharmacokinetic characterization in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371548/),h,1.42,93912,DB00537,Ciprofloxacin
,21371548,AUC(0-∞),"C(max), T(max), and AUC(0-∞) of GT vs CT were 0.945±0.29 vs 2.1±0.46 μg/ml, 6.0±1.42 vs 1.42±0.59 h and 8.54±1.87 vs 9.45±2.12 μg/ml/h, respectively.",Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: pharmacokinetic characterization in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371548/),[μg] / [h·ml],8.54,93913,DB00537,Ciprofloxacin
,21371548,AUC(0-∞),"C(max), T(max), and AUC(0-∞) of GT vs CT were 0.945±0.29 vs 2.1±0.46 μg/ml, 6.0±1.42 vs 1.42±0.59 h and 8.54±1.87 vs 9.45±2.12 μg/ml/h, respectively.",Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: pharmacokinetic characterization in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371548/),[μg] / [h·ml],9.45,93914,DB00537,Ciprofloxacin
,2121409,tmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,1.4,94643,DB00537,Ciprofloxacin
,2121409,tmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,4.6,94644,DB00537,Ciprofloxacin
,2121409,tmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,5.6,94645,DB00537,Ciprofloxacin
,2121409,Cmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),[μM] / [l],53,94646,DB00537,Ciprofloxacin
,2121409,Cmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),[μM] / [l],250,94647,DB00537,Ciprofloxacin
,2121409,Cmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),[μM] / [l],60,94648,DB00537,Ciprofloxacin
,2121409,t1/2,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,4.4,94649,DB00537,Ciprofloxacin
,2121409,t1/2,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,10.8,94650,DB00537,Ciprofloxacin
,2121409,t1/2,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,14.2,94651,DB00537,Ciprofloxacin
,17768026,total run time,Chromatographic separation was achieved on a reversed-phase Shimadzu 2.0 microm C18 column (150 mm x 2.00 mm) with the mobile phase of methanol-0.02% formic acid and step gradient elution resulted in a total run time of about 10.0 min.,Determination of caderofloxacin lactate in rat plasma by high-performance liquid chromatography-mass spectrometry and its application in rat pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17768026/),min,10.0,94756,DB00537,Ciprofloxacin
,17768026,recoveries,"Average recoveries ranged from 88.80 to 93.05% in plasma at the concentrations of 10, 100 and 1000 ng/mL.",Determination of caderofloxacin lactate in rat plasma by high-performance liquid chromatography-mass spectrometry and its application in rat pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17768026/),%,88.80 to 93.05,94757,DB00537,Ciprofloxacin
,18611787,peak concentration (C(max)),"The 'mean' peak concentration (C(max)) was 6.9 +/- 2.2 (S.D.) and 11.8 +/- 5.2 (S.D.) for the 200 and 400 mg groups, respectively.",High dose parenteral ciprofloxacin in pleuro-pulmonary disease: a comparative pharmacolinetics of 400 and 200 mg intravenous. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611787/),,6.9,94770,DB00537,Ciprofloxacin
,18611787,peak concentration (C(max)),"The 'mean' peak concentration (C(max)) was 6.9 +/- 2.2 (S.D.) and 11.8 +/- 5.2 (S.D.) for the 200 and 400 mg groups, respectively.",High dose parenteral ciprofloxacin in pleuro-pulmonary disease: a comparative pharmacolinetics of 400 and 200 mg intravenous. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611787/),,11.8,94771,DB00537,Ciprofloxacin
,18611787,area under the curve in 0-4 h,"The mean concentrations at 1.5 h were 1.2 and 2.6 mg/l and the area under the curve in 0-4 h was 4.6 +/- 0.9 (S.D.) and 7.5 +/- 2.4 (S.D.), respectively for the 200 and 400 mg groups.",High dose parenteral ciprofloxacin in pleuro-pulmonary disease: a comparative pharmacolinetics of 400 and 200 mg intravenous. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611787/),,4.6,94772,DB00537,Ciprofloxacin
,18611787,area under the curve in 0-4 h,"The mean concentrations at 1.5 h were 1.2 and 2.6 mg/l and the area under the curve in 0-4 h was 4.6 +/- 0.9 (S.D.) and 7.5 +/- 2.4 (S.D.), respectively for the 200 and 400 mg groups.",High dose parenteral ciprofloxacin in pleuro-pulmonary disease: a comparative pharmacolinetics of 400 and 200 mg intravenous. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611787/),,7.5,94773,DB00537,Ciprofloxacin
,18611787,MICs,"IV 200 mg did not reach the required levels to cover the minimum inhibitory concentrations (MICs), whereas, 400 mg IV dose clearly will provide an improved coverage for the commonly encountered organisms with MICs in the 1-4 mg/l range.",High dose parenteral ciprofloxacin in pleuro-pulmonary disease: a comparative pharmacolinetics of 400 and 200 mg intravenous. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611787/),[mg] / [l],1-4,94774,DB00537,Ciprofloxacin
,33401303,total flow-rate,"The separation was carried out in a system consisted of a C18 column with acetonitrile and KH2PO4 (0.01 M, 0.1% v/v of triethylamine, pH 2.7) as the mobile phase in a gradient elution at a total flow-rate of 1 mL/min.",Simultaneous HPLC Assay of Gliclazide and Ciprofloxacin in Plasma and its Implementation for Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33401303/),[ml] / [min],1,95410,DB00537,Ciprofloxacin
<,31483886,MIC,"While differences in enrofloxacin and ciprofloxacin pharmacokinetics were seen between pregnant and non-pregnant mares, the recommended drug dose and dose intervals are appropriate for MIC <0.25 µg/mL.",Pharmacokinetics of intravenous and oral administration of enrofloxacin to the late-term pregnant and non-pregnant mares. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31483886/),[μg] / [ml],0.25,95468,DB00537,Ciprofloxacin
>,31483886,MIC,Dosages may need to be adjusted for bacteria with a MIC >0.25 µg/mL.,Pharmacokinetics of intravenous and oral administration of enrofloxacin to the late-term pregnant and non-pregnant mares. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31483886/),[μg] / [ml],0.25,95469,DB00537,Ciprofloxacin
,18094990,serum concentration,"The antibiotic serum concentration was 0.83 mg/l (p.o.) vs 8.44 mg/l (i.v.) before surgery, 0.81 mg/l (p.o.) vs 4.43 mg/l (i.v.) during surgery, and 0.69 mg/l (p.o.) vs 2.77 mg/l (i.v.) after surgery.",Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094990/),[mg] / [l],0.83,95800,DB00537,Ciprofloxacin
,18094990,serum concentration,"The antibiotic serum concentration was 0.83 mg/l (p.o.) vs 8.44 mg/l (i.v.) before surgery, 0.81 mg/l (p.o.) vs 4.43 mg/l (i.v.) during surgery, and 0.69 mg/l (p.o.) vs 2.77 mg/l (i.v.) after surgery.",Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094990/),[mg] / [l],8.44,95801,DB00537,Ciprofloxacin
,18094990,serum concentration,"The antibiotic serum concentration was 0.83 mg/l (p.o.) vs 8.44 mg/l (i.v.) before surgery, 0.81 mg/l (p.o.) vs 4.43 mg/l (i.v.) during surgery, and 0.69 mg/l (p.o.) vs 2.77 mg/l (i.v.) after surgery.",Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094990/),[mg] / [l],0.81,95802,DB00537,Ciprofloxacin
,18094990,serum concentration,"The antibiotic serum concentration was 0.83 mg/l (p.o.) vs 8.44 mg/l (i.v.) before surgery, 0.81 mg/l (p.o.) vs 4.43 mg/l (i.v.) during surgery, and 0.69 mg/l (p.o.) vs 2.77 mg/l (i.v.) after surgery.",Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094990/),[mg] / [l],4.43,95803,DB00537,Ciprofloxacin
,18094990,serum concentration,"The antibiotic serum concentration was 0.83 mg/l (p.o.) vs 8.44 mg/l (i.v.) before surgery, 0.81 mg/l (p.o.) vs 4.43 mg/l (i.v.) during surgery, and 0.69 mg/l (p.o.) vs 2.77 mg/l (i.v.) after surgery.",Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094990/),[mg] / [l],0.69,95804,DB00537,Ciprofloxacin
,18094990,serum concentration,"The antibiotic serum concentration was 0.83 mg/l (p.o.) vs 8.44 mg/l (i.v.) before surgery, 0.81 mg/l (p.o.) vs 4.43 mg/l (i.v.) during surgery, and 0.69 mg/l (p.o.) vs 2.77 mg/l (i.v.) after surgery.",Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094990/),[mg] / [l],2.77,95805,DB00537,Ciprofloxacin
,18094990,bile concentration,The bile concentration was higher after oral administration with 9.20 mg/l than after intravenous application with 5.79 mg/l.,Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094990/),,9.20,95806,DB00537,Ciprofloxacin
,18094990,bile concentration,The bile concentration was higher after oral administration with 9.20 mg/l than after intravenous application with 5.79 mg/l.,Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094990/),,5.79,95807,DB00537,Ciprofloxacin
,6517556,peak serum levels,"Mean peak serum levels were 1.35 to 1.42 micrograms/ml after the 250-mg dose, 2.60 to 2.89 micrograms/ml after the 500-mg dose, and 3.41 to 4.21 micrograms/ml after the 750-mg dose.",Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517556/),[μg] / [ml],1.35 to 1.42,96003,DB00537,Ciprofloxacin
,6517556,peak serum levels,"Mean peak serum levels were 1.35 to 1.42 micrograms/ml after the 250-mg dose, 2.60 to 2.89 micrograms/ml after the 500-mg dose, and 3.41 to 4.21 micrograms/ml after the 750-mg dose.",Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517556/),[μg] / [ml],2.60 to 2.89,96004,DB00537,Ciprofloxacin
,6517556,peak serum levels,"Mean peak serum levels were 1.35 to 1.42 micrograms/ml after the 250-mg dose, 2.60 to 2.89 micrograms/ml after the 500-mg dose, and 3.41 to 4.21 micrograms/ml after the 750-mg dose.",Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517556/),[μg] / [ml],3.41 to 4.21,96005,DB00537,Ciprofloxacin
,6517556,Terminal serum half-lives,"Terminal serum half-lives ranged from 3.8 to 4.3, 4.5 to 4.9, and 3.9 to 6.6 h after the 250-, 500-, and 750-mg doses, respectively.",Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517556/),h,3.8 to 4.3,96006,DB00537,Ciprofloxacin
,6517556,Terminal serum half-lives,"Terminal serum half-lives ranged from 3.8 to 4.3, 4.5 to 4.9, and 3.9 to 6.6 h after the 250-, 500-, and 750-mg doses, respectively.",Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517556/),h,4.5 to 4.9,96007,DB00537,Ciprofloxacin
,6517556,Terminal serum half-lives,"Terminal serum half-lives ranged from 3.8 to 4.3, 4.5 to 4.9, and 3.9 to 6.6 h after the 250-, 500-, and 750-mg doses, respectively.",Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517556/),h,3.9 to 6.6,96008,DB00537,Ciprofloxacin
,28183350,area under the concentration-time curves (AUC0-24h),"Calculations of the area under the concentration-time curves (AUC0-24h) were 8.57 ± 0.59 and 8.37 ± 0.29 μg · h/ml following i.v. and p.o. administration, respectively.",Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28183350/),[h·μg] / [ml],8.57,96224,DB00537,Ciprofloxacin
,28183350,area under the concentration-time curves (AUC0-24h),"Calculations of the area under the concentration-time curves (AUC0-24h) were 8.57 ± 0.59 and 8.37 ± 0.29 μg · h/ml following i.v. and p.o. administration, respectively.",Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28183350/),[h·μg] / [ml],8.37,96225,DB00537,Ciprofloxacin
,28183350,Elimination half-lives (t 1/2β),"Elimination half-lives (t 1/2β) were 6.11 ± 0.99 h and 8.21 ± 0.64 h for i.v. injection and p.o. administration, respectively.",Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28183350/),h,6.11,96226,DB00537,Ciprofloxacin
,28183350,Elimination half-lives (t 1/2β),"Elimination half-lives (t 1/2β) were 6.11 ± 0.99 h and 8.21 ± 0.64 h for i.v. injection and p.o. administration, respectively.",Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28183350/),h,8.21,96227,DB00537,Ciprofloxacin
,28183350,plasma protein binding,The mean in vitro plasma protein binding of sarafloxacin was 39.3%.,Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28183350/),%,39.3,96228,DB00537,Ciprofloxacin
,28183350,AUC0-24h/MIC,"Integration using the sigmoid E max model, the mean values of AUC0-24h/MIC needed for bacteriostatic, bactericidal and bacterial eradication action were 25.4, 40.6, and 94.4 h, respectively.",Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28183350/),h,25.4,96229,DB00537,Ciprofloxacin
,28183350,AUC0-24h/MIC,"Integration using the sigmoid E max model, the mean values of AUC0-24h/MIC needed for bacteriostatic, bactericidal and bacterial eradication action were 25.4, 40.6, and 94.4 h, respectively.",Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28183350/),h,40.6,96230,DB00537,Ciprofloxacin
,28183350,AUC0-24h/MIC,"Integration using the sigmoid E max model, the mean values of AUC0-24h/MIC needed for bacteriostatic, bactericidal and bacterial eradication action were 25.4, 40.6, and 94.4 h, respectively.",Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28183350/),h,94.4,96231,DB00537,Ciprofloxacin
over,28183350,MIC,Sarafloxacin administered at a 10 mg/kg dose may be insufficient for treatment of E. coli O78 infections with an MIC equally to or over 0.125 μg/ml.,Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28183350/),[μg] / [ml],0.125,96232,DB00537,Ciprofloxacin
,30497453,Emax,"The in vivo effectiveness of enrofloxacin against E. coli in different organs varied, with the Emax ranging from - 4.4 to - 5.8 Log10 colony forming units (cfu)/mL or cfu/g.",In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497453/),[cfu·colony·forming·log10·units] / [cfu·g·ml·or],-,96852,DB00537,Ciprofloxacin
,30497453,Emax,"The in vivo effectiveness of enrofloxacin against E. coli in different organs varied, with the Emax ranging from - 4.4 to - 5.8 Log10 colony forming units (cfu)/mL or cfu/g.",In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497453/),[cfu·colony·forming·log10·units] / [cfu·g·ml·or],4.4,96853,DB00537,Ciprofloxacin
,30497453,Emax,"The in vivo effectiveness of enrofloxacin against E. coli in different organs varied, with the Emax ranging from - 4.4 to - 5.8 Log10 colony forming units (cfu)/mL or cfu/g.",In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497453/),[cfu·colony·forming·log10·units] / [cfu·g·ml·or],5.8,96854,DB00537,Ciprofloxacin
,30497453,AUC0-24/MIC ratio,"The AUC0-24/MIC ratio of the combination of enrofloxacin and ciprofloxacin producing bactericidal and elimination effects were 21.29 and 32.13 in blood; 41.68, and 58.52 in the liver; and 27.65 and 46.22 in the lung, respectively.",In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497453/),,21.29,96855,DB00537,Ciprofloxacin
,30497453,AUC0-24/MIC ratio,"The AUC0-24/MIC ratio of the combination of enrofloxacin and ciprofloxacin producing bactericidal and elimination effects were 21.29 and 32.13 in blood; 41.68, and 58.52 in the liver; and 27.65 and 46.22 in the lung, respectively.",In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497453/),,32.13,96856,DB00537,Ciprofloxacin
,30497453,AUC0-24/MIC ratio,"The AUC0-24/MIC ratio of the combination of enrofloxacin and ciprofloxacin producing bactericidal and elimination effects were 21.29 and 32.13 in blood; 41.68, and 58.52 in the liver; and 27.65 and 46.22 in the lung, respectively.",In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497453/),,41.68,96857,DB00537,Ciprofloxacin
,30497453,AUC0-24/MIC ratio,"The AUC0-24/MIC ratio of the combination of enrofloxacin and ciprofloxacin producing bactericidal and elimination effects were 21.29 and 32.13 in blood; 41.68, and 58.52 in the liver; and 27.65 and 46.22 in the lung, respectively.",In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497453/),,58.52,96858,DB00537,Ciprofloxacin
,30497453,AUC0-24/MIC ratio,"The AUC0-24/MIC ratio of the combination of enrofloxacin and ciprofloxacin producing bactericidal and elimination effects were 21.29 and 32.13 in blood; 41.68, and 58.52 in the liver; and 27.65 and 46.22 in the lung, respectively.",In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497453/),,27.65,96859,DB00537,Ciprofloxacin
,30497453,AUC0-24/MIC ratio,"The AUC0-24/MIC ratio of the combination of enrofloxacin and ciprofloxacin producing bactericidal and elimination effects were 21.29 and 32.13 in blood; 41.68, and 58.52 in the liver; and 27.65 and 46.22 in the lung, respectively.",In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497453/),,46.22,96860,DB00537,Ciprofloxacin
,8126763,t1/2 lambda z,"Mean enrofloxacin t1/2 lambda z was 2.4 h, mean Cls was 27.1 ml/min.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126763/),h,2.4,96864,DB00537,Ciprofloxacin
,8126763,Cls,"Mean enrofloxacin t1/2 lambda z was 2.4 h, mean Cls was 27.1 ml/min.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126763/),[ml] / [min],27.1,96865,DB00537,Ciprofloxacin
,8126763,Vss,"kg, and mean Vss was 7.0 l/kg.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126763/),[l] / [kg],7.0,96866,DB00537,Ciprofloxacin
,8126763,Cmax,"After i.v. and p.o. administration, concentrations of ciprofloxacin exceeding minimal inhibitory concentrations of several microorganisms were reached (Cmax = 0.2 microgram/ml, tmax = 2.2 h after intravenous administration; Cmax = 0.2 microgram/ml, tmax = 3.6 h after oral administration).",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126763/),[μg] / [ml],0.2,96867,DB00537,Ciprofloxacin
,8126763,tmax,"After i.v. and p.o. administration, concentrations of ciprofloxacin exceeding minimal inhibitory concentrations of several microorganisms were reached (Cmax = 0.2 microgram/ml, tmax = 2.2 h after intravenous administration; Cmax = 0.2 microgram/ml, tmax = 3.6 h after oral administration).",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126763/),h,2.2,96868,DB00537,Ciprofloxacin
,8126763,tmax,"After i.v. and p.o. administration, concentrations of ciprofloxacin exceeding minimal inhibitory concentrations of several microorganisms were reached (Cmax = 0.2 microgram/ml, tmax = 2.2 h after intravenous administration; Cmax = 0.2 microgram/ml, tmax = 3.6 h after oral administration).",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126763/),h,3.6,96869,DB00537,Ciprofloxacin
,16740105,half-life,"Mean half-life for difloxacin administered IV, IM, and IG was 2.66, 5.72, and 10.75 hours, respectively.","Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740105/),h,2.66,97891,DB00537,Ciprofloxacin
,16740105,half-life,"Mean half-life for difloxacin administered IV, IM, and IG was 2.66, 5.72, and 10.75 hours, respectively.","Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740105/),h,5.72,97892,DB00537,Ciprofloxacin
,16740105,half-life,"Mean half-life for difloxacin administered IV, IM, and IG was 2.66, 5.72, and 10.75 hours, respectively.","Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740105/),h,10.75,97893,DB00537,Ciprofloxacin
,16740105,Clearance,Clearance after IV administration was 0.28 L/kg.h.,"Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740105/),[l] / [h·kg],0.28,97894,DB00537,Ciprofloxacin
,16740105,bioavailability,"After IM administration, the absolute mean +/- SD bioavailability was 95.81 +/- 3.11% and maximum plasma concentration (Cmax) was 1.48 +/- 0.12 mg/L.","Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740105/),%,95.81,97895,DB00537,Ciprofloxacin
,16740105,maximum plasma concentration (Cmax),"After IM administration, the absolute mean +/- SD bioavailability was 95.81 +/- 3.11% and maximum plasma concentration (Cmax) was 1.48 +/- 0.12 mg/L.","Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740105/),[mg] / [l],1.48,97896,DB00537,Ciprofloxacin
,16740105,absolute bioavailability,"After IG administration, the absolute bioavailability was 68.62 +/- 10.60% and Cmax was 0.732 +/- 0.05 mg/L.","Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740105/),%,68.62,97897,DB00537,Ciprofloxacin
,16740105,Cmax,"After IG administration, the absolute bioavailability was 68.62 +/- 10.60% and Cmax was 0.732 +/- 0.05 mg/L.","Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740105/),[mg] / [l],0.732,97898,DB00537,Ciprofloxacin
,8861529,half-life,"Fleroxacin is distinguished by its excellent bioavailability, high concentrations in the plasma and other body fluids, good tissue penetration, and a long half-life of 10-12 h, thus allowing once-a-day administration.",Fleroxacin overview. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8861529/),h,10-12,98573,DB00537,Ciprofloxacin
,29987142,clearance,"In our population, ciprofloxacin clearance is 0.16 to 0.43 liter/h/kg of body weight, volume of distribution 0.06 to 2.88 liters/kg, and bioavailability 59.6%.",Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29987142/),[l] / [h·kg],0.16 to 0.43,98833,DB00537,Ciprofloxacin
,29987142,volume of distribution,"In our population, ciprofloxacin clearance is 0.16 to 0.43 liter/h/kg of body weight, volume of distribution 0.06 to 2.88 liters/kg, and bioavailability 59.6%.",Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29987142/),[l] / [kg],0.06 to 2.88,98834,DB00537,Ciprofloxacin
,29987142,bioavailability,"In our population, ciprofloxacin clearance is 0.16 to 0.43 liter/h/kg of body weight, volume of distribution 0.06 to 2.88 liters/kg, and bioavailability 59.6%.",Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29987142/),%,59.6,98835,DB00537,Ciprofloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0.53,99479,DB00537,Ciprofloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0.34,99480,DB00537,Ciprofloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0. 43,99481,DB00537,Ciprofloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0.39,99482,DB00537,Ciprofloxacin
>or=,11709326,area under the concentration-time curve from 0 to 24 h (AUC(0-24))/MIC ratio,Pharmacodynamic data on ciprofloxacin indicate that a target area under the concentration-time curve from 0 to 24 h (AUC(0-24))/MIC ratio of >or=125 is necessary to achieve optimal bactericidal activity for the treatment of gram-negative pneumonia.,Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),,125,99548,DB00537,Ciprofloxacin
>or=,11709326,AUC(0-24)/MIC ratio,A Monte Carlo simulation was performed to estimate the fractional attainment of an AUC(0-24)/MIC ratio of >or=125.,Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),,125,99549,DB00537,Ciprofloxacin
,11709326,volume of distribution in the central compartment,"The mean fitted PK parameter values are volume of distribution in the central compartment, 0.29 liter/kg; volume of distribution at steady state, 1.1 liters/kg; total clearance, 0.34 liter/h/kg; distributional clearance, 0.89 liter/h/kg; half-life at alpha phase, 0.16 h; and half-life at beta phase, 2.9 h.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),[l] / [kg],0.29,99550,DB00537,Ciprofloxacin
,11709326,volume of distribution at steady state,"The mean fitted PK parameter values are volume of distribution in the central compartment, 0.29 liter/kg; volume of distribution at steady state, 1.1 liters/kg; total clearance, 0.34 liter/h/kg; distributional clearance, 0.89 liter/h/kg; half-life at alpha phase, 0.16 h; and half-life at beta phase, 2.9 h.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),[l] / [kg],1.1,99551,DB00537,Ciprofloxacin
,11709326,total clearance,"The mean fitted PK parameter values are volume of distribution in the central compartment, 0.29 liter/kg; volume of distribution at steady state, 1.1 liters/kg; total clearance, 0.34 liter/h/kg; distributional clearance, 0.89 liter/h/kg; half-life at alpha phase, 0.16 h; and half-life at beta phase, 2.9 h.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),[l] / [h·kg],0.34,99552,DB00537,Ciprofloxacin
,11709326,distributional clearance,"The mean fitted PK parameter values are volume of distribution in the central compartment, 0.29 liter/kg; volume of distribution at steady state, 1.1 liters/kg; total clearance, 0.34 liter/h/kg; distributional clearance, 0.89 liter/h/kg; half-life at alpha phase, 0.16 h; and half-life at beta phase, 2.9 h.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),[l] / [h·kg],0.89,99553,DB00537,Ciprofloxacin
,11709326,half-life at alpha phase,"The mean fitted PK parameter values are volume of distribution in the central compartment, 0.29 liter/kg; volume of distribution at steady state, 1.1 liters/kg; total clearance, 0.34 liter/h/kg; distributional clearance, 0.89 liter/h/kg; half-life at alpha phase, 0.16 h; and half-life at beta phase, 2.9 h.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),h,0.16,99554,DB00537,Ciprofloxacin
,11709326,half-life at beta phase,"The mean fitted PK parameter values are volume of distribution in the central compartment, 0.29 liter/kg; volume of distribution at steady state, 1.1 liters/kg; total clearance, 0.34 liter/h/kg; distributional clearance, 0.89 liter/h/kg; half-life at alpha phase, 0.16 h; and half-life at beta phase, 2.9 h.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),h,2.9,99555,DB00537,Ciprofloxacin
>or=,11709326,overall fractional attainment,"The overall fractional attainment of achieving an AUC(0-24)/MIC ratio of >or=125 against P. aeruginosa isolates with ciprofloxacin (400 mg every 12 h [q12h] and 8 qh) were 10 and 30%, respectively.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),%,125,99556,DB00537,Ciprofloxacin
,11709326,overall fractional attainment,"The overall fractional attainment of achieving an AUC(0-24)/MIC ratio of >or=125 against P. aeruginosa isolates with ciprofloxacin (400 mg every 12 h [q12h] and 8 qh) were 10 and 30%, respectively.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),%,10,99557,DB00537,Ciprofloxacin
,11709326,overall fractional attainment,"The overall fractional attainment of achieving an AUC(0-24)/MIC ratio of >or=125 against P. aeruginosa isolates with ciprofloxacin (400 mg every 12 h [q12h] and 8 qh) were 10 and 30%, respectively.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),%,30,99558,DB00537,Ciprofloxacin
>or=,11709326,AUC(0-24)/MIC ratio,"The overall fractional attainment of achieving an AUC(0-24)/MIC ratio of >or=125 against P. aeruginosa isolates with ciprofloxacin (400 mg every 12 h [q12h] and 8 qh) were 10 and 30%, respectively.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),%,125,99559,DB00537,Ciprofloxacin
,11709326,AUC(0-24)/MIC ratio,"The overall fractional attainment of achieving an AUC(0-24)/MIC ratio of >or=125 against P. aeruginosa isolates with ciprofloxacin (400 mg every 12 h [q12h] and 8 qh) were 10 and 30%, respectively.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),%,10,99560,DB00537,Ciprofloxacin
,11709326,AUC(0-24)/MIC ratio,"The overall fractional attainment of achieving an AUC(0-24)/MIC ratio of >or=125 against P. aeruginosa isolates with ciprofloxacin (400 mg every 12 h [q12h] and 8 qh) were 10 and 30%, respectively.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),%,30,99561,DB00537,Ciprofloxacin
<,11709326,MIC,"A clinical breakpoint MIC of <0.5 microg/ml for susceptibility is suggested, based on an examination of the fractional attainment of the AUC(0-24)/MIC target at each MIC.",Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709326/),[μg] / [ml],0.5,99562,DB00537,Ciprofloxacin
,2073101,MICs,All three antimicrobial agents had roughly equivalent activities when buffered charcoal yeast extract agar medium supplemented with 0.1% alpha-ketoglutarate was used as the test medium; the MICs for 90% of strains were 1.0 micrograms/ml for erythromycin and sparfloxacin and 0.5 microgram/ml for ciprofloxacin.,"In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],1.0,100100,DB00537,Ciprofloxacin
,2073101,MICs,All three antimicrobial agents had roughly equivalent activities when buffered charcoal yeast extract agar medium supplemented with 0.1% alpha-ketoglutarate was used as the test medium; the MICs for 90% of strains were 1.0 micrograms/ml for erythromycin and sparfloxacin and 0.5 microgram/ml for ciprofloxacin.,"In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],0.5,100101,DB00537,Ciprofloxacin
less,2073101,MICs,"Broth macrodilution MICs for two L. pneumophila strains in buffered yeast extract supplemented with 0.1% alpha-ketoglutarate were less than or equal to 0.03 microgram/ml for sparfloxacin, 0.06 microgram/ml for ciprofloxacin, and 0.25 microgram/ml for erythromycin; only erythromycin was inhibited by this medium.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],0.03,100102,DB00537,Ciprofloxacin
,2073101,MICs,"Broth macrodilution MICs for two L. pneumophila strains in buffered yeast extract supplemented with 0.1% alpha-ketoglutarate were less than or equal to 0.03 microgram/ml for sparfloxacin, 0.06 microgram/ml for ciprofloxacin, and 0.25 microgram/ml for erythromycin; only erythromycin was inhibited by this medium.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],0.06,100103,DB00537,Ciprofloxacin
,2073101,MICs,"Broth macrodilution MICs for two L. pneumophila strains in buffered yeast extract supplemented with 0.1% alpha-ketoglutarate were less than or equal to 0.03 microgram/ml for sparfloxacin, 0.06 microgram/ml for ciprofloxacin, and 0.25 microgram/ml for erythromycin; only erythromycin was inhibited by this medium.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],0.25,100104,DB00537,Ciprofloxacin
,2073101,peak levels,"For the pharmacokinetic study, sparfloxacin was given (10 mg/kg of body weight) to infected guinea pigs by the intraperitoneal route; peak levels in serum and lung were 2.6 micrograms/ml and 1.6 micrograms/g, respectively, at 1 h, with a terminal-phase half-life of elimination from serum of 5 h.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],2.6,100105,DB00537,Ciprofloxacin
,2073101,peak levels,"For the pharmacokinetic study, sparfloxacin was given (10 mg/kg of body weight) to infected guinea pigs by the intraperitoneal route; peak levels in serum and lung were 2.6 micrograms/ml and 1.6 micrograms/g, respectively, at 1 h, with a terminal-phase half-life of elimination from serum of 5 h.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [g],1.6,100106,DB00537,Ciprofloxacin
,2073101,terminal-phase half-life of elimination from serum,"For the pharmacokinetic study, sparfloxacin was given (10 mg/kg of body weight) to infected guinea pigs by the intraperitoneal route; peak levels in serum and lung were 2.6 micrograms/ml and 1.6 micrograms/g, respectively, at 1 h, with a terminal-phase half-life of elimination from serum of 5 h.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),h,5,100107,DB00537,Ciprofloxacin
,1329625,peak levels,"The mean peak levels of CP-74,667 in serum following a single oral dose of 20 mg/kg of body weight were similar in all species, with a range of 3.7 micrograms/ml in mice to 5.6 micrograms/ml in dogs.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),[μg] / [ml],3.7,100108,DB00537,Ciprofloxacin
,1329625,peak levels,"The mean peak levels of CP-74,667 in serum following a single oral dose of 20 mg/kg of body weight were similar in all species, with a range of 3.7 micrograms/ml in mice to 5.6 micrograms/ml in dogs.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),[μg] / [ml],5.6,100109,DB00537,Ciprofloxacin
,1329625,elimination half-lives,"In contrast, elimination half-lives were species dependent, with mean values of 2.1, 1.8, 4.5, 7.8, and 13.1 h in mice, rats, rabbits, dogs, and monkeys, respectively.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),h,2.1,100110,DB00537,Ciprofloxacin
,1329625,elimination half-lives,"In contrast, elimination half-lives were species dependent, with mean values of 2.1, 1.8, 4.5, 7.8, and 13.1 h in mice, rats, rabbits, dogs, and monkeys, respectively.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),h,1.8,100111,DB00537,Ciprofloxacin
,1329625,elimination half-lives,"In contrast, elimination half-lives were species dependent, with mean values of 2.1, 1.8, 4.5, 7.8, and 13.1 h in mice, rats, rabbits, dogs, and monkeys, respectively.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),h,4.5,100112,DB00537,Ciprofloxacin
,1329625,elimination half-lives,"In contrast, elimination half-lives were species dependent, with mean values of 2.1, 1.8, 4.5, 7.8, and 13.1 h in mice, rats, rabbits, dogs, and monkeys, respectively.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),h,7.8,100113,DB00537,Ciprofloxacin
,1329625,elimination half-lives,"In contrast, elimination half-lives were species dependent, with mean values of 2.1, 1.8, 4.5, 7.8, and 13.1 h in mice, rats, rabbits, dogs, and monkeys, respectively.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),h,13.1,100114,DB00537,Ciprofloxacin
,1329625,oral bioavailability,"The oral bioavailability of CP-74,667 was 100% in dogs and monkeys, as determined by intravenous-oral crossover experiments.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),%,100,100115,DB00537,Ciprofloxacin
excess,1329625,volume of distribution,"The good tissue penetration of CP-74,667 suggested by a volume of distribution in excess of 2 liters/kg in dogs and monkeys was confirmed by tissue distribution studies with the same species, which demonstrated tissue concentrations (except for those in brain tissue) greater than 1.45 times higher than corresponding levels in serum.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),[l] / [kg],2,100116,DB00537,Ciprofloxacin
,1329625,urinary recoveries,"The mean urinary recoveries of unchanged drug were 17.7% in rats, 7.8% in monkeys, and 4.9% in dogs.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),%,17.7,100117,DB00537,Ciprofloxacin
,1329625,urinary recoveries,"The mean urinary recoveries of unchanged drug were 17.7% in rats, 7.8% in monkeys, and 4.9% in dogs.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),%,7.8,100118,DB00537,Ciprofloxacin
,1329625,urinary recoveries,"The mean urinary recoveries of unchanged drug were 17.7% in rats, 7.8% in monkeys, and 4.9% in dogs.","Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329625/),%,4.9,100119,DB00537,Ciprofloxacin
,23742101,absorption half-life (t(1/2ka)),"The absorption half-life (t(1/2ka)) of difloxacin after oral administration were 2.08 and 1.10 h at 14 and 22 °C, respectively; whereas the elimination half-life (t(1/2β)) was 4.41 and 2.38 h, respectively.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),h,2.08,101272,DB00537,Ciprofloxacin
,23742101,absorption half-life (t(1/2ka)),"The absorption half-life (t(1/2ka)) of difloxacin after oral administration were 2.08 and 1.10 h at 14 and 22 °C, respectively; whereas the elimination half-life (t(1/2β)) was 4.41 and 2.38 h, respectively.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),h,1.10,101273,DB00537,Ciprofloxacin
,23742101,elimination half-life (t(1/2β)),"The absorption half-life (t(1/2ka)) of difloxacin after oral administration were 2.08 and 1.10 h at 14 and 22 °C, respectively; whereas the elimination half-life (t(1/2β)) was 4.41 and 2.38 h, respectively.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),h,4.41,101274,DB00537,Ciprofloxacin
,23742101,elimination half-life (t(1/2β)),"The absorption half-life (t(1/2ka)) of difloxacin after oral administration were 2.08 and 1.10 h at 14 and 22 °C, respectively; whereas the elimination half-life (t(1/2β)) was 4.41 and 2.38 h, respectively.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),h,2.38,101275,DB00537,Ciprofloxacin
,23742101,peak concentration,"For liver, the peak concentration of difloxacin 2.43 ± 0.30 μg/g occurred at 6 h at 14 °C, which was lower than the 3.34 ± 0.24 μg/g peak that occurred at 4 h at 22 °C.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),[μg] / [g],2.43,101276,DB00537,Ciprofloxacin
,23742101,peak concentration,"For liver, the peak concentration of difloxacin 2.43 ± 0.30 μg/g occurred at 6 h at 14 °C, which was lower than the 3.34 ± 0.24 μg/g peak that occurred at 4 h at 22 °C.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),[μg] / [g],3.34,101277,DB00537,Ciprofloxacin
,23742101,bioavailability,"The calculated bioavailability of difloxacin was 68.07% at 22 °C, which was higher than the 53.43% calculated for 14 °C.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),%,68.07,101278,DB00537,Ciprofloxacin
,23742101,bioavailability,"The calculated bioavailability of difloxacin was 68.07% at 22 °C, which was higher than the 53.43% calculated for 14 °C.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),%,53.43,101279,DB00537,Ciprofloxacin
,23742101,t(1/2β),"After intravenous administration, the t(1/2β) were 4.79 and 2.81 h at 14 and 22 °C, respectively.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),h,4.79,101280,DB00537,Ciprofloxacin
,23742101,t(1/2β),"After intravenous administration, the t(1/2β) were 4.79 and 2.81 h at 14 and 22 °C, respectively.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),h,2.81,101281,DB00537,Ciprofloxacin
,23742101,Vd,"The Vd values were 1.20 and 1.75 L/kg at 14 and 22 °C, respectively.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),[l] / [kg],1.20,101282,DB00537,Ciprofloxacin
,23742101,Vd,"The Vd values were 1.20 and 1.75 L/kg at 14 and 22 °C, respectively.",Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23742101/),[l] / [kg],1.75,101283,DB00537,Ciprofloxacin
,21185790,Retention times,"Retention times for ciprofloxacin and IS were approximately 3.6 and 7.0 min, respectively.",Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21185790/),min,3.6,101675,DB00537,Ciprofloxacin
,21185790,Retention times,"Retention times for ciprofloxacin and IS were approximately 3.6 and 7.0 min, respectively.",Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21185790/),min,7.0,101676,DB00537,Ciprofloxacin
,21185790,extraction recoveries,"The mean (SD) extraction recoveries for ciprofloxacin from spiked plasma at 0.08, 1.8 and 3.6 μg/mL were 72.8±12.5% (n=5), 83.5±5.2% and 77.7±2.0%, respectively (n=8 in both cases).",Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21185790/),%,72.8,101677,DB00537,Ciprofloxacin
,21185790,extraction recoveries,"The mean (SD) extraction recoveries for ciprofloxacin from spiked plasma at 0.08, 1.8 and 3.6 μg/mL were 72.8±12.5% (n=5), 83.5±5.2% and 77.7±2.0%, respectively (n=8 in both cases).",Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21185790/),%,83.5,101678,DB00537,Ciprofloxacin
,21185790,extraction recoveries,"The mean (SD) extraction recoveries for ciprofloxacin from spiked plasma at 0.08, 1.8 and 3.6 μg/mL were 72.8±12.5% (n=5), 83.5±5.2% and 77.7±2.0%, respectively (n=8 in both cases).",Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21185790/),%,77.7,101679,DB00537,Ciprofloxacin
,21185790,recovery,The recovery for IS was 94.5±7.9% (n=15).,Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21185790/),%,94.5,101680,DB00537,Ciprofloxacin
,21185790,limits of detection,"The limits of detection and quantification were 10 ng/mL and 20 ng/mL, respectively.",Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21185790/),[ng] / [ml],10,101681,DB00537,Ciprofloxacin
,21185790,limits of detection,"The limits of detection and quantification were 10 ng/mL and 20 ng/mL, respectively.",Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21185790/),[ng] / [ml],20,101682,DB00537,Ciprofloxacin
,27568215,terminal half-life,"After administration of 16 mg/kg of obiltoxaximab, serum concentrations decreased in a biexponential or multiexponential fashion with a terminal half-life of 17 to 23 days.",Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27568215/),d,17 to 23,102240,DB00537,Ciprofloxacin
,27568215,volume of distribution,"Mean volume of distribution was approximately 6.3 to 7.5 L, suggesting obiltoxaximab distribution outside the vascular compartment and potentially into tissues.",Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27568215/),l,6.3 to 7.5,102241,DB00537,Ciprofloxacin
,27568215,systemic clearance,"Mean systemic clearance was approximately 0.27 L/d, suggesting that hepatic metabolism and/or renal excretion are not critical to obiltoxaximab elimination.",Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27568215/),[l] / [d],0.27,102242,DB00537,Ciprofloxacin
,9888133,elimination half-life,"After intravitreal injection, however, elimination half-life of this antibiotic is only 2.2 hours.",[Clearance of liposome-incorporated ciprofloxacin after intravitreal injection in rabbit eyes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9888133/),h,2.2,102682,DB00537,Ciprofloxacin
,16050812,steady-state concentration,"Enrofloxacin and marbofloxacin were administered to six healthy dogs in separate crossover experiments as a single oral dose (5 mg/kg) and as a constant rate IV infusion (1.24 and 0.12 mg/h.kg, respectively) following a loading dose (4.47 and 2 mg/kg, respectively) to achieve a steady-state concentration of approximately 1 microg/mL for 8 h.","Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050812/),[μg] / [ml],1,102899,DB00537,Ciprofloxacin
,9209780,MICs,The MICs of AM-1155 for 11 highly fluoroquinolone-resistant isolates with alterations in both GyrA and ParC ranged from 0.06 to 1.0 microgram/ml.,Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.06 to 1.0,104038,DB00537,Ciprofloxacin
,9209780,MICs inhibiting 50% (,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],90,104039,DB00537,Ciprofloxacin
,9209780,MICs inhibiting 50% (,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.125,104040,DB00537,Ciprofloxacin
,9209780,MIC50,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],90,104041,DB00537,Ciprofloxacin
,9209780,MIC50,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.125,104042,DB00537,Ciprofloxacin
,9209780,MIC90,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],90,104043,DB00537,Ciprofloxacin
,9209780,MIC90,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],1.0,104044,DB00537,Ciprofloxacin
,9209780,MICs,"The MICs of AM-1155 for 20 moderately fluoroquinolone-resistant isolates with alterations only in GyrA ranged from 0.03 to 0.25 microgram/ml (MIC50, 0.06 microgram/ml; MIC90m, 0.125 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.03 to 0.25,104045,DB00537,Ciprofloxacin
,9209780,MIC50,"The MICs of AM-1155 for 20 moderately fluoroquinolone-resistant isolates with alterations only in GyrA ranged from 0.03 to 0.25 microgram/ml (MIC50, 0.06 microgram/ml; MIC90m, 0.125 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.06,104046,DB00537,Ciprofloxacin
,9209780,MIC90m,"The MICs of AM-1155 for 20 moderately fluoroquinolone-resistant isolates with alterations only in GyrA ranged from 0.03 to 0.25 microgram/ml (MIC50, 0.06 microgram/ml; MIC90m, 0.125 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.125,104047,DB00537,Ciprofloxacin
,9209780,MICs,"The MICs of AM-1155 for 24 of the quinolone-susceptible isolates without alterations in either GyrA or ParC ranged from 0.004 to 0.03 microgram/ml (MIC50, 0.008 microgram/ml. MIC90, 0.015 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.004 to 0.03,104048,DB00537,Ciprofloxacin
,9209780,MIC50,"The MICs of AM-1155 for 24 of the quinolone-susceptible isolates without alterations in either GyrA or ParC ranged from 0.004 to 0.03 microgram/ml (MIC50, 0.008 microgram/ml. MIC90, 0.015 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.008,104049,DB00537,Ciprofloxacin
,9209780,MIC90,"The MICs of AM-1155 for 24 of the quinolone-susceptible isolates without alterations in either GyrA or ParC ranged from 0.004 to 0.03 microgram/ml (MIC50, 0.008 microgram/ml. MIC90, 0.015 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.015,104050,DB00537,Ciprofloxacin
,9209780,MICs,MICs for the causative organisms have ranged from 1.0 to 16.0 micrograms/ml.,Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],1.0 to 16.0,104051,DB00537,Ciprofloxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],2.0,104052,DB00537,Ciprofloxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],8.0,104053,DB00537,Ciprofloxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],2.0,104054,DB00537,Ciprofloxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],8.0,104055,DB00537,Ciprofloxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.03 to 1.0,104056,DB00537,Ciprofloxacin
more,2076578,recoveries,The recoveries of CPFX added to brain were more than 97% with a coefficient of variation of less than 4%.,High-performance liquid chromatographic determination of ciprofloxacin in rat brain and cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076578/),%,97,104107,DB00537,Ciprofloxacin
,30649602,Cmax,Ciprofloxacin Cmax was significantly reduced 1 month after surgery (1840.9 ± 485.2 vs 1589.6 ± 321.8 ng/ml; p = 0.032) but not 6 months after.,Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[ng] / [ml],1840.9,104171,DB00537,Ciprofloxacin
,30649602,Cmax,Ciprofloxacin Cmax was significantly reduced 1 month after surgery (1840.9 ± 485.2 vs 1589.6 ± 321.8 ng/ml; p = 0.032) but not 6 months after.,Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[ng] / [ml],1589.6,104172,DB00537,Ciprofloxacin
,30649602,Cmax,Cmax on the sixth month was lower than Cmax in control group (2160.4 ± 408.6 vs 1589.6 ± 321.8 ng/ml; p < 0.001).,Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[ng] / [ml],2160.4,104173,DB00537,Ciprofloxacin
,30649602,Cmax,Cmax on the sixth month was lower than Cmax in control group (2160.4 ± 408.6 vs 1589.6 ± 321.8 ng/ml; p < 0.001).,Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[ng] / [ml],1589.6,104174,DB00537,Ciprofloxacin
,30649602,Cmax,"After correcting by the dose (mg)/patient's body weight, both Cmax and AUClast showed significant decrease 1 and 6 months after surgery: Cmax, 289.1 ± 65.3 and 263.5 ± 52.1 (ng/ml)/(dose (mg)/weight (kg)) respectively vs 429.3 ± 127.6 (ng/ml)/(dose (mg)/weight (kg)) at baseline; AUC, 1340.6 ± 243.0 and 1299.2 ± 415.4 (h × ng/ml)/(dose (mg)/weight (kg)) respectively vs 1896.7 ± 396.8 (h × ng/ml)/(dose (mg)/weight (kg)) at baseline.",Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),,289.1,104175,DB00537,Ciprofloxacin
,30649602,Cmax,"After correcting by the dose (mg)/patient's body weight, both Cmax and AUClast showed significant decrease 1 and 6 months after surgery: Cmax, 289.1 ± 65.3 and 263.5 ± 52.1 (ng/ml)/(dose (mg)/weight (kg)) respectively vs 429.3 ± 127.6 (ng/ml)/(dose (mg)/weight (kg)) at baseline; AUC, 1340.6 ± 243.0 and 1299.2 ± 415.4 (h × ng/ml)/(dose (mg)/weight (kg)) respectively vs 1896.7 ± 396.8 (h × ng/ml)/(dose (mg)/weight (kg)) at baseline.",Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),,263.5,104176,DB00537,Ciprofloxacin
,30649602,Cmax,"After correcting by the dose (mg)/patient's body weight, both Cmax and AUClast showed significant decrease 1 and 6 months after surgery: Cmax, 289.1 ± 65.3 and 263.5 ± 52.1 (ng/ml)/(dose (mg)/weight (kg)) respectively vs 429.3 ± 127.6 (ng/ml)/(dose (mg)/weight (kg)) at baseline; AUC, 1340.6 ± 243.0 and 1299.2 ± 415.4 (h × ng/ml)/(dose (mg)/weight (kg)) respectively vs 1896.7 ± 396.8 (h × ng/ml)/(dose (mg)/weight (kg)) at baseline.",Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[ng] / [ml)],429.3,104177,DB00537,Ciprofloxacin
,30649602,AUC,"After correcting by the dose (mg)/patient's body weight, both Cmax and AUClast showed significant decrease 1 and 6 months after surgery: Cmax, 289.1 ± 65.3 and 263.5 ± 52.1 (ng/ml)/(dose (mg)/weight (kg)) respectively vs 429.3 ± 127.6 (ng/ml)/(dose (mg)/weight (kg)) at baseline; AUC, 1340.6 ± 243.0 and 1299.2 ± 415.4 (h × ng/ml)/(dose (mg)/weight (kg)) respectively vs 1896.7 ± 396.8 (h × ng/ml)/(dose (mg)/weight (kg)) at baseline.",Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[h·ng] / [ml)],1340.6,104178,DB00537,Ciprofloxacin
,30649602,AUC,"After correcting by the dose (mg)/patient's body weight, both Cmax and AUClast showed significant decrease 1 and 6 months after surgery: Cmax, 289.1 ± 65.3 and 263.5 ± 52.1 (ng/ml)/(dose (mg)/weight (kg)) respectively vs 429.3 ± 127.6 (ng/ml)/(dose (mg)/weight (kg)) at baseline; AUC, 1340.6 ± 243.0 and 1299.2 ± 415.4 (h × ng/ml)/(dose (mg)/weight (kg)) respectively vs 1896.7 ± 396.8 (h × ng/ml)/(dose (mg)/weight (kg)) at baseline.",Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[h·ng] / [ml)],1299.2,104179,DB00537,Ciprofloxacin
,30649602,AUC,"After correcting by the dose (mg)/patient's body weight, both Cmax and AUClast showed significant decrease 1 and 6 months after surgery: Cmax, 289.1 ± 65.3 and 263.5 ± 52.1 (ng/ml)/(dose (mg)/weight (kg)) respectively vs 429.3 ± 127.6 (ng/ml)/(dose (mg)/weight (kg)) at baseline; AUC, 1340.6 ± 243.0 and 1299.2 ± 415.4 (h × ng/ml)/(dose (mg)/weight (kg)) respectively vs 1896.7 ± 396.8 (h × ng/ml)/(dose (mg)/weight (kg)) at baseline.",Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[h·ng] / [ml],1896.7,104180,DB00537,Ciprofloxacin
,30649602,Cmax,Cmax 1 month post-surgery showed lower values than the control group (375.4 ± 77.4 vs 263.5 ± 52.1 ng/ml; p < 0.001).,Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[ng] / [ml],375.4,104181,DB00537,Ciprofloxacin
,30649602,Cmax,Cmax 1 month post-surgery showed lower values than the control group (375.4 ± 77.4 vs 263.5 ± 52.1 ng/ml; p < 0.001).,Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30649602/),[ng] / [ml],263.5,104182,DB00537,Ciprofloxacin
,11357519,peak concentration,HPLC analysis of the plasma concentrations in juvenile rats showed that the concentrations of trovafloxacin were considerably lower than those of the other fluoroquinolones that had been studied previously in our laboratory: the peak concentration of trovafloxacin was 14 +/- 2.9 mg/l (mean +/- SD) after a single dose of 600 mg/kg in juvenile rats.,Effects of fluoroquinolones on the locomotor activity in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11357519/),[mg] / [l],14,104393,DB00537,Ciprofloxacin
,30104278,area under the concentration-time curve over 24 h in the steady state divided by the MIC [AUC/MIC],"The maximum daily doses of 6 g meropenem (T>MIC of 80% to 88%) and 1.2 g ciprofloxacin (area under the concentration-time curve over 24 h in the steady state divided by the MIC [AUC/MIC], 176), both given intermittently, in monotherapy failed to suppress regrowth and resulted in substantial emergence of resistance (≥7.6 log10 CFU/ml resistant populations).",Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30104278/),,176,105801,DB00537,Ciprofloxacin
,27824428,flow rate,"Chromatographic separation was achieved in positive ion modes, isocratically on a 3.5 μm C18 analytical column (75 mm×4.6 mm, i.d.) with 0.2% formic acid solution in water: methanol (10:90, v/v) as mobile phase, at a flow rate of 0.5 mL.min-1.",Development and Validation of an LC-MS/MS-ESI Method for Comparative Pharmacokinetic Study of Ciprofloxacin in Healthy Male Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27824428/),[ml] / [min],0.5,105984,DB00537,Ciprofloxacin
,7695254,MICs,"The serum bactericidal activity of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar (0.4 microgram/ml) was assessed with serum ultrafiltrates from five healthy volunteers receiving ciprofloxacin at 400 mg intravenously every 8 h.","Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),[μg] / [ml],0.4,106480,DB00537,Ciprofloxacin
,7695254,total clearances,"In addition, human serum was supplemented with ciprofloxacin to achieve a mean steady-state concentration (Css) that might be achieved in patients with renal failure, with total clearances of 3 to 4 liters/h (elimination rate constant, 0.08 h-1).","Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),[l] / [h],3 to 4,106481,DB00537,Ciprofloxacin
,7695254,elimination rate constant,"In addition, human serum was supplemented with ciprofloxacin to achieve a mean steady-state concentration (Css) that might be achieved in patients with renal failure, with total clearances of 3 to 4 liters/h (elimination rate constant, 0.08 h-1).","Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),1/[h],0.08,106482,DB00537,Ciprofloxacin
,7695254,break,"We previously demonstrated that a breakpoint AUC24/MIC of 125 for ciprofloxacin had a significantly higher probability of treatment success than lower values, with 250 to 500 being optimal.","Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),,125,106483,DB00537,Ciprofloxacin
,7695254,AUC24/MIC,"We previously demonstrated that a breakpoint AUC24/MIC of 125 for ciprofloxacin had a significantly higher probability of treatment success than lower values, with 250 to 500 being optimal.","Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),,125,106484,DB00537,Ciprofloxacin
,7695254,Css,"Volunteer sera (mean Css, 1.55 to 2.48 micrograms/ml) achieved AUC24/MICs of 90 to 145.","Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),[μg] / [ml],1.55 to 2.48,106485,DB00537,Ciprofloxacin
,7695254,AUC24/MICs,"Volunteer sera (mean Css, 1.55 to 2.48 micrograms/ml) achieved AUC24/MICs of 90 to 145.","Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),,90 to 145,106486,DB00537,Ciprofloxacin
,7695254,Css,"Supplemented serum (mean Css, 6.00 to 7.42 micrograms/ml) achieved AUC24/MICs of 350 to 450.","Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),[μg] / [ml],6.00 to 7.42,106487,DB00537,Ciprofloxacin
,7695254,AUC24/MICs,"Supplemented serum (mean Css, 6.00 to 7.42 micrograms/ml) achieved AUC24/MICs of 350 to 450.","Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),,350 to 450,106488,DB00537,Ciprofloxacin
<,7695254,AUC24/MICs,At low concentrations (3 to 6 times the MIC) AUC24/MICs were <125 for two of five volunteers and the killing rates were considerably more rapid for P. aeruginosa than for S. pneumoniae or S.aureus.,"Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695254/),,125,106489,DB00537,Ciprofloxacin
,23322394,response rate,The response rate was 56% (9 responders and 7 non-responders).,Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23322394/),%,56,106574,DB00537,Ciprofloxacin
,23322394,AUC(0-24)/MIC,"The range of AUC(0-24)/MIC values in responders [95.3-3628.4 (geometric mean, 521.6)] was significantly different from that in non-responders [7.0-45.2 (geometric mean, 16.5)] (p = 0.001).",Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23322394/),,95.3-3628.4,106575,DB00537,Ciprofloxacin
,23322394,AUC(0-24)/MIC,"The range of AUC(0-24)/MIC values in responders [95.3-3628.4 (geometric mean, 521.6)] was significantly different from that in non-responders [7.0-45.2 (geometric mean, 16.5)] (p = 0.001).",Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23322394/),,521.6,106576,DB00537,Ciprofloxacin
,23322394,AUC(0-24)/MIC,"The range of AUC(0-24)/MIC values in responders [95.3-3628.4 (geometric mean, 521.6)] was significantly different from that in non-responders [7.0-45.2 (geometric mean, 16.5)] (p = 0.001).",Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23322394/),,7.0-45.2,106577,DB00537,Ciprofloxacin
,23322394,AUC(0-24)/MIC,"The range of AUC(0-24)/MIC values in responders [95.3-3628.4 (geometric mean, 521.6)] was significantly different from that in non-responders [7.0-45.2 (geometric mean, 16.5)] (p = 0.001).",Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23322394/),,16.5,106578,DB00537,Ciprofloxacin
,23322394,AUC/MIC,The target AUC/MIC value of CPFX IV would be considered to be 45-95 in patients with peritonitis.,Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23322394/),,45-95,106579,DB00537,Ciprofloxacin
,9655838,MIC,The lower MIC of SPFX compared with CPFX (0.25 vs. 0.75 microgram/ml) and its higher AUC/dose ratio (resulting from a lower serum peak but a longer half-life) translated into a greater area under the bactericidal curve.,Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9655838/),[μg] / [ml],0.25,106647,DB00537,Ciprofloxacin
,9655838,MIC,The lower MIC of SPFX compared with CPFX (0.25 vs. 0.75 microgram/ml) and its higher AUC/dose ratio (resulting from a lower serum peak but a longer half-life) translated into a greater area under the bactericidal curve.,Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9655838/),[μg] / [ml],0.75,106648,DB00537,Ciprofloxacin
greater,9655838,AUC/MIC ratio,"When the AUC/MIC ratio was greater than 160, the probability of a clinical cure was 100%, independently of the dosage schedule.",Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9655838/),,160,106649,DB00537,Ciprofloxacin
,16875808,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma of HSR-903 were 3.03+/-0.54 and 97.5+/-24.2, respectively, notably higher than those of ciprofloxacin (CPFX).","Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16875808/),,3.03,106946,DB00537,Ciprofloxacin
,16875808,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma of HSR-903 were 3.03+/-0.54 and 97.5+/-24.2, respectively, notably higher than those of ciprofloxacin (CPFX).","Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16875808/),,97.5,106947,DB00537,Ciprofloxacin
,4015070,minimum quantifiable levels,The minimum quantifiable levels were 0.032 micrograms/ml in plasma and 2.7 micrograms/ml in urine.,Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015070/),[μg] / [ml],0.032,107549,DB00537,Ciprofloxacin
,4015070,minimum quantifiable levels,The minimum quantifiable levels were 0.032 micrograms/ml in plasma and 2.7 micrograms/ml in urine.,Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015070/),[μg] / [ml],2.7,107550,DB00537,Ciprofloxacin
,4015070,rates,The decline in drug plasma levels was described by a biexponential process with mean rates of 8.4 h-1 and 0.32 h-1 with corresponding half-lives of ca. 5 min and 2.2 h.,Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015070/),1/[h],8.4,107551,DB00537,Ciprofloxacin
,4015070,rates,The decline in drug plasma levels was described by a biexponential process with mean rates of 8.4 h-1 and 0.32 h-1 with corresponding half-lives of ca. 5 min and 2.2 h.,Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015070/),1/[h],0.32,107552,DB00537,Ciprofloxacin
,4015070,half-lives,The decline in drug plasma levels was described by a biexponential process with mean rates of 8.4 h-1 and 0.32 h-1 with corresponding half-lives of ca. 5 min and 2.2 h.,Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015070/),min,5,107553,DB00537,Ciprofloxacin
,4015070,half-lives,The decline in drug plasma levels was described by a biexponential process with mean rates of 8.4 h-1 and 0.32 h-1 with corresponding half-lives of ca. 5 min and 2.2 h.,Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015070/),h,2.2,107554,DB00537,Ciprofloxacin
,4015070,renal clearance,The mean renal clearance +/- standard deviation was 4.4 +/- 1.0 ml X kg-1 X min-1 and is compatible with passive glomerular filtration in this species.,Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015070/),[ml] / [kg·min],4.4,107555,DB00537,Ciprofloxacin
,16988539,50% inhibition,Another study stated that 50% inhibition of parasite growth in vitro required 6.6 microg/mL after a high dose of ciprofloxacin was used.,Effect of chloroquine on the bioavailability of ciprofloxacin in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988539/),[μg] / [ml],6.6,107990,DB00537,Ciprofloxacin
,16988539,peak serum concentration Cmax,"The peak serum concentration Cmax of ciprofloxacin was 3.42 +/- 0.32 microg/mL, which dropped to 2.8 +/- 0.18 microg/mL when chloroquine was taken together with ciprofloxacin.",Effect of chloroquine on the bioavailability of ciprofloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988539/),[μg] / [ml],3.42,107991,DB00537,Ciprofloxacin
,16988539,peak serum concentration Cmax,"The peak serum concentration Cmax of ciprofloxacin was 3.42 +/- 0.32 microg/mL, which dropped to 2.8 +/- 0.18 microg/mL when chloroquine was taken together with ciprofloxacin.",Effect of chloroquine on the bioavailability of ciprofloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988539/),[μg] / [ml],2.8,107992,DB00537,Ciprofloxacin
,7712674,time to maximal activity,"The mathematic analysis of the effects of ciprofloxacin showed that time to maximal activity was between 10.4 hours (PAF-dependent [Ca2+]i increase), and 15 hours (fMLP-induced superoxide anion and chemiluminescence production).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,10.4,108356,DB00537,Ciprofloxacin
,7712674,time to maximal activity,"The mathematic analysis of the effects of ciprofloxacin showed that time to maximal activity was between 10.4 hours (PAF-dependent [Ca2+]i increase), and 15 hours (fMLP-induced superoxide anion and chemiluminescence production).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,15,108357,DB00537,Ciprofloxacin
,7712674,time to maximal activity,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,4.66,108358,DB00537,Ciprofloxacin
,7712674,time to maximal activity,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,1.90,108359,DB00537,Ciprofloxacin
,7712674,half-life,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,1.90,108360,DB00537,Ciprofloxacin
,7712674,half-life,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,13.03,108361,DB00537,Ciprofloxacin
,7712674,half-life,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,7.28,108362,DB00537,Ciprofloxacin
,32566910,cortical bone/plasma concentration ratio,The average observed cortical bone/plasma concentration ratio was 0.67 at 0.5 to 2 h (n = 7) and 5.1 at 13 to 20 h (n = 9).,Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32566910/),,0.67,108907,DB00537,Ciprofloxacin
,32566910,cortical bone/plasma concentration ratio,The average observed cortical bone/plasma concentration ratio was 0.67 at 0.5 to 2 h (n = 7) and 5.1 at 13 to 20 h (n = 9).,Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32566910/),,5.1,108908,DB00537,Ciprofloxacin
,32566910,clearance,The population mean ciprofloxacin clearance was 20.7 L/h.,Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32566910/),[l] / [h],20.7,108909,DB00537,Ciprofloxacin
,32566910,partition coefficients,The estimated partition coefficients of the organic bone matrix were 3.39 for cortical and 5.11 for cancellous bone.,Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32566910/),,3.39,108910,DB00537,Ciprofloxacin
,32566910,partition coefficients,The estimated partition coefficients of the organic bone matrix were 3.39 for cortical and 5.11 for cancellous bone.,Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32566910/),,5.11,108911,DB00537,Ciprofloxacin
,8909207,concentrations,Mean vitreous concentrations +/- SD in traumatized pig eyes were 0.091 +/- 0.017 microgram/ml in swine that had received 200-mg doses of ciprofloxacin vs 0.312 +/- 0.153 microgram/ml in swine that had received 400-mg doses (P = .02).,The effect of trauma on the ocular penetration of intravenous ciprofloxacin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8909207/),[μg] / [ml],0.091,109796,DB00537,Ciprofloxacin
,8909207,concentrations,Mean vitreous concentrations +/- SD in traumatized pig eyes were 0.091 +/- 0.017 microgram/ml in swine that had received 200-mg doses of ciprofloxacin vs 0.312 +/- 0.153 microgram/ml in swine that had received 400-mg doses (P = .02).,The effect of trauma on the ocular penetration of intravenous ciprofloxacin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8909207/),[μg] / [ml],0.312,109797,DB00537,Ciprofloxacin
,26512539,peak plasma orbifloxacin concentration,"Following oral administration, the mean ± SD peak plasma orbifloxacin concentration was 1.66 ± 0.51 μg/mL for rabbits administered the 10 mg/kg dose and 3.00 ± 0.97 μg/mL for rabbits administered the 20 mg/kg dose and was attained at 2 hours after drug administration.",Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512539/),[μg] / [ml],1.66,109809,DB00537,Ciprofloxacin
,26512539,peak plasma orbifloxacin concentration,"Following oral administration, the mean ± SD peak plasma orbifloxacin concentration was 1.66 ± 0.51 μg/mL for rabbits administered the 10 mg/kg dose and 3.00 ± 0.97 μg/mL for rabbits administered the 20 mg/kg dose and was attained at 2 hours after drug administration.",Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512539/),[μg] / [ml],3.00,109810,DB00537,Ciprofloxacin
,26512539,half-life,The mean ± SD half-life of orbifloxacin in plasma was 7.3 ± 1.1 hours for rabbits administered the 10 mg/kg dose and 8.6 ± 0.55 hours for rabbits administered the 20 mg/kg dose.,Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512539/),h,7.3,109811,DB00537,Ciprofloxacin
,26512539,half-life,The mean ± SD half-life of orbifloxacin in plasma was 7.3 ± 1.1 hours for rabbits administered the 10 mg/kg dose and 8.6 ± 0.55 hours for rabbits administered the 20 mg/kg dose.,Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512539/),h,8.6,109812,DB00537,Ciprofloxacin
,26512539,bioavailability,Mean bioavailability was 52.5% for rabbits administered the 10 mg/kg dose and 46.5% for rabbits administered the 20 mg/kg dose.,Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512539/),%,52.5,109813,DB00537,Ciprofloxacin
,26512539,bioavailability,Mean bioavailability was 52.5% for rabbits administered the 10 mg/kg dose and 46.5% for rabbits administered the 20 mg/kg dose.,Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512539/),%,46.5,109814,DB00537,Ciprofloxacin
,2610494,areas under the concentration-time curve (AUCs),"The areas under the concentration-time curve (AUCs) of ciprofloxacin for regimens A and D were not significantly different (14.5 +/- 2.3 versus 15.7 +/- 2.8 micrograms.h/ml, mean +/- standard deviation).",Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610494/),[h·μg] / [ml],14.5,110179,DB00537,Ciprofloxacin
,2610494,areas under the concentration-time curve (AUCs),"The areas under the concentration-time curve (AUCs) of ciprofloxacin for regimens A and D were not significantly different (14.5 +/- 2.3 versus 15.7 +/- 2.8 micrograms.h/ml, mean +/- standard deviation).",Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610494/),[h·μg] / [ml],15.7,110180,DB00537,Ciprofloxacin
,2610494,AUCs,The AUCs for regimen B (5.4 +/- 1.7 micrograms.h/ml) and regimen C (11.3 +/- 2.4 micrograms.h/ml) were significantly different from the AUCs for regimens A and D.,Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610494/),[h·μg] / [ml],5.4,110181,DB00537,Ciprofloxacin
,2610494,AUCs,The AUCs for regimen B (5.4 +/- 1.7 micrograms.h/ml) and regimen C (11.3 +/- 2.4 micrograms.h/ml) were significantly different from the AUCs for regimens A and D.,Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610494/),[h·μg] / [ml],11.3,110182,DB00537,Ciprofloxacin
,18177323,Steady-state volume of distribution (V(ss)),"Steady-state volume of distribution (V(ss)) and total body clearance (Cl) of orbifloxacin after i.v. administration were estimated to be 1.71+/-0.38 L/kg and 0.91+/-0.20 L/h x kg, respectively.","Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177323/),[l] / [kg],1.71,110220,DB00537,Ciprofloxacin
,18177323,total body clearance (Cl),"Steady-state volume of distribution (V(ss)) and total body clearance (Cl) of orbifloxacin after i.v. administration were estimated to be 1.71+/-0.38 L/kg and 0.91+/-0.20 L/h x kg, respectively.","Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177323/),[l] / [h·kg],0.91,110221,DB00537,Ciprofloxacin
,18177323,maximum plasma concentrations,"Following s.c. and i.m. administration orbifloxacin achieved maximum plasma concentrations of 2.95+/-0.82 and 3.24+/-1.33 mg/L at 0.67+/-0.20 and 0.65+/-0.12 h, respectively.","Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177323/),[mg] / [l],2.95,110222,DB00537,Ciprofloxacin
,18177323,maximum plasma concentrations,"Following s.c. and i.m. administration orbifloxacin achieved maximum plasma concentrations of 2.95+/-0.82 and 3.24+/-1.33 mg/L at 0.67+/-0.20 and 0.65+/-0.12 h, respectively.","Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177323/),[mg] / [l],3.24,110223,DB00537,Ciprofloxacin
,18177323,absolute bio-availabilities,"The absolute bio-availabilities after s.c. and i.m. routes were 110.67+/-11.02% and 109.87+/-8.36%, respectively.","Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177323/),%,110.67,110224,DB00537,Ciprofloxacin
,18177323,absolute bio-availabilities,"The absolute bio-availabilities after s.c. and i.m. routes were 110.67+/-11.02% and 109.87+/-8.36%, respectively.","Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177323/),%,109.87,110225,DB00537,Ciprofloxacin
,2707923,serum peak concentrations,The mean serum peak concentrations were obtained in 1 to 1.5 h by the oral route and the values reached were similar after the oral and intravenous dose (2.56 +/- 0.62 micrograms/ml and 2.6 +/- 0.67 micrograms/ml respectively).,Steady-state serum pharmacokinetics and bioequivalence of 500 mg oral versus 200 mg intravenous ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2707923/),[μg] / [ml],2.56,110857,DB00537,Ciprofloxacin
,2707923,serum peak concentrations,The mean serum peak concentrations were obtained in 1 to 1.5 h by the oral route and the values reached were similar after the oral and intravenous dose (2.56 +/- 0.62 micrograms/ml and 2.6 +/- 0.67 micrograms/ml respectively).,Steady-state serum pharmacokinetics and bioequivalence of 500 mg oral versus 200 mg intravenous ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2707923/),[μg] / [ml],2.6,110858,DB00537,Ciprofloxacin
,2707923,terminal elimination half-life,The terminal elimination half-life was about 4.5 h for oral form and 5 h for intravenous form.,Steady-state serum pharmacokinetics and bioequivalence of 500 mg oral versus 200 mg intravenous ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2707923/),h,4.5,110859,DB00537,Ciprofloxacin
,2707923,terminal elimination half-life,The terminal elimination half-life was about 4.5 h for oral form and 5 h for intravenous form.,Steady-state serum pharmacokinetics and bioequivalence of 500 mg oral versus 200 mg intravenous ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2707923/),h,5,110860,DB00537,Ciprofloxacin
,2707923,absolute bioavailability,The absolute bioavailability of the oral ciprofloxacin was about 83%.,Steady-state serum pharmacokinetics and bioequivalence of 500 mg oral versus 200 mg intravenous ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2707923/),%,83,110861,DB00537,Ciprofloxacin
,11600365,MICs,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.007 to 0.5,110962,DB00537,Ciprofloxacin
,11600365,MICs,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.03 to 2,110963,DB00537,Ciprofloxacin
,11600365,MICs,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.007 to 0.12,110964,DB00537,Ciprofloxacin
,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.007 to 0.5,110965,DB00537,Ciprofloxacin
,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.03 to 2,110966,DB00537,Ciprofloxacin
<,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.003 to 0.06,110967,DB00537,Ciprofloxacin
,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.007 to 0.12,110968,DB00537,Ciprofloxacin
<,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.5,110969,DB00537,Ciprofloxacin
<,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],2,110970,DB00537,Ciprofloxacin
,11600365,MIC(90),For Pseudomonas aeruginosa both compounds had a MIC(90) of 0.5 microg/ml.,"Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.5,110971,DB00537,Ciprofloxacin
,11600365,MIC(90)s,"E-4767 and E-5065 were 356- and 32-fold more potent than ciprofloxacin against Bacteroides spp., and their MIC(90)s for Clostridium spp. were 0.25 and 0.5 microg/ml, respectively.","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.25,110972,DB00537,Ciprofloxacin
,11600365,MIC(90)s,"E-4767 and E-5065 were 356- and 32-fold more potent than ciprofloxacin against Bacteroides spp., and their MIC(90)s for Clostridium spp. were 0.25 and 0.5 microg/ml, respectively.","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.5,110973,DB00537,Ciprofloxacin
<or=,11600365,50% effective dose (ED(50)),"E-4767 was the most effective compound, with a 50% effective dose (ED(50)) of <or=17 mg/kg for all strains tested except ciprofloxacin-resistant S. aureus strains.","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[mg] / [kg],17,110974,DB00537,Ciprofloxacin
<,11600365,ED(50),The ED(50) of E-4767 for these strains was <or=47.5 mg/kg.,"Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[mg] / [kg],47.5,110975,DB00537,Ciprofloxacin
,3578325,peak serum concentrations,Intravenous infusions of 200 mg over one-half hour result in peak serum concentrations of 3.80 +/- 0.62 micrograms/ml.,An overview of the pharmacology of intravenously administered ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578325/),[μg] / [ml],3.80,111229,DB00537,Ciprofloxacin
,3578325,Serum clearance,"Serum clearance in normal subjects averages 23.7 +/- 5.1 liters/hour/1.73 m2, with renal clearance accounting for 66.6 +/- 11.0 percent of the total serum clearance.",An overview of the pharmacology of intravenously administered ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578325/),[l] / [1.73·h·m2],23.7,111230,DB00537,Ciprofloxacin
,2942623,detection limit,"The detection limit of ciprofloxacin was 0.010 mg/l serum and 0.2 mg/l urine and for the metabolite M3, 1 mg/l urine.",Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942623/),[mg] / [l],0.010,111772,DB00537,Ciprofloxacin
,2942623,detection limit,"The detection limit of ciprofloxacin was 0.010 mg/l serum and 0.2 mg/l urine and for the metabolite M3, 1 mg/l urine.",Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942623/),[mg] / [l],1,111773,DB00537,Ciprofloxacin
,2942623,Recovery rates,"Recovery rates of ciprofloxacin from three groups of spiked sera was 94.5 +/- 2.6%, 97.2 +/- 1.1% and 95.0 +/- 1.8% and from urine 99.6%.",Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942623/),%,94.5,111774,DB00537,Ciprofloxacin
,2942623,Recovery rates,"Recovery rates of ciprofloxacin from three groups of spiked sera was 94.5 +/- 2.6%, 97.2 +/- 1.1% and 95.0 +/- 1.8% and from urine 99.6%.",Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942623/),%,97.2,111775,DB00537,Ciprofloxacin
,2942623,Recovery rates,"Recovery rates of ciprofloxacin from three groups of spiked sera was 94.5 +/- 2.6%, 97.2 +/- 1.1% and 95.0 +/- 1.8% and from urine 99.6%.",Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942623/),%,95.0,111776,DB00537,Ciprofloxacin
,2942623,Recovery rates,"Recovery rates of ciprofloxacin from three groups of spiked sera was 94.5 +/- 2.6%, 97.2 +/- 1.1% and 95.0 +/- 1.8% and from urine 99.6%.",Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942623/),%,99.6,111777,DB00537,Ciprofloxacin
,11806288,AUC0-12,Corresponding AUC0-12 ranged from 8.2 to 11.9 mg.h/L.,Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11806288/),[h·mg] / [l],8.2 to 11.9,112241,DB00537,Ciprofloxacin
,11806288,area under the inhibitory curve,"The median area under the inhibitory curve was 52.8, which is about half the proposed target value for ciprofloxacin in pulmonary infections with Gram-negative bacteria such as Pseudomonas aeruginosa.",Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11806288/),,52.8,112242,DB00537,Ciprofloxacin
,8408401,retention times,The retention times were 3.0 min for ciprofloxacin and 5.2 min for difloxacin.,Determination of ciprofloxacin levels in chinchilla middle ear effusion and plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408401/),min,3.0,112442,DB00537,Ciprofloxacin
,8408401,retention times,The retention times were 3.0 min for ciprofloxacin and 5.2 min for difloxacin.,Determination of ciprofloxacin levels in chinchilla middle ear effusion and plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408401/),min,5.2,112443,DB00537,Ciprofloxacin
,8408401,detection limit,The detection limit is 5 ng/ml with a signal-to-noise ratio of 5:1.,Determination of ciprofloxacin levels in chinchilla middle ear effusion and plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408401/),[ng] / [ml],5,112444,DB00537,Ciprofloxacin
,8408401,signal-to-noise ratio,The detection limit is 5 ng/ml with a signal-to-noise ratio of 5:1.,Determination of ciprofloxacin levels in chinchilla middle ear effusion and plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408401/),,5:1,112445,DB00537,Ciprofloxacin
,8408401,Recoveries,"Recoveries (mean +/- S.D., n = 5) at 100 ng/ml in plasma and middle ear fluid were 89.4 +/- 1.2% and 91.4 +/- 1.6%, respectively.",Determination of ciprofloxacin levels in chinchilla middle ear effusion and plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408401/),%,89.4,112446,DB00537,Ciprofloxacin
,8408401,Recoveries,"Recoveries (mean +/- S.D., n = 5) at 100 ng/ml in plasma and middle ear fluid were 89.4 +/- 1.2% and 91.4 +/- 1.6%, respectively.",Determination of ciprofloxacin levels in chinchilla middle ear effusion and plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408401/),%,91.4,112447,DB00537,Ciprofloxacin
,3619418,Serum clearances,"Serum clearances (mean +/- standard deviation) were 26.8 +/- 5.7 and 15.4 +/- 4.3 liters/h per 1.73 m2 in normal and anephric volunteers, respectively.",Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619418/),[l] / [1.73·h·m2],26.8,112778,DB00537,Ciprofloxacin
,3619418,Serum clearances,"Serum clearances (mean +/- standard deviation) were 26.8 +/- 5.7 and 15.4 +/- 4.3 liters/h per 1.73 m2 in normal and anephric volunteers, respectively.",Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619418/),[l] / [1.73·h·m2],15.4,112779,DB00537,Ciprofloxacin
,3619418,half-life,The half-life (mean +/- standard deviation) increased from 4.3 +/- 0.8 h in normal volunteers to 8.6 +/- 3.3 h in anephric volunteers.,Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619418/),h,4.3,112780,DB00537,Ciprofloxacin
,3619418,half-life,The half-life (mean +/- standard deviation) increased from 4.3 +/- 0.8 h in normal volunteers to 8.6 +/- 3.3 h in anephric volunteers.,Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619418/),h,8.6,112781,DB00537,Ciprofloxacin
,17312793,Plasma volume of distribution,"Plasma volume of distribution for i.v. enrofloxacin was 2.15 - 1.01 L/kg, with a mean elimination half-life of 13.3 hr and total body clearance of 0.19+/-0.14 L/kg/hr.",Single-dose intravenous and oral pharmacokinetics of enrofloxacin in goral (Nemorrhaedus goral arnouxianus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312793/),[l] / [kg],2.15 - 1.01,113088,DB00537,Ciprofloxacin
,17312793,elimination half-life,"Plasma volume of distribution for i.v. enrofloxacin was 2.15 - 1.01 L/kg, with a mean elimination half-life of 13.3 hr and total body clearance of 0.19+/-0.14 L/kg/hr.",Single-dose intravenous and oral pharmacokinetics of enrofloxacin in goral (Nemorrhaedus goral arnouxianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312793/),h,13.3,113089,DB00537,Ciprofloxacin
,17312793,total body clearance,"Plasma volume of distribution for i.v. enrofloxacin was 2.15 - 1.01 L/kg, with a mean elimination half-life of 13.3 hr and total body clearance of 0.19+/-0.14 L/kg/hr.",Single-dose intravenous and oral pharmacokinetics of enrofloxacin in goral (Nemorrhaedus goral arnouxianus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312793/),[l] / [h·kg],0.19,113090,DB00537,Ciprofloxacin
,17312793,maximum plasma concentration,"The maximum plasma concentration measured for oral enrofloxacin was 2.77 microg/ml, with a mean half-life of 5.2 hr and systemic availability of 14.6%.",Single-dose intravenous and oral pharmacokinetics of enrofloxacin in goral (Nemorrhaedus goral arnouxianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312793/),[μg] / [ml],2.77,113091,DB00537,Ciprofloxacin
,17312793,half-life,"The maximum plasma concentration measured for oral enrofloxacin was 2.77 microg/ml, with a mean half-life of 5.2 hr and systemic availability of 14.6%.",Single-dose intravenous and oral pharmacokinetics of enrofloxacin in goral (Nemorrhaedus goral arnouxianus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312793/),h,5.2,113092,DB00537,Ciprofloxacin
,17312793,systemic availability,"The maximum plasma concentration measured for oral enrofloxacin was 2.77 microg/ml, with a mean half-life of 5.2 hr and systemic availability of 14.6%.",Single-dose intravenous and oral pharmacokinetics of enrofloxacin in goral (Nemorrhaedus goral arnouxianus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312793/),%,14.6,113093,DB00537,Ciprofloxacin
,17312793,area under the plasma concentration over time curve (AUC),The area under the plasma concentration over time curve (AUC) for oral enrofloxacin was 21.06 microg/hr/ml.,Single-dose intravenous and oral pharmacokinetics of enrofloxacin in goral (Nemorrhaedus goral arnouxianus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312793/),[μg] / [h·ml],21.06,113094,DB00537,Ciprofloxacin
>,17312793,area under the plasma concentration over time curve to minimum inhibitory concentration ratio,The area under the plasma concentration over time curve generated for oral enrofloxacin in goral yields an area under the plasma concentration over time curve to minimum inhibitory concentration ratio > 100 for many gram-positive and gram-negative bacterial pathogens common to small ruminants.,Single-dose intravenous and oral pharmacokinetics of enrofloxacin in goral (Nemorrhaedus goral arnouxianus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312793/),,100,113095,DB00537,Ciprofloxacin
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB00537,Ciprofloxacin
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB00537,Ciprofloxacin
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB00537,Ciprofloxacin
,14603491,total plasma clearance,"By contrast, norfloxacin systemic pharmacokinetics was nonlinear, with total plasma clearance decreasing significantly from 23.0 +/- 3.4 to 14.4 +/- 3.8 mL/min/kg when dose increased from 12.5 to 150 mg/kg.",Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603491/),[ml] / [kg·min],23.0,113561,DB00537,Ciprofloxacin
,14603491,total plasma clearance,"By contrast, norfloxacin systemic pharmacokinetics was nonlinear, with total plasma clearance decreasing significantly from 23.0 +/- 3.4 to 14.4 +/- 3.8 mL/min/kg when dose increased from 12.5 to 150 mg/kg.",Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603491/),[ml] / [kg·min],14.4,113562,DB00537,Ciprofloxacin
,10553702,elimination half-lives,"The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-lives (50 to 98%) and volumes of distribution >1.5 L/kg.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),%,50 to 98,113595,DB00537,Ciprofloxacin
>,10553702,volumes of distribution,"The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-lives (50 to 98%) and volumes of distribution >1.5 L/kg.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),[l] / [kg],1.5,113596,DB00537,Ciprofloxacin
,10553702,24-hour,"Animal models and human studies with ciprofloxacin, grepafloxacin and levofloxacin show that a 24-hour AUC/MIC ratio of about 100, or a Cmax/MIC ratio of about 10 gives maximum clinical and bacteriological efficacy.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),,100,113597,DB00537,Ciprofloxacin
,10553702,AUC/MIC ratio,"Animal models and human studies with ciprofloxacin, grepafloxacin and levofloxacin show that a 24-hour AUC/MIC ratio of about 100, or a Cmax/MIC ratio of about 10 gives maximum clinical and bacteriological efficacy.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),,100,113598,DB00537,Ciprofloxacin
,10553702,Cmax/MIC ratio,"Animal models and human studies with ciprofloxacin, grepafloxacin and levofloxacin show that a 24-hour AUC/MIC ratio of about 100, or a Cmax/MIC ratio of about 10 gives maximum clinical and bacteriological efficacy.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),,10,113599,DB00537,Ciprofloxacin
,3162327,time to maximal serum level,"Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,1.2,113963,DB00537,Ciprofloxacin
,3162327,time to maximal serum level,"Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,1.9,113964,DB00537,Ciprofloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,3.75,113965,DB00537,Ciprofloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,3.9,113966,DB00537,Ciprofloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,4.0,113967,DB00537,Ciprofloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,7.0,113968,DB00537,Ciprofloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,6.2,113969,DB00537,Ciprofloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,5.1,113970,DB00537,Ciprofloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,10.5,113971,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,62,113972,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,46.4,113973,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,12.2,113974,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,27,113975,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,30.6,113976,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,75.7,113977,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,73,113978,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,4.9,113979,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,9.2,113980,DB00537,Ciprofloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,17.8,113981,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,62,113982,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,46.4,113983,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,12.2,113984,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,27,113985,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,30.6,113986,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,75.7,113987,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,73,113988,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,4.9,113989,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,9.2,113990,DB00537,Ciprofloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,17.8,113991,DB00537,Ciprofloxacin
,29067728,elimination half-life (T½),"Following injection, the elimination half-life (T½), peak concentration, area under the curve (AUC), and volume of distribution (VD) for enrofloxacin were 27.9 (29.13) hr, 8.98 (18.09) μg/ml, 367.38 (35.41) hr μg/ml, and 0.575 (20.48) L/kg, respectively (mean value, CV%).",Pharmacokinetics of enrofloxacin and ciprofloxacin in Atlantic horseshoe crabs (Limulus polyphemus) after single injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067728/),h,27.9,114334,DB00537,Ciprofloxacin
,29067728,peak concentration,"Following injection, the elimination half-life (T½), peak concentration, area under the curve (AUC), and volume of distribution (VD) for enrofloxacin were 27.9 (29.13) hr, 8.98 (18.09) μg/ml, 367.38 (35.41) hr μg/ml, and 0.575 (20.48) L/kg, respectively (mean value, CV%).",Pharmacokinetics of enrofloxacin and ciprofloxacin in Atlantic horseshoe crabs (Limulus polyphemus) after single injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067728/),[μg] / [ml],8.98,114335,DB00537,Ciprofloxacin
,29067728,area under the curve (AUC),"Following injection, the elimination half-life (T½), peak concentration, area under the curve (AUC), and volume of distribution (VD) for enrofloxacin were 27.9 (29.13) hr, 8.98 (18.09) μg/ml, 367.38 (35.41) hr μg/ml, and 0.575 (20.48) L/kg, respectively (mean value, CV%).",Pharmacokinetics of enrofloxacin and ciprofloxacin in Atlantic horseshoe crabs (Limulus polyphemus) after single injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067728/),[μg] / [ml],8.98,114336,DB00537,Ciprofloxacin
,29067728,volume of distribution (VD),"Following injection, the elimination half-life (T½), peak concentration, area under the curve (AUC), and volume of distribution (VD) for enrofloxacin were 27.9 (29.13) hr, 8.98 (18.09) μg/ml, 367.38 (35.41) hr μg/ml, and 0.575 (20.48) L/kg, respectively (mean value, CV%).",Pharmacokinetics of enrofloxacin and ciprofloxacin in Atlantic horseshoe crabs (Limulus polyphemus) after single injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067728/),[l] / [kg],0.575,114337,DB00537,Ciprofloxacin
,29067728,elimination T½,"For ciprofloxacin, the elimination T½, peak concentration, and AUC were 61.36 (34.55) hr, 2.34 (24.11) μg/ml, and 304.46 (24.69) μg hr/ml.",Pharmacokinetics of enrofloxacin and ciprofloxacin in Atlantic horseshoe crabs (Limulus polyphemus) after single injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067728/),h,61.36,114338,DB00537,Ciprofloxacin
,29067728,peak concentration,"For ciprofloxacin, the elimination T½, peak concentration, and AUC were 61.36 (34.55) hr, 2.34 (24.11) μg/ml, and 304.46 (24.69) μg hr/ml.",Pharmacokinetics of enrofloxacin and ciprofloxacin in Atlantic horseshoe crabs (Limulus polyphemus) after single injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067728/),[μg] / [ml],2.34,114339,DB00537,Ciprofloxacin
,29067728,AUC,"For ciprofloxacin, the elimination T½, peak concentration, and AUC were 61.36 (34.55) hr, 2.34 (24.11) μg/ml, and 304.46 (24.69) μg hr/ml.",Pharmacokinetics of enrofloxacin and ciprofloxacin in Atlantic horseshoe crabs (Limulus polyphemus) after single injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067728/),[h·μg] / [ml],304.46,114340,DB00537,Ciprofloxacin
,29067728,total AUC produced,The total AUC produced (sum of enrofloxacin and ciprofloxacin) was 682.69 ± 180.61 μg hr/ml.,Pharmacokinetics of enrofloxacin and ciprofloxacin in Atlantic horseshoe crabs (Limulus polyphemus) after single injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067728/),[h·μg] / [ml],682.69,114341,DB00537,Ciprofloxacin
,19646085,Steady-state volume of distribution,"Steady-state volume of distribution and clearance of orbifloxacin after i.v. administration were 0.92 L/kg and 0.24 L/h x kg, respectively.",Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646085/),[l] / [kg],0.92,114431,DB00537,Ciprofloxacin
,19646085,clearance,"Steady-state volume of distribution and clearance of orbifloxacin after i.v. administration were 0.92 L/kg and 0.24 L/h x kg, respectively.",Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646085/),[l] / [h·kg],0.24,114432,DB00537,Ciprofloxacin
,19646085,absolute bioavailability,"Following i.m. administration, a slow and complete absorption with absolute bioavailability of 101.4%, and a maximum concentration (C(max)) of 1.17 microg/mL at 1.04 h were observed.",Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646085/),%,101.4,114433,DB00537,Ciprofloxacin
,19646085,maximum concentration (C(max)),"Following i.m. administration, a slow and complete absorption with absolute bioavailability of 101.4%, and a maximum concentration (C(max)) of 1.17 microg/mL at 1.04 h were observed.",Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646085/),[μg] / [ml],1.17,114434,DB00537,Ciprofloxacin
,19646085,serum protein binding,The in vitro serum protein binding was 14.76%.,Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646085/),%,14.76,114435,DB00537,Ciprofloxacin
,7726507,MICs,"The MICs of E-4695 at which 90% of the isolates were inhibited (MIC90s) were 0.06 to 0.5 microgram/ml for gram-positive cocci, including species of the genera Staphylococcus, Streptococcus, and Enterococcus, and the MIC90s against gram-negative pathogens such as members of the family Enterobacteriaceae (with the exception of Providencia spp. [MIC90, 8 micrograms/ml]) and Pseudomonas aeruginosa were 0.015 to 0.5 microgram/ml.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[μg] / [ml],0.06 to 0.5,114945,DB00537,Ciprofloxacin
,7726507,MIC90,"The MICs of E-4695 at which 90% of the isolates were inhibited (MIC90s) were 0.06 to 0.5 microgram/ml for gram-positive cocci, including species of the genera Staphylococcus, Streptococcus, and Enterococcus, and the MIC90s against gram-negative pathogens such as members of the family Enterobacteriaceae (with the exception of Providencia spp. [MIC90, 8 micrograms/ml]) and Pseudomonas aeruginosa were 0.015 to 0.5 microgram/ml.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[μg] / [ml],8,114946,DB00537,Ciprofloxacin
,7726507,MIC90,"The MICs of E-4695 at which 90% of the isolates were inhibited (MIC90s) were 0.06 to 0.5 microgram/ml for gram-positive cocci, including species of the genera Staphylococcus, Streptococcus, and Enterococcus, and the MIC90s against gram-negative pathogens such as members of the family Enterobacteriaceae (with the exception of Providencia spp. [MIC90, 8 micrograms/ml]) and Pseudomonas aeruginosa were 0.015 to 0.5 microgram/ml.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[μg] / [ml],0.015 to 0.5,114947,DB00537,Ciprofloxacin
,7726507,maximum level,"After an oral dose of 50 mg/kg of body weight, the maximum level in serum, the biological half-life, and the area under the concentration-time curve from 0 to 10 h for E-4695 were 13.2 microgram/ml, 3.3 h, and 45.6 microgram .","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[μg] / [ml],13.2,114948,DB00537,Ciprofloxacin
,7726507,biological half-life,"After an oral dose of 50 mg/kg of body weight, the maximum level in serum, the biological half-life, and the area under the concentration-time curve from 0 to 10 h for E-4695 were 13.2 microgram/ml, 3.3 h, and 45.6 microgram .","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),h,3.3,114949,DB00537,Ciprofloxacin
,7726507,area under the concentration-time curve from 0 to 10 h,"After an oral dose of 50 mg/kg of body weight, the maximum level in serum, the biological half-life, and the area under the concentration-time curve from 0 to 10 h for E-4695 were 13.2 microgram/ml, 3.3 h, and 45.6 microgram .","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),μg,45.6,114950,DB00537,Ciprofloxacin
,7726507,area under the concentration-time curve from 0 to 4 h,The area under the concentration-time curve from 0 to 4 h for ciprofloxacin was 2.3 microgram .,"E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),μg,2.3,114951,DB00537,Ciprofloxacin
,7726507,Fifty-percent effective doses (ED50S),Fifty-percent effective doses (ED50S) against Staphylococcus aureus HS-93 infections in mice were 4.5 mg/kg with E-4695 and 37.6 mg/kg with ciprofloxacin.,"E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],4.5,114952,DB00537,Ciprofloxacin
,7726507,Fifty-percent effective doses (ED50S),Fifty-percent effective doses (ED50S) against Staphylococcus aureus HS-93 infections in mice were 4.5 mg/kg with E-4695 and 37.6 mg/kg with ciprofloxacin.,"E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],37.6,114953,DB00537,Ciprofloxacin
,7726507,ED50,"Infection with Streptococcus pneumoniae 29206 was more effectively treated with E-4695 (ED50, 41,2 mg/kg) than with ciprofloxacin (ED50, 200 mg/kg).","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],"41,2",114954,DB00537,Ciprofloxacin
,7726507,ED50,"Infection with Streptococcus pneumoniae 29206 was more effectively treated with E-4695 (ED50, 41,2 mg/kg) than with ciprofloxacin (ED50, 200 mg/kg).","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],200,114955,DB00537,Ciprofloxacin
,7726507,ED50,The ED50 of E-4695 for infections with Streptococcus pneumoniae 1625 was 132.2 mg/kg; ciprofloxacin was ineffective at 400 mg/kg against this strain.,"E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],132.2,114956,DB00537,Ciprofloxacin
,7726507,ED50S,"E-4695 was also more potent than ciprofloxacin in treatment of infections caused by gram-negative organisms such as Escherichia coli HM-42 (ED50S, 1.0 and 3.9 mg/kg, respectively).","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],1.0,114957,DB00537,Ciprofloxacin
,7726507,ED50S,"E-4695 was also more potent than ciprofloxacin in treatment of infections caused by gram-negative organisms such as Escherichia coli HM-42 (ED50S, 1.0 and 3.9 mg/kg, respectively).","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],3.9,114958,DB00537,Ciprofloxacin
,7726507,ED50S,"The ED50S of E-4695 and ciprofloxacin were 33.0 and 145.5 mg/kg against P. aeruginosa HS-116 and 9.6 and 18.9 mg/kg against P. aeruginosa B-120, respectively.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],33.0,114959,DB00537,Ciprofloxacin
,7726507,ED50S,"The ED50S of E-4695 and ciprofloxacin were 33.0 and 145.5 mg/kg against P. aeruginosa HS-116 and 9.6 and 18.9 mg/kg against P. aeruginosa B-120, respectively.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],145.5,114960,DB00537,Ciprofloxacin
,7726507,ED50S,"The ED50S of E-4695 and ciprofloxacin were 33.0 and 145.5 mg/kg against P. aeruginosa HS-116 and 9.6 and 18.9 mg/kg against P. aeruginosa B-120, respectively.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],9.6,114961,DB00537,Ciprofloxacin
,7726507,ED50S,"The ED50S of E-4695 and ciprofloxacin were 33.0 and 145.5 mg/kg against P. aeruginosa HS-116 and 9.6 and 18.9 mg/kg against P. aeruginosa B-120, respectively.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],18.9,114962,DB00537,Ciprofloxacin
,15751581,steady-state volume of distribution (Vdss),Difloxacin was rapidly distributed to the tissues with a steady-state volume of distribution (Vdss) of 1.51 L/kg and the total body clearance (Cltot) was 0.59 L/kg/h.,Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751581/),[l] / [kg],1.51,115053,DB00537,Ciprofloxacin
,15751581,total body clearance (Cltot),Difloxacin was rapidly distributed to the tissues with a steady-state volume of distribution (Vdss) of 1.51 L/kg and the total body clearance (Cltot) was 0.59 L/kg/h.,Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751581/),[l] / [h·kg],0.59,115054,DB00537,Ciprofloxacin
,15751581,elimination half-lives,"The elimination half-lives after i.v. and i.m. administration were 3.25 h and 3.82 h, respectively.",Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751581/),h,3.25,115055,DB00537,Ciprofloxacin
,15751581,elimination half-lives,"The elimination half-lives after i.v. and i.m. administration were 3.25 h and 3.82 h, respectively.",Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751581/),h,3.82,115056,DB00537,Ciprofloxacin
,15751581,peak plasma concentration (Cmax,"After i.m. administration, difloxacin was rapidly absorbed, with mean peak plasma concentration (Cmax of 3.85 microg/ml achieved at 1.61 h (Tmax) post administration.",Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751581/),[μg] / [ml],3.85,115057,DB00537,Ciprofloxacin
,15751581,Tmax,"After i.m. administration, difloxacin was rapidly absorbed, with mean peak plasma concentration (Cmax of 3.85 microg/ml achieved at 1.61 h (Tmax) post administration.",Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751581/),h,1.61,115058,DB00537,Ciprofloxacin
,15751581,plasma protein binding,The extent of plasma protein binding of difloxacin in rabbits was 21.45% and the systemic bioavailability was 95.29%.,Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751581/),%,21.45,115059,DB00537,Ciprofloxacin
,15751581,systemic bioavailability,The extent of plasma protein binding of difloxacin in rabbits was 21.45% and the systemic bioavailability was 95.29%.,Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751581/),%,95.29,115060,DB00537,Ciprofloxacin
,32156232,plasma AUC/MIC,"In intrinsic PD studies, CIP showed a maximum effect at plasma AUC/MIC=1705 (300 mg/kg, twice daily) for bacterial load in bladder (r2=0.979), kidney (r2=0.951) and rectal temperature (r2=0.67).",Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32156232/),,1705,115542,DB00537,Ciprofloxacin
,32156232,plasma AUC/MIC ratio,A plasma AUC/MIC ratio of 412 was associated with maximum PD effect of Imax=3.7 Log10CFU/bladder and Imax=1.97 Log10CFU/kidney.,Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32156232/),,412,115543,DB00537,Ciprofloxacin
,32156232,Imax,A plasma AUC/MIC ratio of 412 was associated with maximum PD effect of Imax=3.7 Log10CFU/bladder and Imax=1.97 Log10CFU/kidney.,Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32156232/),,3.7,115544,DB00537,Ciprofloxacin
,32156232,Imax,A plasma AUC/MIC ratio of 412 was associated with maximum PD effect of Imax=3.7 Log10CFU/bladder and Imax=1.97 Log10CFU/kidney.,Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32156232/),,1.97,115545,DB00537,Ciprofloxacin
,22024700,Km,"Ciprofloxacin increased the net renal clearance of levofloxacin by 13%, as its estimated affinity for a putative tubular reabsorption transporter was 12-fold higher (Km: 568 μM) compared to levofloxacin (Km: 6,830 μM).","Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024700/),μM,568,115669,DB00537,Ciprofloxacin
,22024700,Km,"Ciprofloxacin increased the net renal clearance of levofloxacin by 13%, as its estimated affinity for a putative tubular reabsorption transporter was 12-fold higher (Km: 568 μM) compared to levofloxacin (Km: 6,830 μM).","Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024700/),μM,"6,830",115670,DB00537,Ciprofloxacin
,10381104,area under the inhibitory curve over 24 h (AUIC24),"Levofloxacin was rapidly and significantly bactericidal against all eight strains evaluated, with eradication of six strains occurring despite area under the inhibitory curve over 24 h (AUIC24) values of only 32-64 SIT(-1) x h (serum inhibitory titre over time).",Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381104/),[h] / [sit],32-64,116896,DB00537,Ciprofloxacin
,10381104,serum inhibitory titre,"Levofloxacin was rapidly and significantly bactericidal against all eight strains evaluated, with eradication of six strains occurring despite area under the inhibitory curve over 24 h (AUIC24) values of only 32-64 SIT(-1) x h (serum inhibitory titre over time).",Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381104/),[h] / [sit],32-64,116897,DB00537,Ciprofloxacin
,10381104,AUIC24,Ciprofloxacin eradicated five strains despite having an AUIC24 of only 44 SIT(-1) x h.,Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381104/),[h] / [sit],44,116898,DB00537,Ciprofloxacin
below,10381104,minimum AUIC,"Furthermore, these data suggest that the minimum AUIC required for clinical efficacy against and eradication of S. pneumoniae with levofloxacin and ciprofloxacin may be well below the 125 SIT(-1) x h identified by other studies.",Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381104/),[h] / [sit],125,116899,DB00537,Ciprofloxacin
,2370242,elimination half-life,The CSF elimination half-life was 260-430 min compared with 145-170 in serum.,Penetration of ciprofloxacin into the cerebrospinal fluid of patients with uninflamed meninges. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2370242/),min,260-430,116956,DB00537,Ciprofloxacin
,2370242,elimination half-life,The CSF elimination half-life was 260-430 min compared with 145-170 in serum.,Penetration of ciprofloxacin into the cerebrospinal fluid of patients with uninflamed meninges. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2370242/),,145-170,116957,DB00537,Ciprofloxacin
,19003804,detection limits,"The obtained detection limits were 2.3x10(-7) mol/L, 5.2x10(-8) mol/L, and 7.8x10(-8) mol/L for ciprofloxacin, norfloxacin, and ofloxacin, respectively.",Determination of quinolone antibiotics in urine by capillary electrophoresis with chemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19003804/),[mol] / [l],2.3x10(-7),117376,DB00537,Ciprofloxacin
,19003804,detection limits,"The obtained detection limits were 2.3x10(-7) mol/L, 5.2x10(-8) mol/L, and 7.8x10(-8) mol/L for ciprofloxacin, norfloxacin, and ofloxacin, respectively.",Determination of quinolone antibiotics in urine by capillary electrophoresis with chemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19003804/),[mol] / [l],5.2x10(-8),117377,DB00537,Ciprofloxacin
,19003804,detection limits,"The obtained detection limits were 2.3x10(-7) mol/L, 5.2x10(-8) mol/L, and 7.8x10(-8) mol/L for ciprofloxacin, norfloxacin, and ofloxacin, respectively.",Determination of quinolone antibiotics in urine by capillary electrophoresis with chemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19003804/),[mol] / [l],7.8x10(-8),117378,DB00537,Ciprofloxacin
,1325892,elimination half-lives,"Their elimination half-lives are 6-10 hours and they have good oral absorption, excellent penetration into many tissues and fluids, and a better drug-interaction profile than other similar agents.",Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325892/),h,6-10,118112,DB00537,Ciprofloxacin
,2073104,total plasma clearance,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),[l] / [h],0.130,118131,DB00537,Ciprofloxacin
,2073104,total plasma clearance,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),[l] / [h],0.090,118132,DB00537,Ciprofloxacin
,2073104,half-life at beta (elimination) phase,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),h,1.90,118133,DB00537,Ciprofloxacin
,2073104,area under the concentration-time curve,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),h,2.83,118134,DB00537,Ciprofloxacin
,2073104,area under the concentration-time curve,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),[h·mg] / [l],43.25,118135,DB00537,Ciprofloxacin
,2073104,area under the concentration-time curve,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),[h·mg] / [l],52.41,118136,DB00537,Ciprofloxacin
,23454303,limit of detection (LOD),"The limit of detection (LOD) and lower limit of quantification (LLOQ) of the assay were 6 ng/mL and 20 ng/mL, respectively.",Optimization of on-line solid phase extraction and HPLC conditions using response surface methodology for determination of WM-5 in mouse plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23454303/),[ng] / [ml],6,118380,DB00537,Ciprofloxacin
,23454303,recovery,The recovery of the method was in the range of 93.74-96.33% with RSD less than 3.06%.,Optimization of on-line solid phase extraction and HPLC conditions using response surface methodology for determination of WM-5 in mouse plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23454303/),%,93.74-96.33,118381,DB00537,Ciprofloxacin
,1325620,flow rates (Qd),All patients were treated by CAVHD/CVVHD using Hospal AN69S 0.43 m2 filters and Fresenius 1.5% peritoneal dialysis fluid at dialysate flow rates (Qd) of 1 and 2 l/h.,Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),[l] / [h],1,119625,DB00537,Ciprofloxacin
,1325620,flow rates (Qd),All patients were treated by CAVHD/CVVHD using Hospal AN69S 0.43 m2 filters and Fresenius 1.5% peritoneal dialysis fluid at dialysate flow rates (Qd) of 1 and 2 l/h.,Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),[l] / [h],2,119626,DB00537,Ciprofloxacin
,1325620,volume of distribution (Vdarea),"For ciprofloxacin, volume of distribution (Vdarea) was 136.5 +/- 9.81, terminal elimination half-life (t1/2) 6.4 +/- 0.8 h, and total body clearance (TBC) 264.3 +/- 22.9 ml/min (mean +/- SEM).",Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),,136.5,119627,DB00537,Ciprofloxacin
,1325620,terminal elimination half-life (t1/2),"For ciprofloxacin, volume of distribution (Vdarea) was 136.5 +/- 9.81, terminal elimination half-life (t1/2) 6.4 +/- 0.8 h, and total body clearance (TBC) 264.3 +/- 22.9 ml/min (mean +/- SEM).",Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),h,6.4,119628,DB00537,Ciprofloxacin
,1325620,total body clearance (TBC),"For ciprofloxacin, volume of distribution (Vdarea) was 136.5 +/- 9.81, terminal elimination half-life (t1/2) 6.4 +/- 0.8 h, and total body clearance (TBC) 264.3 +/- 22.9 ml/min (mean +/- SEM).",Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),[ml] / [min],264.3,119629,DB00537,Ciprofloxacin
,1325620,sieving coefficient (S/C),Mean sieving coefficient (S/C) was 0.76 +/- 0.05 and filter clearances at Qd 1 and 2 l/h were 16.2 +/- 1.9 and 19.9 +/- 1.1 ml/min respectively.,Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),,0.76,119630,DB00537,Ciprofloxacin
,1325620,filter clearances,Mean sieving coefficient (S/C) was 0.76 +/- 0.05 and filter clearances at Qd 1 and 2 l/h were 16.2 +/- 1.9 and 19.9 +/- 1.1 ml/min respectively.,Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),[ml] / [min],16.2,119631,DB00537,Ciprofloxacin
,1325620,filter clearances,Mean sieving coefficient (S/C) was 0.76 +/- 0.05 and filter clearances at Qd 1 and 2 l/h were 16.2 +/- 1.9 and 19.9 +/- 1.1 ml/min respectively.,Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),[ml] / [min],19.9,119632,DB00537,Ciprofloxacin
,1325620,Vdarea,"For vancomycin, Vdarea was 60.7 +/- 5.11, t1/2 24.7 +/- 2.6 h and TBC 31.0 +/- 4.6 ml/min.",Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),,60.7,119633,DB00537,Ciprofloxacin
,1325620,t1/2,"For vancomycin, Vdarea was 60.7 +/- 5.11, t1/2 24.7 +/- 2.6 h and TBC 31.0 +/- 4.6 ml/min.",Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),h,24.7,119634,DB00537,Ciprofloxacin
,1325620,TBC,"For vancomycin, Vdarea was 60.7 +/- 5.11, t1/2 24.7 +/- 2.6 h and TBC 31.0 +/- 4.6 ml/min.",Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),[ml] / [min],31.0,119635,DB00537,Ciprofloxacin
,1325620,S/C,Mean S/C was 0.66 +/- 0.08 and filter clearances at Qd 1 and 2 l/h 12.1 +/- 2.0 and 16.6 +/- 2.0 ml/min.,Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),,0.66,119636,DB00537,Ciprofloxacin
,1325620,filter clearances,Mean S/C was 0.66 +/- 0.08 and filter clearances at Qd 1 and 2 l/h 12.1 +/- 2.0 and 16.6 +/- 2.0 ml/min.,Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),[ml] / [min],12.1,119637,DB00537,Ciprofloxacin
,1325620,filter clearances,Mean S/C was 0.66 +/- 0.08 and filter clearances at Qd 1 and 2 l/h 12.1 +/- 2.0 and 16.6 +/- 2.0 ml/min.,Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325620/),[ml] / [min],16.6,119638,DB00537,Ciprofloxacin
,2760258,T 1/2 h,"The mean (SD) theophylline results were: CL l/kg/h--NOR .038 (.006), C .033 (.006), NAL .045 (.008), P .044 (.007); T 1/2 h--NOR 9.2 (1.8), C 10.6 (1.8), NAL 8.3 (1.8), P 7.5 (1.4).",Effect of quinolone antimicrobials on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760258/),,9.2,119900,DB00537,Ciprofloxacin
,2760258,T 1/2 h,"The mean (SD) theophylline results were: CL l/kg/h--NOR .038 (.006), C .033 (.006), NAL .045 (.008), P .044 (.007); T 1/2 h--NOR 9.2 (1.8), C 10.6 (1.8), NAL 8.3 (1.8), P 7.5 (1.4).",Effect of quinolone antimicrobials on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760258/),,10.6,119901,DB00537,Ciprofloxacin
,2760258,T 1/2 h,"The mean (SD) theophylline results were: CL l/kg/h--NOR .038 (.006), C .033 (.006), NAL .045 (.008), P .044 (.007); T 1/2 h--NOR 9.2 (1.8), C 10.6 (1.8), NAL 8.3 (1.8), P 7.5 (1.4).",Effect of quinolone antimicrobials on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760258/),,8.3,119902,DB00537,Ciprofloxacin
,2939794,Terminal excretion half-lives,"Terminal excretion half-lives averaged 3.67 +/- 0.65, 3.60 +/- 0.26, and 4.00 +/- 0.69 h for the 100-, 150-, and 200-mg doses, respectively.",Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939794/),h,3.67,120326,DB00537,Ciprofloxacin
,2939794,Terminal excretion half-lives,"Terminal excretion half-lives averaged 3.67 +/- 0.65, 3.60 +/- 0.26, and 4.00 +/- 0.69 h for the 100-, 150-, and 200-mg doses, respectively.",Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939794/),h,3.60,120327,DB00537,Ciprofloxacin
,2939794,Terminal excretion half-lives,"Terminal excretion half-lives averaged 3.67 +/- 0.65, 3.60 +/- 0.26, and 4.00 +/- 0.69 h for the 100-, 150-, and 200-mg doses, respectively.",Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939794/),h,4.00,120328,DB00537,Ciprofloxacin
,2939794,Serum clearances,"Serum clearances were 30.1 +/- 3.4, 29.8 +/- 4.0, and 26.9 +/- 4.1 liters/h per 1.73 m2 for these doses.",Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939794/),[l] / [1.73·h·m2],30.1,120329,DB00537,Ciprofloxacin
,2939794,Serum clearances,"Serum clearances were 30.1 +/- 3.4, 29.8 +/- 4.0, and 26.9 +/- 4.1 liters/h per 1.73 m2 for these doses.",Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939794/),[l] / [1.73·h·m2],29.8,120330,DB00537,Ciprofloxacin
,2939794,Serum clearances,"Serum clearances were 30.1 +/- 3.4, 29.8 +/- 4.0, and 26.9 +/- 4.1 liters/h per 1.73 m2 for these doses.",Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939794/),[l] / [1.73·h·m2],26.9,120331,DB00537,Ciprofloxacin
,14638468,survival rates,The survival rates of mice infected with PSSP and PRSP at 14 days after infection were 80% in the DQ-113-treated group and 0 to 10% in the other three groups.,"In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),%,80,120596,DB00537,Ciprofloxacin
,14638468,survival rates,The survival rates of mice infected with PSSP and PRSP at 14 days after infection were 80% in the DQ-113-treated group and 0 to 10% in the other three groups.,"In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),,0,120597,DB00537,Ciprofloxacin
,14638468,50% effective doses (ED50s),"In murine infections caused by PSSP, the 50% effective doses (ED50s) of DQ-113, gatifloxacin, and ciprofloxacin were 6.0, 41.3, and 131.6 mg/kg, respectively.","In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),[mg] / [kg],6.0,120598,DB00537,Ciprofloxacin
,14638468,50% effective doses (ED50s),"In murine infections caused by PSSP, the 50% effective doses (ED50s) of DQ-113, gatifloxacin, and ciprofloxacin were 6.0, 41.3, and 131.6 mg/kg, respectively.","In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),[mg] / [kg],41.3,120599,DB00537,Ciprofloxacin
,14638468,50% effective doses (ED50s),"In murine infections caused by PSSP, the 50% effective doses (ED50s) of DQ-113, gatifloxacin, and ciprofloxacin were 6.0, 41.3, and 131.6 mg/kg, respectively.","In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),[mg] / [kg],131.6,120600,DB00537,Ciprofloxacin
,14638468,ED50s,"Against PRSP-caused pneumonia in mice, the ED50s of DQ-113, gatifloxacin, and ciprofloxacin were 7.6, 64.7, and 125.9 mg/kg, respectively.","In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),[mg] / [kg],7.6,120601,DB00537,Ciprofloxacin
,14638468,ED50s,"Against PRSP-caused pneumonia in mice, the ED50s of DQ-113, gatifloxacin, and ciprofloxacin were 7.6, 64.7, and 125.9 mg/kg, respectively.","In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),[mg] / [kg],64.7,120602,DB00537,Ciprofloxacin
,14638468,ED50s,"Against PRSP-caused pneumonia in mice, the ED50s of DQ-113, gatifloxacin, and ciprofloxacin were 7.6, 64.7, and 125.9 mg/kg, respectively.","In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),[mg] / [kg],125.9,120603,DB00537,Ciprofloxacin
,14638468,viable bacterium counts,"The means +/- standard errors of the means of viable bacterium counts in the lungs of gatifloxacin-treated, ciprofloxacin-treated, and untreated control mice infected with PSSP were 2.91 +/- 0.34, 3.13 +/- 0.48, and 3.86 +/- 0.80 log10 CFU/ml, respectively.","In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),[cfu·log10] / [ml],2.91,120604,DB00537,Ciprofloxacin
,14638468,viable bacterium counts,"The means +/- standard errors of the means of viable bacterium counts in the lungs of gatifloxacin-treated, ciprofloxacin-treated, and untreated control mice infected with PSSP were 2.91 +/- 0.34, 3.13 +/- 0.48, and 3.86 +/- 0.80 log10 CFU/ml, respectively.","In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),[cfu·log10] / [ml],3.13,120605,DB00537,Ciprofloxacin
,14638468,viable bacterium counts,"The means +/- standard errors of the means of viable bacterium counts in the lungs of gatifloxacin-treated, ciprofloxacin-treated, and untreated control mice infected with PSSP were 2.91 +/- 0.34, 3.13 +/- 0.48, and 3.86 +/- 0.80 log10 CFU/ml, respectively.","In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638468/),[cfu·log10] / [ml],3.86,120606,DB00537,Ciprofloxacin
,9758306,oral bioavailability,"It is available in an injectable form, as well as an oral formulation with virtually 100% oral bioavailability.","Levofloxacin, a second-generation fluoroquinolone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758306/),%,100,120914,DB00537,Ciprofloxacin
,9758306,plasma elimination half-life,The plasma elimination half-life ranges from 6-8 hours in individuals with normal renal function.,"Levofloxacin, a second-generation fluoroquinolone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758306/),h,6-8,120915,DB00537,Ciprofloxacin
,2933340,MICs,The MICs of enoxacin against all but one of the gram-negative isolates cultured from 265 urological patients were between 0.03 and 4 mg/l.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.03 and 4,121285,DB00537,Ciprofloxacin
,2933340,MICs,The MICs against 134 gram-positive isolates were between 0.25 and 16 mg/l except for two strains of streptococci.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.25 and 16,121286,DB00537,Ciprofloxacin
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.7 and 6.3,121287,DB00537,Ciprofloxacin
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],3.6,121288,DB00537,Ciprofloxacin
,2933340,urinary recovery,The mean urinary recovery of parent drug within 24 h was 31.2% of the administered dose.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),%,31.2,121289,DB00537,Ciprofloxacin
,16502109,"V(d,ss)","The mean values of EFL pharmacokinetic parameters showed differences only between values of V(d,ss) (3.46+/-0.19 for the females and 4.53+/-0.11 L/kg for the males, p>0.05).",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in male and female turkeys following intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502109/),[l] / [kg],3.46,122083,DB00537,Ciprofloxacin
,16502109,"V(d,ss)","The mean values of EFL pharmacokinetic parameters showed differences only between values of V(d,ss) (3.46+/-0.19 for the females and 4.53+/-0.11 L/kg for the males, p>0.05).",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in male and female turkeys following intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502109/),[l] / [kg],4.53,122084,DB00537,Ciprofloxacin
,16502109,F(%),After oral administration of EFL the values of F(%) were 77.83 in the female and 79.61 in the male turkeys.,Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in male and female turkeys following intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502109/),,77.83,122085,DB00537,Ciprofloxacin
,16502109,F(%),After oral administration of EFL the values of F(%) were 77.83 in the female and 79.61 in the male turkeys.,Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in male and female turkeys following intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502109/),,79.61,122086,DB00537,Ciprofloxacin
,30819273,peak concentration,"Enrofloxacin was detected in all dosed animals, at an average peak concentration of 3 μg/mL in hemolymph, and remained in the body for 20.3 h with an average clearance of 0.19 μg × h/mL.",Enrofloxacin Pharmacokinetics and Sampling Techniques in California Sea Hares (Aplysia californica). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30819273/),[μg] / [ml],3,123333,DB00537,Ciprofloxacin
,30819273,clearance,"Enrofloxacin was detected in all dosed animals, at an average peak concentration of 3 μg/mL in hemolymph, and remained in the body for 20.3 h with an average clearance of 0.19 μg × h/mL.",Enrofloxacin Pharmacokinetics and Sampling Techniques in California Sea Hares (Aplysia californica). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30819273/),[h·μg] / [ml],0.19,123334,DB00537,Ciprofloxacin
>,30809648,AUC/MIC ratio,Population pharmacokinetic modelling was performed with Monte Carlo simulations then used to define dosing regimens that optimize the PTA of an AUC/MIC ratio >125 for different MICs and fractional target attainment (FTA) of empirical and targeted therapy against Pseudomonas aeruginosa.,Defining optimal dosing of ciprofloxacin in patients with septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809648/),,125,123652,DB00537,Ciprofloxacin
≤,30809648,MICs,"With a dose of 400 mg q8h and CLCR of 80 mL/min, >95% PTA was achieved for bacteria with MICs ≤0.25 mg/L.",Defining optimal dosing of ciprofloxacin in patients with septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809648/),[mg] / [l],0.25,123653,DB00537,Ciprofloxacin
≤,30809648,MICs,"In patients with septic shock, standard ciprofloxacin dosing achieved concentrations to successfully treat bacteria with MICs ≤0.25 mg/L and then only in patients with normal or reduced CLCR.",Defining optimal dosing of ciprofloxacin in patients with septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809648/),[mg] / [l],0.25,123654,DB00537,Ciprofloxacin
,14613952,MIC,"The olamufloxacin MIC at which 50% of isolates are inhibited (MIC50) for 81 different Legionella spp. strains (59 type strains and 22 clinical isolates) was 0.008 mg/L, which was identical to sparfloxacin, whereas the MIC50s for erythromycin, levofloxacin and ciprofloxacin were 0.25, 0.032 and 0.032 mg/L, respectively.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [l],0.008,123820,DB00537,Ciprofloxacin
,14613952,MIC50s,"The olamufloxacin MIC at which 50% of isolates are inhibited (MIC50) for 81 different Legionella spp. strains (59 type strains and 22 clinical isolates) was 0.008 mg/L, which was identical to sparfloxacin, whereas the MIC50s for erythromycin, levofloxacin and ciprofloxacin were 0.25, 0.032 and 0.032 mg/L, respectively.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [l],0.25,123821,DB00537,Ciprofloxacin
,14613952,MIC50s,"The olamufloxacin MIC at which 50% of isolates are inhibited (MIC50) for 81 different Legionella spp. strains (59 type strains and 22 clinical isolates) was 0.008 mg/L, which was identical to sparfloxacin, whereas the MIC50s for erythromycin, levofloxacin and ciprofloxacin were 0.25, 0.032 and 0.032 mg/L, respectively.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [l],0.032,123822,DB00537,Ciprofloxacin
,14613952,peak levels,"When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [kg],3.02,123823,DB00537,Ciprofloxacin
,14613952,half-life,"When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),h,3.41,123824,DB00537,Ciprofloxacin
,14613952,AUC0-12,"When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[h·mg] / [kg],12.31,123825,DB00537,Ciprofloxacin
,16958777,Clearance,"Clearance and V(d(ss)) were greater for enrofloxacin (mean +/- SD = 6.34 +/- 1.5 mL/min/kg and 2.32 +/- 0.32 L/kg, respectively) than for marbofloxacin (4.62 +/- 0.67 mL/min/kg and 1.6 +/- 0.25 L/kg, respectively).","Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958777/),[ml] / [kg·min],6.34,124608,DB00537,Ciprofloxacin
,16958777,Clearance,"Clearance and V(d(ss)) were greater for enrofloxacin (mean +/- SD = 6.34 +/- 1.5 mL/min/kg and 2.32 +/- 0.32 L/kg, respectively) than for marbofloxacin (4.62 +/- 0.67 mL/min/kg and 1.6 +/- 0.25 L/kg, respectively).","Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958777/),[ml] / [kg·min],4.62,124609,DB00537,Ciprofloxacin
,16958777,V(d(ss)),"Clearance and V(d(ss)) were greater for enrofloxacin (mean +/- SD = 6.34 +/- 1.5 mL/min/kg and 2.32 +/- 0.32 L/kg, respectively) than for marbofloxacin (4.62 +/- 0.67 mL/min/kg and 1.6 +/- 0.25 L/kg, respectively).","Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958777/),[l] / [kg],2.32,124610,DB00537,Ciprofloxacin
,16958777,V(d(ss)),"Clearance and V(d(ss)) were greater for enrofloxacin (mean +/- SD = 6.34 +/- 1.5 mL/min/kg and 2.32 +/- 0.32 L/kg, respectively) than for marbofloxacin (4.62 +/- 0.67 mL/min/kg and 1.6 +/- 0.25 L/kg, respectively).","Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958777/),[l] / [kg],1.6,124611,DB00537,Ciprofloxacin
,16958777,oral bioavailability,Mean oral bioavailability was not significantly different between marbofloxacin (59%) and enrofloxacin (55%).,"Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958777/),%,59,124612,DB00537,Ciprofloxacin
,16958777,oral bioavailability,Mean oral bioavailability was not significantly different between marbofloxacin (59%) and enrofloxacin (55%).,"Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958777/),%,55,124613,DB00537,Ciprofloxacin
,16958777,fraction not,"Absorbed fraction and first-pass effect were only determinable for enrofloxacin, whereas the percentage of the dose absorbed in the portal circulation was estimated to be 78% and the fraction not extracted during the first pass through the liver was 65%.","Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958777/),%,65,124614,DB00537,Ciprofloxacin
,24862289,volume of distribution,"The mean values of volume of distribution and clearance of CPX in the patients above 65years of age were 78.41±13.17L and 18.39±4.15L/h, respectively.",Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862289/),l,78.41,124854,DB00537,Ciprofloxacin
,24862289,clearance,"The mean values of volume of distribution and clearance of CPX in the patients above 65years of age were 78.41±13.17L and 18.39±4.15L/h, respectively.",Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24862289/),[l] / [h],18.39,124855,DB00537,Ciprofloxacin
,19046687,recovery rate,The method showed a good recovery rate (74.2-127.73%) and precision (RSDs: 1.64-20%).,Approaches for application of sub and supercritical fluid extraction for quantification of orbifloxacin from plasma and milk: application to disposition kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046687/),%,74.2-127.73,124931,DB00537,Ciprofloxacin
,19046687,LOD,"The instrumental LOD and LOQ values were 0.004 microg mL(-1) vs. 0.01 microg mL(-1) or 0.006 microg mL(-1) vs. 0.02 microg mL(-1), for plasma and milk, respectively.",Approaches for application of sub and supercritical fluid extraction for quantification of orbifloxacin from plasma and milk: application to disposition kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046687/),[μg] / [ml],0.004,124932,DB00537,Ciprofloxacin
,19046687,LOD,"The instrumental LOD and LOQ values were 0.004 microg mL(-1) vs. 0.01 microg mL(-1) or 0.006 microg mL(-1) vs. 0.02 microg mL(-1), for plasma and milk, respectively.",Approaches for application of sub and supercritical fluid extraction for quantification of orbifloxacin from plasma and milk: application to disposition kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046687/),[μg] / [ml],0.01,124933,DB00537,Ciprofloxacin
,19046687,LOQ,"The instrumental LOD and LOQ values were 0.004 microg mL(-1) vs. 0.01 microg mL(-1) or 0.006 microg mL(-1) vs. 0.02 microg mL(-1), for plasma and milk, respectively.",Approaches for application of sub and supercritical fluid extraction for quantification of orbifloxacin from plasma and milk: application to disposition kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046687/),[μg] / [ml],0.01,124934,DB00537,Ciprofloxacin
,19046687,LOQ,"The instrumental LOD and LOQ values were 0.004 microg mL(-1) vs. 0.01 microg mL(-1) or 0.006 microg mL(-1) vs. 0.02 microg mL(-1), for plasma and milk, respectively.",Approaches for application of sub and supercritical fluid extraction for quantification of orbifloxacin from plasma and milk: application to disposition kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046687/),[μg] / [ml],0.006,124935,DB00537,Ciprofloxacin
,19046687,LOQ,"The instrumental LOD and LOQ values were 0.004 microg mL(-1) vs. 0.01 microg mL(-1) or 0.006 microg mL(-1) vs. 0.02 microg mL(-1), for plasma and milk, respectively.",Approaches for application of sub and supercritical fluid extraction for quantification of orbifloxacin from plasma and milk: application to disposition kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046687/),[μg] / [ml],0.02,124936,DB00537,Ciprofloxacin
<,15992072,MIC90,"The MIC90 values are < or = 0.25 mg/l for Streptococcus pneumoniae (irrespective of penicillin susceptibility), Haemophilus influenzae (beta-lactamase positive or negative), Morexella catarrhalis, Bordetella pertussis, Legionella sp., Mycoplasma pneumoniae, Clamydia pneumoniae, Mycobacterium tuberculosis, methicillin-sensitive Staphylococcus aureus, beta-haemolytic streptococci (macrolide-sensitive or -resistant), Listeria sp., most Enterobacteriaceae, Salmonella sp., Shigella sp., Neisseria gonorrhoeae, N. menigitidis, Pasteurella spp., Vibrio spp. and Yersinia enterocolitica.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],0.25,124986,DB00537,Ciprofloxacin
,15992072,MIC90s,"For Mycobacterium intracellularae, methicillin-resistant S. aureus (MRSA), ciprofloxacin-resistant S. aureus, Citrobacter freundii, Providencia sp., Serratia sp., P. aeruginosa and other non-fermentive Gram-negative rods, MIC90s are in the range 0.5-4 mg/l.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],0.5-4,124987,DB00537,Ciprofloxacin
,15992072,MIC90s,"For anaerobic bacteria species, MIC90s are also in the range 0.25-4 mg/l.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],0.25-4,124988,DB00537,Ciprofloxacin
,15992072,maximum serum concentration,"A single dose of 400 mg produces a maximum serum concentration of 2.5-4.5 mg/l, half-life of 11-15 h, AUC of 25-40 mg x h/l and volume of distribution of 2.5-3.5 L/kg.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],2.5-4.5,124989,DB00537,Ciprofloxacin
,15992072,half-life,"A single dose of 400 mg produces a maximum serum concentration of 2.5-4.5 mg/l, half-life of 11-15 h, AUC of 25-40 mg x h/l and volume of distribution of 2.5-3.5 L/kg.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),h,11-15,124990,DB00537,Ciprofloxacin
,15992072,AUC,"A single dose of 400 mg produces a maximum serum concentration of 2.5-4.5 mg/l, half-life of 11-15 h, AUC of 25-40 mg x h/l and volume of distribution of 2.5-3.5 L/kg.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[h·mg] / [l],25-40,124991,DB00537,Ciprofloxacin
,15992072,volume of distribution,"A single dose of 400 mg produces a maximum serum concentration of 2.5-4.5 mg/l, half-life of 11-15 h, AUC of 25-40 mg x h/l and volume of distribution of 2.5-3.5 L/kg.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[l] / [kg],2.5-3.5,124992,DB00537,Ciprofloxacin
,15992072,Protein binding,Protein binding is about 50% and two metabolites have been identified (M-1 and M-2).,Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),%,50,124993,DB00537,Ciprofloxacin
>,15992072,Bioavailability,Bioavailability is > 85% and a minority of clearance is via the kidneys.,Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),%,85,124994,DB00537,Ciprofloxacin
<,15992072,MICs,"At present undergoing clinical trials, with a focus on respiratory tract infection, it is likely that moxifloxacin will provide effective therapy for pathogens with MICs of < or = 0.25-0.5 mg/l.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],0.25-0.5,124995,DB00537,Ciprofloxacin
,1790720,tissue/plasma ratio,"Penetration into bronchial mucosa tissue was good as well, as indicated by tissue/plasma ratio values between 1.5 and 4.4.","Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1790720/),,1.5,125216,DB00537,Ciprofloxacin
,1790720,tissue/plasma ratio,"Penetration into bronchial mucosa tissue was good as well, as indicated by tissue/plasma ratio values between 1.5 and 4.4.","Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1790720/),,4.4,125217,DB00537,Ciprofloxacin
,1790720,Tissue/plasma ratio,Tissue/plasma ratio values between 0.8 and 2.1 indicated that penetration to pleural tissues was good as well.,"Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1790720/),,0.8,125218,DB00537,Ciprofloxacin
,1790720,Tissue/plasma ratio,Tissue/plasma ratio values between 0.8 and 2.1 indicated that penetration to pleural tissues was good as well.,"Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1790720/),,2.1,125219,DB00537,Ciprofloxacin
,1881686,Serum peak levels,"Serum peak levels were 2.95 +/- 1 mg/l on day 2, and 2.43 +/- 0.7 mg/l on day 4.",[Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881686/),[mg] / [l],2.95,125702,DB00537,Ciprofloxacin
,1881686,Serum peak levels,"Serum peak levels were 2.95 +/- 1 mg/l on day 2, and 2.43 +/- 0.7 mg/l on day 4.",[Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881686/),[mg] / [l],2.43,125703,DB00537,Ciprofloxacin
,1881686,peak,"Bronchial peak and through levels were 0.95 +/- 0.51 mg/l and 0.21 +/- 0.12 mg/l, respectively, on day 2, and 0.76 +/- 0.17 mg/l and 0.18 +/- 0.14 mg/l, respectively, on day 4.",[Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881686/),[mg] / [l],0.95,125704,DB00537,Ciprofloxacin
,1881686,peak,"Bronchial peak and through levels were 0.95 +/- 0.51 mg/l and 0.21 +/- 0.12 mg/l, respectively, on day 2, and 0.76 +/- 0.17 mg/l and 0.18 +/- 0.14 mg/l, respectively, on day 4.",[Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881686/),[mg] / [l],0.76,125705,DB00537,Ciprofloxacin
,1881686,through levels,"Bronchial peak and through levels were 0.95 +/- 0.51 mg/l and 0.21 +/- 0.12 mg/l, respectively, on day 2, and 0.76 +/- 0.17 mg/l and 0.18 +/- 0.14 mg/l, respectively, on day 4.",[Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881686/),[mg] / [l],0.21,125706,DB00537,Ciprofloxacin
,1881686,through levels,"Bronchial peak and through levels were 0.95 +/- 0.51 mg/l and 0.21 +/- 0.12 mg/l, respectively, on day 2, and 0.76 +/- 0.17 mg/l and 0.18 +/- 0.14 mg/l, respectively, on day 4.",[Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881686/),[mg] / [l],0.76,125707,DB00537,Ciprofloxacin
,1881686,through levels,"Bronchial peak and through levels were 0.95 +/- 0.51 mg/l and 0.21 +/- 0.12 mg/l, respectively, on day 2, and 0.76 +/- 0.17 mg/l and 0.18 +/- 0.14 mg/l, respectively, on day 4.",[Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881686/),[mg] / [l],0.18,125708,DB00537,Ciprofloxacin
,1881686,ratio of br,"The ratio of bronchial/serum peak was 0.32 +/- 0.11 and 0.33 +/- 0.06 on day 2 and 4, respectively.",[Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881686/),,0,125709,DB00537,Ciprofloxacin
,1444289,half-life (t1/2),"Overall, cefpirome exhibited pharmacokinetics similar to those of ceftazidime: half-life (t1/2), 1.95 h; concentration at 1 h (C1h), 47 to 49 micrograms/ml for both antibiotics.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),h,1.95,125770,DB00537,Ciprofloxacin
,1444289,concentration at 1 h (C1h),"Overall, cefpirome exhibited pharmacokinetics similar to those of ceftazidime: half-life (t1/2), 1.95 h; concentration at 1 h (C1h), 47 to 49 micrograms/ml for both antibiotics.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),[μg] / [ml],47 to 49,125771,DB00537,Ciprofloxacin
,1444289,t1/2,"Ceftriaxone displayed the longest t1/2 (7.65 h) and the highest C1h (137.8 micrograms/ml), while we observed the shortest t1/2 (1.05 h) and the lowest C1h (19.85 micrograms/ml) with imipenem.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),h,7.65,125772,DB00537,Ciprofloxacin
,1444289,C1h,"Ceftriaxone displayed the longest t1/2 (7.65 h) and the highest C1h (137.8 micrograms/ml), while we observed the shortest t1/2 (1.05 h) and the lowest C1h (19.85 micrograms/ml) with imipenem.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),[μg] / [ml],137.8,125773,DB00537,Ciprofloxacin
,1444289,t1/2,"Ceftriaxone displayed the longest t1/2 (7.65 h) and the highest C1h (137.8 micrograms/ml), while we observed the shortest t1/2 (1.05 h) and the lowest C1h (19.85 micrograms/ml) with imipenem.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),h,1.05,125774,DB00537,Ciprofloxacin
,1444289,C1h,"Ceftriaxone displayed the longest t1/2 (7.65 h) and the highest C1h (137.8 micrograms/ml), while we observed the shortest t1/2 (1.05 h) and the lowest C1h (19.85 micrograms/ml) with imipenem.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),[μg] / [ml],19.85,125775,DB00537,Ciprofloxacin
,1444289,serum bactericidal activity titers,"Ceftazidime remained the most active agent tested against P. aeruginosa (serum bactericidal activity titers, 1:43 at 1 h) up to 8 h.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),,1:43,125776,DB00537,Ciprofloxacin
,8792592,elimination half-lives,"Mean elimination half-lives after IV and IM administration were 72 and 184 minutes, respectively.",Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792592/),min,72,126043,DB00537,Ciprofloxacin
,8792592,elimination half-lives,"Mean elimination half-lives after IV and IM administration were 72 and 184 minutes, respectively.",Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792592/),min,184,126044,DB00537,Ciprofloxacin
,8792592,tmax,The absorption of intramuscularly administered CIP in sheep was fast: maximal plasma concentration (Cmax) was reached quickly (tmax 31.93 min) and attained values of 0.69 +/- 0.27 mg/l.,Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792592/),min,31.93,126045,DB00537,Ciprofloxacin
,8792592,tmax,The absorption of intramuscularly administered CIP in sheep was fast: maximal plasma concentration (Cmax) was reached quickly (tmax 31.93 min) and attained values of 0.69 +/- 0.27 mg/l.,Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792592/),[mg] / [l],0.69,126046,DB00537,Ciprofloxacin
,8792592,bioavailability,The bioavailability was 49%.,Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792592/),%,49,126047,DB00537,Ciprofloxacin
,11173053,central volume of distribution,"The mean +/- SD of the estimates (coefficient of variation of interindividual variability as a percentage) were central volume of distribution, 39.45+/-52.47l(133%); steady-state volume of distribution, 145.86+/-97.51l(60%), clearance of influx into lung tissue, 35.83+/-22.57l/h(63%), extrapolated elimination rate constant, 0.173+/-0.25/h and extrapolated elimination half-life, 4.02+/-0.89h.",Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11173053/),l,39.45,126198,DB00537,Ciprofloxacin
,11173053,steady-state volume of distribution,"The mean +/- SD of the estimates (coefficient of variation of interindividual variability as a percentage) were central volume of distribution, 39.45+/-52.47l(133%); steady-state volume of distribution, 145.86+/-97.51l(60%), clearance of influx into lung tissue, 35.83+/-22.57l/h(63%), extrapolated elimination rate constant, 0.173+/-0.25/h and extrapolated elimination half-life, 4.02+/-0.89h.",Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11173053/),l,145.86,126199,DB00537,Ciprofloxacin
,11173053,clearance of influx into lung tissue,"The mean +/- SD of the estimates (coefficient of variation of interindividual variability as a percentage) were central volume of distribution, 39.45+/-52.47l(133%); steady-state volume of distribution, 145.86+/-97.51l(60%), clearance of influx into lung tissue, 35.83+/-22.57l/h(63%), extrapolated elimination rate constant, 0.173+/-0.25/h and extrapolated elimination half-life, 4.02+/-0.89h.",Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11173053/),[l] / [h],35.83,126200,DB00537,Ciprofloxacin
,11173053,elimination rate constant,"The mean +/- SD of the estimates (coefficient of variation of interindividual variability as a percentage) were central volume of distribution, 39.45+/-52.47l(133%); steady-state volume of distribution, 145.86+/-97.51l(60%), clearance of influx into lung tissue, 35.83+/-22.57l/h(63%), extrapolated elimination rate constant, 0.173+/-0.25/h and extrapolated elimination half-life, 4.02+/-0.89h.",Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11173053/),1/[h],0.173,126201,DB00537,Ciprofloxacin
,11173053,elimination half-life,"The mean +/- SD of the estimates (coefficient of variation of interindividual variability as a percentage) were central volume of distribution, 39.45+/-52.47l(133%); steady-state volume of distribution, 145.86+/-97.51l(60%), clearance of influx into lung tissue, 35.83+/-22.57l/h(63%), extrapolated elimination rate constant, 0.173+/-0.25/h and extrapolated elimination half-life, 4.02+/-0.89h.",Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11173053/),h,4.02,126202,DB00537,Ciprofloxacin
,23800340,mutant selection window (MSW),The mutant selection window (MSW) of enrofloxacin on isolate AH10 was determined to be 0.5-3 μg/mL based on the mutant prevention concentration (MPC) and minimum inhibitory concentration (MIC) value.,Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23800340/),[μg] / [ml],0.5-3,126407,DB00537,Ciprofloxacin
,23800340,serum maximum concentration (Cmax),"Dosing of 30 μg/g resulted in serum maximum concentration (Cmax) of 7.151 μg/mL, and concentration in serum was above MPC till 24 h post the single dose.",Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23800340/),[μg] / [ml],7.151,126408,DB00537,Ciprofloxacin
more,23800340,withdraw time,A withdraw time of more than 32 d was suggested based on the drug eliminating rate and pharmacokinetic model described by a polyexponential equation.,Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23800340/),d,32,126409,DB00537,Ciprofloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],0.12,126769,DB00537,Ciprofloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],2.0,126770,DB00537,Ciprofloxacin
,12096008,urine flow rates,"Pharmacokinetic parameters reported for healthy young and old individuals were used for the simulation of drug levels in urine, at different mean urine flow rates (1-2.5 L/day).",Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12096008/),[l] / [d],1-2.5,128745,DB00537,Ciprofloxacin
,2118328,Total,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],3.5,128746,DB00537,Ciprofloxacin
,2118328,Total,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],2.9,128747,DB00537,Ciprofloxacin
,2118328,clearance,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],3.5,128748,DB00537,Ciprofloxacin
,2118328,clearance,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],2.9,128749,DB00537,Ciprofloxacin
,2612228,serum half-life,The serum half-life of ciprofloxacin in normal renal function was 5.8 +/- 1.2 h; this rose to 10.8 +/- 2.3 h in the group with clearances of 10-30 ml/min.,Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612228/),h,5.8,129354,DB00537,Ciprofloxacin
,2612228,serum half-life,The serum half-life of ciprofloxacin in normal renal function was 5.8 +/- 1.2 h; this rose to 10.8 +/- 2.3 h in the group with clearances of 10-30 ml/min.,Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612228/),h,10.8,129355,DB00537,Ciprofloxacin
,2612228,clearances,The serum half-life of ciprofloxacin in normal renal function was 5.8 +/- 1.2 h; this rose to 10.8 +/- 2.3 h in the group with clearances of 10-30 ml/min.,Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612228/),[ml] / [min],10-30,129356,DB00537,Ciprofloxacin
,2612228,t1/2,"Compared to the latter group, the t1/2 was lower (7.0 +/- 2.9 h) in the patients with terminal renal failure.",Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612228/),h,7.0,129357,DB00537,Ciprofloxacin
,2612228,clearances,The total renal elimination of the parent compound and its metabolites was approximately 60% over the 48-hour collection period in normal renal function and was reduced by about 20% in the group with clearances within the range of 10-30 ml/min.,Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612228/),[ml] / [min],10-30,129358,DB00537,Ciprofloxacin
,2931047,maximum concentration,"Mean values for the maximum concentration of drug in serum, the time to maximum concentration of drug in serum, and the elimination half-life were 3.23 micrograms/ml, 1.00 h, and 5.04 h, respectively, for the solution.",Pharmacokinetics of three oral formulations of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931047/),[μg] / [ml],3.23,129553,DB00537,Ciprofloxacin
,2931047,time to maximum concentration,"Mean values for the maximum concentration of drug in serum, the time to maximum concentration of drug in serum, and the elimination half-life were 3.23 micrograms/ml, 1.00 h, and 5.04 h, respectively, for the solution.",Pharmacokinetics of three oral formulations of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931047/),h,1.00,129554,DB00537,Ciprofloxacin
,2931047,elimination half-life,"Mean values for the maximum concentration of drug in serum, the time to maximum concentration of drug in serum, and the elimination half-life were 3.23 micrograms/ml, 1.00 h, and 5.04 h, respectively, for the solution.",Pharmacokinetics of three oral formulations of ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931047/),h,5.04,129555,DB00537,Ciprofloxacin
,2931047,renal clearance,The mean renal clearance of ciprofloxacin was 372 ml/min and accounted for at least 50% of the total clearance.,Pharmacokinetics of three oral formulations of ciprofloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931047/),[ml] / [min],372,129556,DB00537,Ciprofloxacin
,2931047,relative bioavailability,"The 250-mg tablet was not bioequivalent to either of the other formulations; the relative bioavailability values were 78.7 and 74.1%, respectively, for the 500-mg tablet and the solution.",Pharmacokinetics of three oral formulations of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931047/),%,78.7,129557,DB00537,Ciprofloxacin
,2931047,relative bioavailability,"The 250-mg tablet was not bioequivalent to either of the other formulations; the relative bioavailability values were 78.7 and 74.1%, respectively, for the 500-mg tablet and the solution.",Pharmacokinetics of three oral formulations of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931047/),%,74.1,129558,DB00537,Ciprofloxacin
,19398644,absolute bioavailability,"An absolute bioavailability of 100.1% +/- 4.76%, a terminal half-life of 4.23 +/- 0.2 h and 3.95 +/- 0.15 h after i.v. and i.m. administration, a steady-state volume of distribution of 1.61 +/- 0.13 liters/kg, and clearance of 0.31 +/- 0.03 liters/h/kg were observed.",Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398644/),%,100.1,129648,DB00537,Ciprofloxacin
,19398644,terminal half-life,"An absolute bioavailability of 100.1% +/- 4.76%, a terminal half-life of 4.23 +/- 0.2 h and 3.95 +/- 0.15 h after i.v. and i.m. administration, a steady-state volume of distribution of 1.61 +/- 0.13 liters/kg, and clearance of 0.31 +/- 0.03 liters/h/kg were observed.",Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398644/),h,4.23,129649,DB00537,Ciprofloxacin
,19398644,terminal half-life,"An absolute bioavailability of 100.1% +/- 4.76%, a terminal half-life of 4.23 +/- 0.2 h and 3.95 +/- 0.15 h after i.v. and i.m. administration, a steady-state volume of distribution of 1.61 +/- 0.13 liters/kg, and clearance of 0.31 +/- 0.03 liters/h/kg were observed.",Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398644/),h,3.95,129650,DB00537,Ciprofloxacin
,19398644,steady-state volume of distribution,"An absolute bioavailability of 100.1% +/- 4.76%, a terminal half-life of 4.23 +/- 0.2 h and 3.95 +/- 0.15 h after i.v. and i.m. administration, a steady-state volume of distribution of 1.61 +/- 0.13 liters/kg, and clearance of 0.31 +/- 0.03 liters/h/kg were observed.",Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398644/),[l] / [kg],1.61,129651,DB00537,Ciprofloxacin
,19398644,clearance,"An absolute bioavailability of 100.1% +/- 4.76%, a terminal half-life of 4.23 +/- 0.2 h and 3.95 +/- 0.15 h after i.v. and i.m. administration, a steady-state volume of distribution of 1.61 +/- 0.13 liters/kg, and clearance of 0.31 +/- 0.03 liters/h/kg were observed.",Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398644/),[l] / [h·kg],0.31,129652,DB00537,Ciprofloxacin
,15317829,V(ss)/F,"Females had a median C(max) of ciprofloxacin that was 30% greater than males and a significantly smaller median (range) V(ss)/F: 81.1 (44.8-111.6) versus 170.9 (140.9-213.4), respectively (p < 0.01).",Sex-related differences in the pharmacokinetics of oral ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317829/),,81.1,129664,DB00537,Ciprofloxacin
,15317829,V(ss)/F,"Females had a median C(max) of ciprofloxacin that was 30% greater than males and a significantly smaller median (range) V(ss)/F: 81.1 (44.8-111.6) versus 170.9 (140.9-213.4), respectively (p < 0.01).",Sex-related differences in the pharmacokinetics of oral ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317829/),,170.9,129665,DB00537,Ciprofloxacin
,15317829,CL(S)/F,"In addition, females had increased exposure to ciprofloxacin, with a slower median (range) CL(S)/F of 28.3 L/h (24.5-33.4) compared to 44.4 L/h (41.4-53.7) for males (p < 0.01).",Sex-related differences in the pharmacokinetics of oral ciprofloxacin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317829/),[l] / [h],28.3,129666,DB00537,Ciprofloxacin
,15317829,CL(S)/F,"In addition, females had increased exposure to ciprofloxacin, with a slower median (range) CL(S)/F of 28.3 L/h (24.5-33.4) compared to 44.4 L/h (41.4-53.7) for males (p < 0.01).",Sex-related differences in the pharmacokinetics of oral ciprofloxacin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317829/),[l] / [h],44.4,129667,DB00537,Ciprofloxacin
,17699040,Steady-state volume of distribution,"Steady-state volume of distribution and clearance of orbifloxacin after intravenous administration were 1.13 +/- 0.08 L/kg and 0.40 +/- 0.11 L/h x kg, respectively.","Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699040/),[l] / [kg],1.13,129826,DB00537,Ciprofloxacin
,17699040,clearance,"Steady-state volume of distribution and clearance of orbifloxacin after intravenous administration were 1.13 +/- 0.08 L/kg and 0.40 +/- 0.11 L/h x kg, respectively.","Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699040/),[l] / [h·kg],0.40,129827,DB00537,Ciprofloxacin
,17699040,maximum plasma concentrations,"Following subcutaneous and intramuscular administration, orbifloxacin achieved maximum plasma concentrations of 1.85 +/- 0.20 and 1.66 +/- 0.14 mg/L at 1.25 +/- 0.22 and 0.87 +/- 0.38 h, respectively.","Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699040/),[mg] / [l],1.85,129828,DB00537,Ciprofloxacin
,17699040,maximum plasma concentrations,"Following subcutaneous and intramuscular administration, orbifloxacin achieved maximum plasma concentrations of 1.85 +/- 0.20 and 1.66 +/- 0.14 mg/L at 1.25 +/- 0.22 and 0.87 +/- 0.38 h, respectively.","Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699040/),[mg] / [l],1.66,129829,DB00537,Ciprofloxacin
,17699040,absolute bioavailabilities,"The absolute bioavailabilities after subcutaneous and intramuscular routes were 108.96 +/- 17.61% and 105.01 +/- 15.61%, respectively.","Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699040/),%,108.96,129830,DB00537,Ciprofloxacin
,17699040,absolute bioavailabilities,"The absolute bioavailabilities after subcutaneous and intramuscular routes were 108.96 +/- 17.61% and 105.01 +/- 15.61%, respectively.","Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699040/),%,105.01,129831,DB00537,Ciprofloxacin
,23486710,maximum waiting time for blood draw,"For ciprofloxacin and piperacillin-tazobactam, which were only incompletely neutralized in combination with the most sensitive test strains, a maximum waiting time for blood draw of 1 h was determined based on pharmacokinetics.",Neutralization of antimicrobial substances in new BacT/Alert FA and FN Plus blood culture bottles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23486710/),h,1,129879,DB00537,Ciprofloxacin
,19753704,Concentrations,"Concentrations in the cerebral cortex, cerebrospinal fluid, skin, and prostate were 5.7, 5.3, 9.2, and 23.5 microg/ml, respectively.",Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19753704/),[μg] / [ml],5.7,130251,DB00537,Ciprofloxacin
,19753704,Concentrations,"Concentrations in the cerebral cortex, cerebrospinal fluid, skin, and prostate were 5.7, 5.3, 9.2, and 23.5 microg/ml, respectively.",Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19753704/),[μg] / [ml],5.3,130252,DB00537,Ciprofloxacin
,19753704,Concentrations,"Concentrations in the cerebral cortex, cerebrospinal fluid, skin, and prostate were 5.7, 5.3, 9.2, and 23.5 microg/ml, respectively.",Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19753704/),[μg] / [ml],9.2,130253,DB00537,Ciprofloxacin
,19753704,Concentrations,"Concentrations in the cerebral cortex, cerebrospinal fluid, skin, and prostate were 5.7, 5.3, 9.2, and 23.5 microg/ml, respectively.",Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19753704/),[μg] / [ml],23.5,130254,DB00537,Ciprofloxacin
,19753704,inhibitory quotient,An inhibitory quotient of 8 or more was achieved for enrofloxacin in the majority of tissues studied.,Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19753704/),,8,130255,DB00537,Ciprofloxacin
,10722485,half-life [t(1/2)],"With each organism, a series of monoexponential pharmacokinetic profiles of GA (half-life [t(1/2)], 7 h) and CI (t(1/2) = 4 h) were simulated to mimic different single doses of GA and two 12-h doses of CI.",Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),h,7,130968,DB00537,Ciprofloxacin
,10722485,t(1/2),"With each organism, a series of monoexponential pharmacokinetic profiles of GA (half-life [t(1/2)], 7 h) and CI (t(1/2) = 4 h) were simulated to mimic different single doses of GA and two 12-h doses of CI.",Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),h,4,130969,DB00537,Ciprofloxacin
,10722485,ratios of the area under the concentration-time curve (AUC) to the MIC,The respective eightfold ranges of the ratios of the area under the concentration-time curve (AUC) to the MIC were 58 to 466 and 116 to 932 (microg. h/ml)/(microg/ml).,Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[h·ml·μg] / [ml·μg],58 to 466,130970,DB00537,Ciprofloxacin
,10722485,ratios of the area under the concentration-time curve (AUC) to the MIC,The respective eightfold ranges of the ratios of the area under the concentration-time curve (AUC) to the MIC were 58 to 466 and 116 to 932 (microg. h/ml)/(microg/ml).,Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[h·ml·μg] / [ml·μg],116 to 932,130971,DB00537,Ciprofloxacin
,10722485,AUC/MIC ratio,The predicted AUC/MIC ratio for GA that might be equivalent to a clinically relevant AUC/MIC breakpoint for CI was estimated to be 102 rather than 125 (microg. h/ml)/(microg/ml).,Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[h·ml·μg] / [ml·μg],102,130972,DB00537,Ciprofloxacin
,10722485,AUC/MIC ratio,The predicted AUC/MIC ratio for GA that might be equivalent to a clinically relevant AUC/MIC breakpoint for CI was estimated to be 102 rather than 125 (microg. h/ml)/(microg/ml).,Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[h·ml·μg] / [ml·μg],125,130973,DB00537,Ciprofloxacin
,10722485,AUC/MIC,The predicted AUC/MIC ratio for GA that might be equivalent to a clinically relevant AUC/MIC breakpoint for CI was estimated to be 102 rather than 125 (microg. h/ml)/(microg/ml).,Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[h·ml·μg] / [ml·μg],102,130974,DB00537,Ciprofloxacin
,10722485,AUC/MIC,The predicted AUC/MIC ratio for GA that might be equivalent to a clinically relevant AUC/MIC breakpoint for CI was estimated to be 102 rather than 125 (microg. h/ml)/(microg/ml).,Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[h·ml·μg] / [ml·μg],125,130975,DB00537,Ciprofloxacin
,10722485,MIC,The respective MIC breakpoints were 0.32 microg/ml (for a 400-mg dose of GA) and 0.18 microg/ml (for two 500-mg doses of CI).,Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[μg] / [ml],0.32,130976,DB00537,Ciprofloxacin
,10722485,MIC,The respective MIC breakpoints were 0.32 microg/ml (for a 400-mg dose of GA) and 0.18 microg/ml (for two 500-mg doses of CI).,Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[μg] / [ml],0.18,130977,DB00537,Ciprofloxacin
,10722485,I(E),"To provide an ""acceptable"" I(E) equal to 200 (log CFU/ml).",Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[cfu·log] / [ml],200,130978,DB00537,Ciprofloxacin
,10722485,AUC/MIC,"h, i.e., the I(E) provided by AUC/MIC of 125 (microg. h/ml)/(microg/ml) for ciprofloxacin, the D(24h)s of GA for all three organisms were much lower (115, 30, and 60 mg) than the clinically proposed 400-mg dose.",Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722485/),[h·ml·μg] / [ml·μg],125,130979,DB00537,Ciprofloxacin
,25155587,AUC/MIC,"Monte Carlo simulation demonstrated that 90% of hypothetical newborns with a PMA of <34 weeks treated with 7.5 mg/kg twice daily and 84% of newborns with a PMA ≥34 weeks and young infants receiving 12.5 mg/kg twice daily would reach the AUC/MIC target of 125, using the standard EUCAST MIC susceptibility breakpoint of 0.5 mg/liter.",Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25155587/),,125,131105,DB00537,Ciprofloxacin
,25155587,MIC susceptibility,"Monte Carlo simulation demonstrated that 90% of hypothetical newborns with a PMA of <34 weeks treated with 7.5 mg/kg twice daily and 84% of newborns with a PMA ≥34 weeks and young infants receiving 12.5 mg/kg twice daily would reach the AUC/MIC target of 125, using the standard EUCAST MIC susceptibility breakpoint of 0.5 mg/liter.",Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25155587/),[mg] / [l],0.5,131106,DB00537,Ciprofloxacin
,8619569,50% protective doses,"In a model of murine pneumonia, trovafloxacin was more efficacious than temafloxacin, while ciprofloxacin failed against S. pneumoniae (50% protective doses, 2.1, 29.5, and >100 mg/kg, respectively).","In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619569/),[mg] / [kg],2.1,131231,DB00537,Ciprofloxacin
,8619569,50% protective doses,"In a model of murine pneumonia, trovafloxacin was more efficacious than temafloxacin, while ciprofloxacin failed against S. pneumoniae (50% protective doses, 2.1, 29.5, and >100 mg/kg, respectively).","In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619569/),[mg] / [kg],29,131232,DB00537,Ciprofloxacin
,2311444,serum half-life,The ciprofloxacin serum half-life in healthy volunteers was 3.9 +/- 0.4 h and in patients with marked renal failure 11.2 +/- 2.5 h.,Transintestinal elimination of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311444/),h,3.9,132302,DB00537,Ciprofloxacin
,2311444,serum half-life,The ciprofloxacin serum half-life in healthy volunteers was 3.9 +/- 0.4 h and in patients with marked renal failure 11.2 +/- 2.5 h.,Transintestinal elimination of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311444/),h,11.2,132303,DB00537,Ciprofloxacin
,8288206,peak serum concentration,"The mean peak serum concentration, time to peak concentration and the area under the curve were 4.17 +/- 1.05mg/L, 1.75 +/- 0.40h and 18.09 +/- 2.69mg/L.h respectively after oral administration of 500mg of ciprofloxacin tablet.",[Pharmacokinetics of ciprofloxacin in young healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8288206/),[mg] / [l],4.17,132768,DB00537,Ciprofloxacin
,8288206,time to peak concentration,"The mean peak serum concentration, time to peak concentration and the area under the curve were 4.17 +/- 1.05mg/L, 1.75 +/- 0.40h and 18.09 +/- 2.69mg/L.h respectively after oral administration of 500mg of ciprofloxacin tablet.",[Pharmacokinetics of ciprofloxacin in young healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8288206/),h,1.75,132769,DB00537,Ciprofloxacin
,8288206,area under the curve,"The mean peak serum concentration, time to peak concentration and the area under the curve were 4.17 +/- 1.05mg/L, 1.75 +/- 0.40h and 18.09 +/- 2.69mg/L.h respectively after oral administration of 500mg of ciprofloxacin tablet.",[Pharmacokinetics of ciprofloxacin in young healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8288206/),[mg] / [h·l],18.09,132770,DB00537,Ciprofloxacin
,8288206,elimination half life,The elimination half life was 2.34 +/- 0.81h and the apparent volume of distribution was 3.71 +/- 0.75L.,[Pharmacokinetics of ciprofloxacin in young healthy volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8288206/),h,2.34,132771,DB00537,Ciprofloxacin
,8288206,apparent volume of distribution,The elimination half life was 2.34 +/- 0.81h and the apparent volume of distribution was 3.71 +/- 0.75L.,[Pharmacokinetics of ciprofloxacin in young healthy volunteers]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8288206/),l,3.71,132772,DB00537,Ciprofloxacin
,8288206,urinary rate,The urinary rate of ciprofloxacin over 24h after dosing was 34.22 +/- 6.57%.,[Pharmacokinetics of ciprofloxacin in young healthy volunteers]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8288206/),%,34.22,132773,DB00537,Ciprofloxacin
,8807050,maximum observed concentrations,"The maximum observed concentrations (mean +/- standard deviation) of azithromycin, clarithromycin, 14H, ciprofloxacin, and cefuroxime in serum were 0.13 +/- 0.07, 1.0 +/- 0.6, 0.60 +/- 0.41, 0.95 +/- 0.32, and 1.1 +/- 0.3 microgram/ml, respectively (all at 6 h).","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[μg] / [ml],0.13,133200,DB00537,Ciprofloxacin
,8807050,maximum observed concentrations,"The maximum observed concentrations (mean +/- standard deviation) of azithromycin, clarithromycin, 14H, ciprofloxacin, and cefuroxime in serum were 0.13 +/- 0.07, 1.0 +/- 0.6, 0.60 +/- 0.41, 0.95 +/- 0.32, and 1.1 +/- 0.3 microgram/ml, respectively (all at 6 h).","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[μg] / [ml],1.0,133201,DB00537,Ciprofloxacin
,8807050,maximum observed concentrations,"The maximum observed concentrations (mean +/- standard deviation) of azithromycin, clarithromycin, 14H, ciprofloxacin, and cefuroxime in serum were 0.13 +/- 0.07, 1.0 +/- 0.6, 0.60 +/- 0.41, 0.95 +/- 0.32, and 1.1 +/- 0.3 microgram/ml, respectively (all at 6 h).","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[μg] / [ml],0.60,133202,DB00537,Ciprofloxacin
,8807050,maximum observed concentrations,"The maximum observed concentrations (mean +/- standard deviation) of azithromycin, clarithromycin, 14H, ciprofloxacin, and cefuroxime in serum were 0.13 +/- 0.07, 1.0 +/- 0.6, 0.60 +/- 0.41, 0.95 +/- 0.32, and 1.1 +/- 0.3 microgram/ml, respectively (all at 6 h).","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[μg] / [ml],0.95,133203,DB00537,Ciprofloxacin
,8807050,maximum observed concentrations,"The maximum observed concentrations (mean +/- standard deviation) of azithromycin, clarithromycin, 14H, ciprofloxacin, and cefuroxime in serum were 0.13 +/- 0.07, 1.0 +/- 0.6, 0.60 +/- 0.41, 0.95 +/- 0.32, and 1.1 +/- 0.3 microgram/ml, respectively (all at 6 h).","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[μg] / [ml],1.1,133204,DB00537,Ciprofloxacin
,8807050,area under the curve,"In ACs azithromycin was not detectable at 6 h, reached its highest concentration at 120 h, and exhibited the greatest area under the curve (7,403 micrograms.hr ml-1).","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[h·μg] / [ml],"7,403",133205,DB00537,Ciprofloxacin
,8807050,peak concentration,"The peak concentration of clarithromycin (181 +/- 94.1 micrograms/ml) was greater and occurred earlier (6 h), but the area under the curve (2,006 micrograms.hr ml-1) was less than that observed for azithromycin.","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[μg] / [ml],181,133206,DB00537,Ciprofloxacin
,8807050,area under the curve,"The peak concentration of clarithromycin (181 +/- 94.1 micrograms/ml) was greater and occurred earlier (6 h), but the area under the curve (2,006 micrograms.hr ml-1) was less than that observed for azithromycin.","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[h·μg] / [ml],"2,006",133207,DB00537,Ciprofloxacin
,8807050,peak concentration,"The peak concentration of ciprofloxacin occurred at 6 h (4.3 +/- 5.2 micrograms/ml), and the area under the curve was 35.0 micrograms.hr ml-1.","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[μg] / [ml],4.3,133208,DB00537,Ciprofloxacin
,8807050,area under the curve,"The peak concentration of ciprofloxacin occurred at 6 h (4.3 +/- 5.2 micrograms/ml), and the area under the curve was 35.0 micrograms.hr ml-1.","Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807050/),[h·μg] / [ml],35.0,133209,DB00537,Ciprofloxacin
,11334149,peak concentrations (Cmax),"The peak concentrations (Cmax) of enrofloxacin (1.13 microg/ml) and ciprofloxacin (0.24 microg/ml) were observed at 0.8 and 1.2 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),[μg] / [ml],1.13,133260,DB00537,Ciprofloxacin
,11334149,peak concentrations (Cmax),"The peak concentrations (Cmax) of enrofloxacin (1.13 microg/ml) and ciprofloxacin (0.24 microg/ml) were observed at 0.8 and 1.2 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),[μg] / [ml],0.24,133261,DB00537,Ciprofloxacin
,11334149,elimination half-life (t1/2beta),"The elimination half-life (t1/2beta), volume of distribution (Vd(area)), total body clearance (Cl(B)) and mean residence time (MRT) of enrofloxacin were 0.74 h, 1.42 L/kg, 1329 ml/h per kg and 1.54 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),h,0.74,133262,DB00537,Ciprofloxacin
,11334149,volume of distribution (Vd(area)),"The elimination half-life (t1/2beta), volume of distribution (Vd(area)), total body clearance (Cl(B)) and mean residence time (MRT) of enrofloxacin were 0.74 h, 1.42 L/kg, 1329 ml/h per kg and 1.54 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),[l] / [kg],1.42,133263,DB00537,Ciprofloxacin
,11334149,volume of distribution (Vd(area)),"The elimination half-life (t1/2beta), volume of distribution (Vd(area)), total body clearance (Cl(B)) and mean residence time (MRT) of enrofloxacin were 0.74 h, 1.42 L/kg, 1329 ml/h per kg and 1.54 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),[ml] / [h·kg],1329,133264,DB00537,Ciprofloxacin
,11334149,total body clearance (Cl(B)),"The elimination half-life (t1/2beta), volume of distribution (Vd(area)), total body clearance (Cl(B)) and mean residence time (MRT) of enrofloxacin were 0.74 h, 1.42 L/kg, 1329 ml/h per kg and 1.54 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),[l] / [kg],1.42,133265,DB00537,Ciprofloxacin
,11334149,total body clearance (Cl(B)),"The elimination half-life (t1/2beta), volume of distribution (Vd(area)), total body clearance (Cl(B)) and mean residence time (MRT) of enrofloxacin were 0.74 h, 1.42 L/kg, 1329 ml/h per kg and 1.54 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),[ml] / [h·kg],1329,133266,DB00537,Ciprofloxacin
,11334149,mean residence time (MRT),"The elimination half-life (t1/2beta), volume of distribution (Vd(area)), total body clearance (Cl(B)) and mean residence time (MRT) of enrofloxacin were 0.74 h, 1.42 L/kg, 1329 ml/h per kg and 1.54 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),h,1.54,133267,DB00537,Ciprofloxacin
,11334149,t1/2beta,"The t1/2beta, area under the plasma concentration-time curve (AUC) and the MRT of ciprofloxacin were 1.38 h, 0.74 microg h/ml and 2.73 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),h,1.38,133268,DB00537,Ciprofloxacin
,11334149,area under the plasma concentration-time curve (AUC),"The t1/2beta, area under the plasma concentration-time curve (AUC) and the MRT of ciprofloxacin were 1.38 h, 0.74 microg h/ml and 2.73 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),[h·μg] / [ml],0.74,133269,DB00537,Ciprofloxacin
,11334149,MRT,"The t1/2beta, area under the plasma concentration-time curve (AUC) and the MRT of ciprofloxacin were 1.38 h, 0.74 microg h/ml and 2.73 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334149/),h,2.73,133270,DB00537,Ciprofloxacin
,31325172,maximum ENF concentration (Cmax ),"After oral administration, the maximum ENF concentration (Cmax ) of 10.99 μg/ml was obtained at 0.60 hr.",Pharmacokinetics and tissue residues of enrofloxacin in the largemouth bass (Micropterus salmoides) after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325172/),[μg] / [ml],10.99,133457,DB00537,Ciprofloxacin
,31325172,absorption half-life (T1/2Ka ),The absorption half-life (T1/2Ka ) of ENF was calculated to be 0.07 hr whereas the elimination half-life (T1/2β ) of the drug was 90.79 hr.,Pharmacokinetics and tissue residues of enrofloxacin in the largemouth bass (Micropterus salmoides) after oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325172/),h,0.07,133458,DB00537,Ciprofloxacin
,31325172,elimination half-life (T1/2β ),The absorption half-life (T1/2Ka ) of ENF was calculated to be 0.07 hr whereas the elimination half-life (T1/2β ) of the drug was 90.79 hr.,Pharmacokinetics and tissue residues of enrofloxacin in the largemouth bass (Micropterus salmoides) after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325172/),h,90.79,133459,DB00537,Ciprofloxacin
,31325172,area under the plasma concentration-time curve (AUC),"The estimates of area under the plasma concentration-time curve (AUC) and apparent volume of distribution (Vd/F) were 1,185.73 μg hr/ml and 2.21 L/kg, respectively.",Pharmacokinetics and tissue residues of enrofloxacin in the largemouth bass (Micropterus salmoides) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325172/),[h·μg] / [ml],"1,185.73",133460,DB00537,Ciprofloxacin
,31325172,apparent volume of distribution (Vd/F),"The estimates of area under the plasma concentration-time curve (AUC) and apparent volume of distribution (Vd/F) were 1,185.73 μg hr/ml and 2.21 L/kg, respectively.",Pharmacokinetics and tissue residues of enrofloxacin in the largemouth bass (Micropterus salmoides) after oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325172/),[l] / [kg],2.21,133461,DB00537,Ciprofloxacin
,31325172,T1/2β,"ENF residues were slowly depleted from the liver and muscle plus skin of largemouth bass with the T1/2β of 124.73 and 115.14 hr, respectively.",Pharmacokinetics and tissue residues of enrofloxacin in the largemouth bass (Micropterus salmoides) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325172/),h,124.73,133462,DB00537,Ciprofloxacin
,31325172,T1/2β,"ENF residues were slowly depleted from the liver and muscle plus skin of largemouth bass with the T1/2β of 124.73 and 115.14 hr, respectively.",Pharmacokinetics and tissue residues of enrofloxacin in the largemouth bass (Micropterus salmoides) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325172/),h,115.14,133463,DB00537,Ciprofloxacin
,31325172,maximal residue limit (MRL),A withdrawal time of 24 days was necessary to ensure that the residues of ENF + CIP in muscle plus skin were less than the maximal residue limit (MRL) of 100 μg/kg established by the European Union.,Pharmacokinetics and tissue residues of enrofloxacin in the largemouth bass (Micropterus salmoides) after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325172/),[μg] / [kg],100,133464,DB00537,Ciprofloxacin
,17186841,maximum concentration/minimum inhibitory concentration [Cmax/MIC],"Using microtube-dilution procedures, percent resistance and 2 pharmacodynamic/pharmacokinetic indices (maximum concentration/minimum inhibitory concentration [Cmax/MIC] [target 0.10] and area under curve/minimum inhibitory concentration [AUC/MIC] [target 0.125]) were compared prospectively at low and high doses (mg/kg) for ciprofloxacin (5 and 20), difloxacin (5 and 10), enrofloxacin (including enrofloxacin+ciprofloxacin) (5 and 20), marbofloxacin (2.5 and 5), and orbifloxacin (2.5 and 7.5).",Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17186841/),,0.10,133638,DB00537,Ciprofloxacin
,17186841,area under curve/minimum inhibitory concentration [AUC/MIC],"Using microtube-dilution procedures, percent resistance and 2 pharmacodynamic/pharmacokinetic indices (maximum concentration/minimum inhibitory concentration [Cmax/MIC] [target 0.10] and area under curve/minimum inhibitory concentration [AUC/MIC] [target 0.125]) were compared prospectively at low and high doses (mg/kg) for ciprofloxacin (5 and 20), difloxacin (5 and 10), enrofloxacin (including enrofloxacin+ciprofloxacin) (5 and 20), marbofloxacin (2.5 and 5), and orbifloxacin (2.5 and 7.5).",Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17186841/),,0.125,133639,DB00537,Ciprofloxacin
,17186841,Percent resistance,Percent resistance for all Gram-negative (n = 180; 20+/-3%; 39+/-5% for Escherichia coli) and Gram-positive isolates (n = 66; 18+/-3%) did not differ among drugs or organisms.,Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17186841/),%,20,133640,DB00537,Ciprofloxacin
,17186841,Percent resistance,Percent resistance for all Gram-negative (n = 180; 20+/-3%; 39+/-5% for Escherichia coli) and Gram-positive isolates (n = 66; 18+/-3%) did not differ among drugs or organisms.,Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17186841/),%,39,133641,DB00537,Ciprofloxacin
,17186841,Percent resistance,Percent resistance for all Gram-negative (n = 180; 20+/-3%; 39+/-5% for Escherichia coli) and Gram-positive isolates (n = 66; 18+/-3%) did not differ among drugs or organisms.,Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17186841/),%,18,133642,DB00537,Ciprofloxacin
,11062191,T:1/2,"With each organism, a series of monoexponential pharmacokinetic profiles of single doses of moxifloxacin (T:1/2 = 12.1 h) and levofloxacin (T:(1/2) = 6.8 h) were simulated.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),h,12.1,133707,DB00537,Ciprofloxacin
,11062191,T:(1/2),"With each organism, a series of monoexponential pharmacokinetic profiles of single doses of moxifloxacin (T:1/2 = 12.1 h) and levofloxacin (T:(1/2) = 6.8 h) were simulated.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),h,6.8,133708,DB00537,Ciprofloxacin
,11062191,ratios of area under the concentration-time curve (AUC) to the MIC,The respective eight-fold ranges of the ratios of area under the concentration-time curve (AUC) to the MIC were 58-475 and 114-934.,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,58-475,133709,DB00537,Ciprofloxacin
,11062191,ratios of area under the concentration-time curve (AUC) to the MIC,The respective eight-fold ranges of the ratios of area under the concentration-time curve (AUC) to the MIC were 58-475 and 114-934.,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,114-934,133710,DB00537,Ciprofloxacin
,11062191,AUC/MIC ratios,"The predicted AUC/MIC ratios for moxifloxacin and levofloxacin that might be equivalent to Schentag's AUC/MIC breakpoint for ciprofloxacin (125) were estimated at 80 and 130, respectively.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,80,133711,DB00537,Ciprofloxacin
,11062191,AUC/MIC ratios,"The predicted AUC/MIC ratios for moxifloxacin and levofloxacin that might be equivalent to Schentag's AUC/MIC breakpoint for ciprofloxacin (125) were estimated at 80 and 130, respectively.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,130,133712,DB00537,Ciprofloxacin
,11062191,MIC,The respective equivalent MIC breakpoints were 0.41 mg/L (for a 400 mg dose of moxifloxacin) and 0.35 mg/L (for a 500 mg dose of levofloxacin).,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),[mg] / [l],0.41,133713,DB00537,Ciprofloxacin
,11062191,MIC,The respective equivalent MIC breakpoints were 0.41 mg/L (for a 400 mg dose of moxifloxacin) and 0.35 mg/L (for a 500 mg dose of levofloxacin).,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),[mg] / [l],0.35,133714,DB00537,Ciprofloxacin
,11062191,I:(E),"To provide an 'acceptable' I:(E) = 200 (log cfu/mL)*h, the D:(24)s of moxifloxacin for all three organisms were much lower (150, 30 and 60 mg, respectively) than the clinically proposed 400 mg dose.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,200,133715,DB00537,Ciprofloxacin
,22738062,peak plasma concentration,"When ciprofloxacin was administered as tablets PO, peak plasma concentration was 4.4 μg/mL (coefficient of variation [CV], 55.9%), terminal half-life (t(1/2)) was 2.6 hours (CV, 10.8%), area under the time-concentration curve was 22.5 μg•h/mL (CV, 62.3%), and systemic absorption was 58.4% (CV, 45.4%).",Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738062/),[μg] / [ml],4.4,135116,DB00537,Ciprofloxacin
,22738062,terminal half-life (t(1/2)),"When ciprofloxacin was administered as tablets PO, peak plasma concentration was 4.4 μg/mL (coefficient of variation [CV], 55.9%), terminal half-life (t(1/2)) was 2.6 hours (CV, 10.8%), area under the time-concentration curve was 22.5 μg•h/mL (CV, 62.3%), and systemic absorption was 58.4% (CV, 45.4%).",Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738062/),h,2.6,135117,DB00537,Ciprofloxacin
,22738062,area under the time-concentration curve,"When ciprofloxacin was administered as tablets PO, peak plasma concentration was 4.4 μg/mL (coefficient of variation [CV], 55.9%), terminal half-life (t(1/2)) was 2.6 hours (CV, 10.8%), area under the time-concentration curve was 22.5 μg•h/mL (CV, 62.3%), and systemic absorption was 58.4% (CV, 45.4%).",Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738062/),[h·μg] / [ml],22.5,135118,DB00537,Ciprofloxacin
,22738062,t(1/2),"For the dose administered IV, t(1/2) was 3.7 hours (CV, 52.3%), clearance was 0.588 L/kg/h (CV, 33.9%), and volume of distribution was 2.39 L/kg (CV, 23.7%).",Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738062/),h,3.7,135119,DB00537,Ciprofloxacin
,22738062,clearance,"For the dose administered IV, t(1/2) was 3.7 hours (CV, 52.3%), clearance was 0.588 L/kg/h (CV, 33.9%), and volume of distribution was 2.39 L/kg (CV, 23.7%).",Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738062/),[l] / [h·kg],0.588,135120,DB00537,Ciprofloxacin
,22738062,volume of distribution,"For the dose administered IV, t(1/2) was 3.7 hours (CV, 52.3%), clearance was 0.588 L/kg/h (CV, 33.9%), and volume of distribution was 2.39 L/kg (CV, 23.7%).",Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738062/),[l] / [kg],2.39,135121,DB00537,Ciprofloxacin
,22738062,t(1/2),"After PO administration as a solution versus IV administration, plasma concentrations were more uniform and consistent among dogs, with absorption of 71% (CV, 7.3%), t(1/2) of 3.1 hours (CV, 18.6%), and peak plasma concentration of 4.67 μg/mL (CV, 17.6%).",Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738062/),h,3.1,135122,DB00537,Ciprofloxacin
,22738062,peak plasma concentration,"After PO administration as a solution versus IV administration, plasma concentrations were more uniform and consistent among dogs, with absorption of 71% (CV, 7.3%), t(1/2) of 3.1 hours (CV, 18.6%), and peak plasma concentration of 4.67 μg/mL (CV, 17.6%).",Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738062/),[μg] / [ml],4.67,135123,DB00537,Ciprofloxacin
≤,22738062,minimum inhibitory concentration,"Because of the wide range in oral absorption of tablets, the dose needed to reach the pharmacokinetic-pharmacodynamic target concentration in this study ranged from 12 to 52 mg/kg (CV, 102%), with a mean dose of 25 mg/kg, once daily, for bacteria with a minimum inhibitory concentration ≤ 0.25 μg/mL.",Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738062/),[μg] / [ml],0.25,135124,DB00537,Ciprofloxacin
,8453847,maximum concentration,The average maximum concentration of ciprofloxacin alone was 3.38 +/- 0.63 (SD) micrograms/ml compared with 0.25 +/- 0.21 (SD) micrograms/ml when ciprofloxacin was administered with the didanosine placebo (p < 0.0001).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),[μg] / [ml],3.38,135141,DB00537,Ciprofloxacin
,8453847,maximum concentration,The average maximum concentration of ciprofloxacin alone was 3.38 +/- 0.63 (SD) micrograms/ml compared with 0.25 +/- 0.21 (SD) micrograms/ml when ciprofloxacin was administered with the didanosine placebo (p < 0.0001).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),[μg] / [ml],0.25,135142,DB00537,Ciprofloxacin
,8453847,area under the plasma drug concentration-time curve from time 0 to the last measurable concentration,The mean (+/- SD) area under the plasma drug concentration-time curve from time 0 to the last measurable concentration for ciprofloxacin alone was 15.50 +/- 2.69 micrograms.hr/ml compared with 0.26 +/- 0.21 micrograms.hr/ml when ciprofloxacin was coadministered with the didanosine-placebo (p < 0.0001).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),[h·μg] / [ml],15.50,135143,DB00537,Ciprofloxacin
,8453847,area under the plasma drug concentration-time curve from time 0 to the last measurable concentration,The mean (+/- SD) area under the plasma drug concentration-time curve from time 0 to the last measurable concentration for ciprofloxacin alone was 15.50 +/- 2.69 micrograms.hr/ml compared with 0.26 +/- 0.21 micrograms.hr/ml when ciprofloxacin was coadministered with the didanosine-placebo (p < 0.0001).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),[h·μg] / [ml],0.26,135144,DB00537,Ciprofloxacin
,8453847,time to maximum concentration,The mean time to maximum concentration of ciprofloxacin alone decreased from 1.56 +/- 0.62 to 0.75 +/- 0.38 hours with buffer administration (p = 0.0012).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),h,1.56,135145,DB00537,Ciprofloxacin
,8453847,time to maximum concentration,The mean time to maximum concentration of ciprofloxacin alone decreased from 1.56 +/- 0.62 to 0.75 +/- 0.38 hours with buffer administration (p = 0.0012).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),h,0.75,135146,DB00537,Ciprofloxacin
,8157551,peak serum concentrations,"Mean peak serum concentrations were 4.48 and 5.44 mg/L for i.v. ciprofloxacin and ofloxacin, respectively.",Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157551/),[mg] / [l],4.48,135187,DB00537,Ciprofloxacin
,8157551,peak serum concentrations,"Mean peak serum concentrations were 4.48 and 5.44 mg/L for i.v. ciprofloxacin and ofloxacin, respectively.",Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157551/),[mg] / [l],5.44,135188,DB00537,Ciprofloxacin
,8157551,peak serum concentrations,"For the oral regimens, mean peak serum concentrations were 2.45 mg/L for ciprofloxacin and 4.44 mg/L for ofloxacin.",Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157551/),[mg] / [l],2.45,135189,DB00537,Ciprofloxacin
,8157551,peak serum concentrations,"For the oral regimens, mean peak serum concentrations were 2.45 mg/L for ciprofloxacin and 4.44 mg/L for ofloxacin.",Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157551/),[mg] / [l],4.44,135190,DB00537,Ciprofloxacin
> or =,8157551,peak SBA,"For the i.v. and oral regimens of both agents, peak SBA was > or = 2 throughout the 12-hour test period against the Enterobacteriaceae and H. influenzae.",Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157551/),,2,135191,DB00537,Ciprofloxacin
,12161971,elimination half-life (t1/2 beta),The elimination half-life (t1/2 beta) was 6.3 +/- 0.11 h.,Pharmacokinetics of difloxacin in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12161971/),h,6.3,135676,DB00537,Ciprofloxacin
,12161971,volume of distribution at steady-state (Vdss),The volume of distribution at steady-state (Vdss) was 1.1 +/- 0.012 L/kg and the total body clearance (Cltot) was 0.13 +/- 0.001 L/kg/h.,Pharmacokinetics of difloxacin in goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12161971/),[l] / [kg],1.1,135677,DB00537,Ciprofloxacin
,12161971,total body clearance (Cltot),The volume of distribution at steady-state (Vdss) was 1.1 +/- 0.012 L/kg and the total body clearance (Cltot) was 0.13 +/- 0.001 L/kg/h.,Pharmacokinetics of difloxacin in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12161971/),[l] / [h·kg],0.13,135678,DB00537,Ciprofloxacin
,12161971,peak serum concentration,"Following a single i.m. administration, difloxacin was rapidly absorbed and the mean peak serum concentration (4.1 +/- 0.23 micrograms/ml) was achieved 1 h post administration.",Pharmacokinetics of difloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12161971/),[μg] / [ml],4.1,135679,DB00537,Ciprofloxacin
,12161971,serum protein binding,The extent of serum protein binding of difloxacin in goats was 13.79 +/- 1.02% and the systemic availability was 95.4 +/- 1.17%.,Pharmacokinetics of difloxacin in goats. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12161971/),%,13.79,135680,DB00537,Ciprofloxacin
,12161971,systemic availability,The extent of serum protein binding of difloxacin in goats was 13.79 +/- 1.02% and the systemic availability was 95.4 +/- 1.17%.,Pharmacokinetics of difloxacin in goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12161971/),%,95.4,135681,DB00537,Ciprofloxacin
,2791447,total body clearance of drug,"Bayesian-derived parameter estimates were total body clearance of drug from plasma, 29.8 L/hr/1.73 m2; renal clearance, 17.0 L/hr/1.73 m2; and nonrenal clearance, 12.7 L/hr/1.73 m2 and were not significantly different from noncompartmentally derived parameters (p = 0.80, p = 0.65 and p = 0.333, respectively).",Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791447/),[l] / [1.73·h·m2],29.8,135996,DB00537,Ciprofloxacin
,2791447,renal clearance,"Bayesian-derived parameter estimates were total body clearance of drug from plasma, 29.8 L/hr/1.73 m2; renal clearance, 17.0 L/hr/1.73 m2; and nonrenal clearance, 12.7 L/hr/1.73 m2 and were not significantly different from noncompartmentally derived parameters (p = 0.80, p = 0.65 and p = 0.333, respectively).",Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791447/),[l] / [1.73·h·m2],17.0,135997,DB00537,Ciprofloxacin
,2791447,nonrenal clearance,"Bayesian-derived parameter estimates were total body clearance of drug from plasma, 29.8 L/hr/1.73 m2; renal clearance, 17.0 L/hr/1.73 m2; and nonrenal clearance, 12.7 L/hr/1.73 m2 and were not significantly different from noncompartmentally derived parameters (p = 0.80, p = 0.65 and p = 0.333, respectively).",Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791447/),[l] / [1.73·h·m2],12.7,135998,DB00537,Ciprofloxacin
,3410603,Peak serum concentration (Cmax),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f) and apparent volume of distribution (Vd/f) were 6.58 +/- 2.88 mg/l, 4.99 +/- 1.79 h, 6.69 +/- 3.73 ml/kg/min, and 2.87 +/- 1.86 l/kg, respectively, during the single dose phase.",Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410603/),[mg] / [l],6.58,136213,DB00537,Ciprofloxacin
,3410603,terminal elimination half-life (t1/2 beta),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f) and apparent volume of distribution (Vd/f) were 6.58 +/- 2.88 mg/l, 4.99 +/- 1.79 h, 6.69 +/- 3.73 ml/kg/min, and 2.87 +/- 1.86 l/kg, respectively, during the single dose phase.",Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410603/),h,4.99,136214,DB00537,Ciprofloxacin
,3410603,terminal elimination half-life (t1/2 beta),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f) and apparent volume of distribution (Vd/f) were 6.58 +/- 2.88 mg/l, 4.99 +/- 1.79 h, 6.69 +/- 3.73 ml/kg/min, and 2.87 +/- 1.86 l/kg, respectively, during the single dose phase.",Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410603/),[ml] / [kg·min],6.69,136215,DB00537,Ciprofloxacin
,3410603,apparent total body clearance (CL/f),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f) and apparent volume of distribution (Vd/f) were 6.58 +/- 2.88 mg/l, 4.99 +/- 1.79 h, 6.69 +/- 3.73 ml/kg/min, and 2.87 +/- 1.86 l/kg, respectively, during the single dose phase.",Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410603/),h,4.99,136216,DB00537,Ciprofloxacin
,3410603,apparent total body clearance (CL/f),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f) and apparent volume of distribution (Vd/f) were 6.58 +/- 2.88 mg/l, 4.99 +/- 1.79 h, 6.69 +/- 3.73 ml/kg/min, and 2.87 +/- 1.86 l/kg, respectively, during the single dose phase.",Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410603/),[ml] / [kg·min],6.69,136217,DB00537,Ciprofloxacin
,3410603,apparent volume of distribution (Vd/f),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f) and apparent volume of distribution (Vd/f) were 6.58 +/- 2.88 mg/l, 4.99 +/- 1.79 h, 6.69 +/- 3.73 ml/kg/min, and 2.87 +/- 1.86 l/kg, respectively, during the single dose phase.",Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410603/),[l] / [kg],2.87,136218,DB00537,Ciprofloxacin
,3410603,Vd/f,"Only the Vd/f increased significantly during the multiple dose phase (4.40 +/- 3.32 vs. 2.71 +/- 1.53 l/kg, p = 0.047).",Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410603/),[l] / [kg],4.40,136219,DB00537,Ciprofloxacin
,3410603,Vd/f,"Only the Vd/f increased significantly during the multiple dose phase (4.40 +/- 3.32 vs. 2.71 +/- 1.53 l/kg, p = 0.047).",Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410603/),[l] / [kg],2.71,136220,DB00537,Ciprofloxacin
,21190922,Peak plasma concentration (Cmax),"Peak plasma concentration (Cmax) of ciprofloxacin, 1.77±0.20 µg/ml was achieved at 0.90±0.04 hours (Tmax).",Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21190922/),[μg] / [ml],1.77,136522,DB00537,Ciprofloxacin
,21190922,Tmax,"Peak plasma concentration (Cmax) of ciprofloxacin, 1.77±0.20 µg/ml was achieved at 0.90±0.04 hours (Tmax).",Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21190922/),h,0.90,136523,DB00537,Ciprofloxacin
,21190922,half-life of absorption (t1/2 abs),"Values for half-life of absorption (t1/2 abs), distribution (t1/2 α) and elimination (t1/2 β) were 0.52±0.04, 0.52±0.04 and 2.62±0.39 hours, respectively.",Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21190922/),h,0.52,136524,DB00537,Ciprofloxacin
,21190922,distribution (t1/2 α),"Values for half-life of absorption (t1/2 abs), distribution (t1/2 α) and elimination (t1/2 β) were 0.52±0.04, 0.52±0.04 and 2.62±0.39 hours, respectively.",Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21190922/),h,0.52,136525,DB00537,Ciprofloxacin
,21190922,elimination (t1/2 β),"Values for half-life of absorption (t1/2 abs), distribution (t1/2 α) and elimination (t1/2 β) were 0.52±0.04, 0.52±0.04 and 2.62±0.39 hours, respectively.",Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21190922/),h,2.62,136526,DB00537,Ciprofloxacin
,21190922,apparent volume of distribution (Vd),"The value for apparent volume of distribution (Vd) was 3.76±0.92 l/kg, area-under-the-curve (AUC) 5.89±0.91 µg.hr/ml and total body clearance (CL) was 1.09±0.11 l/hr/kg.",Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21190922/),[l] / [kg],3.76,136527,DB00537,Ciprofloxacin
,21190922,area-under-the-curve (AUC),"The value for apparent volume of distribution (Vd) was 3.76±0.92 l/kg, area-under-the-curve (AUC) 5.89±0.91 µg.hr/ml and total body clearance (CL) was 1.09±0.11 l/hr/kg.",Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21190922/),[h·μg] / [ml],5.89,136528,DB00537,Ciprofloxacin
,21190922,total body clearance (CL),"The value for apparent volume of distribution (Vd) was 3.76±0.92 l/kg, area-under-the-curve (AUC) 5.89±0.91 µg.hr/ml and total body clearance (CL) was 1.09±0.11 l/hr/kg.",Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21190922/),[l] / [h·kg],1.09,136529,DB00537,Ciprofloxacin
,16269597,total,"In muscle tissue, mean total and extracellular peak concentration (C(max)) values of ciprofloxacin of 1.8 +/- 0.4 microg/mL and 0.7 +/- 0.2 microg/mL were attained at 95 +/- 34 min and 48 +/- 20 min after drug administration, respectively.",Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269597/),[μg] / [ml],1.8,136624,DB00537,Ciprofloxacin
,16269597,extracellular peak concentration (C(max)),"In muscle tissue, mean total and extracellular peak concentration (C(max)) values of ciprofloxacin of 1.8 +/- 0.4 microg/mL and 0.7 +/- 0.2 microg/mL were attained at 95 +/- 34 min and 48 +/- 20 min after drug administration, respectively.",Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269597/),[μg] / [ml],0.7,136625,DB00537,Ciprofloxacin
,16269597,rate constant k(3),"The extracellular-to-intracellular exchange appeared to be very fast, with an estimated rate constant k(3) of 1.69 +/- 0.25 min(-1).",Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269597/),1/[min],1.69,136626,DB00537,Ciprofloxacin
,16269597,intracellular-to-extracellular concentration ratio (C(intra)/C(extra)),An intracellular-to-extracellular concentration ratio (C(intra)/C(extra)) of 3.2 +/- 0.8 was reached at 110 min after injection and followed by sustained intracellular retention of the antibiotic for the remainder of the experiment.,Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269597/),,3.2,136627,DB00537,Ciprofloxacin
,3345156,Peak intraocular concentrations,"Peak intraocular concentrations (mean +/- SD), 0.21 +/- 0.1 mg/L, were detected at one hour following ciprofloxacin administration.",Aqueous humor penetration of ciprofloxacin in the human eye. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345156/),[mg] / [l],0.21,137290,DB00537,Ciprofloxacin
,21913940,elimination half-life (T(1/2β)),"The elimination half-life (T(1/2β)), area under the concentration-time curve (AUC) and total body clearance of EF were 63.5 h, 239.6 μg·h/mL and 0.04 L/h/kg, respectively.","Pharmacokinetics of enrofloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913940/),h,63.5,139461,DB00537,Ciprofloxacin
,21913940,area under the concentration-time curve (AUC),"The elimination half-life (T(1/2β)), area under the concentration-time curve (AUC) and total body clearance of EF were 63.5 h, 239.6 μg·h/mL and 0.04 L/h/kg, respectively.","Pharmacokinetics of enrofloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913940/),[h·μg] / [ml],239.6,139462,DB00537,Ciprofloxacin
,21913940,total body clearance,"The elimination half-life (T(1/2β)), area under the concentration-time curve (AUC) and total body clearance of EF were 63.5 h, 239.6 μg·h/mL and 0.04 L/h/kg, respectively.","Pharmacokinetics of enrofloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913940/),[l] / [h·kg],0.04,139463,DB00537,Ciprofloxacin
,21913940,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)), T(1/2β) and AUC of EF were 4.5 μg/mL, 62.7 h and 205.9 μg·h/mL, respectively.","Pharmacokinetics of enrofloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913940/),[μg] / [ml],4.5,139464,DB00537,Ciprofloxacin
,21913940,T(1/2β),"The maximum plasma concentration (C(max)), T(1/2β) and AUC of EF were 4.5 μg/mL, 62.7 h and 205.9 μg·h/mL, respectively.","Pharmacokinetics of enrofloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913940/),h,62.7,139465,DB00537,Ciprofloxacin
,21913940,AUC,"The maximum plasma concentration (C(max)), T(1/2β) and AUC of EF were 4.5 μg/mL, 62.7 h and 205.9 μg·h/mL, respectively.","Pharmacokinetics of enrofloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913940/),[h·μg] / [ml],205.9,139466,DB00537,Ciprofloxacin
,21913940,bioavailability (F),"Absorption of EF was very good with a bioavailability (F) of 86%, which could be correlated with the unique structure of the alimentary canal in allogynogenetic silver crucian.","Pharmacokinetics of enrofloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913940/),%,86,139467,DB00537,Ciprofloxacin
,2707924,Cmax,"Class C patients showed on the other hand a Cmax 15-25% higher than in other groups (2.74 mcg/ml), a T1/2 1.12-1.42 hours longer than in other groups and a consequent much higher AUCtot (17.70 mcg/h/ml).",Pharmacokinetics of ciprofloxacin in impaired liver function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2707924/),[mcg] / [ml],2.74,139942,DB00537,Ciprofloxacin
,2707924,T1/2,"Class C patients showed on the other hand a Cmax 15-25% higher than in other groups (2.74 mcg/ml), a T1/2 1.12-1.42 hours longer than in other groups and a consequent much higher AUCtot (17.70 mcg/h/ml).",Pharmacokinetics of ciprofloxacin in impaired liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2707924/),h,1.12-1.42,139943,DB00537,Ciprofloxacin
,2707924,AUCtot,"Class C patients showed on the other hand a Cmax 15-25% higher than in other groups (2.74 mcg/ml), a T1/2 1.12-1.42 hours longer than in other groups and a consequent much higher AUCtot (17.70 mcg/h/ml).",Pharmacokinetics of ciprofloxacin in impaired liver function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2707924/),[mcg] / [h·ml],17.70,139944,DB00537,Ciprofloxacin
,8591948,Cmax,"There was insignificant absorption after the initial dose, Cmax = 0.6 +/- 0.6 (mg/L) and AUC0-12 = 3.5 +/- 3.2 (mg.h/L).",Enteric absorption of ciprofloxacin during the immediate postoperative period. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591948/),[mg] / [l],0.6,140012,DB00537,Ciprofloxacin
,8591948,AUC0-12,"There was insignificant absorption after the initial dose, Cmax = 0.6 +/- 0.6 (mg/L) and AUC0-12 = 3.5 +/- 3.2 (mg.h/L).",Enteric absorption of ciprofloxacin during the immediate postoperative period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591948/),[h·mg] / [l],3.5,140013,DB00537,Ciprofloxacin
,3555028,peak serum concentration,"Means for peak serum concentration (3.1 to 5.0 micrograms/ml), elimination half-life (4.8 to 5.3 hours), area under the time-concentration curve, and serum clearance (36.8 to 44.5 liter/hour) were similar to previously reported results for patients without cystic fibrosis.",Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555028/),[μg] / [ml],3.1 to 5.0,140461,DB00537,Ciprofloxacin
,3555028,elimination half-life,"Means for peak serum concentration (3.1 to 5.0 micrograms/ml), elimination half-life (4.8 to 5.3 hours), area under the time-concentration curve, and serum clearance (36.8 to 44.5 liter/hour) were similar to previously reported results for patients without cystic fibrosis.",Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555028/),h,4.8 to 5.3,140462,DB00537,Ciprofloxacin
,3555028,serum clearance,"Means for peak serum concentration (3.1 to 5.0 micrograms/ml), elimination half-life (4.8 to 5.3 hours), area under the time-concentration curve, and serum clearance (36.8 to 44.5 liter/hour) were similar to previously reported results for patients without cystic fibrosis.",Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555028/),[l] / [h],36.8 to 44.5,140463,DB00537,Ciprofloxacin
,3555061,Peak ciprofloxacin concentrations,Peak ciprofloxacin concentrations in vivo averaged 3.2 micrograms/ml.,Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555061/),[μg] / [ml],3.2,140722,DB00537,Ciprofloxacin
,3555061,terminal serum elimination half-life,The terminal serum elimination half-life averaged 4.2 hours.,Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555061/),h,4.2,140723,DB00537,Ciprofloxacin
,3555061,serum b,"The median serum bactericidal titer against a strain of Escherichia coli was 1:16 or more for at least six hours after infusion, but was only 1:2 against a strain of Pseudomonas aeruginosa immediately after the end of the infusion.",Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555061/),,1,140724,DB00537,Ciprofloxacin
,9210686,maximum concentration in plasma (Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[ng] / [ml],511,141082,DB00537,Ciprofloxacin
,9210686,maximum concentration in plasma (Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[ng] / [ml],525,141083,DB00537,Ciprofloxacin
,9210686,time at which,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),h,3.0,141084,DB00537,Ciprofloxacin
,9210686,Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),h,3.0,141085,DB00537,Ciprofloxacin
,9210686,Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),h,2.5,141086,DB00537,Ciprofloxacin
,9210686,area under the concentration-time curve from 0 to 24 h (AUC(0-tau)),"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[h·ng] / [ml],"5,650",141087,DB00537,Ciprofloxacin
,9210686,area under the concentration-time curve from 0 to 24 h (AUC(0-tau)),"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[h·ng] / [ml],"5,023",141088,DB00537,Ciprofloxacin
,9210686,oral clearance,"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[l] / [h·kg],1.28,141089,DB00537,Ciprofloxacin
,9210686,oral clearance,"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[l] / [h·kg],1.18,141090,DB00537,Ciprofloxacin
,8863267,log beta 1,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,2.97,141329,DB00537,Ciprofloxacin
,8863267,log beta 2,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,5.6,141330,DB00537,Ciprofloxacin
,8863267,log beta 1,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,3.77,141331,DB00537,Ciprofloxacin
,8863267,log beta 2,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,7.59,141332,DB00537,Ciprofloxacin
,8863267,log beta 1,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,3.99,141333,DB00537,Ciprofloxacin
,8863267,log beta 2,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,7.2,141334,DB00537,Ciprofloxacin
,28223382,MIC90,Omadacycline was active in vitro against Y. pestis (MIC90 of 1 μg/ml) and B. anthracis (MIC90 of 0.06 μg/ml).,"In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223382/),[μg] / [ml],1,141668,DB00537,Ciprofloxacin
,28223382,MIC90,Omadacycline was active in vitro against Y. pestis (MIC90 of 1 μg/ml) and B. anthracis (MIC90 of 0.06 μg/ml).,"In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223382/),[μg] / [ml],0.06,141669,DB00537,Ciprofloxacin
,28223382,MIC90,Omadacycline was less active in vitro than ciprofloxacin (CIP) against Y. pestis (CIP MIC90 of 0.03 μg/ml) but was more potent in vitro against B. anthracis (CIP MIC90 of 0.12 μg/ml).,"In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223382/),[μg] / [ml],0.03,141670,DB00537,Ciprofloxacin
,28223382,MIC90,Omadacycline was less active in vitro than ciprofloxacin (CIP) against Y. pestis (CIP MIC90 of 0.03 μg/ml) but was more potent in vitro against B. anthracis (CIP MIC90 of 0.12 μg/ml).,"In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223382/),[μg] / [ml],0.12,141671,DB00537,Ciprofloxacin
,3176297,distribution volume Vd(area),Pharmacokinetic analysis of IV data showed that ciprofloxacin was well distributed (distribution volume Vd(area): 3.08-5.59 litre/kg) and exhibited a similar elimination half-life of about 14 h in these 3 fish species.,"Pharmacokinetics of ciprofloxacin in carp, African catfish and rainbow trout. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176297/),[l] / [kg],3.08-5.59,141743,DB00537,Ciprofloxacin
,3176297,elimination half-life,Pharmacokinetic analysis of IV data showed that ciprofloxacin was well distributed (distribution volume Vd(area): 3.08-5.59 litre/kg) and exhibited a similar elimination half-life of about 14 h in these 3 fish species.,"Pharmacokinetics of ciprofloxacin in carp, African catfish and rainbow trout. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176297/),h,14,141744,DB00537,Ciprofloxacin
,3176297,maximum ciprofloxacin plasma concentrations,"After IM administration to carp and trout a rapid absorption was noticed; the maximum ciprofloxacin plasma concentrations (mean: 3.49 and 2.37 micrograms/ml, respectively), were achieved within 1 h after injection.","Pharmacokinetics of ciprofloxacin in carp, African catfish and rainbow trout. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176297/),[μg] / [ml],3.49,141745,DB00537,Ciprofloxacin
,3176297,maximum ciprofloxacin plasma concentrations,"After IM administration to carp and trout a rapid absorption was noticed; the maximum ciprofloxacin plasma concentrations (mean: 3.49 and 2.37 micrograms/ml, respectively), were achieved within 1 h after injection.","Pharmacokinetics of ciprofloxacin in carp, African catfish and rainbow trout. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176297/),[μg] / [ml],2.37,141746,DB00537,Ciprofloxacin
,8787874,CL,CL (in liters per hour) was found to be linearly correlated with weight (typical value of CL = 8.8 + 0.396.,Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787874/),[l] / [h],8,142199,DB00537,Ciprofloxacin
,8787874,V2,"V2 and V3 were directly proportional to weight, with slopes of 0.7 and 1.3 liters/kg, respectively.",Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787874/),,0,142200,DB00537,Ciprofloxacin
,8787874,Bioavailability,"Bioavailability (population mean) was estimated to be 61.8%, and renal clearance (population mean) was estimated to be 11.4 liters/h.",Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787874/),%,61.8,142201,DB00537,Ciprofloxacin
,8787874,renal clearance,"Bioavailability (population mean) was estimated to be 61.8%, and renal clearance (population mean) was estimated to be 11.4 liters/h.",Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787874/),[l] / [h],11.4,142202,DB00537,Ciprofloxacin
,8787874,protein binding,"The protein binding was about 34%, which is similar to the results obtained for adults.",Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787874/),%,34,142203,DB00537,Ciprofloxacin
,14733712,corneal,Nalidixic acid had a higher corneal permeability coefficient (17.3 +/- 3.56 x 10(-6) cm/second) than all other drugs tested (p < 0.01).,Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[cm] / [second],17.3,142241,DB00537,Ciprofloxacin
,14733712,permeability coefficient,Nalidixic acid had a higher corneal permeability coefficient (17.3 +/- 3.56 x 10(-6) cm/second) than all other drugs tested (p < 0.01).,Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[cm] / [second],17.3,142242,DB00537,Ciprofloxacin
,14733712,perme,"Comparing the corneal and scleral permeability coefficients, only values for nalidixic acid were not significantly different (17.35 +/- 3.56 x l0(-6) cm/second versus 22.69 +/- 5.19 x 10(-6) cm/second, p > 0.05), while all other drugs had scleral permeability coefficients 8 to 10 times greater than corneal permeability coefficients.",Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[cm] / [(l0)^6·second],17.35,142243,DB00537,Ciprofloxacin
,14733712,perme,"Comparing the corneal and scleral permeability coefficients, only values for nalidixic acid were not significantly different (17.35 +/- 3.56 x l0(-6) cm/second versus 22.69 +/- 5.19 x 10(-6) cm/second, p > 0.05), while all other drugs had scleral permeability coefficients 8 to 10 times greater than corneal permeability coefficients.",Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),,22.69,142244,DB00537,Ciprofloxacin
,14733712,aqueous humor concentration,"The mean aqueous humor concentration of norfloxacin and ciprofloxacin at 60 minutes to 180 minutes after instillation was around 0.3 microg/mL, a value higher than MIC90 of most bacteria.",Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[μg] / [ml],0.3,142245,DB00537,Ciprofloxacin
≤,23147735,MIC(90)s,"SM-295291 and SM-369926 are new parenteral 2-aryl carbapenems with strong activity against major causative pathogens of community-acquired infections such as methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-resistant strains), Streptococcus pyogenes, Enterococcus faecalis, Klebsiella pneumoniae, Moraxella catarrhalis, Haemophilus influenzae (including β-lactamase-negative ampicillin-resistant strains), and Neisseria gonorrhoeae (including ciprofloxacin-resistant strains), with MIC(90)s of ≤ 1 μg/ml.",Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23147735/),[μg] / [ml],1,142832,DB00537,Ciprofloxacin
,23147735,MIC(50),"Unlike tebipenem (MIC(50), 8 μg/ml), SM-295291 and SM-369926 had no activity against hospital pathogens such as Pseudomonas aeruginosa (MIC(50), ≥ 128 μg/ml).",Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23147735/),[μg] / [ml],8,142833,DB00537,Ciprofloxacin
≥,23147735,MIC(50),"Unlike tebipenem (MIC(50), 8 μg/ml), SM-295291 and SM-369926 had no activity against hospital pathogens such as Pseudomonas aeruginosa (MIC(50), ≥ 128 μg/ml).",Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23147735/),[μg] / [ml],128,142834,DB00537,Ciprofloxacin
,23147735,half-life,"SM-295291 and SM-369926 showed intravenous pharmacokinetics similar to those of meropenem in terms of half-life in monkeys (0.4 h) and were stable against human dehydropeptidase I. SM-368589 and SM-375769, which are medoxomil esters of SM-295291 and SM-369926, respectively, showed good oral bioavailability in rats, dogs, and monkeys (4.2 to 62.3%).",Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23147735/),h,0.4,142835,DB00537,Ciprofloxacin
,23147735,oral bioavailability,"SM-295291 and SM-369926 showed intravenous pharmacokinetics similar to those of meropenem in terms of half-life in monkeys (0.4 h) and were stable against human dehydropeptidase I. SM-368589 and SM-375769, which are medoxomil esters of SM-295291 and SM-369926, respectively, showed good oral bioavailability in rats, dogs, and monkeys (4.2 to 62.3%).",Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23147735/),%,4.2 to 62.3,142836,DB00537,Ciprofloxacin
,21302033,peak plasma concentrations (Cmax),"In the two periods of treatments, the mean peak plasma concentrations (Cmax) were 75.73±28.34 ng/ml (zolpidem alone) and 80.58±22.40 ng/ml (zolpidem after pre-treatment with ciprofloxacin).",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),[ng] / [ml],75.73,143114,DB00537,Ciprofloxacin
,21302033,peak plasma concentrations (Cmax),"In the two periods of treatments, the mean peak plasma concentrations (Cmax) were 75.73±28.34 ng/ml (zolpidem alone) and 80.58±22.40 ng/ml (zolpidem after pre-treatment with ciprofloxacin).",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),[ng] / [ml],80.58,143115,DB00537,Ciprofloxacin
,21302033,tmax,"The tmax, times taken to reach Cmax, were 0.91±0.42 and 1.44±0.61 h, respectively, and the total areas under the curve (AUC0-∞) were 300.2±115.5 and 438.1±142.6 ng h/ml, respectively.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),h,0.91,143116,DB00537,Ciprofloxacin
,21302033,tmax,"The tmax, times taken to reach Cmax, were 0.91±0.42 and 1.44±0.61 h, respectively, and the total areas under the curve (AUC0-∞) were 300.2±115.5 and 438.1±142.6 ng h/ml, respectively.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),h,1.44,143117,DB00537,Ciprofloxacin
,21302033,total areas under the curve (AUC0-∞),"The tmax, times taken to reach Cmax, were 0.91±0.42 and 1.44±0.61 h, respectively, and the total areas under the curve (AUC0-∞) were 300.2±115.5 and 438.1±142.6 ng h/ml, respectively.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),[h·ng] / [ml],300.2,143118,DB00537,Ciprofloxacin
,21302033,total areas under the curve (AUC0-∞),"The tmax, times taken to reach Cmax, were 0.91±0.42 and 1.44±0.61 h, respectively, and the total areas under the curve (AUC0-∞) were 300.2±115.5 and 438.1±142.6 ng h/ml, respectively.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),[h·ng] / [ml],438.1,143119,DB00537,Ciprofloxacin
,21302033,half-life,The half-life of zolpidem was 2.39±0.53 h when administered alone and 3.34±0.87 h after pre-treatment with ciprofloxacin.,Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),h,2.39,143120,DB00537,Ciprofloxacin
,21302033,half-life,The half-life of zolpidem was 2.39±0.53 h when administered alone and 3.34±0.87 h after pre-treatment with ciprofloxacin.,Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),h,3.34,143121,DB00537,Ciprofloxacin
,21302033,bioavailability,"Ciprofloxacin interacts with zolpidem in healthy volunteers, raising its bioavailability by about 46%.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),%,46,143122,DB00537,Ciprofloxacin
,21205443,half-life,"After intramuscular administration of enrofloxacin, the half-life was 5.32 h, concentration maximum was 10.85 μg/mL, distribution volume was 841.96 mL/kg, and area under the time-concentration curve was 57.59 μg×h/mL; after subcutaneous administration these parameters were 4.08 h, 9.76 μg/mL, 915.85 mL/kg, and 47.42 μg×h/mL, respectively.",The pharmacokinetics of enrofloxacin in adult African clawed frogs (Xenopus laevis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21205443/),h,5.32,143878,DB00537,Ciprofloxacin
,21205443,concentration maximum,"After intramuscular administration of enrofloxacin, the half-life was 5.32 h, concentration maximum was 10.85 μg/mL, distribution volume was 841.96 mL/kg, and area under the time-concentration curve was 57.59 μg×h/mL; after subcutaneous administration these parameters were 4.08 h, 9.76 μg/mL, 915.85 mL/kg, and 47.42 μg×h/mL, respectively.",The pharmacokinetics of enrofloxacin in adult African clawed frogs (Xenopus laevis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21205443/),[μg] / [ml],10.85,143879,DB00537,Ciprofloxacin
,21205443,distribution volume,"After intramuscular administration of enrofloxacin, the half-life was 5.32 h, concentration maximum was 10.85 μg/mL, distribution volume was 841.96 mL/kg, and area under the time-concentration curve was 57.59 μg×h/mL; after subcutaneous administration these parameters were 4.08 h, 9.76 μg/mL, 915.85 mL/kg, and 47.42 μg×h/mL, respectively.",The pharmacokinetics of enrofloxacin in adult African clawed frogs (Xenopus laevis). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21205443/),[ml] / [kg],841.96,143880,DB00537,Ciprofloxacin
,21205443,area under the time-concentration curve,"After intramuscular administration of enrofloxacin, the half-life was 5.32 h, concentration maximum was 10.85 μg/mL, distribution volume was 841.96 mL/kg, and area under the time-concentration curve was 57.59 μg×h/mL; after subcutaneous administration these parameters were 4.08 h, 9.76 μg/mL, 915.85 mL/kg, and 47.42 μg×h/mL, respectively.",The pharmacokinetics of enrofloxacin in adult African clawed frogs (Xenopus laevis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21205443/),[h·μg] / [ml],57.59,143881,DB00537,Ciprofloxacin
,21205443,area under the time-concentration curve,"After intramuscular administration of enrofloxacin, the half-life was 5.32 h, concentration maximum was 10.85 μg/mL, distribution volume was 841.96 mL/kg, and area under the time-concentration curve was 57.59 μg×h/mL; after subcutaneous administration these parameters were 4.08 h, 9.76 μg/mL, 915.85 mL/kg, and 47.42 μg×h/mL, respectively.",The pharmacokinetics of enrofloxacin in adult African clawed frogs (Xenopus laevis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21205443/),[h·μg] / [ml],47.42,143882,DB00537,Ciprofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,41,144034,DB00537,Ciprofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,90,144035,DB00537,Ciprofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,30,144036,DB00537,Ciprofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,27,144037,DB00537,Ciprofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,75,144038,DB00537,Ciprofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,16,144039,DB00537,Ciprofloxacin
,21756818,steady state concentrations,"In 2 dosing groups, the steady state concentrations of ciprofloxacin reached to 0.25, 0.5, 1.0, 2.0 and 4.0 mg/L respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],0.25,145262,DB00537,Ciprofloxacin
,21756818,steady state concentrations,"In 2 dosing groups, the steady state concentrations of ciprofloxacin reached to 0.25, 0.5, 1.0, 2.0 and 4.0 mg/L respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],0.5,145263,DB00537,Ciprofloxacin
,21756818,steady state concentrations,"In 2 dosing groups, the steady state concentrations of ciprofloxacin reached to 0.25, 0.5, 1.0, 2.0 and 4.0 mg/L respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],1.0,145264,DB00537,Ciprofloxacin
,21756818,steady state concentrations,"In 2 dosing groups, the steady state concentrations of ciprofloxacin reached to 0.25, 0.5, 1.0, 2.0 and 4.0 mg/L respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],2.0,145265,DB00537,Ciprofloxacin
,21756818,steady state concentrations,"In 2 dosing groups, the steady state concentrations of ciprofloxacin reached to 0.25, 0.5, 1.0, 2.0 and 4.0 mg/L respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],4.0,145266,DB00537,Ciprofloxacin
,21756818,peak concentration,The dose of tobramycin was 2.0 mg×kg(-1)×d(-1) and its peak concentration reached around 2.0 mg/L.,[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],2.0,145267,DB00537,Ciprofloxacin
,21756818,MIC,"Against Pseudomonas aeruginosa, the values of MIC, MPC and SI of ciprofloxacin were 0.25 mg/L, 4.0 mg/L and 16 while 0.25 mg/L, 8.0 mg/L and 32 for tobramycin respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],0.25,145268,DB00537,Ciprofloxacin
,21756818,MPC,"Against Pseudomonas aeruginosa, the values of MIC, MPC and SI of ciprofloxacin were 0.25 mg/L, 4.0 mg/L and 16 while 0.25 mg/L, 8.0 mg/L and 32 for tobramycin respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],4.0,145269,DB00537,Ciprofloxacin
,21756818,MPC,"Against Pseudomonas aeruginosa, the values of MIC, MPC and SI of ciprofloxacin were 0.25 mg/L, 4.0 mg/L and 16 while 0.25 mg/L, 8.0 mg/L and 32 for tobramycin respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],16,145270,DB00537,Ciprofloxacin
,21756818,MPC,"Against Pseudomonas aeruginosa, the values of MIC, MPC and SI of ciprofloxacin were 0.25 mg/L, 4.0 mg/L and 16 while 0.25 mg/L, 8.0 mg/L and 32 for tobramycin respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],0.25,145271,DB00537,Ciprofloxacin
,21756818,MPC,"Against Pseudomonas aeruginosa, the values of MIC, MPC and SI of ciprofloxacin were 0.25 mg/L, 4.0 mg/L and 16 while 0.25 mg/L, 8.0 mg/L and 32 for tobramycin respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],8.0,145272,DB00537,Ciprofloxacin
,21756818,SI,"Against Pseudomonas aeruginosa, the values of MIC, MPC and SI of ciprofloxacin were 0.25 mg/L, 4.0 mg/L and 16 while 0.25 mg/L, 8.0 mg/L and 32 for tobramycin respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],16,145273,DB00537,Ciprofloxacin
,21756818,SI,"Against Pseudomonas aeruginosa, the values of MIC, MPC and SI of ciprofloxacin were 0.25 mg/L, 4.0 mg/L and 16 while 0.25 mg/L, 8.0 mg/L and 32 for tobramycin respectively.",[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),,32,145274,DB00537,Ciprofloxacin
,21756818,MPC,And MPC was 0.5 mg/L and MIC 0.125 mg/L for ciprofloxacin plus tobramycin.,[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],0.5,145275,DB00537,Ciprofloxacin
,21756818,MIC,And MPC was 0.5 mg/L and MIC 0.125 mg/L for ciprofloxacin plus tobramycin.,[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),[mg] / [l],0.125,145276,DB00537,Ciprofloxacin
,21756818,SI,And the value of SI was 4.,[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21756818/),,4,145277,DB00537,Ciprofloxacin
>,22653817,fAUC/MIC,The probability of reaching an fAUC/MIC >100 was calculated for each regimen.,Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),,100,145526,DB00537,Ciprofloxacin
<,22653817,MICs,"For MICs <1 mg/L, all simulated patients reach the efficacy target.",Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),[mg] / [l],1,145527,DB00537,Ciprofloxacin
,22653817,MIC,"However, with higher values of MIC, the proposed regimens were inefficient for patients with moderate or severe renal impairment: 3.4% and 30.2% of patients with moderate renal impairment reached the efficacy target for ciprofloxacin and ofloxacin, respectively, for an MIC of 2 mg/L.",Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),[mg] / [l],2,145528,DB00537,Ciprofloxacin
low,22653817,MIC,"For ciprofloxacin, more than 80% of patients with severe renal impairment were unable to reach the target fAUC/MIC with an MIC as low as 1 mg/L, whereas for levofloxacin, all simulated patients reached the efficacy target until an MIC of 4 mg/L.",Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),[mg] / [l],1,145529,DB00537,Ciprofloxacin
,22653817,MIC,"For ciprofloxacin, more than 80% of patients with severe renal impairment were unable to reach the target fAUC/MIC with an MIC as low as 1 mg/L, whereas for levofloxacin, all simulated patients reached the efficacy target until an MIC of 4 mg/L.",Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),[mg] / [l],4,145530,DB00537,Ciprofloxacin
,3107959,Cmax,Characteristic of this new antibacterial are the high plasma levels following oral administration (Cmax: 4.5 micrograms/ml) and the long elimination half-lives (8-12 h).,A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),[μg] / [ml],4.5,145646,DB00537,Ciprofloxacin
,3107959,elimination half-lives,Characteristic of this new antibacterial are the high plasma levels following oral administration (Cmax: 4.5 micrograms/ml) and the long elimination half-lives (8-12 h).,A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),h,8-12,145647,DB00537,Ciprofloxacin
exceeds,3107959,volume of distribution at steady state,"In addition, the volume of distribution at steady state clearly exceeds 1 l/kg and points to good tissue penetration.",A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),[l] / [kg],1,145648,DB00537,Ciprofloxacin
,3107959,Total systemic clearance,Total systemic clearance was 122 ml/min and total renal clearance reached 89 ml/min.,A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),[ml] / [min],122,145649,DB00537,Ciprofloxacin
,3107959,total renal clearance,Total systemic clearance was 122 ml/min and total renal clearance reached 89 ml/min.,A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),[ml] / [min],89,145650,DB00537,Ciprofloxacin
,3107959,absolute bioavailability,"The absolute bioavailability (extent of absorption) of the tablet amounted to 96%, indicating a complete absorption of this galenic formulation.",A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),%,96,145651,DB00537,Ciprofloxacin
,9081961,Time taken to achieve peak plasma concentration (Tmax),Time taken to achieve peak plasma concentration (Tmax) was 2 hours (A) and 1.67 +/- 0.49 hours (B).,Comparative bioavailability of two brands of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),h,2,145730,DB00537,Ciprofloxacin
,9081961,Time taken to achieve peak plasma concentration (Tmax),Time taken to achieve peak plasma concentration (Tmax) was 2 hours (A) and 1.67 +/- 0.49 hours (B).,Comparative bioavailability of two brands of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),h,1.67,145731,DB00537,Ciprofloxacin
,9081961,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) ranged from 1.8 to 5.1 ug/ml (mean 3.08 +/- 0.99 ug/ml) for 'A' and 2.08 to 5.5 mu g/ml (mean 3.58 +/- 1.37 mu g/me for 'B'.,Comparative bioavailability of two brands of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),[ug] / [ml],1.8 to 5.1,145732,DB00537,Ciprofloxacin
,9081961,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) ranged from 1.8 to 5.1 ug/ml (mean 3.08 +/- 0.99 ug/ml) for 'A' and 2.08 to 5.5 mu g/ml (mean 3.58 +/- 1.37 mu g/me for 'B'.,Comparative bioavailability of two brands of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),[ug] / [ml],3.08,145733,DB00537,Ciprofloxacin
,9081961,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) ranged from 1.8 to 5.1 ug/ml (mean 3.08 +/- 0.99 ug/ml) for 'A' and 2.08 to 5.5 mu g/ml (mean 3.58 +/- 1.37 mu g/me for 'B'.,Comparative bioavailability of two brands of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),[g·mu] / [ml],2.08 to 5.5,145734,DB00537,Ciprofloxacin
,9081961,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) ranged from 1.8 to 5.1 ug/ml (mean 3.08 +/- 0.99 ug/ml) for 'A' and 2.08 to 5.5 mu g/ml (mean 3.58 +/- 1.37 mu g/me for 'B'.,Comparative bioavailability of two brands of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),[g·mu] / [me],3.58,145735,DB00537,Ciprofloxacin
,9081961,Area under plasma concentration time curve,Area under plasma concentration time curve ranged from 30.91 to 118.27 ug/ml/hr (mean 59.97 +/- 26.68 ug/ml/hr) in 'A' and 36.52 to 108.05 (mean 62.80 +/- 22.33 ug/ml/hr) in 'B' which is more than reported in Western literature.,Comparative bioavailability of two brands of ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),[ug] / [h·ml],30.91 to 118.27,145736,DB00537,Ciprofloxacin
,9081961,Area under plasma concentration time curve,Area under plasma concentration time curve ranged from 30.91 to 118.27 ug/ml/hr (mean 59.97 +/- 26.68 ug/ml/hr) in 'A' and 36.52 to 108.05 (mean 62.80 +/- 22.33 ug/ml/hr) in 'B' which is more than reported in Western literature.,Comparative bioavailability of two brands of ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),[ug] / [h·ml],59.97,145737,DB00537,Ciprofloxacin
,9081961,Area under plasma concentration time curve,Area under plasma concentration time curve ranged from 30.91 to 118.27 ug/ml/hr (mean 59.97 +/- 26.68 ug/ml/hr) in 'A' and 36.52 to 108.05 (mean 62.80 +/- 22.33 ug/ml/hr) in 'B' which is more than reported in Western literature.,Comparative bioavailability of two brands of ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),[ug] / [h·ml],36.52 to 108.05,145738,DB00537,Ciprofloxacin
,9081961,Area under plasma concentration time curve,Area under plasma concentration time curve ranged from 30.91 to 118.27 ug/ml/hr (mean 59.97 +/- 26.68 ug/ml/hr) in 'A' and 36.52 to 108.05 (mean 62.80 +/- 22.33 ug/ml/hr) in 'B' which is more than reported in Western literature.,Comparative bioavailability of two brands of ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081961/),[ug] / [h·ml],62.80,145739,DB00537,Ciprofloxacin
,10225572,Cmax,"In study 1, geometric mean Cmax values of ciprofloxacin following the single 500 mg tablet and 500 mg/10 mL suspension doses were 2.36 and 2.18 mg/L, respectively; corresponding geometric mean t(max) values were 1.1 and 1.6 h, respectively.",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[mg] / [l],2.36,145832,DB00537,Ciprofloxacin
,10225572,Cmax,"In study 1, geometric mean Cmax values of ciprofloxacin following the single 500 mg tablet and 500 mg/10 mL suspension doses were 2.36 and 2.18 mg/L, respectively; corresponding geometric mean t(max) values were 1.1 and 1.6 h, respectively.",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[mg] / [l],2.18,145833,DB00537,Ciprofloxacin
,10225572,t(max),"In study 1, geometric mean Cmax values of ciprofloxacin following the single 500 mg tablet and 500 mg/10 mL suspension doses were 2.36 and 2.18 mg/L, respectively; corresponding geometric mean t(max) values were 1.1 and 1.6 h, respectively.",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),h,1.1,145834,DB00537,Ciprofloxacin
,10225572,t(max),"In study 1, geometric mean Cmax values of ciprofloxacin following the single 500 mg tablet and 500 mg/10 mL suspension doses were 2.36 and 2.18 mg/L, respectively; corresponding geometric mean t(max) values were 1.1 and 1.6 h, respectively.",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),h,1.6,145835,DB00537,Ciprofloxacin
,10225572,AUC(0-infinity),"Geometric mean AUC(0-infinity) values were 12.0 and 11.8 mg x h/L, respectively.",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[h·mg] / [l],12.0,145836,DB00537,Ciprofloxacin
,10225572,AUC(0-infinity),"Geometric mean AUC(0-infinity) values were 12.0 and 11.8 mg x h/L, respectively.",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[h·mg] / [l],11.8,145837,DB00537,Ciprofloxacin
,10225572,Cmax,"In study 2, geometric least squares mean Cmax values following ciprofloxacin 500 mg/10 mL and 500 mg/5 mL suspension during fasted conditions were 1.54 and 1.59 mg/L, respectively.",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[mg] / [l],1.54,145838,DB00537,Ciprofloxacin
,10225572,Cmax,"In study 2, geometric least squares mean Cmax values following ciprofloxacin 500 mg/10 mL and 500 mg/5 mL suspension during fasted conditions were 1.54 and 1.59 mg/L, respectively.",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[mg] / [l],1.59,145839,DB00537,Ciprofloxacin
,10225572,AUC(0-infinity),Corresponding geometric least squares mean AUC(0-infinity) values were 7.3 and 8.0 mg x h/L.,Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[h·mg] / [l],7.3,145840,DB00537,Ciprofloxacin
,10225572,AUC(0-infinity),Corresponding geometric least squares mean AUC(0-infinity) values were 7.3 and 8.0 mg x h/L.,Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[h·mg] / [l],8.0,145841,DB00537,Ciprofloxacin
,10225572,Cmax,"Administration of ciprofloxacin 500 mg/10 mL suspension, in either a fasted or fed state, was not associated with significant changes in Cmax (1.54 mg/L for fasted vs 1.37 mg/L for fed) or AUC(0-infinity) values (7.28 mg x h/L for fasted vs 8.19 mg x h/L for fed).",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[mg] / [l],1.54,145842,DB00537,Ciprofloxacin
,10225572,Cmax,"Administration of ciprofloxacin 500 mg/10 mL suspension, in either a fasted or fed state, was not associated with significant changes in Cmax (1.54 mg/L for fasted vs 1.37 mg/L for fed) or AUC(0-infinity) values (7.28 mg x h/L for fasted vs 8.19 mg x h/L for fed).",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[mg] / [l],1.37,145843,DB00537,Ciprofloxacin
,10225572,AUC(0-infinity),"Administration of ciprofloxacin 500 mg/10 mL suspension, in either a fasted or fed state, was not associated with significant changes in Cmax (1.54 mg/L for fasted vs 1.37 mg/L for fed) or AUC(0-infinity) values (7.28 mg x h/L for fasted vs 8.19 mg x h/L for fed).",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[h·mg] / [l],7.28,145844,DB00537,Ciprofloxacin
,10225572,AUC(0-infinity),"Administration of ciprofloxacin 500 mg/10 mL suspension, in either a fasted or fed state, was not associated with significant changes in Cmax (1.54 mg/L for fasted vs 1.37 mg/L for fed) or AUC(0-infinity) values (7.28 mg x h/L for fasted vs 8.19 mg x h/L for fed).",Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225572/),[h·mg] / [l],8.19,145845,DB00537,Ciprofloxacin
,1923916,trough concentration,"The trough concentration 20 hours after the initial dose was 3.7 micrograms/ml, and the serum concentrations after the second dose went from 5.6 to 4.94 micrograms/ml over the 11-hour sampling period.",Absorption of oral ciprofloxacin in a patient with cardiogenic shock. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923916/),[μg] / [ml],3.7,145866,DB00537,Ciprofloxacin
,1923916,peak concentration,The peak concentration of 5.6 micrograms/ml occurred within 30 minutes after ciprofloxacin administration.,Absorption of oral ciprofloxacin in a patient with cardiogenic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923916/),[μg] / [ml],5.6,145867,DB00537,Ciprofloxacin
,27044547,MIC,"The in vitro activities of the two compounds were very similar (MIC range, 0.03 to 0.125 mg/liter).","In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044547/),[mg] / [l],0.03 to 0.125,146450,DB00537,Ciprofloxacin
,27044547,Maximal kill,Maximal kill approached 3 to 4 log10 CFU/thigh compared to the burden at the start of therapy for the highest doses examined.,"In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044547/),,3 to 4,146451,DB00537,Ciprofloxacin
,27044547,AUC/MIC ratios,"The 24-h free-drug AUC/MIC ratios associated with net stasis for ACT-387042 against S. aureus and S. pneumoniae were 43 and 10, respectively.","In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044547/),,43,146452,DB00537,Ciprofloxacin
,27044547,AUC/MIC ratios,"The 24-h free-drug AUC/MIC ratios associated with net stasis for ACT-387042 against S. aureus and S. pneumoniae were 43 and 10, respectively.","In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044547/),,10,146453,DB00537,Ciprofloxacin
,27044547,AUC/MIC ratios,"The 24-h free-drug AUC/MIC ratios associated with net stasis for ACT-292706 against S. aureus and S. pneumoniae were 69 and 25, respectively.","In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044547/),,69,146454,DB00537,Ciprofloxacin
,27044547,AUC/MIC ratios,"The 24-h free-drug AUC/MIC ratios associated with net stasis for ACT-292706 against S. aureus and S. pneumoniae were 69 and 25, respectively.","In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044547/),,25,146455,DB00537,Ciprofloxacin
,10348184,recoveries,"The assay is specific and reproducible within the both drugs and mean recoveries for ciprofloxacin and enrofloxacin, respectively, were 92+/-6% and 90+/-5% for pig plasma over the range used.",Simultaneous determination of enrofloxacin and ciprofloxacin in animal biological fluids by high-performance liquid chromatography. Application in pharmacokinetic studies in pig and rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348184/),%,92,146757,DB00537,Ciprofloxacin
,10348184,recoveries,"The assay is specific and reproducible within the both drugs and mean recoveries for ciprofloxacin and enrofloxacin, respectively, were 92+/-6% and 90+/-5% for pig plasma over the range used.",Simultaneous determination of enrofloxacin and ciprofloxacin in animal biological fluids by high-performance liquid chromatography. Application in pharmacokinetic studies in pig and rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348184/),%,90,146758,DB00537,Ciprofloxacin
,10348184,recoveries,"Mean recoveries for enrofloxacin were 108+/-9% and 102+/-7% for rabbit plasma and TCF, respectively, over the range used.",Simultaneous determination of enrofloxacin and ciprofloxacin in animal biological fluids by high-performance liquid chromatography. Application in pharmacokinetic studies in pig and rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348184/),%,108,146759,DB00537,Ciprofloxacin
,10348184,recoveries,"Mean recoveries for enrofloxacin were 108+/-9% and 102+/-7% for rabbit plasma and TCF, respectively, over the range used.",Simultaneous determination of enrofloxacin and ciprofloxacin in animal biological fluids by high-performance liquid chromatography. Application in pharmacokinetic studies in pig and rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348184/),%,102,146760,DB00537,Ciprofloxacin
,9517948,TRO half-life,"Different monoexponential pharmacokinetic profiles were simulated with a TRO half-life of 9.2 h and a CIP half-life of 4.0 h to provide similar eightfold ranges of the area under the concentration-time curve (AUC)-to-MIC ratios, from 54 to 432 and from 59 to 473 (microg x h/ml)/(microg/ml), respectively.",Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517948/),h,9.2,146776,DB00537,Ciprofloxacin
,9517948,half-life,"Different monoexponential pharmacokinetic profiles were simulated with a TRO half-life of 9.2 h and a CIP half-life of 4.0 h to provide similar eightfold ranges of the area under the concentration-time curve (AUC)-to-MIC ratios, from 54 to 432 and from 59 to 473 (microg x h/ml)/(microg/ml), respectively.",Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517948/),h,4.0,146777,DB00537,Ciprofloxacin
,9517948,area under the concentration-time curve (AUC)-to-MIC ratios,"Different monoexponential pharmacokinetic profiles were simulated with a TRO half-life of 9.2 h and a CIP half-life of 4.0 h to provide similar eightfold ranges of the area under the concentration-time curve (AUC)-to-MIC ratios, from 54 to 432 and from 59 to 473 (microg x h/ml)/(microg/ml), respectively.",Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517948/),[h·ml·μg] / [ml·μg],54 to 432,146778,DB00537,Ciprofloxacin
,9517948,area under the concentration-time curve (AUC)-to-MIC ratios,"Different monoexponential pharmacokinetic profiles were simulated with a TRO half-life of 9.2 h and a CIP half-life of 4.0 h to provide similar eightfold ranges of the area under the concentration-time curve (AUC)-to-MIC ratios, from 54 to 432 and from 59 to 473 (microg x h/ml)/(microg/ml), respectively.",Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517948/),[h·ml·μg] / [ml·μg],59 to 473,146779,DB00537,Ciprofloxacin
,7820262,Recoveries,"Recoveries of enrofloxacin from bovine milk and plasma were 92-107% and 80-84%, respectively.",Simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in bovine milk and plasma by ion-pairing liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820262/),%,92-107,146869,DB00537,Ciprofloxacin
,7820262,Recoveries,"Recoveries of enrofloxacin from bovine milk and plasma were 92-107% and 80-84%, respectively.",Simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in bovine milk and plasma by ion-pairing liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820262/),%,80-84,146870,DB00537,Ciprofloxacin
,7820262,Recoveries,"Recoveries of ciprofloxacin from bovine milk and plasma were 92-105% and 73-75%, respectively.",Simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in bovine milk and plasma by ion-pairing liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820262/),%,92-105,146871,DB00537,Ciprofloxacin
,7820262,Recoveries,"Recoveries of ciprofloxacin from bovine milk and plasma were 92-105% and 73-75%, respectively.",Simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in bovine milk and plasma by ion-pairing liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820262/),%,73-75,146872,DB00537,Ciprofloxacin
,7820262,limit of detection,The limit of detection for the two compounds was 5 ng/ml.,Simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in bovine milk and plasma by ion-pairing liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820262/),[ng] / [ml],5,146873,DB00537,Ciprofloxacin
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,48.59,147172,DB00537,Ciprofloxacin
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,49.9,147173,DB00537,Ciprofloxacin
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,7.73,147174,DB00537,Ciprofloxacin
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,6.6,147175,DB00537,Ciprofloxacin
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.1,147176,DB00537,Ciprofloxacin
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.6,147177,DB00537,Ciprofloxacin
,10223961,interstitium-to-serum concentration ratios,Interstitial ciprofloxacin concentrations were significantly lower than corresponding total serum drug concentrations; the interstitium-to-serum concentration ratios ranged from 0.55 to 0.73.,Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223961/),,0.55 to 0.73,147584,DB00537,Ciprofloxacin
,8525228,Dialysate flux (Qd),Dialysate flux (Qd) was 16.6 ml/min during the first hours and 33.2 ml/min thereafter.,[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],16.6,147649,DB00537,Ciprofloxacin
,8525228,Dialysate flux (Qd),Dialysate flux (Qd) was 16.6 ml/min during the first hours and 33.2 ml/min thereafter.,[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],33.2,147650,DB00537,Ciprofloxacin
,8525228,total ciprofloxacin clearance,"For each Qd, total ciprofloxacin clearance was 1.13 +/- 0.99 and 2.8 +/- 1.71 ml/min (p < 0.001), diffusive clearance was 0.96 +/- 0.87 and 2.47 +/- 1.56 ml/min (p < 0.005) and convective clearance was 0.16 +/- 0.17 and 0.33 +/- 0.2 ml/min (p < 0.05).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],1.13,147651,DB00537,Ciprofloxacin
,8525228,total ciprofloxacin clearance,"For each Qd, total ciprofloxacin clearance was 1.13 +/- 0.99 and 2.8 +/- 1.71 ml/min (p < 0.001), diffusive clearance was 0.96 +/- 0.87 and 2.47 +/- 1.56 ml/min (p < 0.005) and convective clearance was 0.16 +/- 0.17 and 0.33 +/- 0.2 ml/min (p < 0.05).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],2.8,147652,DB00537,Ciprofloxacin
,8525228,diffusive clearance,"For each Qd, total ciprofloxacin clearance was 1.13 +/- 0.99 and 2.8 +/- 1.71 ml/min (p < 0.001), diffusive clearance was 0.96 +/- 0.87 and 2.47 +/- 1.56 ml/min (p < 0.005) and convective clearance was 0.16 +/- 0.17 and 0.33 +/- 0.2 ml/min (p < 0.05).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],0.96,147653,DB00537,Ciprofloxacin
,8525228,diffusive clearance,"For each Qd, total ciprofloxacin clearance was 1.13 +/- 0.99 and 2.8 +/- 1.71 ml/min (p < 0.001), diffusive clearance was 0.96 +/- 0.87 and 2.47 +/- 1.56 ml/min (p < 0.005) and convective clearance was 0.16 +/- 0.17 and 0.33 +/- 0.2 ml/min (p < 0.05).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],2.47,147654,DB00537,Ciprofloxacin
,8525228,convective clearance,"For each Qd, total ciprofloxacin clearance was 1.13 +/- 0.99 and 2.8 +/- 1.71 ml/min (p < 0.001), diffusive clearance was 0.96 +/- 0.87 and 2.47 +/- 1.56 ml/min (p < 0.005) and convective clearance was 0.16 +/- 0.17 and 0.33 +/- 0.2 ml/min (p < 0.05).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],0.16,147655,DB00537,Ciprofloxacin
,8525228,convective clearance,"For each Qd, total ciprofloxacin clearance was 1.13 +/- 0.99 and 2.8 +/- 1.71 ml/min (p < 0.001), diffusive clearance was 0.96 +/- 0.87 and 2.47 +/- 1.56 ml/min (p < 0.005) and convective clearance was 0.16 +/- 0.17 and 0.33 +/- 0.2 ml/min (p < 0.05).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],0.33,147656,DB00537,Ciprofloxacin
,8525228,total amikacin clearance,"Likewise, total amikacin clearance was 3.47 +/- 1.31 and 4.18 +/- 0.53 ml/min (p < 0.001), diffusive clearance was 2.97 +/- 1.24 and 3.86 +/- 0.52 ml/min and convective clearance was 0.50 +/- 0.47 and 0.32 +/- 0.29 ml/min (p = NS).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],3.47,147657,DB00537,Ciprofloxacin
,8525228,total amikacin clearance,"Likewise, total amikacin clearance was 3.47 +/- 1.31 and 4.18 +/- 0.53 ml/min (p < 0.001), diffusive clearance was 2.97 +/- 1.24 and 3.86 +/- 0.52 ml/min and convective clearance was 0.50 +/- 0.47 and 0.32 +/- 0.29 ml/min (p = NS).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],4.18,147658,DB00537,Ciprofloxacin
,8525228,diffusive clearance,"Likewise, total amikacin clearance was 3.47 +/- 1.31 and 4.18 +/- 0.53 ml/min (p < 0.001), diffusive clearance was 2.97 +/- 1.24 and 3.86 +/- 0.52 ml/min and convective clearance was 0.50 +/- 0.47 and 0.32 +/- 0.29 ml/min (p = NS).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],2.97,147659,DB00537,Ciprofloxacin
,8525228,diffusive clearance,"Likewise, total amikacin clearance was 3.47 +/- 1.31 and 4.18 +/- 0.53 ml/min (p < 0.001), diffusive clearance was 2.97 +/- 1.24 and 3.86 +/- 0.52 ml/min and convective clearance was 0.50 +/- 0.47 and 0.32 +/- 0.29 ml/min (p = NS).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],3.86,147660,DB00537,Ciprofloxacin
,8525228,convective clearance,"Likewise, total amikacin clearance was 3.47 +/- 1.31 and 4.18 +/- 0.53 ml/min (p < 0.001), diffusive clearance was 2.97 +/- 1.24 and 3.86 +/- 0.52 ml/min and convective clearance was 0.50 +/- 0.47 and 0.32 +/- 0.29 ml/min (p = NS).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],0.50,147661,DB00537,Ciprofloxacin
,8525228,convective clearance,"Likewise, total amikacin clearance was 3.47 +/- 1.31 and 4.18 +/- 0.53 ml/min (p < 0.001), diffusive clearance was 2.97 +/- 1.24 and 3.86 +/- 0.52 ml/min and convective clearance was 0.50 +/- 0.47 and 0.32 +/- 0.29 ml/min (p = NS).",[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),[ml] / [min],0.32,147662,DB00537,Ciprofloxacin
,8525228,Protein binding,Protein binding was 84% for ciprofloxacin and 77% for amikacin.,[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),%,84,147663,DB00537,Ciprofloxacin
,8525228,Protein binding,Protein binding was 84% for ciprofloxacin and 77% for amikacin.,[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525228/),%,77,147664,DB00537,Ciprofloxacin
,16334955,half-life,Harmonic mean half-life after oral administration was 18.4 hours for all elephants.,Pharmacokinetics of a single dose of enrofloxacin administered orally to captive Asian elephants (Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334955/),h,18.4,147728,DB00537,Ciprofloxacin
,16334955,peak serum concentration,Mean +/- SD peak serum concentration of enrofloxacin was 1.31 +/- 0.40 microg/mL at 5.0 +/- 4.2 hours after administration.,Pharmacokinetics of a single dose of enrofloxacin administered orally to captive Asian elephants (Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334955/),[μg] / [ml],1.31,147729,DB00537,Ciprofloxacin
,16334955,area under the curve,Mean area under the curve was 20.72 +/- 4.25 (microg x h)/mL.,Pharmacokinetics of a single dose of enrofloxacin administered orally to captive Asian elephants (Elephas maximus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334955/),[h·μg] / [ml],20.72,147730,DB00537,Ciprofloxacin
,3555032,t1/2 beta,"Estimates of steady-state pharmacokinetic parameters averaged (+/- SD): t1/2 beta, 3.8 (1) hours; Vd/F, 4.4 (2) liters/kg; Cl/F, 772.9 (301) ml/minute/1.73 m2; Fe, 46 percent; peak, 5.4 (2) mg/liter; and trough, 1.8 (0.8) mg/liter.",Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555032/),h,3.8,147731,DB00537,Ciprofloxacin
,3555032,Vd/F,"Estimates of steady-state pharmacokinetic parameters averaged (+/- SD): t1/2 beta, 3.8 (1) hours; Vd/F, 4.4 (2) liters/kg; Cl/F, 772.9 (301) ml/minute/1.73 m2; Fe, 46 percent; peak, 5.4 (2) mg/liter; and trough, 1.8 (0.8) mg/liter.",Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555032/),[l] / [kg],4.4,147732,DB00537,Ciprofloxacin
,3555032,Cl/F,"Estimates of steady-state pharmacokinetic parameters averaged (+/- SD): t1/2 beta, 3.8 (1) hours; Vd/F, 4.4 (2) liters/kg; Cl/F, 772.9 (301) ml/minute/1.73 m2; Fe, 46 percent; peak, 5.4 (2) mg/liter; and trough, 1.8 (0.8) mg/liter.",Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555032/),[ml] / [1.73·m2·min],772.9,147733,DB00537,Ciprofloxacin
,3555032,Fe,"Estimates of steady-state pharmacokinetic parameters averaged (+/- SD): t1/2 beta, 3.8 (1) hours; Vd/F, 4.4 (2) liters/kg; Cl/F, 772.9 (301) ml/minute/1.73 m2; Fe, 46 percent; peak, 5.4 (2) mg/liter; and trough, 1.8 (0.8) mg/liter.",Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555032/),%,46,147734,DB00537,Ciprofloxacin
,3555032,peak,"Estimates of steady-state pharmacokinetic parameters averaged (+/- SD): t1/2 beta, 3.8 (1) hours; Vd/F, 4.4 (2) liters/kg; Cl/F, 772.9 (301) ml/minute/1.73 m2; Fe, 46 percent; peak, 5.4 (2) mg/liter; and trough, 1.8 (0.8) mg/liter.",Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555032/),[mg] / [l],5.4,147735,DB00537,Ciprofloxacin
,3555032,trough,"Estimates of steady-state pharmacokinetic parameters averaged (+/- SD): t1/2 beta, 3.8 (1) hours; Vd/F, 4.4 (2) liters/kg; Cl/F, 772.9 (301) ml/minute/1.73 m2; Fe, 46 percent; peak, 5.4 (2) mg/liter; and trough, 1.8 (0.8) mg/liter.",Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555032/),[mg] / [l],1.8,147736,DB00537,Ciprofloxacin
,3555032,MIC90,Sputum cultures revealed 43 P. aeruginosa (MIC90 = 2 micrograms/ml) and 15 P. cepacia (MIC90 = 16 micrograms/ml) strains.,Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555032/),[μg] / [ml],2,147737,DB00537,Ciprofloxacin
,3555032,MIC90,Sputum cultures revealed 43 P. aeruginosa (MIC90 = 2 micrograms/ml) and 15 P. cepacia (MIC90 = 16 micrograms/ml) strains.,Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555032/),[μg] / [ml],16,147738,DB00537,Ciprofloxacin
,3555032,MIC90,Posttreatment sputum cultures revealed 35 P. aeruginosa (MIC90 = 16 micrograms/ml) and 15 P. cepacia (MIC90 = 16 micrograms/ml).,Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555032/),[μg] / [ml],16,147739,DB00537,Ciprofloxacin
,19483319,bioavailability,"However, the decrease in bioavailability of ciprofloxacin was slight (15%) compared with that of tetracycline (30%).","Effect of a Kampo preparation, byakkokaninjinto, on pharmacokinetics of ciprofloxacin and tetracycline. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19483319/),%,15,147756,DB00537,Ciprofloxacin
,19483319,bioavailability,"However, the decrease in bioavailability of ciprofloxacin was slight (15%) compared with that of tetracycline (30%).","Effect of a Kampo preparation, byakkokaninjinto, on pharmacokinetics of ciprofloxacin and tetracycline. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19483319/),%,30,147757,DB00537,Ciprofloxacin
,11480524,peak serum concentration (Cmax),The mean peak serum concentration (Cmax) was 2.41+/-0.30 microg/mL at 1.5 hours after administration and decreased to 0.17+/-0.01 microg/mL (Cmin) at 24 hours.,Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],2.41,147826,DB00537,Ciprofloxacin
,11480524,Cmin,The mean peak serum concentration (Cmax) was 2.41+/-0.30 microg/mL at 1.5 hours after administration and decreased to 0.17+/-0.01 microg/mL (Cmin) at 24 hours.,Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],0.17,147827,DB00537,Ciprofloxacin
,11480524,elimination half-life (t1/2),The mean elimination half-life (t1/2) was 9.06+/-1.33 hours and area under the serum concentration vs time curve (AUC) was 20.54+/-1.70 mg h/L.,Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),h,9.06,147828,DB00537,Ciprofloxacin
,11480524,area under the serum concentration vs time curve (AUC),The mean elimination half-life (t1/2) was 9.06+/-1.33 hours and area under the serum concentration vs time curve (AUC) was 20.54+/-1.70 mg h/L.,Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[h·mg] / [l],20.54,147829,DB00537,Ciprofloxacin
,11480524,peritoneal fluid concentration,Highest mean peritoneal fluid concentration was 2.15+/-0.49 microg/mL at 2 hours.,Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],2.15,147830,DB00537,Ciprofloxacin
,11480524,synovial fluid concentration,Highest mean synovial fluid concentration was 1.17+/-0.28 microg/mL at 4 hours.,Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],1.17,147831,DB00537,Ciprofloxacin
,11480524,Highest mean urine concentration,Highest mean urine concentration was 536.67+/-244.79 microg/mL at 2 hours.,Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],536.67,147832,DB00537,Ciprofloxacin
,11480524,endometrial concentration,Highest mean endometrial concentration was 0.72+/-0.23 microg/g at 1.5 hours.,Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [g],0.72,147833,DB00537,Ciprofloxacin
,11480524,CSF concentration,Mean CSF concentration was 0.46+/-0.55 microg/mL at 3 hours.,Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],0.46,147834,DB00537,Ciprofloxacin
<,11480524,minimum inhibitory concentration,"The minimum inhibitory concentration of orbifloxacin required to inhibit 90% of isolates (MIC90) ranged from < or = 0.12 to > 8.0 microg/mL, with gram-negative organisms being more sensitive than gram-positive organisms.",Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],0,147835,DB00537,Ciprofloxacin
>,11480524,minimum inhibitory concentration,"The minimum inhibitory concentration of orbifloxacin required to inhibit 90% of isolates (MIC90) ranged from < or = 0.12 to > 8.0 microg/mL, with gram-negative organisms being more sensitive than gram-positive organisms.",Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],8.0,147836,DB00537,Ciprofloxacin
<,11480524,MIC90),"The minimum inhibitory concentration of orbifloxacin required to inhibit 90% of isolates (MIC90) ranged from < or = 0.12 to > 8.0 microg/mL, with gram-negative organisms being more sensitive than gram-positive organisms.",Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],0,147837,DB00537,Ciprofloxacin
>,11480524,MIC90),"The minimum inhibitory concentration of orbifloxacin required to inhibit 90% of isolates (MIC90) ranged from < or = 0.12 to > 8.0 microg/mL, with gram-negative organisms being more sensitive than gram-positive organisms.",Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480524/),[μg] / [ml],8.0,147838,DB00537,Ciprofloxacin
>,18725050,C(max)/MIC,"We evaluated whether areas under the curve (AUCs) exceeded minimal inhibitory concentration (MIC) values of 0.125, 0.25, 0.5, 1.0, and 2.0 mg/L by 125 times and peak concentrations (C(max)) 10 x MIC (C(max)/MIC >10).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,10,148256,DB00537,Ciprofloxacin
more,18725050,AUC/MIC,The AUC/MIC more than 125 was achieved in 100% for MIC 0.125.,Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,125,148257,DB00537,Ciprofloxacin
,18725050,MIC,The AUC/MIC more than 125 was achieved in 100% for MIC 0.125.,Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,0.125,148258,DB00537,Ciprofloxacin
,18725050,MIC,"For MIC values 0.25, 0.5, 1.0, and 2.0, results were 84%, 31%, 3%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),%,84,148259,DB00537,Ciprofloxacin
,18725050,MIC,"For MIC values 0.25, 0.5, 1.0, and 2.0, results were 84%, 31%, 3%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),%,31,148260,DB00537,Ciprofloxacin
,18725050,MIC,"For MIC values 0.25, 0.5, 1.0, and 2.0, results were 84%, 31%, 3%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),%,3,148261,DB00537,Ciprofloxacin
,18725050,MIC,"For MIC values 0.25, 0.5, 1.0, and 2.0, results were 84%, 31%, 3%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),%,0,148262,DB00537,Ciprofloxacin
more,18725050,C(max)/MIC,"The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,10,148263,DB00537,Ciprofloxacin
,18725050,MIC,"The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,0.125,148264,DB00537,Ciprofloxacin
,18725050,MIC,"The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,0.25,148265,DB00537,Ciprofloxacin
,18725050,MIC,"The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,0,148266,DB00537,Ciprofloxacin
,18725050,MIC,"The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,1.,148267,DB00537,Ciprofloxacin
,18725050,MIC,"The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,2.0,148268,DB00537,Ciprofloxacin
,18725050,MIC,"The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01).",Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,25,148269,DB00537,Ciprofloxacin
less,18725050,MIC,Effective killing concentrations were only achieved in pathogens with MIC less than 0.25.,Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725050/),,0.25,148270,DB00537,Ciprofloxacin
,8983970,serum area under the concentration-time curve (AUC),"The serum area under the concentration-time curve (AUC) values for each mode of drug administration were similar: 32.9 micrograms hr ml-1 for single dose, 31.9 micrograms hr ml-1 for intermittent dose, and 33.8 micrograms hr ml-1 for continuous infusion modes.",Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983970/),[h·μg] / [ml],32.9,148826,DB00537,Ciprofloxacin
,8983970,serum area under the concentration-time curve (AUC),"The serum area under the concentration-time curve (AUC) values for each mode of drug administration were similar: 32.9 micrograms hr ml-1 for single dose, 31.9 micrograms hr ml-1 for intermittent dose, and 33.8 micrograms hr ml-1 for continuous infusion modes.",Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983970/),[h·μg] / [ml],31.9,148827,DB00537,Ciprofloxacin
,8983970,serum area under the concentration-time curve (AUC),"The serum area under the concentration-time curve (AUC) values for each mode of drug administration were similar: 32.9 micrograms hr ml-1 for single dose, 31.9 micrograms hr ml-1 for intermittent dose, and 33.8 micrograms hr ml-1 for continuous infusion modes.",Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983970/),[h·μg] / [ml],33.8,148828,DB00537,Ciprofloxacin
,8983970,percentage penetration,"The percentage penetration into the aqueous and vitreous were also similar; 30.5% and 6.5% for a single dose, 31.6% and 7.4% for intermittent doses and 30.0% and 7.5% for continuous infusion.",Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983970/),%,30.5,148829,DB00537,Ciprofloxacin
,8983970,percentage penetration,"The percentage penetration into the aqueous and vitreous were also similar; 30.5% and 6.5% for a single dose, 31.6% and 7.4% for intermittent doses and 30.0% and 7.5% for continuous infusion.",Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983970/),%,6.5,148830,DB00537,Ciprofloxacin
,8983970,percentage penetration,"The percentage penetration into the aqueous and vitreous were also similar; 30.5% and 6.5% for a single dose, 31.6% and 7.4% for intermittent doses and 30.0% and 7.5% for continuous infusion.",Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983970/),%,31.6,148831,DB00537,Ciprofloxacin
,8983970,percentage penetration,"The percentage penetration into the aqueous and vitreous were also similar; 30.5% and 6.5% for a single dose, 31.6% and 7.4% for intermittent doses and 30.0% and 7.5% for continuous infusion.",Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983970/),%,7.4,148832,DB00537,Ciprofloxacin
,8983970,percentage penetration,"The percentage penetration into the aqueous and vitreous were also similar; 30.5% and 6.5% for a single dose, 31.6% and 7.4% for intermittent doses and 30.0% and 7.5% for continuous infusion.",Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983970/),%,30.0,148833,DB00537,Ciprofloxacin
,8983970,percentage penetration,"The percentage penetration into the aqueous and vitreous were also similar; 30.5% and 6.5% for a single dose, 31.6% and 7.4% for intermittent doses and 30.0% and 7.5% for continuous infusion.",Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983970/),%,7.5,148834,DB00537,Ciprofloxacin
≥,28771831,area under the curve (AUC)/MIC ratio,"Monte Carlo simulations were used to determine the probability of target attainment (PTA) for an area under the curve (AUC)/MIC ratio of ≥100, the pharmacokinetic-pharmacodynamic target for fluoroquinolones.",Ciprofloxacin Pharmacokinetics in Clinical Canine Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771831/),,100,149117,DB00537,Ciprofloxacin
,28771831,volume of distribution,"The values for volume of distribution, peak concentration, and half-life were 10.7 L/kg (11.7%), 1.9 μg/mL (11.66%), and 4.35 hours (7.62%), respectively (mean, % coefficient of variation [CV]).",Ciprofloxacin Pharmacokinetics in Clinical Canine Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771831/),[l] / [kg],10.7,149118,DB00537,Ciprofloxacin
,28771831,peak concentration,"The values for volume of distribution, peak concentration, and half-life were 10.7 L/kg (11.7%), 1.9 μg/mL (11.66%), and 4.35 hours (7.62%), respectively (mean, % coefficient of variation [CV]).",Ciprofloxacin Pharmacokinetics in Clinical Canine Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771831/),[μg] / [ml],1.9,149119,DB00537,Ciprofloxacin
,28771831,half-life,"The values for volume of distribution, peak concentration, and half-life were 10.7 L/kg (11.7%), 1.9 μg/mL (11.66%), and 4.35 hours (7.62%), respectively (mean, % coefficient of variation [CV]).",Ciprofloxacin Pharmacokinetics in Clinical Canine Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771831/),h,4.35,149120,DB00537,Ciprofloxacin
≤,28771831,MIC,Ninety percent PTA was obtained for a MIC ≤ 0.06 μg/mL.,Ciprofloxacin Pharmacokinetics in Clinical Canine Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771831/),[μg] / [ml],0.06,149121,DB00537,Ciprofloxacin
,1590696,maximum concentration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),[μg] / [ml],1.54,149588,DB00537,Ciprofloxacin
,1590696,penetration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),[μg] / [ml],0.5,149589,DB00537,Ciprofloxacin
,1590696,penetration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),%,27,149590,DB00537,Ciprofloxacin
,1590696,penetration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),%,10,149591,DB00537,Ciprofloxacin
,22029792,total body clearance (Cl(B)),The total body clearance (Cl(B)) was lower in diseased (0·131 l kg⁻¹h⁻¹) than healthy ducks (0·191 l kg⁻¹h⁻¹).,Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22029792/),kg⁻¹h⁻¹·l,0·131,149991,DB00537,Ciprofloxacin
,22029792,total body clearance (Cl(B)),The total body clearance (Cl(B)) was lower in diseased (0·131 l kg⁻¹h⁻¹) than healthy ducks (0·191 l kg⁻¹h⁻¹).,Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22029792/),kg⁻¹h⁻¹·l,0·191,149992,DB00537,Ciprofloxacin
,22029792,maximum time (t(max)),"Following intramuscular administration of orbifloxacin, the peak serum concentration (C(max)) was higher in diseased than in healthy ducks, and this was achieved at a maximum time (t(max)) of 1·114 and 0·993 h, respectively.",Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22029792/),h,1·114,149993,DB00537,Ciprofloxacin
,22029792,maximum time (t(max)),"Following intramuscular administration of orbifloxacin, the peak serum concentration (C(max)) was higher in diseased than in healthy ducks, and this was achieved at a maximum time (t(max)) of 1·114 and 0·993 h, respectively.",Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22029792/),h,0·993,149994,DB00537,Ciprofloxacin
,22029792,elimination half-life t (0·5(el)),The drug was eliminated at a significant slower rate in diseased ducks (elimination half-life t (0·5(el))= 5·07 h) than in healthy ducks (elimination half-life t (0·5(el))= 4·18 h).,Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22029792/),h,5·07,149995,DB00537,Ciprofloxacin
,22029792,elimination half-life t (0·5(el)),The drug was eliminated at a significant slower rate in diseased ducks (elimination half-life t (0·5(el))= 5·07 h) than in healthy ducks (elimination half-life t (0·5(el))= 4·18 h).,Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22029792/),h,4·18,149996,DB00537,Ciprofloxacin
,31845357,body clearance,"It was found that during a 2.5-month-long period of growth from 1.4 to 14.6 kg, the AUC after i.v. administration increased almost threefold due to a significant decrease in the body clearance (from a mean of 0.76-0.28 L hr-1 kg-1 ).",The influence of age and body weight gain on enrofloxacin pharmacokinetics in turkeys-Allometric approach to dose optimization. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31845357/),[l] / [h·kg],0.76-0.28,150612,DB00537,Ciprofloxacin
,31845357,elimination half-life,"Over the same period, the mean elimination half-life was prolonged from 2.65 to 7.03 hr.",The influence of age and body weight gain on enrofloxacin pharmacokinetics in turkeys-Allometric approach to dose optimization. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31845357/),h,2.65 to 7.03,150613,DB00537,Ciprofloxacin
exceeded,2120173,aqueous peak,The mean aqueous peak exceeded 0.4 mg/l between 2 and 3.5 h after administration.,Penetration of ciprofloxacin into the aqueous humour of the uninflamed human eye after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120173/),[mg] / [l],0.4,151289,DB00537,Ciprofloxacin
,2292201,serum peaks,Mean serum peaks were 2.80 +/- 1.00 mg/l in 64 +/- 37 min after intake in patients with normal renal function.,Pharmacokinetics of ciprofloxacin in liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292201/),[mg] / [l],2.80,152060,DB00537,Ciprofloxacin
,2292201,t1/2 beta,Elimination was reduced in comparison with healthy volunteers: t1/2 beta 510 +/- 158 min with a total area under the curve of 18.2 +/- 10.3 mg x h/l.,Pharmacokinetics of ciprofloxacin in liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292201/),min,510,152061,DB00537,Ciprofloxacin
,2292201,total area under the curve,Elimination was reduced in comparison with healthy volunteers: t1/2 beta 510 +/- 158 min with a total area under the curve of 18.2 +/- 10.3 mg x h/l.,Pharmacokinetics of ciprofloxacin in liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292201/),[h·mg] / [l],18.2,152062,DB00537,Ciprofloxacin
,2292201,recovery,Mean recovery of the parent compound from urine was 38 +/- 9% of the dose.,Pharmacokinetics of ciprofloxacin in liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292201/),%,38,152063,DB00537,Ciprofloxacin
,23988790,MIC,"The MIC values of the AMPs and antibiotics ranged between 2 to 16 and 0.25 to 512 mg/L, and their MBEC values were 640 and 512 to 5120 mg/L, respectively.",In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23988790/),[mg] / [l],2 to 16,152111,DB00537,Ciprofloxacin
,23988790,MIC,"The MIC values of the AMPs and antibiotics ranged between 2 to 16 and 0.25 to 512 mg/L, and their MBEC values were 640 and 512 to 5120 mg/L, respectively.",In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23988790/),[mg] / [l],0.25 to 512,152112,DB00537,Ciprofloxacin
,23988790,MBEC,"The MIC values of the AMPs and antibiotics ranged between 2 to 16 and 0.25 to 512 mg/L, and their MBEC values were 640 and 512 to 5120 mg/L, respectively.",In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23988790/),[mg] / [l],640,152113,DB00537,Ciprofloxacin
,23988790,MBEC,"The MIC values of the AMPs and antibiotics ranged between 2 to 16 and 0.25 to 512 mg/L, and their MBEC values were 640 and 512 to 5120 mg/L, respectively.",In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23988790/),[mg] / [l],512 to 5120,152114,DB00537,Ciprofloxacin
,26270353,Cmax,The ENR was slowly absorbed and eliminated from the plasma (Cmax = 1.24 ± 0.37 μg/mL; Tmax = 8 h; T1/2Ke = 19.36 h).,Pharmacokinetic study of enrofloxacin in Nile tilapia (Oreochromis niloticus) after a single oral administration in medicated feed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26270353/),[μg] / [ml],1.24,153316,DB00537,Ciprofloxacin
,26270353,Tmax,The ENR was slowly absorbed and eliminated from the plasma (Cmax = 1.24 ± 0.37 μg/mL; Tmax = 8 h; T1/2Ke = 19.36 h).,Pharmacokinetic study of enrofloxacin in Nile tilapia (Oreochromis niloticus) after a single oral administration in medicated feed. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26270353/),h,8,153317,DB00537,Ciprofloxacin
,26270353,T1/2Ke,The ENR was slowly absorbed and eliminated from the plasma (Cmax = 1.24 ± 0.37 μg/mL; Tmax = 8 h; T1/2Ke = 19.36 h).,Pharmacokinetic study of enrofloxacin in Nile tilapia (Oreochromis niloticus) after a single oral administration in medicated feed. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26270353/),h,19.36,153318,DB00537,Ciprofloxacin
,26270353,maximum values,ENR was efficiently distributed in the muscle tissue and reached maximum values (2.17 ± 0.74 μg/g) after 8 h.,Pharmacokinetic study of enrofloxacin in Nile tilapia (Oreochromis niloticus) after a single oral administration in medicated feed. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26270353/),[μg] / [g],2.17,153319,DB00537,Ciprofloxacin
,11168914,t1/2beta,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.14,153369,DB00537,Ciprofloxacin
,11168914,AUC,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],6.71,153370,DB00537,Ciprofloxacin
,11168914,AUC,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.5,153371,DB00537,Ciprofloxacin
,11168914,MRT,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],6.71,153372,DB00537,Ciprofloxacin
,11168914,MRT,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.5,153373,DB00537,Ciprofloxacin
,11168914,ClB,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[ml] / [h·kg],807,153374,DB00537,Ciprofloxacin
,11168914,Cmax.,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[μg] / [ml],0.45,153375,DB00537,Ciprofloxacin
,11168914,t1/2beta,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.79,153376,DB00537,Ciprofloxacin
,11168914,t1/2beta,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],1.84,153377,DB00537,Ciprofloxacin
,11168914,AUC,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.79,153378,DB00537,Ciprofloxacin
,11168914,AUC,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],1.84,153379,DB00537,Ciprofloxacin
,11168914,MRT,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,3.34,153380,DB00537,Ciprofloxacin
,11168914,t1/2beta,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.83,153381,DB00537,Ciprofloxacin
,11168914,AUC,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[?·h·μg] / [ml],11.68,153382,DB00537,Ciprofloxacin
,11168914,MRT,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,2.13,153383,DB00537,Ciprofloxacin
,11168914,ClB,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[ml] / [h·kg],430,153384,DB00537,Ciprofloxacin
,11168914,conversion,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),%,8.5,153385,DB00537,Ciprofloxacin
,11168914,Cmax.,"The Cmax. (0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[μg] / [ml],0.18,153386,DB00537,Ciprofloxacin
,11168914,AUC,"The Cmax. (0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],0.99,153387,DB00537,Ciprofloxacin
,11168914,t1/2beta,"The Cmax. (0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,2.75,153388,DB00537,Ciprofloxacin
,11168914,MRT,"The Cmax. (0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,4.58,153389,DB00537,Ciprofloxacin
,23609512,ƒAUC(0-24)/MIC,The mean ƒAUC(0-24)/MIC was 41.3 ± 18.8 in the patients with DCS and 585.4 ± 219 in patients with a CS isolate.,Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609512/),,41.3,153420,DB00537,Ciprofloxacin
,23609512,ƒAUC(0-24)/MIC,The mean ƒAUC(0-24)/MIC was 41.3 ± 18.8 in the patients with DCS and 585.4 ± 219 in patients with a CS isolate.,Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609512/),,585.4,153421,DB00537,Ciprofloxacin
,23609512,ƒAUC0-24/MIC,"For DCS isolates, the mean ƒAUC0-24/MIC for levofloxacin was 60.5 ± 28.7 and for gatifloxacin, it was 97.9 ± 28.0.",Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609512/),,60.5,153422,DB00537,Ciprofloxacin
,23609512,ƒAUC0-24/MIC,"For DCS isolates, the mean ƒAUC0-24/MIC for levofloxacin was 60.5 ± 28.7 and for gatifloxacin, it was 97.9 ± 28.0.",Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609512/),,97.9,153423,DB00537,Ciprofloxacin
,10459821,"distribution (Vd, lambda(z)/F)","The presence of SO also caused an eight-fold and two-fold increase in drug distribution (Vd, lambda(z)/F) and terminal elimination half-life (t1/2, lambda(z)) from 30.8 L/kg and 1.96 h, respectively.","Influence of Sanguisorba officinalis, a mineral-rich plant drug, on the pharmacokinetics of ciprofloxacin in the rat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10459821/),[l] / [kg],30.8,153790,DB00537,Ciprofloxacin
,10459821,"terminal elimination half-life (t1/2, lambda(z))","The presence of SO also caused an eight-fold and two-fold increase in drug distribution (Vd, lambda(z)/F) and terminal elimination half-life (t1/2, lambda(z)) from 30.8 L/kg and 1.96 h, respectively.","Influence of Sanguisorba officinalis, a mineral-rich plant drug, on the pharmacokinetics of ciprofloxacin in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10459821/),h,1.96,153791,DB00537,Ciprofloxacin
,8787869,maximum ciprofloxacin concentrations,"The maximum ciprofloxacin concentrations in serum for ciprofloxacin given and for ciprofloxacin plus enteral feeding for the oral, gastrostomy, and jejunostomy groups were (mean +/- standard deviation) 2.59 +/- 1.24 versus 1.43 +/- 0.61 micrograms/ml (P < 0.05), 3.68 +/- 1.36 versus 2.27 +/- 0.67 micrograms/ml (P < 0.05), and 3.78 +/- 1.87 versus 1.45 +/- 0.48 micrograms/ml (P < 0.05), respectively.",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [ml],2.59,153801,DB00537,Ciprofloxacin
,8787869,maximum ciprofloxacin concentrations,"The maximum ciprofloxacin concentrations in serum for ciprofloxacin given and for ciprofloxacin plus enteral feeding for the oral, gastrostomy, and jejunostomy groups were (mean +/- standard deviation) 2.59 +/- 1.24 versus 1.43 +/- 0.61 micrograms/ml (P < 0.05), 3.68 +/- 1.36 versus 2.27 +/- 0.67 micrograms/ml (P < 0.05), and 3.78 +/- 1.87 versus 1.45 +/- 0.48 micrograms/ml (P < 0.05), respectively.",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [ml],1.43,153802,DB00537,Ciprofloxacin
,8787869,maximum ciprofloxacin concentrations,"The maximum ciprofloxacin concentrations in serum for ciprofloxacin given and for ciprofloxacin plus enteral feeding for the oral, gastrostomy, and jejunostomy groups were (mean +/- standard deviation) 2.59 +/- 1.24 versus 1.43 +/- 0.61 micrograms/ml (P < 0.05), 3.68 +/- 1.36 versus 2.27 +/- 0.67 micrograms/ml (P < 0.05), and 3.78 +/- 1.87 versus 1.45 +/- 0.48 micrograms/ml (P < 0.05), respectively.",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [ml],3.68,153803,DB00537,Ciprofloxacin
,8787869,maximum ciprofloxacin concentrations,"The maximum ciprofloxacin concentrations in serum for ciprofloxacin given and for ciprofloxacin plus enteral feeding for the oral, gastrostomy, and jejunostomy groups were (mean +/- standard deviation) 2.59 +/- 1.24 versus 1.43 +/- 0.61 micrograms/ml (P < 0.05), 3.68 +/- 1.36 versus 2.27 +/- 0.67 micrograms/ml (P < 0.05), and 3.78 +/- 1.87 versus 1.45 +/- 0.48 micrograms/ml (P < 0.05), respectively.",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [ml],2.27,153804,DB00537,Ciprofloxacin
,8787869,maximum ciprofloxacin concentrations,"The maximum ciprofloxacin concentrations in serum for ciprofloxacin given and for ciprofloxacin plus enteral feeding for the oral, gastrostomy, and jejunostomy groups were (mean +/- standard deviation) 2.59 +/- 1.24 versus 1.43 +/- 0.61 micrograms/ml (P < 0.05), 3.68 +/- 1.36 versus 2.27 +/- 0.67 micrograms/ml (P < 0.05), and 3.78 +/- 1.87 versus 1.45 +/- 0.48 micrograms/ml (P < 0.05), respectively.",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [ml],3.78,153805,DB00537,Ciprofloxacin
,8787869,maximum ciprofloxacin concentrations,"The maximum ciprofloxacin concentrations in serum for ciprofloxacin given and for ciprofloxacin plus enteral feeding for the oral, gastrostomy, and jejunostomy groups were (mean +/- standard deviation) 2.59 +/- 1.24 versus 1.43 +/- 0.61 micrograms/ml (P < 0.05), 3.68 +/- 1.36 versus 2.27 +/- 0.67 micrograms/ml (P < 0.05), and 3.78 +/- 1.87 versus 1.45 +/- 0.48 micrograms/ml (P < 0.05), respectively.",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [ml],1.45,153806,DB00537,Ciprofloxacin
,8787869,area under the concentration-time curve,"Corresponding values for area under the concentration-time curve were 13.4 +/- 8.32 versus 9.44 +/- 4.74 micrograms/h/ml (P < 0.05) 15.9 +/- 6.62 versus 7.44 +/- 3.16 (micrograms/h/ml (P < 0.05), and 18.1 +/- 9.37 versus 5.82 +/- 2.63 micrograms.h/ml (P < 0.05).",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [h·ml],13.4,153807,DB00537,Ciprofloxacin
,8787869,area under the concentration-time curve,"Corresponding values for area under the concentration-time curve were 13.4 +/- 8.32 versus 9.44 +/- 4.74 micrograms/h/ml (P < 0.05) 15.9 +/- 6.62 versus 7.44 +/- 3.16 (micrograms/h/ml (P < 0.05), and 18.1 +/- 9.37 versus 5.82 +/- 2.63 micrograms.h/ml (P < 0.05).",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [h·ml],9.44,153808,DB00537,Ciprofloxacin
,8787869,area under the concentration-time curve,"Corresponding values for area under the concentration-time curve were 13.4 +/- 8.32 versus 9.44 +/- 4.74 micrograms/h/ml (P < 0.05) 15.9 +/- 6.62 versus 7.44 +/- 3.16 (micrograms/h/ml (P < 0.05), and 18.1 +/- 9.37 versus 5.82 +/- 2.63 micrograms.h/ml (P < 0.05).",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [h·ml],15.9,153809,DB00537,Ciprofloxacin
,8787869,area under the concentration-time curve,"Corresponding values for area under the concentration-time curve were 13.4 +/- 8.32 versus 9.44 +/- 4.74 micrograms/h/ml (P < 0.05) 15.9 +/- 6.62 versus 7.44 +/- 3.16 (micrograms/h/ml (P < 0.05), and 18.1 +/- 9.37 versus 5.82 +/- 2.63 micrograms.h/ml (P < 0.05).",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[μg] / [h·ml],7.44,153810,DB00537,Ciprofloxacin
,8787869,area under the concentration-time curve,"Corresponding values for area under the concentration-time curve were 13.4 +/- 8.32 versus 9.44 +/- 4.74 micrograms/h/ml (P < 0.05) 15.9 +/- 6.62 versus 7.44 +/- 3.16 (micrograms/h/ml (P < 0.05), and 18.1 +/- 9.37 versus 5.82 +/- 2.63 micrograms.h/ml (P < 0.05).",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[h·μg] / [ml],18.1,153811,DB00537,Ciprofloxacin
,8787869,area under the concentration-time curve,"Corresponding values for area under the concentration-time curve were 13.4 +/- 8.32 versus 9.44 +/- 4.74 micrograms/h/ml (P < 0.05) 15.9 +/- 6.62 versus 7.44 +/- 3.16 (micrograms/h/ml (P < 0.05), and 18.1 +/- 9.37 versus 5.82 +/- 2.63 micrograms.h/ml (P < 0.05).",Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787869/),[h·μg] / [ml],5.82,153812,DB00537,Ciprofloxacin
,11990328,maximum plasma levels reached,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),[μg] / [ml],2.6,154062,DB00537,Ciprofloxacin
,11990328,maximum plasma levels reached,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),[μg] / [ml],2.6,154063,DB00537,Ciprofloxacin
,11990328,time taken for maximum plasma levels to be reached,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),h,1.3,154064,DB00537,Ciprofloxacin
,11990328,time taken for maximum plasma levels to be reached,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),h,1.5,154065,DB00537,Ciprofloxacin
,11990328,t1/2a,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),h,0.7,154066,DB00537,Ciprofloxacin
,11990328,t1/2a,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),h,0.4,154067,DB00537,Ciprofloxacin
,11990328,elimination half-life,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),h,3.6,154068,DB00537,Ciprofloxacin
,11990328,elimination half-life,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),h,3.2,154069,DB00537,Ciprofloxacin
,11990328,area under the curve,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),[μg] / [h·ml],19.3,154070,DB00537,Ciprofloxacin
,11990328,area under the curve,"No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] microg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination half-life (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] microg/mL x h) in healthy volunteers and cirrhotic patients, respectively.",Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990328/),[μg] / [h·ml],21.9,154071,DB00537,Ciprofloxacin
,16311002,flow rate,"The mobile phase, 0.025 M disodium hydrogen phosphate (pH 3.0) and acetonitrile (80:20 v/v), were delivered at a flow rate of 1.0 ml/min.",Development and validation of an HPLC method for the determination of gatifloxacin stability in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16311002/),[ml] / [min],1.0,154547,DB00537,Ciprofloxacin
> or =,16311002,extraction recovery,The extraction recovery of gatifloxacin and the IS from plasma samples was > or = 85%.,Development and validation of an HPLC method for the determination of gatifloxacin stability in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16311002/),%,85,154548,DB00537,Ciprofloxacin
,23605507,peak concentration in plasma (C(max)),"Systemic ciprofloxacin was detected soon after inhalation [peak concentration in plasma (C(max)) 56.42 μg/L, median time to C max 0.625 h], but total systemic exposure was minimal (area under the plasma concentration-time curve 354.4 μg·h/L).",Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23605507/),[μg] / [l],56.42,154706,DB00537,Ciprofloxacin
,23605507,time to C max,"Systemic ciprofloxacin was detected soon after inhalation [peak concentration in plasma (C(max)) 56.42 μg/L, median time to C max 0.625 h], but total systemic exposure was minimal (area under the plasma concentration-time curve 354.4 μg·h/L).",Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23605507/),h,0.625,154707,DB00537,Ciprofloxacin
,23605507,area under the plasma concentration-time curve,"Systemic ciprofloxacin was detected soon after inhalation [peak concentration in plasma (C(max)) 56.42 μg/L, median time to C max 0.625 h], but total systemic exposure was minimal (area under the plasma concentration-time curve 354.4 μg·h/L).",Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23605507/),[h·μg] / [l],354.4,154708,DB00537,Ciprofloxacin
,23605507,Terminal elimination half-life,"Terminal elimination half-life (9.5 h), apparent total clearance from plasma after non-intravenous administration (91.7 L/h) and apparent volume of distribution (1,262 L) data suggest that elimination from the respiratory tract was prolonged.",Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23605507/),h,9.5,154709,DB00537,Ciprofloxacin
,23605507,apparent total clearance,"Terminal elimination half-life (9.5 h), apparent total clearance from plasma after non-intravenous administration (91.7 L/h) and apparent volume of distribution (1,262 L) data suggest that elimination from the respiratory tract was prolonged.",Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23605507/),[l] / [h],91.7,154710,DB00537,Ciprofloxacin
,23605507,apparent volume of distribution,"Terminal elimination half-life (9.5 h), apparent total clearance from plasma after non-intravenous administration (91.7 L/h) and apparent volume of distribution (1,262 L) data suggest that elimination from the respiratory tract was prolonged.",Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23605507/),l,"1,262",154711,DB00537,Ciprofloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],14,155385,DB00537,Ciprofloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],22,155386,DB00537,Ciprofloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],21,155387,DB00537,Ciprofloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],20,155388,DB00537,Ciprofloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],47,155389,DB00537,Ciprofloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],35,155390,DB00537,Ciprofloxacin
,2116257,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax) of fleroxacin was 15.6 +/- 1.6 mg/L, time to Cmax (tmax) was about 3h, elimination half-life (t1/2) was 16 +/- 1h and the percentage of unchanged fleroxacin excreted in urine was 39 +/- 3% of the dose.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[mg] / [l],15.6,155721,DB00537,Ciprofloxacin
,2116257,time to Cmax (tmax),"The peak plasma concentration (Cmax) of fleroxacin was 15.6 +/- 1.6 mg/L, time to Cmax (tmax) was about 3h, elimination half-life (t1/2) was 16 +/- 1h and the percentage of unchanged fleroxacin excreted in urine was 39 +/- 3% of the dose.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),h,3,155722,DB00537,Ciprofloxacin
,2116257,elimination half-life (t1/2),"The peak plasma concentration (Cmax) of fleroxacin was 15.6 +/- 1.6 mg/L, time to Cmax (tmax) was about 3h, elimination half-life (t1/2) was 16 +/- 1h and the percentage of unchanged fleroxacin excreted in urine was 39 +/- 3% of the dose.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),h,16,155723,DB00537,Ciprofloxacin
,2116257,apparent volume of distribution (Vd/f),"Assuming that the bioavailability (f) is complete, the apparent volume of distribution (Vd/f) was lower in elderly (0.9 +/- 0.1 L/kg) than in younger patients (1.3 +/- 0.1 L/kg) and a 2-fold decrease in apparent total clearance (CL/f) was noted (2.58 +/- 0.42 vs 4.86 +/- 0.72 L/h); plasma concentrations were consequently higher in elderly patients.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[l] / [kg],0.9,155724,DB00537,Ciprofloxacin
,2116257,apparent volume of distribution (Vd/f),"Assuming that the bioavailability (f) is complete, the apparent volume of distribution (Vd/f) was lower in elderly (0.9 +/- 0.1 L/kg) than in younger patients (1.3 +/- 0.1 L/kg) and a 2-fold decrease in apparent total clearance (CL/f) was noted (2.58 +/- 0.42 vs 4.86 +/- 0.72 L/h); plasma concentrations were consequently higher in elderly patients.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[l] / [kg],1.3,155725,DB00537,Ciprofloxacin
,2116257,apparent total clearance (CL/f),"Assuming that the bioavailability (f) is complete, the apparent volume of distribution (Vd/f) was lower in elderly (0.9 +/- 0.1 L/kg) than in younger patients (1.3 +/- 0.1 L/kg) and a 2-fold decrease in apparent total clearance (CL/f) was noted (2.58 +/- 0.42 vs 4.86 +/- 0.72 L/h); plasma concentrations were consequently higher in elderly patients.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[l] / [h],2.58,155726,DB00537,Ciprofloxacin
,2116257,apparent total clearance (CL/f),"Assuming that the bioavailability (f) is complete, the apparent volume of distribution (Vd/f) was lower in elderly (0.9 +/- 0.1 L/kg) than in younger patients (1.3 +/- 0.1 L/kg) and a 2-fold decrease in apparent total clearance (CL/f) was noted (2.58 +/- 0.42 vs 4.86 +/- 0.72 L/h); plasma concentrations were consequently higher in elderly patients.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[l] / [h],4.86,155727,DB00537,Ciprofloxacin
,6486762,distribution volume,"After administration, distribution of ciprofloxacin was very rapid, and the mean distribution volume was very large (177 liters).",Pharmacokinetics of intravenously administered ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486762/),l,177,155769,DB00537,Ciprofloxacin
,6486762,terminal serum half-life,The mean terminal serum half-life was 4.0 h.,Pharmacokinetics of intravenously administered ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486762/),h,4.0,155770,DB00537,Ciprofloxacin
,6486762,maximum level,"The agent penetrated blister fluid rapidly, with the mean maximum level being 0.53 micrograms/ml at 30 min, after which time the blister levels exceeded those in serum.",Pharmacokinetics of intravenously administered ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486762/),[μg] / [ml],0.53,155771,DB00537,Ciprofloxacin
,6486762,urinary recovery,The 48-h urinary recovery of ciprofloxacin was about 80%.,Pharmacokinetics of intravenously administered ciprofloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486762/),%,80,155772,DB00537,Ciprofloxacin
up,8092837,peak concentrations,Kinetic modeling suggested that peak sparfloxacin concentrations in brain tissue may have occurred later than 3 to 5 h and that actual peak concentrations may therefore have been higher (up to 10 micrograms/g of tissue).,Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),,10,155832,DB00537,Ciprofloxacin
,8092837,50% inhibitory concentration (IC50),"The 50% inhibitory concentration (IC50) of ciprofloxacin was 250 microM (95.25 micrograms/ml), but in the presence of biphenyl acetic acid (BPAA), the IC50 of ciprofloxacin was only 0.6 microM (0.23 microgram/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),μM,250,155833,DB00537,Ciprofloxacin
,8092837,50% inhibitory concentration (IC50),"The 50% inhibitory concentration (IC50) of ciprofloxacin was 250 microM (95.25 micrograms/ml), but in the presence of biphenyl acetic acid (BPAA), the IC50 of ciprofloxacin was only 0.6 microM (0.23 microgram/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),[μg] / [ml],95.25,155834,DB00537,Ciprofloxacin
,8092837,IC50,"The 50% inhibitory concentration (IC50) of ciprofloxacin was 250 microM (95.25 micrograms/ml), but in the presence of biphenyl acetic acid (BPAA), the IC50 of ciprofloxacin was only 0.6 microM (0.23 microgram/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),μM,0.6,155835,DB00537,Ciprofloxacin
,8092837,IC50,"The 50% inhibitory concentration (IC50) of ciprofloxacin was 250 microM (95.25 micrograms/ml), but in the presence of biphenyl acetic acid (BPAA), the IC50 of ciprofloxacin was only 0.6 microM (0.23 microgram/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),[μg] / [ml],0.23,155836,DB00537,Ciprofloxacin
>,8092837,IC50,"In contrast, the IC50 of sparfloxacin alone or in the presence of BPAA was > 300 microM (> 100 micrograms/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),μM,300,155837,DB00537,Ciprofloxacin
>,8092837,IC50,"In contrast, the IC50 of sparfloxacin alone or in the presence of BPAA was > 300 microM (> 100 micrograms/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),[μg] / [ml],100,155838,DB00537,Ciprofloxacin
,25218157,AUCprostate,"Moxifloxacin showed a significant tissue distribution in the prostate (AUCprostate,ISF/fu·AUCplasma=1.24±0.37), 59% higher than the value obtained for levofloxacin in a previous study.",Enhanced penetration of moxifloxacin into rat prostate tissue evidenced by microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25218157/),,1.24,156262,DB00537,Ciprofloxacin
,3391864,plasma half life,The mean plasma half life on 200 mg iv was 5.7 +/- 1.7 h and mean plasma clearance 389 ml/min.,"A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391864/),h,5.7,157150,DB00537,Ciprofloxacin
,3391864,plasma clearance,The mean plasma half life on 200 mg iv was 5.7 +/- 1.7 h and mean plasma clearance 389 ml/min.,"A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391864/),[ml] / [min],389,157151,DB00537,Ciprofloxacin
,3391864,peak serum level,The peak serum level after 750 mg orally was 3.6 +/- 2.2 mg/l and occurred between 1 and 3 h.,"A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391864/),[mg] / [l],3.6,157152,DB00537,Ciprofloxacin
,7637197,Urinary excretion,"3. Urinary excretion of T-3761 as active form until 24 hours after oral administration was 27.3%, 63.1%, 41.0% and 63.3% in mice, rats, rabbits and dogs, respectively.","[Absorption, distribution, metabolism and excretion of T-3761, a new quinolone derivative, in experimental animals]. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7637197/),%,27.3,157208,DB00537,Ciprofloxacin
,7637197,Urinary excretion,"3. Urinary excretion of T-3761 as active form until 24 hours after oral administration was 27.3%, 63.1%, 41.0% and 63.3% in mice, rats, rabbits and dogs, respectively.","[Absorption, distribution, metabolism and excretion of T-3761, a new quinolone derivative, in experimental animals]. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7637197/),%,63.1,157209,DB00537,Ciprofloxacin
,7637197,Urinary excretion,"3. Urinary excretion of T-3761 as active form until 24 hours after oral administration was 27.3%, 63.1%, 41.0% and 63.3% in mice, rats, rabbits and dogs, respectively.","[Absorption, distribution, metabolism and excretion of T-3761, a new quinolone derivative, in experimental animals]. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7637197/),%,41.0,157210,DB00537,Ciprofloxacin
,7637197,Urinary excretion,"3. Urinary excretion of T-3761 as active form until 24 hours after oral administration was 27.3%, 63.1%, 41.0% and 63.3% in mice, rats, rabbits and dogs, respectively.","[Absorption, distribution, metabolism and excretion of T-3761, a new quinolone derivative, in experimental animals]. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7637197/),%,63.3,157211,DB00537,Ciprofloxacin
,7637197,Biliary excretion,4. Biliary excretion of T-3761 in mice and rats were 2.9% and 1.4% as active form.,"[Absorption, distribution, metabolism and excretion of T-3761, a new quinolone derivative, in experimental animals]. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7637197/),%,2.9,157212,DB00537,Ciprofloxacin
,7637197,Biliary excretion,4. Biliary excretion of T-3761 in mice and rats were 2.9% and 1.4% as active form.,"[Absorption, distribution, metabolism and excretion of T-3761, a new quinolone derivative, in experimental animals]. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7637197/),%,1.4,157213,DB00537,Ciprofloxacin
,8842573,urinary excretion,The urinary excretion of nitrate during nitrate restriction was 840 +/- 146 mumol/24 h.,Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842573/),[μM] / [24·h],840,157246,DB00537,Ciprofloxacin
,8842573,t1/2,"The subsequent drop in plasma nitrate, with a t1/2 of 451 +/- 42 min, was probably a reflection of the redistribution of nitrate within the body fluids and the renal excretion of nitrate.",Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842573/),min,451,157247,DB00537,Ciprofloxacin
,8842573,plasma clearance,The plasma clearance of nitrate was 30 +/- 2 ml/min/1.73 m2 BSA.,Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842573/),[ml] / [1.73·m2·min],30,157248,DB00537,Ciprofloxacin
,20557446,MIC,"MIC values for wild strains of Gram-negative (Escherichia coli, Pseudomonas aeruginosa) and Gram-positive bacteria (beta-haemolytic streptococci) ranged from 0.25-2 and 1.5-3.0 microg/mL respectively.",Enrofloxacin-based therapeutic strategy for the prevention of endometritis in susceptible mares. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20557446/),[μg] / [ml],0.25-2,157304,DB00537,Ciprofloxacin
,20557446,MIC,"MIC values for wild strains of Gram-negative (Escherichia coli, Pseudomonas aeruginosa) and Gram-positive bacteria (beta-haemolytic streptococci) ranged from 0.25-2 and 1.5-3.0 microg/mL respectively.",Enrofloxacin-based therapeutic strategy for the prevention of endometritis in susceptible mares. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20557446/),[μg] / [ml],1.5-3.0,157305,DB00537,Ciprofloxacin
,1810184,concentrations,The mean concentrations in plasma peaked at 4.94 +/- 2.90 mg/liter at the end of infusion.,Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810184/),[mg] / [l],4.94,157917,DB00537,Ciprofloxacin
,1810184,terminal half-life,"The terminal half-life was 4.95 +/- 2.81 h, and the mean residence time 6.13 +/- 3.17 h.",Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810184/),h,4.95,157918,DB00537,Ciprofloxacin
,1810184,mean residence time,"The terminal half-life was 4.95 +/- 2.81 h, and the mean residence time 6.13 +/- 3.17 h.",Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810184/),h,6.13,157919,DB00537,Ciprofloxacin
,1810184,volume of distribution,A large volume of distribution was calculated: 2.59 +/- 1.43 liters/kg.,Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810184/),[l] / [kg],2.59,157920,DB00537,Ciprofloxacin
,1810184,total body clearance,Mean total body clearance was 23.3 +/- 10.1 liters/h.,Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810184/),[l] / [h],23.3,157921,DB00537,Ciprofloxacin
,1810184,tissue-versus-plasma concentration ratios,"The tissue-versus-plasma concentration ratios ranged from 10.1 to 26.3 (mean value, 16.9 +/- 5.43).",Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810184/),,16.9,157922,DB00537,Ciprofloxacin
,17217405,Steady-state volume of distribution (V(ss)),Steady-state volume of distribution (V(ss)) and total body clearance (Cl) of difloxacin after i.v. administration were estimated to be 1.16 +/- 0.26 L/kg and 0.32 +/- 0.05 L/h x kg respectively.,"Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217405/),[l] / [kg],1.16,158070,DB00537,Ciprofloxacin
,17217405,total body clearance (Cl),Steady-state volume of distribution (V(ss)) and total body clearance (Cl) of difloxacin after i.v. administration were estimated to be 1.16 +/- 0.26 L/kg and 0.32 +/- 0.05 L/h x kg respectively.,"Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217405/),[l] / [h·kg],0.32,158071,DB00537,Ciprofloxacin
,17217405,maximum plasma concentrations,Following s.c. and i.m. administration difloxacin achieved maximum plasma concentrations of 1.33 +/- 0.25 and 1.97 +/- 0.40 mg/L at 3.37 +/- 0.36 and 1.79 +/- 1.14 h respectively.,"Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217405/),[mg] / [l],1.33,158072,DB00537,Ciprofloxacin
,17217405,maximum plasma concentrations,Following s.c. and i.m. administration difloxacin achieved maximum plasma concentrations of 1.33 +/- 0.25 and 1.97 +/- 0.40 mg/L at 3.37 +/- 0.36 and 1.79 +/- 1.14 h respectively.,"Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217405/),[mg] / [l],1.97,158073,DB00537,Ciprofloxacin
,17217405,absolute bioavailabilities,The absolute bioavailabilities after s.c. and i.m. routes were 90.16 +/- 11.99% and 106.79 +/- 13.95% respectively.,"Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217405/),%,90.16,158074,DB00537,Ciprofloxacin
,17217405,absolute bioavailabilities,The absolute bioavailabilities after s.c. and i.m. routes were 90.16 +/- 11.99% and 106.79 +/- 13.95% respectively.,"Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217405/),%,106.79,158075,DB00537,Ciprofloxacin
,10590278,MIC(90)s,"The MIC(90)s of levofloxacin and ciprofloxacin for 20 independent isolates of such bacteria were 1 and 8 mg/L, respectively.",Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],1,158593,DB00537,Ciprofloxacin
,10590278,MIC(90)s,"The MIC(90)s of levofloxacin and ciprofloxacin for 20 independent isolates of such bacteria were 1 and 8 mg/L, respectively.",Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],8,158594,DB00537,Ciprofloxacin
<,10590278,MIC,Rats were infected with two types of organism: either fully susceptible to levofloxacin MIC < or = 0.5 mg/L) or borderline susceptible (MIC 1-2 mg/L).,Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],0.5,158595,DB00537,Ciprofloxacin
,10590278,MIC,Rats were infected with two types of organism: either fully susceptible to levofloxacin MIC < or = 0.5 mg/L) or borderline susceptible (MIC 1-2 mg/L).,Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],1-2,158596,DB00537,Ciprofloxacin
,10590278,MIC,"Fully levofloxacin-susceptible bacteria comprised one penicillin-susceptible (MIC 0.004 mg/L) Streptococcus gordonii, and one penicillin-tolerant as well as one intermediate penicillin-resistant (MIC 0.125 mg/L) isogenic strains.",Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],0.004,158597,DB00537,Ciprofloxacin
,10590278,MIC,"Fully levofloxacin-susceptible bacteria comprised one penicillin-susceptible (MIC 0.004 mg/L) Streptococcus gordonii, and one penicillin-tolerant as well as one intermediate penicillin-resistant (MIC 0.125 mg/L) isogenic strains.",Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],0.125,158598,DB00537,Ciprofloxacin
,10590278,MIC,Borderline levofloxacin-susceptible bacteria comprised one penicillin-susceptible Streptococcus sanguis and one highly penicillin-resistant Streptococcus mitis (MIC 2 mg/L).,Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],2,158599,DB00537,Ciprofloxacin
,21928725,Cmax1,"The following mean values of ciprofloxacin blood concentrations were obtained from the analyzed patients: Cmax1 = 2.34 (+/- 1.15) microg/mL, Cssmax = 2.49 (+/- 1.44) pg/mL, Cssmin = 0.42 (+/- 0.22) pg/mL.",The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21928725/),[μg] / [ml],2.34,159308,DB00537,Ciprofloxacin
,21928725,Cssmax,"The following mean values of ciprofloxacin blood concentrations were obtained from the analyzed patients: Cmax1 = 2.34 (+/- 1.15) microg/mL, Cssmax = 2.49 (+/- 1.44) pg/mL, Cssmin = 0.42 (+/- 0.22) pg/mL.",The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21928725/),[pg] / [ml],2.49,159309,DB00537,Ciprofloxacin
,21928725,Cssmin,"The following mean values of ciprofloxacin blood concentrations were obtained from the analyzed patients: Cmax1 = 2.34 (+/- 1.15) microg/mL, Cssmax = 2.49 (+/- 1.44) pg/mL, Cssmin = 0.42 (+/- 0.22) pg/mL.",The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21928725/),[pg] / [ml],0.42,159310,DB00537,Ciprofloxacin
,21928725,Cmax1/MIC,"The mean values of the Cmax1/MIC and Cssmax/MIC indexes were 3.66 +/- 2.34) and 3.38 (+/-1.73), respectively.",The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21928725/),,3.66,159311,DB00537,Ciprofloxacin
,21928725,Cssmax/MIC,"The mean values of the Cmax1/MIC and Cssmax/MIC indexes were 3.66 +/- 2.34) and 3.38 (+/-1.73), respectively.",The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21928725/),,3.38,159312,DB00537,Ciprofloxacin
,11767010,elimination half-life,"The elimination half-life and volume of distribution were 3.88 and 0.08 h and 3.97 +/- 0.22 L/kg, respectively.","The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11767010/),h,3.88,159841,DB00537,Ciprofloxacin
,11767010,volume of distribution,"The elimination half-life and volume of distribution were 3.88 and 0.08 h and 3.97 +/- 0.22 L/kg, respectively.","The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11767010/),h,0.08,159842,DB00537,Ciprofloxacin
,11767010,volume of distribution,"The elimination half-life and volume of distribution were 3.88 and 0.08 h and 3.97 +/- 0.22 L/kg, respectively.","The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11767010/),[l] / [kg],3.97,159843,DB00537,Ciprofloxacin
,11767010,total body clearance,"The total body clearance and T/P ratio were 0.709 +/- 0.025 L/kg per h and 6.13 +/- 0.54, respectively.","The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11767010/),[l] / [h·kg],0.709,159844,DB00537,Ciprofloxacin
,11767010,T/P ratio,"The total body clearance and T/P ratio were 0.709 +/- 0.025 L/kg per h and 6.13 +/- 0.54, respectively.","The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11767010/),,6.13,159845,DB00537,Ciprofloxacin
,11767010,minimum therapeutic plasma concentration,"To maintain a minimum therapeutic plasma concentration of 0.10 microg/ml, a satisfactory intravenous dosage regimen of ciprofloxacin, computed on the basis of disposition kinetic data obtained in healthy buffalo calves, would be 3 mg/kg repeated at 12 h intervals.","The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11767010/),[μg] / [ml],0.10,159846,DB00537,Ciprofloxacin
,3463543,MICs,The MICs of enoxacin against all but one of the gram-negative isolates cultured from 265 urological patients were between 0.03 and 4 mg/l.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.03 and 4,159866,DB00537,Ciprofloxacin
,3463543,MICs,The MICs against 134 gram-positive isolates were between 0.25 and 16 mg/l except two strains of streptococci.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.25 and 16,159867,DB00537,Ciprofloxacin
,3463543,peak serum concentrations,Oral administration of 400 mg enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.7 and 6.3,159868,DB00537,Ciprofloxacin
,3463543,peak serum concentrations,Oral administration of 400 mg enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],3.6,159869,DB00537,Ciprofloxacin
,3463543,urinary recovery,The mean urinary recovery of parent drug within 24 h was 31.2% of the administered dose.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),%,31.2,159870,DB00537,Ciprofloxacin
,10829566,Tmax,"Serum levels reached their peak Tmax, at 2.321 and 2.524 hrs.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),h,2.321,160957,DB00537,Ciprofloxacin
,10829566,Tmax,"Serum levels reached their peak Tmax, at 2.321 and 2.524 hrs.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),h,2.524,160958,DB00537,Ciprofloxacin
,10829566,absorption half-life (t0.5 (ab)),"in healthy and infected rabbits after oral administration, with absorption half-life (t0.5 (ab)) of 1.22 and 2.41 hrs.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),h,1.22,160959,DB00537,Ciprofloxacin
,10829566,absorption half-life (t0.5 (ab)),"in healthy and infected rabbits after oral administration, with absorption half-life (t0.5 (ab)) of 1.22 and 2.41 hrs.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),h,2.41,160960,DB00537,Ciprofloxacin
,10829566,elimination half-life (t0.5 (B)),and elimination half-life (t0.5 (B)) of 2.24 and 1.28 hour respectively.,Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),h,2.24,160961,DB00537,Ciprofloxacin
,10829566,elimination half-life (t0.5 (B)),and elimination half-life (t0.5 (B)) of 2.24 and 1.28 hour respectively.,Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),h,1.28,160962,DB00537,Ciprofloxacin
,10829566,t0.5 (B)),"Following I/V injection the kinetics of Ciprofloxacin follow two compartment model with (t0.5 (B)) 1.201 and 0.82 hour for normal and infected rabbits, (Vd (area)) of 0.653 and 0.563 L/kg and total body clearance CL(B) of 0.385 and 0.358 L/kg/hr respectively.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),h,1.201,160963,DB00537,Ciprofloxacin
,10829566,t0.5 (B)),"Following I/V injection the kinetics of Ciprofloxacin follow two compartment model with (t0.5 (B)) 1.201 and 0.82 hour for normal and infected rabbits, (Vd (area)) of 0.653 and 0.563 L/kg and total body clearance CL(B) of 0.385 and 0.358 L/kg/hr respectively.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),h,0.82,160964,DB00537,Ciprofloxacin
,10829566,Vd (area)),"Following I/V injection the kinetics of Ciprofloxacin follow two compartment model with (t0.5 (B)) 1.201 and 0.82 hour for normal and infected rabbits, (Vd (area)) of 0.653 and 0.563 L/kg and total body clearance CL(B) of 0.385 and 0.358 L/kg/hr respectively.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),[l] / [kg],0.653,160965,DB00537,Ciprofloxacin
,10829566,Vd (area)),"Following I/V injection the kinetics of Ciprofloxacin follow two compartment model with (t0.5 (B)) 1.201 and 0.82 hour for normal and infected rabbits, (Vd (area)) of 0.653 and 0.563 L/kg and total body clearance CL(B) of 0.385 and 0.358 L/kg/hr respectively.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),[l] / [kg],0.563,160966,DB00537,Ciprofloxacin
,10829566,total body clearance CL(B),"Following I/V injection the kinetics of Ciprofloxacin follow two compartment model with (t0.5 (B)) 1.201 and 0.82 hour for normal and infected rabbits, (Vd (area)) of 0.653 and 0.563 L/kg and total body clearance CL(B) of 0.385 and 0.358 L/kg/hr respectively.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),[l] / [h·kg],0.385,160967,DB00537,Ciprofloxacin
,10829566,total body clearance CL(B),"Following I/V injection the kinetics of Ciprofloxacin follow two compartment model with (t0.5 (B)) 1.201 and 0.82 hour for normal and infected rabbits, (Vd (area)) of 0.653 and 0.563 L/kg and total body clearance CL(B) of 0.385 and 0.358 L/kg/hr respectively.",Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829566/),[l] / [h·kg],0.358,160968,DB00537,Ciprofloxacin
over,32052471,Overall elimination half-life (T½),"Overall elimination half-life (T½) was over 75 hr, and varied among species.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in clinically diseased or injured Eastern box turtles (Terrapene carolina carolina), yellow-bellied sliders (Trachemys scripta scripta), and river cooters (Pseudemys concinna). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052471/),h,75,161221,DB00537,Ciprofloxacin
,32052471,T½,"T½ was 63 hr in EBT and 79 hr in YBS, which is longer than in previous reports.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in clinically diseased or injured Eastern box turtles (Terrapene carolina carolina), yellow-bellied sliders (Trachemys scripta scripta), and river cooters (Pseudemys concinna). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052471/),h,63,161222,DB00537,Ciprofloxacin
,32052471,T½,"T½ was 63 hr in EBT and 79 hr in YBS, which is longer than in previous reports.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in clinically diseased or injured Eastern box turtles (Terrapene carolina carolina), yellow-bellied sliders (Trachemys scripta scripta), and river cooters (Pseudemys concinna). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052471/),h,79,161223,DB00537,Ciprofloxacin
,32052471,volume of distribution (steady-state),"The volume of distribution (steady-state) was 1.4 L/kg across turtle species, but highly variable-ranging from 0.4 L/kg in RC to 1.9 L/kg in YBS.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in clinically diseased or injured Eastern box turtles (Terrapene carolina carolina), yellow-bellied sliders (Trachemys scripta scripta), and river cooters (Pseudemys concinna). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052471/),[l] / [kg],1.4,161224,DB00537,Ciprofloxacin
,32052471,volume of distribution (steady-state),"The volume of distribution (steady-state) was 1.4 L/kg across turtle species, but highly variable-ranging from 0.4 L/kg in RC to 1.9 L/kg in YBS.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in clinically diseased or injured Eastern box turtles (Terrapene carolina carolina), yellow-bellied sliders (Trachemys scripta scripta), and river cooters (Pseudemys concinna). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052471/),[l] / [kg],0.4,161225,DB00537,Ciprofloxacin
,32052471,volume of distribution (steady-state),"The volume of distribution (steady-state) was 1.4 L/kg across turtle species, but highly variable-ranging from 0.4 L/kg in RC to 1.9 L/kg in YBS.","Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in clinically diseased or injured Eastern box turtles (Terrapene carolina carolina), yellow-bellied sliders (Trachemys scripta scripta), and river cooters (Pseudemys concinna). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052471/),[l] / [kg],1.9,161226,DB00537,Ciprofloxacin
,32052471,minimum inhibitory concentration,Antibiotic concentrations were above a minimum inhibitory concentration value of 0.5 µg/ml for over 200 hr.,"Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in clinically diseased or injured Eastern box turtles (Terrapene carolina carolina), yellow-bellied sliders (Trachemys scripta scripta), and river cooters (Pseudemys concinna). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052471/),[μg] / [ml],0.5,161227,DB00537,Ciprofloxacin
,25989138,tissue penetration factors,"Enrofloxacin had tissue penetration factors of 1.6 and 2.5 in the ileum and colon, while ciprofloxacin, an active metabolite of enrofloxacin, was less able to cross into the intestine (tissue penetration factors of 0.7 and 1.7).","Pharmacokinetics of enrofloxacin and ceftiofur in plasma, interstitial fluid, and gastrointestinal tract of calves after subcutaneous injection, and bactericidal impacts on representative enteric bacteria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989138/),,1.6,161913,DB00537,Ciprofloxacin
,25989138,tissue penetration factors,"Enrofloxacin had tissue penetration factors of 1.6 and 2.5 in the ileum and colon, while ciprofloxacin, an active metabolite of enrofloxacin, was less able to cross into the intestine (tissue penetration factors of 0.7 and 1.7).","Pharmacokinetics of enrofloxacin and ceftiofur in plasma, interstitial fluid, and gastrointestinal tract of calves after subcutaneous injection, and bactericidal impacts on representative enteric bacteria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989138/),,2.5,161914,DB00537,Ciprofloxacin
,25989138,tissue penetration factors,"Enrofloxacin had tissue penetration factors of 1.6 and 2.5 in the ileum and colon, while ciprofloxacin, an active metabolite of enrofloxacin, was less able to cross into the intestine (tissue penetration factors of 0.7 and 1.7).","Pharmacokinetics of enrofloxacin and ceftiofur in plasma, interstitial fluid, and gastrointestinal tract of calves after subcutaneous injection, and bactericidal impacts on representative enteric bacteria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989138/),,0.7,161915,DB00537,Ciprofloxacin
,25989138,tissue penetration factors,"Enrofloxacin had tissue penetration factors of 1.6 and 2.5 in the ileum and colon, while ciprofloxacin, an active metabolite of enrofloxacin, was less able to cross into the intestine (tissue penetration factors of 0.7 and 1.7).","Pharmacokinetics of enrofloxacin and ceftiofur in plasma, interstitial fluid, and gastrointestinal tract of calves after subcutaneous injection, and bactericidal impacts on representative enteric bacteria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989138/),,1.7,161916,DB00537,Ciprofloxacin
,25989138,tissue penetration factors,Ceftiofur was rapidly eliminated leading to tissue penetration factors of 0.39 and 0.25.,"Pharmacokinetics of enrofloxacin and ceftiofur in plasma, interstitial fluid, and gastrointestinal tract of calves after subcutaneous injection, and bactericidal impacts on representative enteric bacteria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989138/),,0.39,161917,DB00537,Ciprofloxacin
,25989138,tissue penetration factors,Ceftiofur was rapidly eliminated leading to tissue penetration factors of 0.39 and 0.25.,"Pharmacokinetics of enrofloxacin and ceftiofur in plasma, interstitial fluid, and gastrointestinal tract of calves after subcutaneous injection, and bactericidal impacts on representative enteric bacteria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989138/),,0.25,161918,DB00537,Ciprofloxacin
,9430772,Vd(ss),"Mean volume of distribution (Vd(ss)) and clearance (Cl) were significantly smaller in newborn calves: Vd(ss) was 1.8 and 2.3 L/kg, while clearance was 0.19 and 0.39 L/kg.h in newborn and one-week-old calves, respectively.",Pharmacokinetics of enrofloxacin in newborn and one-week-old calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430772/),[l] / [kg],1.8,161941,DB00537,Ciprofloxacin
,9430772,Vd(ss),"Mean volume of distribution (Vd(ss)) and clearance (Cl) were significantly smaller in newborn calves: Vd(ss) was 1.8 and 2.3 L/kg, while clearance was 0.19 and 0.39 L/kg.h in newborn and one-week-old calves, respectively.",Pharmacokinetics of enrofloxacin in newborn and one-week-old calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430772/),[l] / [kg],2.3,161942,DB00537,Ciprofloxacin
,9430772,clearance,"Mean volume of distribution (Vd(ss)) and clearance (Cl) were significantly smaller in newborn calves: Vd(ss) was 1.8 and 2.3 L/kg, while clearance was 0.19 and 0.39 L/kg.h in newborn and one-week-old calves, respectively.",Pharmacokinetics of enrofloxacin in newborn and one-week-old calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430772/),[l] / [h·kg],0.19,161943,DB00537,Ciprofloxacin
,9430772,clearance,"Mean volume of distribution (Vd(ss)) and clearance (Cl) were significantly smaller in newborn calves: Vd(ss) was 1.8 and 2.3 L/kg, while clearance was 0.19 and 0.39 L/kg.h in newborn and one-week-old calves, respectively.",Pharmacokinetics of enrofloxacin in newborn and one-week-old calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430772/),[l] / [h·kg],0.39,161944,DB00537,Ciprofloxacin
,9430772,t1/2 beta,"Mean elimination half-life (t1/2 beta) did not differ significantly in newborn and in one-week-old calves: mean t1/2 beta was 6.6 h and 4.9 h, respectively.",Pharmacokinetics of enrofloxacin in newborn and one-week-old calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430772/),h,6.6,161945,DB00537,Ciprofloxacin
,9430772,t1/2 beta,"Mean elimination half-life (t1/2 beta) did not differ significantly in newborn and in one-week-old calves: mean t1/2 beta was 6.6 h and 4.9 h, respectively.",Pharmacokinetics of enrofloxacin in newborn and one-week-old calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430772/),h,4.9,161946,DB00537,Ciprofloxacin
,8517694,AUIC,A 24-h AUIC of 125 SIT-1.h (inverse serum inhibitory titer integrated over time) was found to be a significant breakpoint for probabilities of both clinical and microbiologic cures.,Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517694/),[h] / [sit],125,162392,DB00537,Ciprofloxacin
below,8517694,AUIC,"At an AUIC below 125 (19 patients), the percent probabilities of clinical and microbiologic cures were 42 and 26%, respectively.",Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517694/),,125,162393,DB00537,Ciprofloxacin
above,8517694,AUIC,"At an AUIC above 125 (45 patients), the probabilities were 80% (P < 0.005) and 82% (P < 0.001), respectively.",Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517694/),,125,162394,DB00537,Ciprofloxacin
exceeded,8517694,time to eradication,"At an AUIC below 125 (21 patients), the median time to eradication exceeded 32 days; at an AUIC of 125 to 250 (15 patients), time to eradication was 6.6 days: and at AUIC above 250 (28 patients), the median time to eradication was 1.9 days (groups differed; P < 0.005).",Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517694/),d,32,162395,DB00537,Ciprofloxacin
,8517694,time to eradication,"At an AUIC below 125 (21 patients), the median time to eradication exceeded 32 days; at an AUIC of 125 to 250 (15 patients), time to eradication was 6.6 days: and at AUIC above 250 (28 patients), the median time to eradication was 1.9 days (groups differed; P < 0.005).",Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517694/),d,6.6,162396,DB00537,Ciprofloxacin
,8517694,time to eradication,"At an AUIC below 125 (21 patients), the median time to eradication exceeded 32 days; at an AUIC of 125 to 250 (15 patients), time to eradication was 6.6 days: and at AUIC above 250 (28 patients), the median time to eradication was 1.9 days (groups differed; P < 0.005).",Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517694/),d,1.9,162397,DB00537,Ciprofloxacin
,21893387,AUC(24h)/MIC ratios,Maximum losses in susceptibility occurred at AUC(24h)/MIC ratios of 54 (orbifloxacin) and 57.3 (difloxacin).,Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21893387/),,54,162481,DB00537,Ciprofloxacin
,21893387,AUC(24h)/MIC ratios,Maximum losses in susceptibility occurred at AUC(24h)/MIC ratios of 54 (orbifloxacin) and 57.3 (difloxacin).,Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21893387/),,57.3,162482,DB00537,Ciprofloxacin
,21893387,AUC(24h)/MIC ratios,"AUC(24h)/MIC ratios of 169.8 (orbifloxacin) and 199.5 (difloxacin) were estimated to be protective against the selection of E. coli mutants, and the corresponding ratios based on AUC(24h)/MPC predictions were 34 (orbifloxacin) and 36.3 (difloxacin).",Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21893387/),,169.8,162483,DB00537,Ciprofloxacin
,21893387,AUC(24h)/MIC ratios,"AUC(24h)/MIC ratios of 169.8 (orbifloxacin) and 199.5 (difloxacin) were estimated to be protective against the selection of E. coli mutants, and the corresponding ratios based on AUC(24h)/MPC predictions were 34 (orbifloxacin) and 36.3 (difloxacin).",Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21893387/),,199.5,162484,DB00537,Ciprofloxacin
,21893387,AUC(24h)/MIC ratios,"AUC(24h)/MIC ratios of 169.8 (orbifloxacin) and 199.5 (difloxacin) were estimated to be protective against the selection of E. coli mutants, and the corresponding ratios based on AUC(24h)/MPC predictions were 34 (orbifloxacin) and 36.3 (difloxacin).",Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21893387/),,34,162485,DB00537,Ciprofloxacin
,21893387,ratios,"AUC(24h)/MIC ratios of 169.8 (orbifloxacin) and 199.5 (difloxacin) were estimated to be protective against the selection of E. coli mutants, and the corresponding ratios based on AUC(24h)/MPC predictions were 34 (orbifloxacin) and 36.3 (difloxacin).",Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21893387/),,34,162486,DB00537,Ciprofloxacin
,21893387,ratios,"AUC(24h)/MIC ratios of 169.8 (orbifloxacin) and 199.5 (difloxacin) were estimated to be protective against the selection of E. coli mutants, and the corresponding ratios based on AUC(24h)/MPC predictions were 34 (orbifloxacin) and 36.3 (difloxacin).",Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21893387/),,36.3,162487,DB00537,Ciprofloxacin
,12168566,half-life,In all critically ill patients ciprofloxacin elimination was significantly slowed; the mean half-life was similarly prolonged to about 14 h in patients on haemofiltration and those with approximately normal renal function.,Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12168566/),h,14,162650,DB00537,Ciprofloxacin
,12168566,plasma concentration,"Although a unique dose recommendation can hardly be made because of the high variability of pharmacokinetics during haemofiltration, a daily dose of 800 mg (400 mg b.i.d.) in average can be regarded as appropriated for reaching a target plasma concentration of 2 to 3 micrograms/mL (mean concentration).",Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12168566/),[μg] / [ml],2 to 3,162651,DB00537,Ciprofloxacin
,3814211,Terminal half-lives,Terminal half-lives ranging from 26 to 44 h were determined for the elimination of radioactivity from the plasma (observation time up to 48 h after dosing).,"Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814211/),h,26 to 44,162652,DB00537,Ciprofloxacin
,3814211,reaching,"After reaching maximum concentration of 0.25 microgram/ml after administration of 5 mg/kg to rats and 0.88 microgram/ml after dosing with 30 mg/kg to a rhesus monkey, the unchanged drug was eliminated from plasma corresponding to half-lives ranging from 3 h (rat) and 4.4 h (monkey).","Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814211/),[μg] / [ml],0.25,162653,DB00537,Ciprofloxacin
,3814211,maximum concentration,"After reaching maximum concentration of 0.25 microgram/ml after administration of 5 mg/kg to rats and 0.88 microgram/ml after dosing with 30 mg/kg to a rhesus monkey, the unchanged drug was eliminated from plasma corresponding to half-lives ranging from 3 h (rat) and 4.4 h (monkey).","Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814211/),[μg] / [ml],0.25,162654,DB00537,Ciprofloxacin
,3814211,maximum concentration,"After reaching maximum concentration of 0.25 microgram/ml after administration of 5 mg/kg to rats and 0.88 microgram/ml after dosing with 30 mg/kg to a rhesus monkey, the unchanged drug was eliminated from plasma corresponding to half-lives ranging from 3 h (rat) and 4.4 h (monkey).","Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814211/),[μg] / [ml],0.88,162655,DB00537,Ciprofloxacin
,3814211,half-lives,"After reaching maximum concentration of 0.25 microgram/ml after administration of 5 mg/kg to rats and 0.88 microgram/ml after dosing with 30 mg/kg to a rhesus monkey, the unchanged drug was eliminated from plasma corresponding to half-lives ranging from 3 h (rat) and 4.4 h (monkey).","Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814211/),h,3,162656,DB00537,Ciprofloxacin
,3814211,half-lives,"After reaching maximum concentration of 0.25 microgram/ml after administration of 5 mg/kg to rats and 0.88 microgram/ml after dosing with 30 mg/kg to a rhesus monkey, the unchanged drug was eliminated from plasma corresponding to half-lives ranging from 3 h (rat) and 4.4 h (monkey).","Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814211/),h,4.4,162657,DB00537,Ciprofloxacin
,3814211,renal excretion,"After oral dosing renal excretion amounted to 6-14% (rat) and 30% (monkey), respectively.","Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814211/),%,6-14,162658,DB00537,Ciprofloxacin
,3814211,renal excretion,"After oral dosing renal excretion amounted to 6-14% (rat) and 30% (monkey), respectively.","Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814211/),%,30,162659,DB00537,Ciprofloxacin
,8843301,Di,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],126,163923,DB00537,Ciprofloxacin
,8843301,Di,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],100,163924,DB00537,Ciprofloxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],126,163925,DB00537,Ciprofloxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],73,163926,DB00537,Ciprofloxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],103,163927,DB00537,Ciprofloxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],72,163928,DB00537,Ciprofloxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],100,163929,DB00537,Ciprofloxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],100,163930,DB00537,Ciprofloxacin
,8843301,metabolic clearance,"The estimated metabolic clearance was 25 ml/min (coefficient of variation, 43%), and the calculated steady-state volume of distribution was 84 liters (coefficient of variation, 16%).",Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],25,163931,DB00537,Ciprofloxacin
,8843301,steady-state volume of distribution,"The estimated metabolic clearance was 25 ml/min (coefficient of variation, 43%), and the calculated steady-state volume of distribution was 84 liters (coefficient of variation, 16%).",Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),l,84,163932,DB00537,Ciprofloxacin
,8843301,Formation clearances,"Formation clearances of N-demethylfleroxacin and fleroxacin N-oxide were estimated to be 54 and 33% of fleroxacin's metabolic clearance, respectively.",Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),%,54,163933,DB00537,Ciprofloxacin
,8843301,Formation clearances,"Formation clearances of N-demethylfleroxacin and fleroxacin N-oxide were estimated to be 54 and 33% of fleroxacin's metabolic clearance, respectively.",Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),%,33,163934,DB00537,Ciprofloxacin
,8851573,CL/F,"The predicted CL/F and V/F were 83.5 ml/min and 101 liters, respectively, for a typical male subject (CLCR, 70 ml/min; LBW, 54 kg; age, 54 years).",Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851573/),[ml] / [min],83.5,164576,DB00537,Ciprofloxacin
,8851573,V/F,"The predicted CL/F and V/F were 83.5 ml/min and 101 liters, respectively, for a typical male subject (CLCR, 70 ml/min; LBW, 54 kg; age, 54 years).",Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851573/),l,101,164577,DB00537,Ciprofloxacin
,8851573,V/F,V/F was found to be 20.4 liters greater in males than in females.,Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851573/),l,20.4,164578,DB00537,Ciprofloxacin
,2152392,terminal half life,Pharmacokinetic analysis showed that ciprofloxacin was readily absorbed with a terminal half life of 2.5 hours and considerable nonrenal elimination.,Peroral treatment with ciprofloxacin of patients with spinal cord lesion and bacteriuria caused by multiply resistant bacteria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2152392/),h,2.5,164807,DB00537,Ciprofloxacin
,2941279,rate of penetration,The rate of penetration of ciprofloxacin into nasal secretion was 73% following the first oral dose and 90% following the 15th oral dose.,Single and multiple dose pharmacokinetics of ciprofloxacin. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941279/),%,73,165362,DB00537,Ciprofloxacin
,2941279,rate of penetration,The rate of penetration of ciprofloxacin into nasal secretion was 73% following the first oral dose and 90% following the 15th oral dose.,Single and multiple dose pharmacokinetics of ciprofloxacin. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941279/),%,90,165363,DB00537,Ciprofloxacin
,29465160,apparent elimination rate constant (λz ),"After intravenous injection, initial concentration of 5.83 μg/ml, apparent elimination rate constant (λz ) of 0.039 hr-1 , apparent elimination half-life (T1/2λz ) of 17.90 hr, systemic total body clearance (Cl) of 75.47 ml hr-1 kg-1 , volume of distribution (Vz) of 1,948.76 ml/kg, and volume of distribution at steady-state (Vss) of 1,863.97 ml/kg were determined, respectively.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),1/[h],0.039,165645,DB00537,Ciprofloxacin
,29465160,apparent elimination half-life (T1/2λz ),"After intravenous injection, initial concentration of 5.83 μg/ml, apparent elimination rate constant (λz ) of 0.039 hr-1 , apparent elimination half-life (T1/2λz ) of 17.90 hr, systemic total body clearance (Cl) of 75.47 ml hr-1 kg-1 , volume of distribution (Vz) of 1,948.76 ml/kg, and volume of distribution at steady-state (Vss) of 1,863.97 ml/kg were determined, respectively.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),h,17.90,165646,DB00537,Ciprofloxacin
,29465160,systemic total body clearance (Cl),"After intravenous injection, initial concentration of 5.83 μg/ml, apparent elimination rate constant (λz ) of 0.039 hr-1 , apparent elimination half-life (T1/2λz ) of 17.90 hr, systemic total body clearance (Cl) of 75.47 ml hr-1 kg-1 , volume of distribution (Vz) of 1,948.76 ml/kg, and volume of distribution at steady-state (Vss) of 1,863.97 ml/kg were determined, respectively.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),[ml] / [h·kg],75.47,165647,DB00537,Ciprofloxacin
,29465160,volume of distribution (Vz),"After intravenous injection, initial concentration of 5.83 μg/ml, apparent elimination rate constant (λz ) of 0.039 hr-1 , apparent elimination half-life (T1/2λz ) of 17.90 hr, systemic total body clearance (Cl) of 75.47 ml hr-1 kg-1 , volume of distribution (Vz) of 1,948.76 ml/kg, and volume of distribution at steady-state (Vss) of 1,863.97 ml/kg were determined, respectively.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),[ml] / [kg],"1,948.76",165648,DB00537,Ciprofloxacin
,29465160,volume of distribution at steady-state (Vss),"After intravenous injection, initial concentration of 5.83 μg/ml, apparent elimination rate constant (λz ) of 0.039 hr-1 , apparent elimination half-life (T1/2λz ) of 17.90 hr, systemic total body clearance (Cl) of 75.47 ml hr-1 kg-1 , volume of distribution (Vz) of 1,948.76 ml/kg, and volume of distribution at steady-state (Vss) of 1,863.97 ml/kg were determined, respectively.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),[ml] / [kg],"1,863.97",165649,DB00537,Ciprofloxacin
,29465160,λz,"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),1/[h],0.027,165650,DB00537,Ciprofloxacin
,29465160,T1/2λz,"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),h,25.69,165651,DB00537,Ciprofloxacin
,29465160,T1/2λz,"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),h,10.26,165652,DB00537,Ciprofloxacin
,29465160,mean absorption time (MAT),"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),h,25.69,165653,DB00537,Ciprofloxacin
,29465160,mean absorption time (MAT),"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),h,10.26,165654,DB00537,Ciprofloxacin
,29465160,absorption half-life (T1/2ka ),"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),h,25.69,165655,DB00537,Ciprofloxacin
,29465160,absorption half-life (T1/2ka ),"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),h,10.26,165656,DB00537,Ciprofloxacin
,29465160,bioavailability,"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),h,7.11,165657,DB00537,Ciprofloxacin
,29465160,bioavailability,"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),%,96.46,165658,DB00537,Ciprofloxacin
,29465160,peak concentration,"While after intramuscular administration, the λz , T1/2λz , mean absorption time (MAT), absorption half-life (T1/2ka ), and bioavailability were determined as 0.027 hr-1 , 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),[μg] / [ml],3.11,165659,DB00537,Ciprofloxacin
≤,29465160,MIC,"It was shown that orbifloxacin was completely but relatively slowly absorbed, extensively distributed, and slowly eliminated in crucian carp, and an orbifloxacin dosage of 10 mg/kg administered intravenously or intramuscularly would be expected to successfully treat crucian carp infected by strains with MIC values ≤0.5 μg/ml.",Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29465160/),[μg] / [ml],0.5,165660,DB00537,Ciprofloxacin
>,8452185,steady-state volume of distribution (Vd-ss,"Renal impairment had no influence on the complete absorption of fleroxacin from the gastrointestinal tract, the maximal plasma concentration, and the steady-state volume of distribution (Vd-ss > 1 L/kg).",Pharmacokinetics of fleroxacin in renal impairment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[l] / [kg],1,165994,DB00537,Ciprofloxacin
,8452185,systemic clearance,"However, systemic clearance in patients was significantly decreased (p < 0.05) to 44.4 mL/min compared with 87.1 mL/min in healthy subjects.",Pharmacokinetics of fleroxacin in renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[ml] / [min],44.4,165995,DB00537,Ciprofloxacin
,8452185,systemic clearance,"However, systemic clearance in patients was significantly decreased (p < 0.05) to 44.4 mL/min compared with 87.1 mL/min in healthy subjects.",Pharmacokinetics of fleroxacin in renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[ml] / [min],87.1,165996,DB00537,Ciprofloxacin
,8452185,renal clearance,This decrease could be ascribed to a reduction in renal clearance from 59.1 mL/min in healthy subjects to 8.8 mL/min in patients.,Pharmacokinetics of fleroxacin in renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[ml] / [min],59.1,165997,DB00537,Ciprofloxacin
,8452185,renal clearance,This decrease could be ascribed to a reduction in renal clearance from 59.1 mL/min in healthy subjects to 8.8 mL/min in patients.,Pharmacokinetics of fleroxacin in renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[ml] / [min],8.8,165998,DB00537,Ciprofloxacin
,8452185,elimination half-life,"As a consequence of reduced clearance, the mean elimination half-life in patients increased from 13.6 hours to 21.4 hours and the area under the concentration-time curve from 87.0 mg.h/L to 170.5 mg.h/L.",Pharmacokinetics of fleroxacin in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),h,13.6,165999,DB00537,Ciprofloxacin
,8452185,elimination half-life,"As a consequence of reduced clearance, the mean elimination half-life in patients increased from 13.6 hours to 21.4 hours and the area under the concentration-time curve from 87.0 mg.h/L to 170.5 mg.h/L.",Pharmacokinetics of fleroxacin in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),h,21.4,166000,DB00537,Ciprofloxacin
,8452185,area under the concentration-time curve,"As a consequence of reduced clearance, the mean elimination half-life in patients increased from 13.6 hours to 21.4 hours and the area under the concentration-time curve from 87.0 mg.h/L to 170.5 mg.h/L.",Pharmacokinetics of fleroxacin in renal impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[h·mg] / [l],87.0,166001,DB00537,Ciprofloxacin
,8452185,area under the concentration-time curve,"As a consequence of reduced clearance, the mean elimination half-life in patients increased from 13.6 hours to 21.4 hours and the area under the concentration-time curve from 87.0 mg.h/L to 170.5 mg.h/L.",Pharmacokinetics of fleroxacin in renal impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[h·mg] / [l],170.5,166002,DB00537,Ciprofloxacin
,12401357,detection limits,"The detection limits of enrofloxacin and ciprofloxacin (100 microl of whole blood on a disk) were 0.005 and 0.01 microg/ml, respectively.",Liquid chromatography analysis of enrofloxacin and ciprofloxacin in chicken blood spotted on filter-paper disks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401357/),[μg] / [ml],0.005,166093,DB00537,Ciprofloxacin
,12401357,detection limits,"The detection limits of enrofloxacin and ciprofloxacin (100 microl of whole blood on a disk) were 0.005 and 0.01 microg/ml, respectively.",Liquid chromatography analysis of enrofloxacin and ciprofloxacin in chicken blood spotted on filter-paper disks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401357/),[μg] / [ml],0.01,166094,DB00537,Ciprofloxacin
above,12401357,recoveries,"The whole procedure was verified in intra-laboratory studies (recoveries of both compounds were above 90%), and its applicability was tested with blood from the chicken receiving enrofloxacin in a single oral dose at a level of 10 mg/kg body mass.",Liquid chromatography analysis of enrofloxacin and ciprofloxacin in chicken blood spotted on filter-paper disks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401357/),%,90,166095,DB00537,Ciprofloxacin
,2542469,Metabolism,Metabolism is minimal (ca. 15-20% for ciprofloxacin and norfloxacin).,Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),%,15-20,166231,DB00537,Ciprofloxacin
,2542469,serum half-life,"Because the transintestinal route of elimination compensates for loss of renal elimination, the serum half-life of ciprofloxacvin is raised only to 5-10 hours even in total renal failure.",Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),h,5-10,166232,DB00537,Ciprofloxacin
,16723548,MICs,"Its activity was studied in an in vitro pharmacokinetic-pharmacodynamic model against five Staphylococcus aureus strains, either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin (CIP) resistance: the ATCC 25923 reference strain (MICs of CIP and GAT: 0.5 and 0.1 microg/ml, respectively), its efflux mutant SA-1 (16 and 0.5 microg/ml; mutation in the norA promoter region), and three clinical strains, Sa2102 (2 and 0.2 microg/ml), Sa2667 (4 and 0.5 microg/ml), and Sa2669 (16 and 1 microg/ml), carrying mutations in the grlA (Ser80Tyr or Phe) and gyrA (Ser84Ala) quinolone resistance-determining regions (QRDRs) for Sa2669.",Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723548/),[μg] / [ml],0.5,166330,DB00537,Ciprofloxacin
,16723548,MICs,"Its activity was studied in an in vitro pharmacokinetic-pharmacodynamic model against five Staphylococcus aureus strains, either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin (CIP) resistance: the ATCC 25923 reference strain (MICs of CIP and GAT: 0.5 and 0.1 microg/ml, respectively), its efflux mutant SA-1 (16 and 0.5 microg/ml; mutation in the norA promoter region), and three clinical strains, Sa2102 (2 and 0.2 microg/ml), Sa2667 (4 and 0.5 microg/ml), and Sa2669 (16 and 1 microg/ml), carrying mutations in the grlA (Ser80Tyr or Phe) and gyrA (Ser84Ala) quinolone resistance-determining regions (QRDRs) for Sa2669.",Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723548/),[μg] / [ml],0.1,166331,DB00537,Ciprofloxacin
,16723548,MICs,"Its activity was studied in an in vitro pharmacokinetic-pharmacodynamic model against five Staphylococcus aureus strains, either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin (CIP) resistance: the ATCC 25923 reference strain (MICs of CIP and GAT: 0.5 and 0.1 microg/ml, respectively), its efflux mutant SA-1 (16 and 0.5 microg/ml; mutation in the norA promoter region), and three clinical strains, Sa2102 (2 and 0.2 microg/ml), Sa2667 (4 and 0.5 microg/ml), and Sa2669 (16 and 1 microg/ml), carrying mutations in the grlA (Ser80Tyr or Phe) and gyrA (Ser84Ala) quinolone resistance-determining regions (QRDRs) for Sa2669.",Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723548/),[μg] / [ml],16,166332,DB00537,Ciprofloxacin
,16723548,MICs,"Its activity was studied in an in vitro pharmacokinetic-pharmacodynamic model against five Staphylococcus aureus strains, either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin (CIP) resistance: the ATCC 25923 reference strain (MICs of CIP and GAT: 0.5 and 0.1 microg/ml, respectively), its efflux mutant SA-1 (16 and 0.5 microg/ml; mutation in the norA promoter region), and three clinical strains, Sa2102 (2 and 0.2 microg/ml), Sa2667 (4 and 0.5 microg/ml), and Sa2669 (16 and 1 microg/ml), carrying mutations in the grlA (Ser80Tyr or Phe) and gyrA (Ser84Ala) quinolone resistance-determining regions (QRDRs) for Sa2669.",Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723548/),[μg] / [ml],1,166333,DB00537,Ciprofloxacin
,16723548,maximum concentration of drug,"Thus, mean maximum concentration of drug in serum values for the two administration intervals were 5.36 and 5.80 microg/ml, respectively, and the corresponding half-life at beta-phase values were 8.68 and 7.80 h (goodness of fit coefficient, >0.98).",Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723548/),[μg] / [ml],5.36,166334,DB00537,Ciprofloxacin
,16723548,maximum concentration of drug,"Thus, mean maximum concentration of drug in serum values for the two administration intervals were 5.36 and 5.80 microg/ml, respectively, and the corresponding half-life at beta-phase values were 8.68 and 7.80 h (goodness of fit coefficient, >0.98).",Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723548/),[μg] / [ml],5.80,166335,DB00537,Ciprofloxacin
,16723548,half-life at beta-phase,"Thus, mean maximum concentration of drug in serum values for the two administration intervals were 5.36 and 5.80 microg/ml, respectively, and the corresponding half-life at beta-phase values were 8.68 and 7.80 h (goodness of fit coefficient, >0.98).",Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723548/),h,8.68,166336,DB00537,Ciprofloxacin
,16723548,half-life at beta-phase,"Thus, mean maximum concentration of drug in serum values for the two administration intervals were 5.36 and 5.80 microg/ml, respectively, and the corresponding half-life at beta-phase values were 8.68 and 7.80 h (goodness of fit coefficient, >0.98).",Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723548/),h,7.80,166337,DB00537,Ciprofloxacin
,16723548,bacterial killing and regrowth curve,Therapeutic concentrations of GAT allowed the complete eradication of the susceptible strain within 12 h (difference between the bacterial counts at the beginning of the treatment and at a defined time: -2.18 at the 1-h time point [t(1)] and -6.80 at t(24) and t(48); the bacterial killing and regrowth curve from 0 to 48 h was 30.2 h x log CFU/milliliter).,Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723548/),[cfu·h·log] / [milliliter],30.2,166338,DB00537,Ciprofloxacin
,29084496,clearance (CL),"The final population primary parameter mean estimates were: clearance (CL), 0.21 L/kg/h (SD, 0.09 L/kg/h) and volume of distribution (Vd), 0.84 L/kg (SD, 0.12 L/kg).",Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084496/),[l] / [h·kg],0.21,166460,DB00537,Ciprofloxacin
,29084496,volume of distribution (Vd),"The final population primary parameter mean estimates were: clearance (CL), 0.21 L/kg/h (SD, 0.09 L/kg/h) and volume of distribution (Vd), 0.84 L/kg (SD, 0.12 L/kg).",Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084496/),[l] / [kg],0.84,166461,DB00537,Ciprofloxacin
,29084496,CL,"In the critically ill ECMO patient, the primary pharmacokinetic parameter estimates were: CL, 0.15 L/kg/h and Vd, 0.99 L/kg.",Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084496/),[l] / [h·kg],0.15,166462,DB00537,Ciprofloxacin
,29084496,Vd,"In the critically ill ECMO patient, the primary pharmacokinetic parameter estimates were: CL, 0.15 L/kg/h and Vd, 0.99 L/kg.",Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084496/),[l] / [kg],0.99,166463,DB00537,Ciprofloxacin
greater,28394614,Cmax/MIC,"Pharmacokinetics and biodistribution studies further demonstrated that the efficacious fast-releasing prodrug retained drug dosing in the lung above the MIC over a 48 h period with corresponding Cmax/MIC and AUC0-24h/MIC ratios being greater than 10 and 125, respectively; the thresholds for optimal bactericidal efficacy.",Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy against Aerosolized Intracellular Alveolar Infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28394614/),,10,166515,DB00537,Ciprofloxacin
greater,28394614,AUC0-24h/MIC ratios,"Pharmacokinetics and biodistribution studies further demonstrated that the efficacious fast-releasing prodrug retained drug dosing in the lung above the MIC over a 48 h period with corresponding Cmax/MIC and AUC0-24h/MIC ratios being greater than 10 and 125, respectively; the thresholds for optimal bactericidal efficacy.",Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy against Aerosolized Intracellular Alveolar Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28394614/),,125,166516,DB00537,Ciprofloxacin
,9163658,serum elimination half-lives,The median serum elimination half-lives were 17.3 h for SPX and 5.3 h for CPX.,"Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),h,17.3,168219,DB00537,Ciprofloxacin
,9163658,serum elimination half-lives,The median serum elimination half-lives were 17.3 h for SPX and 5.3 h for CPX.,"Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),h,5.3,168220,DB00537,Ciprofloxacin
,9163658,Peak levels,"Peak levels (median+/-68% confidence range) of CPX were attained in AMs (7.6+/-1.7 mg x L(-1)) at 5 h after admission, and in both ELF (2.13+/-0.91 mg x L(-1)) and PMNs (9.1+/-6.2 mg x L(-1)) at 2.5 h after administration.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],7.6,168221,DB00537,Ciprofloxacin
,9163658,Peak levels,"Peak levels (median+/-68% confidence range) of CPX were attained in AMs (7.6+/-1.7 mg x L(-1)) at 5 h after admission, and in both ELF (2.13+/-0.91 mg x L(-1)) and PMNs (9.1+/-6.2 mg x L(-1)) at 2.5 h after administration.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],2.13,168222,DB00537,Ciprofloxacin
,9163658,Peak levels,"Peak levels (median+/-68% confidence range) of CPX were attained in AMs (7.6+/-1.7 mg x L(-1)) at 5 h after admission, and in both ELF (2.13+/-0.91 mg x L(-1)) and PMNs (9.1+/-6.2 mg x L(-1)) at 2.5 h after administration.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],9.1,168223,DB00537,Ciprofloxacin
,9163658,peak levels,"SPX achieved comparable peak levels in PMNs (median+/-68% range, 9.4+/-1.1 mg x L(-1) at 5 h), but peak concentrations attained in AMs and ELF (35.1+/-15.4 and 32.2+/-28.2 mg x L(-1), respectively, at 24 h) were several times higher than those of CPX.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],9.4,168224,DB00537,Ciprofloxacin
,9163658,peak concentrations,"SPX achieved comparable peak levels in PMNs (median+/-68% range, 9.4+/-1.1 mg x L(-1) at 5 h), but peak concentrations attained in AMs and ELF (35.1+/-15.4 and 32.2+/-28.2 mg x L(-1), respectively, at 24 h) were several times higher than those of CPX.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],35.1,168225,DB00537,Ciprofloxacin
,9163658,peak concentrations,"SPX achieved comparable peak levels in PMNs (median+/-68% range, 9.4+/-1.1 mg x L(-1) at 5 h), but peak concentrations attained in AMs and ELF (35.1+/-15.4 and 32.2+/-28.2 mg x L(-1), respectively, at 24 h) were several times higher than those of CPX.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],32.2,168226,DB00537,Ciprofloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,11.0,168227,DB00537,Ciprofloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,65.5,168228,DB00537,Ciprofloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,63.0,168229,DB00537,Ciprofloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,4.94,168230,DB00537,Ciprofloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,10.6,168231,DB00537,Ciprofloxacin
,26643328,AUC24/MIC ratio,"Resistant K. pneumoniae mutants were intensively enriched at an AUC24/MIC ratio of 60 to 360 h (AUC24/MPC ratio from 2.5 to 15 h) but not at the lower or higher AUC24/MIC and AUC24/MPC ratios, in accordance with the MSW hypothesis.",Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643328/),h,60 to 360,169539,DB00537,Ciprofloxacin
,26643328,AUC24/MPC ratio,"Resistant K. pneumoniae mutants were intensively enriched at an AUC24/MIC ratio of 60 to 360 h (AUC24/MPC ratio from 2.5 to 15 h) but not at the lower or higher AUC24/MIC and AUC24/MPC ratios, in accordance with the MSW hypothesis.",Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643328/),h,2.5 to 15,169540,DB00537,Ciprofloxacin
,26643328,AUC24/MPC ratios,"These relationships predict highly variable ""antimutant"" AUC24/MPC ratios (20 to 290 h) compared to AUC24/MIC ratios (1,310 to 2,610 h).",Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643328/),h,20 to 290,169541,DB00537,Ciprofloxacin
,26643328,AUC24/MIC ratios,"These relationships predict highly variable ""antimutant"" AUC24/MPC ratios (20 to 290 h) compared to AUC24/MIC ratios (1,310 to 2,610 h).",Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643328/),h,"1,310 to 2,610",169542,DB00537,Ciprofloxacin
,2941402,serum Tmax,There were no significant differences in serum Tmax (1.2-1.3 h) or in overall serum elimination half-life (3.7-4.0 h) but Cmax in elderly patients was more than double that in young volunteers (P less than 0.005).,"Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941402/),h,1.2-1.3,169719,DB00537,Ciprofloxacin
,2941402,overall serum elimination half-life,There were no significant differences in serum Tmax (1.2-1.3 h) or in overall serum elimination half-life (3.7-4.0 h) but Cmax in elderly patients was more than double that in young volunteers (P less than 0.005).,"Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941402/),h,3.7-4.0,169720,DB00537,Ciprofloxacin
,2941402,serum AUC,"The serum AUC value was greater both in fasting students (1.4 mg/h/l) compared with the same subjects after food (1.09: P less than 0.01) and, after food, in elderly patients (1.95) compared with students (0.81: P less than 0.005).","Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941402/),[mg] / [h·l],1.4,169721,DB00537,Ciprofloxacin
,24219009,total clearance,"For 5.4 kg koalas (average weight), point estimates for total clearance (SE%) were 2.58 L/h (15%), central volume of distribution 0.249 L (14%), and peripheral volume 2.77 L (20%).",Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24219009/),[l] / [h],2.58,169785,DB00537,Ciprofloxacin
,24219009,central volume of distribution,"For 5.4 kg koalas (average weight), point estimates for total clearance (SE%) were 2.58 L/h (15%), central volume of distribution 0.249 L (14%), and peripheral volume 2.77 L (20%).",Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24219009/),l,0.249,169786,DB00537,Ciprofloxacin
,24219009,peripheral volume,"For 5.4 kg koalas (average weight), point estimates for total clearance (SE%) were 2.58 L/h (15%), central volume of distribution 0.249 L (14%), and peripheral volume 2.77 L (20%).",Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24219009/),l,2.77,169787,DB00537,Ciprofloxacin
,24219009,fAUC0-24 /MIC,MCS using a target fAUC0-24 /MIC of 40 predicted highest treatable MICs of 0.0625 mg/L for intravenous dosing and 0.0313 mg/L for subcutaneous dosing of 10 mg/kg enrofloxacin every 24 h.,Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24219009/),,40,169788,DB00537,Ciprofloxacin
≤,24219009,MICs,"Thus, the frequently used dosage of 10 mg/kg enrofloxacin every 24 h subcutaneously may be appropriate against gram-positive bacteria with MICs ≤ 0.03 mg/L (PTA > 90%), but appears inadequate against gram-negative bacteria and Chlamydiae in koalas.",Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24219009/),[mg] / [l],0.03,169789,DB00537,Ciprofloxacin
,18471145,K(a),"The typical PPK parameters were K(a) = 3.33 h(-1), CL = 1.25 L/h/kg, and V = 2.98 L/kg of enrofloxacin, and the interindividual variability for CL and V were 20.2% and 24.3%, respectively, the population mean estimates of K(a), CL, and V for ciprofloxacin were 1.12 h(-1), 2.36 L/h/kg, 8.20 L/kg, respectively, and their interindividual variability was 36.9%, 15.8% and 14.1%, respectively.",Population pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin in ill cows. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471145/),1/[h],3.33,170147,DB00537,Ciprofloxacin
,18471145,CL,"The typical PPK parameters were K(a) = 3.33 h(-1), CL = 1.25 L/h/kg, and V = 2.98 L/kg of enrofloxacin, and the interindividual variability for CL and V were 20.2% and 24.3%, respectively, the population mean estimates of K(a), CL, and V for ciprofloxacin were 1.12 h(-1), 2.36 L/h/kg, 8.20 L/kg, respectively, and their interindividual variability was 36.9%, 15.8% and 14.1%, respectively.",Population pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin in ill cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471145/),[l] / [h·kg],1.25,170148,DB00537,Ciprofloxacin
,18471145,V,"The typical PPK parameters were K(a) = 3.33 h(-1), CL = 1.25 L/h/kg, and V = 2.98 L/kg of enrofloxacin, and the interindividual variability for CL and V were 20.2% and 24.3%, respectively, the population mean estimates of K(a), CL, and V for ciprofloxacin were 1.12 h(-1), 2.36 L/h/kg, 8.20 L/kg, respectively, and their interindividual variability was 36.9%, 15.8% and 14.1%, respectively.",Population pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin in ill cows. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471145/),[l] / [kg],2.98,170149,DB00537,Ciprofloxacin
,18471145,K(a),"The typical PPK parameters were K(a) = 3.33 h(-1), CL = 1.25 L/h/kg, and V = 2.98 L/kg of enrofloxacin, and the interindividual variability for CL and V were 20.2% and 24.3%, respectively, the population mean estimates of K(a), CL, and V for ciprofloxacin were 1.12 h(-1), 2.36 L/h/kg, 8.20 L/kg, respectively, and their interindividual variability was 36.9%, 15.8% and 14.1%, respectively.",Population pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin in ill cows. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471145/),1/[h],1.12,170150,DB00537,Ciprofloxacin
,18471145,CL,"The typical PPK parameters were K(a) = 3.33 h(-1), CL = 1.25 L/h/kg, and V = 2.98 L/kg of enrofloxacin, and the interindividual variability for CL and V were 20.2% and 24.3%, respectively, the population mean estimates of K(a), CL, and V for ciprofloxacin were 1.12 h(-1), 2.36 L/h/kg, 8.20 L/kg, respectively, and their interindividual variability was 36.9%, 15.8% and 14.1%, respectively.",Population pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin in ill cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471145/),[l] / [h·kg],2.36,170151,DB00537,Ciprofloxacin
,18471145,CL,"The typical PPK parameters were K(a) = 3.33 h(-1), CL = 1.25 L/h/kg, and V = 2.98 L/kg of enrofloxacin, and the interindividual variability for CL and V were 20.2% and 24.3%, respectively, the population mean estimates of K(a), CL, and V for ciprofloxacin were 1.12 h(-1), 2.36 L/h/kg, 8.20 L/kg, respectively, and their interindividual variability was 36.9%, 15.8% and 14.1%, respectively.",Population pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin in ill cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471145/),[l] / [kg],8.20,170152,DB00537,Ciprofloxacin
,18471145,V,"The typical PPK parameters were K(a) = 3.33 h(-1), CL = 1.25 L/h/kg, and V = 2.98 L/kg of enrofloxacin, and the interindividual variability for CL and V were 20.2% and 24.3%, respectively, the population mean estimates of K(a), CL, and V for ciprofloxacin were 1.12 h(-1), 2.36 L/h/kg, 8.20 L/kg, respectively, and their interindividual variability was 36.9%, 15.8% and 14.1%, respectively.",Population pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin in ill cows. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471145/),[l] / [kg],8.20,170153,DB00537,Ciprofloxacin
,16239356,relative bioavailability,The relative bioavailability of ciprofloxacin ER compared to ciprofloxacin IR was 93.8% in the single-dose study and 97.7% in the steady-state study.,Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239356/),%,93.8,170415,DB00537,Ciprofloxacin
,16239356,relative bioavailability,The relative bioavailability of ciprofloxacin ER compared to ciprofloxacin IR was 93.8% in the single-dose study and 97.7% in the steady-state study.,Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239356/),%,97.7,170416,DB00537,Ciprofloxacin
,25406952,AUC,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[h·mg] / [l],27.93,170438,DB00537,Ciprofloxacin
,25406952,AUC,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[h·mg] / [l],41.62,170439,DB00537,Ciprofloxacin
,25406952,Cmax,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[mg] / [l],1.37,170440,DB00537,Ciprofloxacin
,25406952,Cmax,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[mg] / [l],1.64,170441,DB00537,Ciprofloxacin
,25406952,T1/2b,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),h,16.28,170442,DB00537,Ciprofloxacin
,25406952,T1/2b,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),h,21.43,170443,DB00537,Ciprofloxacin
,25406952,oral plasma clearance,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[l] / [h],23.17,170444,DB00537,Ciprofloxacin
,25406952,oral plasma clearance,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[l] / [h],16.00,170445,DB00537,Ciprofloxacin
,2195927,peak concentration,The peak concentration was greatest in the serum after multiple doses of 23 mg/kg (mean +/- SEM; 5.68 +/- 0.54 micrograms/ml) and least in the TCF after a single dose of 11 mg/kg (0.43 +/- 0.54 micrograms/ml).,Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2195927/),[μg] / [ml],5.68,170467,DB00537,Ciprofloxacin
,2195927,peak concentration,The peak concentration was greatest in the serum after multiple doses of 23 mg/kg (mean +/- SEM; 5.68 +/- 0.54 micrograms/ml) and least in the TCF after a single dose of 11 mg/kg (0.43 +/- 0.54 micrograms/ml).,Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2195927/),[μg] / [ml],0.43,170468,DB00537,Ciprofloxacin
,2195927,time to peak concentration,"The time to peak concentration was not influenced by multiple dosing or drug dose, but was longer for TCF (6.41 +/- 0.52 hour) than for serum (1.53 +/- 0.52 hour).",Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2195927/),h,6.41,170469,DB00537,Ciprofloxacin
,2195927,time to peak concentration,"The time to peak concentration was not influenced by multiple dosing or drug dose, but was longer for TCF (6.41 +/- 0.52 hour) than for serum (1.53 +/- 0.52 hour).",Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2195927/),h,1.53,170470,DB00537,Ciprofloxacin
,2195927,AUC0----12,The AUC0----12 was greatest in the serum after multiple doses of 23 mg/kg (31.95 +/- 1.90 micrograms.h/ml) and least in the TCF after a single dose of 11 mg/kg (3.87 +/- 1.90 micrograms.h/ml).,Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2195927/),[h·μg] / [ml],31.95,170471,DB00537,Ciprofloxacin
,2195927,AUC0----12,The AUC0----12 was greatest in the serum after multiple doses of 23 mg/kg (31.95 +/- 1.90 micrograms.h/ml) and least in the TCF after a single dose of 11 mg/kg (3.87 +/- 1.90 micrograms.h/ml).,Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2195927/),[h·μg] / [ml],3.87,170472,DB00537,Ciprofloxacin
,2195927,elimination half-life,"The elimination half-life was not influenced by multiple dosing or dose concentration, but was greater for TCF (14.59 +/- 1.91 hours) than for serum (5.14 +/- 1.91 hours).",Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2195927/),h,14.59,170473,DB00537,Ciprofloxacin
,2195927,elimination half-life,"The elimination half-life was not influenced by multiple dosing or dose concentration, but was greater for TCF (14.59 +/- 1.91 hours) than for serum (5.14 +/- 1.91 hours).",Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2195927/),h,5.14,170474,DB00537,Ciprofloxacin
,1864115,peak serum levels,Mean peak serum levels 30 minutes after administration were 1.98 +/- 0.07 mg/L.,Pleural penetration of ciprofloxacin in patients with empyema thoracis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864115/),[mg] / [l],1.98,170778,DB00537,Ciprofloxacin
,1864115,Terminal serum half-lives,Terminal serum half-lives ranged from 3.9 to 5.1 h.,Pleural penetration of ciprofloxacin in patients with empyema thoracis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864115/),h,3.9 to 5.1,170779,DB00537,Ciprofloxacin
,1864115,percentage penetration into the inflammatory compartment,The mean percentage penetration into the inflammatory compartment was approximately 210 percent.,Pleural penetration of ciprofloxacin in patients with empyema thoracis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864115/),%,210,170780,DB00537,Ciprofloxacin
,25881712,kab,The antibacterial drug was significantly faster absorbed (kab of 0.61 ± 0.54 h(-1) and Tmax 7.81 ± 3.52 h) at lower concentrations (Cmax of 1.34 ± 0.18 μg·g(-1)) during the first 24 h of treatment in the probiotic's group.,Effect of probiotics on enrofloxacin disposition in gastrointestinal tract of poultry. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881712/),1/[h],0.61,170912,DB00537,Ciprofloxacin
,25881712,Tmax,The antibacterial drug was significantly faster absorbed (kab of 0.61 ± 0.54 h(-1) and Tmax 7.81 ± 3.52 h) at lower concentrations (Cmax of 1.34 ± 0.18 μg·g(-1)) during the first 24 h of treatment in the probiotic's group.,Effect of probiotics on enrofloxacin disposition in gastrointestinal tract of poultry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881712/),h,7.81,170913,DB00537,Ciprofloxacin
,25881712,Cmax,The antibacterial drug was significantly faster absorbed (kab of 0.61 ± 0.54 h(-1) and Tmax 7.81 ± 3.52 h) at lower concentrations (Cmax of 1.34 ± 0.18 μg·g(-1)) during the first 24 h of treatment in the probiotic's group.,Effect of probiotics on enrofloxacin disposition in gastrointestinal tract of poultry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881712/),[μg] / [g],1.34,170914,DB00537,Ciprofloxacin
,25881712,kab,"The values of kab , Tmax , and Cmax for the group, treated solely with enrofloxacin, were 0.10 ± 0.065 h(-1), 15.42 ± 3.07 h, and 1.61 ± 0.24 μg·g(-1), respectively.",Effect of probiotics on enrofloxacin disposition in gastrointestinal tract of poultry. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881712/),1/[h],0.10,170915,DB00537,Ciprofloxacin
,25881712,Tmax,"The values of kab , Tmax , and Cmax for the group, treated solely with enrofloxacin, were 0.10 ± 0.065 h(-1), 15.42 ± 3.07 h, and 1.61 ± 0.24 μg·g(-1), respectively.",Effect of probiotics on enrofloxacin disposition in gastrointestinal tract of poultry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881712/),h,15.42,170916,DB00537,Ciprofloxacin
,25881712,Cmax,"The values of kab , Tmax , and Cmax for the group, treated solely with enrofloxacin, were 0.10 ± 0.065 h(-1), 15.42 ± 3.07 h, and 1.61 ± 0.24 μg·g(-1), respectively.",Effect of probiotics on enrofloxacin disposition in gastrointestinal tract of poultry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881712/),[μg] / [g],1.61,170917,DB00537,Ciprofloxacin
<,25881712,MIC,The selected dose is appropriate for treatment of infections caused by pathogens with MIC < 0.06 μg·mL(-1) irrespective of antibiotic administration alone or in combination with probiotics.,Effect of probiotics on enrofloxacin disposition in gastrointestinal tract of poultry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881712/),[μg] / [ml],0.06,170918,DB00537,Ciprofloxacin
,7853464,Vd(area),"The drug was widely distributed (Vd(area) almost 3 l/kg), being distributed in the dog more rapidly than in other species (t1/2(lambda 1) 3 min approximately).",Disposition of ciprofloxacin following intravenous administration in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853464/),[l] / [kg],3,171261,DB00537,Ciprofloxacin
,7853464,t1/2(lambda 1),"The drug was widely distributed (Vd(area) almost 3 l/kg), being distributed in the dog more rapidly than in other species (t1/2(lambda 1) 3 min approximately).",Disposition of ciprofloxacin following intravenous administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853464/),min,3,171262,DB00537,Ciprofloxacin
,7853464,elimination half-life (t1/2 lambda 2),The elimination half-life (t1/2 lambda 2) was 129-180 min which is similar to values obtained in other species.,Disposition of ciprofloxacin following intravenous administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853464/),min,129-180,171263,DB00537,Ciprofloxacin
,1489195,oral bioavailability,The results showed that cystic fibrosis patients have increased oral bioavailability of ciprofloxacin (80% in cystic fibrosis patients versus 57% in volunteers) and increased total clearance (688 ml/min in CF patients versus 528 ml/min in volunteers).,Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489195/),%,80,171575,DB00537,Ciprofloxacin
,1489195,oral bioavailability,The results showed that cystic fibrosis patients have increased oral bioavailability of ciprofloxacin (80% in cystic fibrosis patients versus 57% in volunteers) and increased total clearance (688 ml/min in CF patients versus 528 ml/min in volunteers).,Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489195/),%,57,171576,DB00537,Ciprofloxacin
,1489195,total clearance,The results showed that cystic fibrosis patients have increased oral bioavailability of ciprofloxacin (80% in cystic fibrosis patients versus 57% in volunteers) and increased total clearance (688 ml/min in CF patients versus 528 ml/min in volunteers).,Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489195/),[ml] / [min],688,171577,DB00537,Ciprofloxacin
,1489195,total clearance,The results showed that cystic fibrosis patients have increased oral bioavailability of ciprofloxacin (80% in cystic fibrosis patients versus 57% in volunteers) and increased total clearance (688 ml/min in CF patients versus 528 ml/min in volunteers).,Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489195/),[ml] / [min],528,171578,DB00537,Ciprofloxacin
,10223923,MICs,The MICs of ofloxacin and ciprofloxacin ranged from 1 to 2 micrograms/ml.,"Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),[μg] / [ml],1 to 2,171737,DB00537,Ciprofloxacin
,10223923,MICs,"Trovafloxacin was 8- to 32-fold more potent, with MICs of 0.06 to 0.12 microgram/ml.","Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),[μg] / [ml],0.06 to 0.12,171738,DB00537,Ciprofloxacin
,10223923,Times to 99.9% killing,Times to 99.9% killing were only 1 to 3 h.,"Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),h,1 to 3,171739,DB00537,Ciprofloxacin
,10223923,area under the inhibitory curve/MIC ratio (AUC/MIC),"Although the rate of killing with ofloxacin was substantially slower than that with trovafloxacin, ofloxacin was also able to eradicate all eight strains from the model, despite a simulated area under the inhibitory curve/MIC ratio (AUC/MIC) of only 49.","Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),,49,171740,DB00537,Ciprofloxacin
,10223923,AUC/MIC,"In contrast, ciprofloxacin eradicated only five strains (AUC/MIC = 44) from the model.","Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),,44,171741,DB00537,Ciprofloxacin
,10223923,AUC/MIC,"Against the other three strains (AUC/MIC = 22), the antibacterial activity of ciprofloxacin was substantially diminished.","Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223923/),,22,171742,DB00537,Ciprofloxacin
,3094441,Elimination half-lives,"Elimination half-lives in serum were species dependent, ranging from 1.57 h in rabbits to 9.42 h in dogs.","Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094441/),h,1.57,172049,DB00537,Ciprofloxacin
,3094441,Elimination half-lives,"Elimination half-lives in serum were species dependent, ranging from 1.57 h in rabbits to 9.42 h in dogs.","Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094441/),h,9.42,172050,DB00537,Ciprofloxacin
,14693523,peak,"To simulate the kinetics of drugs in humans, rats were infused intravenously with garenoxacin every 24 h (peak and trough levels in serum, 6.1 and 1.0 mg/liter, respectively; area under the concentration-time curve [AUC], 63.4 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],6.1,172211,DB00537,Ciprofloxacin
,14693523,trough levels,"To simulate the kinetics of drugs in humans, rats were infused intravenously with garenoxacin every 24 h (peak and trough levels in serum, 6.1 and 1.0 mg/liter, respectively; area under the concentration-time curve [AUC], 63.4 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],6.1,172212,DB00537,Ciprofloxacin
,14693523,trough levels,"To simulate the kinetics of drugs in humans, rats were infused intravenously with garenoxacin every 24 h (peak and trough levels in serum, 6.1 and 1.0 mg/liter, respectively; area under the concentration-time curve [AUC], 63.4 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],1.0,172213,DB00537,Ciprofloxacin
,14693523,area under the concentration-time curve [AUC],"To simulate the kinetics of drugs in humans, rats were infused intravenously with garenoxacin every 24 h (peak and trough levels in serum, 6.1 and 1.0 mg/liter, respectively; area under the concentration-time curve [AUC], 63.4 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),mg,63.4,172214,DB00537,Ciprofloxacin
,14693523,peak,"h/liter) or levofloxacin every 12 h (peak and trough levels in serum, 7.3 and 1.5 mg/liter, respectively; AUC, 55.6 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],7.3,172215,DB00537,Ciprofloxacin
,14693523,trough levels,"h/liter) or levofloxacin every 12 h (peak and trough levels in serum, 7.3 and 1.5 mg/liter, respectively; AUC, 55.6 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],1.5,172216,DB00537,Ciprofloxacin
,14693523,AUC,"h/liter) or levofloxacin every 12 h (peak and trough levels in serum, 7.3 and 1.5 mg/liter, respectively; AUC, 55.6 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),mg,55.6,172217,DB00537,Ciprofloxacin
,14693523,cure rate,"Garenoxacin and vancomycin also sterilized 70% of the vegetations infected with ciprofloxacin-resistant MRSA isolate P8-4, whereas treatment with levofloxacin failed against this organism (cure rate, 0%; P < 0.05 versus the results obtained with the comparator drugs).",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),%,0,172218,DB00537,Ciprofloxacin
,24802212,Peak plasma concentration (Cmax),"Peak plasma concentration (Cmax) of ciprofloxacin, 0.26±0.03 mg l(-1) was achieved at 4.40±0.1 h (Tmax).",Determination of the presence and pharmacokinetic profile of ciprofloxacin by TLC and HPLC method respectively in broiler chicken after single oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802212/),[mg] / [l],0.26,172374,DB00537,Ciprofloxacin
,24802212,Tmax,"Peak plasma concentration (Cmax) of ciprofloxacin, 0.26±0.03 mg l(-1) was achieved at 4.40±0.1 h (Tmax).",Determination of the presence and pharmacokinetic profile of ciprofloxacin by TLC and HPLC method respectively in broiler chicken after single oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802212/),h,4.40,172375,DB00537,Ciprofloxacin
,24802212,Biological half-life,Biological half-life of ciprofloxacin was 5.25±0.02 h.,Determination of the presence and pharmacokinetic profile of ciprofloxacin by TLC and HPLC method respectively in broiler chicken after single oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802212/),h,5.25,172376,DB00537,Ciprofloxacin
,24802212,Area under the curve (AUC),"Area under the curve (AUC) was 13.397±0.13 mg ml(-1) h, elimination rate constant was 0.13±0.02 h(-1), volume of distribution was 0.194±0.04 l kg(-1) and bioavailability was 49±0.48%.",Determination of the presence and pharmacokinetic profile of ciprofloxacin by TLC and HPLC method respectively in broiler chicken after single oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802212/),[h·mg] / [ml],13.397,172377,DB00537,Ciprofloxacin
,24802212,elimination rate constant,"Area under the curve (AUC) was 13.397±0.13 mg ml(-1) h, elimination rate constant was 0.13±0.02 h(-1), volume of distribution was 0.194±0.04 l kg(-1) and bioavailability was 49±0.48%.",Determination of the presence and pharmacokinetic profile of ciprofloxacin by TLC and HPLC method respectively in broiler chicken after single oral administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802212/),1/[h],0.13,172378,DB00537,Ciprofloxacin
,24802212,volume of distribution,"Area under the curve (AUC) was 13.397±0.13 mg ml(-1) h, elimination rate constant was 0.13±0.02 h(-1), volume of distribution was 0.194±0.04 l kg(-1) and bioavailability was 49±0.48%.",Determination of the presence and pharmacokinetic profile of ciprofloxacin by TLC and HPLC method respectively in broiler chicken after single oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802212/),[l] / [kg],0.194,172379,DB00537,Ciprofloxacin
,24802212,bioavailability,"Area under the curve (AUC) was 13.397±0.13 mg ml(-1) h, elimination rate constant was 0.13±0.02 h(-1), volume of distribution was 0.194±0.04 l kg(-1) and bioavailability was 49±0.48%.",Determination of the presence and pharmacokinetic profile of ciprofloxacin by TLC and HPLC method respectively in broiler chicken after single oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802212/),%,49,172380,DB00537,Ciprofloxacin
,3435125,peak levels,"Mean peak levels in serum were 1.4, 2.0, and 3.2 mg/liter for the 100-, 150-, and 200-mg doses, respectively.",Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435125/),[mg] / [l],1.4,172528,DB00537,Ciprofloxacin
,3435125,peak levels,"Mean peak levels in serum were 1.4, 2.0, and 3.2 mg/liter for the 100-, 150-, and 200-mg doses, respectively.",Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435125/),[mg] / [l],2.0,172529,DB00537,Ciprofloxacin
,3435125,peak levels,"Mean peak levels in serum were 1.4, 2.0, and 3.2 mg/liter for the 100-, 150-, and 200-mg doses, respectively.",Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435125/),[mg] / [l],3.2,172530,DB00537,Ciprofloxacin
,3435125,terminal half-life,The terminal half-life (from noncompartmental analysis) averaged between 4.2 and 4.6 h.,Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435125/),h,4.2 and 4.6,172531,DB00537,Ciprofloxacin
,3435125,urinary recovery,Average urinary recovery ranged between 45.8 and 48.1%.,Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435125/),%,45,172532,DB00537,Ciprofloxacin
,3435125,urinary recovery,Average urinary recovery ranged between 45.8 and 48.1%.,Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435125/),%,48,172533,DB00537,Ciprofloxacin
,3094438,elimination half-life,"After a single dose, the elimination half-life of ciprofloxacin was decreased by a third in the CF patients as compared with the controls (2.62 versus 3.93 h, respectively; P less than 0.01).",Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094438/),h,2.62,172689,DB00537,Ciprofloxacin
,3094438,elimination half-life,"After a single dose, the elimination half-life of ciprofloxacin was decreased by a third in the CF patients as compared with the controls (2.62 versus 3.93 h, respectively; P less than 0.01).",Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094438/),h,3.93,172690,DB00537,Ciprofloxacin
,3094438,MIC,"In CF patients, ciprofloxacin exhibited levels in respiratory secretions above the reported MIC for Pseudomonas aeruginosa: 1.36 and 1.86 micrograms/ml at 2 h after a single dose and at steady state, respectively.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094438/),[μg] / [ml],1.36,172691,DB00537,Ciprofloxacin
,3094438,MIC,"In CF patients, ciprofloxacin exhibited levels in respiratory secretions above the reported MIC for Pseudomonas aeruginosa: 1.36 and 1.86 micrograms/ml at 2 h after a single dose and at steady state, respectively.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094438/),[μg] / [ml],1.86,172692,DB00537,Ciprofloxacin
,16343856,cumulative renal excretion,"The median proportions of cumulative renal excretion of the administered dose of the parent drug up to 36 h were 43.1% for ciprofloxacin XR (range, 13.7-50.8%; mean +/- standard deviation (S.D.), 40.5 +/- 9.9%) and 79.8% for levofloxacin (range, 74.0-88.2%; mean +/- S.D., 80.4 +/- 5.5%).",Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343856/),%,43.1,172916,DB00537,Ciprofloxacin
,16343856,cumulative renal excretion,"The median proportions of cumulative renal excretion of the administered dose of the parent drug up to 36 h were 43.1% for ciprofloxacin XR (range, 13.7-50.8%; mean +/- standard deviation (S.D.), 40.5 +/- 9.9%) and 79.8% for levofloxacin (range, 74.0-88.2%; mean +/- S.D., 80.4 +/- 5.5%).",Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343856/),%,40.5,172917,DB00537,Ciprofloxacin
,16343856,cumulative renal excretion,"The median proportions of cumulative renal excretion of the administered dose of the parent drug up to 36 h were 43.1% for ciprofloxacin XR (range, 13.7-50.8%; mean +/- standard deviation (S.D.), 40.5 +/- 9.9%) and 79.8% for levofloxacin (range, 74.0-88.2%; mean +/- S.D., 80.4 +/- 5.5%).",Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343856/),%,79.8,172918,DB00537,Ciprofloxacin
,16343856,cumulative renal excretion,"The median proportions of cumulative renal excretion of the administered dose of the parent drug up to 36 h were 43.1% for ciprofloxacin XR (range, 13.7-50.8%; mean +/- standard deviation (S.D.), 40.5 +/- 9.9%) and 79.8% for levofloxacin (range, 74.0-88.2%; mean +/- S.D., 80.4 +/- 5.5%).",Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343856/),%,80.4,172919,DB00537,Ciprofloxacin
,17163255,Maximum paracetamol concentration (C(max)),"Maximum paracetamol concentration (C(max)) in saliva was significantly decreased when co-administered with ciprofloxacin (19.50 vs 13.70 microg/mL, p < 0.05).",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),[μg] / [ml],19.50,172930,DB00537,Ciprofloxacin
,17163255,Maximum paracetamol concentration (C(max)),"Maximum paracetamol concentration (C(max)) in saliva was significantly decreased when co-administered with ciprofloxacin (19.50 vs 13.70 microg/mL, p < 0.05).",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),[μg] / [ml],13.70,172931,DB00537,Ciprofloxacin
,17163255,Time to paracetamol C(max),"Time to paracetamol C(max) was significantly increased (1.43h vs 0.77h; p < 0.05) and paracetamol half-life was prolonged (1.19 to 1.53h, p = 0.05) in the presence of ciprofloxacin, whereas the area under the concentration-time curve was not affected.",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),h,1.43,172932,DB00537,Ciprofloxacin
,17163255,Time to paracetamol C(max),"Time to paracetamol C(max) was significantly increased (1.43h vs 0.77h; p < 0.05) and paracetamol half-life was prolonged (1.19 to 1.53h, p = 0.05) in the presence of ciprofloxacin, whereas the area under the concentration-time curve was not affected.",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),h,0.77,172933,DB00537,Ciprofloxacin
,17163255,half-life,"Time to paracetamol C(max) was significantly increased (1.43h vs 0.77h; p < 0.05) and paracetamol half-life was prolonged (1.19 to 1.53h, p = 0.05) in the presence of ciprofloxacin, whereas the area under the concentration-time curve was not affected.",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),h,1.19,172934,DB00537,Ciprofloxacin
,17163255,half-life,"Time to paracetamol C(max) was significantly increased (1.43h vs 0.77h; p < 0.05) and paracetamol half-life was prolonged (1.19 to 1.53h, p = 0.05) in the presence of ciprofloxacin, whereas the area under the concentration-time curve was not affected.",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),h,1.53,172935,DB00537,Ciprofloxacin
,2937737,serum concentration versus time curves,"Neither serum kinetics nor urinary recovery differed significantly between the two groups, as indicated by the serum concentration versus time curves ranging from 1.1 to 1.4 mg X h/l, the elimination half-life of 4.4 to 5.1 h and the 24 h urinary recovery which amounted to 35% to 41% of the dose administered.",Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2937737/),[h·mg] / [l],1.1 to 1.4,173288,DB00537,Ciprofloxacin
,2937737,elimination half-life,"Neither serum kinetics nor urinary recovery differed significantly between the two groups, as indicated by the serum concentration versus time curves ranging from 1.1 to 1.4 mg X h/l, the elimination half-life of 4.4 to 5.1 h and the 24 h urinary recovery which amounted to 35% to 41% of the dose administered.",Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2937737/),h,4.4 to 5.1,173289,DB00537,Ciprofloxacin
,17303451,peak plasma concentration (C(max),Enrofloxacin peak plasma concentration (C(max)=3.30+/-0.90 microg/mL) was reached at 24.17+/-9.17 min.,Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303451/),[μg] / [ml],3.30,173858,DB00537,Ciprofloxacin
,17303451,terminal half-life (t(1/2lambda)),"The terminal half-life (t(1/2lambda)) and area under the curve (AUC) were 2.85+/-0.54 h and 4.18+/-0.69 microg h/mL, respectively.",Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303451/),h,2.85,173859,DB00537,Ciprofloxacin
,17303451,area under the curve (AUC),"The terminal half-life (t(1/2lambda)) and area under the curve (AUC) were 2.85+/-0.54 h and 4.18+/-0.69 microg h/mL, respectively.",Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303451/),[h·μg] / [ml],4.18,173860,DB00537,Ciprofloxacin
,17303451,AUC,"The AUC and C(max) for ciprofloxacin were 0.25+/-0.06 microg/mL and 0.66+/-0.16 microg h/mL, respectively.",Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303451/),[μg] / [ml],0.25,173861,DB00537,Ciprofloxacin
,17303451,C(max),"The AUC and C(max) for ciprofloxacin were 0.25+/-0.06 microg/mL and 0.66+/-0.16 microg h/mL, respectively.",Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303451/),[h·μg] / [ml],0.66,173862,DB00537,Ciprofloxacin
<,17303451,MIC(90),"Taking into account the values obtained for the efficacy indices, an IM dose of 15 mg/kg of enrofloxacin would appear to be adequate for treating infections caused by highly susceptible bacteria (MIC(90)<0.03 microg/mL) in greater rheas.",Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303451/),[μg] / [ml],0.03,173863,DB00537,Ciprofloxacin
,20630222,maximum milk concentrations,"Following SC and P407 administration, difloxacin achieved maximum milk concentrations of 1.34+/-0.12 and 2.97+/-1.18 mg/L, respectively, at 4.00+/-0.00 h (SC) and 3.60+/-0.89 h (P407) after administration.",Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20630222/),[mg] / [l],1.34,174024,DB00537,Ciprofloxacin
,20630222,maximum milk concentrations,"Following SC and P407 administration, difloxacin achieved maximum milk concentrations of 1.34+/-0.12 and 2.97+/-1.18 mg/L, respectively, at 4.00+/-0.00 h (SC) and 3.60+/-0.89 h (P407) after administration.",Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20630222/),[mg] / [l],2.97,174025,DB00537,Ciprofloxacin
,20630222,absolute bioavailabilities,"The absolute bioavailabilities after SC and P407 administration were 81.74+/-15.60% and 72.58+/-20.45%, respectively.",Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20630222/),%,81.74,174026,DB00537,Ciprofloxacin
,20630222,absolute bioavailabilities,"The absolute bioavailabilities after SC and P407 administration were 81.74+/-15.60% and 72.58+/-20.45%, respectively.",Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20630222/),%,72.58,174027,DB00537,Ciprofloxacin
<or=,20630222,minimum inhibitory concentrations,"From these data, a 15 mg/kg dose of difloxacin P407 would appear to be effective against Staphylococcus aureus isolated from mastitic goats' milk with minimum inhibitory concentrations <or=0.25mg/L.",Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20630222/),[mg] / [l],0.25,174028,DB00537,Ciprofloxacin
,2509509,signal-to-noise ratio,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],4,174056,DB00537,Ciprofloxacin
,2509509,detection limits,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],4,174057,DB00537,Ciprofloxacin
,2509509,detection limits,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],2.5,174058,DB00537,Ciprofloxacin
,2509509,detection limits,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],10,174059,DB00537,Ciprofloxacin
,2509509,detection limits,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],20,174060,DB00537,Ciprofloxacin
,18247149,peak plasma concentration,"Enrofloxacin peak plasma concentration (5%: 0.73 +/- 0.32; 10%: 0.60 +/- 0.14 microg/mL) was reached at 1.21 +/- 0.52 and 1.38 +/- 0.52 h to 5 and 10%, respectively.",Pharmacokinetic behaviour of enrofloxacin and its metabolite ciprofloxacin after subcutaneous administration in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18247149/),[μg] / [ml],0.73,174475,DB00537,Ciprofloxacin
,18247149,peak plasma concentration,"Enrofloxacin peak plasma concentration (5%: 0.73 +/- 0.32; 10%: 0.60 +/- 0.14 microg/mL) was reached at 1.21 +/- 0.52 and 1.38 +/- 0.52 h to 5 and 10%, respectively.",Pharmacokinetic behaviour of enrofloxacin and its metabolite ciprofloxacin after subcutaneous administration in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18247149/),[μg] / [ml],0.60,174476,DB00537,Ciprofloxacin
,18247149,terminal half-live,"The terminal half-live and area under curve were 2.34 +/- 0.46 and 2.59 +/- 0.46 h, and 3.09 +/- 0.81 and 2.93 +/- 0.58 microg x h/mL, to 5 and 10%, respectively.",Pharmacokinetic behaviour of enrofloxacin and its metabolite ciprofloxacin after subcutaneous administration in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18247149/),h,2.34,174477,DB00537,Ciprofloxacin
,18247149,terminal half-live,"The terminal half-live and area under curve were 2.34 +/- 0.46 and 2.59 +/- 0.46 h, and 3.09 +/- 0.81 and 2.93 +/- 0.58 microg x h/mL, to 5 and 10%, respectively.",Pharmacokinetic behaviour of enrofloxacin and its metabolite ciprofloxacin after subcutaneous administration in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18247149/),[h·μg] / [ml],3.09,174478,DB00537,Ciprofloxacin
,18247149,area under curve,"The terminal half-live and area under curve were 2.34 +/- 0.46 and 2.59 +/- 0.46 h, and 3.09 +/- 0.81 and 2.93 +/- 0.58 microg x h/mL, to 5 and 10%, respectively.",Pharmacokinetic behaviour of enrofloxacin and its metabolite ciprofloxacin after subcutaneous administration in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18247149/),h,2.59,174479,DB00537,Ciprofloxacin
,18247149,area under curve,"The terminal half-live and area under curve were 2.34 +/- 0.46 and 2.59 +/- 0.46 h, and 3.09 +/- 0.81 and 2.93 +/- 0.58 microg x h/mL, to 5 and 10%, respectively.",Pharmacokinetic behaviour of enrofloxacin and its metabolite ciprofloxacin after subcutaneous administration in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18247149/),[h·μg] / [ml],2.93,174480,DB00537,Ciprofloxacin
≤,20736424,minimum inhibitory concentration [MIC],"A 45-year-old, class 3 obese (185 kg; body mass index 53.7), critically ill trauma patient receiving continuous venovenous hemodiafiltration (CVVHDF) was treated with ciprofloxacin 800 mg intravenously every 12 hours for presumed Enterobacter aerogenes (ciprofloxacin minimum inhibitory concentration [MIC] ≤1 μg/mL) lumbar spine osteomyelitis.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[μg] / [ml],1,174870,DB00537,Ciprofloxacin
,20736424,steady-state maximum (C(max)),"The observed steady-state maximum (C(max)) and calculated minimum (C(min)) ciprofloxacin plasma concentrations measured on treatment day 8 were 13 μg/mL and 4.8 μg/mL, respectively, corresponding to an estimated half-life, area under the curve (AUC(0-24)), total systemic clearance, and clearance by CVVHDF of 7.6 hours, 192 μg·h/mL, 139 mL/min, and 26 mL/min, respectively.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[μg] / [ml],13,174871,DB00537,Ciprofloxacin
,20736424,minimum (C(min)),"The observed steady-state maximum (C(max)) and calculated minimum (C(min)) ciprofloxacin plasma concentrations measured on treatment day 8 were 13 μg/mL and 4.8 μg/mL, respectively, corresponding to an estimated half-life, area under the curve (AUC(0-24)), total systemic clearance, and clearance by CVVHDF of 7.6 hours, 192 μg·h/mL, 139 mL/min, and 26 mL/min, respectively.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[μg] / [ml],4.8,174872,DB00537,Ciprofloxacin
,20736424,half-life,"The observed steady-state maximum (C(max)) and calculated minimum (C(min)) ciprofloxacin plasma concentrations measured on treatment day 8 were 13 μg/mL and 4.8 μg/mL, respectively, corresponding to an estimated half-life, area under the curve (AUC(0-24)), total systemic clearance, and clearance by CVVHDF of 7.6 hours, 192 μg·h/mL, 139 mL/min, and 26 mL/min, respectively.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),h,7.6,174873,DB00537,Ciprofloxacin
,20736424,area under the curve (AUC(0-24)),"The observed steady-state maximum (C(max)) and calculated minimum (C(min)) ciprofloxacin plasma concentrations measured on treatment day 8 were 13 μg/mL and 4.8 μg/mL, respectively, corresponding to an estimated half-life, area under the curve (AUC(0-24)), total systemic clearance, and clearance by CVVHDF of 7.6 hours, 192 μg·h/mL, 139 mL/min, and 26 mL/min, respectively.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[h·μg] / [ml],192,174874,DB00537,Ciprofloxacin
,20736424,area under the curve (AUC(0-24)),"The observed steady-state maximum (C(max)) and calculated minimum (C(min)) ciprofloxacin plasma concentrations measured on treatment day 8 were 13 μg/mL and 4.8 μg/mL, respectively, corresponding to an estimated half-life, area under the curve (AUC(0-24)), total systemic clearance, and clearance by CVVHDF of 7.6 hours, 192 μg·h/mL, 139 mL/min, and 26 mL/min, respectively.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[ml] / [min],139,174875,DB00537,Ciprofloxacin
,20736424,total systemic clearance,"The observed steady-state maximum (C(max)) and calculated minimum (C(min)) ciprofloxacin plasma concentrations measured on treatment day 8 were 13 μg/mL and 4.8 μg/mL, respectively, corresponding to an estimated half-life, area under the curve (AUC(0-24)), total systemic clearance, and clearance by CVVHDF of 7.6 hours, 192 μg·h/mL, 139 mL/min, and 26 mL/min, respectively.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[h·μg] / [ml],192,174876,DB00537,Ciprofloxacin
,20736424,total systemic clearance,"The observed steady-state maximum (C(max)) and calculated minimum (C(min)) ciprofloxacin plasma concentrations measured on treatment day 8 were 13 μg/mL and 4.8 μg/mL, respectively, corresponding to an estimated half-life, area under the curve (AUC(0-24)), total systemic clearance, and clearance by CVVHDF of 7.6 hours, 192 μg·h/mL, 139 mL/min, and 26 mL/min, respectively.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[ml] / [min],139,174877,DB00537,Ciprofloxacin
,20736424,total systemic clearance,"The observed steady-state maximum (C(max)) and calculated minimum (C(min)) ciprofloxacin plasma concentrations measured on treatment day 8 were 13 μg/mL and 4.8 μg/mL, respectively, corresponding to an estimated half-life, area under the curve (AUC(0-24)), total systemic clearance, and clearance by CVVHDF of 7.6 hours, 192 μg·h/mL, 139 mL/min, and 26 mL/min, respectively.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[ml] / [min],26,174878,DB00537,Ciprofloxacin
,20736424,clearance,"The observed steady-state maximum (C(max)) and calculated minimum (C(min)) ciprofloxacin plasma concentrations measured on treatment day 8 were 13 μg/mL and 4.8 μg/mL, respectively, corresponding to an estimated half-life, area under the curve (AUC(0-24)), total systemic clearance, and clearance by CVVHDF of 7.6 hours, 192 μg·h/mL, 139 mL/min, and 26 mL/min, respectively.","High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[ml] / [min],26,174879,DB00537,Ciprofloxacin
>,20736424,AUC(0-24)/MIC ratios,These concentrations produced AUC(0-24)/MIC ratios >125 and plasma C(max)/MIC ratios >10 for MICs ≤1 μg/mL.,"High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),,125,174880,DB00537,Ciprofloxacin
>,20736424,plasma C(max)/MIC ratios,These concentrations produced AUC(0-24)/MIC ratios >125 and plasma C(max)/MIC ratios >10 for MICs ≤1 μg/mL.,"High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),,10,174881,DB00537,Ciprofloxacin
≤,20736424,MICs,These concentrations produced AUC(0-24)/MIC ratios >125 and plasma C(max)/MIC ratios >10 for MICs ≤1 μg/mL.,"High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[μg] / [ml],1,174882,DB00537,Ciprofloxacin
>,20736424,AUC(0-24)/MIC ratios,Pharmacodynamic outcome studies suggest that AUC(0-24)/MIC ratios >125 and plasma C(max)/MIC ratios >10 are good predictors of clinical and microbiologic success of ciprofloxacin against gram-negative pathogens.,"High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),,125,174883,DB00537,Ciprofloxacin
>,20736424,plasma C(max)/MIC ratios,Pharmacodynamic outcome studies suggest that AUC(0-24)/MIC ratios >125 and plasma C(max)/MIC ratios >10 are good predictors of clinical and microbiologic success of ciprofloxacin against gram-negative pathogens.,"High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),,10,174884,DB00537,Ciprofloxacin
≤,20736424,MICs,These pharmacodynamic goals were achieved in the plasma with high-dose ciprofloxacin for MICs ≤1 μg/mL.,"High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[μg] / [ml],1,174885,DB00537,Ciprofloxacin
>,20736424,MICs,Critically ill obese patients with deep-seated infection involving organisms with MICs >0.5 μg/mL likely require ciprofloxacin dosages greater than traditional daily doses of 400-800 mg during CVVHDF to achieve optimal pharmacodynamic targets.,"High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736424/),[μg] / [ml],0.5,174886,DB00537,Ciprofloxacin
,20129633,percent bound,There was no significant difference in plasma protein binding of enrofloxacin between cows (percent bound: 59.4%) and steers (percent bound: 60.8%).,Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in lactating dairy cows and beef steers following intravenous administration of enrofloxacin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129633/),%,59.4,174967,DB00537,Ciprofloxacin
,20129633,percent bound,There was no significant difference in plasma protein binding of enrofloxacin between cows (percent bound: 59.4%) and steers (percent bound: 60.8%).,Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in lactating dairy cows and beef steers following intravenous administration of enrofloxacin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129633/),%,60.8,174968,DB00537,Ciprofloxacin
,20129633,percent bound,Ciprofloxacin was more extensively bound to plasma proteins in steers (percent bound: 49.6%) than in cows (percent bound: 33.8%).,Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in lactating dairy cows and beef steers following intravenous administration of enrofloxacin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129633/),%,49.6,174969,DB00537,Ciprofloxacin
,20129633,percent bound,Ciprofloxacin was more extensively bound to plasma proteins in steers (percent bound: 49.6%) than in cows (percent bound: 33.8%).,Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in lactating dairy cows and beef steers following intravenous administration of enrofloxacin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129633/),%,33.8,174970,DB00537,Ciprofloxacin
,20129633,steady state volume of distribution,The steady state volume of distribution of enrofloxacin is comparable in cows (1.55 L/kg) and steers (1.59 L/kg).,Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in lactating dairy cows and beef steers following intravenous administration of enrofloxacin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129633/),[l] / [kg],1.55,174971,DB00537,Ciprofloxacin
,20129633,steady state volume of distribution,The steady state volume of distribution of enrofloxacin is comparable in cows (1.55 L/kg) and steers (1.59 L/kg).,Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in lactating dairy cows and beef steers following intravenous administration of enrofloxacin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129633/),[l] / [kg],1.59,174972,DB00537,Ciprofloxacin
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.6,176468,DB00537,Ciprofloxacin
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.7,176469,DB00537,Ciprofloxacin
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.2,176470,DB00537,Ciprofloxacin
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.0,176471,DB00537,Ciprofloxacin
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,1.8,176472,DB00537,Ciprofloxacin
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,4.3,176473,DB00537,Ciprofloxacin
,26463606,clearance,The mean values of clearance and volume of distribution (V1) were 17.8 L/h and 49.8 L respectively.,[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26463606/),[l] / [h],17.8,176474,DB00537,Ciprofloxacin
,26463606,volume of distribution (V1),The mean values of clearance and volume of distribution (V1) were 17.8 L/h and 49.8 L respectively.,[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26463606/),l,49.8,176475,DB00537,Ciprofloxacin
,26463606,maximum steady-state concentrations (C(max)),"At the doses of 200 and 400 mg, the maximum steady-state concentrations (C(max)) were (4.2 ± 1.1) and (5.3 ± 1.21) mg/L, the minimum steady-state concentrations (C(min)) (1.1 ± 1.1) and (0.8 ± 0.4) mg/L and the area under concentration-time curve measured in steady-state up to 24 h after dosing (AUC(0-24 h)) were (45.5 ± 28.1) and (47.2 ± 11.3) mg · h · L⁻¹ respectively.",[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26463606/),[mg] / [l],4.2,176476,DB00537,Ciprofloxacin
,26463606,maximum steady-state concentrations (C(max)),"At the doses of 200 and 400 mg, the maximum steady-state concentrations (C(max)) were (4.2 ± 1.1) and (5.3 ± 1.21) mg/L, the minimum steady-state concentrations (C(min)) (1.1 ± 1.1) and (0.8 ± 0.4) mg/L and the area under concentration-time curve measured in steady-state up to 24 h after dosing (AUC(0-24 h)) were (45.5 ± 28.1) and (47.2 ± 11.3) mg · h · L⁻¹ respectively.",[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26463606/),[mg] / [l],5.3,176477,DB00537,Ciprofloxacin
,26463606,minimum steady-state concentrations (C(min)),"At the doses of 200 and 400 mg, the maximum steady-state concentrations (C(max)) were (4.2 ± 1.1) and (5.3 ± 1.21) mg/L, the minimum steady-state concentrations (C(min)) (1.1 ± 1.1) and (0.8 ± 0.4) mg/L and the area under concentration-time curve measured in steady-state up to 24 h after dosing (AUC(0-24 h)) were (45.5 ± 28.1) and (47.2 ± 11.3) mg · h · L⁻¹ respectively.",[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26463606/),[mg] / [l],1.1,176478,DB00537,Ciprofloxacin
,26463606,minimum steady-state concentrations (C(min)),"At the doses of 200 and 400 mg, the maximum steady-state concentrations (C(max)) were (4.2 ± 1.1) and (5.3 ± 1.21) mg/L, the minimum steady-state concentrations (C(min)) (1.1 ± 1.1) and (0.8 ± 0.4) mg/L and the area under concentration-time curve measured in steady-state up to 24 h after dosing (AUC(0-24 h)) were (45.5 ± 28.1) and (47.2 ± 11.3) mg · h · L⁻¹ respectively.",[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26463606/),[mg] / [l],0.8,176479,DB00537,Ciprofloxacin
,26463606,area under concentration-time curve measured in steady-state up to 24 h after dosing (AUC(0-24 h)),"At the doses of 200 and 400 mg, the maximum steady-state concentrations (C(max)) were (4.2 ± 1.1) and (5.3 ± 1.21) mg/L, the minimum steady-state concentrations (C(min)) (1.1 ± 1.1) and (0.8 ± 0.4) mg/L and the area under concentration-time curve measured in steady-state up to 24 h after dosing (AUC(0-24 h)) were (45.5 ± 28.1) and (47.2 ± 11.3) mg · h · L⁻¹ respectively.",[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26463606/),h·l⁻¹·mg,45.5,176480,DB00537,Ciprofloxacin
,26463606,area under concentration-time curve measured in steady-state up to 24 h after dosing (AUC(0-24 h)),"At the doses of 200 and 400 mg, the maximum steady-state concentrations (C(max)) were (4.2 ± 1.1) and (5.3 ± 1.21) mg/L, the minimum steady-state concentrations (C(min)) (1.1 ± 1.1) and (0.8 ± 0.4) mg/L and the area under concentration-time curve measured in steady-state up to 24 h after dosing (AUC(0-24 h)) were (45.5 ± 28.1) and (47.2 ± 11.3) mg · h · L⁻¹ respectively.",[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26463606/),h·l⁻¹·mg,47.2,176481,DB00537,Ciprofloxacin
,16104876,Clearance,"Clearance and distribution volumes of CPA were significantly (P < 0.01) lower (4.7 L/h and 42.3 L, respectively) when patients were treated with CF prior to CPA compared to that observed when the patients did not receive CF (5.9 L/h and 48.1 L, respectively).",The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16104876/),[l] / [h],4.7,177703,DB00537,Ciprofloxacin
,16104876,Clearance,"Clearance and distribution volumes of CPA were significantly (P < 0.01) lower (4.7 L/h and 42.3 L, respectively) when patients were treated with CF prior to CPA compared to that observed when the patients did not receive CF (5.9 L/h and 48.1 L, respectively).",The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16104876/),[l] / [h],5.9,177704,DB00537,Ciprofloxacin
,16104876,distribution volumes,"Clearance and distribution volumes of CPA were significantly (P < 0.01) lower (4.7 L/h and 42.3 L, respectively) when patients were treated with CF prior to CPA compared to that observed when the patients did not receive CF (5.9 L/h and 48.1 L, respectively).",The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16104876/),l,42.3,177705,DB00537,Ciprofloxacin
,16104876,distribution volumes,"Clearance and distribution volumes of CPA were significantly (P < 0.01) lower (4.7 L/h and 42.3 L, respectively) when patients were treated with CF prior to CPA compared to that observed when the patients did not receive CF (5.9 L/h and 48.1 L, respectively).",The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16104876/),[l] / [h],5.9,177706,DB00537,Ciprofloxacin
,16104876,distribution volumes,"Clearance and distribution volumes of CPA were significantly (P < 0.01) lower (4.7 L/h and 42.3 L, respectively) when patients were treated with CF prior to CPA compared to that observed when the patients did not receive CF (5.9 L/h and 48.1 L, respectively).",The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16104876/),l,48.1,177707,DB00537,Ciprofloxacin
,8722536,peak concentration (CPmax),"In order to test this hypothesis, we generated time concentration kill curves for P. aeruginosa ATCC 27853 and a clinical isolate P. aeruginosa PSA 9258 using an in-vitro model to simulate the pharmacokinetic characteristics found in vivo for ciprofloxacin at a peak concentration (CPmax) of 5 mg/L and an elimination T1/2 of 4.5 h, and ofloxacin at a CPmax of 5 mg/L and a T1/2 of both 4.5 h and 6 h, and at a CPmax of 8.0 mg/L and a T1/2 of 6 h.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[mg] / [l],5,178464,DB00537,Ciprofloxacin
,8722536,elimination T1/2,"In order to test this hypothesis, we generated time concentration kill curves for P. aeruginosa ATCC 27853 and a clinical isolate P. aeruginosa PSA 9258 using an in-vitro model to simulate the pharmacokinetic characteristics found in vivo for ciprofloxacin at a peak concentration (CPmax) of 5 mg/L and an elimination T1/2 of 4.5 h, and ofloxacin at a CPmax of 5 mg/L and a T1/2 of both 4.5 h and 6 h, and at a CPmax of 8.0 mg/L and a T1/2 of 6 h.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),h,4.5,178465,DB00537,Ciprofloxacin
,8722536,CPmax,"In order to test this hypothesis, we generated time concentration kill curves for P. aeruginosa ATCC 27853 and a clinical isolate P. aeruginosa PSA 9258 using an in-vitro model to simulate the pharmacokinetic characteristics found in vivo for ciprofloxacin at a peak concentration (CPmax) of 5 mg/L and an elimination T1/2 of 4.5 h, and ofloxacin at a CPmax of 5 mg/L and a T1/2 of both 4.5 h and 6 h, and at a CPmax of 8.0 mg/L and a T1/2 of 6 h.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[mg] / [l],5,178466,DB00537,Ciprofloxacin
,8722536,T1/2,"In order to test this hypothesis, we generated time concentration kill curves for P. aeruginosa ATCC 27853 and a clinical isolate P. aeruginosa PSA 9258 using an in-vitro model to simulate the pharmacokinetic characteristics found in vivo for ciprofloxacin at a peak concentration (CPmax) of 5 mg/L and an elimination T1/2 of 4.5 h, and ofloxacin at a CPmax of 5 mg/L and a T1/2 of both 4.5 h and 6 h, and at a CPmax of 8.0 mg/L and a T1/2 of 6 h.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),h,4.5,178467,DB00537,Ciprofloxacin
,8722536,T1/2,"In order to test this hypothesis, we generated time concentration kill curves for P. aeruginosa ATCC 27853 and a clinical isolate P. aeruginosa PSA 9258 using an in-vitro model to simulate the pharmacokinetic characteristics found in vivo for ciprofloxacin at a peak concentration (CPmax) of 5 mg/L and an elimination T1/2 of 4.5 h, and ofloxacin at a CPmax of 5 mg/L and a T1/2 of both 4.5 h and 6 h, and at a CPmax of 8.0 mg/L and a T1/2 of 6 h.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),h,6,178468,DB00537,Ciprofloxacin
,8722536,CPmax,"In order to test this hypothesis, we generated time concentration kill curves for P. aeruginosa ATCC 27853 and a clinical isolate P. aeruginosa PSA 9258 using an in-vitro model to simulate the pharmacokinetic characteristics found in vivo for ciprofloxacin at a peak concentration (CPmax) of 5 mg/L and an elimination T1/2 of 4.5 h, and ofloxacin at a CPmax of 5 mg/L and a T1/2 of both 4.5 h and 6 h, and at a CPmax of 8.0 mg/L and a T1/2 of 6 h.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[mg] / [l],8.0,178469,DB00537,Ciprofloxacin
,8722536,CPmax,Ofloxacin at a CPmax of 8 mg/L and T1/2 of 6 h achieved a T3 kill of P. aeruginosa ATCC 27853 in 0.74 h and of P. aeruginosa PSA 9258 in 0.16 h.,A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[mg] / [l],8,178470,DB00537,Ciprofloxacin
,8722536,T1/2,Ofloxacin at a CPmax of 8 mg/L and T1/2 of 6 h achieved a T3 kill of P. aeruginosa ATCC 27853 in 0.74 h and of P. aeruginosa PSA 9258 in 0.16 h.,A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),h,6,178471,DB00537,Ciprofloxacin
,8722536,area under the kill curve (AUKC),"The area under the kill curve (AUKC) was 1.10 x 10(4)and 1.96 x 10(3) mL-h/cfu for ciprofloxacin against P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively and that of ofloxacin at CPmax 8 mg/L and a T1/2 of 6 h was 9.78 x 10(4)and 2.20 x 10(4) mL-h/cfu respectively.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[ml-h] / [cfu],1.10 x 10(4),178472,DB00537,Ciprofloxacin
,8722536,area under the kill curve (AUKC),"The area under the kill curve (AUKC) was 1.10 x 10(4)and 1.96 x 10(3) mL-h/cfu for ciprofloxacin against P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively and that of ofloxacin at CPmax 8 mg/L and a T1/2 of 6 h was 9.78 x 10(4)and 2.20 x 10(4) mL-h/cfu respectively.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[ml-h] / [cfu],1.96 x 10(3),178473,DB00537,Ciprofloxacin
,8722536,CPmax,"The area under the kill curve (AUKC) was 1.10 x 10(4)and 1.96 x 10(3) mL-h/cfu for ciprofloxacin against P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively and that of ofloxacin at CPmax 8 mg/L and a T1/2 of 6 h was 9.78 x 10(4)and 2.20 x 10(4) mL-h/cfu respectively.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[mg] / [l],8,178474,DB00537,Ciprofloxacin
,8722536,T1/2,"The area under the kill curve (AUKC) was 1.10 x 10(4)and 1.96 x 10(3) mL-h/cfu for ciprofloxacin against P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively and that of ofloxacin at CPmax 8 mg/L and a T1/2 of 6 h was 9.78 x 10(4)and 2.20 x 10(4) mL-h/cfu respectively.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[ml-h] / [cfu],6,178475,DB00537,Ciprofloxacin
,8722536,T1/2,"The area under the kill curve (AUKC) was 1.10 x 10(4)and 1.96 x 10(3) mL-h/cfu for ciprofloxacin against P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively and that of ofloxacin at CPmax 8 mg/L and a T1/2 of 6 h was 9.78 x 10(4)and 2.20 x 10(4) mL-h/cfu respectively.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[ml-h] / [cfu],9.78 x 10(4),178476,DB00537,Ciprofloxacin
,8722536,T1/2,"The area under the kill curve (AUKC) was 1.10 x 10(4)and 1.96 x 10(3) mL-h/cfu for ciprofloxacin against P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively and that of ofloxacin at CPmax 8 mg/L and a T1/2 of 6 h was 9.78 x 10(4)and 2.20 x 10(4) mL-h/cfu respectively.",A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722536/),[ml-h] / [cfu],2.20 x 10(4),178477,DB00537,Ciprofloxacin
,7619414,duration of,Mean duration of ear drainage at baseline was 10.7 months (0.75 to 36 months).,Topical ciprofloxacin for otorrhea after tympanostomy tube placement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619414/),month,10.7,178844,DB00537,Ciprofloxacin
,24798283,-to-unbound plasma drug concentration ratios,"ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations).","Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798283/),,4.0,179003,DB00537,Ciprofloxacin
,24798283,-to-unbound plasma drug concentration ratios,"ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations).","Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798283/),,12.6,179004,DB00537,Ciprofloxacin
,24798283,-to-unbound plasma drug concentration ratios,"ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations).","Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798283/),,19.1,179005,DB00537,Ciprofloxacin
,15189301,t(1/2(d)),"After intravenous administration, distribution was rapid (t(1/2(d)), 0.22 +/- 0.23 h) and wide as reflected by the steady-state volume of distribution of 3.85 +/- 1.34 L/kg.",Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189301/),h,0.22,179149,DB00537,Ciprofloxacin
,15189301,steady-state volume of distribution,"After intravenous administration, distribution was rapid (t(1/2(d)), 0.22 +/- 0.23 h) and wide as reflected by the steady-state volume of distribution of 3.85 +/- 1.34 L/kg.",Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189301/),[l] / [kg],3.85,179150,DB00537,Ciprofloxacin
,15189301,plasma clearance,"Furthermore, elimination was rapid with a plasma clearance of 0.64 +/- 0.28 L/h.kg and a t(1/2(el)) of 4.53 +/- 0.74 h.",Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189301/),[l] / [h·kg],0.64,179151,DB00537,Ciprofloxacin
,15189301,t(1/2(el)),"Furthermore, elimination was rapid with a plasma clearance of 0.64 +/- 0.28 L/h.kg and a t(1/2(el)) of 4.53 +/- 0.74 h.",Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189301/),h,4.53,179152,DB00537,Ciprofloxacin
,15189301,half-life,"After repeat oral administration, absorption was rapid with a half-life of 0.23 +/- 0.22 h and T(max) of 1.30 +/- 0.67 h.",Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189301/),h,0.23,179153,DB00537,Ciprofloxacin
,15189301,T(max),"After repeat oral administration, absorption was rapid with a half-life of 0.23 +/- 0.22 h and T(max) of 1.30 +/- 0.67 h.",Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189301/),h,1.30,179154,DB00537,Ciprofloxacin
,15189301,bioavailability,"However bioavailability was low (33 +/- 12%), the peak plasma concentration at steady-state was 1.26 +/- 0.67 microg/mL.",Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189301/),%,33,179155,DB00537,Ciprofloxacin
,15189301,peak plasma concentration at steady-state,"However bioavailability was low (33 +/- 12%), the peak plasma concentration at steady-state was 1.26 +/- 0.67 microg/mL.",Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189301/),[μg] / [ml],1.26,179156,DB00537,Ciprofloxacin
,18606841,MIC,"The potent in vitro activity of oritavancin, a semisynthetic lipoglycopeptide, against B. anthracis (MIC against Ames strain, 0.015 microg/ml) prompted us to test its efficacy in a mouse aerosol-anthrax model.",Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18606841/),[μg] / [ml],0.015,179213,DB00537,Ciprofloxacin
,2940974,peak levels,Significantly higher peak levels of ciprofloxacin in serum were observed after multiple dosing (3.51 versus 2.26 micrograms/ml; P less than 0.01).,Tissue penetration of ciprofloxacin after single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940974/),[μg] / [ml],3.51,179482,DB00537,Ciprofloxacin
,2940974,peak levels,Significantly higher peak levels of ciprofloxacin in serum were observed after multiple dosing (3.51 versus 2.26 micrograms/ml; P less than 0.01).,Tissue penetration of ciprofloxacin after single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940974/),[μg] / [ml],2.26,179483,DB00537,Ciprofloxacin
,2940974,nonrenal clearance,Increased elimination half-life occurred after multiple dosing; this seems to be mostly related to decreased systemic clearance secondary to a diminished nonrenal clearance (240.0 versus 125.0 ml/min).,Tissue penetration of ciprofloxacin after single and multiple doses. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940974/),[ml] / [min],240.0,179484,DB00537,Ciprofloxacin
,2940974,nonrenal clearance,Increased elimination half-life occurred after multiple dosing; this seems to be mostly related to decreased systemic clearance secondary to a diminished nonrenal clearance (240.0 versus 125.0 ml/min).,Tissue penetration of ciprofloxacin after single and multiple doses. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940974/),[ml] / [min],125.0,179485,DB00537,Ciprofloxacin
,8592896,maximal plasma concentrations,"The maximal plasma concentrations attained after administration of 10 and 20 mg/kg were 1.55 and 3.08 mg/l, respectively, and agree with results reported in the literature for this species.",Ciprofloxacin pharmacokinetics in dogs following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592896/),[mg] / [l],1.55,179583,DB00537,Ciprofloxacin
,8592896,maximal plasma concentrations,"The maximal plasma concentrations attained after administration of 10 and 20 mg/kg were 1.55 and 3.08 mg/l, respectively, and agree with results reported in the literature for this species.",Ciprofloxacin pharmacokinetics in dogs following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592896/),[mg] / [l],3.08,179584,DB00537,Ciprofloxacin
,8592896,elimination rate,The elimination rate was significantly smaller after administration of the 40 mg/kg (0.0014/min) than 10 and 20 mg/kg doses (near 0.0024/min).,Ciprofloxacin pharmacokinetics in dogs following oral administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592896/),1/[min],0.0014,179585,DB00537,Ciprofloxacin
,8592896,elimination rate,The elimination rate was significantly smaller after administration of the 40 mg/kg (0.0014/min) than 10 and 20 mg/kg doses (near 0.0024/min).,Ciprofloxacin pharmacokinetics in dogs following oral administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592896/),1/[min],0.0024,179586,DB00537,Ciprofloxacin
,3300537,washout time,Ciprofloxacin was administered after overnight fasting; the washout time between the two doses was 1 week.,Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300537/),,1,179789,DB00537,Ciprofloxacin
,9098664,oral bioavailability,"In its new formulation as the oral tromethamine salt, fosfomycin has 34 to 41% oral bioavailability, has a mean elimination half-life of 5.7 hours, and is primarily excreted unchanged in the urine.","Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098664/),%,34 to 41,179835,DB00537,Ciprofloxacin
,9098664,elimination half-life,"In its new formulation as the oral tromethamine salt, fosfomycin has 34 to 41% oral bioavailability, has a mean elimination half-life of 5.7 hours, and is primarily excreted unchanged in the urine.","Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098664/),h,5.7,179836,DB00537,Ciprofloxacin
,9098664,eradication rates,"Bacteriological eradication rates of 75 to 90% were achieved 5 to 11 days after therapy, with eradication rates of 62 to 93% 4 to 6 weeks after therapy.","Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098664/),%,75 to 90,179837,DB00537,Ciprofloxacin
,9098664,eradication rates,"Bacteriological eradication rates of 75 to 90% were achieved 5 to 11 days after therapy, with eradication rates of 62 to 93% 4 to 6 weeks after therapy.","Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098664/),%,62 to 93,179838,DB00537,Ciprofloxacin
,12435668,ratio of,"The ratio of the concentration in skin blister fluid/concentration in plasma reached values above 4, indicating a preferential penetration of ciprofloxacin into inflamed lesions.",Target site concentrations of ciprofloxacin after single intravenous and oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12435668/),,4,179872,DB00537,Ciprofloxacin
,10213238,elimination half-life,"The elimination half-life of ciprofloxacin in control and traumatized eyes was 6.02 hours and 5.02 hours, respectively, and infection prolonged the half-life to 15.06 hours.",Effects of trauma and infection on ciprofloxacin levels in the vitreous cavity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213238/),h,6.02,180072,DB00537,Ciprofloxacin
,10213238,elimination half-life,"The elimination half-life of ciprofloxacin in control and traumatized eyes was 6.02 hours and 5.02 hours, respectively, and infection prolonged the half-life to 15.06 hours.",Effects of trauma and infection on ciprofloxacin levels in the vitreous cavity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213238/),h,5.02,180073,DB00537,Ciprofloxacin
,10213238,half-life,"The elimination half-life of ciprofloxacin in control and traumatized eyes was 6.02 hours and 5.02 hours, respectively, and infection prolonged the half-life to 15.06 hours.",Effects of trauma and infection on ciprofloxacin levels in the vitreous cavity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213238/),h,15.06,180074,DB00537,Ciprofloxacin
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],77.8,180503,DB00537,Ciprofloxacin
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],31.8,180504,DB00537,Ciprofloxacin
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,9.7,180505,DB00537,Ciprofloxacin
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,4.5,180506,DB00537,Ciprofloxacin
,30453178,Elimination half-life (t1/2β),"Elimination half-life (t1/2β), total body clearance (Cltot), volume of distribution at steady state (Vdss) and mean residence time (MRT) of DF were 5.45 ± 0.14 h, 0.22 ± 0.01 L/kg/h, 1.54 ± 0.06 L/kg and 6.92 ± 0.19 h, respectively.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),h,5.45,181435,DB00537,Ciprofloxacin
,30453178,total body clearance (Cltot),"Elimination half-life (t1/2β), total body clearance (Cltot), volume of distribution at steady state (Vdss) and mean residence time (MRT) of DF were 5.45 ± 0.14 h, 0.22 ± 0.01 L/kg/h, 1.54 ± 0.06 L/kg and 6.92 ± 0.19 h, respectively.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),[l] / [h·kg],0.22,181436,DB00537,Ciprofloxacin
,30453178,volume of distribution at steady state (Vdss),"Elimination half-life (t1/2β), total body clearance (Cltot), volume of distribution at steady state (Vdss) and mean residence time (MRT) of DF were 5.45 ± 0.14 h, 0.22 ± 0.01 L/kg/h, 1.54 ± 0.06 L/kg and 6.92 ± 0.19 h, respectively.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),[l] / [h·kg],0.22,181437,DB00537,Ciprofloxacin
,30453178,mean residence time (MRT),"Elimination half-life (t1/2β), total body clearance (Cltot), volume of distribution at steady state (Vdss) and mean residence time (MRT) of DF were 5.45 ± 0.14 h, 0.22 ± 0.01 L/kg/h, 1.54 ± 0.06 L/kg and 6.92 ± 0.19 h, respectively.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),h,6.92,181438,DB00537,Ciprofloxacin
,30453178,peak plasma concentration (Cmax),"Following PO administration, DF was rapidly absorbed, with peak plasma concentration (Cmax) of 3.67 μg/mL attained at 1.90 h (Tmax) after administration.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),[μg] / [ml],3.67,181439,DB00537,Ciprofloxacin
,30453178,Tmax,"Following PO administration, DF was rapidly absorbed, with peak plasma concentration (Cmax) of 3.67 μg/mL attained at 1.90 h (Tmax) after administration.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),h,1.90,181440,DB00537,Ciprofloxacin
,30453178,Absorption half-life (t1/2ab),"Absorption half-life (t1/2ab), elimination half-life (t1/2el), mean absorption time (MAT) were 0.5 h, 5.26 h and 1.11 h, respectively.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),h,0.5,181441,DB00537,Ciprofloxacin
,30453178,elimination half-life (t1/2el),"Absorption half-life (t1/2ab), elimination half-life (t1/2el), mean absorption time (MAT) were 0.5 h, 5.26 h and 1.11 h, respectively.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),h,5.26,181442,DB00537,Ciprofloxacin
,30453178,mean absorption time (MAT),"Absorption half-life (t1/2ab), elimination half-life (t1/2el), mean absorption time (MAT) were 0.5 h, 5.26 h and 1.11 h, respectively.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),h,1.11,181443,DB00537,Ciprofloxacin
,30453178,bioavailability (F),The bioavailability (F) following PO administration of DF was high (84.40%).,Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),%,84.40,181444,DB00537,Ciprofloxacin
<,30453178,MIC90,"For a successful clinical effect of DF in quails, a multiple dosage regimen of 10 mg/kg bodyweight, administered orally every 24 h is recommended to maintain effective plasma concentrations with bacterial infections, in which MIC90 is <0.2 μg/mL.",Pharmacokinetics of difloxacin in Japanese quails (Coturnix japonica) after single intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453178/),[μg] / [ml],0.2,181445,DB00537,Ciprofloxacin
,2114952,plasma concentrations,Tissue concentrations after onset of the procedures showed ciprofloxacin plasma concentrations of 2.09-0.47 micrograms g in the native and 3.98-1.99 micrograms/g in the heterologous valvular tissues.,Pharmacokinetic behavior of ciprofloxacin both in native cardiac and porcine valves treated in glutaraldehyde. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2114952/),g·μg,2.09-0.47,181477,DB00537,Ciprofloxacin
,2114952,plasma concentrations,Tissue concentrations after onset of the procedures showed ciprofloxacin plasma concentrations of 2.09-0.47 micrograms g in the native and 3.98-1.99 micrograms/g in the heterologous valvular tissues.,Pharmacokinetic behavior of ciprofloxacin both in native cardiac and porcine valves treated in glutaraldehyde. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2114952/),[μg] / [g],3.98-1.99,181478,DB00537,Ciprofloxacin
≥,32941947,AUC/MIC,We aimed to investigate whether the PK/PD target (AUC/MIC ≥125) is attained in patients with adequate and impaired renal function receiving regular and reduced ciprofloxacin doses.,Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32941947/),,125,181762,DB00537,Ciprofloxacin
≥,32941947,AUC0-24/MIC,"Using the clinical breakpoint MIC of the most isolated bacteria (Escherichia coli, 0.25 mg/L), AUC0-24/MIC ≥125 was attained in 13/32 (41%) patients with adequate renal function receiving regular doses and in 1/8 (13%) patients with impaired renal function receiving reduced doses.",Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32941947/),,125,181763,DB00537,Ciprofloxacin
,32941947,drug exposure (AUC0-24),"Median drug exposure (AUC0-24) for patients with impaired renal function was 19.0 [interquartile range (IQR) 14.2-23.3] mg/L•h, which was statistically significantly lower than that for patients with adequate renal function [29.3 (IQR 25.0-36.0) mg/L•h] (P < 0.01).",Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32941947/),[mg] / [h·l],19.0,181764,DB00537,Ciprofloxacin
,32941947,drug exposure (AUC0-24),"Median drug exposure (AUC0-24) for patients with impaired renal function was 19.0 [interquartile range (IQR) 14.2-23.3] mg/L•h, which was statistically significantly lower than that for patients with adequate renal function [29.3 (IQR 25.0-36.0) mg/L•h] (P < 0.01).",Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32941947/),[mg] / [h·l],29.3,181765,DB00537,Ciprofloxacin
≥,32941947,AUC0-24/MIC,AUC0-24/MIC ≥125 is not attained in the majority of adult patients on general wards for clinically relevant bacteria with MICs at or just below the clinical breakpoint.,Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32941947/),,125,181766,DB00537,Ciprofloxacin
,27010278,elimination half-life (t½),"The enrofloxacin elimination half-life (t½), peak hemolymph concentration (CMAX), and area under the curve (AUC) were 38.82 hr, 90.92 μg/ml, and 1,199 hr·μg/ml, respectively.",POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND ITS METABOLITE CIPROFLOXACIN IN THE GREEN SEA URCHIN (STRONGYLOCENTROTUS DROEBACHIENSIS) FOLLOWING INTRACOELOMIC AND IMMERSION ADMINISTRATION. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010278/),h,38.82,181847,DB00537,Ciprofloxacin
,27010278,peak hemolymph concentration (CMAX),"The enrofloxacin elimination half-life (t½), peak hemolymph concentration (CMAX), and area under the curve (AUC) were 38.82 hr, 90.92 μg/ml, and 1,199 hr·μg/ml, respectively.",POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND ITS METABOLITE CIPROFLOXACIN IN THE GREEN SEA URCHIN (STRONGYLOCENTROTUS DROEBACHIENSIS) FOLLOWING INTRACOELOMIC AND IMMERSION ADMINISTRATION. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010278/),[μg] / [ml],90.92,181848,DB00537,Ciprofloxacin
,27010278,area under the curve (AUC),"The enrofloxacin elimination half-life (t½), peak hemolymph concentration (CMAX), and area under the curve (AUC) were 38.82 hr, 90.92 μg/ml, and 1,199 hr·μg/ml, respectively.",POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND ITS METABOLITE CIPROFLOXACIN IN THE GREEN SEA URCHIN (STRONGYLOCENTROTUS DROEBACHIENSIS) FOLLOWING INTRACOELOMIC AND IMMERSION ADMINISTRATION. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010278/),[h·μg] / [ml],"1,199",181849,DB00537,Ciprofloxacin
,27010278,t½,"The enrofloxacin t½, CMAX, and AUC were 33.46 hr, 0.48 μg/ml, and 32.88 hr·μg/ml, respectively.",POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND ITS METABOLITE CIPROFLOXACIN IN THE GREEN SEA URCHIN (STRONGYLOCENTROTUS DROEBACHIENSIS) FOLLOWING INTRACOELOMIC AND IMMERSION ADMINISTRATION. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010278/),h,33.46,181850,DB00537,Ciprofloxacin
,27010278,CMAX,"The enrofloxacin t½, CMAX, and AUC were 33.46 hr, 0.48 μg/ml, and 32.88 hr·μg/ml, respectively.",POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND ITS METABOLITE CIPROFLOXACIN IN THE GREEN SEA URCHIN (STRONGYLOCENTROTUS DROEBACHIENSIS) FOLLOWING INTRACOELOMIC AND IMMERSION ADMINISTRATION. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010278/),[μg] / [ml],0.48,181851,DB00537,Ciprofloxacin
,27010278,AUC,"The enrofloxacin t½, CMAX, and AUC were 33.46 hr, 0.48 μg/ml, and 32.88 hr·μg/ml, respectively.",POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND ITS METABOLITE CIPROFLOXACIN IN THE GREEN SEA URCHIN (STRONGYLOCENTROTUS DROEBACHIENSIS) FOLLOWING INTRACOELOMIC AND IMMERSION ADMINISTRATION. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010278/),[h·μg] / [ml],32.88,181852,DB00537,Ciprofloxacin
,16207305,terminal half-life (t(1/2)),"In the i.v. study, the terminal half-life (t(1/2)), apparent volume of distribution, and systemic clearance were respectively 1.81 h, 385 mL/kg, and 4.71 mL/min/kg.","Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207305/),h,1.81,181971,DB00537,Ciprofloxacin
,16207305,apparent volume of distribution,"In the i.v. study, the terminal half-life (t(1/2)), apparent volume of distribution, and systemic clearance were respectively 1.81 h, 385 mL/kg, and 4.71 mL/min/kg.","Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207305/),[ml] / [kg],385,181972,DB00537,Ciprofloxacin
,16207305,systemic clearance,"In the i.v. study, the terminal half-life (t(1/2)), apparent volume of distribution, and systemic clearance were respectively 1.81 h, 385 mL/kg, and 4.71 mL/min/kg.","Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207305/),[ml] / [kg·min],4.71,181973,DB00537,Ciprofloxacin
,16207305,t(1/2),"Following bath administration the t(1/2), peak hemolymph concentration (C(max)), and area under the curve to infinity (AUC(0-infinity)) were 1.01 h, 0.5 +/- 0.12 mug/mL, and 0.98 microg.h/mL, respectively.","Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207305/),h,1.01,181974,DB00537,Ciprofloxacin
,16207305,peak hemolymph concentration (C(max)),"Following bath administration the t(1/2), peak hemolymph concentration (C(max)), and area under the curve to infinity (AUC(0-infinity)) were 1.01 h, 0.5 +/- 0.12 mug/mL, and 0.98 microg.h/mL, respectively.","Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207305/),[μg] / [ml],0.5,181975,DB00537,Ciprofloxacin
,16207305,area under the curve to infinity (AUC(0-infinity)),"Following bath administration the t(1/2), peak hemolymph concentration (C(max)), and area under the curve to infinity (AUC(0-infinity)) were 1.01 h, 0.5 +/- 0.12 mug/mL, and 0.98 microg.h/mL, respectively.","Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207305/),[h·μg] / [ml],0.98,181976,DB00537,Ciprofloxacin
,16207305,t(1/2),"After oral administration, the t(1/2), C(max), and AUC(0-infinity) were 1.01 h, 10.95 microg/mL, 26.71 mug.h/mL, respectively.","Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207305/),h,1.01,181977,DB00537,Ciprofloxacin
,16207305,C(max),"After oral administration, the t(1/2), C(max), and AUC(0-infinity) were 1.01 h, 10.95 microg/mL, 26.71 mug.h/mL, respectively.","Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207305/),[μg] / [ml],10.95,181978,DB00537,Ciprofloxacin
,16207305,AUC(0-infinity),"After oral administration, the t(1/2), C(max), and AUC(0-infinity) were 1.01 h, 10.95 microg/mL, 26.71 mug.h/mL, respectively.","Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207305/),[h·μg] / [ml],26.71,181979,DB00537,Ciprofloxacin
,17101261,maximum concentration,The median maximum concentration of levofloxacin in plasma was 6.1 mg/L and that of ciprofloxacin was 2.3 mg/L.,"Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),[mg] / [l],6.1,182004,DB00537,Ciprofloxacin
,17101261,maximum concentration,The median maximum concentration of levofloxacin in plasma was 6.1 mg/L and that of ciprofloxacin was 2.3 mg/L.,"Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),[mg] / [l],2.3,182005,DB00537,Ciprofloxacin
,17101261,cumulative level of renal excretion,The median cumulative level of renal excretion of the administered dose of the parent drug was 81.2% for levofloxacin and 36.2% for ciprofloxacin.,"Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),%,81.2,182006,DB00537,Ciprofloxacin
,17101261,cumulative level of renal excretion,The median cumulative level of renal excretion of the administered dose of the parent drug was 81.2% for levofloxacin and 36.2% for ciprofloxacin.,"Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),%,36.2,182007,DB00537,Ciprofloxacin
,17101261,UBTs,"The median UBTs of both quinolones measured within the first 12h were between 0 and 1:> or =1024, correlating with the minimum inhibitory concentrations (MICs) of the strains.","Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),,0 and 1:> or =,182008,DB00537,Ciprofloxacin
,17101261,UBTs,"The median UBTs of both quinolones measured within the first 12h were between 0 and 1:> or =1024, correlating with the minimum inhibitory concentrations (MICs) of the strains.","Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),,1024,182009,DB00537,Ciprofloxacin
,1663561,Peak enrofloxacin concentration,"Peak enrofloxacin concentration, mean (+/- SEM), at 1 h following a 15-mg/kg IM dose was 3.87 (+/- 0.27) micrograms/ml and declined with a mean residence time of 3.05 h.",Intramuscular and oral disposition of enrofloxacin in African grey parrots following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663561/),[μg] / [ml],3.87,182183,DB00537,Ciprofloxacin
,1663561,mean residence time,"Peak enrofloxacin concentration, mean (+/- SEM), at 1 h following a 15-mg/kg IM dose was 3.87 (+/- 0.27) micrograms/ml and declined with a mean residence time of 3.05 h.",Intramuscular and oral disposition of enrofloxacin in African grey parrots following single and multiple doses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663561/),h,3.05,182184,DB00537,Ciprofloxacin
,1663561,Peak enrofloxacin plasma concentrations,"Peak enrofloxacin plasma concentrations at 2 to 4 h following oral doses of 3, 15, and 30 mg/kg were 0.31 (+/- 0.11), 1.12 (+/- 0.11), and 1.69 (+/- 0.23) micrograms/ml, respectively, and declined with a mean residence time of 3.44-5.28 h.",Intramuscular and oral disposition of enrofloxacin in African grey parrots following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663561/),[μg] / [ml],0.31,182185,DB00537,Ciprofloxacin
,1663561,Peak enrofloxacin plasma concentrations,"Peak enrofloxacin plasma concentrations at 2 to 4 h following oral doses of 3, 15, and 30 mg/kg were 0.31 (+/- 0.11), 1.12 (+/- 0.11), and 1.69 (+/- 0.23) micrograms/ml, respectively, and declined with a mean residence time of 3.44-5.28 h.",Intramuscular and oral disposition of enrofloxacin in African grey parrots following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663561/),[μg] / [ml],1.12,182186,DB00537,Ciprofloxacin
,1663561,Peak enrofloxacin plasma concentrations,"Peak enrofloxacin plasma concentrations at 2 to 4 h following oral doses of 3, 15, and 30 mg/kg were 0.31 (+/- 0.11), 1.12 (+/- 0.11), and 1.69 (+/- 0.23) micrograms/ml, respectively, and declined with a mean residence time of 3.44-5.28 h.",Intramuscular and oral disposition of enrofloxacin in African grey parrots following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663561/),[μg] / [ml],1.69,182187,DB00537,Ciprofloxacin
,1663561,mean residence time,"Peak enrofloxacin plasma concentrations at 2 to 4 h following oral doses of 3, 15, and 30 mg/kg were 0.31 (+/- 0.11), 1.12 (+/- 0.11), and 1.69 (+/- 0.23) micrograms/ml, respectively, and declined with a mean residence time of 3.44-5.28 h.",Intramuscular and oral disposition of enrofloxacin in African grey parrots following single and multiple doses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663561/),h,3.44-5.28,182188,DB00537,Ciprofloxacin
,1663561,relative bioavailability,The relative bioavailability of the 15-mg/kg oral dose was 48%.,Intramuscular and oral disposition of enrofloxacin in African grey parrots following single and multiple doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663561/),%,48,182189,DB00537,Ciprofloxacin
,9061885,peak concentrations,The peak concentrations of enrofloxacin after intramuscular administration (1.67 micrograms/ml at 0.9 h) were higher than after an oral dose (0.99 microgram/ml at 1.38 h).,The plasma kinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Muscovy duck. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061885/),[μg] / [ml],1.67,182779,DB00537,Ciprofloxacin
,9061885,peak concentrations,The peak concentrations of enrofloxacin after intramuscular administration (1.67 micrograms/ml at 0.9 h) were higher than after an oral dose (0.99 microgram/ml at 1.38 h).,The plasma kinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Muscovy duck. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061885/),[μg] / [ml],0.99,182780,DB00537,Ciprofloxacin
,9061885,relative bioavailability,"The relative bioavailability of enrofloxacin after administration directly into the crop was 68%, while the metabolic conversion of enrofloxacin to ciprofloxacin was quite low (< 10%) with both routes of administration.",The plasma kinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Muscovy duck. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061885/),%,68,182781,DB00537,Ciprofloxacin
,2817866,peak,"Oral ciprofloxacin (750 mg twice a day) produced peak and trough concentrations in serum of 2.56 +/- 1.80 and 0.97 +/- 0.81 micrograms/ml and steady-state salivary and nasal secretory concentrations of 1.29 +/- 1.0 and 1.84 +/- 0.91 micrograms/ml, respectively.",Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817866/),[μg] / [ml],2.56,182934,DB00537,Ciprofloxacin
,2817866,trough concentrations,"Oral ciprofloxacin (750 mg twice a day) produced peak and trough concentrations in serum of 2.56 +/- 1.80 and 0.97 +/- 0.81 micrograms/ml and steady-state salivary and nasal secretory concentrations of 1.29 +/- 1.0 and 1.84 +/- 0.91 micrograms/ml, respectively.",Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817866/),[μg] / [ml],0.97,182935,DB00537,Ciprofloxacin
,2817866,steady-state salivary,"Oral ciprofloxacin (750 mg twice a day) produced peak and trough concentrations in serum of 2.56 +/- 1.80 and 0.97 +/- 0.81 micrograms/ml and steady-state salivary and nasal secretory concentrations of 1.29 +/- 1.0 and 1.84 +/- 0.91 micrograms/ml, respectively.",Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817866/),[μg] / [ml],1.29,182936,DB00537,Ciprofloxacin
,2817866,nasal secretory concentrations,"Oral ciprofloxacin (750 mg twice a day) produced peak and trough concentrations in serum of 2.56 +/- 1.80 and 0.97 +/- 0.81 micrograms/ml and steady-state salivary and nasal secretory concentrations of 1.29 +/- 1.0 and 1.84 +/- 0.91 micrograms/ml, respectively.",Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817866/),[μg] / [ml],1.29,182937,DB00537,Ciprofloxacin
,2817866,nasal secretory concentrations,"Oral ciprofloxacin (750 mg twice a day) produced peak and trough concentrations in serum of 2.56 +/- 1.80 and 0.97 +/- 0.81 micrograms/ml and steady-state salivary and nasal secretory concentrations of 1.29 +/- 1.0 and 1.84 +/- 0.91 micrograms/ml, respectively.",Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817866/),[μg] / [ml],1.84,182938,DB00537,Ciprofloxacin
,3209529,terminal half-life,"The mean terminal half-life was 3.33, 3.73 and 3.45 h for 50, 100 and 250 mg doses, respectively.",Pharmacokinetics of intravenous ciprofloxacin at three different doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209529/),h,3.33,183793,DB00537,Ciprofloxacin
,3209529,terminal half-life,"The mean terminal half-life was 3.33, 3.73 and 3.45 h for 50, 100 and 250 mg doses, respectively.",Pharmacokinetics of intravenous ciprofloxacin at three different doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209529/),h,3.73,183794,DB00537,Ciprofloxacin
,3209529,terminal half-life,"The mean terminal half-life was 3.33, 3.73 and 3.45 h for 50, 100 and 250 mg doses, respectively.",Pharmacokinetics of intravenous ciprofloxacin at three different doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209529/),h,3.45,183795,DB00537,Ciprofloxacin
,32565494,Cmax,The Cmax of plasma ERFX was 1.6 ± 0.4 µg/ml at 2.3 ± 0.5 hr post-administration and gradually decreased to 0.14 ± 0.03 µg/ml at 24 hr following administration.,Pharmacokinetics in plasma and alveolar regions of healthy calves subcutaneously administered a single dose of enrofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565494/),[μg] / [ml],1.6,183843,DB00537,Ciprofloxacin
,32565494,Cmax,The Cmax of plasma ERFX was 1.6 ± 0.4 µg/ml at 2.3 ± 0.5 hr post-administration and gradually decreased to 0.14 ± 0.03 µg/ml at 24 hr following administration.,Pharmacokinetics in plasma and alveolar regions of healthy calves subcutaneously administered a single dose of enrofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565494/),[μg] / [ml],0.14,183844,DB00537,Ciprofloxacin
,32565494,mean residence time between 0 and 24 h,The mean residence time between 0 and 24 hr (MRT0-24) in plasma was 6.9 ± 1.0 hr.,Pharmacokinetics in plasma and alveolar regions of healthy calves subcutaneously administered a single dose of enrofloxacin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565494/),h,6.9,183845,DB00537,Ciprofloxacin
,32565494,plasma half-life (t1/2),"The plasma half-life (t1/2) of ERFX was 6.5 ± 0.7 hr, while that in ELF and alveolar cells was 6.5 ± 3.6 and 7.4 ± 4.3 hr, respectively.",Pharmacokinetics in plasma and alveolar regions of healthy calves subcutaneously administered a single dose of enrofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565494/),h,6.5,183846,DB00537,Ciprofloxacin
,32565494,plasma half-life (t1/2),"The plasma half-life (t1/2) of ERFX was 6.5 ± 0.7 hr, while that in ELF and alveolar cells was 6.5 ± 3.6 and 7.4 ± 4.3 hr, respectively.",Pharmacokinetics in plasma and alveolar regions of healthy calves subcutaneously administered a single dose of enrofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565494/),h,6.5,183847,DB00537,Ciprofloxacin
,32565494,plasma half-life (t1/2),"The plasma half-life (t1/2) of ERFX was 6.5 ± 0.7 hr, while that in ELF and alveolar cells was 6.5 ± 3.6 and 7.4 ± 4.3 hr, respectively.",Pharmacokinetics in plasma and alveolar regions of healthy calves subcutaneously administered a single dose of enrofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565494/),h,7.4,183848,DB00537,Ciprofloxacin
,24712165,time of maximal plasma concentration,The kinetic behavior was characterized by a relatively slow absorption (time of maximal plasma concentration = 4.50 +/- 3.45 hr) with peak plasma concentration of 4.81 +/- 1.12 microg/ml.,Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),h,4.50,183895,DB00537,Ciprofloxacin
,24712165,peak plasma concentration,The kinetic behavior was characterized by a relatively slow absorption (time of maximal plasma concentration = 4.50 +/- 3.45 hr) with peak plasma concentration of 4.81 +/- 1.12 microg/ml.,Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),[μg] / [ml],4.81,183896,DB00537,Ciprofloxacin
,24712165,half-life during the terminal elimination phase (t1/2 lambda,"The long half-life during the terminal elimination phase (t1/2 lambda = 27.91 +/- 7.55 hr) of enrofloxacin after intramuscular administration, calculated in the present study, could suggest that the antibiotic is eliminated relatively slowly and/or the presence of a slow absorption in urutu pit vipers.",Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),h,27.91,183897,DB00537,Ciprofloxacin
,24712165,peak plasma concentration,"Ciprofloxacin reached a peak plasma concentration of 0.35 microg/ml at 13.45 hr, and the fraction of enrofloxacin metabolized to ciprofloxacin was 13.06%.",Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),[μg] / [ml],0.35,183898,DB00537,Ciprofloxacin
,24712165,minimum inhibitory concentration (MIC90),"If enrofloxacin's minimum inhibitory concentration (MIC90) values of 0.5 microg/ml were used, the ratios AUC(e+c): MIC90 (276 +/- 67 hr) and Cmax(e+c): MIC90 (10 +/- 2) reach the proposed threshold values (125 hr and 10, respectively) for optimized efficacy and minimized resistance development when treating infections caused by Pseudomonas.",Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),[μg] / [ml],0.5,183899,DB00537,Ciprofloxacin
,24712165,ratios AUC(e+c): MIC90,"If enrofloxacin's minimum inhibitory concentration (MIC90) values of 0.5 microg/ml were used, the ratios AUC(e+c): MIC90 (276 +/- 67 hr) and Cmax(e+c): MIC90 (10 +/- 2) reach the proposed threshold values (125 hr and 10, respectively) for optimized efficacy and minimized resistance development when treating infections caused by Pseudomonas.",Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),h,276,183900,DB00537,Ciprofloxacin
,24712165,Cmax(e+c): MIC90,"If enrofloxacin's minimum inhibitory concentration (MIC90) values of 0.5 microg/ml were used, the ratios AUC(e+c): MIC90 (276 +/- 67 hr) and Cmax(e+c): MIC90 (10 +/- 2) reach the proposed threshold values (125 hr and 10, respectively) for optimized efficacy and minimized resistance development when treating infections caused by Pseudomonas.",Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),h,10,183901,DB00537,Ciprofloxacin
,24712165,Cmax(e+c): MIC90,"If enrofloxacin's minimum inhibitory concentration (MIC90) values of 0.5 microg/ml were used, the ratios AUC(e+c): MIC90 (276 +/- 67 hr) and Cmax(e+c): MIC90 (10 +/- 2) reach the proposed threshold values (125 hr and 10, respectively) for optimized efficacy and minimized resistance development when treating infections caused by Pseudomonas.",Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),h,125,183902,DB00537,Ciprofloxacin
,24712165,Cmax(e+c): MIC90,"If enrofloxacin's minimum inhibitory concentration (MIC90) values of 0.5 microg/ml were used, the ratios AUC(e+c): MIC90 (276 +/- 67 hr) and Cmax(e+c): MIC90 (10 +/- 2) reach the proposed threshold values (125 hr and 10, respectively) for optimized efficacy and minimized resistance development when treating infections caused by Pseudomonas.",Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),,10,183903,DB00537,Ciprofloxacin
<,24712165,MIC,The administration of 10 mg/kg of enrofloxacin by the i.m. route should be considered to be a judicious choice in urutu pit vipers against infections caused by microorganisms with MIC values < or = 0.5 microg/ml.,Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712165/),[μg] / [ml],0.5,183904,DB00537,Ciprofloxacin
,9458187,Peak plasma concentrations,Peak plasma concentrations of ofloxacin in adult rats were 20.5 +/- 5.6 mg/l (mean +/- SD) following treatment with a single dose of 600 mg/kg body wt.,"Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9458187/),[mg] / [l],20.5,183940,DB00537,Ciprofloxacin
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],1.0,184129,DB00537,Ciprofloxacin
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184130,DB00537,Ciprofloxacin
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],10.1,184131,DB00537,Ciprofloxacin
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184132,DB00537,Ciprofloxacin
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],17.3,184133,DB00537,Ciprofloxacin
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184134,DB00537,Ciprofloxacin
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.2,184135,DB00537,Ciprofloxacin
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184136,DB00537,Ciprofloxacin
,2292168,absolute bioavailability,The absolute bioavailability of ciprofloxacin is approximately 70%.,Clinical pharmacokinetics of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292168/),%,70,184213,DB00537,Ciprofloxacin
,2292168,terminal disposition half-life (t1/2),The terminal disposition half-life (t1/2) is about 3 to 4 hours.,Clinical pharmacokinetics of ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292168/),h,3 to 4,184214,DB00537,Ciprofloxacin
,27423043,limit of detection,"The limit of detection and the limit of quantification for human plasma were 0.01μg/mL and 0.03μg/mL, respectively.",Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),[μg] / [ml],0.01,184526,DB00537,Ciprofloxacin
,27423043,limit of quantification,"The limit of detection and the limit of quantification for human plasma were 0.01μg/mL and 0.03μg/mL, respectively.",Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),[μg] / [ml],0.03,184527,DB00537,Ciprofloxacin
,27423043,limit,"For the prostate tissue, the limit of detection and the limit of quantification were 0.1μg/g and 0.3μg/g, respectively.",Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),[μg] / [g],0.1,184528,DB00537,Ciprofloxacin
,27423043,recoveries,The average recoveries of levofloxacin were in the range from 99 to 106%.,Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),%,99 to 106,184529,DB00537,Ciprofloxacin
,27423043,concentration,The mean (±SD) LVF concentration in prostate was 6.22±3.52μg/g and in plasma 2.54±1.14μg/mL.,Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),[μg] / [g],6.22,184530,DB00537,Ciprofloxacin
,27423043,concentration,The mean (±SD) LVF concentration in prostate was 6.22±3.52μg/g and in plasma 2.54±1.14μg/mL.,Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),μ,2.54,184531,DB00537,Ciprofloxacin
,15985052,maximum concentrations,"Mean maximum concentrations of ciprofloxacin in plasma, cutaneous microdialysates and theoretical peripheral compartment were 7.01+/-1.69, 2.95+/-0.64 and 3.37+/-0.60 micromol/L, respectively, and were achieved after about 2.0+/-0.6, 2.4+/-0.9 and 4.8+/-0.9 h.",Penetration of ciprofloxacin and its desethylenemetabolite into skin in humans after a single oral dose of the parent drug assessed by cutaneous microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985052/),[μM] / [l],7.01,184700,DB00537,Ciprofloxacin
,15985052,maximum concentrations,"Mean maximum concentrations of ciprofloxacin in plasma, cutaneous microdialysates and theoretical peripheral compartment were 7.01+/-1.69, 2.95+/-0.64 and 3.37+/-0.60 micromol/L, respectively, and were achieved after about 2.0+/-0.6, 2.4+/-0.9 and 4.8+/-0.9 h.",Penetration of ciprofloxacin and its desethylenemetabolite into skin in humans after a single oral dose of the parent drug assessed by cutaneous microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985052/),[μM] / [l],2.95,184701,DB00537,Ciprofloxacin
,15985052,maximum concentrations,"Mean maximum concentrations of ciprofloxacin in plasma, cutaneous microdialysates and theoretical peripheral compartment were 7.01+/-1.69, 2.95+/-0.64 and 3.37+/-0.60 micromol/L, respectively, and were achieved after about 2.0+/-0.6, 2.4+/-0.9 and 4.8+/-0.9 h.",Penetration of ciprofloxacin and its desethylenemetabolite into skin in humans after a single oral dose of the parent drug assessed by cutaneous microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985052/),[μM] / [l],3.37,184702,DB00537,Ciprofloxacin
,15985052,penetration,"The extent of penetration into cutaneous microdialysates and theoretical peripheral compartment relative to plasma were 0.550+/-0.150 and 0.788+/-0.131, respectively, and differed significantly.",Penetration of ciprofloxacin and its desethylenemetabolite into skin in humans after a single oral dose of the parent drug assessed by cutaneous microdialysis. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985052/),,0.550,184703,DB00537,Ciprofloxacin
,15985052,penetration,"The extent of penetration into cutaneous microdialysates and theoretical peripheral compartment relative to plasma were 0.550+/-0.150 and 0.788+/-0.131, respectively, and differed significantly.",Penetration of ciprofloxacin and its desethylenemetabolite into skin in humans after a single oral dose of the parent drug assessed by cutaneous microdialysis. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985052/),,0.788,184704,DB00537,Ciprofloxacin
,24344508,volume of distribution,"This compound presented a relatively high volume of distribution (2.09 L/kg), a total body clearance of 0.24 L/kg x h, and a long permanence as shown by an elimination half-life of 7.81 hours after IV administration and a terminal half-life of 6.58 hours after IM administration.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),[l] / [kg],2.09,184798,DB00537,Ciprofloxacin
,24344508,total body clearance,"This compound presented a relatively high volume of distribution (2.09 L/kg), a total body clearance of 0.24 L/kg x h, and a long permanence as shown by an elimination half-life of 7.81 hours after IV administration and a terminal half-life of 6.58 hours after IM administration.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),[l] / [h·kg],0.24,184799,DB00537,Ciprofloxacin
,24344508,elimination half-life,"This compound presented a relatively high volume of distribution (2.09 L/kg), a total body clearance of 0.24 L/kg x h, and a long permanence as shown by an elimination half-life of 7.81 hours after IV administration and a terminal half-life of 6.58 hours after IM administration.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),h,7.81,184800,DB00537,Ciprofloxacin
,24344508,terminal half-life,"This compound presented a relatively high volume of distribution (2.09 L/kg), a total body clearance of 0.24 L/kg x h, and a long permanence as shown by an elimination half-life of 7.81 hours after IV administration and a terminal half-life of 6.58 hours after IM administration.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),h,6.58,184801,DB00537,Ciprofloxacin
,24344508,areas under the concentration-time curves (AUC),"The areas under the concentration-time curves (AUC) were 21.92 and 34.38 microg x h/mL for IM and IV administration, respectively.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),[h·μg] / [ml],21.92,184802,DB00537,Ciprofloxacin
,24344508,areas under the concentration-time curves (AUC),"The areas under the concentration-time curves (AUC) were 21.92 and 34.38 microg x h/mL for IM and IV administration, respectively.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),[h·μg] / [ml],34.38,184803,DB00537,Ciprofloxacin
,24344508,time to reach maximum concentration,Enrofloxacin was rapidly absorbed after IM administration with a time to reach maximum concentration of 0.72 hours and bioavailability of 78.76%.,Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),h,0.72,184804,DB00537,Ciprofloxacin
,24344508,bioavailability,Enrofloxacin was rapidly absorbed after IM administration with a time to reach maximum concentration of 0.72 hours and bioavailability of 78.76%.,Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),%,78.76,184805,DB00537,Ciprofloxacin
,24344508,peak drug concentration (C(max)),"After IM administration, the peak drug concentration (C(max)) was 3.92 microg/mL.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),[μg] / [ml],3.92,184806,DB00537,Ciprofloxacin
,24344508,C(max)/MIC,"Values of minimum inhibitory concentration (MIC), C(max), and AUC have been used to predict the clinical efficacy of a drug in treating bacterial infections, with a C(max)/MIC value of 10 and an AUC/MIC ratio of 125-250 associated with optimal bactericidal effects.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),,10,184807,DB00537,Ciprofloxacin
,24344508,AUC/MIC ratio,"Values of minimum inhibitory concentration (MIC), C(max), and AUC have been used to predict the clinical efficacy of a drug in treating bacterial infections, with a C(max)/MIC value of 10 and an AUC/MIC ratio of 125-250 associated with optimal bactericidal effects.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),,125-250,184808,DB00537,Ciprofloxacin
,24344508,MIC,"By using the study data and a MIC breakpoint of 0.25 microg/mL, values of C(max)/MIC were 13.74 and 15.94 and for AUC/MIC were 90.73 and 139.63, for the IV and IM routes respectively.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),[μg] / [ml],0.25,184809,DB00537,Ciprofloxacin
,24344508,C(max)/MIC,"By using the study data and a MIC breakpoint of 0.25 microg/mL, values of C(max)/MIC were 13.74 and 15.94 and for AUC/MIC were 90.73 and 139.63, for the IV and IM routes respectively.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),,13.74,184810,DB00537,Ciprofloxacin
,24344508,C(max)/MIC,"By using the study data and a MIC breakpoint of 0.25 microg/mL, values of C(max)/MIC were 13.74 and 15.94 and for AUC/MIC were 90.73 and 139.63, for the IV and IM routes respectively.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),,15.94,184811,DB00537,Ciprofloxacin
,24344508,AUC/MIC,"By using the study data and a MIC breakpoint of 0.25 microg/mL, values of C(max)/MIC were 13.74 and 15.94 and for AUC/MIC were 90.73 and 139.63, for the IV and IM routes respectively.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),,90.73,184812,DB00537,Ciprofloxacin
,24344508,AUC/MIC,"By using the study data and a MIC breakpoint of 0.25 microg/mL, values of C(max)/MIC were 13.74 and 15.94 and for AUC/MIC were 90.73 and 139.63, for the IV and IM routes respectively.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),,139.63,184813,DB00537,Ciprofloxacin
<,24344508,MIC,"For the treatment of infectious diseases caused by microorganisms with MIC < or = 0.25 microg/mL, the calculated optimal dosages were 7.5 and 9.5 mg/kg q24h by the IV and IM routes, respectively.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),[μg] / [ml],0.25,184814,DB00537,Ciprofloxacin
<,24344508,MIC,"To treat caracara by the IV route against microorganisms with MIC < or = 0.25 microg/mL, the dose should be higher than the 5 mg/kg used in our study, but possible side effects derived from an increase in the IV dose and efficacy in sick birds should be assessed.",Pharmacokinetic and pharmacodynamic properties of enrofloxacin in southern crested caracaras (Caracara plancus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344508/),[μg] / [ml],0.25,184815,DB00537,Ciprofloxacin
,29277683,"AUCELF to AUCu,plasma ratios","CIP concentrations in ELF were much higher after CIP-Cu microparticles IT administration compared to the other two formulations, with mean AUCELF to AUCu,plasma ratios equal to 1069, 203 and 9.8 after CIP-Cu microparticles, CIP-Ca microparticles and CIP solution pulmonary administration, respectively.",New aerosol formulation to control ciprofloxacin pulmonary concentration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277683/),,1069,184887,DB00537,Ciprofloxacin
,29277683,"AUCELF to AUCu,plasma ratios","CIP concentrations in ELF were much higher after CIP-Cu microparticles IT administration compared to the other two formulations, with mean AUCELF to AUCu,plasma ratios equal to 1069, 203 and 9.8 after CIP-Cu microparticles, CIP-Ca microparticles and CIP solution pulmonary administration, respectively.",New aerosol formulation to control ciprofloxacin pulmonary concentration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277683/),,203,184888,DB00537,Ciprofloxacin
,29277683,"AUCELF to AUCu,plasma ratios","CIP concentrations in ELF were much higher after CIP-Cu microparticles IT administration compared to the other two formulations, with mean AUCELF to AUCu,plasma ratios equal to 1069, 203 and 9.8 after CIP-Cu microparticles, CIP-Ca microparticles and CIP solution pulmonary administration, respectively.",New aerosol formulation to control ciprofloxacin pulmonary concentration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277683/),,9.8,184889,DB00537,Ciprofloxacin
,16377676,50% effective doses (ED50s),"In murine lung infections caused by PSSP, the 50% effective doses (ED50s) of DX-619, sitafloxacin, and ciprofloxacin were 9.15, 11.1, and 127.6 mg/kg of body weight, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[mg] / [kg],9.15,185191,DB00537,Ciprofloxacin
,16377676,50% effective doses (ED50s),"In murine lung infections caused by PSSP, the 50% effective doses (ED50s) of DX-619, sitafloxacin, and ciprofloxacin were 9.15, 11.1, and 127.6 mg/kg of body weight, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[mg] / [kg],11.1,185192,DB00537,Ciprofloxacin
,16377676,50% effective doses (ED50s),"In murine lung infections caused by PSSP, the 50% effective doses (ED50s) of DX-619, sitafloxacin, and ciprofloxacin were 9.15, 11.1, and 127.6 mg/kg of body weight, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[mg] / [kg],127.6,185193,DB00537,Ciprofloxacin
,16377676,ED50s,"Against PRSP-mediated pneumonia in mice, the ED50s of DX-619, sitafloxacin, and ciprofloxacin were 0.69, 4.84, and 38.75 mg/kg, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[mg] / [kg],0.69,185194,DB00537,Ciprofloxacin
,16377676,ED50s,"Against PRSP-mediated pneumonia in mice, the ED50s of DX-619, sitafloxacin, and ciprofloxacin were 0.69, 4.84, and 38.75 mg/kg, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[mg] / [kg],4.84,185195,DB00537,Ciprofloxacin
,16377676,ED50s,"Against PRSP-mediated pneumonia in mice, the ED50s of DX-619, sitafloxacin, and ciprofloxacin were 0.69, 4.84, and 38.75 mg/kg, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[mg] / [kg],38.75,185196,DB00537,Ciprofloxacin
,16377676,viable bacterial counts,"The mean +/- standard error of the mean viable bacterial counts in murine lungs infected with PSSP and treated with DX-619, sitafloxacin, ciprofloxacin (10 mg/kg twice daily), and saline (twice daily) were 1.75 +/- 0.06, 1.92 +/- 0.23, 6.48 +/- 0.28, and 7.57 +/- 0.13 log10 CFU/ml, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[cfu·log10] / [ml],1.75,185197,DB00537,Ciprofloxacin
,16377676,viable bacterial counts,"The mean +/- standard error of the mean viable bacterial counts in murine lungs infected with PSSP and treated with DX-619, sitafloxacin, ciprofloxacin (10 mg/kg twice daily), and saline (twice daily) were 1.75 +/- 0.06, 1.92 +/- 0.23, 6.48 +/- 0.28, and 7.57 +/- 0.13 log10 CFU/ml, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[cfu·log10] / [ml],1.92,185198,DB00537,Ciprofloxacin
,16377676,viable bacterial counts,"The mean +/- standard error of the mean viable bacterial counts in murine lungs infected with PSSP and treated with DX-619, sitafloxacin, ciprofloxacin (10 mg/kg twice daily), and saline (twice daily) were 1.75 +/- 0.06, 1.92 +/- 0.23, 6.48 +/- 0.28, and 7.57 +/- 0.13 log10 CFU/ml, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[cfu·log10] / [ml],6.48,185199,DB00537,Ciprofloxacin
,16377676,viable bacterial counts,"The mean +/- standard error of the mean viable bacterial counts in murine lungs infected with PSSP and treated with DX-619, sitafloxacin, ciprofloxacin (10 mg/kg twice daily), and saline (twice daily) were 1.75 +/- 0.06, 1.92 +/- 0.23, 6.48 +/- 0.28, and 7.57 +/- 0.13 log10 CFU/ml, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[cfu·log10] / [ml],7.57,185200,DB00537,Ciprofloxacin
,16377676,numbers,"Furthermore, the numbers of viable bacteria in lungs infected with PRSP and treated with the three agents and not treated (control) were 1.73 +/- 0.04, 2.28 +/- 0.17, 4.61 +/- 0.59, and 5.54 +/- 0.72 log10 CFU/ml, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[cfu·log10] / [ml],1.73,185201,DB00537,Ciprofloxacin
,16377676,numbers,"Furthermore, the numbers of viable bacteria in lungs infected with PRSP and treated with the three agents and not treated (control) were 1.73 +/- 0.04, 2.28 +/- 0.17, 4.61 +/- 0.59, and 5.54 +/- 0.72 log10 CFU/ml, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[cfu·log10] / [ml],2.28,185202,DB00537,Ciprofloxacin
,16377676,numbers,"Furthermore, the numbers of viable bacteria in lungs infected with PRSP and treated with the three agents and not treated (control) were 1.73 +/- 0.04, 2.28 +/- 0.17, 4.61 +/- 0.59, and 5.54 +/- 0.72 log10 CFU/ml, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[cfu·log10] / [ml],4.61,185203,DB00537,Ciprofloxacin
,16377676,numbers,"Furthermore, the numbers of viable bacteria in lungs infected with PRSP and treated with the three agents and not treated (control) were 1.73 +/- 0.04, 2.28 +/- 0.17, 4.61 +/- 0.59, and 5.54 +/- 0.72 log10 CFU/ml, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),[cfu·log10] / [ml],5.54,185204,DB00537,Ciprofloxacin
,16377676,area under the concentration-time curve (AUC)/MIC ratio,"The pharmacokinetic parameter of the area under the concentration-time curve (AUC)/MIC ratio in the lungs for DX-619, sitafloxacin, and ciprofloxacin were 171.0, 21.92, and 1.22, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),,171.0,185205,DB00537,Ciprofloxacin
,16377676,area under the concentration-time curve (AUC)/MIC ratio,"The pharmacokinetic parameter of the area under the concentration-time curve (AUC)/MIC ratio in the lungs for DX-619, sitafloxacin, and ciprofloxacin were 171.0, 21.92, and 1.22, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),,21.92,185206,DB00537,Ciprofloxacin
,16377676,area under the concentration-time curve (AUC)/MIC ratio,"The pharmacokinetic parameter of the area under the concentration-time curve (AUC)/MIC ratio in the lungs for DX-619, sitafloxacin, and ciprofloxacin were 171.0, 21.92, and 1.22, respectively.","In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377676/),,1.22,185207,DB00537,Ciprofloxacin
>,10654631,area under the 24-hour inhibitory concentration curve (AUIC24),"However, in patients who received ciprofloxacin therapy, when exposure was at an area under the 24-hour inhibitory concentration curve (AUIC24)>110 (microg x h/mL)/microg/mL, resistance was decreased to 11%, a rate similar to that seen in respiratory isolates not exposed to ciprofloxacin (7%).","Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10654631/),[h·μg] / [ml·ml)·μg],110,185325,DB00537,Ciprofloxacin
,2185691,oral clearance,"The mean ciprofloxacin oral clearance values were 0.35 +/- 0.06, 0.41 +/- 0.15, and 0.38 +/- 0.11 liter/h per kg for doses 1, 13, and 28, respectively, in group A patients.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.35,185862,DB00537,Ciprofloxacin
,2185691,oral clearance,"The mean ciprofloxacin oral clearance values were 0.35 +/- 0.06, 0.41 +/- 0.15, and 0.38 +/- 0.11 liter/h per kg for doses 1, 13, and 28, respectively, in group A patients.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.41,185863,DB00537,Ciprofloxacin
,2185691,oral clearance,"The mean ciprofloxacin oral clearance values were 0.35 +/- 0.06, 0.41 +/- 0.15, and 0.38 +/- 0.11 liter/h per kg for doses 1, 13, and 28, respectively, in group A patients.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.38,185864,DB00537,Ciprofloxacin
,2185691,oral clearance,"The mean oral clearance values in group B patients for the respective doses were 0.53 +/- 0.36, 0.32 +/- 0.13, and 0.36 +/- 0.17 liter/h per kg.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.53,185865,DB00537,Ciprofloxacin
,2185691,oral clearance,"The mean oral clearance values in group B patients for the respective doses were 0.53 +/- 0.36, 0.32 +/- 0.13, and 0.36 +/- 0.17 liter/h per kg.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.32,185866,DB00537,Ciprofloxacin
,2185691,oral clearance,"The mean oral clearance values in group B patients for the respective doses were 0.53 +/- 0.36, 0.32 +/- 0.13, and 0.36 +/- 0.17 liter/h per kg.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.36,185867,DB00537,Ciprofloxacin
≥,31790556,AUC24/MIC,An AUC24/MIC of ≥125 was defined as target ratio.,Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),,125,186070,DB00537,Ciprofloxacin
,31790556,AUC24,Ciprofloxacin AUC24 was 16.9 mg*h/L in the prednisone prophase versus 29.3 mg*h/L with concomitant chemotherapy.,Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[h·mg] / [l],16.9,186071,DB00537,Ciprofloxacin
,31790556,AUC24,Ciprofloxacin AUC24 was 16.9 mg*h/L in the prednisone prophase versus 29.3 mg*h/L with concomitant chemotherapy.,Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[h·mg] / [l],29.3,186072,DB00537,Ciprofloxacin
,31790556,MIC,"Overall, 100%, 81%, and 18% of patients at, respectively, MIC of 0.063, 0.125, and 0.25 mg/L achieved AUC24/MIC ≥ 125.",Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[mg] / [l],0.063,186073,DB00537,Ciprofloxacin
,31790556,MIC,"Overall, 100%, 81%, and 18% of patients at, respectively, MIC of 0.063, 0.125, and 0.25 mg/L achieved AUC24/MIC ≥ 125.",Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[mg] / [l],0.125,186074,DB00537,Ciprofloxacin
,31790556,MIC,"Overall, 100%, 81%, and 18% of patients at, respectively, MIC of 0.063, 0.125, and 0.25 mg/L achieved AUC24/MIC ≥ 125.",Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[mg] / [l],0.25,186075,DB00537,Ciprofloxacin
≥,31790556,AUC24/MIC,"Overall, 100%, 81%, and 18% of patients at, respectively, MIC of 0.063, 0.125, and 0.25 mg/L achieved AUC24/MIC ≥ 125.",Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),,125,186076,DB00537,Ciprofloxacin
,3144537,urinary recovery,"The urinary recovery of fleroxacin was 49.5% over 72 h; the N-demethyl and N-oxide metabolites accounted for 6.9% and 5.7%, respectively, of the administered dose.",The metabolism and pharmacokinetics of fleroxacin in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144537/),%,49.5,186324,DB00537,Ciprofloxacin
,3144537,urinary recovery,"The urinary recovery of fleroxacin was 49.5% over 72 h; the N-demethyl and N-oxide metabolites accounted for 6.9% and 5.7%, respectively, of the administered dose.",The metabolism and pharmacokinetics of fleroxacin in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144537/),%,6.9,186325,DB00537,Ciprofloxacin
,3144537,urinary recovery,"The urinary recovery of fleroxacin was 49.5% over 72 h; the N-demethyl and N-oxide metabolites accounted for 6.9% and 5.7%, respectively, of the administered dose.",The metabolism and pharmacokinetics of fleroxacin in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144537/),%,5.7,186326,DB00537,Ciprofloxacin
,26957490,clearance,"The mean (SD) parameter estimates were: clearance, 10.7 (5.3) L/h; volume of distribution of the central compartment, 21.3 (11.3) L; rate constant for drug distribution from the central compartment to the peripheral compartment, 10.9 (4.3) L/h; and rate constant for drug distribution from the peripheral compartment to the central compartment, 2.3 (1.8) L/h.",Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26957490/),[l] / [h],10.7,186576,DB00537,Ciprofloxacin
,26957490,volume of distribution of the central compartment,"The mean (SD) parameter estimates were: clearance, 10.7 (5.3) L/h; volume of distribution of the central compartment, 21.3 (11.3) L; rate constant for drug distribution from the central compartment to the peripheral compartment, 10.9 (4.3) L/h; and rate constant for drug distribution from the peripheral compartment to the central compartment, 2.3 (1.8) L/h.",Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26957490/),l,21.3,186577,DB00537,Ciprofloxacin
,26957490,rate constant for drug distribution,"The mean (SD) parameter estimates were: clearance, 10.7 (5.3) L/h; volume of distribution of the central compartment, 21.3 (11.3) L; rate constant for drug distribution from the central compartment to the peripheral compartment, 10.9 (4.3) L/h; and rate constant for drug distribution from the peripheral compartment to the central compartment, 2.3 (1.8) L/h.",Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26957490/),[l] / [h],10.9,186578,DB00537,Ciprofloxacin
,26957490,rate constant for drug distribution from the peripheral,"The mean (SD) parameter estimates were: clearance, 10.7 (5.3) L/h; volume of distribution of the central compartment, 21.3 (11.3) L; rate constant for drug distribution from the central compartment to the peripheral compartment, 10.9 (4.3) L/h; and rate constant for drug distribution from the peripheral compartment to the central compartment, 2.3 (1.8) L/h.",Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26957490/),[l] / [h],2.3,186579,DB00537,Ciprofloxacin
,26957490,clearance,"After accounting for patient weight, the mean ciprofloxacin clearance was not statistically different between CVVHF and CVVHDF [11.8 (9.9) and 10.3 (7.4) L/h, respectively, P = 0.43].",Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26957490/),[l] / [h],11.8,186580,DB00537,Ciprofloxacin
,26957490,clearance,"After accounting for patient weight, the mean ciprofloxacin clearance was not statistically different between CVVHF and CVVHDF [11.8 (9.9) and 10.3 (7.4) L/h, respectively, P = 0.43].",Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26957490/),[l] / [h],10.3,186581,DB00537,Ciprofloxacin
up to,15992094,half-life,"In addition, grepafloxacin achieves high lung concentrations, and its long half-life (up to 15 h) enables once daily dosing.","Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992094/),h,15,186659,DB00537,Ciprofloxacin
,27115201,maximum total drug concentration (Cmax),"In the anterior chamber, the maximum total drug concentration (Cmax) amounted to 0.373 ± 0.281 μg/mL and was reached (Tmax) after 116 ± 36 min.",An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27115201/),[μg] / [ml],0.373,186854,DB00537,Ciprofloxacin
,27115201,Tmax,"In the anterior chamber, the maximum total drug concentration (Cmax) amounted to 0.373 ± 0.281 μg/mL and was reached (Tmax) after 116 ± 36 min.",An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27115201/),min,116,186855,DB00537,Ciprofloxacin
,27115201,area under the concentration-time curve AUC(0-n),Calculated area under the concentration-time curve AUC(0-n) for ciprofloxacin in the anterior chamber was 78.8 ± 47.1 μg min/mL.,An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27115201/),[min·μg] / [ml],78.8,186856,DB00537,Ciprofloxacin
,27115201,Cmax,"For the vitreous, Cmax was 0.02 ± 0.03 μg/mL and maximum drug concentration was reached 107 ± 60 min after topical administration.",An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27115201/),[μg] / [ml],0.02,186857,DB00537,Ciprofloxacin
,27115201,AUC(0-n),AUC(0-n) for ciprofloxacin in the vitreous was 0.269 ± 0.370 μg min/mL.,An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27115201/),[min·μg] / [ml],0.269,186858,DB00537,Ciprofloxacin
,1606348,total body clearance,"The mean total body clearance, steady-state volume of distribution, or elimination half-life ranged from 36 to 41 L/h, 146 to 169 L, and 3.5 to 3.7 h for the 200-, 300-, and 400-mg doses, respectively.","Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606348/),[l] / [h],36 to 41,186968,DB00537,Ciprofloxacin
,1606348,steady-state volume of distribution,"The mean total body clearance, steady-state volume of distribution, or elimination half-life ranged from 36 to 41 L/h, 146 to 169 L, and 3.5 to 3.7 h for the 200-, 300-, and 400-mg doses, respectively.","Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606348/),l,146 to 169,186969,DB00537,Ciprofloxacin
,1606348,elimination half-life,"The mean total body clearance, steady-state volume of distribution, or elimination half-life ranged from 36 to 41 L/h, 146 to 169 L, and 3.5 to 3.7 h for the 200-, 300-, and 400-mg doses, respectively.","Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606348/),h,3.5 to 3.7,186970,DB00537,Ciprofloxacin
,15037323,maximum plasma concentration,The mean maximum plasma concentration of gatifloxacin was 3.35 mg/l and that of ciprofloxacin 2.12 mg/l.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),[mg] / [l],3.35,187098,DB00537,Ciprofloxacin
,15037323,maximum plasma concentration,The mean maximum plasma concentration of gatifloxacin was 3.35 mg/l and that of ciprofloxacin 2.12 mg/l.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),[mg] / [l],2.12,187099,DB00537,Ciprofloxacin
,15037323,cumulative renal excretion,The mean (median) cumulative renal excretion of the parent drug was for gatifloxacin 81 (83)% of the administered dose within 120 h and for ciprofloxacin 43 (45)%.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),%,81,187100,DB00537,Ciprofloxacin
,15037323,cumulative renal excretion,The mean (median) cumulative renal excretion of the parent drug was for gatifloxacin 81 (83)% of the administered dose within 120 h and for ciprofloxacin 43 (45)%.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),%,43,187101,DB00537,Ciprofloxacin
,15037323,UBTs,The median UBTs measured within the first 6h for gatifloxacin were between 1:16 and 1:>or=1024 for the Gram-negative strains including P. aeruginosa and between 1:8 and 1:>or=1024 for the five Gram-positive strains.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),,1,187102,DB00537,Ciprofloxacin
,15037323,UBTs,The median UBTs measured within the first 6h for gatifloxacin were between 1:16 and 1:>or=1024 for the Gram-negative strains including P. aeruginosa and between 1:8 and 1:>or=1024 for the five Gram-positive strains.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),,1024,187103,DB00537,Ciprofloxacin
>,15037323,UBTs,The median UBTs measured within the first 6h for gatifloxacin were between 1:16 and 1:>or=1024 for the Gram-negative strains including P. aeruginosa and between 1:8 and 1:>or=1024 for the five Gram-positive strains.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),,1,187104,DB00537,Ciprofloxacin
>,15037323,UBTs,The median UBTs measured within the first 6h for gatifloxacin were between 1:16 and 1:>or=1024 for the Gram-negative strains including P. aeruginosa and between 1:8 and 1:>or=1024 for the five Gram-positive strains.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),,1024,187105,DB00537,Ciprofloxacin
,15037323,UBTs,The median UBTs for ciprofloxacin were between 1:64 and 1:>or=1024 for the Gram-negative strains (incl P. aeruginosa) and between 1:1.5 and 1:768 for the five Gram-positive strains.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),,1,187106,DB00537,Ciprofloxacin
,15037323,UBTs,The median UBTs for ciprofloxacin were between 1:64 and 1:>or=1024 for the Gram-negative strains (incl P. aeruginosa) and between 1:1.5 and 1:768 for the five Gram-positive strains.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),,1024,187107,DB00537,Ciprofloxacin
,15037323,UBTs,The median UBTs for ciprofloxacin were between 1:64 and 1:>or=1024 for the Gram-negative strains (incl P. aeruginosa) and between 1:1.5 and 1:768 for the five Gram-positive strains.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),,1,187108,DB00537,Ciprofloxacin
,15037323,UBTs,The median UBTs for ciprofloxacin were between 1:64 and 1:>or=1024 for the Gram-negative strains (incl P. aeruginosa) and between 1:1.5 and 1:768 for the five Gram-positive strains.,"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037323/),,1.5,187109,DB00537,Ciprofloxacin
,20462172,elimination half-life,"The elimination half-life, the volume of distribution, and the area under the concentration vs time curve (AUC) were 4.31 h, 1.10 l/kg and 9.24 microg x h/ml, respectively.",Pharmacokinetics of enrofloxacin after single intravenous administration in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462172/),h,4.31,187188,DB00537,Ciprofloxacin
,20462172,volume of distribution,"The elimination half-life, the volume of distribution, and the area under the concentration vs time curve (AUC) were 4.31 h, 1.10 l/kg and 9.24 microg x h/ml, respectively.",Pharmacokinetics of enrofloxacin after single intravenous administration in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462172/),[l] / [kg],1.10,187189,DB00537,Ciprofloxacin
,20462172,area under the concentration vs time curve (AUC),"The elimination half-life, the volume of distribution, and the area under the concentration vs time curve (AUC) were 4.31 h, 1.10 l/kg and 9.24 microg x h/ml, respectively.",Pharmacokinetics of enrofloxacin after single intravenous administration in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462172/),[h·μg] / [ml],9.24,187190,DB00537,Ciprofloxacin
,20462172,ratio between the AUCs,Enrofloxacin was metabolised to ciprofloxacin and the ratio between the AUCs of ciprofloxacin and enrofloxacin was 0.26 after intravenous administration.,Pharmacokinetics of enrofloxacin after single intravenous administration in sheep. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462172/),,0.26,187191,DB00537,Ciprofloxacin
,9797213,AUC/MICs,"The AMEs of TR and CI against gram-negative bacteria with similar susceptibilities to both drugs were related to AUC/MICs that varied over similar eight-fold ranges [from 54 to 432 and from 59 to 473 (microg . h/ml)/(microg/ml), respectively].",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[h·ml·μg] / [ml·μg],54 to 432,187562,DB00537,Ciprofloxacin
,9797213,AUC/MICs,"The AMEs of TR and CI against gram-negative bacteria with similar susceptibilities to both drugs were related to AUC/MICs that varied over similar eight-fold ranges [from 54 to 432 and from 59 to 473 (microg . h/ml)/(microg/ml), respectively].",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[h·ml·μg] / [ml·μg],59 to 473,187563,DB00537,Ciprofloxacin
,9797213,half-lives,"In each experiment monoexponential pharmacokinetic profiles of TR and CI were simulated with half-lives of 9.2 and 4.0 h, respectively.",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),h,9.2,187564,DB00537,Ciprofloxacin
,9797213,half-lives,"In each experiment monoexponential pharmacokinetic profiles of TR and CI were simulated with half-lives of 9.2 and 4.0 h, respectively.",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),h,4.0,187565,DB00537,Ciprofloxacin
,9797213,MIC,"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[μg] / [ml],0.25,187566,DB00537,Ciprofloxacin
,9797213,MIC of CI [MICCI],"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[μg] / [ml],0.12,187567,DB00537,Ciprofloxacin
,9797213,MICTR,"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[μg] / [ml],0.3,187568,DB00537,Ciprofloxacin
,9797213,MICCI,"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),,0,187569,DB00537,Ciprofloxacin
,9797213,MICTR,"Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml).",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),μ,0.25,187570,DB00537,Ciprofloxacin
,9797213,AUC/MIC breakpoint,"The predicted value of the AUC/MIC breakpoint for TR [mean for all three bacteria, 63 (microg . h/ml)/(microg/ml)] was approximately twofold lower than that for CI.",A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797213/),[h·ml·μg] / [ml·μg],63,187571,DB00537,Ciprofloxacin
,2136565,peak plasma concentration,"2. The peak plasma concentration of ciprofloxacin (Cmax = 1.26 +/- 0.21 mg/l), the time to reach Cmax (Tmax = 1.99 +/- 0.26 h), the area under the time-plasma concentration curve (AUC = 5.52 +/- 0.84 mg h l-1), the terminal phase half-life (T1/2 = 3.05 +/- 0.56 h), the volume of distribution (Vd/F = 195.4 +/- 14.0 l) and total body clearance (CL/F = 46.3 +/- 2.6 l/h), both expressed as functions of the oral bioavailability (F) of ciprofloxacin were within the corresponding values reported in the literature for other healthy population groups.","Pharmacokinetics of oral ciprofloxacin in healthy, young Brazilian subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136565/),[mg] / [l],1.26,187649,DB00537,Ciprofloxacin
,2136565,time to reach Cmax (Tmax,"2. The peak plasma concentration of ciprofloxacin (Cmax = 1.26 +/- 0.21 mg/l), the time to reach Cmax (Tmax = 1.99 +/- 0.26 h), the area under the time-plasma concentration curve (AUC = 5.52 +/- 0.84 mg h l-1), the terminal phase half-life (T1/2 = 3.05 +/- 0.56 h), the volume of distribution (Vd/F = 195.4 +/- 14.0 l) and total body clearance (CL/F = 46.3 +/- 2.6 l/h), both expressed as functions of the oral bioavailability (F) of ciprofloxacin were within the corresponding values reported in the literature for other healthy population groups.","Pharmacokinetics of oral ciprofloxacin in healthy, young Brazilian subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136565/),h,1.99,187650,DB00537,Ciprofloxacin
,2136565,area under the time-plasma concentration curve (AUC,"2. The peak plasma concentration of ciprofloxacin (Cmax = 1.26 +/- 0.21 mg/l), the time to reach Cmax (Tmax = 1.99 +/- 0.26 h), the area under the time-plasma concentration curve (AUC = 5.52 +/- 0.84 mg h l-1), the terminal phase half-life (T1/2 = 3.05 +/- 0.56 h), the volume of distribution (Vd/F = 195.4 +/- 14.0 l) and total body clearance (CL/F = 46.3 +/- 2.6 l/h), both expressed as functions of the oral bioavailability (F) of ciprofloxacin were within the corresponding values reported in the literature for other healthy population groups.","Pharmacokinetics of oral ciprofloxacin in healthy, young Brazilian subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136565/),[h·mg] / [l],5.52,187651,DB00537,Ciprofloxacin
,2136565,terminal phase half-life (T1/2,"2. The peak plasma concentration of ciprofloxacin (Cmax = 1.26 +/- 0.21 mg/l), the time to reach Cmax (Tmax = 1.99 +/- 0.26 h), the area under the time-plasma concentration curve (AUC = 5.52 +/- 0.84 mg h l-1), the terminal phase half-life (T1/2 = 3.05 +/- 0.56 h), the volume of distribution (Vd/F = 195.4 +/- 14.0 l) and total body clearance (CL/F = 46.3 +/- 2.6 l/h), both expressed as functions of the oral bioavailability (F) of ciprofloxacin were within the corresponding values reported in the literature for other healthy population groups.","Pharmacokinetics of oral ciprofloxacin in healthy, young Brazilian subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136565/),h,3.05,187652,DB00537,Ciprofloxacin
,2136565,volume of distribution (Vd/F,"2. The peak plasma concentration of ciprofloxacin (Cmax = 1.26 +/- 0.21 mg/l), the time to reach Cmax (Tmax = 1.99 +/- 0.26 h), the area under the time-plasma concentration curve (AUC = 5.52 +/- 0.84 mg h l-1), the terminal phase half-life (T1/2 = 3.05 +/- 0.56 h), the volume of distribution (Vd/F = 195.4 +/- 14.0 l) and total body clearance (CL/F = 46.3 +/- 2.6 l/h), both expressed as functions of the oral bioavailability (F) of ciprofloxacin were within the corresponding values reported in the literature for other healthy population groups.","Pharmacokinetics of oral ciprofloxacin in healthy, young Brazilian subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136565/),l,195.4,187653,DB00537,Ciprofloxacin
,2136565,total body clearance (CL/F,"2. The peak plasma concentration of ciprofloxacin (Cmax = 1.26 +/- 0.21 mg/l), the time to reach Cmax (Tmax = 1.99 +/- 0.26 h), the area under the time-plasma concentration curve (AUC = 5.52 +/- 0.84 mg h l-1), the terminal phase half-life (T1/2 = 3.05 +/- 0.56 h), the volume of distribution (Vd/F = 195.4 +/- 14.0 l) and total body clearance (CL/F = 46.3 +/- 2.6 l/h), both expressed as functions of the oral bioavailability (F) of ciprofloxacin were within the corresponding values reported in the literature for other healthy population groups.","Pharmacokinetics of oral ciprofloxacin in healthy, young Brazilian subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136565/),[l] / [h],46.3,187654,DB00537,Ciprofloxacin
,18768301,clearance,"Ciprofloxacin clearance was 13.6+/-5.8L/h, the volume of distribution was 62.0+/-10.7 L and the ciprofloxacin half-life was 3.7+/-1.8h.",Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18768301/),[l] / [h],13.6,187713,DB00537,Ciprofloxacin
,18768301,volume of distribution,"Ciprofloxacin clearance was 13.6+/-5.8L/h, the volume of distribution was 62.0+/-10.7 L and the ciprofloxacin half-life was 3.7+/-1.8h.",Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18768301/),l,62.0,187714,DB00537,Ciprofloxacin
,18768301,half-life,"Ciprofloxacin clearance was 13.6+/-5.8L/h, the volume of distribution was 62.0+/-10.7 L and the ciprofloxacin half-life was 3.7+/-1.8h.",Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18768301/),h,3.7,187715,DB00537,Ciprofloxacin
,18768301,minimum inhibitory concentration (MIC),"When the minimum inhibitory concentration (MIC) was equal to 1mg/L the inhibitory ratio (IR) was > or = 8 in only 10.8% of cases, and the AUC/MIC ratio (AUIC) was 42.0+/-36.",Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18768301/),[mg] / [l],1,187716,DB00537,Ciprofloxacin
>,18768301,inhibitory ratio (IR),"When the minimum inhibitory concentration (MIC) was equal to 1mg/L the inhibitory ratio (IR) was > or = 8 in only 10.8% of cases, and the AUC/MIC ratio (AUIC) was 42.0+/-36.",Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18768301/),,8,187717,DB00537,Ciprofloxacin
,18768301,AUC/MIC ratio (AUIC),"When the minimum inhibitory concentration (MIC) was equal to 1mg/L the inhibitory ratio (IR) was > or = 8 in only 10.8% of cases, and the AUC/MIC ratio (AUIC) was 42.0+/-36.",Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18768301/),,42.0,187718,DB00537,Ciprofloxacin
,15592331,elimination half-life,"Ciprofloxacin increased the area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of tizanidine by 10-fold (range, 6-fold to 24-fold; P < .001) and its peak concentration by 7-fold (range, 4-fold to 21-fold; P < .001), whereas its elimination half-life was only prolonged from 1.5 to 1.8 hours (P = .007).",Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592331/),h,1.5,187837,DB00537,Ciprofloxacin
,15592331,elimination half-life,"Ciprofloxacin increased the area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of tizanidine by 10-fold (range, 6-fold to 24-fold; P < .001) and its peak concentration by 7-fold (range, 4-fold to 21-fold; P < .001), whereas its elimination half-life was only prolonged from 1.5 to 1.8 hours (P = .007).",Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592331/),h,1.8,187838,DB00537,Ciprofloxacin
,1864290,penetration,"The penetration of ciprofloxacin into the vitreous humor, based primarily on the data from one report, is about 20%.",Use of quinolones for treatment of ear and eye infections. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864290/),%,20,188476,DB00537,Ciprofloxacin
,8031070,Peak levels of drug,Peak levels of drug in serum were 2.95 +/- 1 mg/liter on day 2 and 2.43 +/- 0.7 mg/liter on day 4.,Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031070/),[mg] / [l],2.95,189088,DB00537,Ciprofloxacin
,8031070,Peak levels of drug,Peak levels of drug in serum were 2.95 +/- 1 mg/liter on day 2 and 2.43 +/- 0.7 mg/liter on day 4.,Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031070/),[mg] / [l],2.43,189089,DB00537,Ciprofloxacin
,8031070,Peak,"Peak and trough levels in bronchial secretions were 0.95 +/- 0.51 and 0.21 +/- 0.12 mg/liter, respectively, on day 2 and 0.76 +/- 0.17 and 0.18 +/- 0.14 mg/liter, respectively, on day 4.",Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031070/),[mg] / [l],0.95,189090,DB00537,Ciprofloxacin
,8031070,Peak,"Peak and trough levels in bronchial secretions were 0.95 +/- 0.51 and 0.21 +/- 0.12 mg/liter, respectively, on day 2 and 0.76 +/- 0.17 and 0.18 +/- 0.14 mg/liter, respectively, on day 4.",Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031070/),[mg] / [l],0.76,189091,DB00537,Ciprofloxacin
,8031070,trough levels,"Peak and trough levels in bronchial secretions were 0.95 +/- 0.51 and 0.21 +/- 0.12 mg/liter, respectively, on day 2 and 0.76 +/- 0.17 and 0.18 +/- 0.14 mg/liter, respectively, on day 4.",Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031070/),[mg] / [l],0.21,189092,DB00537,Ciprofloxacin
,8031070,trough levels,"Peak and trough levels in bronchial secretions were 0.95 +/- 0.51 and 0.21 +/- 0.12 mg/liter, respectively, on day 2 and 0.76 +/- 0.17 and 0.18 +/- 0.14 mg/liter, respectively, on day 4.",Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031070/),[mg] / [l],0.18,189093,DB00537,Ciprofloxacin
,8031070,ratios,"The ratios of peak concentrations in bronchial secretions/serum were 0.32 +/- 0.11 and 0.33 +/- 0.06 on days 2 and 4, respectively.",Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031070/),,0,189094,DB00537,Ciprofloxacin
,21154639,flow rate,"The analyte was separated on a Peerless basic C(18) column (33 × 4.6 mm, 3 µm) with an isocratic mobile phase of methanol-water containing formic acid (0.5%, v/v; 9:1, v/v) at a flow rate of 0.5 mL/min.","Development and validation of a liquid chromatography-tandem mass spectrometry method to determine ulifloxacin, the active metabolite of prulifloxacin in rat and rabbit plasma: application to toxicokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21154639/),[ml] / [min],0.5,189506,DB00537,Ciprofloxacin
,8513847,CL,Ciprofloxacin pretreatment significantly reduced diazepam CL (without ciprofloxacin: 19.5 ml.h-1 kg-1; with ciprofloxacin: 12.3 ml.h-1 kg-1).,The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),[ml] / [h·kg],19.5,189791,DB00537,Ciprofloxacin
,8513847,CL,Ciprofloxacin pretreatment significantly reduced diazepam CL (without ciprofloxacin: 19.5 ml.h-1 kg-1; with ciprofloxacin: 12.3 ml.h-1 kg-1).,The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),[ml] / [h·kg],12.3,189792,DB00537,Ciprofloxacin
,8513847,t1/2,"Diazepam t1/2 was also prolonged (without ciprofloxacin: 36.7 h; with ciprofloxacin: 71.1 h), but volume of distribution was unaltered (without ciprofloxacin: 1.1 l.kg-1; with ciprofloxacin: 1.1 l.kg-1).",The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),h,36.7,189793,DB00537,Ciprofloxacin
,8513847,t1/2,"Diazepam t1/2 was also prolonged (without ciprofloxacin: 36.7 h; with ciprofloxacin: 71.1 h), but volume of distribution was unaltered (without ciprofloxacin: 1.1 l.kg-1; with ciprofloxacin: 1.1 l.kg-1).",The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),h,71.1,189794,DB00537,Ciprofloxacin
,8513847,volume of distribution,"Diazepam t1/2 was also prolonged (without ciprofloxacin: 36.7 h; with ciprofloxacin: 71.1 h), but volume of distribution was unaltered (without ciprofloxacin: 1.1 l.kg-1; with ciprofloxacin: 1.1 l.kg-1).",The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),[l] / [kg],1.1,189795,DB00537,Ciprofloxacin
,9521952,maximum plasma concentrations,"The maximum plasma concentrations, with the means varying from 1.7 to 3.6 mg/L, were reached within 1 hour, almost regardless of whether single-dose administration or steady state.",Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521952/),[mg] / [l],1.7 to 3.6,190169,DB00537,Ciprofloxacin
,9521952,Terminal half-life,"Terminal half-life values, with the means varying only between 4.2 and 5.1, suggest that dosing recommendations based on body weight are pertinent, although caution should be exercised in small infants.",Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521952/),,4.2 and 5.1,190170,DB00537,Ciprofloxacin
,8452353,50% protective doses,"The 50% protective doses of ciprofloxacin and penicillin G were 25.52 +/- 1.95 and 0.307 +/- 0.006 mg/kg of body weight, respectively, an 83-fold difference in efficacy.",Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452353/),[mg] / [kg],25.52,190222,DB00537,Ciprofloxacin
,8452353,50% protective doses,"The 50% protective doses of ciprofloxacin and penicillin G were 25.52 +/- 1.95 and 0.307 +/- 0.006 mg/kg of body weight, respectively, an 83-fold difference in efficacy.",Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452353/),[mg] / [kg],0.307,190223,DB00537,Ciprofloxacin
,8452353,peak concentration/MIC ratio,"For 100% protection with ciprofloxacin, the peak concentration/MIC ratio must reach a value of 10.6.",Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452353/),,10.6,190224,DB00537,Ciprofloxacin
,25704771,run time,"The analytes were resolved on a Gemini C18 column (4.6 mm × 250 mm; 5 μm particle size) using a gradient elution mode with a run time of 15 min, comprising re-equilibration, at 60°C (± 1°C).",Simultaneous determination of eperisone hydrochloride and paracetamol in mouse plasma by high performance liquid chromatography-photodiode array detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25704771/),min,15,190431,DB00537,Ciprofloxacin
,1854156,maximum concentration,"The relative F with calcium was 0.98, maximum concentration of drug in serum increased significantly from 1.98 to 2.42 mg/liter (P = 0.039), and time to maximum concentration of drug in serum decreased from 1.82 to 1.26 h (P = 0.038).",Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854156/),[mg] / [l],1.98,190807,DB00537,Ciprofloxacin
,1854156,maximum concentration,"The relative F with calcium was 0.98, maximum concentration of drug in serum increased significantly from 1.98 to 2.42 mg/liter (P = 0.039), and time to maximum concentration of drug in serum decreased from 1.82 to 1.26 h (P = 0.038).",Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854156/),[mg] / [l],2,190808,DB00537,Ciprofloxacin
,1854156,time to maximum concentration of drug,"The relative F with calcium was 0.98, maximum concentration of drug in serum increased significantly from 1.98 to 2.42 mg/liter (P = 0.039), and time to maximum concentration of drug in serum decreased from 1.82 to 1.26 h (P = 0.038).",Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854156/),h,1.82,190809,DB00537,Ciprofloxacin
,1854156,time to maximum concentration of drug,"The relative F with calcium was 0.98, maximum concentration of drug in serum increased significantly from 1.98 to 2.42 mg/liter (P = 0.039), and time to maximum concentration of drug in serum decreased from 1.82 to 1.26 h (P = 0.038).",Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854156/),h,1,190810,DB00537,Ciprofloxacin
,9131538,half-life,"The half-life for enrofloxacin following i.m. administration was 28.9 h, considerably longer than values calculated for other animals such as dogs, birds, rabbits, and tortoises.","Pharmacokinetics of enrofloxacin in the red pacu (Colossoma brachypomum) after intramuscular, oral and bath administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131538/),h,28.9,191097,DB00537,Ciprofloxacin
,9131538,maximum concentration (Cmax),"The 4 h maximum concentration (Cmax) of 1.64 micrograms/ml, following a single 5.0 mg/kg dosing easily exceeds the in vitro minimum inhibitory concentration (MIC) for 20 bacterial organisms known to infect fish.","Pharmacokinetics of enrofloxacin in the red pacu (Colossoma brachypomum) after intramuscular, oral and bath administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131538/),[μg] / [ml],1.64,191098,DB00537,Ciprofloxacin
,9131538,Cmax,The gavage method of oral enrofloxacin administration produced a Cmax of 0.94 microgram/mL at 6-8 h.,"Pharmacokinetics of enrofloxacin in the red pacu (Colossoma brachypomum) after intramuscular, oral and bath administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131538/),[μg] / [ml],0.94,191099,DB00537,Ciprofloxacin
,9131538,Cmax,The Cmax of 0.17 microgram/mL was noted on the 2 hour post-treatment plasma sample.,"Pharmacokinetics of enrofloxacin in the red pacu (Colossoma brachypomum) after intramuscular, oral and bath administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131538/),[μg] / [ml],0.17,191100,DB00537,Ciprofloxacin
,16735422,Cmax,"Median PD BP, respectively, in the 200 mg twice daily group and the 400 mg twice daily group, were 0.16 and 0.28 mg/L for Cmax, and 0.19 and 0.29 mg/L for AUC24.",Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16735422/),,0.28,191123,DB00537,Ciprofloxacin
,16735422,AUC24,"Median PD BP, respectively, in the 200 mg twice daily group and the 400 mg twice daily group, were 0.16 and 0.28 mg/L for Cmax, and 0.19 and 0.29 mg/L for AUC24.",Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16735422/),[mg] / [l],0.19,191124,DB00537,Ciprofloxacin
,16735422,AUC24,"Median PD BP, respectively, in the 200 mg twice daily group and the 400 mg twice daily group, were 0.16 and 0.28 mg/L for Cmax, and 0.19 and 0.29 mg/L for AUC24.",Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16735422/),[mg] / [l],0.29,191125,DB00537,Ciprofloxacin
<,16735422,MIC,Optimal pharmacodynamic exposure with fixed 200 or 400 mg twice daily regimens of ciprofloxacin may be ensured only against fully susceptible microorganisms with an MIC<0.3 mg/L.,Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16735422/),[mg] / [l],0.3,191126,DB00537,Ciprofloxacin
,1451014,Peak aqueous,Peak aqueous and vitreous levels of ciprofloxacin were obtained at 1 hour (0.59 and 27.26 micrograms/mL respectively); the vitreous level fell to below 1.0 micrograms/mL 12 hours after injection.,Toxicity and pharmacokinetics of intravitreally injected ciprofloxacin in rabbit eyes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451014/),,0,191576,DB00537,Ciprofloxacin
,8222478,total clearance,"Ciprofloxacin total clearance was significantly increased in obese subjects compared with control subjects (897.44 +/- 159.57 versus 744.44 +/- 120.51 ml/min, respectively; p < 0.05).",Intravenous ciprofloxacin disposition in obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222478/),[ml] / [min],897.44,191691,DB00537,Ciprofloxacin
,8222478,total clearance,"Ciprofloxacin total clearance was significantly increased in obese subjects compared with control subjects (897.44 +/- 159.57 versus 744.44 +/- 120.51 ml/min, respectively; p < 0.05).",Intravenous ciprofloxacin disposition in obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222478/),[ml] / [min],744.44,191692,DB00537,Ciprofloxacin
,8222478,renal clearance,Ciprofloxacin renal clearance in obese subjects (637.58 +/- 128.89 ml/min) was 29% higher than in control subjects (495.47 +/- 137.85 ml/min; p < 0.05).,Intravenous ciprofloxacin disposition in obesity. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222478/),[ml] / [min],637.58,191693,DB00537,Ciprofloxacin
,8222478,renal clearance,Ciprofloxacin renal clearance in obese subjects (637.58 +/- 128.89 ml/min) was 29% higher than in control subjects (495.47 +/- 137.85 ml/min; p < 0.05).,Intravenous ciprofloxacin disposition in obesity. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222478/),[ml] / [min],495.47,191694,DB00537,Ciprofloxacin
,8222478,steady-state volume of distribution (Vss),"Ciprofloxacin steady-state volume of distribution (Vss) was significantly larger in obese group (269.17 +/- 51.64 versus 219.03 +/- 35.80 L; p < 0.01) compared with the control group, and when it was normalized by total body weight, obese subjects exhibited lower Vss/kg than control subjects (2.46 +/- 0.42 versus 3.06 +/- 0.31 L/kg; p < 0.001).",Intravenous ciprofloxacin disposition in obesity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222478/),l,269.17,191695,DB00537,Ciprofloxacin
,8222478,steady-state volume of distribution (Vss),"Ciprofloxacin steady-state volume of distribution (Vss) was significantly larger in obese group (269.17 +/- 51.64 versus 219.03 +/- 35.80 L; p < 0.01) compared with the control group, and when it was normalized by total body weight, obese subjects exhibited lower Vss/kg than control subjects (2.46 +/- 0.42 versus 3.06 +/- 0.31 L/kg; p < 0.001).",Intravenous ciprofloxacin disposition in obesity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222478/),l,219.03,191696,DB00537,Ciprofloxacin
,8222478,Vss/kg,"Ciprofloxacin steady-state volume of distribution (Vss) was significantly larger in obese group (269.17 +/- 51.64 versus 219.03 +/- 35.80 L; p < 0.01) compared with the control group, and when it was normalized by total body weight, obese subjects exhibited lower Vss/kg than control subjects (2.46 +/- 0.42 versus 3.06 +/- 0.31 L/kg; p < 0.001).",Intravenous ciprofloxacin disposition in obesity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222478/),[l] / [kg],2.46,191697,DB00537,Ciprofloxacin
,8222478,Vss/kg,"Ciprofloxacin steady-state volume of distribution (Vss) was significantly larger in obese group (269.17 +/- 51.64 versus 219.03 +/- 35.80 L; p < 0.01) compared with the control group, and when it was normalized by total body weight, obese subjects exhibited lower Vss/kg than control subjects (2.46 +/- 0.42 versus 3.06 +/- 0.31 L/kg; p < 0.001).",Intravenous ciprofloxacin disposition in obesity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222478/),[l] / [kg],3.06,191698,DB00537,Ciprofloxacin
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,94.5,191903,DB00537,Ciprofloxacin
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,93,191904,DB00537,Ciprofloxacin
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,93.7,191905,DB00537,Ciprofloxacin
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,95.1,191906,DB00537,Ciprofloxacin
,17343888,Steady-state volume of distribution (V(ss)),"Steady-state volume of distribution (V(ss)) and clearance (Cl) of difloxacin after IV administration were 1.68+/-0.21L/kg and 0.21+/-0.03L/hkg, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of difloxacin in sheep. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17343888/),[l] / [kg],1.68,192359,DB00537,Ciprofloxacin
,17343888,clearance (Cl),"Steady-state volume of distribution (V(ss)) and clearance (Cl) of difloxacin after IV administration were 1.68+/-0.21L/kg and 0.21+/-0.03L/hkg, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of difloxacin in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17343888/),[l] / [hkg],0.21,192360,DB00537,Ciprofloxacin
,17343888,maximum plasma concentration,"Following IM and SC administration difloxacin achieved maximum plasma concentration of 1.89+/-0.55 and 1.39+/-0.14mg/L at 2.42+/-1.28 and 5.33+/-1.03h, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of difloxacin in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17343888/),[mg] / [l],1.89,192361,DB00537,Ciprofloxacin
,17343888,maximum plasma concentration,"Following IM and SC administration difloxacin achieved maximum plasma concentration of 1.89+/-0.55 and 1.39+/-0.14mg/L at 2.42+/-1.28 and 5.33+/-1.03h, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of difloxacin in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17343888/),[mg] / [l],1.39,192362,DB00537,Ciprofloxacin
,17343888,absolute bioavailabilities,"The absolute bioavailabilities after IM and SC routes were 99.92+/-26.50 and 82.35+/-25.65%, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of difloxacin in sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17343888/),%,99.92,192363,DB00537,Ciprofloxacin
,17343888,absolute bioavailabilities,"The absolute bioavailabilities after IM and SC routes were 99.92+/-26.50 and 82.35+/-25.65%, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of difloxacin in sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17343888/),%,82.35,192364,DB00537,Ciprofloxacin
,23942542,trough concentrations,"Pharmacokinetic parameters of ciprofloxacin were not significantly different between the 2 groups: trough concentrations were 1.24 ± 0.95 μg/mL (0.25-3.67 μg/mL) versus 1.30 ± 0.61 μg/mL (0.21-2.36 μg/mL) (P = 0.76); Cmax 3.30 ± 2.16 μg/mL (1.54-8.62 μg/mL) versus 4.24 ± 1.99 μg/mL (2.24-9.02 μg/mL) (P = 0.356); tmax 2.8 ± 1.5 versus 3.1 ± 2.8 hours (P = 0.799); and AUC0-10 20.2 ± 12.1 μg·h·mL (9-51.07 μg·h·mL) versus 24.4 ± 13.0 μg·h·mL (5.57-52.48 μg·h·mL) (P = 0.493), in the oral fed versus NGT, respectively.",Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23942542/),[μg] / [ml],1.24,192649,DB00537,Ciprofloxacin
,23942542,trough concentrations,"Pharmacokinetic parameters of ciprofloxacin were not significantly different between the 2 groups: trough concentrations were 1.24 ± 0.95 μg/mL (0.25-3.67 μg/mL) versus 1.30 ± 0.61 μg/mL (0.21-2.36 μg/mL) (P = 0.76); Cmax 3.30 ± 2.16 μg/mL (1.54-8.62 μg/mL) versus 4.24 ± 1.99 μg/mL (2.24-9.02 μg/mL) (P = 0.356); tmax 2.8 ± 1.5 versus 3.1 ± 2.8 hours (P = 0.799); and AUC0-10 20.2 ± 12.1 μg·h·mL (9-51.07 μg·h·mL) versus 24.4 ± 13.0 μg·h·mL (5.57-52.48 μg·h·mL) (P = 0.493), in the oral fed versus NGT, respectively.",Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23942542/),[μg] / [ml],1.30,192650,DB00537,Ciprofloxacin
,23942542,Cmax,"Pharmacokinetic parameters of ciprofloxacin were not significantly different between the 2 groups: trough concentrations were 1.24 ± 0.95 μg/mL (0.25-3.67 μg/mL) versus 1.30 ± 0.61 μg/mL (0.21-2.36 μg/mL) (P = 0.76); Cmax 3.30 ± 2.16 μg/mL (1.54-8.62 μg/mL) versus 4.24 ± 1.99 μg/mL (2.24-9.02 μg/mL) (P = 0.356); tmax 2.8 ± 1.5 versus 3.1 ± 2.8 hours (P = 0.799); and AUC0-10 20.2 ± 12.1 μg·h·mL (9-51.07 μg·h·mL) versus 24.4 ± 13.0 μg·h·mL (5.57-52.48 μg·h·mL) (P = 0.493), in the oral fed versus NGT, respectively.",Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23942542/),[μg] / [ml],3.30,192651,DB00537,Ciprofloxacin
,23942542,Cmax,"Pharmacokinetic parameters of ciprofloxacin were not significantly different between the 2 groups: trough concentrations were 1.24 ± 0.95 μg/mL (0.25-3.67 μg/mL) versus 1.30 ± 0.61 μg/mL (0.21-2.36 μg/mL) (P = 0.76); Cmax 3.30 ± 2.16 μg/mL (1.54-8.62 μg/mL) versus 4.24 ± 1.99 μg/mL (2.24-9.02 μg/mL) (P = 0.356); tmax 2.8 ± 1.5 versus 3.1 ± 2.8 hours (P = 0.799); and AUC0-10 20.2 ± 12.1 μg·h·mL (9-51.07 μg·h·mL) versus 24.4 ± 13.0 μg·h·mL (5.57-52.48 μg·h·mL) (P = 0.493), in the oral fed versus NGT, respectively.",Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23942542/),[μg] / [ml],4.24,192652,DB00537,Ciprofloxacin
,23942542,tmax,"Pharmacokinetic parameters of ciprofloxacin were not significantly different between the 2 groups: trough concentrations were 1.24 ± 0.95 μg/mL (0.25-3.67 μg/mL) versus 1.30 ± 0.61 μg/mL (0.21-2.36 μg/mL) (P = 0.76); Cmax 3.30 ± 2.16 μg/mL (1.54-8.62 μg/mL) versus 4.24 ± 1.99 μg/mL (2.24-9.02 μg/mL) (P = 0.356); tmax 2.8 ± 1.5 versus 3.1 ± 2.8 hours (P = 0.799); and AUC0-10 20.2 ± 12.1 μg·h·mL (9-51.07 μg·h·mL) versus 24.4 ± 13.0 μg·h·mL (5.57-52.48 μg·h·mL) (P = 0.493), in the oral fed versus NGT, respectively.",Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23942542/),h,2.8,192653,DB00537,Ciprofloxacin
,23942542,tmax,"Pharmacokinetic parameters of ciprofloxacin were not significantly different between the 2 groups: trough concentrations were 1.24 ± 0.95 μg/mL (0.25-3.67 μg/mL) versus 1.30 ± 0.61 μg/mL (0.21-2.36 μg/mL) (P = 0.76); Cmax 3.30 ± 2.16 μg/mL (1.54-8.62 μg/mL) versus 4.24 ± 1.99 μg/mL (2.24-9.02 μg/mL) (P = 0.356); tmax 2.8 ± 1.5 versus 3.1 ± 2.8 hours (P = 0.799); and AUC0-10 20.2 ± 12.1 μg·h·mL (9-51.07 μg·h·mL) versus 24.4 ± 13.0 μg·h·mL (5.57-52.48 μg·h·mL) (P = 0.493), in the oral fed versus NGT, respectively.",Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23942542/),h,3.1,192654,DB00537,Ciprofloxacin
,23942542,AUC0-10,"Pharmacokinetic parameters of ciprofloxacin were not significantly different between the 2 groups: trough concentrations were 1.24 ± 0.95 μg/mL (0.25-3.67 μg/mL) versus 1.30 ± 0.61 μg/mL (0.21-2.36 μg/mL) (P = 0.76); Cmax 3.30 ± 2.16 μg/mL (1.54-8.62 μg/mL) versus 4.24 ± 1.99 μg/mL (2.24-9.02 μg/mL) (P = 0.356); tmax 2.8 ± 1.5 versus 3.1 ± 2.8 hours (P = 0.799); and AUC0-10 20.2 ± 12.1 μg·h·mL (9-51.07 μg·h·mL) versus 24.4 ± 13.0 μg·h·mL (5.57-52.48 μg·h·mL) (P = 0.493), in the oral fed versus NGT, respectively.",Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23942542/),h·ml·μg,20.2,192655,DB00537,Ciprofloxacin
,23942542,AUC0-10,"Pharmacokinetic parameters of ciprofloxacin were not significantly different between the 2 groups: trough concentrations were 1.24 ± 0.95 μg/mL (0.25-3.67 μg/mL) versus 1.30 ± 0.61 μg/mL (0.21-2.36 μg/mL) (P = 0.76); Cmax 3.30 ± 2.16 μg/mL (1.54-8.62 μg/mL) versus 4.24 ± 1.99 μg/mL (2.24-9.02 μg/mL) (P = 0.356); tmax 2.8 ± 1.5 versus 3.1 ± 2.8 hours (P = 0.799); and AUC0-10 20.2 ± 12.1 μg·h·mL (9-51.07 μg·h·mL) versus 24.4 ± 13.0 μg·h·mL (5.57-52.48 μg·h·mL) (P = 0.493), in the oral fed versus NGT, respectively.",Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23942542/),h·ml·μg,24.4,192656,DB00537,Ciprofloxacin
,23941961,serum peak concentration (Cmax),"The serum peak concentration (Cmax), terminal half-life (t1/2K10), volume of distribution (Vd(area)/F) and mean residence time (MRT) of enrofloxacin were 1.89 ± 0.35 μg/ml, 5.14 ± 0.66 h, 5.59 ± 0.99 l/kg/h and 8.52 ± 1.29 h, respectively.",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),[μg] / [ml],1.89,192709,DB00537,Ciprofloxacin
,23941961,terminal half-life (t1/2K10),"The serum peak concentration (Cmax), terminal half-life (t1/2K10), volume of distribution (Vd(area)/F) and mean residence time (MRT) of enrofloxacin were 1.89 ± 0.35 μg/ml, 5.14 ± 0.66 h, 5.59 ± 0.99 l/kg/h and 8.52 ± 1.29 h, respectively.",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),h,5.14,192710,DB00537,Ciprofloxacin
,23941961,terminal half-life (t1/2K10),"The serum peak concentration (Cmax), terminal half-life (t1/2K10), volume of distribution (Vd(area)/F) and mean residence time (MRT) of enrofloxacin were 1.89 ± 0.35 μg/ml, 5.14 ± 0.66 h, 5.59 ± 0.99 l/kg/h and 8.52 ± 1.29 h, respectively.",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),[l] / [h·kg],5.59,192711,DB00537,Ciprofloxacin
,23941961,volume of distribution (Vd(area)/F),"The serum peak concentration (Cmax), terminal half-life (t1/2K10), volume of distribution (Vd(area)/F) and mean residence time (MRT) of enrofloxacin were 1.89 ± 0.35 μg/ml, 5.14 ± 0.66 h, 5.59 ± 0.99 l/kg/h and 8.52 ± 1.29 h, respectively.",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),h,5.14,192712,DB00537,Ciprofloxacin
,23941961,volume of distribution (Vd(area)/F),"The serum peak concentration (Cmax), terminal half-life (t1/2K10), volume of distribution (Vd(area)/F) and mean residence time (MRT) of enrofloxacin were 1.89 ± 0.35 μg/ml, 5.14 ± 0.66 h, 5.59 ± 0.99 l/kg/h and 8.52 ± 1.29 h, respectively.",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),[l] / [h·kg],5.59,192713,DB00537,Ciprofloxacin
,23941961,mean residence time (MRT),"The serum peak concentration (Cmax), terminal half-life (t1/2K10), volume of distribution (Vd(area)/F) and mean residence time (MRT) of enrofloxacin were 1.89 ± 0.35 μg/ml, 5.14 ± 0.66 h, 5.59 ± 0.99 l/kg/h and 8.52 ± 1.29 h, respectively.",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),h,8.52,192714,DB00537,Ciprofloxacin
,23941961,percent metabolite conversion ratio,The percent metabolite conversion ratio of ciprofloxacin to enrofloxacin was 79.,Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),,79,192715,DB00537,Ciprofloxacin
,23941961,binding,The binding of enrofloxacin to plasma proteins was 11%.,Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),%,11,192716,DB00537,Ciprofloxacin
,23941961,MIC,"The MIC, MBC and MPC for enrofloxacin against P. multocida were 0.05, 0.06 μg/ml and 1.50 μg/ml.",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),[μg] / [ml],0.05,192717,DB00537,Ciprofloxacin
,23941961,MBC,"The MIC, MBC and MPC for enrofloxacin against P. multocida were 0.05, 0.06 μg/ml and 1.50 μg/ml.",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),[μg] / [ml],0.06,192718,DB00537,Ciprofloxacin
,23941961,MPC,"The MIC, MBC and MPC for enrofloxacin against P. multocida were 0.05, 0.06 μg/ml and 1.50 μg/ml.",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),[μg] / [ml],1.50,192719,DB00537,Ciprofloxacin
,23941961,AUC24h/MIC,"Modeling of ex-vivo growth inhibition data to the sigmoid Emax equation provided AUC24h/MIC values to produce bacteriostatic (19 h), bactericidal (43 h) and bacterial eradication (64 h).",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),h,19,192720,DB00537,Ciprofloxacin
,23941961,AUC24h/MIC,"Modeling of ex-vivo growth inhibition data to the sigmoid Emax equation provided AUC24h/MIC values to produce bacteriostatic (19 h), bactericidal (43 h) and bacterial eradication (64 h).",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),h,43,192721,DB00537,Ciprofloxacin
,23941961,AUC24h/MIC,"Modeling of ex-vivo growth inhibition data to the sigmoid Emax equation provided AUC24h/MIC values to produce bacteriostatic (19 h), bactericidal (43 h) and bacterial eradication (64 h).",Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23941961/),h,64,192722,DB00537,Ciprofloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,50,193204,DB00537,Ciprofloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,30,193205,DB00537,Ciprofloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,10,193206,DB00537,Ciprofloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,0,193207,DB00537,Ciprofloxacin
less,11418508,C(max)/MIC ratio,"Resistance (at least four-fold increase in MIC) developed when the C(max)/MIC ratio was less than four or the AUC above the MIC was less than 10, and the resulting cultures regrew fully.",The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418508/),,four,194647,DB00537,Ciprofloxacin
less,11418508,AUC above the MIC,"Resistance (at least four-fold increase in MIC) developed when the C(max)/MIC ratio was less than four or the AUC above the MIC was less than 10, and the resulting cultures regrew fully.",The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418508/),,10,194648,DB00537,Ciprofloxacin
higher,11418508,C(max)/MIC ratio,"In contrast, pneumococci with a two- to four-fold increase in sparfloxacin MIC were selected in the presence of serum concentrations of sparfloxacin despite a C(max)/MIC ratio higher than 12, but these isolates remained clinically susceptible by breakpoint MIC and their growth was inhibited by repeated dosage of sparfloxacin.",The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418508/),,12,194649,DB00537,Ciprofloxacin
,1482143,relative bioavailability,"The relative bioavailability of fleroxacin given with sucralfate, calculated from the area under the concentration-time curve, was 76% compared with that of fleroxacin alone.",Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482143/),%,76,194657,DB00537,Ciprofloxacin
,1482143,bioavailabilities,This is significantly better than the bioavailabilities of other quinolones (1.8 to 12.3%) when they are administered with sucralfate.,Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482143/),%,1.8 to 12.3,194658,DB00537,Ciprofloxacin
,1510398,elimination half-life,The elimination half-life of CIP was significantly (P less than 0.001) longer in the infants (2.73 +/- 0.28 h; mean +/- standard deviation) than it was in the children (1.28 +/- 0.52 h).,Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510398/),h,2.73,194708,DB00537,Ciprofloxacin
,1510398,elimination half-life,The elimination half-life of CIP was significantly (P less than 0.001) longer in the infants (2.73 +/- 0.28 h; mean +/- standard deviation) than it was in the children (1.28 +/- 0.52 h).,Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510398/),h,1.28,194709,DB00537,Ciprofloxacin
,1510398,area under the serum CIP concentration-time curve (AUC) from time zero to infinity,The area under the serum CIP concentration-time curve (AUC) from time zero to infinity was 16.1 +/- 7.4 mg.h.liter-1 among the infants and 5.3 +/- 3.3 mg.h.liter-1 in the children (P less than 0.01).,Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510398/),[h·mg] / [l],16.1,194710,DB00537,Ciprofloxacin
,1510398,area under the serum CIP concentration-time curve (AUC) from time zero to infinity,The area under the serum CIP concentration-time curve (AUC) from time zero to infinity was 16.1 +/- 7.4 mg.h.liter-1 among the infants and 5.3 +/- 3.3 mg.h.liter-1 in the children (P less than 0.01).,Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510398/),[h·mg] / [l],5.3,194711,DB00537,Ciprofloxacin
,1510398,mean residence time,"In contrast, the mean residence time was twofold longer in the infants (4.6 h) than it was in the children (2.4 h; P less than 0.001).",Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510398/),h,4.6,194712,DB00537,Ciprofloxacin
,1510398,mean residence time,"In contrast, the mean residence time was twofold longer in the infants (4.6 h) than it was in the children (2.4 h; P less than 0.001).",Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510398/),h,2.4,194713,DB00537,Ciprofloxacin
,2369809,elimination half-life,The ciprofloxacin elimination half-life was 3.9 +/- 0.4 hr in the healthy volunteers and 11.2 +/- 2.5 hr in the patients with severe renal failure.,Transintestinal elimination of ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369809/),h,3.9,195024,DB00537,Ciprofloxacin
,2369809,elimination half-life,The ciprofloxacin elimination half-life was 3.9 +/- 0.4 hr in the healthy volunteers and 11.2 +/- 2.5 hr in the patients with severe renal failure.,Transintestinal elimination of ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369809/),h,11.2,195025,DB00537,Ciprofloxacin
,2369809,total 7-day recovery,"The total 7-day recovery of ciprofloxacin and its metabolites in urine and feces ranged from 74.0% to 114.7% of the dose (mean, 96.3 +/- 14.1%) in normal subjects and from 48.5% to 109.1% (mean, 88.1 +/- 20.9%) in patients.",Transintestinal elimination of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369809/),%,74.0,195026,DB00537,Ciprofloxacin
,2369809,total 7-day recovery,"The total 7-day recovery of ciprofloxacin and its metabolites in urine and feces ranged from 74.0% to 114.7% of the dose (mean, 96.3 +/- 14.1%) in normal subjects and from 48.5% to 109.1% (mean, 88.1 +/- 20.9%) in patients.",Transintestinal elimination of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369809/),%,114.7,195027,DB00537,Ciprofloxacin
,2369809,total 7-day recovery,"The total 7-day recovery of ciprofloxacin and its metabolites in urine and feces ranged from 74.0% to 114.7% of the dose (mean, 96.3 +/- 14.1%) in normal subjects and from 48.5% to 109.1% (mean, 88.1 +/- 20.9%) in patients.",Transintestinal elimination of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369809/),%,96.3,195028,DB00537,Ciprofloxacin
,2369809,total 7-day recovery,"The total 7-day recovery of ciprofloxacin and its metabolites in urine and feces ranged from 74.0% to 114.7% of the dose (mean, 96.3 +/- 14.1%) in normal subjects and from 48.5% to 109.1% (mean, 88.1 +/- 20.9%) in patients.",Transintestinal elimination of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369809/),%,48.5,195029,DB00537,Ciprofloxacin
,2369809,total 7-day recovery,"The total 7-day recovery of ciprofloxacin and its metabolites in urine and feces ranged from 74.0% to 114.7% of the dose (mean, 96.3 +/- 14.1%) in normal subjects and from 48.5% to 109.1% (mean, 88.1 +/- 20.9%) in patients.",Transintestinal elimination of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369809/),%,109.1,195030,DB00537,Ciprofloxacin
,2369809,total 7-day recovery,"The total 7-day recovery of ciprofloxacin and its metabolites in urine and feces ranged from 74.0% to 114.7% of the dose (mean, 96.3 +/- 14.1%) in normal subjects and from 48.5% to 109.1% (mean, 88.1 +/- 20.9%) in patients.",Transintestinal elimination of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369809/),%,88.1,195031,DB00537,Ciprofloxacin
<,10974576,AUC/MIC(24),LVX AUC/MIC(24) of </=20 CFU/ml.,"In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10974576/),[cfu] / [ml],20,195484,DB00537,Ciprofloxacin
<,10974576,C(max)/MIC,Selection of fluoroquinolone resistance only occurred at C(max)/MIC < 5.0 (p = 0.03).,"In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10974576/),,5.0,195485,DB00537,Ciprofloxacin
,10350500,"apparent drug distribution volume (Vd,lambdaz/F","Oral TM also caused a 3-fold increase in both apparent drug distribution volume (Vd,lambdaz/F: 92. 0 vs 30.8 L/kg) and terminal elimination half-life (t1/2,lambdaz; 5. 71 vs 1.96 h).",Effects of taraxacum mongolicum on the bioavailability and disposition of ciprofloxacin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10350500/),[l] / [kg],92. 0,195906,DB00537,Ciprofloxacin
,10350500,"apparent drug distribution volume (Vd,lambdaz/F","Oral TM also caused a 3-fold increase in both apparent drug distribution volume (Vd,lambdaz/F: 92. 0 vs 30.8 L/kg) and terminal elimination half-life (t1/2,lambdaz; 5. 71 vs 1.96 h).",Effects of taraxacum mongolicum on the bioavailability and disposition of ciprofloxacin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10350500/),[l] / [kg],30.8,195907,DB00537,Ciprofloxacin
,10350500,"terminal elimination half-life (t1/2,lambdaz","Oral TM also caused a 3-fold increase in both apparent drug distribution volume (Vd,lambdaz/F: 92. 0 vs 30.8 L/kg) and terminal elimination half-life (t1/2,lambdaz; 5. 71 vs 1.96 h).",Effects of taraxacum mongolicum on the bioavailability and disposition of ciprofloxacin in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10350500/),h,5. 71,195908,DB00537,Ciprofloxacin
,10350500,"terminal elimination half-life (t1/2,lambdaz","Oral TM also caused a 3-fold increase in both apparent drug distribution volume (Vd,lambdaz/F: 92. 0 vs 30.8 L/kg) and terminal elimination half-life (t1/2,lambdaz; 5. 71 vs 1.96 h).",Effects of taraxacum mongolicum on the bioavailability and disposition of ciprofloxacin in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10350500/),h,1.96,195909,DB00537,Ciprofloxacin
,31170198,in vivo recoveries,"The in vivo recoveries of MD were 23.21% ± 3.42% for skeletal muscle and 20.62% ± 3.19% for plasma, and were concentration independent.",Microdialysis combined with liquid chromatography-tandem mass spectrometry for the quantitation of gemifloxacin and its application to a muscle penetration study in healthy and MRSA-infected rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31170198/),%,23.21,196489,DB00537,Ciprofloxacin
,31170198,in vivo recoveries,"The in vivo recoveries of MD were 23.21% ± 3.42% for skeletal muscle and 20.62% ± 3.19% for plasma, and were concentration independent.",Microdialysis combined with liquid chromatography-tandem mass spectrometry for the quantitation of gemifloxacin and its application to a muscle penetration study in healthy and MRSA-infected rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31170198/),%,20.62,196490,DB00537,Ciprofloxacin
,31170198,areas under the concentration-time curves (AUCs) from 0 to 9 h,"The mean areas under the concentration-time curves (AUCs) from 0 to 9 h for skeletal muscle and plasma were 3641.50 ± 915.65 h*ng/mL and 7068.32 ± 1964.19 h*ng/mL in MRSA-infected rats and 3774.72 ± 700.36 h*ng/mL and 6927.49 ± 1714.86 h*ng/mL in healthy rats, respectively.",Microdialysis combined with liquid chromatography-tandem mass spectrometry for the quantitation of gemifloxacin and its application to a muscle penetration study in healthy and MRSA-infected rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31170198/),[h·ng] / [ml],3641.50,196491,DB00537,Ciprofloxacin
,31170198,areas under the concentration-time curves (AUCs) from 0 to 9 h,"The mean areas under the concentration-time curves (AUCs) from 0 to 9 h for skeletal muscle and plasma were 3641.50 ± 915.65 h*ng/mL and 7068.32 ± 1964.19 h*ng/mL in MRSA-infected rats and 3774.72 ± 700.36 h*ng/mL and 6927.49 ± 1714.86 h*ng/mL in healthy rats, respectively.",Microdialysis combined with liquid chromatography-tandem mass spectrometry for the quantitation of gemifloxacin and its application to a muscle penetration study in healthy and MRSA-infected rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31170198/),[h·ng] / [ml],7068.32,196492,DB00537,Ciprofloxacin
,31170198,areas under the concentration-time curves (AUCs) from 0 to 9 h,"The mean areas under the concentration-time curves (AUCs) from 0 to 9 h for skeletal muscle and plasma were 3641.50 ± 915.65 h*ng/mL and 7068.32 ± 1964.19 h*ng/mL in MRSA-infected rats and 3774.72 ± 700.36 h*ng/mL and 6927.49 ± 1714.86 h*ng/mL in healthy rats, respectively.",Microdialysis combined with liquid chromatography-tandem mass spectrometry for the quantitation of gemifloxacin and its application to a muscle penetration study in healthy and MRSA-infected rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31170198/),[h·ng] / [ml],3774.72,196493,DB00537,Ciprofloxacin
,31170198,areas under the concentration-time curves (AUCs) from 0 to 9 h,"The mean areas under the concentration-time curves (AUCs) from 0 to 9 h for skeletal muscle and plasma were 3641.50 ± 915.65 h*ng/mL and 7068.32 ± 1964.19 h*ng/mL in MRSA-infected rats and 3774.72 ± 700.36 h*ng/mL and 6927.49 ± 1714.86 h*ng/mL in healthy rats, respectively.",Microdialysis combined with liquid chromatography-tandem mass spectrometry for the quantitation of gemifloxacin and its application to a muscle penetration study in healthy and MRSA-infected rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31170198/),[h·ng] / [ml],6927.49,196494,DB00537,Ciprofloxacin
,2920479,bioavailability,"Absorption of norfloxacin, ciprofloxacin, and enoxacin is incomplete, whereas the bioavailability of pefloxacin, ofloxacin and fleroxacin is almost 100%.",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),%,100,197116,DB00537,Ciprofloxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],1.5,197117,DB00537,Ciprofloxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],10.7,197118,DB00537,Ciprofloxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],78,197119,DB00537,Ciprofloxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],5.5,197120,DB00537,Ciprofloxacin
,2920479,apparent volume of distribution,Protein binding is low (less than or equal to 30%) and apparent volume of distribution is between 1.5 and 3.1 liters/kg.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[l] / [kg],1.5 and 3.1,197121,DB00537,Ciprofloxacin
,2920479,half-lives,"Norfloxacin and ciprofloxacin have the shortest half-lives (+/- 4h), while fleroxacin and pefloxacin have the longest (10-12h).",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),h,10-12,197122,DB00537,Ciprofloxacin
,8467353,Basal-to-apical flux,Basal-to-apical flux of ciprofloxacin (10 microM) exceeds apical-to-basal flux indicating net secretion.,Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8467353/),μM,10,197136,DB00537,Ciprofloxacin
,8467353,Km,"Net ciprofloxacin secretion is abolished by azide/2-deoxy-D-glucose treatment, displays saturation kinetics (Km = 0.89 +/- 0.23 mM, Vmax 44.3 +/- 4.9 nmol cm-2.h) and competition by other fluoroquinolones.",Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8467353/),mM,0.89,197137,DB00537,Ciprofloxacin
,8467353,Vmax,"Net ciprofloxacin secretion is abolished by azide/2-deoxy-D-glucose treatment, displays saturation kinetics (Km = 0.89 +/- 0.23 mM, Vmax 44.3 +/- 4.9 nmol cm-2.h) and competition by other fluoroquinolones.",Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8467353/),[h·nM] / [(cm)^2],44.3,197138,DB00537,Ciprofloxacin
,19932750,gastric retention period,"Abdominal X-ray imaging of formula F10, loaded with barium sulfate, in six healthy volunteers revealed a mean gastric retention period of 5.50+/-0.77h.","Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: development, optimization and in vitro-in vivo evaluation in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19932750/),h,5.50,197519,DB00537,Ciprofloxacin
,19272845,Excitation/emission wavelengths,"Excitation/emission wavelengths were 279/442nm for ciprofloxacin and 290/500nm for ofloxacin, moxifloxacin and internal standard.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),nm,279/,198151,DB00537,Ciprofloxacin
,19272845,Excitation/emission wavelengths,"Excitation/emission wavelengths were 279/442nm for ciprofloxacin and 290/500nm for ofloxacin, moxifloxacin and internal standard.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),nm,442,198152,DB00537,Ciprofloxacin
,19272845,Excitation/emission wavelengths,"Excitation/emission wavelengths were 279/442nm for ciprofloxacin and 290/500nm for ofloxacin, moxifloxacin and internal standard.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),nm,290,198153,DB00537,Ciprofloxacin
,19272845,recovery,"Ofloxacin, ciprofloxacin and moxifloxacin were extracted from plasma with a mean recovery of 95%, 86.4% and 94.2%, respectively.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),%,95,198154,DB00537,Ciprofloxacin
,19272845,recovery,"Ofloxacin, ciprofloxacin and moxifloxacin were extracted from plasma with a mean recovery of 95%, 86.4% and 94.2%, respectively.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),%,86.4,198155,DB00537,Ciprofloxacin
,19272845,recovery,"Ofloxacin, ciprofloxacin and moxifloxacin were extracted from plasma with a mean recovery of 95%, 86.4% and 94.2%, respectively.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),%,94.2,198156,DB00537,Ciprofloxacin
,2731404,elimination half-life (t 1/2),"The elimination half-life (t 1/2) and the area under the serum concentration versus time curve (AUC) were, respectively, 3.71 hours and 16.18 microgram.",The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731404/),h,3.71,198487,DB00537,Ciprofloxacin
,2731404,area under the serum concentration versus time curve (AUC),"The elimination half-life (t 1/2) and the area under the serum concentration versus time curve (AUC) were, respectively, 3.71 hours and 16.18 microgram.",The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731404/),μg,16.18,198488,DB00537,Ciprofloxacin
,2731404,Cmax,"The formation of oxociprofloxacin was reduced by approximately one half in the cirrhotic subjects, as the Cmax was 0.29 micrograms/ml in normal subjects versus 0.14 micrograms/ml in cirrhotic patients and the mean AUC(0-t) was 1.54 micrograms.",The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731404/),[μg] / [ml],0.29,198489,DB00537,Ciprofloxacin
,2731404,Cmax,"The formation of oxociprofloxacin was reduced by approximately one half in the cirrhotic subjects, as the Cmax was 0.29 micrograms/ml in normal subjects versus 0.14 micrograms/ml in cirrhotic patients and the mean AUC(0-t) was 1.54 micrograms.",The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731404/),[μg] / [ml],0.14,198490,DB00537,Ciprofloxacin
,2731404,AUC(0-t),"The formation of oxociprofloxacin was reduced by approximately one half in the cirrhotic subjects, as the Cmax was 0.29 micrograms/ml in normal subjects versus 0.14 micrograms/ml in cirrhotic patients and the mean AUC(0-t) was 1.54 micrograms.",The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731404/),μg,1.54,198491,DB00537,Ciprofloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,4,198508,DB00537,Ciprofloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,7.4,198509,DB00537,Ciprofloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,6.8,198510,DB00537,Ciprofloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,12.1,198511,DB00537,Ciprofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,730,198512,DB00537,Ciprofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,1,198513,DB00537,Ciprofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,130,198514,DB00537,Ciprofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,920,198515,DB00537,Ciprofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,690,198516,DB00537,Ciprofloxacin
,6517559,peak levels,"There was a significant buildup in mean concentrations in serum from day 1 to day 7; mean peak levels (attained after 1 to 2 h) were 1.9 and 2.8 micrograms/ml, respectively.",Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517559/),[μg] / [ml],1.9,198548,DB00537,Ciprofloxacin
,6517559,peak levels,"There was a significant buildup in mean concentrations in serum from day 1 to day 7; mean peak levels (attained after 1 to 2 h) were 1.9 and 2.8 micrograms/ml, respectively.",Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517559/),[μg] / [ml],2.8,198549,DB00537,Ciprofloxacin
,6517559,terminal half-life,The terminal half-life was 3.5 to 4 h.,Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517559/),h,3.5 to 4,198550,DB00537,Ciprofloxacin
,6517559,minimum mean concentrations,About 40% of the drug was excreted into the urine during the 12-h period after dosing; minimum mean concentrations in urine were 105 micrograms/ml on day 1 and 174 micrograms/ml on day 7.,Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517559/),[μg] / [ml],105,198551,DB00537,Ciprofloxacin
,6517559,minimum mean concentrations,About 40% of the drug was excreted into the urine during the 12-h period after dosing; minimum mean concentrations in urine were 105 micrograms/ml on day 1 and 174 micrograms/ml on day 7.,Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517559/),[μg] / [ml],174,198552,DB00537,Ciprofloxacin
,21820876,maximum tolerated dose,The maximum tolerated dose of UB-8902 was 512 mg/kg.,Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21820876/),[mg] / [kg],512,198759,DB00537,Ciprofloxacin
,21820876,PD(50),"PD(50) values were 16, 128 and 32 mg/kg for Ab58, Ab661 and Ab33, respectively.",Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21820876/),[mg] / [kg],16,198760,DB00537,Ciprofloxacin
,21820876,PD(50),"PD(50) values were 16, 128 and 32 mg/kg for Ab58, Ab661 and Ab33, respectively.",Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21820876/),[mg] / [kg],128,198761,DB00537,Ciprofloxacin
,21820876,PD(50),"PD(50) values were 16, 128 and 32 mg/kg for Ab58, Ab661 and Ab33, respectively.",Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21820876/),[mg] / [kg],32,198762,DB00537,Ciprofloxacin
,8729890,trough serum quinidine concentration (SQC),A trough serum quinidine concentration (SQC) on day 7 was 6.3 micrograms/mL (normal 2-5) with normal QT and QTc intervals.,Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729890/),[μg] / [ml],6.3,198923,DB00537,Ciprofloxacin
,9687400,absorption rate constant,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),1/[h],0. 201,198972,DB00537,Ciprofloxacin
,9687400,clearance/bioavailability (CL/F,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),[l] / [h],60.9,198973,DB00537,Ciprofloxacin
,9687400,volume of the central compartment/bioavailability,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),l,231,198974,DB00537,Ciprofloxacin
,9687400,intercompartmental clearance,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),[l] / [h],60.3,198975,DB00537,Ciprofloxacin
,9687400,volume of the peripheral compartment/bioavailability (Vp/F,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),l,"1,050",198976,DB00537,Ciprofloxacin
,9687400,distribution,"The distribution and elimination half-lives were 1.24 and 25.4 h, respectively.",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),h,1.24,198977,DB00537,Ciprofloxacin
,9687400,elimination half-lives,"The distribution and elimination half-lives were 1.24 and 25.4 h, respectively.",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),h,25.4,198978,DB00537,Ciprofloxacin
,1622184,Peak levels,Peak levels (mean +/- standard deviation) were 4.0 +/- 0.7 micrograms/ml in serum and 2.6 +/- 0.6 micrograms/ml in ascitic fluid; the areas under the curve (0 to 12 h) were 29.1 +/- 6.5 micrograms.h/ml in serum and 20.7 +/- 5.0 micrograms.h/ml in ascitic fluid.,Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1622184/),[μg] / [ml],4.0,199001,DB00537,Ciprofloxacin
,1622184,Peak levels,Peak levels (mean +/- standard deviation) were 4.0 +/- 0.7 micrograms/ml in serum and 2.6 +/- 0.6 micrograms/ml in ascitic fluid; the areas under the curve (0 to 12 h) were 29.1 +/- 6.5 micrograms.h/ml in serum and 20.7 +/- 5.0 micrograms.h/ml in ascitic fluid.,Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1622184/),[μg] / [ml],2.6,199002,DB00537,Ciprofloxacin
,1622184,areas under the curve (0 to 12 h),Peak levels (mean +/- standard deviation) were 4.0 +/- 0.7 micrograms/ml in serum and 2.6 +/- 0.6 micrograms/ml in ascitic fluid; the areas under the curve (0 to 12 h) were 29.1 +/- 6.5 micrograms.h/ml in serum and 20.7 +/- 5.0 micrograms.h/ml in ascitic fluid.,Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1622184/),[h·μg] / [ml],29.1,199003,DB00537,Ciprofloxacin
,1622184,areas under the curve (0 to 12 h),Peak levels (mean +/- standard deviation) were 4.0 +/- 0.7 micrograms/ml in serum and 2.6 +/- 0.6 micrograms/ml in ascitic fluid; the areas under the curve (0 to 12 h) were 29.1 +/- 6.5 micrograms.h/ml in serum and 20.7 +/- 5.0 micrograms.h/ml in ascitic fluid.,Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1622184/),[h·μg] / [ml],20.7,199004,DB00537,Ciprofloxacin
,8452186,maximal plasma concentrations,"After administration of the standard dose of 400 mg once daily, the maximal plasma concentrations were 5-7 mg/L at steady-state and the minimal concentrations were approximately 1 mg/L at the end of the dosing interval.",Penetration of fleroxacin into body tissues and fluids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452186/),[mg] / [l],5-7,199192,DB00537,Ciprofloxacin
,8452186,minimal concentrations,"After administration of the standard dose of 400 mg once daily, the maximal plasma concentrations were 5-7 mg/L at steady-state and the minimal concentrations were approximately 1 mg/L at the end of the dosing interval.",Penetration of fleroxacin into body tissues and fluids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452186/),[mg] / [l],1,199193,DB00537,Ciprofloxacin
,24054830,AUCs,"The geometric mean AUCs after the last dose were 0.383, 1.472, and 0.781 mg · h/L with ciprofloxacin DPI 32.5 mg qd, 65 mg qd, and 32.5 mg bid, respectively.","Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24054830/),[h·mg] / [l],0.383,199682,DB00537,Ciprofloxacin
,24054830,AUCs,"The geometric mean AUCs after the last dose were 0.383, 1.472, and 0.781 mg · h/L with ciprofloxacin DPI 32.5 mg qd, 65 mg qd, and 32.5 mg bid, respectively.","Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24054830/),[h·mg] / [l],1.472,199683,DB00537,Ciprofloxacin
,24054830,AUCs,"The geometric mean AUCs after the last dose were 0.383, 1.472, and 0.781 mg · h/L with ciprofloxacin DPI 32.5 mg qd, 65 mg qd, and 32.5 mg bid, respectively.","Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24054830/),[h·mg] / [l],0.781,199684,DB00537,Ciprofloxacin
,24054830,t(½),The range of geometric mean t(½) in plasma was 3.4 to 9.5 hours.,"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24054830/),h,3.4 to 9.5,199685,DB00537,Ciprofloxacin
,24054830,concentrations,"Geometric mean ciprofloxacin concentrations (%CV) in induced sputum were 57.7 (118.2), 177.5 (53.4), and 149.7 (249.7) mg/L 0.75 hours after the last dose of ciprofloxacin DPI 32.5 mg qd, 65 mg qd, and 32.5 mg bid, respectively.","Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24054830/),mg,57.,199686,DB00537,Ciprofloxacin
,24054830,concentrations,"Geometric mean ciprofloxacin concentrations (%CV) in induced sputum were 57.7 (118.2), 177.5 (53.4), and 149.7 (249.7) mg/L 0.75 hours after the last dose of ciprofloxacin DPI 32.5 mg qd, 65 mg qd, and 32.5 mg bid, respectively.","Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24054830/),mg,177.5,199687,DB00537,Ciprofloxacin
,24054830,concentrations,"Geometric mean ciprofloxacin concentrations (%CV) in induced sputum were 57.7 (118.2), 177.5 (53.4), and 149.7 (249.7) mg/L 0.75 hours after the last dose of ciprofloxacin DPI 32.5 mg qd, 65 mg qd, and 32.5 mg bid, respectively.","Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24054830/),mg,149.7,199688,DB00537,Ciprofloxacin
,10379934,"time to peak plasma concentration, Tmax","The time to peak plasma concentration, Tmax, was 12 hr and peak concentration, Cmax, was 2.64 microg/ml.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),h,12,200103,DB00537,Ciprofloxacin
,10379934,"peak concentration, Cmax,","The time to peak plasma concentration, Tmax, was 12 hr and peak concentration, Cmax, was 2.64 microg/ml.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),[μg] / [ml],2.64,200104,DB00537,Ciprofloxacin
,10379934,absorption rate constant (k(a)),The absorption rate constant (k(a)) was 0.23 hr(-1) (r=0.996).,Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),1/[hr],0.23,200105,DB00537,Ciprofloxacin
,10379934,distribution rate constant (alpha),"The distribution rate constant (alpha) was 0.085 hr(-1) (r=0.972), and the half-life (t(1,2alpha)) was 8.15 hr.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),1/[hr],0.085,200106,DB00537,Ciprofloxacin
,10379934,"half-life (t(1,2alpha))","The distribution rate constant (alpha) was 0.085 hr(-1) (r=0.972), and the half-life (t(1,2alpha)) was 8.15 hr.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),h,8.15,200107,DB00537,Ciprofloxacin
,10379934,elimination rate constant (beta),"The elimination rate constant (beta) was 0.023 hr(-1) (r=0.909), and the half-life (t(1/2beta)) was 30.13 hr.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),1/[hr],0.023,200108,DB00537,Ciprofloxacin
,10379934,half-life (t(1/2beta)),"The elimination rate constant (beta) was 0.023 hr(-1) (r=0.909), and the half-life (t(1/2beta)) was 30.13 hr.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),h,30.13,200109,DB00537,Ciprofloxacin
,10379934,"area under the curve, AUC","The estimated area under the curve, AUC, was 56.7 microg.hr/ml.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),[h·μg] / [ml],56.7,200110,DB00537,Ciprofloxacin
,10379934,peak concentrations,"The peak concentrations of drug in liver, kidney, muscle, and skin were 13.39 (12 hr), 5.53 (12 hr), 1.82 (24 hr), and 0.78 microg/g (40 hr), respectively.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),,13.39,200111,DB00537,Ciprofloxacin
,10379934,peak concentrations,"The peak concentrations of drug in liver, kidney, muscle, and skin were 13.39 (12 hr), 5.53 (12 hr), 1.82 (24 hr), and 0.78 microg/g (40 hr), respectively.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),h,5.53,200112,DB00537,Ciprofloxacin
,10379934,peak concentrations,"The peak concentrations of drug in liver, kidney, muscle, and skin were 13.39 (12 hr), 5.53 (12 hr), 1.82 (24 hr), and 0.78 microg/g (40 hr), respectively.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),h,1.82,200113,DB00537,Ciprofloxacin
,10379934,peak concentrations,"The peak concentrations of drug in liver, kidney, muscle, and skin were 13.39 (12 hr), 5.53 (12 hr), 1.82 (24 hr), and 0.78 microg/g (40 hr), respectively.",Pharmacokinetic and depletion studies of sarafloxacin after oral administration to eel (Anguilla anguilla). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379934/),[μg] / [g],0.78,200114,DB00537,Ciprofloxacin
,19614838,slope of the terminal phase,"Plasma pharmacokinetic parameters were derived from plasma concentration-time data using a compartmental and noncompartmental analysis, and validated a relatively rapid elimination from the blood compartment, with a slope of the terminal phase of 0.21 +/- 0.02 and 0.19 +/- 0.06 per hour and a half-life of 3.16 +/- 0.43 and 3.84 +/- 0.59 h, for i.v. and i.m. dosing, respectively.",Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),1/[h],0.21,200383,DB00537,Ciprofloxacin
,19614838,slope of the terminal phase,"Plasma pharmacokinetic parameters were derived from plasma concentration-time data using a compartmental and noncompartmental analysis, and validated a relatively rapid elimination from the blood compartment, with a slope of the terminal phase of 0.21 +/- 0.02 and 0.19 +/- 0.06 per hour and a half-life of 3.16 +/- 0.43 and 3.84 +/- 0.59 h, for i.v. and i.m. dosing, respectively.",Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),1/[h],0.19,200384,DB00537,Ciprofloxacin
,19614838,half-life,"Plasma pharmacokinetic parameters were derived from plasma concentration-time data using a compartmental and noncompartmental analysis, and validated a relatively rapid elimination from the blood compartment, with a slope of the terminal phase of 0.21 +/- 0.02 and 0.19 +/- 0.06 per hour and a half-life of 3.16 +/- 0.43 and 3.84 +/- 0.59 h, for i.v. and i.m. dosing, respectively.",Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),h,3.16,200385,DB00537,Ciprofloxacin
,19614838,half-life,"Plasma pharmacokinetic parameters were derived from plasma concentration-time data using a compartmental and noncompartmental analysis, and validated a relatively rapid elimination from the blood compartment, with a slope of the terminal phase of 0.21 +/- 0.02 and 0.19 +/- 0.06 per hour and a half-life of 3.16 +/- 0.43 and 3.84 +/- 0.59 h, for i.v. and i.m. dosing, respectively.",Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),h,3.84,200386,DB00537,Ciprofloxacin
,19614838,volume of distribution V((d(ss))),"OBFX was widely distributed with a volume of distribution V((d(ss))) of 1.31 +/- 0.12 L/kg, as suggested by the low percentage of protein binding (22.5%).",Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),[l] / [kg],1.31,200387,DB00537,Ciprofloxacin
,19614838,percentage of protein binding,"OBFX was widely distributed with a volume of distribution V((d(ss))) of 1.31 +/- 0.12 L/kg, as suggested by the low percentage of protein binding (22.5%).",Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),%,22.5,200388,DB00537,Ciprofloxacin
,19614838,systemic body clearance (Cl(B)),The systemic body clearance (Cl(B)) was 0.32 +/- 0.12 L/h x kg.,Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),[l] / [h·kg],0.32,200389,DB00537,Ciprofloxacin
,19614838,maximum plasma concentration (C(max)),"Following i.m. administration, the maximum plasma concentration (C(max)) of 1.53 +/- 0.34 microg/mL was reached at t(max) 1.25 +/- 0.21 h.",Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),[μg] / [ml],1.53,200390,DB00537,Ciprofloxacin
,19614838,t(max),"Following i.m. administration, the maximum plasma concentration (C(max)) of 1.53 +/- 0.34 microg/mL was reached at t(max) 1.25 +/- 0.21 h.",Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),h,1.25,200391,DB00537,Ciprofloxacin
,19614838,bioavailability,"The drug was completely absorbed after i.m. administration, with a bioavailability of 114.63 +/- 11.39%.",Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19614838/),%,114.63,200392,DB00537,Ciprofloxacin
,8067740,MIC for 90%,"A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200513,DB00537,Ciprofloxacin
,8067740,MIC90],"A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200514,DB00537,Ciprofloxacin
,8067740,MIC90,"A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200515,DB00537,Ciprofloxacin
,8067740,MIC90,"A-80556 was also the most active of the quinolones tested against ciprofloxacin-resistant S. aureus, with an MIC90 of 4.0 micrograms/ml; that of ciprofloxacin was > 128 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],4.0,200516,DB00537,Ciprofloxacin
>,8067740,MIC90,"A-80556 was also the most active of the quinolones tested against ciprofloxacin-resistant S. aureus, with an MIC90 of 4.0 micrograms/ml; that of ciprofloxacin was > 128 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],128,200517,DB00537,Ciprofloxacin
,8067740,MIC90,"A-80556 was slightly less active against Escherichia coli (MIC90, 0.06 microgram/ml) and other enteric organisms than ciprofloxacin (MIC90 for E. coli, < or = 0.03 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.06,200518,DB00537,Ciprofloxacin
< or =,8067740,MIC90,"A-80556 was slightly less active against Escherichia coli (MIC90, 0.06 microgram/ml) and other enteric organisms than ciprofloxacin (MIC90 for E. coli, < or = 0.03 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.03,200519,DB00537,Ciprofloxacin
,8067740,MIC90,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],4.0,200520,DB00537,Ciprofloxacin
,8067740,MIC90,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],2.0,200521,DB00537,Ciprofloxacin
,8067740,MIC90s,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200522,DB00537,Ciprofloxacin
,8067740,MIC90s,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.5,200523,DB00537,Ciprofloxacin
,8067740,MIC90,"Against Bacteroides fragilis, the MIC90 of A-80556 was 2.0 micrograms/ml; that of ciprofloxacin was 16 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],2.0,200524,DB00537,Ciprofloxacin
,8067740,MIC90,"Against Bacteroides fragilis, the MIC90 of A-80556 was 2.0 micrograms/ml; that of ciprofloxacin was 16 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],16,200525,DB00537,Ciprofloxacin
,10997596,AUC0-24h/MIC ratio,"In a neutropenic murine thigh model of infection, caused by Gram-negative bacilli, a AUC0-24h/MIC ratio of approximately 100 was necessary to protect >90% of the animals, which is similar to data reported previously for other quinolones.",Pharmacodynamics to combat resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997596/),,100,201289,DB00537,Ciprofloxacin
,10997596,AUC-24h/MIC ratio,"However, in order to achieve the same protection in an immunocompetent murine infection caused by Streptococcus pneumoniae, the AUC-24h/MIC ratio was approximately 25.",Pharmacodynamics to combat resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997596/),,25,201290,DB00537,Ciprofloxacin
,30656701,half-life,"After i.v. administration, the half-life, area under the curve (AUCtot ), clearance and the volume of distribution were 12.41 ± 2.62 hr, 64.5 ± 14.44 μg ml-1 hr-1 , 0.19 ± 0.04 L h-1 kg-1 , and 2.09 ± 0.48 L/kg, respectively.",Pharmacokinetics of an intravenous and oral dose of enrofloxacin in white rhinoceros (Ceratotherium simum). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30656701/),h,12.41,201631,DB00537,Ciprofloxacin
,30656701,area under the curve (AUCtot ),"After i.v. administration, the half-life, area under the curve (AUCtot ), clearance and the volume of distribution were 12.41 ± 2.62 hr, 64.5 ± 14.44 μg ml-1 hr-1 , 0.19 ± 0.04 L h-1 kg-1 , and 2.09 ± 0.48 L/kg, respectively.",Pharmacokinetics of an intravenous and oral dose of enrofloxacin in white rhinoceros (Ceratotherium simum). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30656701/),[μg] / [h·ml],64.5,201632,DB00537,Ciprofloxacin
,30656701,area under the curve (AUCtot ),"After i.v. administration, the half-life, area under the curve (AUCtot ), clearance and the volume of distribution were 12.41 ± 2.62 hr, 64.5 ± 14.44 μg ml-1 hr-1 , 0.19 ± 0.04 L h-1 kg-1 , and 2.09 ± 0.48 L/kg, respectively.",Pharmacokinetics of an intravenous and oral dose of enrofloxacin in white rhinoceros (Ceratotherium simum). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30656701/),[l] / [h·kg],0.19,201633,DB00537,Ciprofloxacin
,30656701,volume of distribution,"After i.v. administration, the half-life, area under the curve (AUCtot ), clearance and the volume of distribution were 12.41 ± 2.62 hr, 64.5 ± 14.44 μg ml-1 hr-1 , 0.19 ± 0.04 L h-1 kg-1 , and 2.09 ± 0.48 L/kg, respectively.",Pharmacokinetics of an intravenous and oral dose of enrofloxacin in white rhinoceros (Ceratotherium simum). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30656701/),[l] / [kg],2.09,201634,DB00537,Ciprofloxacin
,30656701,oral bioavailability,After combined i.v. and oral enrofloxacin administration oral bioavailability was 33.30 ± 38.33%.,Pharmacokinetics of an intravenous and oral dose of enrofloxacin in white rhinoceros (Ceratotherium simum). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30656701/),%,33.30,201635,DB00537,Ciprofloxacin
,30656701,MIC,"After i.v. enrofloxacin administration, the efficacy marker AUC24 : MIC exceeded the recommended ratio of 125 against bacteria with an MIC of 0.5 μg/mL.",Pharmacokinetics of an intravenous and oral dose of enrofloxacin in white rhinoceros (Ceratotherium simum). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30656701/),[μg] / [ml],0.5,201636,DB00537,Ciprofloxacin
,30656701,Cmax: MIC ratio,Subsequent intravenous and oral enrofloxacin administration resulted in a low Cmax: MIC ratio of 3.1.,Pharmacokinetics of an intravenous and oral dose of enrofloxacin in white rhinoceros (Ceratotherium simum). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30656701/),,3.1,201637,DB00537,Ciprofloxacin
,10942176,Cmax,Cmax after a 1-hour 200-mg infusion were similar to those observed during the 500 mg bid peroral regimen (2.1 +/- 0.9 mg/L vs 2.6 +/- 1.0 mg/L; p = 0.054).,Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10942176/),[mg] / [l],2.1,202123,DB00537,Ciprofloxacin
,10942176,Cmax,Cmax after a 1-hour 200-mg infusion were similar to those observed during the 500 mg bid peroral regimen (2.1 +/- 0.9 mg/L vs 2.6 +/- 1.0 mg/L; p = 0.054).,Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10942176/),[mg] / [l],2.6,202124,DB00537,Ciprofloxacin
,10942176,absolute oral bioavailability,The absolute oral bioavailability (84.1%) allowed a total body exposure 2.1-fold greater after 500 mg bid oral administration than after 200 mg bid i.v. administration (AUC(0-tau) 11.4 +/- 4.3 mg/L x h vs 5.5 +/- 1.8 mg/L x h).,Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10942176/),%,84.1,202125,DB00537,Ciprofloxacin
,10942176,AUC(0-tau),The absolute oral bioavailability (84.1%) allowed a total body exposure 2.1-fold greater after 500 mg bid oral administration than after 200 mg bid i.v. administration (AUC(0-tau) 11.4 +/- 4.3 mg/L x h vs 5.5 +/- 1.8 mg/L x h).,Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10942176/),[mg] / [h·l],11.4,202126,DB00537,Ciprofloxacin
,10942176,AUC(0-tau),The absolute oral bioavailability (84.1%) allowed a total body exposure 2.1-fold greater after 500 mg bid oral administration than after 200 mg bid i.v. administration (AUC(0-tau) 11.4 +/- 4.3 mg/L x h vs 5.5 +/- 1.8 mg/L x h).,Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10942176/),[mg] / [h·l],5.5,202127,DB00537,Ciprofloxacin
<,10942176,MIC,The results show that in malabsorption-free elderly patients a regimen of 500 mg os bid may be considered a valid therapeutic approach from the beginning of therapy for mild to moderate LRTI caused by sensitive microorganisms (MIC < 0.1 mg/L).,Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10942176/),[mg] / [l],0.1,202128,DB00537,Ciprofloxacin
,2113797,maximum concentration,"The maximum concentration in serum and the time to achieve that maximum were 6.2 +/- 2.2 micrograms/ml and 0.94 +/- 0.62 h, respectively.",Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2113797/),[μg] / [ml],6.2,202388,DB00537,Ciprofloxacin
,2113797,time to achieve that maximum,"The maximum concentration in serum and the time to achieve that maximum were 6.2 +/- 2.2 micrograms/ml and 0.94 +/- 0.62 h, respectively.",Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2113797/),h,0.94,202389,DB00537,Ciprofloxacin
,2113797,absorption half-life,"The absorption half-life, alpha half-life, beta half-life, apparent steady-state volume of distribution, apparent total body clearance, and renal clearance were 0.56 +/- 0.37 h, 0.78 +/- 0.51 h, 10.56 +/- 1.40 h, 0.85 +/- 0.31 liters/kg, 129.2 +/- 19.6 ml/min, and 53.3 +/- 16.7 ml/min, respectively.",Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2113797/),h,0.56,202390,DB00537,Ciprofloxacin
,2113797,renal clearance,"The absorption half-life, alpha half-life, beta half-life, apparent steady-state volume of distribution, apparent total body clearance, and renal clearance were 0.56 +/- 0.37 h, 0.78 +/- 0.51 h, 10.56 +/- 1.40 h, 0.85 +/- 0.31 liters/kg, 129.2 +/- 19.6 ml/min, and 53.3 +/- 16.7 ml/min, respectively.",Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2113797/),[ml] / [min],53.3,202391,DB00537,Ciprofloxacin
,11939681,total AUC:MIC ratios,"With use of composite data, total AUC:MIC ratios associated with 50%, 90%, and 99% of Emax were 34:1, 56:1, and 95:1, respectively",Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939681/),,34:1,202408,DB00537,Ciprofloxacin
,11939681,total AUC:MIC ratios,"With use of composite data, total AUC:MIC ratios associated with 50%, 90%, and 99% of Emax were 34:1, 56:1, and 95:1, respectively",Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939681/),,56:,202409,DB00537,Ciprofloxacin
,11939681,total AUC:MIC ratios,"With use of composite data, total AUC:MIC ratios associated with 50%, 90%, and 99% of Emax were 34:1, 56:1, and 95:1, respectively",Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939681/),:,95,202410,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],2.52,202837,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],4.98,202838,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],5.40,202839,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],4.59,202840,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],6.53,202841,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],8.01,202842,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],2.30,202843,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],5.41,202844,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],8.05,202845,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],6.87,202846,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],9.53,202847,DB00537,Ciprofloxacin
,2393295,maximum observed amifloxacin concentrations,"Mean +/- standard deviation maximum observed amifloxacin concentrations in plasma were 2.52 +/- 1.12, 4.98 +/- 1.44, 5.40 +/- 2.02, 4.59 +/- 2.17, 6.53 +/- 2.44, and 8.01 +/- 3.00 micrograms/ml after the initial dose and 2.30 +/- 0.98, 5.41 +/- 0.74, 8.05 +/- 1.68, 6.87 +/- 2.81, 9.53 +/- 0.50, and 11.9 +/- 1.92 micrograms/ml on day 11 of the study for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),[μg] / [ml],11.9,202848,DB00537,Ciprofloxacin
,2393295,time to the maximum observed amifloxacin concentration,"Amifloxacin was rapidly absorbed, as evidenced by the mean time to the maximum observed amifloxacin concentration of 0.98 h.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),h,0.98,202849,DB00537,Ciprofloxacin
,2393295,terminal amifloxacin half-life,Mean values for the terminal amifloxacin half-life in plasma ranged from 3.58 to 5.78 h.,Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),h,3.58 to 5.78,202850,DB00537,Ciprofloxacin
,2393295,concentrations,"Mean amifloxacin concentrations in urine on day 11 in samples collected 0 to 2 h after dosing were 105, 417, 376, 336, 518, and 464 micrograms/ml for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),,37,202851,DB00537,Ciprofloxacin
,2393295,concentrations,"Mean amifloxacin concentrations in urine on day 11 in samples collected 0 to 2 h after dosing were 105, 417, 376, 336, 518, and 464 micrograms/ml for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),,336,202852,DB00537,Ciprofloxacin
,2393295,concentrations,"Mean amifloxacin concentrations in urine on day 11 in samples collected 0 to 2 h after dosing were 105, 417, 376, 336, 518, and 464 micrograms/ml for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),,518,202853,DB00537,Ciprofloxacin
,2393295,concentrations,"Mean amifloxacin concentrations in urine on day 11 in samples collected 0 to 2 h after dosing were 105, 417, 376, 336, 518, and 464 micrograms/ml for the 200-, 400-, and 600-mg q12h and 400-, 600-, and 800-mg q8h regimens, respectively.",Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),,464,202854,DB00537,Ciprofloxacin
,2393295,amount,The mean amount of the dose excreted in the urine as amifloxacin was 53.9%.,Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393295/),,53,202855,DB00537,Ciprofloxacin
,15848296,AUC/MIC ratios,With S. pneumoniae ATCC 49619 eight-fold ranging AUC/MIC ratios (60-500 h) were simulated for each quinolone.,Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,60-500,204555,DB00537,Ciprofloxacin
,15848296,AUC/MICs,"In addition, two larger AUC/MICs, i.e., 1080 and 2150 h for ABT492 and 1460 and 3660 h for levofloxacin which correspond to 100 and 200 mg doses of ABT492 and 200 and 500 mg doses of levofloxacin, respectively, were mimicked.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1080,204556,DB00537,Ciprofloxacin
,15848296,AUC/MICs,"In addition, two larger AUC/MICs, i.e., 1080 and 2150 h for ABT492 and 1460 and 3660 h for levofloxacin which correspond to 100 and 200 mg doses of ABT492 and 200 and 500 mg doses of levofloxacin, respectively, were mimicked.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,2150,204557,DB00537,Ciprofloxacin
,15848296,AUC/MICs,"In addition, two larger AUC/MICs, i.e., 1080 and 2150 h for ABT492 and 1460 and 3660 h for levofloxacin which correspond to 100 and 200 mg doses of ABT492 and 200 and 500 mg doses of levofloxacin, respectively, were mimicked.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1460,204558,DB00537,Ciprofloxacin
,15848296,AUC/MICs,"In addition, two larger AUC/MICs, i.e., 1080 and 2150 h for ABT492 and 1460 and 3660 h for levofloxacin which correspond to 100 and 200 mg doses of ABT492 and 200 and 500 mg doses of levofloxacin, respectively, were mimicked.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,3660,204559,DB00537,Ciprofloxacin
,15848296,AUC/MIC ratios,Each ciprofloxacin-resistant organism was exposed to the clinical doses of ABT492 (400 mg) and levofloxacin (500 mg); the respective AUC/MIC ratios were from 580 to 3470 h and from 28 to 110 h.,Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,580 to 3470,204560,DB00537,Ciprofloxacin
,15848296,AUC/MIC ratios,Each ciprofloxacin-resistant organism was exposed to the clinical doses of ABT492 (400 mg) and levofloxacin (500 mg); the respective AUC/MIC ratios were from 580 to 3470 h and from 28 to 110 h.,Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,28 to 110,204561,DB00537,Ciprofloxacin
,15848296,AUC/MICs,"At comparable AUC/MICs (from 60 to 500 h), regrowth of S. pneumoniae ATCC 49619 followed initial killing, and the times to regrowth were longer with levofloxacin than ABT492.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,60 to 500,204562,DB00537,Ciprofloxacin
,15848296,AUC/MICs,"However, no regrowth of S. pneumoniae ATCC 49619 occurred at the higher AUC/MICs of ABT492 (1080 and 2150 h) and levofloxacin (1460 and 3660 h).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1080,204563,DB00537,Ciprofloxacin
,15848296,AUC/MICs,"However, no regrowth of S. pneumoniae ATCC 49619 occurred at the higher AUC/MICs of ABT492 (1080 and 2150 h) and levofloxacin (1460 and 3660 h).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,2150,204564,DB00537,Ciprofloxacin
,15848296,AUC/MICs,"However, no regrowth of S. pneumoniae ATCC 49619 occurred at the higher AUC/MICs of ABT492 (1080 and 2150 h) and levofloxacin (1460 and 3660 h).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1460,204565,DB00537,Ciprofloxacin
,15848296,AUC/MICs,"However, no regrowth of S. pneumoniae ATCC 49619 occurred at the higher AUC/MICs of ABT492 (1080 and 2150 h) and levofloxacin (1460 and 3660 h).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,3660,204566,DB00537,Ciprofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,3470,204567,DB00537,Ciprofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,2310,204568,DB00537,Ciprofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1160,204569,DB00537,Ciprofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,55,204570,DB00537,Ciprofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,110,204571,DB00537,Ciprofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,28,204572,DB00537,Ciprofloxacin
,15848296,AUC/MIC,"Regrowth of S. pneumoniae 804 was observed with both ABT492 and levofloxacin (AUC/MIC 580 and 55 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,580,204573,DB00537,Ciprofloxacin
,15848296,AUC/MIC,"Regrowth of S. pneumoniae 804 was observed with both ABT492 and levofloxacin (AUC/MIC 580 and 55 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,55,204574,DB00537,Ciprofloxacin
,18035427,C(max),"Peak ciprofloxacin plasma levels were observed at about 1h, with a mean C(max) of 1.33+/-0.96 ng/mL (range <0.5-3.45 ng/mL) and an estimated half-life of 3.0+/-1.2h.",Pharmacokinetics of CIPRODEX otic in pediatric and adolescent patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18035427/),[ng] / [ml],1.33,204670,DB00537,Ciprofloxacin
,18035427,half-life,"Peak ciprofloxacin plasma levels were observed at about 1h, with a mean C(max) of 1.33+/-0.96 ng/mL (range <0.5-3.45 ng/mL) and an estimated half-life of 3.0+/-1.2h.",Pharmacokinetics of CIPRODEX otic in pediatric and adolescent patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18035427/),h,3.0,204671,DB00537,Ciprofloxacin
,18035427,C(max),Peak dexamethasone plasma levels were observed within 2h with a mean C(max) of 0.90+/-1.04 ng/mL (range <0.05-5.10 ng/mL) and an estimated half-life of 3.9+/-2.9h.,Pharmacokinetics of CIPRODEX otic in pediatric and adolescent patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18035427/),[ng] / [ml],0.90,204672,DB00537,Ciprofloxacin
,18035427,half-life,Peak dexamethasone plasma levels were observed within 2h with a mean C(max) of 0.90+/-1.04 ng/mL (range <0.05-5.10 ng/mL) and an estimated half-life of 3.9+/-2.9h.,Pharmacokinetics of CIPRODEX otic in pediatric and adolescent patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18035427/),h,3.9,204673,DB00537,Ciprofloxacin
,10624593,fecal ciprofloxacin,"After more than 3 days of i.v. ciprofloxacin, the mean fecal ciprofloxacin concentration was 185.3 +/- 158.7 micrograms/g in patients of group A and 108.7 +/- 76.9 micrograms/g in patients without concurrent sucralfate (group B).",Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate--a microbiological and pharmacokinetic study in patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10624593/),[μg] / [g],185.,205017,DB00537,Ciprofloxacin
,10624593,fecal ciprofloxacin,"After more than 3 days of i.v. ciprofloxacin, the mean fecal ciprofloxacin concentration was 185.3 +/- 158.7 micrograms/g in patients of group A and 108.7 +/- 76.9 micrograms/g in patients without concurrent sucralfate (group B).",Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate--a microbiological and pharmacokinetic study in patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10624593/),[μg] / [g],108.7,205018,DB00537,Ciprofloxacin
,10624593,concentration,"After more than 3 days of i.v. ciprofloxacin, the mean fecal ciprofloxacin concentration was 185.3 +/- 158.7 micrograms/g in patients of group A and 108.7 +/- 76.9 micrograms/g in patients without concurrent sucralfate (group B).",Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate--a microbiological and pharmacokinetic study in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10624593/),[μg] / [g],185.,205019,DB00537,Ciprofloxacin
,10624593,concentration,"After more than 3 days of i.v. ciprofloxacin, the mean fecal ciprofloxacin concentration was 185.3 +/- 158.7 micrograms/g in patients of group A and 108.7 +/- 76.9 micrograms/g in patients without concurrent sucralfate (group B).",Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate--a microbiological and pharmacokinetic study in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10624593/),[μg] / [g],108.7,205020,DB00537,Ciprofloxacin
,8286801,Fr,"For 12 volunteers, the mean +/- SD Fr of ciprofloxacin staggered with calcium was 0.87 +/- 0.23 (noncompartmental model) and 0.98 +/- 0.27 (compartmental model).",Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8286801/),,0.87,205961,DB00537,Ciprofloxacin
,8286801,Fr,"For 12 volunteers, the mean +/- SD Fr of ciprofloxacin staggered with calcium was 0.87 +/- 0.23 (noncompartmental model) and 0.98 +/- 0.27 (compartmental model).",Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8286801/),,0.98,205962,DB00537,Ciprofloxacin
,8286801,time to maximum concentration,"Other statistically significant findings were a decrease in the time to maximum concentration of ciprofloxacin staggered with calcium in serum compared with ciprofloxacin alone (from 1.76 +/- 0.54 to 1.23 +/- 0.52 h in the noncompartmental model; p < 0.05), and a decrease in the same parameter (from 1.92 +/- 0.96 to 0.77 +/- 0.53 in the compartmental model; p < 0.005).",Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8286801/),h,1.76,205963,DB00537,Ciprofloxacin
,8286801,time to maximum concentration,"Other statistically significant findings were a decrease in the time to maximum concentration of ciprofloxacin staggered with calcium in serum compared with ciprofloxacin alone (from 1.76 +/- 0.54 to 1.23 +/- 0.52 h in the noncompartmental model; p < 0.05), and a decrease in the same parameter (from 1.92 +/- 0.96 to 0.77 +/- 0.53 in the compartmental model; p < 0.005).",Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8286801/),h,1.23,205964,DB00537,Ciprofloxacin
,8286801,time to maximum concentration,"Other statistically significant findings were a decrease in the time to maximum concentration of ciprofloxacin staggered with calcium in serum compared with ciprofloxacin alone (from 1.76 +/- 0.54 to 1.23 +/- 0.52 h in the noncompartmental model; p < 0.05), and a decrease in the same parameter (from 1.92 +/- 0.96 to 0.77 +/- 0.53 in the compartmental model; p < 0.005).",Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8286801/),,1.92,205965,DB00537,Ciprofloxacin
,8286801,time to maximum concentration,"Other statistically significant findings were a decrease in the time to maximum concentration of ciprofloxacin staggered with calcium in serum compared with ciprofloxacin alone (from 1.76 +/- 0.54 to 1.23 +/- 0.52 h in the noncompartmental model; p < 0.05), and a decrease in the same parameter (from 1.92 +/- 0.96 to 0.77 +/- 0.53 in the compartmental model; p < 0.005).",Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8286801/),,0.77,205966,DB00537,Ciprofloxacin
,8286801,Maximum concentration,"Maximum concentration of ciprofloxacin staggered with calcium was decreased in the noncompartmental model compared with ciprofloxacin alone (from 2.11 +/- 0.72 to 1.60 +/- 0.33, respectively; p < 0.05).",Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8286801/),,2.11,205967,DB00537,Ciprofloxacin
,8286801,Maximum concentration,"Maximum concentration of ciprofloxacin staggered with calcium was decreased in the noncompartmental model compared with ciprofloxacin alone (from 2.11 +/- 0.72 to 1.60 +/- 0.33, respectively; p < 0.05).",Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8286801/),,1.60,205968,DB00537,Ciprofloxacin
,3372029,Maximal serum concentrations,"Maximal serum concentrations of 6 and 4 mg/l, respectively, were recorded immediately after infusion.",Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3372029/),[mg] / [l],6,206542,DB00537,Ciprofloxacin
,3372029,Maximal serum concentrations,"Maximal serum concentrations of 6 and 4 mg/l, respectively, were recorded immediately after infusion.",Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3372029/),[mg] / [l],4,206543,DB00537,Ciprofloxacin
,3372029,serum concentrations,After 2 h serum concentrations ranged from 0.6 to 1.3 mg/l in both groups.,Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3372029/),[mg] / [l],0.6 to 1.3,206544,DB00537,Ciprofloxacin
less,3372029,MIC,"The tissue concentrations obtained provide a full antibacterial coverage for gynecological infections, since the MIC for the most pathogenic bacteria is less than 1 mg/l.",Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3372029/),[mg] / [l],1,206545,DB00537,Ciprofloxacin
,3438149,peak serum levels,The mean peak serum levels after 200 mg i.v. were 3.5 mg/l measured 0.5 hour after the gift.,Influence of haemodialysis on the pharmacokinetics of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438149/),[mg] / [l],3.5,207005,DB00537,Ciprofloxacin
,3438149,peak serum level,After an oral dose of 250 mg the mean peak serum level measured one hour after the gift amounted to 1.5 mg/l.,Influence of haemodialysis on the pharmacokinetics of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438149/),[mg] / [l],1.5,207006,DB00537,Ciprofloxacin
,3438149,serum half life,The serum half life was 8.5 h without dialysis and 5.5 h with dialysis.,Influence of haemodialysis on the pharmacokinetics of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438149/),h,8.5,207007,DB00537,Ciprofloxacin
,3438149,serum half life,The serum half life was 8.5 h without dialysis and 5.5 h with dialysis.,Influence of haemodialysis on the pharmacokinetics of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438149/),h,5.5,207008,DB00537,Ciprofloxacin
,22814020,MIC,"The aim of the study was a comparison of concentrations and pharmacokinetics for ciprofloxacin at steady-state in patients after total and partial nephrectomy and evaluation of the effectiveness of the iv dose 200 mg/24 h against the theoretical value of MIC, 0.5 μg/ml.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[μg] / [ml],0.5,207190,DB00537,Ciprofloxacin
,22814020,CL(CR),"The research was carried out on two groups of patients after nephrectomy: total (group 1, n = 21; mean [SD], age, 62.9 [14.4] years; weight, 76.0 [14.6] kg; creatinine clearance, CL(CR), 90.7 [22.2] ml/min) and partial (group 2, n = 15; 61.7 [9.3] years; 87.8 [16.4] kg; CL(CR), 107.8 [36.4] ml/min).",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[ml] / [min],107.8,207191,DB00537,Ciprofloxacin
,22814020,C(ss)(max),"The mean values of plasma concentrations of ciprofloxacin at steady state in group 1 and 2 were: C(ss)(max), 2.012 and 1.345; C(ss)(min), 0.437 and 0.244 μg/ml, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),,2.012,207192,DB00537,Ciprofloxacin
,22814020,C(ss)(max),"The mean values of plasma concentrations of ciprofloxacin at steady state in group 1 and 2 were: C(ss)(max), 2.012 and 1.345; C(ss)(min), 0.437 and 0.244 μg/ml, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),,1.345,207193,DB00537,Ciprofloxacin
,22814020,C(ss),"The mean values of plasma concentrations of ciprofloxacin at steady state in group 1 and 2 were: C(ss)(max), 2.012 and 1.345; C(ss)(min), 0.437 and 0.244 μg/ml, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[μg] / [ml],0.437,207194,DB00537,Ciprofloxacin
,22814020,C(ss),"The mean values of plasma concentrations of ciprofloxacin at steady state in group 1 and 2 were: C(ss)(max), 2.012 and 1.345; C(ss)(min), 0.437 and 0.244 μg/ml, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[μg] / [ml],0.244,207195,DB00537,Ciprofloxacin
,22814020,AUC((0-last)),"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[h·μg] / [ml],30.9,207196,DB00537,Ciprofloxacin
,22814020,AUC((0-last)),"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[h·μg] / [ml],19.5,207197,DB00537,Ciprofloxacin
,22814020,AUMC((0-last)),"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[h(2·μg] / [ml],177.91,207198,DB00537,Ciprofloxacin
,22814020,AUMC((0-last)),"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[h(2·μg] / [ml],91.9,207199,DB00537,Ciprofloxacin
,22814020,t(1/2β),"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),h,13.9,207200,DB00537,Ciprofloxacin
,22814020,t(1/2β),"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),h,9.8,207201,DB00537,Ciprofloxacin
,22814020,MRT,"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),h,16.5,207202,DB00537,Ciprofloxacin
,22814020,MRT,"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),h,9.77,207203,DB00537,Ciprofloxacin
,22814020,V(d),"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),l,115.0,207204,DB00537,Ciprofloxacin
,22814020,V(d),"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),l,142.2,207205,DB00537,Ciprofloxacin
,22814020,CL,"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[l] / [h],6.2,207206,DB00537,Ciprofloxacin
,22814020,CL,"The main pharmacokinetic parameters for ciprofloxacin in group 1 and 2 were as follows: AUC((0-last)), 30.9 [17.9] and 19.5 [8.7] μg h/ml; AUMC((0-last)), 177.91 [11.1] and 91.9 [66.5] μg h(2)/ml; t(1/2β), 13.9 [7.7] and 9.8 [3.3] h; MRT, 16.5 [12.1] and 9.77 [5.4] h; V(d), 115.0 [67.2] and 142.2 [78.7] l; CL, 6.2 [3.3] and 10.8 [5.7] l/h, respectively.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[l] / [h],10.8,207207,DB00537,Ciprofloxacin
,22814020,MIC,"With the assumed MIC = 0.5 μg/ml, the values of C(ss)(max)/MIC < 10 and AUC/MIC < 125 were obtained in all the patients.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),[μg] / [ml],0.5,207208,DB00537,Ciprofloxacin
<,22814020,C(ss)(max)/MIC,"With the assumed MIC = 0.5 μg/ml, the values of C(ss)(max)/MIC < 10 and AUC/MIC < 125 were obtained in all the patients.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),,10,207209,DB00537,Ciprofloxacin
<,22814020,AUC/MIC,"With the assumed MIC = 0.5 μg/ml, the values of C(ss)(max)/MIC < 10 and AUC/MIC < 125 were obtained in all the patients.",Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814020/),,125,207210,DB00537,Ciprofloxacin
≥,34160669,AUC0-24 h/MIC ratio,Monte Carlo simulations investigated dosing regimens to achieve a target AUC0-24 h/MIC ratio ≥ 125.,Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34160669/),,125,207987,DB00537,Ciprofloxacin
≤,34160669,MICs,"The recommended IV dose of 10 mg/kg q8h, not exceeding 400 mg q8h, would achieve AUC0-24 h to successfully treat bacteria with MICs ≤ 0.25 (e.g. Salmonella, Escherichia coli, Proteus, Haemophilus, Enterobacter, and Klebsiella).",Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34160669/),,0.25,207988,DB00537,Ciprofloxacin
≤,34160669,MICs,The oral recommended dose of 20 mg/kg q12h (not exceeding 750 mg) would cover bacteria with MICs ≤ 0.125 but may be insufficient for bacteria with higher MIC and a dose increase according bodyweight and eGFR would be needed.,Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34160669/),,0.125,207989,DB00537,Ciprofloxacin
,30085856,peak plasma concentration,"For total fluoroquinolones (enrofloxacin and ciprofloxacin), the mean (range) of peak plasma concentration, time to maximum plasma concentration, and terminal half-life after SC administration were 4.90 μg/mL (3.44 to 6.08 μg/mL), 1.59 hours (0.5 to 2.00 hours), and 4.63 hours (4.02 to 5.20 hours), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin following single-dose subcutaneous injection in black-tailed prairie dogs (Cynomys ludovicianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085856/),[μg] / [ml],4.90,208213,DB00537,Ciprofloxacin
,30085856,time to maximum plasma concentration,"For total fluoroquinolones (enrofloxacin and ciprofloxacin), the mean (range) of peak plasma concentration, time to maximum plasma concentration, and terminal half-life after SC administration were 4.90 μg/mL (3.44 to 6.08 μg/mL), 1.59 hours (0.5 to 2.00 hours), and 4.63 hours (4.02 to 5.20 hours), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin following single-dose subcutaneous injection in black-tailed prairie dogs (Cynomys ludovicianus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085856/),h,1.59,208214,DB00537,Ciprofloxacin
,30085856,terminal half-life,"For total fluoroquinolones (enrofloxacin and ciprofloxacin), the mean (range) of peak plasma concentration, time to maximum plasma concentration, and terminal half-life after SC administration were 4.90 μg/mL (3.44 to 6.08 μg/mL), 1.59 hours (0.5 to 2.00 hours), and 4.63 hours (4.02 to 5.20 hours), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin following single-dose subcutaneous injection in black-tailed prairie dogs (Cynomys ludovicianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085856/),h,4.63,208215,DB00537,Ciprofloxacin
≤,30085856,minimum inhibitory concentration,"Results indicated that administration of enrofloxacin (20 mg/kg, SC, q 24 h) in black-tailed prairie dogs may be appropriate for treatment of infections with bacteria for which the minimum inhibitory concentration of enrofloxacin is ≤ 0.5 μg/mL.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin following single-dose subcutaneous injection in black-tailed prairie dogs (Cynomys ludovicianus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085856/),[μg] / [ml],0.5,208216,DB00537,Ciprofloxacin
,3619432,Bioavailability,"Bioavailability at the two doses was similar: 69 and 69.1% for the 200- and 750-mg doses, respectively.",Effect of dose size on bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619432/),%,69,208935,DB00537,Ciprofloxacin
,3619432,Bioavailability,"Bioavailability at the two doses was similar: 69 and 69.1% for the 200- and 750-mg doses, respectively.",Effect of dose size on bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619432/),%,69.1,208936,DB00537,Ciprofloxacin
,2116256,Cmax,"In healthy subjects, Cmax was 6.8 +/- 0.7 mg/L; tmax = about 1h, t1/2 = 14 +/- 2h, total clearance = 4.86 +/- 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 +/- 4% (HPLC).","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),[mg] / [l],6.8,209034,DB00537,Ciprofloxacin
,2116256,tmax,"In healthy subjects, Cmax was 6.8 +/- 0.7 mg/L; tmax = about 1h, t1/2 = 14 +/- 2h, total clearance = 4.86 +/- 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 +/- 4% (HPLC).","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),h,1,209035,DB00537,Ciprofloxacin
,2116256,t1/2,"In healthy subjects, Cmax was 6.8 +/- 0.7 mg/L; tmax = about 1h, t1/2 = 14 +/- 2h, total clearance = 4.86 +/- 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 +/- 4% (HPLC).","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),h,14,209036,DB00537,Ciprofloxacin
,2116256,total clearance,"In healthy subjects, Cmax was 6.8 +/- 0.7 mg/L; tmax = about 1h, t1/2 = 14 +/- 2h, total clearance = 4.86 +/- 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 +/- 4% (HPLC).","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),[l] / [h],4.86,209037,DB00537,Ciprofloxacin
,2116256,Dialysance,Dialysance of fleroxacin and of its metabolites was approximately 3.6 to 4.8 L/h.,"Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),[l] / [h],3.6 to 4.8,209038,DB00537,Ciprofloxacin
,3157705,peak serum levels,"Mean peak serum levels were 1.45 micrograms/mL and 2.46 micrograms/mL for 250-mg and 500-mg doses, and time to peak was 1 and 1.3 hours.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),[μg] / [ml],1.45,209132,DB00537,Ciprofloxacin
,3157705,peak serum levels,"Mean peak serum levels were 1.45 micrograms/mL and 2.46 micrograms/mL for 250-mg and 500-mg doses, and time to peak was 1 and 1.3 hours.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),[μg] / [ml],2.46,209133,DB00537,Ciprofloxacin
,3157705,time to peak,"Mean peak serum levels were 1.45 micrograms/mL and 2.46 micrograms/mL for 250-mg and 500-mg doses, and time to peak was 1 and 1.3 hours.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),h,1,209134,DB00537,Ciprofloxacin
,3157705,time to peak,"Mean peak serum levels were 1.45 micrograms/mL and 2.46 micrograms/mL for 250-mg and 500-mg doses, and time to peak was 1 and 1.3 hours.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),h,1.3,209135,DB00537,Ciprofloxacin
,3157705,Half-life (T1/2)alpha,"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),,0.32,209136,DB00537,Ciprofloxacin
,3157705,Half-life (T1/2)alpha,"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),,0.43,209137,DB00537,Ciprofloxacin
,3157705,T1/2 beta,"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),,3.97,209138,DB00537,Ciprofloxacin
,3157705,T1/2 beta,"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),,4.15,209139,DB00537,Ciprofloxacin
,3157705,volume of distribution (area),"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),l,80,209140,DB00537,Ciprofloxacin
,3157705,volume of distribution (area),"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),l,90,209141,DB00537,Ciprofloxacin
,3157705,Area under the concentration curve (AUC),Area under the concentration curve (AUC) was 5.65 h X micrograms/mL and 10.37h X micrograms/mL.,The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),[h·μg] / [ml],5.65,209142,DB00537,Ciprofloxacin
,3157705,Area under the concentration curve (AUC),Area under the concentration curve (AUC) was 5.65 h X micrograms/mL and 10.37h X micrograms/mL.,The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),[h·μg] / [ml],10.37,209143,DB00537,Ciprofloxacin
,3157705,Serum clearance,Serum clearance was 23L for both doses.,The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),l,23,209144,DB00537,Ciprofloxacin
,23464606,half-life,"Considering a maximum residue limit of 100 μg/kg for the sum of the ENR and CIP residues in the fillet, the results obtained in the depletion study allowed the estimation of a half-life for ENR of 2.75 days and a withdrawal period of 23 days.",Depletion study and estimation of the withdrawal period for enrofloxacin in pacu (Piaractus mesopotamicus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23464606/),d,2.75,209235,DB00537,Ciprofloxacin
,17057790,half-life,The concentration of intravitreal moxifloxacin showed an exponential decay with a half-life of 1.72 hours.,Intravitreal clearance of moxifloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17057790/),h,1.72,209750,DB00537,Ciprofloxacin
,6489328,Renal clearance,Renal clearance averaged 5 ml/min X kg.,Dose- and sex-independent disposition of ciprofloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489328/),[ml] / [kg·min],5,209784,DB00537,Ciprofloxacin
,12584678,Maximum concentration (Cmax),"Maximum concentration (Cmax) was 2.12 +/- 0.59, 2.1 +/- 0.34, and 4.74 +/- 1.05 mcg/ml for enrofloxacin and 1.30 +/- 0.31, 1.30 +/- 0.32, and 1.86 +/- 0.35 mcg/ml for ciprofloxacin when enrofloxacin was given at dosages of 7.5, 10, and 20 mg/kg, respectively.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),[mcg] / [ml],2.12,209843,DB00537,Ciprofloxacin
,12584678,Maximum concentration (Cmax),"Maximum concentration (Cmax) was 2.12 +/- 0.59, 2.1 +/- 0.34, and 4.74 +/- 1.05 mcg/ml for enrofloxacin and 1.30 +/- 0.31, 1.30 +/- 0.32, and 1.86 +/- 0.35 mcg/ml for ciprofloxacin when enrofloxacin was given at dosages of 7.5, 10, and 20 mg/kg, respectively.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),[mcg] / [ml],2.1,209844,DB00537,Ciprofloxacin
,12584678,Maximum concentration (Cmax),"Maximum concentration (Cmax) was 2.12 +/- 0.59, 2.1 +/- 0.34, and 4.74 +/- 1.05 mcg/ml for enrofloxacin and 1.30 +/- 0.31, 1.30 +/- 0.32, and 1.86 +/- 0.35 mcg/ml for ciprofloxacin when enrofloxacin was given at dosages of 7.5, 10, and 20 mg/kg, respectively.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),[mcg] / [ml],4.74,209845,DB00537,Ciprofloxacin
,12584678,Maximum concentration (Cmax),"Maximum concentration (Cmax) was 2.12 +/- 0.59, 2.1 +/- 0.34, and 4.74 +/- 1.05 mcg/ml for enrofloxacin and 1.30 +/- 0.31, 1.30 +/- 0.32, and 1.86 +/- 0.35 mcg/ml for ciprofloxacin when enrofloxacin was given at dosages of 7.5, 10, and 20 mg/kg, respectively.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),[mcg] / [ml],1.30,209846,DB00537,Ciprofloxacin
,12584678,Maximum concentration (Cmax),"Maximum concentration (Cmax) was 2.12 +/- 0.59, 2.1 +/- 0.34, and 4.74 +/- 1.05 mcg/ml for enrofloxacin and 1.30 +/- 0.31, 1.30 +/- 0.32, and 1.86 +/- 0.35 mcg/ml for ciprofloxacin when enrofloxacin was given at dosages of 7.5, 10, and 20 mg/kg, respectively.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),[mcg] / [ml],1.30,209847,DB00537,Ciprofloxacin
,12584678,Maximum concentration (Cmax),"Maximum concentration (Cmax) was 2.12 +/- 0.59, 2.1 +/- 0.34, and 4.74 +/- 1.05 mcg/ml for enrofloxacin and 1.30 +/- 0.31, 1.30 +/- 0.32, and 1.86 +/- 0.35 mcg/ml for ciprofloxacin when enrofloxacin was given at dosages of 7.5, 10, and 20 mg/kg, respectively.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),[mcg] / [ml],1.86,209848,DB00537,Ciprofloxacin
,12584678,Disappearance half-life,"Disappearance half-life was similar for all dosages, ranging from 4.6 to 5.2 hours for enrofloxacin and 8.8 to 10.7 hours for ciprofloxacin.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),h,4.6 to 5.2,209849,DB00537,Ciprofloxacin
,12584678,Disappearance half-life,"Disappearance half-life was similar for all dosages, ranging from 4.6 to 5.2 hours for enrofloxacin and 8.8 to 10.7 hours for ciprofloxacin.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),h,8.8 to 10.7,209850,DB00537,Ciprofloxacin
,12584678,minimum inhibitory concentration (MIC),"For organisms with a minimum inhibitory concentration (MIC) of 0.5 mcg enrofloxacin/ml, an inhibitory quotient (IQ; Cmax:MIC) of 8 or more was achieved in plasma only at 20 mg/kg.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),mcg,0.5,209851,DB00537,Ciprofloxacin
,12584678,inhibitory quotient (IQ; Cmax:MIC),"For organisms with a minimum inhibitory concentration (MIC) of 0.5 mcg enrofloxacin/ml, an inhibitory quotient (IQ; Cmax:MIC) of 8 or more was achieved in plasma only at 20 mg/kg.","Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584678/),,8,209852,DB00537,Ciprofloxacin
,2393263,bioavailability,"The overall mean (standard deviation) bioavailability observed was 63.4% (14.6%), similar to that observed in those with normal renal function (69.0% [15.7%]).",Effect of renal function on the bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393263/),%,63.4,209961,DB00537,Ciprofloxacin
,2393263,bioavailability,"The overall mean (standard deviation) bioavailability observed was 63.4% (14.6%), similar to that observed in those with normal renal function (69.0% [15.7%]).",Effect of renal function on the bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393263/),%,69.0,209962,DB00537,Ciprofloxacin
,2393263,bioavailability,The mean bioavailability in the subgroup of subjects with renal insufficiency was 59.9% (13.3%).,Effect of renal function on the bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393263/),%,59.9,209963,DB00537,Ciprofloxacin
,2393263,bioavailability,The observed range in bioavailability was 33.9 to 91.4%.,Effect of renal function on the bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393263/),%,33.9 to 91.4,209964,DB00537,Ciprofloxacin
,9499632,elimination half-life (t0.5 beta),The elimination half-life (t0.5 beta) was 2.78 +/- 0.08 hours.,Disposition kinetics of ciprofloxacin in lactating goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499632/),h,2.78,210044,DB00537,Ciprofloxacin
,9499632,serum protein binding,The extent of serum protein binding of ciprofloxacin in goats was 14.2 +/- 1.4%.,Disposition kinetics of ciprofloxacin in lactating goats. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499632/),%,14.2,210045,DB00537,Ciprofloxacin
,9499632,Volume of distribution at steady-state,Volume of distribution at steady-state was 2.14 +/- 0.07 L/kg.,Disposition kinetics of ciprofloxacin in lactating goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499632/),[l] / [kg],2.14,210046,DB00537,Ciprofloxacin
,9499632,Total body clearance,Total body clearance of ciprofloxacin in goats was 14.7 +/- 0.43 ml/min/kg.,Disposition kinetics of ciprofloxacin in lactating goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499632/),[ml] / [kg·min],14.7,210047,DB00537,Ciprofloxacin
,9499632,peak serum concentration,"Following a single intramuscular administration, ciprofloxacin was rapidly absorbed and the mean peak serum concentration (1.92 +/- 0.05 micrograms ml-1) was achieved 1 hour post administration.",Disposition kinetics of ciprofloxacin in lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499632/),[μg] / [ml],1.92,210048,DB00537,Ciprofloxacin
,9499632,systemic availability,The systemic availability of ciprofloxacin after intramuscular administration was 95.9 +/- 6.4%.,Disposition kinetics of ciprofloxacin in lactating goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499632/),%,95.9,210049,DB00537,Ciprofloxacin
,18716443,elimination rate constant (beta),"The elimination rate constant (beta) and elimination half-life (t1/2beta) were 0.446 +/- 0.04 h(-1) and 1.630 +/- 0.17 h, espectively.",Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716443/),1/[h],0.446,210526,DB00537,Ciprofloxacin
,18716443,elimination half-life (t1/2beta),"The elimination rate constant (beta) and elimination half-life (t1/2beta) were 0.446 +/- 0.04 h(-1) and 1.630 +/- 0.17 h, espectively.",Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716443/),h,1.630,210527,DB00537,Ciprofloxacin
,18716443,apparent volume of distribution at steady state (Vdss),The apparent volume of distribution at steady state (Vdss) was 2.012 +/- 0.37 l/kg and the total body clearance (ClB) was 16.27 +/- 1.87 ml/min/kg.,Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716443/),[l] / [kg],2.012,210528,DB00537,Ciprofloxacin
,18716443,total body clearance (ClB),The apparent volume of distribution at steady state (Vdss) was 2.012 +/- 0.37 l/kg and the total body clearance (ClB) was 16.27 +/- 1.87 ml/min/kg.,Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716443/),[ml] / [kg·min],16.27,210529,DB00537,Ciprofloxacin
,18716443,Urinary recovery,Urinary recovery of ciprofloxacin was 29.70% +/- 10.34% of the administered dose within 36 h post administration.,Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716443/),%,29.70,210530,DB00537,Ciprofloxacin
,18716443,serum protein binding,In vitro serum protein binding was 41% +/- 13.10%.,Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716443/),%,41,210531,DB00537,Ciprofloxacin
≥,23587780,%ƒT>MIC,"The probability of target attainment (PTA) was the proportion of cases achieving a %ƒT>MIC ≥ 50% for cefepime, meropenem and piperacillin/tazobactam, an ƒAUC/MIC ≥ 90 for ciprofloxacin and the aminoglycosides, and a total AUC/MIC ≥ 60 for colistin.","Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23587780/),%,50,210549,DB00537,Ciprofloxacin
≥,23587780,ƒAUC/MIC,"The probability of target attainment (PTA) was the proportion of cases achieving a %ƒT>MIC ≥ 50% for cefepime, meropenem and piperacillin/tazobactam, an ƒAUC/MIC ≥ 90 for ciprofloxacin and the aminoglycosides, and a total AUC/MIC ≥ 60 for colistin.","Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23587780/),,90,210550,DB00537,Ciprofloxacin
≥,23587780,total AUC/MIC,"The probability of target attainment (PTA) was the proportion of cases achieving a %ƒT>MIC ≥ 50% for cefepime, meropenem and piperacillin/tazobactam, an ƒAUC/MIC ≥ 90 for ciprofloxacin and the aminoglycosides, and a total AUC/MIC ≥ 60 for colistin.","Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23587780/),,60,210551,DB00537,Ciprofloxacin
,12423224,terminal half-life (t(1/2)),"In plasma, enrofloxacin had a terminal half-life (t(1/2)), volume of distribution (area method), and systemic clearance of 6.7 +/- 2.9 h, 1.9 +/- 0.4 L/kg, and 3.7 +/- 1.4 mL/kg/min, respectively.",Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),h,6.7,211291,DB00537,Ciprofloxacin
,12423224,volume of distribution (area method,"In plasma, enrofloxacin had a terminal half-life (t(1/2)), volume of distribution (area method), and systemic clearance of 6.7 +/- 2.9 h, 1.9 +/- 0.4 L/kg, and 3.7 +/- 1.4 mL/kg/min, respectively.",Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),[l] / [kg],1.9,211292,DB00537,Ciprofloxacin
,12423224,systemic clearance,"In plasma, enrofloxacin had a terminal half-life (t(1/2)), volume of distribution (area method), and systemic clearance of 6.7 +/- 2.9 h, 1.9 +/- 0.4 L/kg, and 3.7 +/- 1.4 mL/kg/min, respectively.",Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),[ml] / [kg·min],3.7,211293,DB00537,Ciprofloxacin
,12423224,maximum plasma concentration (Cmax),Ciprofloxacin had a maximum plasma concentration (Cmax) of 0.28 +/- 0.09 microg/mL.,Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),[μg] / [ml],0.28,211294,DB00537,Ciprofloxacin
,12423224,Cmax,"In endometrial tissue, the enrofloxacin Cmax was 1.7 +/- 0.5 microg/g, and the t(1/2) was 7.8 +/- 3.7 h.",Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),[μg] / [g],1.7,211295,DB00537,Ciprofloxacin
,12423224,t(1/2),"In endometrial tissue, the enrofloxacin Cmax was 1.7 +/- 0.5 microg/g, and the t(1/2) was 7.8 +/- 3.7 h.",Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),h,7.8,211296,DB00537,Ciprofloxacin
,12423224,Cmax,Ciprofloxacin Cmax in tissues was 0.15 +/- 0.04 microg/g and the t(1/2) was 5.2 +/- 2.0 h.,Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),[μg] / [g],0.15,211297,DB00537,Ciprofloxacin
,12423224,t(1/2),Ciprofloxacin Cmax in tissues was 0.15 +/- 0.04 microg/g and the t(1/2) was 5.2 +/- 2.0 h.,Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),h,5.2,211298,DB00537,Ciprofloxacin
,12423224,concentration ratios (w/w:w/v,"The tissue:plasma enrofloxacin concentration ratios (w/w:w/v) were 0.175 +/- 0.08 and 0.47 +/- 0.06 for Cmax and AUC, respectively.",Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),,0.175,211299,DB00537,Ciprofloxacin
,12423224,concentration ratios (w/w:w/v,"The tissue:plasma enrofloxacin concentration ratios (w/w:w/v) were 0.175 +/- 0.08 and 0.47 +/- 0.06 for Cmax and AUC, respectively.",Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423224/),,0.47,211300,DB00537,Ciprofloxacin
,21913941,plasma half-life,"The mean ± SD enrofloxacin plasma half-life, volume of distribution, clearance, and peak concentration were 26.6 ± 6.2 h (harmonic mean), 6.4 ± 1.2 L/kg, 0.18 ± 0.08 L/kg/h, and 1.1 ± 0.3 μg/mL, respectively.","Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913941/),h,26.6,211532,DB00537,Ciprofloxacin
,21913941,volume of distribution,"The mean ± SD enrofloxacin plasma half-life, volume of distribution, clearance, and peak concentration were 26.6 ± 6.2 h (harmonic mean), 6.4 ± 1.2 L/kg, 0.18 ± 0.08 L/kg/h, and 1.1 ± 0.3 μg/mL, respectively.","Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913941/),[l] / [kg],6.4,211533,DB00537,Ciprofloxacin
,21913941,clearance,"The mean ± SD enrofloxacin plasma half-life, volume of distribution, clearance, and peak concentration were 26.6 ± 6.2 h (harmonic mean), 6.4 ± 1.2 L/kg, 0.18 ± 0.08 L/kg/h, and 1.1 ± 0.3 μg/mL, respectively.","Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913941/),[l] / [kg],6.4,211534,DB00537,Ciprofloxacin
,21913941,peak concentration,"The mean ± SD enrofloxacin plasma half-life, volume of distribution, clearance, and peak concentration were 26.6 ± 6.2 h (harmonic mean), 6.4 ± 1.2 L/kg, 0.18 ± 0.08 L/kg/h, and 1.1 ± 0.3 μg/mL, respectively.","Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913941/),[μg] / [ml],1.1,211535,DB00537,Ciprofloxacin
,21913941,half-life,"The half-life of enrofloxacin from the tissues was 23.6 h, and the maximum concentration was 1.26 μg/mL.","Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913941/),h,23.6,211536,DB00537,Ciprofloxacin
,21913941,maximum concentration,"The half-life of enrofloxacin from the tissues was 23.6 h, and the maximum concentration was 1.26 μg/mL.","Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913941/),[μg] / [ml],1.26,211537,DB00537,Ciprofloxacin
,21913941,Plasma protein binding,"Plasma protein binding was 31.1% and 37.13% for high and low concentrations, respectively.","Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913941/),%,31.1,211538,DB00537,Ciprofloxacin
,21913941,Plasma protein binding,"Plasma protein binding was 31.1% and 37.13% for high and low concentrations, respectively.","Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913941/),%,37.13,211539,DB00537,Ciprofloxacin
,17499154,T(max),"However, a delay in T(max) was observed in the exposed group (from 0.16(+/-0.003) to 0.37(+/-0.14)h).",The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),h,0.16,211681,DB00537,Ciprofloxacin
,17499154,T(max),"However, a delay in T(max) was observed in the exposed group (from 0.16(+/-0.003) to 0.37(+/-0.14)h).",The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),h,0.37,211682,DB00537,Ciprofloxacin
,17499154,t(1/2),"A small, but significant increase in t(1/2) (p<0.05) was detected (1.74(+/-0.25) vs. 1.45(+/-0.12)h).",The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),h,1.74,211683,DB00537,Ciprofloxacin
,17499154,t(1/2),"A small, but significant increase in t(1/2) (p<0.05) was detected (1.74(+/-0.25) vs. 1.45(+/-0.12)h).",The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),h,1.45,211684,DB00537,Ciprofloxacin
,17499154,CL/F,A significant reduction (p<0.05) of CL/F from 30.54(+/-1.9) to 24.01(+/-3.81)mL/min/kg was seen in the treated group.,The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),[ml] / [kg·min],30.54,211685,DB00537,Ciprofloxacin
,17499154,CL/F,A significant reduction (p<0.05) of CL/F from 30.54(+/-1.9) to 24.01(+/-3.81)mL/min/kg was seen in the treated group.,The effect of chronic cadmium exposure on the pharmacokinetics of theophylline and ciprofloxacin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499154/),[ml] / [kg·min],24.01,211686,DB00537,Ciprofloxacin
,23859001,AUC(24)/MPC ratios,"Urine AUC(24)/MPC ratios considering ciprofloxacin concentrations ranged 3819-7767, indicating that selection of resistant E. coli mutants in dogs with uncomplicated UTIs is unlikely in the bladder given that an AUC(24)/MPC = 39 is considered to be protective against mutant selection for ciprofloxacin.",Fluoroquinolone levels in healthy dog urine following a 20-mg/kg oral dose of enrofloxacin exceed mutant prevention concentration targets against Escherichia coli isolated from canine urinary tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23859001/),,3819-7767,211748,DB00537,Ciprofloxacin
,23859001,AUC(24)/MPC,"Urine AUC(24)/MPC ratios considering ciprofloxacin concentrations ranged 3819-7767, indicating that selection of resistant E. coli mutants in dogs with uncomplicated UTIs is unlikely in the bladder given that an AUC(24)/MPC = 39 is considered to be protective against mutant selection for ciprofloxacin.",Fluoroquinolone levels in healthy dog urine following a 20-mg/kg oral dose of enrofloxacin exceed mutant prevention concentration targets against Escherichia coli isolated from canine urinary tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23859001/),,39,211749,DB00537,Ciprofloxacin
,3443151,clearance,Total theophylline clearance fell from 2.3 l.h-1 to 0.8 l.h-1 when ciprofloxacin was added to the treatment regimen and returned to 2.1 l.h-1 after ciprofloxacin was discontinued.,A clinically significant interaction between ciprofloxacin and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443151/),[l] / [h],2.3,212122,DB00537,Ciprofloxacin
,3443151,clearance,Total theophylline clearance fell from 2.3 l.h-1 to 0.8 l.h-1 when ciprofloxacin was added to the treatment regimen and returned to 2.1 l.h-1 after ciprofloxacin was discontinued.,A clinically significant interaction between ciprofloxacin and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443151/),[l] / [h],0.8,212123,DB00537,Ciprofloxacin
,3443151,clearance,Total theophylline clearance fell from 2.3 l.h-1 to 0.8 l.h-1 when ciprofloxacin was added to the treatment regimen and returned to 2.1 l.h-1 after ciprofloxacin was discontinued.,A clinically significant interaction between ciprofloxacin and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443151/),[l] / [h],2.1,212124,DB00537,Ciprofloxacin
,25622984,Cmax,"Following oral administration, plasma concentrations were of therapeutic relevance (Cmax median 5.45 μg/mL, range 2.98-6.9 μg/mL), with terminal-phase half-life (t½ ) shorter than in other species (median 3.09 h, range 1.79-5.30 h).",Pharmacokinetics of enrofloxacin following oral and subcutaneous administration in the common ringtail possum (Pseudocheirus peregrinus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622984/),[μg] / [ml],5.45,212522,DB00537,Ciprofloxacin
,25622984,terminal-phase half-life (t½ ),"Following oral administration, plasma concentrations were of therapeutic relevance (Cmax median 5.45 μg/mL, range 2.98-6.9 μg/mL), with terminal-phase half-life (t½ ) shorter than in other species (median 3.09 h, range 1.79-5.30 h).",Pharmacokinetics of enrofloxacin following oral and subcutaneous administration in the common ringtail possum (Pseudocheirus peregrinus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622984/),h,3.09,212523,DB00537,Ciprofloxacin
,3800345,peak levels,"The means of the individual peak levels for the 200-, 400-, and 600-mg groups were 2.17, 4.09, and 6.12 micrograms/ml, respectively.",Difloxacin metabolism and pharmacokinetics in humans after single oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800345/),[μg] / [ml],2.17,212699,DB00537,Ciprofloxacin
,3800345,peak levels,"The means of the individual peak levels for the 200-, 400-, and 600-mg groups were 2.17, 4.09, and 6.12 micrograms/ml, respectively.",Difloxacin metabolism and pharmacokinetics in humans after single oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800345/),[μg] / [ml],4.09,212700,DB00537,Ciprofloxacin
,3800345,peak levels,"The means of the individual peak levels for the 200-, 400-, and 600-mg groups were 2.17, 4.09, and 6.12 micrograms/ml, respectively.",Difloxacin metabolism and pharmacokinetics in humans after single oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800345/),[μg] / [ml],6.12,212701,DB00537,Ciprofloxacin
,3800345,terminal-phase half-lives,"The mean respective terminal-phase half-lives were 20.6, 27.1, and 28.8 h; the mean half-life for all subjects was 25.7 h.",Difloxacin metabolism and pharmacokinetics in humans after single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800345/),h,20.6,212702,DB00537,Ciprofloxacin
,3800345,terminal-phase half-lives,"The mean respective terminal-phase half-lives were 20.6, 27.1, and 28.8 h; the mean half-life for all subjects was 25.7 h.",Difloxacin metabolism and pharmacokinetics in humans after single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800345/),h,27.1,212703,DB00537,Ciprofloxacin
,3800345,terminal-phase half-lives,"The mean respective terminal-phase half-lives were 20.6, 27.1, and 28.8 h; the mean half-life for all subjects was 25.7 h.",Difloxacin metabolism and pharmacokinetics in humans after single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800345/),h,28.8,212704,DB00537,Ciprofloxacin
,3800345,half-life,"The mean respective terminal-phase half-lives were 20.6, 27.1, and 28.8 h; the mean half-life for all subjects was 25.7 h.",Difloxacin metabolism and pharmacokinetics in humans after single oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800345/),h,25.7,212705,DB00537,Ciprofloxacin
,3800345,renal clearances,"Group mean renal clearances ranged from 4.1 to 5.6 ml/min, indicating extensive reabsorption from the glomerular filtrate.",Difloxacin metabolism and pharmacokinetics in humans after single oral doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800345/),[ml] / [min],4.1 to 5.6,212706,DB00537,Ciprofloxacin
,17163266,t(max ),"Moreover, a significant delay in t(max )(from 1 to 1.5 hours) and a statistical increase of 29% in MRT were also observed with phenazopyridine co-administration.",Ciprofloxacin bioavailability is enhanced by oral co-administration with phenazopyridine: a pharmacokinetic study in a Mexican population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163266/),h,1,213282,DB00537,Ciprofloxacin
,17163266,t(max ),"Moreover, a significant delay in t(max )(from 1 to 1.5 hours) and a statistical increase of 29% in MRT were also observed with phenazopyridine co-administration.",Ciprofloxacin bioavailability is enhanced by oral co-administration with phenazopyridine: a pharmacokinetic study in a Mexican population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163266/),h,1.5,213283,DB00537,Ciprofloxacin
,23047470,retention time,The detector wavelength was set at 278 nm and the retention time was 10 min.,Pharmacokinetics and bioequivalence evaluation of two brands of ciprofloxacin 500 mg tablets in Iranian healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23047470/),min,10,214348,DB00537,Ciprofloxacin
,23047470,Cmax,"The Cmax of 1476.8±319.9 ng/mL and 1 423.0±278.4 ng/mL were attained in about 1.67 and 1.58 h for test and reference formulations, respectively.",Pharmacokinetics and bioequivalence evaluation of two brands of ciprofloxacin 500 mg tablets in Iranian healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23047470/),[ng] / [ml],1476.8,214349,DB00537,Ciprofloxacin
,23047470,Cmax,"The Cmax of 1476.8±319.9 ng/mL and 1 423.0±278.4 ng/mL were attained in about 1.67 and 1.58 h for test and reference formulations, respectively.",Pharmacokinetics and bioequivalence evaluation of two brands of ciprofloxacin 500 mg tablets in Iranian healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23047470/),[ng] / [ml],1 423.0,214350,DB00537,Ciprofloxacin
,23047470,AUC0-∞,"The mean±SD values for AUC0-∞ were 9 665.3±2 880.2 and 9 716.1±2 572.1 ng.hr/mL for test and reference formulations, respectively.",Pharmacokinetics and bioequivalence evaluation of two brands of ciprofloxacin 500 mg tablets in Iranian healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23047470/),[h·ng] / [ml],9 665.3,214351,DB00537,Ciprofloxacin
,23047470,AUC0-∞,"The mean±SD values for AUC0-∞ were 9 665.3±2 880.2 and 9 716.1±2 572.1 ng.hr/mL for test and reference formulations, respectively.",Pharmacokinetics and bioequivalence evaluation of two brands of ciprofloxacin 500 mg tablets in Iranian healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23047470/),[h·ng] / [ml],9 716.1,214352,DB00537,Ciprofloxacin
,3659579,time to peak serum concentrations,"The time to peak serum concentrations was about 80 min in both age groups, although the maximum concentration attained was significantly greater in the old (1.7 mg/l) than the young (1.2 mg/l).",Pharmacokinetics of ciprofloxacin in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3659579/),min,80,214358,DB00537,Ciprofloxacin
,3659579,maximum concentration attained,"The time to peak serum concentrations was about 80 min in both age groups, although the maximum concentration attained was significantly greater in the old (1.7 mg/l) than the young (1.2 mg/l).",Pharmacokinetics of ciprofloxacin in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3659579/),[mg] / [l],1.7,214359,DB00537,Ciprofloxacin
,3659579,maximum concentration attained,"The time to peak serum concentrations was about 80 min in both age groups, although the maximum concentration attained was significantly greater in the old (1.7 mg/l) than the young (1.2 mg/l).",Pharmacokinetics of ciprofloxacin in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3659579/),[mg] / [l],1.2,214360,DB00537,Ciprofloxacin
,3659579,terminal elimination half-life,"Area under the plasma concentration-time curve, corrected for body weight, was on average 48% greater in the elderly, but the mean terminal elimination half-life was not significantly different, averaging 4.3 h in the old and 3.7 h in the young.",Pharmacokinetics of ciprofloxacin in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3659579/),h,4.3,214361,DB00537,Ciprofloxacin
,3659579,terminal elimination half-life,"Area under the plasma concentration-time curve, corrected for body weight, was on average 48% greater in the elderly, but the mean terminal elimination half-life was not significantly different, averaging 4.3 h in the old and 3.7 h in the young.",Pharmacokinetics of ciprofloxacin in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3659579/),h,3.7,214362,DB00537,Ciprofloxacin
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB00537,Ciprofloxacin
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB00537,Ciprofloxacin
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB00537,Ciprofloxacin
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB00537,Ciprofloxacin
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB00537,Ciprofloxacin
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB00537,Ciprofloxacin
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB00537,Ciprofloxacin
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB00537,Ciprofloxacin
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB00537,Ciprofloxacin
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB00537,Ciprofloxacin
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB00537,Ciprofloxacin
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB00537,Ciprofloxacin
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB00537,Ciprofloxacin
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB00537,Ciprofloxacin
exceeded,1622175,volume of distribution,The volume of distribution exceeded 1 liter/kg in healthy controls and was not affected by liver impairment (P greater than 0.05).,Fleroxacin pharmacokinetics in patients with liver cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1622175/),[l] / [kg],1,214595,DB00537,Ciprofloxacin
,7855046,steady state plasma concentrations,"The effects of two fluoroquinolones, enoxacin (ENOX) and ciprofloxacin (CIPRO), have been studied in male Sprague-Dawley rats (n = 33-46) at steady state plasma concentrations of 0-33 mg.l-1, achieved by supplementing an intravenous bolus dose with a constant rate infusion.",Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7855046/),[mg] / [l],0-33,215443,DB00537,Ciprofloxacin
,3777907,Serum clearances,Serum clearances averaged 23.0 +/- 9.1 liters/h per 1.73 m2 for the 100-mg dose and 23.7 +/- 5.1 liters/h per 1.73 m2 for the 200-mg dose.,Dose ranging study and constant infusion evaluation of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777907/),[l] / [1.73·h·m2],23.0,215883,DB00537,Ciprofloxacin
,3777907,Serum clearances,Serum clearances averaged 23.0 +/- 9.1 liters/h per 1.73 m2 for the 100-mg dose and 23.7 +/- 5.1 liters/h per 1.73 m2 for the 200-mg dose.,Dose ranging study and constant infusion evaluation of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777907/),[l] / [1.73·h·m2],23.7,215884,DB00537,Ciprofloxacin
longer,3777907,Half-lives,Half-lives were slightly longer than 4 h.,Dose ranging study and constant infusion evaluation of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777907/),h,4,215885,DB00537,Ciprofloxacin
,3777907,serum clearance,"For the constant-infusion arm, serum clearance was 28.9 +/- 2.7 liters/h per 1.73 m2, with renal clearance accounting for 58% of serum clearance.",Dose ranging study and constant infusion evaluation of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777907/),[l] / [1.73·h·m2],28.9,215886,DB00537,Ciprofloxacin
,28205238,elimination half-life (T1/2λz ),"In healthy fish, the elimination half-life (T1/2λz ), maximum plasma concentration (Cmax ), time to peak (Tmax ), and area under the concentration-time curve (AUC) values were 64.66 h, 3.55 μg/mL, 0.5 h, and 163.04 μg·h/mL, respectively.",Comparative pharmacokinetics of enrofloxacin in healthy and Aeromonas hydrophila-infected crucian carp (Carassius auratus gibelio). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205238/),h,64.66,216194,DB00537,Ciprofloxacin
,28205238,maximum plasma concentration (Cmax ),"In healthy fish, the elimination half-life (T1/2λz ), maximum plasma concentration (Cmax ), time to peak (Tmax ), and area under the concentration-time curve (AUC) values were 64.66 h, 3.55 μg/mL, 0.5 h, and 163.04 μg·h/mL, respectively.",Comparative pharmacokinetics of enrofloxacin in healthy and Aeromonas hydrophila-infected crucian carp (Carassius auratus gibelio). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205238/),[μg] / [ml],3.55,216195,DB00537,Ciprofloxacin
,28205238,maximum plasma concentration (Cmax ),"In healthy fish, the elimination half-life (T1/2λz ), maximum plasma concentration (Cmax ), time to peak (Tmax ), and area under the concentration-time curve (AUC) values were 64.66 h, 3.55 μg/mL, 0.5 h, and 163.04 μg·h/mL, respectively.",Comparative pharmacokinetics of enrofloxacin in healthy and Aeromonas hydrophila-infected crucian carp (Carassius auratus gibelio). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205238/),h,0.5,216196,DB00537,Ciprofloxacin
,28205238,time to peak (Tmax ),"In healthy fish, the elimination half-life (T1/2λz ), maximum plasma concentration (Cmax ), time to peak (Tmax ), and area under the concentration-time curve (AUC) values were 64.66 h, 3.55 μg/mL, 0.5 h, and 163.04 μg·h/mL, respectively.",Comparative pharmacokinetics of enrofloxacin in healthy and Aeromonas hydrophila-infected crucian carp (Carassius auratus gibelio). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205238/),[μg] / [ml],3.55,216197,DB00537,Ciprofloxacin
,28205238,time to peak (Tmax ),"In healthy fish, the elimination half-life (T1/2λz ), maximum plasma concentration (Cmax ), time to peak (Tmax ), and area under the concentration-time curve (AUC) values were 64.66 h, 3.55 μg/mL, 0.5 h, and 163.04 μg·h/mL, respectively.",Comparative pharmacokinetics of enrofloxacin in healthy and Aeromonas hydrophila-infected crucian carp (Carassius auratus gibelio). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205238/),h,0.5,216198,DB00537,Ciprofloxacin
,28205238,area under the concentration-time curve (AUC),"In healthy fish, the elimination half-life (T1/2λz ), maximum plasma concentration (Cmax ), time to peak (Tmax ), and area under the concentration-time curve (AUC) values were 64.66 h, 3.55 μg/mL, 0.5 h, and 163.04 μg·h/mL, respectively.",Comparative pharmacokinetics of enrofloxacin in healthy and Aeromonas hydrophila-infected crucian carp (Carassius auratus gibelio). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205238/),[h·μg] / [ml],163.04,216199,DB00537,Ciprofloxacin
,8257144,steady-state peak concentrations,"Mean steady-state peak concentrations in serum for regimens A, B, and C were 3.0, 4.4, and 6.5 micrograms/ml, respectively (P < 0.01, all comparisons) and mean half-lives were 4.5, 4.3, and 6.5 h, respectively (P < 0.05, C versus A and B).",Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257144/),[μg] / [ml],3.0,216218,DB00537,Ciprofloxacin
,8257144,steady-state peak concentrations,"Mean steady-state peak concentrations in serum for regimens A, B, and C were 3.0, 4.4, and 6.5 micrograms/ml, respectively (P < 0.01, all comparisons) and mean half-lives were 4.5, 4.3, and 6.5 h, respectively (P < 0.05, C versus A and B).",Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257144/),[μg] / [ml],4.4,216219,DB00537,Ciprofloxacin
,8257144,steady-state peak concentrations,"Mean steady-state peak concentrations in serum for regimens A, B, and C were 3.0, 4.4, and 6.5 micrograms/ml, respectively (P < 0.01, all comparisons) and mean half-lives were 4.5, 4.3, and 6.5 h, respectively (P < 0.05, C versus A and B).",Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257144/),[μg] / [ml],6.5,216220,DB00537,Ciprofloxacin
,8257144,half-lives,"Mean steady-state peak concentrations in serum for regimens A, B, and C were 3.0, 4.4, and 6.5 micrograms/ml, respectively (P < 0.01, all comparisons) and mean half-lives were 4.5, 4.3, and 6.5 h, respectively (P < 0.05, C versus A and B).",Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257144/),h,4.5,216221,DB00537,Ciprofloxacin
,8257144,half-lives,"Mean steady-state peak concentrations in serum for regimens A, B, and C were 3.0, 4.4, and 6.5 micrograms/ml, respectively (P < 0.01, all comparisons) and mean half-lives were 4.5, 4.3, and 6.5 h, respectively (P < 0.05, C versus A and B).",Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257144/),h,4.3,216222,DB00537,Ciprofloxacin
,8257144,half-lives,"Mean steady-state peak concentrations in serum for regimens A, B, and C were 3.0, 4.4, and 6.5 micrograms/ml, respectively (P < 0.01, all comparisons) and mean half-lives were 4.5, 4.3, and 6.5 h, respectively (P < 0.05, C versus A and B).",Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257144/),h,6.5,216223,DB00537,Ciprofloxacin
,8257144,steady-state areas under the concentration-time curve,"Mean steady-state areas under the concentration-time curve were 14.1, 21.1, and 48.1 micrograms/h/ml for regimens A, B, and C, respectively (P < 0.05, all comparisons).",Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257144/),[μg] / [h·ml],14.1,216224,DB00537,Ciprofloxacin
,8257144,steady-state areas under the concentration-time curve,"Mean steady-state areas under the concentration-time curve were 14.1, 21.1, and 48.1 micrograms/h/ml for regimens A, B, and C, respectively (P < 0.05, all comparisons).",Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257144/),[μg] / [h·ml],21.1,216225,DB00537,Ciprofloxacin
,8257144,steady-state areas under the concentration-time curve,"Mean steady-state areas under the concentration-time curve were 14.1, 21.1, and 48.1 micrograms/h/ml for regimens A, B, and C, respectively (P < 0.05, all comparisons).",Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257144/),[μg] / [h·ml],48.1,216226,DB00537,Ciprofloxacin
,8851589,Plateau concentrations,"Plateau concentrations (2 to 8 h; given as mean micrograms per gram +/- standard error of the mean) of drug in kidneys (15.11 +/- 0.55), prostate glands (5.08 +/- 0.19), and lungs (5.75 +/- 0.22) were also well above the MIC90 for most relevant pathogens.",Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851589/),,15.11,216408,DB00537,Ciprofloxacin
,8851589,Plateau concentrations,"Plateau concentrations (2 to 8 h; given as mean micrograms per gram +/- standard error of the mean) of drug in kidneys (15.11 +/- 0.55), prostate glands (5.08 +/- 0.19), and lungs (5.75 +/- 0.22) were also well above the MIC90 for most relevant pathogens.",Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851589/),,5.08,216409,DB00537,Ciprofloxacin
,8851589,Plateau concentrations,"Plateau concentrations (2 to 8 h; given as mean micrograms per gram +/- standard error of the mean) of drug in kidneys (15.11 +/- 0.55), prostate glands (5.08 +/- 0.19), and lungs (5.75 +/- 0.22) were also well above the MIC90 for most relevant pathogens.",Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851589/),,5.75,216410,DB00537,Ciprofloxacin
,26411498,elimination half-life (T1/2β ),"After intravenous administration, the elimination half-life (T1/2β ), area under the concentration-time curve (AUC) and total body clearance of EF were 19.82 h, 75.79 μg h/mL and 0.13 L/h/kg, respectively.","Pharmacokinetics of enrofloxacin in snakehead fish, Channa argus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26411498/),h,19.82,216976,DB00537,Ciprofloxacin
,26411498,area under the concentration-time curve (AUC),"After intravenous administration, the elimination half-life (T1/2β ), area under the concentration-time curve (AUC) and total body clearance of EF were 19.82 h, 75.79 μg h/mL and 0.13 L/h/kg, respectively.","Pharmacokinetics of enrofloxacin in snakehead fish, Channa argus. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26411498/),[h·μg] / [ml],75.79,216977,DB00537,Ciprofloxacin
,26411498,total body clearance,"After intravenous administration, the elimination half-life (T1/2β ), area under the concentration-time curve (AUC) and total body clearance of EF were 19.82 h, 75.79 μg h/mL and 0.13 L/h/kg, respectively.","Pharmacokinetics of enrofloxacin in snakehead fish, Channa argus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26411498/),[l] / [h·kg],0.13,216978,DB00537,Ciprofloxacin
,26411498,maximum plasma concentration (Cmax ),"Following p.o. administration, the maximum plasma concentration (Cmax ), T1/2β and AUC of EF were 1.86 μg/mL, 35.8 h and 49.98 μg h/mL, respectively.","Pharmacokinetics of enrofloxacin in snakehead fish, Channa argus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26411498/),[μg] / [ml],1.86,216979,DB00537,Ciprofloxacin
,26411498,T1/2β,"Following p.o. administration, the maximum plasma concentration (Cmax ), T1/2β and AUC of EF were 1.86 μg/mL, 35.8 h and 49.98 μg h/mL, respectively.","Pharmacokinetics of enrofloxacin in snakehead fish, Channa argus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26411498/),h,35.8,216980,DB00537,Ciprofloxacin
,26411498,AUC,"Following p.o. administration, the maximum plasma concentration (Cmax ), T1/2β and AUC of EF were 1.86 μg/mL, 35.8 h and 49.98 μg h/mL, respectively.","Pharmacokinetics of enrofloxacin in snakehead fish, Channa argus. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26411498/),[h·μg] / [ml],49.98,216981,DB00537,Ciprofloxacin
,26411498,bioavailability (F),"Absorption of EF was good with a bioavailability (F) of 65.82%, which was higher than that calculated in most seawater fish.","Pharmacokinetics of enrofloxacin in snakehead fish, Channa argus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26411498/),%,65.82,216982,DB00537,Ciprofloxacin
,19728130,volume of distribution,The kinetic analysis revealed the volume of distribution in healthy vs. febrile dogs as 2.12 +/- 0.32 vs.,Effect of induced pyrexia on the disposition kinetics of ciprofloxacin in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19728130/),,2.12,217433,DB00537,Ciprofloxacin
,19728130,elimination half life,"The elimination half life was 2.23 +/- 0.78 and 2.07 +/- 0.74 hours in healthy and febrile dogs, respectively.",Effect of induced pyrexia on the disposition kinetics of ciprofloxacin in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19728130/),h,2.23,217434,DB00537,Ciprofloxacin
,19728130,elimination half life,"The elimination half life was 2.23 +/- 0.78 and 2.07 +/- 0.74 hours in healthy and febrile dogs, respectively.",Effect of induced pyrexia on the disposition kinetics of ciprofloxacin in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19728130/),h,2.07,217435,DB00537,Ciprofloxacin
,19728130,total plasma clearance,"Similarly, dogs under healthy and febrile conditions showed comparable total plasma clearance of 0.66 +/- 0.06 and 0.60 +/- 0.07 L/Kg/h, respectively.",Effect of induced pyrexia on the disposition kinetics of ciprofloxacin in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19728130/),[l] / [h·kg],0.66,217436,DB00537,Ciprofloxacin
,19728130,total plasma clearance,"Similarly, dogs under healthy and febrile conditions showed comparable total plasma clearance of 0.66 +/- 0.06 and 0.60 +/- 0.07 L/Kg/h, respectively.",Effect of induced pyrexia on the disposition kinetics of ciprofloxacin in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19728130/),[l] / [h·kg],0.60,217437,DB00537,Ciprofloxacin
,20233180,renal clearance,"Addition of probenecid reduced the median renal clearance from 23.8 to 8.25 l h(-1)[65% reduction (59, 71), P < 0.01] for ciprofloxacin and from 20.5 to 8.26 l h(-1) (66% reduction (57, 73), P < 0.01] for M1 (estimated by modelling).",Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233180/),[l] / [h],23,218047,DB00537,Ciprofloxacin
,20233180,renal clearance,"Addition of probenecid reduced the median renal clearance from 23.8 to 8.25 l h(-1)[65% reduction (59, 71), P < 0.01] for ciprofloxacin and from 20.5 to 8.26 l h(-1) (66% reduction (57, 73), P < 0.01] for M1 (estimated by modelling).",Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233180/),[l] / [h],20.5 to 8.26,218048,DB00537,Ciprofloxacin
,7801085,cmax,"Ciprofloxacin occurred early in the concentration-time curves after intravenous and oral administration of the parent drug enrofloxacin with cmax 0.2 and 0.3 microgram/ml, respectively, at tmax 2 and 4 h, respectively.",[Pharmacokinetics of baytril (enrofloxacin) in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7801085/),[μg] / [ml],0.2,218229,DB00537,Ciprofloxacin
,7801085,cmax,"Ciprofloxacin occurred early in the concentration-time curves after intravenous and oral administration of the parent drug enrofloxacin with cmax 0.2 and 0.3 microgram/ml, respectively, at tmax 2 and 4 h, respectively.",[Pharmacokinetics of baytril (enrofloxacin) in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7801085/),[μg] / [ml],0.3,218230,DB00537,Ciprofloxacin
,7801085,tmax,"Ciprofloxacin occurred early in the concentration-time curves after intravenous and oral administration of the parent drug enrofloxacin with cmax 0.2 and 0.3 microgram/ml, respectively, at tmax 2 and 4 h, respectively.",[Pharmacokinetics of baytril (enrofloxacin) in dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7801085/),h,2,218231,DB00537,Ciprofloxacin
,7801085,tmax,"Ciprofloxacin occurred early in the concentration-time curves after intravenous and oral administration of the parent drug enrofloxacin with cmax 0.2 and 0.3 microgram/ml, respectively, at tmax 2 and 4 h, respectively.",[Pharmacokinetics of baytril (enrofloxacin) in dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7801085/),h,4,218232,DB00537,Ciprofloxacin
more,7801085,Oral bioavailability,Oral bioavailability calculated with bioassay results was more than 100% whereas availability of enrofloxacin was only 53%.,[Pharmacokinetics of baytril (enrofloxacin) in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7801085/),%,100,218233,DB00537,Ciprofloxacin
,7801085,availability,Oral bioavailability calculated with bioassay results was more than 100% whereas availability of enrofloxacin was only 53%.,[Pharmacokinetics of baytril (enrofloxacin) in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7801085/),%,53,218234,DB00537,Ciprofloxacin
,7801085,Clearance,Clearance was 10.3 ml/min.,[Pharmacokinetics of baytril (enrofloxacin) in dogs]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7801085/),[ml] / [min],10.3,218235,DB00537,Ciprofloxacin
,7801085,Elimination half life,"Elimination half life was 3.7 and 2.4 h, respectively.",[Pharmacokinetics of baytril (enrofloxacin) in dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7801085/),h,3.7,218236,DB00537,Ciprofloxacin
,7801085,Elimination half life,"Elimination half life was 3.7 and 2.4 h, respectively.",[Pharmacokinetics of baytril (enrofloxacin) in dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7801085/),h,2.4,218237,DB00537,Ciprofloxacin
,2931415,elimination half-life,"The elimination half-life was 8.7 +/- 0.9 h (mean +/- S.E.M.) in six renal failure patients not on haemodialysis, as compared to 4.4 +/- 0.2 h in six patients with normal renal function.",The pharmacokinetics of ciprofloxacin in patients with impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931415/),h,8.7,218278,DB00537,Ciprofloxacin
,2931415,elimination half-life,"The elimination half-life was 8.7 +/- 0.9 h (mean +/- S.E.M.) in six renal failure patients not on haemodialysis, as compared to 4.4 +/- 0.2 h in six patients with normal renal function.",The pharmacokinetics of ciprofloxacin in patients with impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931415/),h,4.4,218279,DB00537,Ciprofloxacin
,2931415,urinary recovery,"The urinary recovery of unchanged ciprofloxacin was 5.3 +/- 1.7% of dose over 24 h in the renal failure patients, as compared to 37.0 +/- 3.7% in the patients with normal renal function.",The pharmacokinetics of ciprofloxacin in patients with impaired renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931415/),%,5.3,218280,DB00537,Ciprofloxacin
,2931415,urinary recovery,"The urinary recovery of unchanged ciprofloxacin was 5.3 +/- 1.7% of dose over 24 h in the renal failure patients, as compared to 37.0 +/- 3.7% in the patients with normal renal function.",The pharmacokinetics of ciprofloxacin in patients with impaired renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931415/),%,37.0,218281,DB00537,Ciprofloxacin
,2931415,half-life,"In haemodialysis patients, the half-life was 5.8 +/- 0.9 h on an interdialysis day, and 3.2 +/- 0.4 h during haemodialysis.",The pharmacokinetics of ciprofloxacin in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931415/),h,5.8,218282,DB00537,Ciprofloxacin
,2931415,half-life,"In haemodialysis patients, the half-life was 5.8 +/- 0.9 h on an interdialysis day, and 3.2 +/- 0.4 h during haemodialysis.",The pharmacokinetics of ciprofloxacin in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2931415/),h,3.2,218283,DB00537,Ciprofloxacin
,10856681,elimination half-life,The data were best represented by a two-compartment pharmacokinetic model with a mean elimination half-life of 2.72+/-1.04 h.,Intravenous pharmacokinetics of ciprofloxacin in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856681/),h,2.72,219344,DB00537,Ciprofloxacin
,10856681,area under the curve (AUC,"Mean pharmacokinetic parameters obtained were area under the curve (AUC: 10.320+/-5.137 microg/ml per h), mean residence time (MRT: 3.334+/-1.428 h), apparent volume of distribution (Vdss: 3.373+/-0.893 l/kg) and total body drug clearance (tCl 19.596+/-9.059 ml/min per kg).",Intravenous pharmacokinetics of ciprofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856681/),[μg] / [h·ml],10.320,219345,DB00537,Ciprofloxacin
,10856681,mean residence time (MRT,"Mean pharmacokinetic parameters obtained were area under the curve (AUC: 10.320+/-5.137 microg/ml per h), mean residence time (MRT: 3.334+/-1.428 h), apparent volume of distribution (Vdss: 3.373+/-0.893 l/kg) and total body drug clearance (tCl 19.596+/-9.059 ml/min per kg).",Intravenous pharmacokinetics of ciprofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856681/),h,3.334,219346,DB00537,Ciprofloxacin
,10856681,apparent volume of distribution (Vdss,"Mean pharmacokinetic parameters obtained were area under the curve (AUC: 10.320+/-5.137 microg/ml per h), mean residence time (MRT: 3.334+/-1.428 h), apparent volume of distribution (Vdss: 3.373+/-0.893 l/kg) and total body drug clearance (tCl 19.596+/-9.059 ml/min per kg).",Intravenous pharmacokinetics of ciprofloxacin in goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856681/),[l] / [kg],3.373,219347,DB00537,Ciprofloxacin
,10856681,total body drug clearance (tCl,"Mean pharmacokinetic parameters obtained were area under the curve (AUC: 10.320+/-5.137 microg/ml per h), mean residence time (MRT: 3.334+/-1.428 h), apparent volume of distribution (Vdss: 3.373+/-0.893 l/kg) and total body drug clearance (tCl 19.596+/-9.059 ml/min per kg).",Intravenous pharmacokinetics of ciprofloxacin in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856681/),[ml] / [kg·min],19.596,219348,DB00537,Ciprofloxacin
≥,21653603,AUC(24)/MIC,"The defined targets were free AUC(24)/MIC ≥90 h (as a predictor of clinical outcome) and T(MSW) ≤20% (as a predictor of selecting resistance), where T(MSW) is the time spent within the mutant selection window over 24 h.",Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21653603/),h,90,219434,DB00537,Ciprofloxacin
≤,21653603,T(MSW),"Trial 2 showed that ≤ 18% of patients reached the target of T(MSW) ≤ 20% for MIC breakpoints of 0.5 and 1 mg/L, regardless of the administered dose.",Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21653603/),%,20,219435,DB00537,Ciprofloxacin
,21653603,MIC,"Trial 2 showed that ≤ 18% of patients reached the target of T(MSW) ≤ 20% for MIC breakpoints of 0.5 and 1 mg/L, regardless of the administered dose.",Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21653603/),[mg] / [l],0.5,219436,DB00537,Ciprofloxacin
,21653603,MIC,"Trial 2 showed that ≤ 18% of patients reached the target of T(MSW) ≤ 20% for MIC breakpoints of 0.5 and 1 mg/L, regardless of the administered dose.",Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21653603/),[mg] / [l],1,219437,DB00537,Ciprofloxacin
,11883887,elimination half-life,"Mean (SD) elimination half-life and mean residence time of ciprofloxacin in plasma were 8.84 (2.13) and 8.54 (1.64) hours, respectively, after i.v. administration and 11.89 (1.95) and 13.32 (2.65) hours, respectively, after oral administration.",Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883887/),h,8.84,219686,DB00537,Ciprofloxacin
,11883887,elimination half-life,"Mean (SD) elimination half-life and mean residence time of ciprofloxacin in plasma were 8.84 (2.13) and 8.54 (1.64) hours, respectively, after i.v. administration and 11.89 (1.95) and 13.32 (2.65) hours, respectively, after oral administration.",Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883887/),h,11.89,219687,DB00537,Ciprofloxacin
,11883887,mean residence time,"Mean (SD) elimination half-life and mean residence time of ciprofloxacin in plasma were 8.84 (2.13) and 8.54 (1.64) hours, respectively, after i.v. administration and 11.89 (1.95) and 13.32 (2.65) hours, respectively, after oral administration.",Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883887/),h,8.54,219688,DB00537,Ciprofloxacin
,11883887,mean residence time,"Mean (SD) elimination half-life and mean residence time of ciprofloxacin in plasma were 8.84 (2.13) and 8.54 (1.64) hours, respectively, after i.v. administration and 11.89 (1.95) and 13.32 (2.65) hours, respectively, after oral administration.",Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883887/),h,13.32,219689,DB00537,Ciprofloxacin
,11883887,maximal plasma concentration,"Mean maximal plasma concentration of ciprofloxacin was 2.63 (0.20) microg ml(-1), and the interval from oral administration until maximum concentration was 0.36 (0.07) hours.",Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883887/),[μg] / [ml],2.63,219690,DB00537,Ciprofloxacin
,11883887,interval from oral administration until maximum concentration,"Mean maximal plasma concentration of ciprofloxacin was 2.63 (0.20) microg ml(-1), and the interval from oral administration until maximum concentration was 0.36 (0.07) hours.",Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883887/),h,0.36,219691,DB00537,Ciprofloxacin
,11883887,oral bioavailability,The mean oral bioavailability of ciprofloxacin was found to be 69.12 (6.95) per cent.,Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883887/),%,69.12,219692,DB00537,Ciprofloxacin
,15385831,clearances,"On the other hand, ciprofloxacin administration only marginally decreased R-(-)- and S-(+)-mexiletine clearances (2 to 5 L/h; P < 0.05) secondary to a decrease in mexiletine nonrenal clearance.",Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385831/),[l] / [h],2 to 5,220254,DB00537,Ciprofloxacin
,8428409,Cmax,The mean Cmax was 3.4 +/- 1.0 mg/l and tmax was 2.3 +/- 0.9 hours.,Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[mg] / [l],3.4,220398,DB00537,Ciprofloxacin
,8428409,tmax,The mean Cmax was 3.4 +/- 1.0 mg/l and tmax was 2.3 +/- 0.9 hours.,Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),h,2.3,220399,DB00537,Ciprofloxacin
,8428409,AUC,"The mean AUC in Group I was 14.7 mg.h/l, Group II was 33.7 (p < 0.001), Group III 63.8 (p < 0.001), HD 57.9 (p < 0.0001) and CAPD 44.3 (p < 0.001).",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[h·mg] / [l],14.7,220400,DB00537,Ciprofloxacin
,8428409,AUC,"The mean AUC in Group I was 14.7 mg.h/l, Group II was 33.7 (p < 0.001), Group III 63.8 (p < 0.001), HD 57.9 (p < 0.0001) and CAPD 44.3 (p < 0.001).",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[h·mg] / [l],33.7,220401,DB00537,Ciprofloxacin
,8428409,AUC,"The mean AUC in Group I was 14.7 mg.h/l, Group II was 33.7 (p < 0.001), Group III 63.8 (p < 0.001), HD 57.9 (p < 0.0001) and CAPD 44.3 (p < 0.001).",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[h·mg] / [l],63.8,220402,DB00537,Ciprofloxacin
,8428409,AUC,"The mean AUC in Group I was 14.7 mg.h/l, Group II was 33.7 (p < 0.001), Group III 63.8 (p < 0.001), HD 57.9 (p < 0.0001) and CAPD 44.3 (p < 0.001).",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[h·mg] / [l],57.9,220403,DB00537,Ciprofloxacin
,8428409,AUC,"The mean AUC in Group I was 14.7 mg.h/l, Group II was 33.7 (p < 0.001), Group III 63.8 (p < 0.001), HD 57.9 (p < 0.0001) and CAPD 44.3 (p < 0.001).",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[h·mg] / [l],44.3,220404,DB00537,Ciprofloxacin
,8428409,Half-life,"Half-life in Group I was 4.6 h, and was shorter than Group III (11.1 h, p < 0.001), HD (13.4 h, p < 0.001) and CAPD (8.9 h, p < 0.001).",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),h,4.6,220405,DB00537,Ciprofloxacin
,8428409,Half-life,"Half-life in Group I was 4.6 h, and was shorter than Group III (11.1 h, p < 0.001), HD (13.4 h, p < 0.001) and CAPD (8.9 h, p < 0.001).",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),h,11.1,220406,DB00537,Ciprofloxacin
,8428409,Half-life,"Half-life in Group I was 4.6 h, and was shorter than Group III (11.1 h, p < 0.001), HD (13.4 h, p < 0.001) and CAPD (8.9 h, p < 0.001).",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),h,13.4,220407,DB00537,Ciprofloxacin
,8428409,Half-life,"Half-life in Group I was 4.6 h, and was shorter than Group III (11.1 h, p < 0.001), HD (13.4 h, p < 0.001) and CAPD (8.9 h, p < 0.001).",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),h,8.9,220408,DB00537,Ciprofloxacin
,8428409,dial,The dialysis clearance in CAPD patients was 0.53 +/- 0.39 l/h.,Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[l] / [h],0.53,220409,DB00537,Ciprofloxacin
,8428409,clearance,The dialysis clearance in CAPD patients was 0.53 +/- 0.39 l/h.,Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[l] / [h],0.53,220410,DB00537,Ciprofloxacin
,8428409,Peritoneal effluent concentrations,"Peritoneal effluent concentrations varied from 0.6 mg/l during the first exchange, to a peak of 2.2 mg/l during the second, to 0.13 mg/l in the 48 hour (9th) exchange.",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[mg] / [l],0.6,220411,DB00537,Ciprofloxacin
,8428409,Peritoneal effluent concentrations,"Peritoneal effluent concentrations varied from 0.6 mg/l during the first exchange, to a peak of 2.2 mg/l during the second, to 0.13 mg/l in the 48 hour (9th) exchange.",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[mg] / [l],2.2,220412,DB00537,Ciprofloxacin
,8428409,Peritoneal effluent concentrations,"Peritoneal effluent concentrations varied from 0.6 mg/l during the first exchange, to a peak of 2.2 mg/l during the second, to 0.13 mg/l in the 48 hour (9th) exchange.",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[mg] / [l],0.13,220413,DB00537,Ciprofloxacin
,8428409,peak,"Peritoneal effluent concentrations varied from 0.6 mg/l during the first exchange, to a peak of 2.2 mg/l during the second, to 0.13 mg/l in the 48 hour (9th) exchange.",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[mg] / [l],2.2,220414,DB00537,Ciprofloxacin
,8428409,peak,"Peritoneal effluent concentrations varied from 0.6 mg/l during the first exchange, to a peak of 2.2 mg/l during the second, to 0.13 mg/l in the 48 hour (9th) exchange.",Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428409/),[mg] / [l],0.13,220415,DB00537,Ciprofloxacin
,1781714,maximum concentrations,"After the drug oral administration in a dose of 1000 mg the maximum concentrations were: 6.34 +/- 4.2 micrograms/ml on the average and 2.1 +/- 0.8 micrograms/ml in 6 hours (0.4 micrograms/g in the muscles, 1.4 micrograms/g in the skin and 0.34 micrograms/g in the bones).",[Ciprofloxacin in the prevention and treatment of surgical infections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781714/),[μg] / [ml],6.34,220583,DB00537,Ciprofloxacin
,1781714,maximum concentrations,"After the drug oral administration in a dose of 1000 mg the maximum concentrations were: 6.34 +/- 4.2 micrograms/ml on the average and 2.1 +/- 0.8 micrograms/ml in 6 hours (0.4 micrograms/g in the muscles, 1.4 micrograms/g in the skin and 0.34 micrograms/g in the bones).",[Ciprofloxacin in the prevention and treatment of surgical infections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781714/),[μg] / [ml],2.1,220584,DB00537,Ciprofloxacin
,1781714,maximum concentrations,"After the drug oral administration in a dose of 1000 mg the maximum concentrations were: 6.34 +/- 4.2 micrograms/ml on the average and 2.1 +/- 0.8 micrograms/ml in 6 hours (0.4 micrograms/g in the muscles, 1.4 micrograms/g in the skin and 0.34 micrograms/g in the bones).",[Ciprofloxacin in the prevention and treatment of surgical infections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781714/),,1.4,220585,DB00537,Ciprofloxacin
,1781714,maximum concentrations,"After the drug oral administration in a dose of 1000 mg the maximum concentrations were: 6.34 +/- 4.2 micrograms/ml on the average and 2.1 +/- 0.8 micrograms/ml in 6 hours (0.4 micrograms/g in the muscles, 1.4 micrograms/g in the skin and 0.34 micrograms/g in the bones).",[Ciprofloxacin in the prevention and treatment of surgical infections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781714/),,0,220586,DB00537,Ciprofloxacin
,10850849,total area under the curve (AUC0-infinity),"For IV administration, mean +/- SD total area under the curve (AUC0-infinity) was 48.54 +/- 10.46 microg x h/ml, clearance was 103.72 +/- 0.06 ml/kg/h, half-life (t1/2beta) was 17.10 +/- 0.09 hours, and apparent volume of distribution was 2.49 +/- 0.43 L/kg.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),[h·μg] / [ml],48.54,220726,DB00537,Ciprofloxacin
,10850849,clearance,"For IV administration, mean +/- SD total area under the curve (AUC0-infinity) was 48.54 +/- 10.46 microg x h/ml, clearance was 103.72 +/- 0.06 ml/kg/h, half-life (t1/2beta) was 17.10 +/- 0.09 hours, and apparent volume of distribution was 2.49 +/- 0.43 L/kg.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),[ml] / [h·kg],103.72,220727,DB00537,Ciprofloxacin
,10850849,half-life (t1/2beta),"For IV administration, mean +/- SD total area under the curve (AUC0-infinity) was 48.54 +/- 10.46 microg x h/ml, clearance was 103.72 +/- 0.06 ml/kg/h, half-life (t1/2beta) was 17.10 +/- 0.09 hours, and apparent volume of distribution was 2.49 +/- 0.43 L/kg.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),h,17.10,220728,DB00537,Ciprofloxacin
,10850849,apparent volume of distribution,"For IV administration, mean +/- SD total area under the curve (AUC0-infinity) was 48.54 +/- 10.46 microg x h/ml, clearance was 103.72 +/- 0.06 ml/kg/h, half-life (t1/2beta) was 17.10 +/- 0.09 hours, and apparent volume of distribution was 2.49 +/- 0.43 L/kg.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),[l] / [kg],2.49,220729,DB00537,Ciprofloxacin
,10850849,AUC0-infinity,"For oral administration, AUC0-infinity was 58.47 +/- 16.37 microg x h/ml, t1/2beta was 18.39 +/- 0.06 hours, maximum concentration (Cmax) was 2.12 +/- 00.51 microg/ml, time to Cmax was 2.20 +/- 2.17 hours, mean absorption time was 2.09 +/- 0.51 hours, and bioavailability was 42 +/- 0.42%.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),[h·μg] / [ml],58.47,220730,DB00537,Ciprofloxacin
,10850849,t1/2beta,"For oral administration, AUC0-infinity was 58.47 +/- 16.37 microg x h/ml, t1/2beta was 18.39 +/- 0.06 hours, maximum concentration (Cmax) was 2.12 +/- 00.51 microg/ml, time to Cmax was 2.20 +/- 2.17 hours, mean absorption time was 2.09 +/- 0.51 hours, and bioavailability was 42 +/- 0.42%.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),h,18.39,220731,DB00537,Ciprofloxacin
,10850849,maximum concentration (Cmax),"For oral administration, AUC0-infinity was 58.47 +/- 16.37 microg x h/ml, t1/2beta was 18.39 +/- 0.06 hours, maximum concentration (Cmax) was 2.12 +/- 00.51 microg/ml, time to Cmax was 2.20 +/- 2.17 hours, mean absorption time was 2.09 +/- 0.51 hours, and bioavailability was 42 +/- 0.42%.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),[μg] / [ml],2.12,220732,DB00537,Ciprofloxacin
,10850849,time to Cmax,"For oral administration, AUC0-infinity was 58.47 +/- 16.37 microg x h/ml, t1/2beta was 18.39 +/- 0.06 hours, maximum concentration (Cmax) was 2.12 +/- 00.51 microg/ml, time to Cmax was 2.20 +/- 2.17 hours, mean absorption time was 2.09 +/- 0.51 hours, and bioavailability was 42 +/- 0.42%.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),h,2.20,220733,DB00537,Ciprofloxacin
,10850849,mean absorption time,"For oral administration, AUC0-infinity was 58.47 +/- 16.37 microg x h/ml, t1/2beta was 18.39 +/- 0.06 hours, maximum concentration (Cmax) was 2.12 +/- 00.51 microg/ml, time to Cmax was 2.20 +/- 2.17 hours, mean absorption time was 2.09 +/- 0.51 hours, and bioavailability was 42 +/- 0.42%.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),h,2.09,220734,DB00537,Ciprofloxacin
,10850849,bioavailability,"For oral administration, AUC0-infinity was 58.47 +/- 16.37 microg x h/ml, t1/2beta was 18.39 +/- 0.06 hours, maximum concentration (Cmax) was 2.12 +/- 00.51 microg/ml, time to Cmax was 2.20 +/- 2.17 hours, mean absorption time was 2.09 +/- 0.51 hours, and bioavailability was 42 +/- 0.42%.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),%,42,220735,DB00537,Ciprofloxacin
,10850849,Cmax to minimum inhibitory concentration ratio,"Using a target Cmax to minimum inhibitory concentration ratio of 1:8 to 1:10, computer modeling suggests that 2.5 to 10 mg of enrofloxacin/kg administered every 24 hours would be effective in foals, depending on minimum inhibitory concentration of the pathogen.",Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850849/),,1,220736,DB00537,Ciprofloxacin
,6467798,elimination t1/2,Ciprofloxacin elimination t1/2 increased from 3.71 hr after the first dose to 6.51 hr after the thirteenth dose (P less than 0.05).,Multiple-dose ciprofloxacin kinetics in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467798/),h,3.71,220738,DB00537,Ciprofloxacin
,6467798,elimination t1/2,Ciprofloxacin elimination t1/2 increased from 3.71 hr after the first dose to 6.51 hr after the thirteenth dose (P less than 0.05).,Multiple-dose ciprofloxacin kinetics in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467798/),h,6.51,220739,DB00537,Ciprofloxacin
,6467798,Apparent plasma clearance,Apparent plasma clearance decreased from 0.823 to 0.629 l/kg/hr because of decreased nonrenal clearance.,Multiple-dose ciprofloxacin kinetics in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467798/),[l] / [h·kg],0.823,220740,DB00537,Ciprofloxacin
,6467798,Apparent plasma clearance,Apparent plasma clearance decreased from 0.823 to 0.629 l/kg/hr because of decreased nonrenal clearance.,Multiple-dose ciprofloxacin kinetics in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467798/),[l] / [h·kg],0.629,220741,DB00537,Ciprofloxacin
,20950349,Steady-state volume of distribution (Vd(ss)),"Steady-state volume of distribution (Vd(ss)) and total body clearance (Cl) after i.v. administration were estimated to be 1.27 L/kg and 0.60 L/h·kg, respectively.",Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950349/),[l] / [kg],1.27,221052,DB00537,Ciprofloxacin
,20950349,total body clearance (Cl),"Steady-state volume of distribution (Vd(ss)) and total body clearance (Cl) after i.v. administration were estimated to be 1.27 L/kg and 0.60 L/h·kg, respectively.",Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950349/),[l] / [h·kg],0.60,221053,DB00537,Ciprofloxacin
,20950349,bioavailability,"Following 15 and 20 mg/kg p.o. dose, bioavailability was 102% and 117%, respectively.",Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950349/),%,102,221054,DB00537,Ciprofloxacin
,20950349,bioavailability,"Following 15 and 20 mg/kg p.o. dose, bioavailability was 102% and 117%, respectively.",Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950349/),%,117,221055,DB00537,Ciprofloxacin
,20950349,terminal half-lives (T(1/2) λ(z) ),The harmonic mean of the corresponding terminal half-lives (T(1/2) λ(z) ) across all the dose groups was 1.71 h.,Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950349/),h,1.71,221056,DB00537,Ciprofloxacin
≥,20950349,C(max) /MIC(90),"The C(max) /MIC(90) and AUC(0∞24) /MIC(90) for the 15 and 20 mg/kg p.o. doses were ≥5.22 and ≥8.98, and ≥25.80 and ≥39.37 h, respectively.",Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950349/),h,5.22,221057,DB00537,Ciprofloxacin
≥,20950349,AUC(0∞24) /MIC(90),"The C(max) /MIC(90) and AUC(0∞24) /MIC(90) for the 15 and 20 mg/kg p.o. doses were ≥5.22 and ≥8.98, and ≥25.80 and ≥39.37 h, respectively.",Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950349/),h,8.98,221058,DB00537,Ciprofloxacin
≥,20950349,AUC(0∞24) /MIC(90),"The C(max) /MIC(90) and AUC(0∞24) /MIC(90) for the 15 and 20 mg/kg p.o. doses were ≥5.22 and ≥8.98, and ≥25.80 and ≥39.37 h, respectively.",Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950349/),h,25.80,221059,DB00537,Ciprofloxacin
≥,20950349,AUC(0∞24) /MIC(90),"The C(max) /MIC(90) and AUC(0∞24) /MIC(90) for the 15 and 20 mg/kg p.o. doses were ≥5.22 and ≥8.98, and ≥25.80 and ≥39.37 h, respectively.",Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950349/),h,39.37,221060,DB00537,Ciprofloxacin
,12405867,urinary flow rate,"Urine concentrations were estimated from simulated plasma concentrations, literature values of renal clearance and an average urinary flow rate of 2 L/day.",Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405867/),[l] / [d],2,222574,DB00537,Ciprofloxacin
,25050456,Peak sputum concentrations,"Peak sputum concentrations of 34.9 mg/L (range 2.03-229) and 376 mg/L (8.95-1283) for ciprofloxacin 32.5 mg and 65 mg, respectively, indicated targeting of ciprofloxacin DPI to the lung.","Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25050456/),[mg] / [l],34.9,222717,DB00537,Ciprofloxacin
,25050456,Peak sputum concentrations,"Peak sputum concentrations of 34.9 mg/L (range 2.03-229) and 376 mg/L (8.95-1283) for ciprofloxacin 32.5 mg and 65 mg, respectively, indicated targeting of ciprofloxacin DPI to the lung.","Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25050456/),[mg] / [l],376,222718,DB00537,Ciprofloxacin
,25050456,peak plasma concentrations,This contrasted with low systemic exposure (peak plasma concentrations: 0.0790 mg/L [32.5 mg] and 0.182 mg/L [65 mg]).,"Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25050456/),[mg] / [l],0.0790,222719,DB00537,Ciprofloxacin
,25050456,peak plasma concentrations,This contrasted with low systemic exposure (peak plasma concentrations: 0.0790 mg/L [32.5 mg] and 0.182 mg/L [65 mg]).,"Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25050456/),[mg] / [l],0.182,222720,DB00537,Ciprofloxacin
,17216308,elimination half-lives (t(1/2beta)),"The mean i.v., i.m. and s.c. elimination half-lives (t(1/2beta)) were 5.56 +/- 0.33 h, 6.12 +/- 0.42 h and 7.26 +/- 0.6 h, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),h,5.56,222941,DB00537,Ciprofloxacin
,17216308,elimination half-lives (t(1/2beta)),"The mean i.v., i.m. and s.c. elimination half-lives (t(1/2beta)) were 5.56 +/- 0.33 h, 6.12 +/- 0.42 h and 7.26 +/- 0.6 h, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),h,6.12,222942,DB00537,Ciprofloxacin
,17216308,elimination half-lives (t(1/2beta)),"The mean i.v., i.m. and s.c. elimination half-lives (t(1/2beta)) were 5.56 +/- 0.33 h, 6.12 +/- 0.42 h and 7.26 +/- 0.6 h, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),h,7.26,222943,DB00537,Ciprofloxacin
,17216308,steady-state volume of distribution (V(dss)),The steady-state volume of distribution (V(dss)) was 1.12 +/- 0.09 L/kg and total body clearance (Cl(B)) was 2.19 +/- 0.1 ml/(min x kg).,"Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),[l] / [kg],1.12,222944,DB00537,Ciprofloxacin
,17216308,total body clearance (Cl(B)),The steady-state volume of distribution (V(dss)) was 1.12 +/- 0.09 L/kg and total body clearance (Cl(B)) was 2.19 +/- 0.1 ml/(min x kg).,"Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),[ml] / [kg·min],2.19,222945,DB00537,Ciprofloxacin
,17216308,absorption half lives (t(1/2ab)),"The absorption half lives (t(1/2ab)) were 0.38 +/- 0.027 h and 2.1 +/- 0.09 h, with systemic bioavailabilities (F) of 96.5% +/- 6.4% and 84% +/- 5.5% after i.m. and s.c. administration, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),h,0.38,222946,DB00537,Ciprofloxacin
,17216308,absorption half lives (t(1/2ab)),"The absorption half lives (t(1/2ab)) were 0.38 +/- 0.027 h and 2.1 +/- 0.09 h, with systemic bioavailabilities (F) of 96.5% +/- 6.4% and 84% +/- 5.5% after i.m. and s.c. administration, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),h,2.1,222947,DB00537,Ciprofloxacin
,17216308,systemic bioavailabilities (F),"The absorption half lives (t(1/2ab)) were 0.38 +/- 0.027 h and 2.1 +/- 0.09 h, with systemic bioavailabilities (F) of 96.5% +/- 6.4% and 84% +/- 5.5% after i.m. and s.c. administration, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),%,96.5,222948,DB00537,Ciprofloxacin
,17216308,systemic bioavailabilities (F),"The absorption half lives (t(1/2ab)) were 0.38 +/- 0.027 h and 2.1 +/- 0.09 h, with systemic bioavailabilities (F) of 96.5% +/- 6.4% and 84% +/- 5.5% after i.m. and s.c. administration, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),%,84,222949,DB00537,Ciprofloxacin
,17216308,peak plasma concentrations (C(max)),"After i.m. and s.c. dosing, peak plasma concentrations (C(max)) of 3.38 +/- 0.13 microg/ml and 2.18 +/- 0.12 microg/ml were attained after (t(max)) 1.22 +/- 0.20 h and 3.7 +/- 0.52 h.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),[μg] / [ml],3.38,222950,DB00537,Ciprofloxacin
,17216308,peak plasma concentrations (C(max)),"After i.m. and s.c. dosing, peak plasma concentrations (C(max)) of 3.38 +/- 0.13 microg/ml and 2.18 +/- 0.12 microg/ml were attained after (t(max)) 1.22 +/- 0.20 h and 3.7 +/- 0.52 h.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),[μg] / [ml],2.18,222951,DB00537,Ciprofloxacin
,17216308,t(max),"After i.m. and s.c. dosing, peak plasma concentrations (C(max)) of 3.38 +/- 0.13 microg/ml and 2.18 +/- 0.12 microg/ml were attained after (t(max)) 1.22 +/- 0.20 h and 3.7 +/- 0.52 h.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),h,1.22,222952,DB00537,Ciprofloxacin
,17216308,t(max),"After i.m. and s.c. dosing, peak plasma concentrations (C(max)) of 3.38 +/- 0.13 microg/ml and 2.18 +/- 0.12 microg/ml were attained after (t(max)) 1.22 +/- 0.20 h and 3.7 +/- 0.52 h.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),h,3.7,222953,DB00537,Ciprofloxacin
,17216308,MIC90,The MIC90 of difloxacin for Mannheimia haemolytica was 0.29 +/- 0.04 microg/ml.,"Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),[μg] / [ml],0.29,222954,DB00537,Ciprofloxacin
,17216308,AUC/MIC90,"The AUC/MIC90 and C(max)/MIC90 ratios for difloxacin following i.m. administration were 120 and 11.65, respectively and following s.c. administration were 97.58 and 7.51, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),,120,222955,DB00537,Ciprofloxacin
,17216308,AUC/MIC90,"The AUC/MIC90 and C(max)/MIC90 ratios for difloxacin following i.m. administration were 120 and 11.65, respectively and following s.c. administration were 97.58 and 7.51, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),,97.58,222956,DB00537,Ciprofloxacin
,17216308,C(max)/MIC90,"The AUC/MIC90 and C(max)/MIC90 ratios for difloxacin following i.m. administration were 120 and 11.65, respectively and following s.c. administration were 97.58 and 7.51, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),,11.65,222957,DB00537,Ciprofloxacin
,17216308,C(max)/MIC90,"The AUC/MIC90 and C(max)/MIC90 ratios for difloxacin following i.m. administration were 120 and 11.65, respectively and following s.c. administration were 97.58 and 7.51, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),,97.58,222958,DB00537,Ciprofloxacin
,17216308,C(max)/MIC90,"The AUC/MIC90 and C(max)/MIC90 ratios for difloxacin following i.m. administration were 120 and 11.65, respectively and following s.c. administration were 97.58 and 7.51, respectively.","Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216308/),,7.51,222959,DB00537,Ciprofloxacin
,8587154,t1/2 beta,"Mean t1/2 beta of antimicrobial activity in serum was 1.7, 5.9 and 5.6 h after i.v., i.m. and s.c. administration, respectively.","Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587154/),h,1.7,223545,DB00537,Ciprofloxacin
,8587154,t1/2 beta,"Mean t1/2 beta of antimicrobial activity in serum was 1.7, 5.9 and 5.6 h after i.v., i.m. and s.c. administration, respectively.","Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587154/),h,5.9,223546,DB00537,Ciprofloxacin
,8587154,t1/2 beta,"Mean t1/2 beta of antimicrobial activity in serum was 1.7, 5.9 and 5.6 h after i.v., i.m. and s.c. administration, respectively.","Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587154/),h,5.6,223547,DB00537,Ciprofloxacin
,8587154,fraction bound,The enrofloxacin fraction bound in vitro to serum proteins was 36-45%.,"Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587154/),%,36-45,223548,DB00537,Ciprofloxacin
,8587154,tmax,"After i.v. injection, the peak concentration of enrofloxacin in milk was reached between 0.7 and 1.3 h but occurred much later for ciprofloxacin (tmax 5-8 h).","Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587154/),h,5-8,223549,DB00537,Ciprofloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],11.28,223929,DB00537,Ciprofloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],6.52,223930,DB00537,Ciprofloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],13.28,223931,DB00537,Ciprofloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],3.52,223932,DB00537,Ciprofloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],4.82,223933,DB00537,Ciprofloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],5.79,223934,DB00537,Ciprofloxacin
,28461311,area under the concentration-time curve from time zero to infinity,"Plasma clearance was approximately 32% lower in infected animals, leading to a significantly higher level of plasma CIP exposure (area under the concentration-time curve from time zero to infinity, 27.3 ± 12.1 μg · h/ml and 13.3 ± 3.5 μg · h/ml in infected and healthy rats, respectively).",Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28461311/),[h·μg] / [ml],27.3,224362,DB00537,Ciprofloxacin
,28461311,area under the concentration-time curve from time zero to infinity,"Plasma clearance was approximately 32% lower in infected animals, leading to a significantly higher level of plasma CIP exposure (area under the concentration-time curve from time zero to infinity, 27.3 ± 12.1 μg · h/ml and 13.3 ± 3.5 μg · h/ml in infected and healthy rats, respectively).",Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28461311/),[h·μg] / [ml],13.3,224363,DB00537,Ciprofloxacin
,28461311,lung penetration factor,"Despite the plasma exposure, infected animals showed a four times lower tissue concentration/plasma concentration ratio (lung penetration factor = 0.44 and 1.69 in infected and healthy rats, respectively), and lung clearance (CLlung) was added to the model for these animals (CLlung = 0.643 liters/h/kg) to explain the lower tissue concentrations.",Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28461311/),,0.44,224364,DB00537,Ciprofloxacin
,28461311,lung penetration factor,"Despite the plasma exposure, infected animals showed a four times lower tissue concentration/plasma concentration ratio (lung penetration factor = 0.44 and 1.69 in infected and healthy rats, respectively), and lung clearance (CLlung) was added to the model for these animals (CLlung = 0.643 liters/h/kg) to explain the lower tissue concentrations.",Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28461311/),,1.69,224365,DB00537,Ciprofloxacin
,28461311,CLlung,"Despite the plasma exposure, infected animals showed a four times lower tissue concentration/plasma concentration ratio (lung penetration factor = 0.44 and 1.69 in infected and healthy rats, respectively), and lung clearance (CLlung) was added to the model for these animals (CLlung = 0.643 liters/h/kg) to explain the lower tissue concentrations.",Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28461311/),[l] / [h·kg],0.643,224366,DB00537,Ciprofloxacin
,18790614,MPC/MIC ratios,"Staphylococcus aureus ATCC 43300 and ATCC 6538 exhibiting different MPC/MIC ratios (4 and 16, respectively) were exposed to ciprofloxacin twice daily by bolus administration and continuous infusion for 3 days.",Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18790614/),,4,224871,DB00537,Ciprofloxacin
,18790614,MPC/MIC ratios,"Staphylococcus aureus ATCC 43300 and ATCC 6538 exhibiting different MPC/MIC ratios (4 and 16, respectively) were exposed to ciprofloxacin twice daily by bolus administration and continuous infusion for 3 days.",Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18790614/),,16,224872,DB00537,Ciprofloxacin
,9820354,area under the curve,The remaining 73% (11/15) had an area under the curve comparable with that of controls (8.3+/-1.6 (mg/[L x h]).,Bioavailability of oral ciprofloxacin in early postsurgical patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9820354/),[mg] / [h·l],8.3,225018,DB00537,Ciprofloxacin
,9820354,area under the curve,"When elective surgery patients were stratified by presence or absence of obesity (25% above ideal body weight), mean area under the curve in nonobese patients was 9.80+/-2.37 vs 0.91+/-0.56 (mg/(L x h) in obese patients (P<.05).",Bioavailability of oral ciprofloxacin in early postsurgical patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9820354/),[mg] / [h·l],9.80,225019,DB00537,Ciprofloxacin
,9820354,area under the curve,"When elective surgery patients were stratified by presence or absence of obesity (25% above ideal body weight), mean area under the curve in nonobese patients was 9.80+/-2.37 vs 0.91+/-0.56 (mg/(L x h) in obese patients (P<.05).",Bioavailability of oral ciprofloxacin in early postsurgical patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9820354/),[mg] / [h·l],0.91,225020,DB00537,Ciprofloxacin
,2185690,Peak,"Peak and trough levels in plasma were, respectively, 6.19 +/- 1.73 and 0.54 +/- 0.25 micrograms/ml in group 1 patients and 11.59 +/- 3.95 and 0.89 +/- 0.57 micrograms/ml in group 2 patients.","Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185690/),[μg] / [ml],6.19,225639,DB00537,Ciprofloxacin
,2185690,Peak,"Peak and trough levels in plasma were, respectively, 6.19 +/- 1.73 and 0.54 +/- 0.25 micrograms/ml in group 1 patients and 11.59 +/- 3.95 and 0.89 +/- 0.57 micrograms/ml in group 2 patients.","Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185690/),[μg] / [ml],11.59,225640,DB00537,Ciprofloxacin
,2185690,trough levels,"Peak and trough levels in plasma were, respectively, 6.19 +/- 1.73 and 0.54 +/- 0.25 micrograms/ml in group 1 patients and 11.59 +/- 3.95 and 0.89 +/- 0.57 micrograms/ml in group 2 patients.","Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185690/),[μg] / [ml],0.54,225641,DB00537,Ciprofloxacin
,2185690,trough levels,"Peak and trough levels in plasma were, respectively, 6.19 +/- 1.73 and 0.54 +/- 0.25 micrograms/ml in group 1 patients and 11.59 +/- 3.95 and 0.89 +/- 0.57 micrograms/ml in group 2 patients.","Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185690/),[μg] / [ml],0.89,225642,DB00537,Ciprofloxacin
,2185690,Peak concentrations,Peak concentrations in myocardia were achieved by hour 1 and were 31.6 +/- 25.0 micrograms/g for group 1 and 21.8 +/- 13.0 micrograms/g for group 2.,"Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185690/),[μg] / [g],31.6,225643,DB00537,Ciprofloxacin
,2185690,Peak concentrations,Peak concentrations in myocardia were achieved by hour 1 and were 31.6 +/- 25.0 micrograms/g for group 1 and 21.8 +/- 13.0 micrograms/g for group 2.,"Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185690/),[μg] / [g],21.8,225644,DB00537,Ciprofloxacin
,2185690,Peak concentrations,"Peak concentrations in heart valves, achieved between hours 1 and 3, were 5.8 +/- 3.2 and 8.3 +/- 3.1 micrograms/g for groups 1 and 2, respectively.","Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185690/),[μg] / [g],5.8,225645,DB00537,Ciprofloxacin
,2185690,Peak concentrations,"Peak concentrations in heart valves, achieved between hours 1 and 3, were 5.8 +/- 3.2 and 8.3 +/- 3.1 micrograms/g for groups 1 and 2, respectively.","Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185690/),[μg] / [g],8.3,225646,DB00537,Ciprofloxacin
,3176294,elimination half-life,"Ciprofloxacin was rapidly and well distributed in the body, exhibited a short elimination half-life of 2.5 h in both species, and was rapidly absorbed after oral administration (Tmax:2 to 3 h).","Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176294/),h,2.5,225987,DB00537,Ciprofloxacin
,3176294,Tmax,"Ciprofloxacin was rapidly and well distributed in the body, exhibited a short elimination half-life of 2.5 h in both species, and was rapidly absorbed after oral administration (Tmax:2 to 3 h).","Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176294/),h,2 to 3,225988,DB00537,Ciprofloxacin
,3176294,oral bioavailability,The oral bioavailability in calves was 53 +/- 14% and for 1 pig 37.3%.,"Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176294/),%,53,225989,DB00537,Ciprofloxacin
,3176294,oral bioavailability,The oral bioavailability in calves was 53 +/- 14% and for 1 pig 37.3%.,"Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176294/),%,37.3,225990,DB00537,Ciprofloxacin
>,15196904,recoveries,Analyte recoveries were > 87%.,Detection of enrofloxacin and its metabolite ciprofloxacin in equine hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196904/),%,87,226305,DB00537,Ciprofloxacin
,15196904,ratios,"Enrofloxacin:ciprofloxacin ratios were 21:1 and 13:1 following intravenous and oral administration, respectively.",Detection of enrofloxacin and its metabolite ciprofloxacin in equine hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196904/),,21,226306,DB00537,Ciprofloxacin
,15196904,ratios,"Enrofloxacin:ciprofloxacin ratios were 21:1 and 13:1 following intravenous and oral administration, respectively.",Detection of enrofloxacin and its metabolite ciprofloxacin in equine hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196904/),,13,226307,DB00537,Ciprofloxacin
,3578321,Peak serum concentration (Cmax),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f), and apparent volume of distribution (Vd/f) of ciprofloxacin were 5.97 +/- 2.95 mg/liter, 5.31 +/- 2.00 hours, 8.12 +/- 3.83 ml/kg/minute, and 3.63 +/- 1.91 liters/kg during the period of acute illness.",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),[mg] / [l],5.97,226785,DB00537,Ciprofloxacin
,3578321,terminal elimination half-life (t1/2 beta),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f), and apparent volume of distribution (Vd/f) of ciprofloxacin were 5.97 +/- 2.95 mg/liter, 5.31 +/- 2.00 hours, 8.12 +/- 3.83 ml/kg/minute, and 3.63 +/- 1.91 liters/kg during the period of acute illness.",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),h,5.31,226786,DB00537,Ciprofloxacin
,3578321,terminal elimination half-life (t1/2 beta),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f), and apparent volume of distribution (Vd/f) of ciprofloxacin were 5.97 +/- 2.95 mg/liter, 5.31 +/- 2.00 hours, 8.12 +/- 3.83 ml/kg/minute, and 3.63 +/- 1.91 liters/kg during the period of acute illness.",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),[ml] / [kg·min],8.12,226787,DB00537,Ciprofloxacin
,3578321,apparent total body clearance (CL/f),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f), and apparent volume of distribution (Vd/f) of ciprofloxacin were 5.97 +/- 2.95 mg/liter, 5.31 +/- 2.00 hours, 8.12 +/- 3.83 ml/kg/minute, and 3.63 +/- 1.91 liters/kg during the period of acute illness.",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),h,5.31,226788,DB00537,Ciprofloxacin
,3578321,apparent total body clearance (CL/f),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f), and apparent volume of distribution (Vd/f) of ciprofloxacin were 5.97 +/- 2.95 mg/liter, 5.31 +/- 2.00 hours, 8.12 +/- 3.83 ml/kg/minute, and 3.63 +/- 1.91 liters/kg during the period of acute illness.",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),[ml] / [kg·min],8.12,226789,DB00537,Ciprofloxacin
,3578321,apparent volume of distribution (Vd/f),"Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f), and apparent volume of distribution (Vd/f) of ciprofloxacin were 5.97 +/- 2.95 mg/liter, 5.31 +/- 2.00 hours, 8.12 +/- 3.83 ml/kg/minute, and 3.63 +/- 1.91 liters/kg during the period of acute illness.",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),[l] / [kg],3.63,226790,DB00537,Ciprofloxacin
,3578321,Cmax,"Cmax and Vd/f values were moderately increased during the convalescent phase (8.56 +/- 3.43 mg/liter versus 5.87 +/- 2.25 mg/liter, p = 0.138, and 5.95 +/- 3.23 liters/kg versus 3.46 +/- 1.40 liters/kg, 0.05 less than p less than 0.1).",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),[mg] / [l],8.56,226791,DB00537,Ciprofloxacin
,3578321,Cmax,"Cmax and Vd/f values were moderately increased during the convalescent phase (8.56 +/- 3.43 mg/liter versus 5.87 +/- 2.25 mg/liter, p = 0.138, and 5.95 +/- 3.23 liters/kg versus 3.46 +/- 1.40 liters/kg, 0.05 less than p less than 0.1).",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),[mg] / [l],5.87,226792,DB00537,Ciprofloxacin
,3578321,Vd/f,"Cmax and Vd/f values were moderately increased during the convalescent phase (8.56 +/- 3.43 mg/liter versus 5.87 +/- 2.25 mg/liter, p = 0.138, and 5.95 +/- 3.23 liters/kg versus 3.46 +/- 1.40 liters/kg, 0.05 less than p less than 0.1).",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),[l] / [kg],5.95,226793,DB00537,Ciprofloxacin
,3578321,Vd/f,"Cmax and Vd/f values were moderately increased during the convalescent phase (8.56 +/- 3.43 mg/liter versus 5.87 +/- 2.25 mg/liter, p = 0.138, and 5.95 +/- 3.23 liters/kg versus 3.46 +/- 1.40 liters/kg, 0.05 less than p less than 0.1).",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),[l] / [kg],3.46,226794,DB00537,Ciprofloxacin
,3578321,t1/2 beta,"The CL/f and t1/2 beta (four to 12 hours) values, however, were not significantly altered.",Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578321/),h,four to 12,226795,DB00537,Ciprofloxacin
,1656737,minimum inhibitory concentration,"Azithromycin is an azalide antibiotic that has a minimum inhibitory concentration against C. trachomatis of between 0.03 and 0.25 mg/L, as well as good in vitro activity against other sexually transmitted pathogens that are often present concurrently.",Azithromycin in the treatment of uncomplicated genital chlamydial infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1656737/),[mg] / [l],0.03 and 0.25,227033,DB00537,Ciprofloxacin
,1656737,tissue half-life,"More importantly, azithromycin has high tissue bioavailability and a tissue half-life of between 2 and 4 days.",Azithromycin in the treatment of uncomplicated genital chlamydial infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1656737/),d,2 and 4,227034,DB00537,Ciprofloxacin
,10949977,"terminal elimination half-life (t(1/2,lambda z))","Results showed that the disposition of ciprofloxacin in control animals was biexponential with a mean (+/-SD) terminal elimination half-life (t(1/2,lambda z)) of 0.93+/-0.30 h.",Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10949977/),h,0.93,227273,DB00537,Ciprofloxacin
,10949977,"apparent volume of distribution (V(d,lambda z)","A large apparent volume of distribution (V(d,lambda z): 6.96+/-1.56 L/kg) was observed.",Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10949977/),[l] / [kg],6.96,227274,DB00537,Ciprofloxacin
,10949977,AUC(0-infinity),"Relative to controls, antibiotic exposure (AUC(0-infinity) was also significantly higher (p<0.05) in the presence of iron (1.89+/-0.15 vs. 1.00+/-0.39 mg/h/L).",Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10949977/),[mg] / [h·l],1.89,227275,DB00537,Ciprofloxacin
,10949977,AUC(0-infinity),"Relative to controls, antibiotic exposure (AUC(0-infinity) was also significantly higher (p<0.05) in the presence of iron (1.89+/-0.15 vs. 1.00+/-0.39 mg/h/L).",Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10949977/),[mg] / [h·l],1.00,227276,DB00537,Ciprofloxacin
,10949977,M/H ratios,A strong assay dependency was observed for ciprofloxacin concentrations observed post-distribution; the respective M/H ratios for AUC(0-infinity) and urinary recovery were 1.1 and 0.9 for controls and 0.7 and 0.5 for animals receiving oral iron.,Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10949977/),,1.1,227277,DB00537,Ciprofloxacin
,10949977,M/H ratios,A strong assay dependency was observed for ciprofloxacin concentrations observed post-distribution; the respective M/H ratios for AUC(0-infinity) and urinary recovery were 1.1 and 0.9 for controls and 0.7 and 0.5 for animals receiving oral iron.,Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10949977/),,0.9,227278,DB00537,Ciprofloxacin
,10949977,M/H ratios,A strong assay dependency was observed for ciprofloxacin concentrations observed post-distribution; the respective M/H ratios for AUC(0-infinity) and urinary recovery were 1.1 and 0.9 for controls and 0.7 and 0.5 for animals receiving oral iron.,Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10949977/),,0.7,227279,DB00537,Ciprofloxacin
,10949977,M/H ratios,A strong assay dependency was observed for ciprofloxacin concentrations observed post-distribution; the respective M/H ratios for AUC(0-infinity) and urinary recovery were 1.1 and 0.9 for controls and 0.7 and 0.5 for animals receiving oral iron.,Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10949977/),,0.5,227280,DB00537,Ciprofloxacin
,2128442,peak concentration,The mean (+/- the standard deviation) peak concentration in plasma was 8.2 +/- 4.0 mg/liter at 8.3 h.,Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),[mg] / [l],8.2,227286,DB00537,Ciprofloxacin
,2128442,elimination half-life,"The harmonic mean elimination half-life was 10.5 h, which is comparable to that reported for healthy volunteers.",Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),h,10.5,227287,DB00537,Ciprofloxacin
,2128442,renal clearance,"This increase resulted from reduced renal clearance (mean [+/- standard deviation], 38 +/- 22 ml/min), as the volume of distribution in the patients (1.4 +/- 0.7 liter/kg) did not differ from that reported for healthy subjects.",Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),[ml] / [min],38,227288,DB00537,Ciprofloxacin
,2128442,volume of distribution,"This increase resulted from reduced renal clearance (mean [+/- standard deviation], 38 +/- 22 ml/min), as the volume of distribution in the patients (1.4 +/- 0.7 liter/kg) did not differ from that reported for healthy subjects.",Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),[l] / [kg],1.4,227289,DB00537,Ciprofloxacin
,2128442,Maximum concentrations,"Maximum concentrations in T-drain bile were high (median, 22.1 mg/liter) and exceeded those measured in plasma by a factor of 2 to 3; the individual ratios of the area under the curve for bile divided by that for plasma ranged from 1.3 to 9.9.",Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),[mg] / [l],22.1,227290,DB00537,Ciprofloxacin
less,2508586,minimum inhibitory concentrations,Patients infected with Enterobacteriaceae or Haemophilus influenzae with minimum inhibitory concentrations of less than 0.25 mg/L responded well to intravenous ciprofloxacin therapy (200 mg every 12 hours).,"Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508586/),[mg] / [l],0.25,227291,DB00537,Ciprofloxacin
<,1444310,MICs,"Since the MICs for 90% of all Enterobacteriaceae are <2 micrograms/ml, fleroxacin should be particularly useful in treating gram-negative infections affecting these tissues.","Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444310/),[μg] / [ml],2,229014,DB00537,Ciprofloxacin
,3830244,peak plasma concentration,The peak plasma concentration (2-5 mg X l-1) was reached within 2 h after drug administration.,Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[mg] / [l],2-5,229069,DB00537,Ciprofloxacin
,3830244,Apparent volume of distribution,"Apparent volume of distribution, 6.6 (N), 5.0 (I), 2.7 (II) and 4.2 (IIIa) l X kg-1 and total plasma clearance, 770 (N), 440 (I), 378 (II) and 314 (IIIa) ml X min-1 were decreased in relation to the degree of renal impairment.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[l] / [kg],6.6,229070,DB00537,Ciprofloxacin
,3830244,Apparent volume of distribution,"Apparent volume of distribution, 6.6 (N), 5.0 (I), 2.7 (II) and 4.2 (IIIa) l X kg-1 and total plasma clearance, 770 (N), 440 (I), 378 (II) and 314 (IIIa) ml X min-1 were decreased in relation to the degree of renal impairment.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[l] / [kg],5.0,229071,DB00537,Ciprofloxacin
,3830244,Apparent volume of distribution,"Apparent volume of distribution, 6.6 (N), 5.0 (I), 2.7 (II) and 4.2 (IIIa) l X kg-1 and total plasma clearance, 770 (N), 440 (I), 378 (II) and 314 (IIIa) ml X min-1 were decreased in relation to the degree of renal impairment.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[l] / [kg],2.7,229072,DB00537,Ciprofloxacin
,3830244,Apparent volume of distribution,"Apparent volume of distribution, 6.6 (N), 5.0 (I), 2.7 (II) and 4.2 (IIIa) l X kg-1 and total plasma clearance, 770 (N), 440 (I), 378 (II) and 314 (IIIa) ml X min-1 were decreased in relation to the degree of renal impairment.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[l] / [kg],4.2,229073,DB00537,Ciprofloxacin
,3830244,total plasma clearance,"Apparent volume of distribution, 6.6 (N), 5.0 (I), 2.7 (II) and 4.2 (IIIa) l X kg-1 and total plasma clearance, 770 (N), 440 (I), 378 (II) and 314 (IIIa) ml X min-1 were decreased in relation to the degree of renal impairment.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[ml] / [min],770,229074,DB00537,Ciprofloxacin
,3830244,total plasma clearance,"Apparent volume of distribution, 6.6 (N), 5.0 (I), 2.7 (II) and 4.2 (IIIa) l X kg-1 and total plasma clearance, 770 (N), 440 (I), 378 (II) and 314 (IIIa) ml X min-1 were decreased in relation to the degree of renal impairment.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[ml] / [min],440,229075,DB00537,Ciprofloxacin
,3830244,total plasma clearance,"Apparent volume of distribution, 6.6 (N), 5.0 (I), 2.7 (II) and 4.2 (IIIa) l X kg-1 and total plasma clearance, 770 (N), 440 (I), 378 (II) and 314 (IIIa) ml X min-1 were decreased in relation to the degree of renal impairment.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[ml] / [min],378,229076,DB00537,Ciprofloxacin
,3830244,total plasma clearance,"Apparent volume of distribution, 6.6 (N), 5.0 (I), 2.7 (II) and 4.2 (IIIa) l X kg-1 and total plasma clearance, 770 (N), 440 (I), 378 (II) and 314 (IIIa) ml X min-1 were decreased in relation to the degree of renal impairment.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[ml] / [min],314,229077,DB00537,Ciprofloxacin
,3830244,plasma half-lives,"Mean plasma half-lives for patients in the 4 groups were 7.3 (N), 10.4 (I), 7.2 (II) and 9.3 (IIIa) h.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),h,7.3,229078,DB00537,Ciprofloxacin
,3830244,plasma half-lives,"Mean plasma half-lives for patients in the 4 groups were 7.3 (N), 10.4 (I), 7.2 (II) and 9.3 (IIIa) h.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),h,10.4,229079,DB00537,Ciprofloxacin
,3830244,plasma half-lives,"Mean plasma half-lives for patients in the 4 groups were 7.3 (N), 10.4 (I), 7.2 (II) and 9.3 (IIIa) h.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),h,7.2,229080,DB00537,Ciprofloxacin
,3830244,plasma half-lives,"Mean plasma half-lives for patients in the 4 groups were 7.3 (N), 10.4 (I), 7.2 (II) and 9.3 (IIIa) h.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),h,9.3,229081,DB00537,Ciprofloxacin
,3830244,renal clearances,"In groups N, I and II, 40, 16 and 8% of the administered dose was eliminated through the kidney, with mean renal clearances of 305 +/- 63, 61 +/- 21 and 21 +/- 3 ml X min-1.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[ml] / [min],305,229082,DB00537,Ciprofloxacin
,3830244,renal clearances,"In groups N, I and II, 40, 16 and 8% of the administered dose was eliminated through the kidney, with mean renal clearances of 305 +/- 63, 61 +/- 21 and 21 +/- 3 ml X min-1.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[ml] / [min],61,229083,DB00537,Ciprofloxacin
,3830244,renal clearances,"In groups N, I and II, 40, 16 and 8% of the administered dose was eliminated through the kidney, with mean renal clearances of 305 +/- 63, 61 +/- 21 and 21 +/- 3 ml X min-1.",Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[ml] / [min],21,229084,DB00537,Ciprofloxacin
,3830244,extraction ratio,Ciprofloxacin was partly removed by haemodialysis (IIIb): the dialyser extraction ratio was 23% and the dialysis clearance was 40 ml X min-1.,Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),%,23,229085,DB00537,Ciprofloxacin
,3830244,clearance,Ciprofloxacin was partly removed by haemodialysis (IIIb): the dialyser extraction ratio was 23% and the dialysis clearance was 40 ml X min-1.,Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830244/),[ml] / [min],40,229086,DB00537,Ciprofloxacin
,12902890,overall response rate,"The overall response rate was 49%, which included 3 of 29 complete responses (10%) and 11 of 29 partial responses (38%).",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),%,49,229295,DB00537,Ciprofloxacin
,12902890,complete,"Median complete and partial response durations were 20+ and 5.5 months, respectively.",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),month,20,229296,DB00537,Ciprofloxacin
,12902890,partial response durations,"Median complete and partial response durations were 20+ and 5.5 months, respectively.",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),month,5.5,229297,DB00537,Ciprofloxacin
,12902890,Overall median survival,"Overall median survival was 10 months (range, 2-30+).",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),month,10,229298,DB00537,Ciprofloxacin
,11696079,elimination half-lives (t1/2beta),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t1/2beta) were 3.37 +/- 0.46, 4.66 +/- 1.34, 7.20 +/- 1.92 (pigs) and 2.53 +/- 0.82, 6.81 +/- 2.04, 3.89 +/- 1.19 h (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),,3.37,229520,DB00537,Ciprofloxacin
,11696079,elimination half-lives (t1/2beta),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t1/2beta) were 3.37 +/- 0.46, 4.66 +/- 1.34, 7.20 +/- 1.92 (pigs) and 2.53 +/- 0.82, 6.81 +/- 2.04, 3.89 +/- 1.19 h (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),,4.66,229521,DB00537,Ciprofloxacin
,11696079,elimination half-lives (t1/2beta),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t1/2beta) were 3.37 +/- 0.46, 4.66 +/- 1.34, 7.20 +/- 1.92 (pigs) and 2.53 +/- 0.82, 6.81 +/- 2.04, 3.89 +/- 1.19 h (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),h,7.20,229522,DB00537,Ciprofloxacin
,11696079,elimination half-lives (t1/2beta),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t1/2beta) were 3.37 +/- 0.46, 4.66 +/- 1.34, 7.20 +/- 1.92 (pigs) and 2.53 +/- 0.82, 6.81 +/- 2.04, 3.89 +/- 1.19 h (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),h,2.53,229523,DB00537,Ciprofloxacin
,11696079,elimination half-lives (t1/2beta),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t1/2beta) were 3.37 +/- 0.46, 4.66 +/- 1.34, 7.20 +/- 1.92 (pigs) and 2.53 +/- 0.82, 6.81 +/- 2.04, 3.89 +/- 1.19 h (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),h,6.81,229524,DB00537,Ciprofloxacin
,11696079,elimination half-lives (t1/2beta),"Following i.v., i.m. and p.o. doses, the elimination half-lives (t1/2beta) were 3.37 +/- 0.46, 4.66 +/- 1.34, 7.20 +/- 1.92 (pigs) and 2.53 +/- 0.82, 6.81 +/- 2.04, 3.89 +/- 1.19 h (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),h,3.89,229525,DB00537,Ciprofloxacin
,11696079,bioavailabilities (F),"After i.m. and p.o. doses, bioavailabilities (F) were 81.8 +/- 9.8 and 42.6 +/- 8.2% (pigs) and 72.1 +/- 8.1 and 59.6 +/- 13.8% (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),%,81.8,229526,DB00537,Ciprofloxacin
,11696079,bioavailabilities (F),"After i.m. and p.o. doses, bioavailabilities (F) were 81.8 +/- 9.8 and 42.6 +/- 8.2% (pigs) and 72.1 +/- 8.1 and 59.6 +/- 13.8% (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),%,42.6,229527,DB00537,Ciprofloxacin
,11696079,bioavailabilities (F),"After i.m. and p.o. doses, bioavailabilities (F) were 81.8 +/- 9.8 and 42.6 +/- 8.2% (pigs) and 72.1 +/- 8.1 and 59.6 +/- 13.8% (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),%,72.1,229528,DB00537,Ciprofloxacin
,11696079,bioavailabilities (F),"After i.m. and p.o. doses, bioavailabilities (F) were 81.8 +/- 9.8 and 42.6 +/- 8.2% (pigs) and 72.1 +/- 8.1 and 59.6 +/- 13.8% (broilers), respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),%,59.6,229529,DB00537,Ciprofloxacin
,11696079,Steady-state distribution volumes (Vd(ss)),"Steady-state distribution volumes (Vd(ss)) of 1.92 +/- 0.27 and 3.40 +/- 1.26 L/kg and total body clearances (ClB) of 0.51 +/- 0.03 and 1.20 +/- 0.20 L/kg/h were determined in pigs and broilers, respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),[l] / [kg],1.92,229530,DB00537,Ciprofloxacin
,11696079,Steady-state distribution volumes (Vd(ss)),"Steady-state distribution volumes (Vd(ss)) of 1.92 +/- 0.27 and 3.40 +/- 1.26 L/kg and total body clearances (ClB) of 0.51 +/- 0.03 and 1.20 +/- 0.20 L/kg/h were determined in pigs and broilers, respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),[l] / [kg],3.40,229531,DB00537,Ciprofloxacin
,11696079,total body clearances (ClB),"Steady-state distribution volumes (Vd(ss)) of 1.92 +/- 0.27 and 3.40 +/- 1.26 L/kg and total body clearances (ClB) of 0.51 +/- 0.03 and 1.20 +/- 0.20 L/kg/h were determined in pigs and broilers, respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),[l] / [h·kg],0.51,229532,DB00537,Ciprofloxacin
,11696079,total body clearances (ClB),"Steady-state distribution volumes (Vd(ss)) of 1.92 +/- 0.27 and 3.40 +/- 1.26 L/kg and total body clearances (ClB) of 0.51 +/- 0.03 and 1.20 +/- 0.20 L/kg/h were determined in pigs and broilers, respectively.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),[l] / [h·kg],1.20,229533,DB00537,Ciprofloxacin
<,11696079,MIC90,"Based on the single-dose pharmacokinetic parameters determined, multiple dosage regimens were recommended as: a dosage of 10 mg/kg given intramuscularly every 12 h in pigs, or administered orally every 8 h in broilers, can maintain effective plasma concentrations with bacteria infections, in which MIC90 are <0.25 microg/mL.","Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696079/),[μg] / [ml],0.25,229534,DB00537,Ciprofloxacin
less,2808194,MICs,"The MICs of temafloxacin for 90% of Haemophilus influenzae, Neisseria spp., Enterobacteriaceae, Bacteroides fragilis and Ch. trachomatis were all less than or equal to 1 mg/l, an activity comparable with or superior to that of ofloxacin and superior to those of fleroxacin and norfloxacin.","The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),[mg] / [l],1,229876,DB00537,Ciprofloxacin
,2808194,peak plasma levels,Mean peak plasma levels of 3.3 mg/l were achieved.,"The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),[mg] / [l],3.3,229877,DB00537,Ciprofloxacin
,2808194,plasma elimination half life,The mean plasma elimination half life was 6.8 h and the percentage penetration into blister fluid was 104.5%.,"The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),h,6.8,229878,DB00537,Ciprofloxacin
,2808194,percentage penetration into blister fluid,The mean plasma elimination half life was 6.8 h and the percentage penetration into blister fluid was 104.5%.,"The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),%,104.5,229879,DB00537,Ciprofloxacin
,8586400,C0,"Its main pharmacokinetic parameters were: C0 4.61 +/- 1.64 mg/L, t1/2 beta 3.86 +/- 0.67 h and AUC 7.06 +/- 1.21 mg/L.h.",[Pharmacokinetics of ciprofloxacin injection in healthy volunteers]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8586400/),[mg] / [l],4.61,230100,DB00537,Ciprofloxacin
,8586400,t1/2 beta,"Its main pharmacokinetic parameters were: C0 4.61 +/- 1.64 mg/L, t1/2 beta 3.86 +/- 0.67 h and AUC 7.06 +/- 1.21 mg/L.h.",[Pharmacokinetics of ciprofloxacin injection in healthy volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8586400/),h,3.86,230101,DB00537,Ciprofloxacin
,8586400,AUC,"Its main pharmacokinetic parameters were: C0 4.61 +/- 1.64 mg/L, t1/2 beta 3.86 +/- 0.67 h and AUC 7.06 +/- 1.21 mg/L.h.",[Pharmacokinetics of ciprofloxacin injection in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8586400/),[mg] / [h·l],7.06,230102,DB00537,Ciprofloxacin
,8586400,urinary recovery rate,The urinary recovery rate of ciprofloxacin over 12 h after dosing was 60.85%.,[Pharmacokinetics of ciprofloxacin injection in healthy volunteers]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8586400/),%,60.85,230103,DB00537,Ciprofloxacin
,7625789,bioavailabilities,"Following oral administration of medicated feed, the bioavailabilities of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 30.1, 44.7, 2.2, and 55.5%, respectively.","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),%,30.1,230418,DB00537,Ciprofloxacin
,7625789,bioavailabilities,"Following oral administration of medicated feed, the bioavailabilities of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 30.1, 44.7, 2.2, and 55.5%, respectively.","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),%,44.7,230419,DB00537,Ciprofloxacin
,7625789,bioavailabilities,"Following oral administration of medicated feed, the bioavailabilities of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 30.1, 44.7, 2.2, and 55.5%, respectively.","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),%,2.2,230420,DB00537,Ciprofloxacin
,7625789,bioavailabilities,"Following oral administration of medicated feed, the bioavailabilities of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 30.1, 44.7, 2.2, and 55.5%, respectively.","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),%,55.5,230421,DB00537,Ciprofloxacin
,7625789,volumes of distribution at steady state,"Following intravenous administration, the volumes of distribution at steady state of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 5.4, 3.5, 2.3, and 6.1 liters/kg, respectively.","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),[l] / [kg],5.4,230422,DB00537,Ciprofloxacin
,7625789,volumes of distribution at steady state,"Following intravenous administration, the volumes of distribution at steady state of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 5.4, 3.5, 2.3, and 6.1 liters/kg, respectively.","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),[l] / [kg],3.5,230423,DB00537,Ciprofloxacin
,7625789,volumes of distribution at steady state,"Following intravenous administration, the volumes of distribution at steady state of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 5.4, 3.5, 2.3, and 6.1 liters/kg, respectively.","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),[l] / [kg],2.3,230424,DB00537,Ciprofloxacin
,7625789,volumes of distribution at steady state,"Following intravenous administration, the volumes of distribution at steady state of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 5.4, 3.5, 2.3, and 6.1 liters/kg, respectively.","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),[l] / [kg],6.1,230425,DB00537,Ciprofloxacin
less,7625789,elimination half-life,"The elimination half-life of three of the quinolones, oxolinic acid, flumequine, and sarafloxacin, was less than or equal to 24 h, with oxolinic acid showing the shortest (18.2 h).","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),h,24,230426,DB00537,Ciprofloxacin
,7625789,elimination half-life,"The elimination half-life of three of the quinolones, oxolinic acid, flumequine, and sarafloxacin, was less than or equal to 24 h, with oxolinic acid showing the shortest (18.2 h).","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),h,18.2,230427,DB00537,Ciprofloxacin
,7625789,elimination half-life,"On the other hand, the elimination half-life of enrofloxacin was estimated to be 34.2 h, almost twice that of oxolinic acid.","Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625789/),h,34.2,230428,DB00537,Ciprofloxacin
,10049257,half-lives,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),h,9.2,230600,DB00537,Ciprofloxacin
,10049257,half-lives,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),h,4,230601,DB00537,Ciprofloxacin
,10049257,ratios of area under the concentration-time curve (AUC) to MIC,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),[h·μg] / [milliliter]],58 to 466,230602,DB00537,Ciprofloxacin
,10049257,ratios of area under the concentration-time curve (AUC) to MIC,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),[h·μg] / [milliliter]],116 to 932,230603,DB00537,Ciprofloxacin
,10049257,ratios of area under the concentration-time curve (AUC) to MIC,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),[h·μg] / [milliliter]],58,230604,DB00537,Ciprofloxacin
,10049257,ratios of area under the concentration-time curve (AUC) to MIC,"A series of pharmacokinetic profiles of trovafloxacin and ciprofloxacin with respective half-lives of 9.2 and 4 h were simulated at different ratios of area under the concentration-time curve (AUC) to MIC (in [micrograms x hours/milliliter]/[micrograms/milliliter]): 58 to 466 with trovafloxacin and 116 to 932 with ciprofloxacin for S. aureus and 58 to 233 and 116 to 466 for E. coli, respectively.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),[h·μg] / [milliliter]],116,230605,DB00537,Ciprofloxacin
,10049257,c/b ratios,"Since the c/b ratios for trovafloxacin and ciprofloxacin against E. coli were much lower (0.3 to 0.4) than that for ampicillin-sulbactam as examined previously (1.9), the inoculum effect with the quinolones may be much less pronounced than with the beta-lactams.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),,0.3 to 0.4,230606,DB00537,Ciprofloxacin
,10049257,c/b ratios,"Since the c/b ratios for trovafloxacin and ciprofloxacin against E. coli were much lower (0.3 to 0.4) than that for ampicillin-sulbactam as examined previously (1.9), the inoculum effect with the quinolones may be much less pronounced than with the beta-lactams.",Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049257/),,1,230607,DB00537,Ciprofloxacin
,15907873,half-time of absorption (T1/2Ka),"After oral gavage in eels, the half-time of absorption (T1/2Ka) was 0.10 h, the half-time of elimination (T1/2Ke) was 51.87 h, and the maximum plasma concentration (Cmax) was 0.4552 microg/ml at Tmax 0.88 h.",Pharmacokinetics of ciprofloxacin in eels by high-performance liquid chromatography with fluorescence detection. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907873/),h,0.10,232054,DB00537,Ciprofloxacin
,15907873,half-time of elimination (T1/2Ke),"After oral gavage in eels, the half-time of absorption (T1/2Ka) was 0.10 h, the half-time of elimination (T1/2Ke) was 51.87 h, and the maximum plasma concentration (Cmax) was 0.4552 microg/ml at Tmax 0.88 h.",Pharmacokinetics of ciprofloxacin in eels by high-performance liquid chromatography with fluorescence detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907873/),h,51.87,232055,DB00537,Ciprofloxacin
,15907873,maximum plasma concentration (Cmax),"After oral gavage in eels, the half-time of absorption (T1/2Ka) was 0.10 h, the half-time of elimination (T1/2Ke) was 51.87 h, and the maximum plasma concentration (Cmax) was 0.4552 microg/ml at Tmax 0.88 h.",Pharmacokinetics of ciprofloxacin in eels by high-performance liquid chromatography with fluorescence detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907873/),[μg] / [ml],0.4552,232056,DB00537,Ciprofloxacin
,15907873,Tmax,"After oral gavage in eels, the half-time of absorption (T1/2Ka) was 0.10 h, the half-time of elimination (T1/2Ke) was 51.87 h, and the maximum plasma concentration (Cmax) was 0.4552 microg/ml at Tmax 0.88 h.",Pharmacokinetics of ciprofloxacin in eels by high-performance liquid chromatography with fluorescence detection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907873/),h,0.88,232057,DB00537,Ciprofloxacin
,15907873,(T1/2Ka),"After bath treatment, the (T1/2Ka) was 0.02 h, the (T1/2Ke) was 15.46 h, and the Cmax was 0.1175 microg/mL at Tmax 0.22 h.",Pharmacokinetics of ciprofloxacin in eels by high-performance liquid chromatography with fluorescence detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907873/),h,0.02,232058,DB00537,Ciprofloxacin
,15907873,(T1/2Ke),"After bath treatment, the (T1/2Ka) was 0.02 h, the (T1/2Ke) was 15.46 h, and the Cmax was 0.1175 microg/mL at Tmax 0.22 h.",Pharmacokinetics of ciprofloxacin in eels by high-performance liquid chromatography with fluorescence detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907873/),h,15.46,232059,DB00537,Ciprofloxacin
,15907873,Cmax,"After bath treatment, the (T1/2Ka) was 0.02 h, the (T1/2Ke) was 15.46 h, and the Cmax was 0.1175 microg/mL at Tmax 0.22 h.",Pharmacokinetics of ciprofloxacin in eels by high-performance liquid chromatography with fluorescence detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907873/),[μg] / [ml],0.1175,232060,DB00537,Ciprofloxacin
,15907873,Tmax,"After bath treatment, the (T1/2Ka) was 0.02 h, the (T1/2Ke) was 15.46 h, and the Cmax was 0.1175 microg/mL at Tmax 0.22 h.",Pharmacokinetics of ciprofloxacin in eels by high-performance liquid chromatography with fluorescence detection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907873/),h,0.22,232061,DB00537,Ciprofloxacin
,18931471,minimum inhibitory concentrations (MICs),Six isolates with levofloxacin minimum inhibitory concentrations (MICs) of 2 to 4 microg/mL were selected for this study.,Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18931471/),[μg] / [ml],2 to 4,232273,DB00537,Ciprofloxacin
,10428924,maximum concentrations (C(max)),"Mean maximum concentrations (C(max)) +/- standard deviations of enrofloxacin (0.24 +/- 0.08 microg/ml), ciprofloxacin (0.11 +/- 0.03 [total, 0.34 +/- 0.10] microg/ml), and danofloxacin (0.23 +/- 0.05 microg/ml) were detected in the plasma of calves by HPLC.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.24,232395,DB00537,Ciprofloxacin
,10428924,maximum concentrations (C(max)),"Mean maximum concentrations (C(max)) +/- standard deviations of enrofloxacin (0.24 +/- 0.08 microg/ml), ciprofloxacin (0.11 +/- 0.03 [total, 0.34 +/- 0.10] microg/ml), and danofloxacin (0.23 +/- 0.05 microg/ml) were detected in the plasma of calves by HPLC.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.11,232396,DB00537,Ciprofloxacin
,10428924,maximum concentrations (C(max)),"Mean maximum concentrations (C(max)) +/- standard deviations of enrofloxacin (0.24 +/- 0.08 microg/ml), ciprofloxacin (0.11 +/- 0.03 [total, 0.34 +/- 0.10] microg/ml), and danofloxacin (0.23 +/- 0.05 microg/ml) were detected in the plasma of calves by HPLC.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.34,232397,DB00537,Ciprofloxacin
,10428924,maximum concentrations (C(max)),"Mean maximum concentrations (C(max)) +/- standard deviations of enrofloxacin (0.24 +/- 0.08 microg/ml), ciprofloxacin (0.11 +/- 0.03 [total, 0.34 +/- 0.10] microg/ml), and danofloxacin (0.23 +/- 0.05 microg/ml) were detected in the plasma of calves by HPLC.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.23,232398,DB00537,Ciprofloxacin
,10428924,C(max),The C(max) were 0.49 +/- 0.17 microg/ml (enrofloxacin equivalents) and 0.24 +/- 0.03 microg/ml (danofloxacin) when they were measured by microbiological assay.,"Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.49,232399,DB00537,Ciprofloxacin
,10428924,C(max),The C(max) were 0.49 +/- 0.17 microg/ml (enrofloxacin equivalents) and 0.24 +/- 0.03 microg/ml (danofloxacin) when they were measured by microbiological assay.,"Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.24,232400,DB00537,Ciprofloxacin
,10428924,C(max),"Mean C(max) in exudate (HPLC) were 0.18 +/- 0.07 microg/ml (enrofloxacin), 0.10 +/- 0.04 microg/ml (ciprofloxacin), 0.27 +/- 0.09 microg/ml (enrofloxacin plus ciprofloxacin), and 0.19 +/- 0.05 microg/ml (danofloxacin), and concentrations in exudate exceeded those in plasma from 8 h (enrofloxacin and ciprofloxacin) or 6 h (danofloxacin) after drug administration.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.18,232401,DB00537,Ciprofloxacin
,10428924,C(max),"Mean C(max) in exudate (HPLC) were 0.18 +/- 0.07 microg/ml (enrofloxacin), 0.10 +/- 0.04 microg/ml (ciprofloxacin), 0.27 +/- 0.09 microg/ml (enrofloxacin plus ciprofloxacin), and 0.19 +/- 0.05 microg/ml (danofloxacin), and concentrations in exudate exceeded those in plasma from 8 h (enrofloxacin and ciprofloxacin) or 6 h (danofloxacin) after drug administration.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.10,232402,DB00537,Ciprofloxacin
,10428924,C(max),"Mean C(max) in exudate (HPLC) were 0.18 +/- 0.07 microg/ml (enrofloxacin), 0.10 +/- 0.04 microg/ml (ciprofloxacin), 0.27 +/- 0.09 microg/ml (enrofloxacin plus ciprofloxacin), and 0.19 +/- 0.05 microg/ml (danofloxacin), and concentrations in exudate exceeded those in plasma from 8 h (enrofloxacin and ciprofloxacin) or 6 h (danofloxacin) after drug administration.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.27,232403,DB00537,Ciprofloxacin
,10428924,C(max),"Mean C(max) in exudate (HPLC) were 0.18 +/- 0.07 microg/ml (enrofloxacin), 0.10 +/- 0.04 microg/ml (ciprofloxacin), 0.27 +/- 0.09 microg/ml (enrofloxacin plus ciprofloxacin), and 0.19 +/- 0.05 microg/ml (danofloxacin), and concentrations in exudate exceeded those in plasma from 8 h (enrofloxacin and ciprofloxacin) or 6 h (danofloxacin) after drug administration.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.19,232404,DB00537,Ciprofloxacin
,10428924,C(max),The C(max) were 0.34 +/- 0.09 microg/ml (enrofloxacin equivalents) and 0.22 +/- 0.04 microg/ml (danofloxacin) in exudate when they were measured by the microbiological assay.,"Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.34,232405,DB00537,Ciprofloxacin
,10428924,C(max),The C(max) were 0.34 +/- 0.09 microg/ml (enrofloxacin equivalents) and 0.22 +/- 0.04 microg/ml (danofloxacin) in exudate when they were measured by the microbiological assay.,"Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.22,232406,DB00537,Ciprofloxacin
,10428924,maximum mean concentration,"The maximum mean concentration achieved in bronchial secretions (HPLC) were 0.07 +/- 0.04 microg/ml (enrofloxacin), 0.04 +/- 0.07 microg/ml (ciprofloxacin), 0.10 +/- 0. 05 microg/ml (enrofloxacin plus ciprofloxacin), and 0.12 +/- 0.09 microg/ml (danofloxacin).","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.07,232407,DB00537,Ciprofloxacin
,10428924,maximum mean concentration,"The maximum mean concentration achieved in bronchial secretions (HPLC) were 0.07 +/- 0.04 microg/ml (enrofloxacin), 0.04 +/- 0.07 microg/ml (ciprofloxacin), 0.10 +/- 0. 05 microg/ml (enrofloxacin plus ciprofloxacin), and 0.12 +/- 0.09 microg/ml (danofloxacin).","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.04,232408,DB00537,Ciprofloxacin
,10428924,maximum mean concentration,"The maximum mean concentration achieved in bronchial secretions (HPLC) were 0.07 +/- 0.04 microg/ml (enrofloxacin), 0.04 +/- 0.07 microg/ml (ciprofloxacin), 0.10 +/- 0. 05 microg/ml (enrofloxacin plus ciprofloxacin), and 0.12 +/- 0.09 microg/ml (danofloxacin).","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.10,232409,DB00537,Ciprofloxacin
,10428924,maximum mean concentration,"The maximum mean concentration achieved in bronchial secretions (HPLC) were 0.07 +/- 0.04 microg/ml (enrofloxacin), 0.04 +/- 0.07 microg/ml (ciprofloxacin), 0.10 +/- 0. 05 microg/ml (enrofloxacin plus ciprofloxacin), and 0.12 +/- 0.09 microg/ml (danofloxacin).","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.12,232410,DB00537,Ciprofloxacin
,10428924,maximum mean concentration,The maximum mean concentration in bronchial secretions from a limited number of animals from which samples were available for microbiological assay were 0.27 +/- 0.11 microg/ml (n = 4 [enrofloxacin equivalents]) and 0.14 +/- 0.02 microg/ml (n = 3 [danofloxacin]).,"Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.27,232411,DB00537,Ciprofloxacin
,10428924,maximum mean concentration,The maximum mean concentration in bronchial secretions from a limited number of animals from which samples were available for microbiological assay were 0.27 +/- 0.11 microg/ml (n = 4 [enrofloxacin equivalents]) and 0.14 +/- 0.02 microg/ml (n = 3 [danofloxacin]).,"Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.14,232412,DB00537,Ciprofloxacin
,10428924,MIC,"With predictive models of efficacy (C(max)/MIC and area under the concentration-time curve/MIC ratios in plasma) for Pasteurella multocida (MIC of enrofloxacin, 0.06 microg/ml [24]; MIC of danofloxacin, 0.06 microg/ml [6]), enrofloxacin produced scores of 8.17 and 52.00, respectively, compared to those of danofloxacin, which were 4.02 and 23.05, respectively.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),[μg] / [ml],0.06,232413,DB00537,Ciprofloxacin
,10428924,MIC,"With predictive models of efficacy (C(max)/MIC and area under the concentration-time curve/MIC ratios in plasma) for Pasteurella multocida (MIC of enrofloxacin, 0.06 microg/ml [24]; MIC of danofloxacin, 0.06 microg/ml [6]), enrofloxacin produced scores of 8.17 and 52.00, respectively, compared to those of danofloxacin, which were 4.02 and 23.05, respectively.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),,8,232414,DB00537,Ciprofloxacin
,10428924,MIC,"With predictive models of efficacy (C(max)/MIC and area under the concentration-time curve/MIC ratios in plasma) for Pasteurella multocida (MIC of enrofloxacin, 0.06 microg/ml [24]; MIC of danofloxacin, 0.06 microg/ml [6]), enrofloxacin produced scores of 8.17 and 52.00, respectively, compared to those of danofloxacin, which were 4.02 and 23.05, respectively.","Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428924/),,52.00,232415,DB00537,Ciprofloxacin
,2255585,relative bioavailability,The relative bioavailability was 30% when ciprofloxacin was given with ferrous fumarate.,Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255585/),%,30,232540,DB00537,Ciprofloxacin
,2255585,maximum blood level,The maximum blood level decreased from 2.1 +/- 0.9 (control) to 0.6 +/- 0.2 mg/l (with ferrous fumarate).,Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255585/),[mg] / [l],2.1,232541,DB00537,Ciprofloxacin
,2255585,maximum blood level,The maximum blood level decreased from 2.1 +/- 0.9 (control) to 0.6 +/- 0.2 mg/l (with ferrous fumarate).,Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255585/),[mg] / [l],0.6,232542,DB00537,Ciprofloxacin
,32734117,half-lives (t ½),"The enrofloxacin and ciprofloxacin mean half-lives (t ½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h) were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (C max) were 12.31 and 0.24 µg/mL, respectively, and time required to reach the C max (T max) were 1 and 2 h respectively.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),h,0.95,232711,DB00537,Ciprofloxacin
,32734117,half-lives (t ½),"The enrofloxacin and ciprofloxacin mean half-lives (t ½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h) were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (C max) were 12.31 and 0.24 µg/mL, respectively, and time required to reach the C max (T max) were 1 and 2 h respectively.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),h,24.36,232712,DB00537,Ciprofloxacin
,32734117,half-lives (t ½),"The enrofloxacin and ciprofloxacin mean half-lives (t ½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h) were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (C max) were 12.31 and 0.24 µg/mL, respectively, and time required to reach the C max (T max) were 1 and 2 h respectively.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),h,11.06,232713,DB00537,Ciprofloxacin
,32734117,area under the curve (AUC0-24h),"The enrofloxacin and ciprofloxacin mean half-lives (t ½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h) were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (C max) were 12.31 and 0.24 µg/mL, respectively, and time required to reach the C max (T max) were 1 and 2 h respectively.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),[μg] / [h·ml],60.56,232714,DB00537,Ciprofloxacin
,32734117,area under the curve (AUC0-24h),"The enrofloxacin and ciprofloxacin mean half-lives (t ½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h) were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (C max) were 12.31 and 0.24 µg/mL, respectively, and time required to reach the C max (T max) were 1 and 2 h respectively.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),[μg] / [h·ml],3.14,232715,DB00537,Ciprofloxacin
,32734117,maximum concentrations (C max),"The enrofloxacin and ciprofloxacin mean half-lives (t ½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h) were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (C max) were 12.31 and 0.24 µg/mL, respectively, and time required to reach the C max (T max) were 1 and 2 h respectively.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),[μg] / [ml],12.31,232716,DB00537,Ciprofloxacin
,32734117,maximum concentrations (C max),"The enrofloxacin and ciprofloxacin mean half-lives (t ½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h) were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (C max) were 12.31 and 0.24 µg/mL, respectively, and time required to reach the C max (T max) were 1 and 2 h respectively.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),[μg] / [ml],0.24,232717,DB00537,Ciprofloxacin
,32734117,time required to reach the C max (T max),"The enrofloxacin and ciprofloxacin mean half-lives (t ½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h) were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (C max) were 12.31 and 0.24 µg/mL, respectively, and time required to reach the C max (T max) were 1 and 2 h respectively.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),h,1,232718,DB00537,Ciprofloxacin
,32734117,time required to reach the C max (T max),"The enrofloxacin and ciprofloxacin mean half-lives (t ½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h) were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (C max) were 12.31 and 0.24 µg/mL, respectively, and time required to reach the C max (T max) were 1 and 2 h respectively.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),h,2,232719,DB00537,Ciprofloxacin
≤,32734117,MIC,"Based on the pharmacokinetic indices when using susceptibility breakpoints when determined at mammalian body temperature it is predicted that single oral administration of enrofloxacin (10 mg/kg) would result in plasma concentrations effective against susceptible bacterial species inhibited by an enrofloxacin MIC ≤ 0.5 µg/mL in vitro, but additional studies will be required to determine its efficacy in vivo.",Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32734117/),[μg] / [ml],0.5,232720,DB00537,Ciprofloxacin
,14661070,plasma maximum concentration ( C(max)),"Across dose and study day, mean garenoxacin plasma maximum concentration ( C(max)) and area under the concentration-time curve (AUC(tau)) values were in the range 12-26 mg/l and 33-133 mgxh/l, respectively.",Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661070/),[mg] / [l],12-26,233549,DB00537,Ciprofloxacin
,14661070,area under the concentration-time curve (AUC(tau)),"Across dose and study day, mean garenoxacin plasma maximum concentration ( C(max)) and area under the concentration-time curve (AUC(tau)) values were in the range 12-26 mg/l and 33-133 mgxh/l, respectively.",Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661070/),[h·mg] / [l],33-133,233550,DB00537,Ciprofloxacin
,14661070,T(max),Values determined for T(max) (0.25-1.0 h) and T(1/2) (3.8-6.4 h) of garenoxacin in plasma did not vary with dose or study day.,Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661070/),h,0.25-1.0,233551,DB00537,Ciprofloxacin
,14661070,T(1/2),Values determined for T(max) (0.25-1.0 h) and T(1/2) (3.8-6.4 h) of garenoxacin in plasma did not vary with dose or study day.,Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661070/),h,3.8-6.4,233552,DB00537,Ciprofloxacin
≥,32307575,ƒAUC0-24/MIC,Target attainment of an ƒAUC0-24/MIC ≥ 100 for different MICs was calculated for standard dosing regimens.,Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32307575/),,100,233797,DB00537,Ciprofloxacin
,32307575,ƒAUC0-24,"The median ƒAUC0-24 and ƒCmax were 29.9 mg•h/L and 3.1 mg/L, respectively.",Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32307575/),[h·mg] / [l],29.9,233798,DB00537,Ciprofloxacin
,32307575,ƒCmax,"The median ƒAUC0-24 and ƒCmax were 29.9 mg•h/L and 3.1 mg/L, respectively.",Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32307575/),[mg] / [l],3.1,233799,DB00537,Ciprofloxacin
≥,32307575,ƒAUC0-24/MIC,"The proportion of patients achieving the target ƒAUC0-24/MIC ≥ 100 were 61.9% and 16.7% with MICs of 0.25 and 0.5 mg/L, respectively.",Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32307575/),,100,233800,DB00537,Ciprofloxacin
,32307575,MICs,"The proportion of patients achieving the target ƒAUC0-24/MIC ≥ 100 were 61.9% and 16.7% with MICs of 0.25 and 0.5 mg/L, respectively.",Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32307575/),[mg] / [l],0.25,233801,DB00537,Ciprofloxacin
,32307575,MICs,"The proportion of patients achieving the target ƒAUC0-24/MIC ≥ 100 were 61.9% and 16.7% with MICs of 0.25 and 0.5 mg/L, respectively.",Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32307575/),[mg] / [l],0.5,233802,DB00537,Ciprofloxacin
,9580344,partition coefficient,"The mean partition coefficient values obtained were 1.04 +/- 0.02 and 1.32 +/- 0.03 for ofloxacin and ciprofloxacin, respectively.",A comparative study of ofloxacin and ciprofloxacin erythrocyte distribution. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580344/),,1.04,233803,DB00537,Ciprofloxacin
,9580344,partition coefficient,"The mean partition coefficient values obtained were 1.04 +/- 0.02 and 1.32 +/- 0.03 for ofloxacin and ciprofloxacin, respectively.",A comparative study of ofloxacin and ciprofloxacin erythrocyte distribution. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580344/),,1.32,233804,DB00537,Ciprofloxacin
,9580344,partition coefficients,The partition coefficients obtained from the linear relationship between plasma and erythrocyte concentrations established from the in vivo data were 0.80 +/- 0.58 for ofloxacin and 0.61 +/- 0.30 for ciprofloxacin.,A comparative study of ofloxacin and ciprofloxacin erythrocyte distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580344/),,0.80,233805,DB00537,Ciprofloxacin
,9580344,partition coefficients,The partition coefficients obtained from the linear relationship between plasma and erythrocyte concentrations established from the in vivo data were 0.80 +/- 0.58 for ofloxacin and 0.61 +/- 0.30 for ciprofloxacin.,A comparative study of ofloxacin and ciprofloxacin erythrocyte distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580344/),,0.61,233806,DB00537,Ciprofloxacin
,26872361,MIC90,The pulmonary concentrations (enrofloxacin + ciprofloxacin combined) exceeded the MIC90 of 0.06 μg/mL at 48 hours after administration.,"Comparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or Tulathromycin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26872361/),[μg] / [ml],0.06,234114,DB00537,Ciprofloxacin
,26872361,MIC90,"For florfenicol, the interstitial fluid concentration was almost 98% of the plasma concentration, and the pulmonary concentrations were over 200% of the plasma concentrations, exceeding the breakpoint (≤ 2 μg/mL), and the MIC90 for Mannheimia haemolytica (1.0 μg/mL) for the duration of the study.","Comparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or Tulathromycin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26872361/),[μg] / [ml],1.0,234115,DB00537,Ciprofloxacin
≤,26872361,MIC,Airway concentrations exceeded the MIC breakpoint for susceptible respiratory pathogens (≤ 2 μg/mL) for a short time at 48 hours after administration.,"Comparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or Tulathromycin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26872361/),[μg] / [ml],2,234116,DB00537,Ciprofloxacin
,28470147,maximum concentration,"The urine OBFX concentration peaked at 0-4, 4-8 or 4-8 h after administration, with a maximum concentration of 383±171 µg ml-1.",Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28470147/),[μg] / [ml],383,234235,DB00537,Ciprofloxacin
,28470147,UBTs,"Notably, median UBTs and AUBTs were extremely low (0-0.5 and 2-5, respectively) in OBFX-resistant E. coli strains with MIC ≥8 µg ml-1.",Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28470147/),,0-0.5,234236,DB00537,Ciprofloxacin
,28470147,AUBTs,"Notably, median UBTs and AUBTs were extremely low (0-0.5 and 2-5, respectively) in OBFX-resistant E. coli strains with MIC ≥8 µg ml-1.",Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28470147/),,2-5,234237,DB00537,Ciprofloxacin
≥,28470147,MIC,"Notably, median UBTs and AUBTs were extremely low (0-0.5 and 2-5, respectively) in OBFX-resistant E. coli strains with MIC ≥8 µg ml-1.",Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28470147/),[μg] / [ml],8,234238,DB00537,Ciprofloxacin
,3207556,"oral clearance of theophylline at steady state, (CL/F)ss","The oral clearance of theophylline at steady state, (CL/F)ss, decreased from a mean (+/- s.d.) value of 0.035 (+/- 0.008) 1 h-1 kg-1 to 0.024 (+/- 0.004) 1 h-1 kg-1 during ciprofloxacin treatment.",Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207556/),[1] / [h·kg],0.035,234462,DB00537,Ciprofloxacin
,3207556,"oral clearance of theophylline at steady state, (CL/F)ss","The oral clearance of theophylline at steady state, (CL/F)ss, decreased from a mean (+/- s.d.) value of 0.035 (+/- 0.008) 1 h-1 kg-1 to 0.024 (+/- 0.004) 1 h-1 kg-1 during ciprofloxacin treatment.",Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207556/),[1] / [h·kg],0.024,234463,DB00537,Ciprofloxacin
,3207556,"clearance, CL/F","Single sample estimates of theophylline clearance, CL/F, similarly decreased from 0.040 (+/- 0.014) 1 h-1 kg-1 to 0.018 (+/- 0.008) 1 h-1 kg-1.",Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207556/),[1] / [h·kg],0.040,234464,DB00537,Ciprofloxacin
,3207556,"clearance, CL/F","Single sample estimates of theophylline clearance, CL/F, similarly decreased from 0.040 (+/- 0.014) 1 h-1 kg-1 to 0.018 (+/- 0.008) 1 h-1 kg-1.",Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207556/),[1] / [h·kg],0.018,234465,DB00537,Ciprofloxacin
,15934603,half-life,"Mean half-life following i.v., s.c., and p.o. administration was 11.2, 8.7, and 16.1 hours, respectively.","Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),h,11.2,234681,DB00537,Ciprofloxacin
,15934603,half-life,"Mean half-life following i.v., s.c., and p.o. administration was 11.2, 8.7, and 16.1 hours, respectively.","Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),h,8.7,234682,DB00537,Ciprofloxacin
,15934603,half-life,"Mean half-life following i.v., s.c., and p.o. administration was 11.2, 8.7, and 16.1 hours, respectively.","Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),h,16.1,234683,DB00537,Ciprofloxacin
,15934603,total systemic availability,"For s.c. and p.o administration, mean total systemic availability was 90.18% and 29.31%, respectively; mean maximum plasma concentration was 3.79 and 1.81 microg/mL, respectively; and area under the curve (AUC) was 50.05 and 33.97 (microg x h)/mL, respectively.","Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),%,90.18,234684,DB00537,Ciprofloxacin
,15934603,total systemic availability,"For s.c. and p.o administration, mean total systemic availability was 90.18% and 29.31%, respectively; mean maximum plasma concentration was 3.79 and 1.81 microg/mL, respectively; and area under the curve (AUC) was 50.05 and 33.97 (microg x h)/mL, respectively.","Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),%,29.31,234685,DB00537,Ciprofloxacin
,15934603,maximum plasma concentration,"For s.c. and p.o administration, mean total systemic availability was 90.18% and 29.31%, respectively; mean maximum plasma concentration was 3.79 and 1.81 microg/mL, respectively; and area under the curve (AUC) was 50.05 and 33.97 (microg x h)/mL, respectively.","Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),[μg] / [ml],3.79,234686,DB00537,Ciprofloxacin
,15934603,maximum plasma concentration,"For s.c. and p.o administration, mean total systemic availability was 90.18% and 29.31%, respectively; mean maximum plasma concentration was 3.79 and 1.81 microg/mL, respectively; and area under the curve (AUC) was 50.05 and 33.97 (microg x h)/mL, respectively.","Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),[μg] / [ml],1.81,234687,DB00537,Ciprofloxacin
,15934603,area under the curve (AUC),"For s.c. and p.o administration, mean total systemic availability was 90.18% and 29.31%, respectively; mean maximum plasma concentration was 3.79 and 1.81 microg/mL, respectively; and area under the curve (AUC) was 50.05 and 33.97 (microg x h)/mL, respectively.","Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),[h·μg] / [ml],50.05,234688,DB00537,Ciprofloxacin
,15934603,area under the curve (AUC),"For s.c. and p.o administration, mean total systemic availability was 90.18% and 29.31%, respectively; mean maximum plasma concentration was 3.79 and 1.81 microg/mL, respectively; and area under the curve (AUC) was 50.05 and 33.97 (microg x h)/mL, respectively.","Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),[h·μg] / [ml],33.97,234689,DB00537,Ciprofloxacin
>,15934603,ratio for AUC to minimum inhibitory concentration,The s.c. or p.o administration of a single dose of enrofloxacin yielded a ratio for AUC to minimum inhibitory concentration > 100 for many grampositive and gram-negative bacterial pathogens common to camelids.,"Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15934603/),,100,234690,DB00537,Ciprofloxacin
,16958784,"elimination half-lives (t(1/2,beta))","After intravenous and oral administrations of enrofloxacin, the elimination half-lives (t(1/2,beta)), area under the drug concentration-time curves (AUC), oral bioavailability (F) were 17.44 +/- 4.66 h and 34.13 +/- 11.50 h, 48.1 +/- 15.7 microgxh/mL and 27.3 +/- 12.4 microgxh/mL, and 64.59 +/- 4.58% respectively.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),h,17.44,234811,DB00537,Ciprofloxacin
,16958784,area under the drug concentration-time curves (AUC),"After intravenous and oral administrations of enrofloxacin, the elimination half-lives (t(1/2,beta)), area under the drug concentration-time curves (AUC), oral bioavailability (F) were 17.44 +/- 4.66 h and 34.13 +/- 11.50 h, 48.1 +/- 15.7 microgxh/mL and 27.3 +/- 12.4 microgxh/mL, and 64.59 +/- 4.58% respectively.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),h,34.13,234812,DB00537,Ciprofloxacin
,16958784,area under the drug concentration-time curves (AUC),"After intravenous and oral administrations of enrofloxacin, the elimination half-lives (t(1/2,beta)), area under the drug concentration-time curves (AUC), oral bioavailability (F) were 17.44 +/- 4.66 h and 34.13 +/- 11.50 h, 48.1 +/- 15.7 microgxh/mL and 27.3 +/- 12.4 microgxh/mL, and 64.59 +/- 4.58% respectively.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),[h·μg] / [ml],48.1,234813,DB00537,Ciprofloxacin
,16958784,area under the drug concentration-time curves (AUC),"After intravenous and oral administrations of enrofloxacin, the elimination half-lives (t(1/2,beta)), area under the drug concentration-time curves (AUC), oral bioavailability (F) were 17.44 +/- 4.66 h and 34.13 +/- 11.50 h, 48.1 +/- 15.7 microgxh/mL and 27.3 +/- 12.4 microgxh/mL, and 64.59 +/- 4.58% respectively.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),[h·μg] / [ml],27.3,234814,DB00537,Ciprofloxacin
,16958784,oral bioavailability (F),"After intravenous and oral administrations of enrofloxacin, the elimination half-lives (t(1/2,beta)), area under the drug concentration-time curves (AUC), oral bioavailability (F) were 17.44 +/- 4.66 h and 34.13 +/- 11.50 h, 48.1 +/- 15.7 microgxh/mL and 27.3 +/- 12.4 microgxh/mL, and 64.59 +/- 4.58% respectively.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),[h·μg] / [ml],27.3,234815,DB00537,Ciprofloxacin
,16958784,oral bioavailability (F),"After intravenous and oral administrations of enrofloxacin, the elimination half-lives (t(1/2,beta)), area under the drug concentration-time curves (AUC), oral bioavailability (F) were 17.44 +/- 4.66 h and 34.13 +/- 11.50 h, 48.1 +/- 15.7 microgxh/mL and 27.3 +/- 12.4 microgxh/mL, and 64.59 +/- 4.58% respectively.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),%,64.59,234816,DB00537,Ciprofloxacin
,16958784,maximum concentration (C(max)),The 3.44 +/- 0.81 h maximum concentration (C(max)) of 1.2 +/- 0.2 microg/mL.,Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),h,3.44,234817,DB00537,Ciprofloxacin
,16958784,maximum concentration (C(max)),The 3.44 +/- 0.81 h maximum concentration (C(max)) of 1.2 +/- 0.2 microg/mL.,Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),[μg] / [ml],1.2,234818,DB00537,Ciprofloxacin
,16958784,C(max),"Ciprofloxacin, an active metabolite of enrofloxacin, was detected at all the determined time-points from 0.25 to 72 h, with the C(max) of 0.17 +/- 0.08 microg/mL for intravenous dose.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),[μg] / [ml],0.17,234819,DB00537,Ciprofloxacin
,16958784,C(max),"After oral administration, ciprofloxacin was detected at all the time-points except 0.25 h, with the C(max) of 0.03 +/- 0.01 microg/mL at 6.67 +/- 2.31 h.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),[μg] / [ml],0.03,234820,DB00537,Ciprofloxacin
,16958784,"terminal half-life t(1/2,beta)","Ciprofloxacin was eliminated with terminal half-life t(1/2,beta) of 52.08 +/- 17.34 h for intravenous administration and 52.43 +/- 22.37 h for oral administration.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),h,52.08,234821,DB00537,Ciprofloxacin
,16958784,"terminal half-life t(1/2,beta)","Ciprofloxacin was eliminated with terminal half-life t(1/2,beta) of 52.08 +/- 17.34 h for intravenous administration and 52.43 +/- 22.37 h for oral administration.",Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958784/),h,52.43,234822,DB00537,Ciprofloxacin
,16530028,absolute recovery,The mean absolute recovery for human serum was 98.8+/-5.7%.,Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16530028/),%,98.8,234899,DB00537,Ciprofloxacin
,1667252,peak concentration,"After oral administration of NM441 at a dose of 20 mg/kg to dogs, the peak concentration of NM394 in plasma was 2.39 micrograms/ml, whereas it was 0.63 micrograms/ml for NM394 administered alone.","In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1667252/),[μg] / [ml],2.39,235216,DB00537,Ciprofloxacin
,1667252,peak concentration,"After oral administration of NM441 at a dose of 20 mg/kg to dogs, the peak concentration of NM394 in plasma was 2.39 micrograms/ml, whereas it was 0.63 micrograms/ml for NM394 administered alone.","In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1667252/),[μg] / [ml],0.63,235217,DB00537,Ciprofloxacin
,12856383,Ka,"The final model is summarized as follows: CL(L/h) = 30.3 x (WT/70)0.75 x (1 + 0.045 [AGE-2.5]), VC(L) = 56.7 x (WT/70)1.0, VP(L) = 89.8 x (WT/70)1.0, Q(L/h) = 37.5 x (WT/70)0.75, Ka (1/h) = 1.27 x (1 + [-0.611 x CF]), absorption lag time = 0.35 hours, and bioavailability fraction = 61.1%, where WT and AGE are the patient's body weight (kg) and age (years), respectively, and the variable CF equals 1 for CF patients and 0 for non-CF patients.",Population pharmacokinetics of ciprofloxacin in pediatric patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856383/),,1.,235246,DB00537,Ciprofloxacin
,12856383,absorption lag time,"The final model is summarized as follows: CL(L/h) = 30.3 x (WT/70)0.75 x (1 + 0.045 [AGE-2.5]), VC(L) = 56.7 x (WT/70)1.0, VP(L) = 89.8 x (WT/70)1.0, Q(L/h) = 37.5 x (WT/70)0.75, Ka (1/h) = 1.27 x (1 + [-0.611 x CF]), absorption lag time = 0.35 hours, and bioavailability fraction = 61.1%, where WT and AGE are the patient's body weight (kg) and age (years), respectively, and the variable CF equals 1 for CF patients and 0 for non-CF patients.",Population pharmacokinetics of ciprofloxacin in pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856383/),h,0.35,235247,DB00537,Ciprofloxacin
,12856383,bioavailability fraction,"The final model is summarized as follows: CL(L/h) = 30.3 x (WT/70)0.75 x (1 + 0.045 [AGE-2.5]), VC(L) = 56.7 x (WT/70)1.0, VP(L) = 89.8 x (WT/70)1.0, Q(L/h) = 37.5 x (WT/70)0.75, Ka (1/h) = 1.27 x (1 + [-0.611 x CF]), absorption lag time = 0.35 hours, and bioavailability fraction = 61.1%, where WT and AGE are the patient's body weight (kg) and age (years), respectively, and the variable CF equals 1 for CF patients and 0 for non-CF patients.",Population pharmacokinetics of ciprofloxacin in pediatric patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856383/),%,61.1,235248,DB00537,Ciprofloxacin
,28588496,elimination half-life (t1/2β),"The main parameters of elimination half-life (t1/2β), Tmax, and area under the curve (AUC) were 14.99 ± 4.19, 3.99 ± 0.10, and 38.93 ± 1.52 μg h/ml, respectively, revealing that the enrofloxacin concentration remained high and with a sustainable distribution in plasma.",Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28588496/),[h·μg] / [ml],14.99,237464,DB00537,Ciprofloxacin
,28588496,Tmax,"The main parameters of elimination half-life (t1/2β), Tmax, and area under the curve (AUC) were 14.99 ± 4.19, 3.99 ± 0.10, and 38.93 ± 1.52 μg h/ml, respectively, revealing that the enrofloxacin concentration remained high and with a sustainable distribution in plasma.",Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28588496/),[h·μg] / [ml],3.99,237465,DB00537,Ciprofloxacin
,28588496,area under the curve (AUC),"The main parameters of elimination half-life (t1/2β), Tmax, and area under the curve (AUC) were 14.99 ± 4.19, 3.99 ± 0.10, and 38.93 ± 1.52 μg h/ml, respectively, revealing that the enrofloxacin concentration remained high and with a sustainable distribution in plasma.",Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28588496/),[h·μg] / [ml],38.93,237466,DB00537,Ciprofloxacin
,28588496,withdrawal periods,"Moreover, the analysis on the evaluation of enrofloxacin and ciprofloxacin in muscle, fat, liver and kidney showed that the recovery were more than 84% recovery in accordance with the veterinary drug residue guidelines of United States pharmacopeia, and the withdrawal periods were 4.28, 3.81, 4.84, and 3.51 days, respectively, suggesting that the withdrawal period was 5 d after oral administration of 5 mg/kg twice per day.",Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28588496/),,3,237467,DB00537,Ciprofloxacin
,28588496,withdrawal periods,"Moreover, the analysis on the evaluation of enrofloxacin and ciprofloxacin in muscle, fat, liver and kidney showed that the recovery were more than 84% recovery in accordance with the veterinary drug residue guidelines of United States pharmacopeia, and the withdrawal periods were 4.28, 3.81, 4.84, and 3.51 days, respectively, suggesting that the withdrawal period was 5 d after oral administration of 5 mg/kg twice per day.",Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28588496/),,4.84,237468,DB00537,Ciprofloxacin
,28588496,withdrawal periods,"Moreover, the analysis on the evaluation of enrofloxacin and ciprofloxacin in muscle, fat, liver and kidney showed that the recovery were more than 84% recovery in accordance with the veterinary drug residue guidelines of United States pharmacopeia, and the withdrawal periods were 4.28, 3.81, 4.84, and 3.51 days, respectively, suggesting that the withdrawal period was 5 d after oral administration of 5 mg/kg twice per day.",Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28588496/),,3.51,237469,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,0.83,238048,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,4.53,238049,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,5.80,238050,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,7.31,238051,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,6.00,238052,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,3.53,238053,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,8.85,238054,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,2.87,238055,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,4.60,238056,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,4.65,238057,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,3.87,238058,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,2.68,238059,DB00537,Ciprofloxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,2.35,238060,DB00537,Ciprofloxacin
,9764930,distribution half-lives,"2. The serum concentrations of difloxacin in pig and chicken after intravenous administration were best described by a two-compartment open model, giving distribution half-lives of 0.50 and 0.66 h and elimination half-lives of 7.92 and 4.10 h for pig and chicken respectively.",Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),h,0.50,238549,DB00537,Ciprofloxacin
,9764930,distribution half-lives,"2. The serum concentrations of difloxacin in pig and chicken after intravenous administration were best described by a two-compartment open model, giving distribution half-lives of 0.50 and 0.66 h and elimination half-lives of 7.92 and 4.10 h for pig and chicken respectively.",Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),h,0.66,238550,DB00537,Ciprofloxacin
,9764930,elimination half-lives,"2. The serum concentrations of difloxacin in pig and chicken after intravenous administration were best described by a two-compartment open model, giving distribution half-lives of 0.50 and 0.66 h and elimination half-lives of 7.92 and 4.10 h for pig and chicken respectively.",Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),h,7.92,238551,DB00537,Ciprofloxacin
,9764930,elimination half-lives,"2. The serum concentrations of difloxacin in pig and chicken after intravenous administration were best described by a two-compartment open model, giving distribution half-lives of 0.50 and 0.66 h and elimination half-lives of 7.92 and 4.10 h for pig and chicken respectively.",Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),h,4.10,238552,DB00537,Ciprofloxacin
,9764930,steady-state distribution volumes,The steady-state distribution volumes were 1.70 and 3.06 l/kg for pig and chicken respectively.,Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),[l] / [kg],1.70,238553,DB00537,Ciprofloxacin
,9764930,steady-state distribution volumes,The steady-state distribution volumes were 1.70 and 3.06 l/kg for pig and chicken respectively.,Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),[l] / [kg],3.06,238554,DB00537,Ciprofloxacin
,9764930,maximal levels,"3. After oral administration of 5 mg/kg to pig and chicken, the serum concentrations reached maximal levels of 3.61 and 0.96 microg/ml respectively at 1.25 and 1.40 h.",Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),[μg] / [ml],3.61,238555,DB00537,Ciprofloxacin
,9764930,maximal levels,"3. After oral administration of 5 mg/kg to pig and chicken, the serum concentrations reached maximal levels of 3.61 and 0.96 microg/ml respectively at 1.25 and 1.40 h.",Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),[μg] / [ml],0.96,238556,DB00537,Ciprofloxacin
,9764930,elimination half-lives,The elimination half-lives were 11.8 and 7.35 h for pig and chicken respectively.,Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),h,11.8,238557,DB00537,Ciprofloxacin
,9764930,elimination half-lives,The elimination half-lives were 11.8 and 7.35 h for pig and chicken respectively.,Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),h,7.35,238558,DB00537,Ciprofloxacin
,9764930,bioavailabilities,4. The bioavailabilities of difloxacin were calculated as 93.7 (pig) and 86.9% (chicken).,Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),%,93.7,238559,DB00537,Ciprofloxacin
,9764930,bioavailabilities,4. The bioavailabilities of difloxacin were calculated as 93.7 (pig) and 86.9% (chicken).,Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764930/),%,86.9,238560,DB00537,Ciprofloxacin
,3578334,apparent oral bioavailability,"The apparent oral bioavailability was 85 percent, based on comparison of the total areas under the serum concentration curves of the 100-mg dose.",Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578334/),%,85,238984,DB00537,Ciprofloxacin
,3578334,serum half-life,"The serum half-life ranged from 3.0 to 3.4 hours after the oral doses, and was 2.9 hours after the intravenous dose.",Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578334/),h,3.0 to 3.4,238985,DB00537,Ciprofloxacin
,3578334,serum half-life,"The serum half-life ranged from 3.0 to 3.4 hours after the oral doses, and was 2.9 hours after the intravenous dose.",Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578334/),h,2.9,238986,DB00537,Ciprofloxacin
,3578334,"elimination-phase apparent distribution volume coefficient, delta d,area","The elimination-phase apparent distribution volume coefficient, delta d,area, was 2.76 liters/kg, and the total body clearance was 42.0 liters/hour.",Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578334/),[l] / [kg],2.76,238987,DB00537,Ciprofloxacin
,3578334,total body clearance,"The elimination-phase apparent distribution volume coefficient, delta d,area, was 2.76 liters/kg, and the total body clearance was 42.0 liters/hour.",Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578334/),[l] / [h],42.0,238988,DB00537,Ciprofloxacin
,3578334,urinary excretion,The 24-hour urinary excretion was 42.2 +/- 15.6 percent after the 100-mg intravenous dose and 42.5 +/- 17.6 percent after the 500-mg twice-daily oral dose during steady state.,Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578334/),%,42.2,238989,DB00537,Ciprofloxacin
,3578334,urinary excretion,The 24-hour urinary excretion was 42.2 +/- 15.6 percent after the 100-mg intravenous dose and 42.5 +/- 17.6 percent after the 500-mg twice-daily oral dose during steady state.,Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578334/),%,42.5,238990,DB00537,Ciprofloxacin
,8723457,maximum,"Mean maximum and minimum plasma ciprofloxacin concentrations were 4.2 +/- 1.1 and 0.70 +/- 0.55 microgram/ml, respectively.",Ciprofloxacin pharmacokinetics in burn patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723457/),[μg] / [ml],4.2,239012,DB00537,Ciprofloxacin
,8723457,minimum plasma ciprofloxacin concentrations,"Mean maximum and minimum plasma ciprofloxacin concentrations were 4.2 +/- 1.1 and 0.70 +/- 0.55 microgram/ml, respectively.",Ciprofloxacin pharmacokinetics in burn patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723457/),[μg] / [ml],0.70,239013,DB00537,Ciprofloxacin
,8723457,clearance (CL),"Mean values for clearance (CL), renal clearance (CLR), volume of distribution, terminal elimination rate constant, half-life (t1/2), and area under the concentration-time curve (AUC) were 29.1 +/- 17.5 liters/h, 13.5 +/- 10.1 liters/h, 1.75 +/- 0.41 liters/kg, 0.222 +/- 0.098 h-1, 4.5 +/- 3.9 h, and 20.7 +/- 16.6 micrograms.h/ml, respectively.",Ciprofloxacin pharmacokinetics in burn patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723457/),[l] / [h],29.1,239014,DB00537,Ciprofloxacin
,8723457,area under the concentration-time curve (AUC),"Mean values for clearance (CL), renal clearance (CLR), volume of distribution, terminal elimination rate constant, half-life (t1/2), and area under the concentration-time curve (AUC) were 29.1 +/- 17.5 liters/h, 13.5 +/- 10.1 liters/h, 1.75 +/- 0.41 liters/kg, 0.222 +/- 0.098 h-1, 4.5 +/- 3.9 h, and 20.7 +/- 16.6 micrograms.h/ml, respectively.",Ciprofloxacin pharmacokinetics in burn patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723457/),[h·μg] / [ml],20.7,239015,DB00537,Ciprofloxacin
above,8723457,AUC/MIC ratio,"An AUC/MIC ratio above 125 SIT-1 (where SIT is serum inhibitory titer), which has been strongly correlated with clinical response and time to bacterial eradication, was achieved in five of eight patients (63%) with a MIC of 0.25 microgram/ml.",Ciprofloxacin pharmacokinetics in burn patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723457/),1/[sit],125,239016,DB00537,Ciprofloxacin
,8723457,MIC,"An AUC/MIC ratio above 125 SIT-1 (where SIT is serum inhibitory titer), which has been strongly correlated with clinical response and time to bacterial eradication, was achieved in five of eight patients (63%) with a MIC of 0.25 microgram/ml.",Ciprofloxacin pharmacokinetics in burn patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723457/),[μg] / [ml],0.25,239017,DB00537,Ciprofloxacin
above,8723457,AUC/MIC ratio,"At a ciprofloxacin dosage of 400 mg i.v. every 12 h, an AUC/MIC ratio above 125 SIT-1 would have been achieved in only two of eight patients (25%).",Ciprofloxacin pharmacokinetics in burn patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723457/),1/[sit],125,239018,DB00537,Ciprofloxacin
,16187554,Maximum serum concentration (Cmax),Maximum serum concentration (Cmax) was 2.25 +/- 0.70 microg/mL at 3.12 +/- 2.63 h and Cmax after the 5th dose was 2.41 +/- 0.86 microg/mL at 97.86 +/- 1.45 h.,Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187554/),[μg] / [ml],2.25,239085,DB00537,Ciprofloxacin
,16187554,Cmax,Maximum serum concentration (Cmax) was 2.25 +/- 0.70 microg/mL at 3.12 +/- 2.63 h and Cmax after the 5th dose was 2.41 +/- 0.86 microg/mL at 97.86 +/- 1.45 h.,Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187554/),[μg] / [ml],2.41,239086,DB00537,Ciprofloxacin
,16187554,elimination half-life (t(1/2)),The mean elimination half-life (t(1/2)) was 8.75 +/- 2.77 h and area under the serum concentration versus time curve (AUC) was 25.13 +/- 8.79 microg h/mL.,Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187554/),h,8.75,239087,DB00537,Ciprofloxacin
,16187554,area under the serum concentration versus time curve (AUC),The mean elimination half-life (t(1/2)) was 8.75 +/- 2.77 h and area under the serum concentration versus time curve (AUC) was 25.13 +/- 8.79 microg h/mL.,Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187554/),[h·μg] / [ml],25.13,239088,DB00537,Ciprofloxacin
,16187554,synovial fluid concentration,Highest mean synovial fluid concentration was 1.26 +/- 0.49 microg/mL at 100 h.,Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187554/),[μg] / [ml],1.26,239089,DB00537,Ciprofloxacin
,16187554,peritoneal fluid concentration,Highest mean peritoneal fluid concentration was 1.50 +/- 0.56 microg/mL at 98 h.,Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187554/),[μg] / [ml],1.50,239090,DB00537,Ciprofloxacin
,16187554,endometrial concentration,Highest mean endometrial concentration was 0.78 +/- 0.48 microg/g at 97.5 h.,Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187554/),[μg] / [g],0.78,239091,DB00537,Ciprofloxacin
,16187554,cerebrospinal fluid concentration,Mean cerebrospinal fluid concentration was 0.87 +/- 0.52 microg/mL at 99 h.,Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187554/),[μg] / [ml],0.87,239092,DB00537,Ciprofloxacin
,16187554,Highest mean urine concentration,Highest mean urine concentration was 92.05 +/- 30.35 microg/mL at 104 h.,Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187554/),[μg] / [ml],92.05,239093,DB00537,Ciprofloxacin
,9755295,plasma elimination half-life (t1/2),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),h,13.8,239139,DB00537,Ciprofloxacin
,9755295,plasma elimination half-life (t1/2),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),h,7.5,239140,DB00537,Ciprofloxacin
,9755295,maximal plasma concentration (Cmax),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),[mg] / [l],0.8,239141,DB00537,Ciprofloxacin
,9755295,maximal plasma concentration (Cmax),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),[mg] / [l],2.3,239142,DB00537,Ciprofloxacin
,9755295,volume of distribution (Vd),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),[l] / [kg],2.5,239143,DB00537,Ciprofloxacin
,9755295,volume of distribution (Vd),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),[l] / [kg],0.4,239144,DB00537,Ciprofloxacin
,16518709,MIC90,"To describe the PD function the MIC distribution pattern of more than 3,000 isolates of S. pneumoniae as the representative pathogen for RTI (MIC90, range: 0.125; 0.006-4 mg/l) was built into the population PK/PD model for RTI, while 126 isolates of methicillin-susceptible Staphylococcus aureus strains (MIC90, range: 0.125; 0.03-4 mg/l) were the basis for the PD function in cSSSI.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0.125,239150,DB00537,Ciprofloxacin
,16518709,MIC90,"To describe the PD function the MIC distribution pattern of more than 3,000 isolates of S. pneumoniae as the representative pathogen for RTI (MIC90, range: 0.125; 0.006-4 mg/l) was built into the population PK/PD model for RTI, while 126 isolates of methicillin-susceptible Staphylococcus aureus strains (MIC90, range: 0.125; 0.03-4 mg/l) were the basis for the PD function in cSSSI.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0.006-4,239151,DB00537,Ciprofloxacin
,16518709,MIC90,"To describe the PD function the MIC distribution pattern of more than 3,000 isolates of S. pneumoniae as the representative pathogen for RTI (MIC90, range: 0.125; 0.006-4 mg/l) was built into the population PK/PD model for RTI, while 126 isolates of methicillin-susceptible Staphylococcus aureus strains (MIC90, range: 0.125; 0.03-4 mg/l) were the basis for the PD function in cSSSI.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0,239152,DB00537,Ciprofloxacin
,16518709,MIC90,"To describe the PD function the MIC distribution pattern of more than 3,000 isolates of S. pneumoniae as the representative pathogen for RTI (MIC90, range: 0.125; 0.006-4 mg/l) was built into the population PK/PD model for RTI, while 126 isolates of methicillin-susceptible Staphylococcus aureus strains (MIC90, range: 0.125; 0.03-4 mg/l) were the basis for the PD function in cSSSI.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0.03-4,239153,DB00537,Ciprofloxacin
>,16518709,AUIC,"Overall, a target hit rate was THR = 99% for RTI, while it amounted to THR = 97.5% for cSSSI when applying a threshold of AUIC > 30 [h] as the PK/PD surrogate parameter which is predictive for a positive clinical outcome.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),,30,239154,DB00537,Ciprofloxacin
>,16518709,AUIC,"A target hit rate of THR = 93.6 % (RTI) and 97.3% (cSSSI), respectively, was predicted when assuming that an AUIC of > 125 [h] is indicative of clinical success (as shown for ciprofloxacin and severe RTIs due to gram-negative infections).",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[h],125,239155,DB00537,Ciprofloxacin
,16518709,MIC,From the simulations performed for RTI an analysis of the overall likelihood of therapeutic failure broken down according to MICs suggests that the risk of a negative clinical outcome at a MIC = 1 mg/l is approximately 0.25% (for MIC = 2 mg/l: predicted likelihood approximately 0.5%) assuming that a cutoff of AUIC = 30 [h] is applicable.,The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],1,239156,DB00537,Ciprofloxacin
,16518709,MIC,From the simulations performed for RTI an analysis of the overall likelihood of therapeutic failure broken down according to MICs suggests that the risk of a negative clinical outcome at a MIC = 1 mg/l is approximately 0.25% (for MIC = 2 mg/l: predicted likelihood approximately 0.5%) assuming that a cutoff of AUIC = 30 [h] is applicable.,The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),,2,239157,DB00537,Ciprofloxacin
,16518709,AUIC,From the simulations performed for RTI an analysis of the overall likelihood of therapeutic failure broken down according to MICs suggests that the risk of a negative clinical outcome at a MIC = 1 mg/l is approximately 0.25% (for MIC = 2 mg/l: predicted likelihood approximately 0.5%) assuming that a cutoff of AUIC = 30 [h] is applicable.,The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),h,30,239158,DB00537,Ciprofloxacin
,16518709,MIC,"Likewise, for cSSSI the probability to fail is predicted as 1.6% at a MIC = 2 mg/l (no strains with MICs between 0.5 and 1 mg/l available from the clinical isolates).",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],2,239159,DB00537,Ciprofloxacin
,16518709,MICs,"Likewise, for cSSSI the probability to fail is predicted as 1.6% at a MIC = 2 mg/l (no strains with MICs between 0.5 and 1 mg/l available from the clinical isolates).",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0.5 and 1,239160,DB00537,Ciprofloxacin
,3182465,volume of distribution,"Pharmacokinetic parameters were calculated on the basis of an open three-compartment model, which resulted in a high volume of distribution for both substances (166-246 1 for ofloxacin, 178-2611 for ciprofloxacin).",Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182465/),1,166-246,239210,DB00537,Ciprofloxacin
,3182465,volume of distribution,"Pharmacokinetic parameters were calculated on the basis of an open three-compartment model, which resulted in a high volume of distribution for both substances (166-246 1 for ofloxacin, 178-2611 for ciprofloxacin).",Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182465/),,178-2611,239211,DB00537,Ciprofloxacin
,2360821,CL,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),[l] / [h],52.2,239805,DB00537,Ciprofloxacin
,2360821,CL,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),[l] / [h],33.9,239806,DB00537,Ciprofloxacin
,2360821,CLR,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),[l] / [h],26.5,239807,DB00537,Ciprofloxacin
,2360821,CLR,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),[l] / [h],16.2,239808,DB00537,Ciprofloxacin
,2360821,CLNR,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),[l] / [h],25.8,239809,DB00537,Ciprofloxacin
,2360821,CLNR,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),[l] / [h],17.7,239810,DB00537,Ciprofloxacin
,2360821,Vss,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),l,224,239811,DB00537,Ciprofloxacin
,2360821,Vss,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),l,166,239812,DB00537,Ciprofloxacin
,2360821,fractional urinary excretion,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),,0.56,239813,DB00537,Ciprofloxacin
,2360821,fractional urinary excretion,"The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively.",Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360821/),,0.43,239814,DB00537,Ciprofloxacin
,6660852,peak level,"Absorption appeared to be rapid, with a mean peak level of 2.4 micrograms/ml attained 1.25 h after administration.",Pharmacokinetics and tissue penetration of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6660852/),[μg] / [ml],2.4,240110,DB00537,Ciprofloxacin
,6660852,serum elimination half-life,The serum elimination half-life was 3.9 h.,Pharmacokinetics and tissue penetration of ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6660852/),h,3.9,240111,DB00537,Ciprofloxacin
,6660852,percent penetration,"The agent penetrated blister fluid well, the percent penetration being 57%.",Pharmacokinetics and tissue penetration of ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6660852/),%,57,240112,DB00537,Ciprofloxacin
,6660852,Urinary recovery,Urinary recovery of ciprofloxacin was 30%.,Pharmacokinetics and tissue penetration of ciprofloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6660852/),%,30,240113,DB00537,Ciprofloxacin
,2729942,half-life,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),h,5.2,240577,DB00537,Ciprofloxacin
,2729942,half-life,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),h,8.2,240578,DB00537,Ciprofloxacin
,2729942,area under the caffeine concentration-time curve,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[h·μg] / [ml],16.3,240579,DB00537,Ciprofloxacin
,2729942,area under the caffeine concentration-time curve,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[h·μg] / [ml],25.9,240580,DB00537,Ciprofloxacin
,2729942,total body clearance,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[ml] / [1.73·m2·min],106,240581,DB00537,Ciprofloxacin
,2729942,total body clearance,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[ml] / [1.73·m2·min],58.2,240582,DB00537,Ciprofloxacin
,3125788,elimination half-life,"Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg).","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),h,9 to 10,242057,DB00537,Ciprofloxacin
,3125788,maximum concentration,"Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg).","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),[μg] / [ml],2.3,242058,DB00537,Ciprofloxacin
exceeds,3125788,volume of distribution,The volume of distribution clearly exceeds 1 liter/kg and suggests a good tissue penetration.,"Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),[l] / [kg],1,242059,DB00537,Ciprofloxacin
,3125788,renal clearance of unbound drug,"The renal clearance of unbound drug was 137 ml/min, and probenecid had no significant effect on renal elimination.","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),[ml] / [min],137,242060,DB00537,Ciprofloxacin
,3125788,absolute bioavailability,The absolute bioavailability of the administered tablet was practically 100%.,"Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),%,100,242061,DB00537,Ciprofloxacin
,8647752,peak plasma,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[mg] / [l],3.4,242420,DB00537,Ciprofloxacin
,8647752,peak plasma,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[mg] / [l],2.6,242421,DB00537,Ciprofloxacin
,8647752,lung concentrations,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[μg] / [g],1.4,242422,DB00537,Ciprofloxacin
,8647752,lung concentrations,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[mg] / [l],2.6,242423,DB00537,Ciprofloxacin
,8647752,lung concentrations,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[μg] / [g],0.6,242424,DB00537,Ciprofloxacin
,8647752,terminal half-life phase of elimination,The terminal half-life phase of elimination from plasma and lung was c. 1 h.,"In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),h,c.,242425,DB00537,Ciprofloxacin
,8647752,terminal half-life phase of elimination,The terminal half-life phase of elimination from plasma and lung was c. 1 h.,"In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),h,1,242426,DB00537,Ciprofloxacin
,3428007,clearance,The following pharmacokinetic parameters (mean +/- SD) were estimated from the serum level versus time curves: clearance 11.51 +/- 2.85 (ml/min/kg); Vd area 3.08 +/- 1.20 ml/kg; terminal half-life 3.10 +/- 0.92 h; mean residence time 5.64 +/- 1.40 h.,Ciprofloxacin penetration in pancreatic juice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428007/),,11.51,242621,DB00537,Ciprofloxacin
,3428007,Vd area,The following pharmacokinetic parameters (mean +/- SD) were estimated from the serum level versus time curves: clearance 11.51 +/- 2.85 (ml/min/kg); Vd area 3.08 +/- 1.20 ml/kg; terminal half-life 3.10 +/- 0.92 h; mean residence time 5.64 +/- 1.40 h.,Ciprofloxacin penetration in pancreatic juice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428007/),[ml] / [kg],3.08,242622,DB00537,Ciprofloxacin
,3428007,terminal half-life,The following pharmacokinetic parameters (mean +/- SD) were estimated from the serum level versus time curves: clearance 11.51 +/- 2.85 (ml/min/kg); Vd area 3.08 +/- 1.20 ml/kg; terminal half-life 3.10 +/- 0.92 h; mean residence time 5.64 +/- 1.40 h.,Ciprofloxacin penetration in pancreatic juice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428007/),h,3.10,242623,DB00537,Ciprofloxacin
,3428007,mean residence time,The following pharmacokinetic parameters (mean +/- SD) were estimated from the serum level versus time curves: clearance 11.51 +/- 2.85 (ml/min/kg); Vd area 3.08 +/- 1.20 ml/kg; terminal half-life 3.10 +/- 0.92 h; mean residence time 5.64 +/- 1.40 h.,Ciprofloxacin penetration in pancreatic juice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428007/),h,5.64,242624,DB00537,Ciprofloxacin
,3428007,pan,The pancreatic juice/serum ciprofloxacin concentration ratio increased gradually fom 0.63 +/- 0.45 after 0.5 h to 6.18 +/- 4.59 after 12 h (mean +/- SD).,Ciprofloxacin penetration in pancreatic juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428007/),,0.63,242625,DB00537,Ciprofloxacin
,3428007,pan,The pancreatic juice/serum ciprofloxacin concentration ratio increased gradually fom 0.63 +/- 0.45 after 0.5 h to 6.18 +/- 4.59 after 12 h (mean +/- SD).,Ciprofloxacin penetration in pancreatic juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428007/),,6.18,242626,DB00537,Ciprofloxacin
,3428007,concentration ratio,The pancreatic juice/serum ciprofloxacin concentration ratio increased gradually fom 0.63 +/- 0.45 after 0.5 h to 6.18 +/- 4.59 after 12 h (mean +/- SD).,Ciprofloxacin penetration in pancreatic juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428007/),,0.63,242627,DB00537,Ciprofloxacin
,3428007,concentration ratio,The pancreatic juice/serum ciprofloxacin concentration ratio increased gradually fom 0.63 +/- 0.45 after 0.5 h to 6.18 +/- 4.59 after 12 h (mean +/- SD).,Ciprofloxacin penetration in pancreatic juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428007/),,6.18,242628,DB00537,Ciprofloxacin
,1919272,Peak levels,"Peak levels were obtained in the aqueous and vitreous bodies (0.62 micrograms/ml and 0.19 micrograms/ml, respectively) one hour after transscleral iontophoresis of negatively charged ciprofloxacin at 5 mA for 15 minutes.",Experimental transscleral iontophoresis of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919272/),[μg] / [ml],0.62,243093,DB00537,Ciprofloxacin
,1919272,Peak levels,"Peak levels were obtained in the aqueous and vitreous bodies (0.62 micrograms/ml and 0.19 micrograms/ml, respectively) one hour after transscleral iontophoresis of negatively charged ciprofloxacin at 5 mA for 15 minutes.",Experimental transscleral iontophoresis of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919272/),[μg] / [ml],0.19,243094,DB00537,Ciprofloxacin
,3804907,distribution volume,The mean distribution volume was 2.1 (+/- 0.6) l/kg of ideal body weight; it did not correlate significantly with renal function.,Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3804907/),[l] / [kg],2.1,243449,DB00537,Ciprofloxacin
,7811026,percent relative bioavailability,"However, Ensure reduced the percent relative bioavailability of ciprofloxacin (72% +/- 14%; range, 52 to 96%) significantly more than ofloxacin (90% +/- 8.3%; range, 74 to 105%) (P < 0.005).",Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7811026/),%,72,243455,DB00537,Ciprofloxacin
,7811026,percent relative bioavailability,"However, Ensure reduced the percent relative bioavailability of ciprofloxacin (72% +/- 14%; range, 52 to 96%) significantly more than ofloxacin (90% +/- 8.3%; range, 74 to 105%) (P < 0.005).",Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7811026/),%,90,243456,DB00537,Ciprofloxacin
,17107697,elimination half-live,"The elimination half-live and the mean residence time of EFL after i.v. injection for the serum were after oral administration 6.64+/-0.90 h, 8.96+/-1.18 h and 6.92+/-0.97 h, 11.91+/-1.87 h, respectively.",Pharmacokinetics of enrofloxacin in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),h,6.64,243567,DB00537,Ciprofloxacin
,17107697,elimination half-live,"The elimination half-live and the mean residence time of EFL after i.v. injection for the serum were after oral administration 6.64+/-0.90 h, 8.96+/-1.18 h and 6.92+/-0.97 h, 11.91+/-1.87 h, respectively.",Pharmacokinetics of enrofloxacin in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),h,6.92,243568,DB00537,Ciprofloxacin
,17107697,mean residence time,"The elimination half-live and the mean residence time of EFL after i.v. injection for the serum were after oral administration 6.64+/-0.90 h, 8.96+/-1.18 h and 6.92+/-0.97 h, 11.91+/-1.87 h, respectively.",Pharmacokinetics of enrofloxacin in turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),h,8.96,243569,DB00537,Ciprofloxacin
,17107697,mean residence time,"The elimination half-live and the mean residence time of EFL after i.v. injection for the serum were after oral administration 6.64+/-0.90 h, 8.96+/-1.18 h and 6.92+/-0.97 h, 11.91+/-1.87 h, respectively.",Pharmacokinetics of enrofloxacin in turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),h,11.91,243570,DB00537,Ciprofloxacin
,17107697,MAT,"After single p.o. administration, EFL was absorbed slowly (MAT=2.76+/-0.48 h) with time to reach maximum serum concentrations of 6.33+/-2.54 h.",Pharmacokinetics of enrofloxacin in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),h,2.76,243571,DB00537,Ciprofloxacin
,17107697,time to reach maximum serum concentrations,"After single p.o. administration, EFL was absorbed slowly (MAT=2.76+/-0.48 h) with time to reach maximum serum concentrations of 6.33+/-2.54 h.",Pharmacokinetics of enrofloxacin in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),h,6.33,243572,DB00537,Ciprofloxacin
,17107697,Maximum serum concentrations,Maximum serum concentrations was 1.23+/-0.30 microg mL(-1).,Pharmacokinetics of enrofloxacin in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),[μg] / [ml],1.23,243573,DB00537,Ciprofloxacin
,17107697,Oral bioavailability,Oral bioavailability for for EFL after oral administration was found to be 69.20+/-1.49%.,Pharmacokinetics of enrofloxacin in turkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),%,69.20,243574,DB00537,Ciprofloxacin
,17107697,ratios C(max)/MIC,"The ratios C(max)/MIC and AUC(0 --> 24)/MIC were respectively from 161.23+/-5.9 h to 12.90+/-0.5 h for the pharmacodynamic predictor C(max)/MIC, and from 2153.44+/-66.6 h to 137.82+/-4.27 h for AUC(0 --> 24)/MIC, for the different clinically significant microorganisms, whose values for MIC varies from 0.008 microg L(-1) to 0.125 microg mL(-1).",Pharmacokinetics of enrofloxacin in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),h,161.23,243575,DB00537,Ciprofloxacin
,17107697,AUC(0 --> 24)/MIC,"The ratios C(max)/MIC and AUC(0 --> 24)/MIC were respectively from 161.23+/-5.9 h to 12.90+/-0.5 h for the pharmacodynamic predictor C(max)/MIC, and from 2153.44+/-66.6 h to 137.82+/-4.27 h for AUC(0 --> 24)/MIC, for the different clinically significant microorganisms, whose values for MIC varies from 0.008 microg L(-1) to 0.125 microg mL(-1).",Pharmacokinetics of enrofloxacin in turkeys. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),h,12.90,243576,DB00537,Ciprofloxacin
,17107697,MIC,"The ratios C(max)/MIC and AUC(0 --> 24)/MIC were respectively from 161.23+/-5.9 h to 12.90+/-0.5 h for the pharmacodynamic predictor C(max)/MIC, and from 2153.44+/-66.6 h to 137.82+/-4.27 h for AUC(0 --> 24)/MIC, for the different clinically significant microorganisms, whose values for MIC varies from 0.008 microg L(-1) to 0.125 microg mL(-1).",Pharmacokinetics of enrofloxacin in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),[μg] / [l],0.008,243577,DB00537,Ciprofloxacin
,17107697,MIC,"The ratios C(max)/MIC and AUC(0 --> 24)/MIC were respectively from 161.23+/-5.9 h to 12.90+/-0.5 h for the pharmacodynamic predictor C(max)/MIC, and from 2153.44+/-66.6 h to 137.82+/-4.27 h for AUC(0 --> 24)/MIC, for the different clinically significant microorganisms, whose values for MIC varies from 0.008 microg L(-1) to 0.125 microg mL(-1).",Pharmacokinetics of enrofloxacin in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107697/),[μg] / [ml],0.125,243578,DB00537,Ciprofloxacin
,3286510,amounts,"The amounts of unchanged drug excreted in urine (48 h period) were found to be 35%, 24% and 77% for ciprofloxacin, norfloxacin and ofloxacin respectively, indicating different excretion kinetics.","Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286510/),%,35,245079,DB00537,Ciprofloxacin
,3286510,amounts,"The amounts of unchanged drug excreted in urine (48 h period) were found to be 35%, 24% and 77% for ciprofloxacin, norfloxacin and ofloxacin respectively, indicating different excretion kinetics.","Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286510/),%,24,245080,DB00537,Ciprofloxacin
,3286510,amounts,"The amounts of unchanged drug excreted in urine (48 h period) were found to be 35%, 24% and 77% for ciprofloxacin, norfloxacin and ofloxacin respectively, indicating different excretion kinetics.","Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286510/),%,77,245081,DB00537,Ciprofloxacin
,23030707,steady-state concentration,Ciprofloxacin was administered to six healthy Holstein cows as a constant rate intravenous infusion (flow rate was weight adjusted) to achieve a steady-state concentration of approximately 300 ng/mL for 7 days.,A Holstein cow-calf model for the transfer of ciprofloxacin through milk after a long-term intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23030707/),[ng] / [ml],300,245372,DB00537,Ciprofloxacin
,22511133,trough concentrations,"The median (interquartile range) trough concentrations (mg/L) for meropenem was 12.1 (7.8-18.4), 105.0 (74.4-204.0)/3.8 (3.4-21.8) for piperacillin/tazobactam, 12.0 (9.8-16.0) for vancomycin, and 3.7 (3.0-5.6) for ciprofloxacin.",Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511133/),[mg] / [l],12.1,247298,DB00537,Ciprofloxacin
,22511133,trough concentrations,"The median (interquartile range) trough concentrations (mg/L) for meropenem was 12.1 (7.8-18.4), 105.0 (74.4-204.0)/3.8 (3.4-21.8) for piperacillin/tazobactam, 12.0 (9.8-16.0) for vancomycin, and 3.7 (3.0-5.6) for ciprofloxacin.",Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511133/),[mg] / [l],105.0,247299,DB00537,Ciprofloxacin
,22511133,trough concentrations,"The median (interquartile range) trough concentrations (mg/L) for meropenem was 12.1 (7.8-18.4), 105.0 (74.4-204.0)/3.8 (3.4-21.8) for piperacillin/tazobactam, 12.0 (9.8-16.0) for vancomycin, and 3.7 (3.0-5.6) for ciprofloxacin.",Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511133/),[mg] / [l],3.8,247300,DB00537,Ciprofloxacin
,22511133,trough concentrations,"The median (interquartile range) trough concentrations (mg/L) for meropenem was 12.1 (7.8-18.4), 105.0 (74.4-204.0)/3.8 (3.4-21.8) for piperacillin/tazobactam, 12.0 (9.8-16.0) for vancomycin, and 3.7 (3.0-5.6) for ciprofloxacin.",Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511133/),[mg] / [l],12.0,247301,DB00537,Ciprofloxacin
,22511133,trough concentrations,"The median (interquartile range) trough concentrations (mg/L) for meropenem was 12.1 (7.8-18.4), 105.0 (74.4-204.0)/3.8 (3.4-21.8) for piperacillin/tazobactam, 12.0 (9.8-16.0) for vancomycin, and 3.7 (3.0-5.6) for ciprofloxacin.",Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511133/),[mg] / [l],3.7,247302,DB00537,Ciprofloxacin
,19646086,Peak muscle concentration (C(max)),Peak muscle concentration (C(max)) of ER was 1.98 +/- 0.22 microg/g whereas CP was measurable at concentrations close to the detection limit of the analytical method after p.o. administration at a single dosage of 10 mg/kg b.w.,Dispositions and residue depletion of enrofloxacin and its metabolite ciprofloxacin in muscle tissue of giant freshwater prawns (Macrobrachium rosenbergii). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646086/),[μg] / [g],1.98,247361,DB00537,Ciprofloxacin
,19646086,elimination half-life,The elimination half-life and area under the curve of ER were 39.33 +/- 7.27 h and 168.7 +/- 28.7 microg x h/g after p.o. administration at a single dose of 10 mg/kg x b.w. respectively.,Dispositions and residue depletion of enrofloxacin and its metabolite ciprofloxacin in muscle tissue of giant freshwater prawns (Macrobrachium rosenbergii). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646086/),h,39.33,247362,DB00537,Ciprofloxacin
,19646086,area under the curve,The elimination half-life and area under the curve of ER were 39.33 +/- 7.27 h and 168.7 +/- 28.7 microg x h/g after p.o. administration at a single dose of 10 mg/kg x b.w. respectively.,Dispositions and residue depletion of enrofloxacin and its metabolite ciprofloxacin in muscle tissue of giant freshwater prawns (Macrobrachium rosenbergii). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646086/),[h·μg] / [g],168.7,247363,DB00537,Ciprofloxacin
,19646086,maximum concentrations,The maximum concentrations of ER and CP were 2.77 +/- 0.91 and 0.06 +/- 0.006 microg/g during medicated-feed treatment and postdosing respectively.,Dispositions and residue depletion of enrofloxacin and its metabolite ciprofloxacin in muscle tissue of giant freshwater prawns (Macrobrachium rosenbergii). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646086/),[μg] / [g],2.77,247364,DB00537,Ciprofloxacin
,19646086,maximum concentrations,The maximum concentrations of ER and CP were 2.77 +/- 0.91 and 0.06 +/- 0.006 microg/g during medicated-feed treatment and postdosing respectively.,Dispositions and residue depletion of enrofloxacin and its metabolite ciprofloxacin in muscle tissue of giant freshwater prawns (Macrobrachium rosenbergii). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646086/),[μg] / [g],0.06,247365,DB00537,Ciprofloxacin
,19646086,elimination half-life,"The values of elimination half-life and absorption half-life of ER after single p.o. administration at a dosage of 10 mg/kg b.w. corresponded well with the values determined from medicated-feed treated group, showing 41.01 +/- 6.62 and 11.36 +/- 3.15 h respectively in M. rosenbergii.",Dispositions and residue depletion of enrofloxacin and its metabolite ciprofloxacin in muscle tissue of giant freshwater prawns (Macrobrachium rosenbergii). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646086/),h,41.01,247366,DB00537,Ciprofloxacin
,19646086,absorption half-life,"The values of elimination half-life and absorption half-life of ER after single p.o. administration at a dosage of 10 mg/kg b.w. corresponded well with the values determined from medicated-feed treated group, showing 41.01 +/- 6.62 and 11.36 +/- 3.15 h respectively in M. rosenbergii.",Dispositions and residue depletion of enrofloxacin and its metabolite ciprofloxacin in muscle tissue of giant freshwater prawns (Macrobrachium rosenbergii). ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646086/),h,11.36,247367,DB00537,Ciprofloxacin
,1489182,MIC,The fleroxacin MIC required to inhibit 90% of strains tested on buffered charcoal yeast extract agar medium supplemented with 0.1% alpha-ketoglutarate was 0.64 micrograms/ml and was 0.04 microgram/ml when testing was done with buffered yeast extract broth supplemented with 0.1% alpha-ketoglutarate.,"In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [ml],0.64,247453,DB00537,Ciprofloxacin
,1489182,MIC,The fleroxacin MIC required to inhibit 90% of strains tested on buffered charcoal yeast extract agar medium supplemented with 0.1% alpha-ketoglutarate was 0.64 micrograms/ml and was 0.04 microgram/ml when testing was done with buffered yeast extract broth supplemented with 0.1% alpha-ketoglutarate.,"In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [ml],0.04,247454,DB00537,Ciprofloxacin
,1489182,peak levels,"Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak levels in plasma and lungs to be 3.3 micrograms/ml and 3.5 micrograms/g, respectively, at 0.5 h and 0.8 microgram/ml and 0.8 microgram/g, respectively, at 1 h.","In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [ml],3.3,247455,DB00537,Ciprofloxacin
,1489182,peak levels,"Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak levels in plasma and lungs to be 3.3 micrograms/ml and 3.5 micrograms/g, respectively, at 0.5 h and 0.8 microgram/ml and 0.8 microgram/g, respectively, at 1 h.","In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [g],3.5,247456,DB00537,Ciprofloxacin
,1489182,peak levels,"Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak levels in plasma and lungs to be 3.3 micrograms/ml and 3.5 micrograms/g, respectively, at 0.5 h and 0.8 microgram/ml and 0.8 microgram/g, respectively, at 1 h.","In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [ml],0.8,247457,DB00537,Ciprofloxacin
,1489182,peak levels,"Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak levels in plasma and lungs to be 3.3 micrograms/ml and 3.5 micrograms/g, respectively, at 0.5 h and 0.8 microgram/ml and 0.8 microgram/g, respectively, at 1 h.","In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [g],0.8,247458,DB00537,Ciprofloxacin
,1489182,half-life of the terminal phase of elimination,The half-life of the terminal phase of elimination from plasma and lung was approximately 2 h.,"In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),h,2,247459,DB00537,Ciprofloxacin
,15766947,volume of distribution (V(ss),The high volume of distribution (V(ss)=5.01 L/Kg) suggests good tissue penetration.,Pharmacokinetics of enrofloxacin following intravenous administration to greater rheas: a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15766947/),[l] / [kg],5.01,247995,DB00537,Ciprofloxacin
,15766947,clearance,ENR presents a high clearance (3.95 L/kg h) explaining the low AUC values (3.57 mg h/L) and a short permanence (t(1/2beta)=2.66 h and MRT=1.23 h).,Pharmacokinetics of enrofloxacin following intravenous administration to greater rheas: a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15766947/),[l] / [h·kg],3.95,247996,DB00537,Ciprofloxacin
,15766947,AUC,ENR presents a high clearance (3.95 L/kg h) explaining the low AUC values (3.57 mg h/L) and a short permanence (t(1/2beta)=2.66 h and MRT=1.23 h).,Pharmacokinetics of enrofloxacin following intravenous administration to greater rheas: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15766947/),[h·mg] / [l],3.57,247997,DB00537,Ciprofloxacin
,15766947,t(1/2beta),ENR presents a high clearance (3.95 L/kg h) explaining the low AUC values (3.57 mg h/L) and a short permanence (t(1/2beta)=2.66 h and MRT=1.23 h).,Pharmacokinetics of enrofloxacin following intravenous administration to greater rheas: a preliminary study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15766947/),h,2.66,247998,DB00537,Ciprofloxacin
,15766947,MRT,ENR presents a high clearance (3.95 L/kg h) explaining the low AUC values (3.57 mg h/L) and a short permanence (t(1/2beta)=2.66 h and MRT=1.23 h).,Pharmacokinetics of enrofloxacin following intravenous administration to greater rheas: a preliminary study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15766947/),h,1.23,247999,DB00537,Ciprofloxacin
,11319632,peak,"We found significantly higher peak and trough levels of ciprofloxacin in plasma for obese subjects (9.97+/-5.64 and 0.44+/-0.10 microg/ml vs 2.59+/-1.06 and 0.19+/-0.09 microg/ml in lean subjects, P<0.05), while concentration-time curves of interstitial fluid of muscle and subcutaneous fat did not differ between the groups.",Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319632/),[μg] / [ml],9.97,248598,DB00537,Ciprofloxacin
,11319632,peak,"We found significantly higher peak and trough levels of ciprofloxacin in plasma for obese subjects (9.97+/-5.64 and 0.44+/-0.10 microg/ml vs 2.59+/-1.06 and 0.19+/-0.09 microg/ml in lean subjects, P<0.05), while concentration-time curves of interstitial fluid of muscle and subcutaneous fat did not differ between the groups.",Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319632/),[μg] / [ml],2.59,248599,DB00537,Ciprofloxacin
,11319632,trough levels,"We found significantly higher peak and trough levels of ciprofloxacin in plasma for obese subjects (9.97+/-5.64 and 0.44+/-0.10 microg/ml vs 2.59+/-1.06 and 0.19+/-0.09 microg/ml in lean subjects, P<0.05), while concentration-time curves of interstitial fluid of muscle and subcutaneous fat did not differ between the groups.",Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319632/),[μg] / [ml],0.44,248600,DB00537,Ciprofloxacin
,11319632,trough levels,"We found significantly higher peak and trough levels of ciprofloxacin in plasma for obese subjects (9.97+/-5.64 and 0.44+/-0.10 microg/ml vs 2.59+/-1.06 and 0.19+/-0.09 microg/ml in lean subjects, P<0.05), while concentration-time curves of interstitial fluid of muscle and subcutaneous fat did not differ between the groups.",Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319632/),[μg] / [ml],0.19,248601,DB00537,Ciprofloxacin
,11319632,AUC(tissue)/AUC(plasma) ratio,"Tissue penetration, expressed as AUC(tissue)/AUC(plasma) ratio was significantly lower in obese subjects (0.45+/-0.27 vs 0.82+/-0.36, P<0.01).",Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319632/),,0.45,248602,DB00537,Ciprofloxacin
,11319632,AUC(tissue)/AUC(plasma) ratio,"Tissue penetration, expressed as AUC(tissue)/AUC(plasma) ratio was significantly lower in obese subjects (0.45+/-0.27 vs 0.82+/-0.36, P<0.01).",Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319632/),,0.82,248603,DB00537,Ciprofloxacin
,9840238,peak concentration,"The median (range) peak concentration after i. v. infusion was 4.1 (1.5-7.4) mg/l, and that after NG administration was 2.3 (0.7-5.8) mg/l, occurring 1.25 (0.75-3.33) h after dosing.",Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840238/),[mg] / [l],4.1,248636,DB00537,Ciprofloxacin
,9840238,peak concentration,"The median (range) peak concentration after i. v. infusion was 4.1 (1.5-7.4) mg/l, and that after NG administration was 2.3 (0.7-5.8) mg/l, occurring 1.25 (0.75-3.33) h after dosing.",Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840238/),[mg] / [l],2.3,248637,DB00537,Ciprofloxacin
,9840238,areas under plasma concentration-time curves,"The median [range] areas under plasma concentration-time curves were similar for the two administration routes (10.3 [3.3-34.6] and 8.4 [3.6-53.4] for i.v. infusion and NG administration, respectively).",Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840238/),,10.3,248638,DB00537,Ciprofloxacin
,9840238,areas under plasma concentration-time curves,"The median [range] areas under plasma concentration-time curves were similar for the two administration routes (10.3 [3.3-34.6] and 8.4 [3.6-53.4] for i.v. infusion and NG administration, respectively).",Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840238/),,8.4,248639,DB00537,Ciprofloxacin
,9840238,bioavailability,"Ciprofloxacin bioavailability ranges from 31 to 82 % (median, 44%).",Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840238/),%,44,248640,DB00537,Ciprofloxacin
less,3348609,MIC90,The MICs of A-61827 for 90% of strains (MIC90) of staphylococci and streptococci were less than or equal to 1 microgram/ml and were generally 1 to 4 twofold dilutions less than those of ciprofloxacin for these bacteria.,"A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348609/),[μg] / [ml],1,249281,DB00537,Ciprofloxacin
less,3348609,MIC90S,The MIC90S of A-61827 for members of the family Enterobacteriaceae and Pseudomonas aeruginosa were also less than or equal to 1 microgram/ml.,"A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348609/),[μg] / [ml],1,249282,DB00537,Ciprofloxacin
,3348609,MIC90,The MIC90 of A-61827 for Legionella pneumophila was 0.25 microgram/ml.,"A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348609/),[μg] / [ml],0.25,249283,DB00537,Ciprofloxacin
less,3348609,MIC90,The MIC90 of A-61827 for all anaerobic bacteria was less than or equal to 4 micrograms/ml compared with less than or equal to 32 micrograms/ml for ciprofloxacin.,"A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348609/),[μg] / [ml],4,249284,DB00537,Ciprofloxacin
less,3348609,MIC90,The MIC90 of A-61827 for all anaerobic bacteria was less than or equal to 4 micrograms/ml compared with less than or equal to 32 micrograms/ml for ciprofloxacin.,"A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348609/),[μg] / [ml],32,249285,DB00537,Ciprofloxacin
,3348609,peak concentrations,"After oral administration of 100 mg/kg to mice, the peak concentrations of A-61827 and ciprofloxacin in serum were 2.3 and 2.4 micrograms/ml and the half-lives in serum were 3.9 and 1.2 h, respectively.","A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348609/),[μg] / [ml],2.3,249286,DB00537,Ciprofloxacin
,3348609,peak concentrations,"After oral administration of 100 mg/kg to mice, the peak concentrations of A-61827 and ciprofloxacin in serum were 2.3 and 2.4 micrograms/ml and the half-lives in serum were 3.9 and 1.2 h, respectively.","A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348609/),[μg] / [ml],2.4,249287,DB00537,Ciprofloxacin
,3348609,half-lives,"After oral administration of 100 mg/kg to mice, the peak concentrations of A-61827 and ciprofloxacin in serum were 2.3 and 2.4 micrograms/ml and the half-lives in serum were 3.9 and 1.2 h, respectively.","A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348609/),h,3.9,249288,DB00537,Ciprofloxacin
,3348609,half-lives,"After oral administration of 100 mg/kg to mice, the peak concentrations of A-61827 and ciprofloxacin in serum were 2.3 and 2.4 micrograms/ml and the half-lives in serum were 3.9 and 1.2 h, respectively.","A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348609/),h,1.2,249289,DB00537,Ciprofloxacin
,11673035,MIC,The serum bactericidal activity against 2 Streptococcus pneumoniae strains (ciprofloxacin MIC 1 and 4 mg/l) was measured in 12 volunteers who received oral single doses of gemifloxacin 320 mg and trovafloxacin 200 mg in a crossover fashion.,Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],1,249355,DB00537,Ciprofloxacin
,11673035,MIC,The serum bactericidal activity against 2 Streptococcus pneumoniae strains (ciprofloxacin MIC 1 and 4 mg/l) was measured in 12 volunteers who received oral single doses of gemifloxacin 320 mg and trovafloxacin 200 mg in a crossover fashion.,Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],4,249356,DB00537,Ciprofloxacin
,11673035,MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],0.015,249357,DB00537,Ciprofloxacin
,11673035,MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],0.03,249358,DB00537,Ciprofloxacin
,11673035,C(max)/MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,104,249359,DB00537,Ciprofloxacin
,11673035,C(max)/MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,52,249360,DB00537,Ciprofloxacin
,11673035,AUC(0-24 h)/MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,532,249361,DB00537,Ciprofloxacin
,11673035,AUC(0-24 h)/MIC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,266,249362,DB00537,Ciprofloxacin
,11673035,area under the bactericidal curve (AUBC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,168,249363,DB00537,Ciprofloxacin
,11673035,area under the bactericidal curve (AUBC,"The 4-fold increase in ciprofloxacin MIC from the susceptible to the resistant strain resulted in a 2-fold increase in MIC (from 0.015 to 0.03 mg/l), a 2-fold decrease in C(max)/MIC (104 vs 52) and in AUC(0-24 h)/MIC (532 vs 266), but a 5.6-fold decrease in area under the bactericidal curve (AUBC: 168 vs 30) for gemifloxacin.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,30,249364,DB00537,Ciprofloxacin
,11673035,MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],0.25,249365,DB00537,Ciprofloxacin
,11673035,MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),[mg] / [l],0.06,249366,DB00537,Ciprofloxacin
,11673035,C(max)/MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,8.6,249367,DB00537,Ciprofloxacin
,11673035,C(max)/MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,36,249368,DB00537,Ciprofloxacin
,11673035,AUC(0-24 h)/MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,85,249369,DB00537,Ciprofloxacin
,11673035,AUC(0-24 h)/MIC,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,356,249370,DB00537,Ciprofloxacin
,11673035,AUBCs,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,2,249371,DB00537,Ciprofloxacin
,11673035,AUBCs,"Trovafloxacin showed a 4-fold higher MIC (0.25 vs 0.06 mg/l), a 4-fold lower C(max)/MIC (8.6 vs 36), a 4-fold lower AUC(0-24 h)/MIC (85 vs 356) and a 11-fold lower AUBCs (2 vs 22) against the resistant isolate compared with the susceptible one.",Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673035/),,22,249372,DB00537,Ciprofloxacin
,2462556,serum half-life,Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a serum half-life of about 8-12 h.,In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),h,8-12,250028,DB00537,Ciprofloxacin
,2462556,mean plasma concentrations,"The mean plasma concentrations of three or four volunteers at each time were 4.2, 3.6 and 1.2 mg/l, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),[mg] / [l],4.2,250029,DB00537,Ciprofloxacin
,2462556,mean plasma concentrations,"The mean plasma concentrations of three or four volunteers at each time were 4.2, 3.6 and 1.2 mg/l, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),[mg] / [l],3.6,250030,DB00537,Ciprofloxacin
,2462556,mean plasma concentrations,"The mean plasma concentrations of three or four volunteers at each time were 4.2, 3.6 and 1.2 mg/l, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),[mg] / [l],1.2,250031,DB00537,Ciprofloxacin
,2462556,prostatic fluid/plasma ratios,"The corresponding prostatic fluid/plasma ratios were 0.30, 0.27 and 1.96, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),,0.30,250032,DB00537,Ciprofloxacin
,2462556,prostatic fluid/plasma ratios,"The corresponding prostatic fluid/plasma ratios were 0.30, 0.27 and 1.96, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),,0.27,250033,DB00537,Ciprofloxacin
,2462556,prostatic fluid/plasma ratios,"The corresponding prostatic fluid/plasma ratios were 0.30, 0.27 and 1.96, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),,1.96,250034,DB00537,Ciprofloxacin
,17573085,clearance (Cl),The plasma difloxacin clearance (Cl) for the IV route was (mean +/- SD) 0.41 +/- 0.05 L/h kg.,Disposition kinetics and pharmacokinetics--pharmacodynamic integration of difloxacin against Staphylococcus aureus isolates from rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573085/),[l] / [h·kg],0.41,250156,DB00537,Ciprofloxacin
,17573085,steady-state volume of distribution (V(ss)),The steady-state volume of distribution (V(ss)) was 1.95 +/- 0.17 L/kg.,Disposition kinetics and pharmacokinetics--pharmacodynamic integration of difloxacin against Staphylococcus aureus isolates from rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573085/),[l] / [kg],1.95,250157,DB00537,Ciprofloxacin
,17573085,terminal half-life,"The terminal half-life [Formula: see text] was (mean+/-SD) 4.19+/-0.34 h, 7.53 +/- 1.32 h and 8.00 +/- 0.45 h after IV, IM and oral, respectively.",Disposition kinetics and pharmacokinetics--pharmacodynamic integration of difloxacin against Staphylococcus aureus isolates from rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573085/),h,4.19,250158,DB00537,Ciprofloxacin
,17573085,terminal half-life,"The terminal half-life [Formula: see text] was (mean+/-SD) 4.19+/-0.34 h, 7.53 +/- 1.32 h and 8.00 +/- 0.45 h after IV, IM and oral, respectively.",Disposition kinetics and pharmacokinetics--pharmacodynamic integration of difloxacin against Staphylococcus aureus isolates from rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573085/),h,7.53,250159,DB00537,Ciprofloxacin
,17573085,terminal half-life,"The terminal half-life [Formula: see text] was (mean+/-SD) 4.19+/-0.34 h, 7.53 +/- 1.32 h and 8.00 +/- 0.45 h after IV, IM and oral, respectively.",Disposition kinetics and pharmacokinetics--pharmacodynamic integration of difloxacin against Staphylococcus aureus isolates from rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573085/),h,8.00,250160,DB00537,Ciprofloxacin
,17573085,MIC,"From this data, it seems that a 5 mg/kg dose difloxacin would be effective by SC and oral routes in rabbits against bacterial isolates with MIC0.1 microg/mL.",Disposition kinetics and pharmacokinetics--pharmacodynamic integration of difloxacin against Staphylococcus aureus isolates from rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573085/),[μg] / [ml],0,250161,DB00537,Ciprofloxacin
≥,26406268,AUC24 /MIC,"First of all, effective dosages (ED) of ciprofloxacin were defined as those achieving a target AUC24 /MIC ≥ 125.",Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26406268/),,125,250941,DB00537,Ciprofloxacin
,26406268,MICs,"Based on the AUC24 /MIC, for low MICs (0.125 μg/mL), all dosing regimens recommended by French guidelines were effective.",Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26406268/),[μg] / [ml],0.125,250942,DB00537,Ciprofloxacin
,26406268,MICs,"For intermediate MICs (0.25 and 0.5 μg/mL), simulated doses higher than those recommended were needed to achieve the efficacy target.",Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26406268/),[μg] / [ml],0.25,250943,DB00537,Ciprofloxacin
,26406268,MICs,"For intermediate MICs (0.25 and 0.5 μg/mL), simulated doses higher than those recommended were needed to achieve the efficacy target.",Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26406268/),[μg] / [ml],0.5,250944,DB00537,Ciprofloxacin
≤,22968336,minimum inhibitory concentrations (MIC),In the cases where ciprofloxacin was applied in targeted antibiotic therapy the minimum inhibitory concentrations (MIC) were ≤0.5 mg/l.,Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),[mg] / [l],0.5,251393,DB00537,Ciprofloxacin
,22968336,maximum,"The maximum and minimum plasma concentrations of ciprofloxacin were 1.74 (0.58-7.90) and 0.45 (0.16-2.96) mg/l, respectively.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),[mg] / [l],1.74,251394,DB00537,Ciprofloxacin
,22968336,minimum plasma concentrations,"The maximum and minimum plasma concentrations of ciprofloxacin were 1.74 (0.58-7.90) and 0.45 (0.16-2.96) mg/l, respectively.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),[mg] / [l],0.45,251395,DB00537,Ciprofloxacin
,22968336,k(el),"The main pharmacokinetic parameters for ciprofloxacin in the analyzed patients were as follows: k(el), 0.21 h-1; t(1/2kel), 3.37 h; AUC(0-inf), 10.10 mg×h/l; AUMC(0-last), 15.36 mg×h(2)/l; MRT, 1.71 h; V(d), 214.8 l; Cl, 39.70 l/h.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),1/[h],0.21,251396,DB00537,Ciprofloxacin
,22968336,t(1/2kel),"The main pharmacokinetic parameters for ciprofloxacin in the analyzed patients were as follows: k(el), 0.21 h-1; t(1/2kel), 3.37 h; AUC(0-inf), 10.10 mg×h/l; AUMC(0-last), 15.36 mg×h(2)/l; MRT, 1.71 h; V(d), 214.8 l; Cl, 39.70 l/h.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),h,3.37,251397,DB00537,Ciprofloxacin
,22968336,AUC(0-inf),"The main pharmacokinetic parameters for ciprofloxacin in the analyzed patients were as follows: k(el), 0.21 h-1; t(1/2kel), 3.37 h; AUC(0-inf), 10.10 mg×h/l; AUMC(0-last), 15.36 mg×h(2)/l; MRT, 1.71 h; V(d), 214.8 l; Cl, 39.70 l/h.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),[h·mg] / [l],10.10,251398,DB00537,Ciprofloxacin
,22968336,AUMC(0-last),"The main pharmacokinetic parameters for ciprofloxacin in the analyzed patients were as follows: k(el), 0.21 h-1; t(1/2kel), 3.37 h; AUC(0-inf), 10.10 mg×h/l; AUMC(0-last), 15.36 mg×h(2)/l; MRT, 1.71 h; V(d), 214.8 l; Cl, 39.70 l/h.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),[h(2·mg] / [l],15.36,251399,DB00537,Ciprofloxacin
,22968336,MRT,"The main pharmacokinetic parameters for ciprofloxacin in the analyzed patients were as follows: k(el), 0.21 h-1; t(1/2kel), 3.37 h; AUC(0-inf), 10.10 mg×h/l; AUMC(0-last), 15.36 mg×h(2)/l; MRT, 1.71 h; V(d), 214.8 l; Cl, 39.70 l/h.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),h,1.71,251400,DB00537,Ciprofloxacin
,22968336,V(d),"The main pharmacokinetic parameters for ciprofloxacin in the analyzed patients were as follows: k(el), 0.21 h-1; t(1/2kel), 3.37 h; AUC(0-inf), 10.10 mg×h/l; AUMC(0-last), 15.36 mg×h(2)/l; MRT, 1.71 h; V(d), 214.8 l; Cl, 39.70 l/h.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),l,214.8,251401,DB00537,Ciprofloxacin
,22968336,Cl,"The main pharmacokinetic parameters for ciprofloxacin in the analyzed patients were as follows: k(el), 0.21 h-1; t(1/2kel), 3.37 h; AUC(0-inf), 10.10 mg×h/l; AUMC(0-last), 15.36 mg×h(2)/l; MRT, 1.71 h; V(d), 214.8 l; Cl, 39.70 l/h.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),[l] / [h],39.70,251402,DB00537,Ciprofloxacin
,22968336,MIC,"Considering the maximum value of MIC (0.5 mg/l) only 30% and 25% of analyzed patients had desired values of the PK/PD indexes AUIC>125 and C(max) /MIC>10, respectively.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),[mg] / [l],0.5,251403,DB00537,Ciprofloxacin
>,22968336,AUIC,"Considering the maximum value of MIC (0.5 mg/l) only 30% and 25% of analyzed patients had desired values of the PK/PD indexes AUIC>125 and C(max) /MIC>10, respectively.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),,125,251404,DB00537,Ciprofloxacin
>,22968336,C(max) /MIC,"Considering the maximum value of MIC (0.5 mg/l) only 30% and 25% of analyzed patients had desired values of the PK/PD indexes AUIC>125 and C(max) /MIC>10, respectively.",Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968336/),,10,251405,DB00537,Ciprofloxacin
,21062312,C(0),The mean C(0) was 20.5 μg/mL (±8.8) immediately after i.v. administration.,Pharmacokinetics and toxicity of ciprofloxacin in adult horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21062312/),[μg] / [ml],20.5,251977,DB00537,Ciprofloxacin
,21062312,C(max),The C(max) was 0.6 μg/mL (±0.36) at T(max) 1.46 (±0.66) h after the administration of oral ciprofloxacin.,Pharmacokinetics and toxicity of ciprofloxacin in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21062312/),[μg] / [ml],0.6,251978,DB00537,Ciprofloxacin
,21062312,T(max),The C(max) was 0.6 μg/mL (±0.36) at T(max) 1.46 (±0.66) h after the administration of oral ciprofloxacin.,Pharmacokinetics and toxicity of ciprofloxacin in adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21062312/),h,1.46,251979,DB00537,Ciprofloxacin
,21062312,elimination half-life,"The mean elimination half-life after i.v. administration was 5.8 (±1.6) h, and after oral administration the terminal half-life was 3.6 (±1.7) h.",Pharmacokinetics and toxicity of ciprofloxacin in adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21062312/),h,5.8,251980,DB00537,Ciprofloxacin
,21062312,terminal half-life,"The mean elimination half-life after i.v. administration was 5.8 (±1.6) h, and after oral administration the terminal half-life was 3.6 (±1.7) h.",Pharmacokinetics and toxicity of ciprofloxacin in adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21062312/),h,3.6,251981,DB00537,Ciprofloxacin
,24252110,encapsulation efficiency,"The optimized ciprofloxacin liposome, which had a high encapsulation efficiency of 93.96%, and an average particle size of 349.6 nm with a span of 0.42, showed sustained in-vitro release.",In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252110/),%,93.96,252049,DB00537,Ciprofloxacin
,24252110,ratio of the AUClung,"The ratio of the AUClung value between ciprofloxacin liposome and ciprofloxacin solution was 288.33, whereas the relative bioavailability was 72.42%, and the drug targeting efficiency of ciprofloxacin liposome and ciprofloxacin solution by intratracheal administration were 799.71 and 2.01, respectively.",In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252110/),,288.33,252050,DB00537,Ciprofloxacin
,24252110,relative bioavailability,"The ratio of the AUClung value between ciprofloxacin liposome and ciprofloxacin solution was 288.33, whereas the relative bioavailability was 72.42%, and the drug targeting efficiency of ciprofloxacin liposome and ciprofloxacin solution by intratracheal administration were 799.71 and 2.01, respectively.",In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252110/),%,72.42,252051,DB00537,Ciprofloxacin
,24252110,drug targeting efficiency,"The ratio of the AUClung value between ciprofloxacin liposome and ciprofloxacin solution was 288.33, whereas the relative bioavailability was 72.42%, and the drug targeting efficiency of ciprofloxacin liposome and ciprofloxacin solution by intratracheal administration were 799.71 and 2.01, respectively.",In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252110/),,79,252052,DB00537,Ciprofloxacin
,24252110,drug targeting efficiency,"The ratio of the AUClung value between ciprofloxacin liposome and ciprofloxacin solution was 288.33, whereas the relative bioavailability was 72.42%, and the drug targeting efficiency of ciprofloxacin liposome and ciprofloxacin solution by intratracheal administration were 799.71 and 2.01, respectively.",In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252110/),,2,252053,DB00537,Ciprofloxacin
,2599998,MICs,MICs of Pseudomonas species isolated from the sputum at the start of the trial were in the range 0.25-4 mg/l.,Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2599998/),[mg] / [l],0.25-4,252214,DB00537,Ciprofloxacin
,9181604,steady state volume of distribution,The steady state volume of distribution was determined to 3.9 +/- 0.5 1/kg body weight which indicates that enrofloxacin was widely distributed in the body.,Bioavailability of enrofloxacin after oral administration to fed and fasted pigs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181604/),[1] / [kg],3.9,252332,DB00537,Ciprofloxacin
,9181604,bioavailability,The bioavailability was determined to 83 +/- 13% in fed and to 101 +/- 32% in fasted pigs.,Bioavailability of enrofloxacin after oral administration to fed and fasted pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181604/),%,83,252333,DB00537,Ciprofloxacin
,9181604,bioavailability,The bioavailability was determined to 83 +/- 13% in fed and to 101 +/- 32% in fasted pigs.,Bioavailability of enrofloxacin after oral administration to fed and fasted pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181604/),%,101,252334,DB00537,Ciprofloxacin
>,30855292,AUC/MIC,"Thirty-one patients (93.4%) did not reach the target AUC/MIC value of >125, and 29 patients (87.9%) did not reach the target Cmax/MIC value of >8.",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,125,252711,DB00537,Ciprofloxacin
>,30855292,Cmax/MIC,"Thirty-one patients (93.4%) did not reach the target AUC/MIC value of >125, and 29 patients (87.9%) did not reach the target Cmax/MIC value of >8.",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,8,252712,DB00537,Ciprofloxacin
,30855292,AUC/MIC,"The AUC/MIC and Cmax/MIC ratios in the clinical success group were significantly higher than those in the clinical failure group (61.1 [31.7-214.9] vs. 10.4 [3.8-66.1], Z = -4.157; 9.6 [4.2-17.8] vs. 1.3 [0.4-4.7], Z = -4.018; both P < 0.001).",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,61.1,252713,DB00537,Ciprofloxacin
,30855292,Cmax/MIC ratios,"The AUC/MIC and Cmax/MIC ratios in the clinical success group were significantly higher than those in the clinical failure group (61.1 [31.7-214.9] vs. 10.4 [3.8-66.1], Z = -4.157; 9.6 [4.2-17.8] vs. 1.3 [0.4-4.7], Z = -4.018; both P < 0.001).",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,10.4,252714,DB00537,Ciprofloxacin
,30855292,Cmax/MIC ratios,"The AUC/MIC and Cmax/MIC ratios in the clinical success group were significantly higher than those in the clinical failure group (61.1 [31.7-214.9] vs. 10.4 [3.8-66.1], Z = -4.157; 9.6 [4.2-17.8] vs. 1.3 [0.4-4.7], Z = -4.018; both P < 0.001).",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,9.6,252715,DB00537,Ciprofloxacin
,30855292,Cmax/MIC ratios,"The AUC/MIC and Cmax/MIC ratios in the clinical success group were significantly higher than those in the clinical failure group (61.1 [31.7-214.9] vs. 10.4 [3.8-66.1], Z = -4.157; 9.6 [4.2-17.8] vs. 1.3 [0.4-4.7], Z = -4.018; both P < 0.001).",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,1.3,252716,DB00537,Ciprofloxacin
,30855292,AUC/MIC,"The AUC/MIC and Cmax/MIC ratios in the patients for whom the pathogens were eradicated were significantly higher than those in the patients without the pathogens eradicated (75.3 [31.7-214.9] vs. 10.5 [3.8-66.1], Z = -3.938; 11.4 [4.2-17.8] vs. 1.4 [0.4-5.4], Z = -3.793; P < 0.001 for both).",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,75.3,252717,DB00537,Ciprofloxacin
,30855292,Cmax/MIC ratios,"The AUC/MIC and Cmax/MIC ratios in the patients for whom the pathogens were eradicated were significantly higher than those in the patients without the pathogens eradicated (75.3 [31.7-214.9] vs. 10.5 [3.8-66.1], Z = -3.938; 11.4 [4.2-17.8] vs. 1.4 [0.4-5.4], Z = -3.793; P < 0.001 for both).",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,10.5,252718,DB00537,Ciprofloxacin
,30855292,Cmax/MIC ratios,"The AUC/MIC and Cmax/MIC ratios in the patients for whom the pathogens were eradicated were significantly higher than those in the patients without the pathogens eradicated (75.3 [31.7-214.9] vs. 10.5 [3.8-66.1], Z = -3.938; 11.4 [4.2-17.8] vs. 1.4 [0.4-5.4], Z = -3.793; P < 0.001 for both).",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,11.4,252719,DB00537,Ciprofloxacin
,30855292,Cmax/MIC ratios,"The AUC/MIC and Cmax/MIC ratios in the patients for whom the pathogens were eradicated were significantly higher than those in the patients without the pathogens eradicated (75.3 [31.7-214.9] vs. 10.5 [3.8-66.1], Z = -3.938; 11.4 [4.2-17.8] vs. 1.4 [0.4-5.4], Z = -3.793; P < 0.001 for both).",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,1.4,252720,DB00537,Ciprofloxacin
>,30855292,AUC/MIC,"Consequently, the target values, AUC/MIC > 125 and Cmax/MIC > 8, cannot be reached.",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,125,252721,DB00537,Ciprofloxacin
>,30855292,Cmax/MIC,"Consequently, the target values, AUC/MIC > 125 and Cmax/MIC > 8, cannot be reached.",Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30855292/),,8,252722,DB00537,Ciprofloxacin
,2944477,peak,Serum concentrations reached a mean peak of 3.6 micrograms/ml 1 to 2 h after the oral dose.,Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2944477/),[μg] / [ml],3.6,252761,DB00537,Ciprofloxacin
,2944477,terminal serum half-life,"The mean terminal serum half-life was 16.8 h, and the mean peritoneal fluid/serum concentration ratio was 0.64.",Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2944477/),h,16.8,252762,DB00537,Ciprofloxacin
,2944477,peritoneal fluid/serum concentration ratio,"The mean terminal serum half-life was 16.8 h, and the mean peritoneal fluid/serum concentration ratio was 0.64.",Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2944477/),,0.64,252763,DB00537,Ciprofloxacin
,2944477,peak ciprofloxacin concentration,"The mean peak ciprofloxacin concentration in peritoneal fluid was 1.3 micrograms/ml, and the bioactivity of the drug in peritoneal fluid was confirmed.",Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2944477/),[μg] / [ml],1.3,252764,DB00537,Ciprofloxacin
,12584677,skin:plasma ratios,"After dosing on Day 0 and after five to seven daily treatments, dogs with pyoderma had significantly higher mean orbifloxacin skin:plasma ratios (1.40 and 1.44, respectively) than did clinically normal dogs (0.81 and 0.96, respectively).",Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584677/),,1,253019,DB00537,Ciprofloxacin
,12584677,skin:plasma ratios,"After dosing on Day 0 and after five to seven daily treatments, dogs with pyoderma had significantly higher mean orbifloxacin skin:plasma ratios (1.40 and 1.44, respectively) than did clinically normal dogs (0.81 and 0.96, respectively).",Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584677/),,1.44,253020,DB00537,Ciprofloxacin
,16434544,plasma concentration,"In vivo pharmacokinetic studies showed that the ciprofloxacin plasma concentration was more than 2-fold increased in Bcrp1(-/-) compared with wild-type mice (1.77 +/- 0.73 versus 0.85 +/- 0.39 microg/ml, p < 0.01) after oral administration of ciprofloxacin (10 mg/kg).","Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16434544/),,1,253324,DB00537,Ciprofloxacin
,16434544,plasma concentration,"In vivo pharmacokinetic studies showed that the ciprofloxacin plasma concentration was more than 2-fold increased in Bcrp1(-/-) compared with wild-type mice (1.77 +/- 0.73 versus 0.85 +/- 0.39 microg/ml, p < 0.01) after oral administration of ciprofloxacin (10 mg/kg).","Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16434544/),,0.85,253325,DB00537,Ciprofloxacin
,16434544,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve in Bcrp1(-/-) mice was 1.5-fold higher than that in wild-type mice (48.63 +/- 5.66 versus 33.10 +/- 4.68 min x microg/ml, p < 0.05) after i.v. administration (10 mg/kg).","Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16434544/),[min·μg] / [ml],48.63,253326,DB00537,Ciprofloxacin
,16434544,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve in Bcrp1(-/-) mice was 1.5-fold higher than that in wild-type mice (48.63 +/- 5.66 versus 33.10 +/- 4.68 min x microg/ml, p < 0.05) after i.v. administration (10 mg/kg).","Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16434544/),[min·μg] / [ml],33.10,253327,DB00537,Ciprofloxacin
,20444043,maximum concentration of drug (C(max)),"In plasma, the maximum concentration of drug (C(max)), the time at which this maximum concentration of drug (T(max)) was reached, the elimination half-life (t(1/2)(beta)) and the area under the concentration vs. time curve (AUC) were, respectively, 694.7 ng/mL, 1.0 h, 9.3 h and 8903.2 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),[ng] / [ml],694.7,253472,DB00537,Ciprofloxacin
,20444043,time at which this maximum concentration of drug (T(max)),"In plasma, the maximum concentration of drug (C(max)), the time at which this maximum concentration of drug (T(max)) was reached, the elimination half-life (t(1/2)(beta)) and the area under the concentration vs. time curve (AUC) were, respectively, 694.7 ng/mL, 1.0 h, 9.3 h and 8903.2 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),h,1.0,253473,DB00537,Ciprofloxacin
,20444043,time at which this maximum concentration of drug (T(max)),"In plasma, the maximum concentration of drug (C(max)), the time at which this maximum concentration of drug (T(max)) was reached, the elimination half-life (t(1/2)(beta)) and the area under the concentration vs. time curve (AUC) were, respectively, 694.7 ng/mL, 1.0 h, 9.3 h and 8903.2 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),h,9.3,253474,DB00537,Ciprofloxacin
,20444043,elimination half-life (t(1/2)(beta)),"In plasma, the maximum concentration of drug (C(max)), the time at which this maximum concentration of drug (T(max)) was reached, the elimination half-life (t(1/2)(beta)) and the area under the concentration vs. time curve (AUC) were, respectively, 694.7 ng/mL, 1.0 h, 9.3 h and 8903.2 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),h,1.0,253475,DB00537,Ciprofloxacin
,20444043,elimination half-life (t(1/2)(beta)),"In plasma, the maximum concentration of drug (C(max)), the time at which this maximum concentration of drug (T(max)) was reached, the elimination half-life (t(1/2)(beta)) and the area under the concentration vs. time curve (AUC) were, respectively, 694.7 ng/mL, 1.0 h, 9.3 h and 8903.2 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),h,9.3,253476,DB00537,Ciprofloxacin
,20444043,area under the concentration vs. time curve (AUC),"In plasma, the maximum concentration of drug (C(max)), the time at which this maximum concentration of drug (T(max)) was reached, the elimination half-life (t(1/2)(beta)) and the area under the concentration vs. time curve (AUC) were, respectively, 694.7 ng/mL, 1.0 h, 9.3 h and 8903.2 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),[h·ng] / [ml],8903.2,253477,DB00537,Ciprofloxacin
,20444043,C(max),"In nasal secretions, C(max), T(max), t(1/2)(beta) and AUC were, respectively, 871.4 ng/mL, 2.0 h, 12.5 h and 11 198.5 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),[ng] / [ml],871.4,253478,DB00537,Ciprofloxacin
,20444043,T(max),"In nasal secretions, C(max), T(max), t(1/2)(beta) and AUC were, respectively, 871.4 ng/mL, 2.0 h, 12.5 h and 11 198.5 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),h,2.0,253479,DB00537,Ciprofloxacin
,20444043,T(max),"In nasal secretions, C(max), T(max), t(1/2)(beta) and AUC were, respectively, 871.4 ng/mL, 2.0 h, 12.5 h and 11 198.5 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),h,12.5,253480,DB00537,Ciprofloxacin
,20444043,t(1/2)(beta),"In nasal secretions, C(max), T(max), t(1/2)(beta) and AUC were, respectively, 871.4 ng/mL, 2.0 h, 12.5 h and 11 198.5 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),h,2.0,253481,DB00537,Ciprofloxacin
,20444043,t(1/2)(beta),"In nasal secretions, C(max), T(max), t(1/2)(beta) and AUC were, respectively, 871.4 ng/mL, 2.0 h, 12.5 h and 11 198.5 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),h,12.5,253482,DB00537,Ciprofloxacin
,20444043,AUC,"In nasal secretions, C(max), T(max), t(1/2)(beta) and AUC were, respectively, 871.4 ng/mL, 2.0 h, 12.5 h and 11 198.5 ngxh/mL.",Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444043/),[h·ng] / [ml],11 198.5,253483,DB00537,Ciprofloxacin
,15490984,serum half-life,"The pharmacokinetic parameters determined for ciprofloxacin were (mean +/- SEM) serum half-life 10.1 +/- 1.2 hours, maximum serum concentration 2.7 +/- 0.5 mg/L, time to maximum serum concentration 1.6 +/- 0.1 hours after the first dose, and peritoneal clearance 1.2% +/- 0.1% of the mean calculated total body clearance.",Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490984/),h,10.1,253668,DB00537,Ciprofloxacin
,15490984,maximum serum concentration,"The pharmacokinetic parameters determined for ciprofloxacin were (mean +/- SEM) serum half-life 10.1 +/- 1.2 hours, maximum serum concentration 2.7 +/- 0.5 mg/L, time to maximum serum concentration 1.6 +/- 0.1 hours after the first dose, and peritoneal clearance 1.2% +/- 0.1% of the mean calculated total body clearance.",Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490984/),[mg] / [l],2.7,253669,DB00537,Ciprofloxacin
,15490984,time to maximum serum concentration,"The pharmacokinetic parameters determined for ciprofloxacin were (mean +/- SEM) serum half-life 10.1 +/- 1.2 hours, maximum serum concentration 2.7 +/- 0.5 mg/L, time to maximum serum concentration 1.6 +/- 0.1 hours after the first dose, and peritoneal clearance 1.2% +/- 0.1% of the mean calculated total body clearance.",Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490984/),h,1.6,253670,DB00537,Ciprofloxacin
>,15490984,serum area under the concentration-time curve:MIC,"While all patients achieved serum area under the concentration-time curve:MIC > 125 for Escherichia coli and Klebsiella species after the first dose, only 2 patients achieved this goal for Pseudomonas aeruginosa.",Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490984/),,125,253671,DB00537,Ciprofloxacin
,7988628,AUC,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[h·mg] / [l],736,253766,DB00537,Ciprofloxacin
,7988628,AUC,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[h·mg] / [l],734,253767,DB00537,Ciprofloxacin
,7988628,Cmax,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[mg] / [l],466,253768,DB00537,Ciprofloxacin
,7988628,Cmax,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[mg] / [l],483,253769,DB00537,Ciprofloxacin
,7988628,tmax,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),h,0.6,253770,DB00537,Ciprofloxacin
,7988628,tmax,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),h,0.5,253771,DB00537,Ciprofloxacin
,7988628,elimination rate,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[mg] / [h·l],134,253772,DB00537,Ciprofloxacin
,7988628,elimination rate,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[mg] / [h·l],133,253773,DB00537,Ciprofloxacin
,25633891,clearance,The clearance of all drugs except rifampicin in sodium chloride 0.9% was comparable (mean 1.76 ± 0.11 l/h).,Anti-infective drugs during continuous hemodialysis - using the bench to learn what to do at the bedside. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633891/),[l] / [h],1.76,255173,DB00537,Ciprofloxacin
,10566812,elimination half-life,"Mean (+/-SD) elimination half-life and mean residence time of enrofloxacin in plasma were 9.64+/-1.49 and 12.77+/-2.15 hours, respectively, after i.v. administration and 12.06+/-0.68 and 17.15+/-1.04 hours, respectively, after i.m. administration.",Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10566812/),h,9.64,255542,DB00537,Ciprofloxacin
,10566812,elimination half-life,"Mean (+/-SD) elimination half-life and mean residence time of enrofloxacin in plasma were 9.64+/-1.49 and 12.77+/-2.15 hours, respectively, after i.v. administration and 12.06+/-0.68 and 17.15+/-1.04 hours, respectively, after i.m. administration.",Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10566812/),h,12.06,255543,DB00537,Ciprofloxacin
,10566812,mean residence time,"Mean (+/-SD) elimination half-life and mean residence time of enrofloxacin in plasma were 9.64+/-1.49 and 12.77+/-2.15 hours, respectively, after i.v. administration and 12.06+/-0.68 and 17.15+/-1.04 hours, respectively, after i.m. administration.",Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10566812/),h,12.77,255544,DB00537,Ciprofloxacin
,10566812,mean residence time,"Mean (+/-SD) elimination half-life and mean residence time of enrofloxacin in plasma were 9.64+/-1.49 and 12.77+/-2.15 hours, respectively, after i.v. administration and 12.06+/-0.68 and 17.15+/-1.04 hours, respectively, after i.m. administration.",Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10566812/),h,17.15,255545,DB00537,Ciprofloxacin
,10566812,Half-life at alpha phase,"Half-life at alpha phase of enrofloxacin was 0.23+/-0.05 and 1.94+/-0.70 hours for i.v. and i.m. administration, respectively.",Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10566812/),h,0.23,255546,DB00537,Ciprofloxacin
,10566812,Half-life at alpha phase,"Half-life at alpha phase of enrofloxacin was 0.23+/-0.05 and 1.94+/-0.70 hours for i.v. and i.m. administration, respectively.",Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10566812/),h,1.94,255547,DB00537,Ciprofloxacin
,10566812,Maximal plasma concentration,"Maximal plasma concentration was 1.17 +/-0.23 microg/ml, and interval from injection until maximum concentration was 1.81+/-0.23 hours.",Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10566812/),[μg] / [ml],1.17,255548,DB00537,Ciprofloxacin
,10566812,interval from injection until maximum concentration,"Maximal plasma concentration was 1.17 +/-0.23 microg/ml, and interval from injection until maximum concentration was 1.81+/-0.23 hours.",Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10566812/),h,1.81,255549,DB00537,Ciprofloxacin
,10566812,maximal residue limit,"Enrofloxacin administered i.m. at a dosage of 2.5 mg/kg for 3 successive days, with a withdrawal time of 10 days, resulted in a sum of concentrations of enrofloxacin and ciprofloxacin that were less than the European Union maximal residue limit of 30 ng/g in edible tissues.",Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10566812/),[ng] / [g],30,255550,DB00537,Ciprofloxacin
,2360834,peak concentrations,"The peak concentrations in pleural fluid 1.5 h after one and three injections were (mean +/- standard error of the mean) 0.52 +/- 0.09 and 0.77 +/- 0.15 mg/liter, respectively; the corresponding 8-h concentrations were 0.19 +/- 0.05 and 0.39 +/- 0.10 mg/liter.",Penetration of ciprofloxacin into human pleural fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360834/),[mg] / [l],0.52,256517,DB00537,Ciprofloxacin
,2360834,peak concentrations,"The peak concentrations in pleural fluid 1.5 h after one and three injections were (mean +/- standard error of the mean) 0.52 +/- 0.09 and 0.77 +/- 0.15 mg/liter, respectively; the corresponding 8-h concentrations were 0.19 +/- 0.05 and 0.39 +/- 0.10 mg/liter.",Penetration of ciprofloxacin into human pleural fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360834/),[mg] / [l],0.77,256518,DB00537,Ciprofloxacin
,2360834,peak concentrations,"The peak concentrations in pleural fluid 1.5 h after one and three injections were (mean +/- standard error of the mean) 0.52 +/- 0.09 and 0.77 +/- 0.15 mg/liter, respectively; the corresponding 8-h concentrations were 0.19 +/- 0.05 and 0.39 +/- 0.10 mg/liter.",Penetration of ciprofloxacin into human pleural fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360834/),[mg] / [l],0.19,256519,DB00537,Ciprofloxacin
,2360834,peak concentrations,"The peak concentrations in pleural fluid 1.5 h after one and three injections were (mean +/- standard error of the mean) 0.52 +/- 0.09 and 0.77 +/- 0.15 mg/liter, respectively; the corresponding 8-h concentrations were 0.19 +/- 0.05 and 0.39 +/- 0.10 mg/liter.",Penetration of ciprofloxacin into human pleural fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360834/),[mg] / [l],0.39,256520,DB00537,Ciprofloxacin
,2360834,concentrations,"The peak concentrations in pleural fluid 1.5 h after one and three injections were (mean +/- standard error of the mean) 0.52 +/- 0.09 and 0.77 +/- 0.15 mg/liter, respectively; the corresponding 8-h concentrations were 0.19 +/- 0.05 and 0.39 +/- 0.10 mg/liter.",Penetration of ciprofloxacin into human pleural fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360834/),[mg] / [l],0.19,256521,DB00537,Ciprofloxacin
,2360834,concentrations,"The peak concentrations in pleural fluid 1.5 h after one and three injections were (mean +/- standard error of the mean) 0.52 +/- 0.09 and 0.77 +/- 0.15 mg/liter, respectively; the corresponding 8-h concentrations were 0.19 +/- 0.05 and 0.39 +/- 0.10 mg/liter.",Penetration of ciprofloxacin into human pleural fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360834/),[mg] / [l],0.39,256522,DB00537,Ciprofloxacin
,11760222,plasma clearance (CL),"Results showed that repeated exposure of rifabutin, relative to control, caused a 16% increase in the plasma clearance (CL) of ciprofloxacin after i.v. dosing (4.19 vs. 4.87 L/h/kg).",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[l] / [h·kg],4.19,256851,DB00537,Ciprofloxacin
,11760222,plasma clearance (CL),"Results showed that repeated exposure of rifabutin, relative to control, caused a 16% increase in the plasma clearance (CL) of ciprofloxacin after i.v. dosing (4.19 vs. 4.87 L/h/kg).",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[l] / [h·kg],4.87,256852,DB00537,Ciprofloxacin
,11760222,elimination half-life (T1/2),Estimates of elimination half-life (T1/2) were not affected by rifabutin (control: 0.81 vs. rifabutin pretreated: 1.18 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,0.81,256853,DB00537,Ciprofloxacin
,11760222,elimination half-life (T1/2),Estimates of elimination half-life (T1/2) were not affected by rifabutin (control: 0.81 vs. rifabutin pretreated: 1.18 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,1.18,256854,DB00537,Ciprofloxacin
,11760222,maximal plasma concentration (Cmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[μg] / [ml],1.34,256855,DB00537,Ciprofloxacin
,11760222,maximal plasma concentration (Cmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[μg] / [ml],0.91,256856,DB00537,Ciprofloxacin
,11760222,time to Cmax (Tmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,0.17,256857,DB00537,Ciprofloxacin
,11760222,time to Cmax (Tmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,0.33,256858,DB00537,Ciprofloxacin
,11760222,T1/2,"With or without rifabutin pretreatment, the T1/2 estimates of ciprofloxacin for p.o. dosing were similar (2.37-2.58 h) and were approximately twice as long as those obtained after i.v. dosing.",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,2.37-2.58,256859,DB00537,Ciprofloxacin
,11760222,oral bioavailability (F),"Since the changes in systemic exposure as a result of rifabutin pretreatment were similar after i.v. and p.o. dosing, the oral bioavailability (F) of ciprofloxacin remained unaffected by rifabutin at approximately 38%.",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),%,38,256860,DB00537,Ciprofloxacin
,10678493,relative bioavailability,"The relative bioavailability of ciprofloxacin, under the influence of fennel, was estimated to be 0.52.",Effect of oral administration of fennel (Foeniculum vulgare) on ciprofloxacin absorption and disposition in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678493/),,0.52,257073,DB00537,Ciprofloxacin
,10678493,apparent volume of distribution,"In addition, its apparent volume of distribution and terminal elimination half-life were significantly (P < 0.05) increased, from 30.8 +/- 11.1 (L kg(-1)) and 2.0 +/- 0.4 (h) to 143.8 +/- 31.6 (L kg(-1)) and 5.2 +/- 2.0 (h), respectively.",Effect of oral administration of fennel (Foeniculum vulgare) on ciprofloxacin absorption and disposition in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678493/),[l] / [kg],30.8,257074,DB00537,Ciprofloxacin
,10678493,apparent volume of distribution,"In addition, its apparent volume of distribution and terminal elimination half-life were significantly (P < 0.05) increased, from 30.8 +/- 11.1 (L kg(-1)) and 2.0 +/- 0.4 (h) to 143.8 +/- 31.6 (L kg(-1)) and 5.2 +/- 2.0 (h), respectively.",Effect of oral administration of fennel (Foeniculum vulgare) on ciprofloxacin absorption and disposition in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678493/),[l] / [kg],143.8,257075,DB00537,Ciprofloxacin
,10678493,terminal elimination half-life,"In addition, its apparent volume of distribution and terminal elimination half-life were significantly (P < 0.05) increased, from 30.8 +/- 11.1 (L kg(-1)) and 2.0 +/- 0.4 (h) to 143.8 +/- 31.6 (L kg(-1)) and 5.2 +/- 2.0 (h), respectively.",Effect of oral administration of fennel (Foeniculum vulgare) on ciprofloxacin absorption and disposition in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678493/),h,2.0,257076,DB00537,Ciprofloxacin
,10678493,terminal elimination half-life,"In addition, its apparent volume of distribution and terminal elimination half-life were significantly (P < 0.05) increased, from 30.8 +/- 11.1 (L kg(-1)) and 2.0 +/- 0.4 (h) to 143.8 +/- 31.6 (L kg(-1)) and 5.2 +/- 2.0 (h), respectively.",Effect of oral administration of fennel (Foeniculum vulgare) on ciprofloxacin absorption and disposition in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678493/),h,5.2,257077,DB00537,Ciprofloxacin
,11749141,elimination half-life (t(1/2beta)),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,1.39,257768,DB00537,Ciprofloxacin
,11749141,area under the plasma concentration-time curve (AUC),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,7.82,257769,DB00537,Ciprofloxacin
,11749141,area under the plasma concentration-time curve (AUC),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,2.37,257770,DB00537,Ciprofloxacin
,11749141,volume of distribution (V(d(area))),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,7.82,257771,DB00537,Ciprofloxacin
,11749141,volume of distribution (V(d(area))),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,2.37,257772,DB00537,Ciprofloxacin
,11749141,mean residence time (MRT),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,7.82,257773,DB00537,Ciprofloxacin
,11749141,mean residence time (MRT),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,2.37,257774,DB00537,Ciprofloxacin
,11749141,total systemic clearance (Cl(B)),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),[ml] / [h·kg],802.9,257775,DB00537,Ciprofloxacin
,11749141,t(1/2beta),"The t(1/2beta), AUC and MRT of ciprofloxacin were 1.82 h, 2.55 microg x h x mL and 3.59 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,1.82,257776,DB00537,Ciprofloxacin
,11749141,AUC,"The t(1/2beta), AUC and MRT of ciprofloxacin were 1.82 h, 2.55 microg x h x mL and 3.59 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,2.55,257777,DB00537,Ciprofloxacin
,11749141,MRT,"The t(1/2beta), AUC and MRT of ciprofloxacin were 1.82 h, 2.55 microg x h x mL and 3.59 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,3.59,257778,DB00537,Ciprofloxacin
,11749141,t(1/2beta),"Co-administration of probenecid did not affect the t(1/2beta), AUC, V(d (area)) and Cl(B) of enrofloxacin, whereas the values of t(1/2beta) (3.85 h), AUC (6.29 microg x h x mL), MRT (7.34 h) and metabolite ratio (0.86) of ciprofloxacin were significantly increased.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,3.85,257779,DB00537,Ciprofloxacin
,11749141,AUC,"Co-administration of probenecid did not affect the t(1/2beta), AUC, V(d (area)) and Cl(B) of enrofloxacin, whereas the values of t(1/2beta) (3.85 h), AUC (6.29 microg x h x mL), MRT (7.34 h) and metabolite ratio (0.86) of ciprofloxacin were significantly increased.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,6.29,257780,DB00537,Ciprofloxacin
,11749141,MRT,"Co-administration of probenecid did not affect the t(1/2beta), AUC, V(d (area)) and Cl(B) of enrofloxacin, whereas the values of t(1/2beta) (3.85 h), AUC (6.29 microg x h x mL), MRT (7.34 h) and metabolite ratio (0.86) of ciprofloxacin were significantly increased.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,7.34,257781,DB00537,Ciprofloxacin
,11749141,metabolite ratio,"Co-administration of probenecid did not affect the t(1/2beta), AUC, V(d (area)) and Cl(B) of enrofloxacin, whereas the values of t(1/2beta) (3.85 h), AUC (6.29 microg x h x mL), MRT (7.34 h) and metabolite ratio (0.86) of ciprofloxacin were significantly increased.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),,0.86,257782,DB00537,Ciprofloxacin
,1940278,bioavailability,Ofloxacin has favorable pharmacokinetics with almost 100% bioavailability; peak serum concentrations obtained one to two hours following oral dosing are higher than those achieved with ciprofloxacin.,Ofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940278/),,100,258002,DB00537,Ciprofloxacin
,9344173,plasma clearances,"The fitted parameters obtained from the model were used to calculate plasma clearances (0.729 +/- 0.212 L/h/kg for enrofloxacin, 0.468 +/- 0.094 L/h/kg for ciprofloxacin), distribution volumes (2.45 +/- 0.49 L/kg for enrofloxacin, 1.92 +/- 0.33 L/kg for ciprofloxacin), mean residence times (3.47 +/- 0.78 h for enrofloxacin, 4.20 +/- 0.82 h for ciprofloxacin), and the fractions of enrofloxacin metabolized to ciprofloxacin after intravenous and oral administrations of enrofloxacin.",A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344173/),[l] / [h·kg],0.729,258974,DB00537,Ciprofloxacin
,9344173,plasma clearances,"The fitted parameters obtained from the model were used to calculate plasma clearances (0.729 +/- 0.212 L/h/kg for enrofloxacin, 0.468 +/- 0.094 L/h/kg for ciprofloxacin), distribution volumes (2.45 +/- 0.49 L/kg for enrofloxacin, 1.92 +/- 0.33 L/kg for ciprofloxacin), mean residence times (3.47 +/- 0.78 h for enrofloxacin, 4.20 +/- 0.82 h for ciprofloxacin), and the fractions of enrofloxacin metabolized to ciprofloxacin after intravenous and oral administrations of enrofloxacin.",A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344173/),[l] / [h·kg],0.468,258975,DB00537,Ciprofloxacin
,9344173,distribution volumes,"The fitted parameters obtained from the model were used to calculate plasma clearances (0.729 +/- 0.212 L/h/kg for enrofloxacin, 0.468 +/- 0.094 L/h/kg for ciprofloxacin), distribution volumes (2.45 +/- 0.49 L/kg for enrofloxacin, 1.92 +/- 0.33 L/kg for ciprofloxacin), mean residence times (3.47 +/- 0.78 h for enrofloxacin, 4.20 +/- 0.82 h for ciprofloxacin), and the fractions of enrofloxacin metabolized to ciprofloxacin after intravenous and oral administrations of enrofloxacin.",A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344173/),[l] / [kg],2.45,258976,DB00537,Ciprofloxacin
,9344173,distribution volumes,"The fitted parameters obtained from the model were used to calculate plasma clearances (0.729 +/- 0.212 L/h/kg for enrofloxacin, 0.468 +/- 0.094 L/h/kg for ciprofloxacin), distribution volumes (2.45 +/- 0.49 L/kg for enrofloxacin, 1.92 +/- 0.33 L/kg for ciprofloxacin), mean residence times (3.47 +/- 0.78 h for enrofloxacin, 4.20 +/- 0.82 h for ciprofloxacin), and the fractions of enrofloxacin metabolized to ciprofloxacin after intravenous and oral administrations of enrofloxacin.",A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344173/),[l] / [kg],1.92,258977,DB00537,Ciprofloxacin
,9344173,mean residence times,"The fitted parameters obtained from the model were used to calculate plasma clearances (0.729 +/- 0.212 L/h/kg for enrofloxacin, 0.468 +/- 0.094 L/h/kg for ciprofloxacin), distribution volumes (2.45 +/- 0.49 L/kg for enrofloxacin, 1.92 +/- 0.33 L/kg for ciprofloxacin), mean residence times (3.47 +/- 0.78 h for enrofloxacin, 4.20 +/- 0.82 h for ciprofloxacin), and the fractions of enrofloxacin metabolized to ciprofloxacin after intravenous and oral administrations of enrofloxacin.",A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344173/),h,3.47,258978,DB00537,Ciprofloxacin
,9344173,mean residence times,"The fitted parameters obtained from the model were used to calculate plasma clearances (0.729 +/- 0.212 L/h/kg for enrofloxacin, 0.468 +/- 0.094 L/h/kg for ciprofloxacin), distribution volumes (2.45 +/- 0.49 L/kg for enrofloxacin, 1.92 +/- 0.33 L/kg for ciprofloxacin), mean residence times (3.47 +/- 0.78 h for enrofloxacin, 4.20 +/- 0.82 h for ciprofloxacin), and the fractions of enrofloxacin metabolized to ciprofloxacin after intravenous and oral administrations of enrofloxacin.",A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344173/),h,4.20,258979,DB00537,Ciprofloxacin
,9344173,fractions,"It was shown that enrofloxacin was largely metabolized to ciprofloxacin and that the fractions of metabolized enrofloxacin were similar after intravenous and oral administrations of enrofloxacin (40.44 +/- 10.08 and 40.17 +/- 8.33%, respectively), the hepatic first-pass effect being low (7.15 +/- 1.99%).",A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344173/),,40.,258980,DB00537,Ciprofloxacin
,9344173,fractions,"It was shown that enrofloxacin was largely metabolized to ciprofloxacin and that the fractions of metabolized enrofloxacin were similar after intravenous and oral administrations of enrofloxacin (40.44 +/- 10.08 and 40.17 +/- 8.33%, respectively), the hepatic first-pass effect being low (7.15 +/- 1.99%).",A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344173/),,40.17,258981,DB00537,Ciprofloxacin
,9344173,hepatic first-pass effect,"It was shown that enrofloxacin was largely metabolized to ciprofloxacin and that the fractions of metabolized enrofloxacin were similar after intravenous and oral administrations of enrofloxacin (40.44 +/- 10.08 and 40.17 +/- 8.33%, respectively), the hepatic first-pass effect being low (7.15 +/- 1.99%).",A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344173/),%,7.15,258982,DB00537,Ciprofloxacin
,30076955,formation clearances,The formation clearances of N‑oxide fleroxacin and N‑demethylfleroxacin were 0.520 L/h and 0.496 L/h in patients with CF; these formation clearances were 0.378 L/h and 0.353 L/h in healthy volunteers.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),[l] / [h],0.520,259050,DB00537,Ciprofloxacin
,30076955,formation clearances,The formation clearances of N‑oxide fleroxacin and N‑demethylfleroxacin were 0.520 L/h and 0.496 L/h in patients with CF; these formation clearances were 0.378 L/h and 0.353 L/h in healthy volunteers.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),[l] / [h],0.496,259051,DB00537,Ciprofloxacin
,30076955,formation clearances,The formation clearances of N‑oxide fleroxacin and N‑demethylfleroxacin were 0.520 L/h and 0.496 L/h in patients with CF; these formation clearances were 0.378 L/h and 0.353 L/h in healthy volunteers.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),[l] / [h],0.378,259052,DB00537,Ciprofloxacin
,30076955,formation clearances,The formation clearances of N‑oxide fleroxacin and N‑demethylfleroxacin were 0.520 L/h and 0.496 L/h in patients with CF; these formation clearances were 0.378 L/h and 0.353 L/h in healthy volunteers.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),[l] / [h],0.353,259053,DB00537,Ciprofloxacin
,30076955,Renal clearance,Renal clearance in patients with CF divided by that in healthy volunteers was 1.53 for N‑oxide fleroxacin and 1.70 for N‑demethyl fleroxacin.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),,1.53,259054,DB00537,Ciprofloxacin
,30076955,Renal clearance,Renal clearance in patients with CF divided by that in healthy volunteers was 1.53 for N‑oxide fleroxacin and 1.70 for N‑demethyl fleroxacin.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),,1.70,259055,DB00537,Ciprofloxacin
,11967606,Peak concentrations (C(max)),"Peak concentrations (C(max)) for group A were D(0) 6.1+/-1.2 mg/l, D(2) 9.0+/-1.8 mg/l and D(7) 5.8+/-1.3 mg/l and, for group B, 7.4+/-1.3 mg/l, 7.8+/-1.6 mg/l and 6.4+/-1.3 mg/l, respectively, for the study periods.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [l],6.1,259171,DB00537,Ciprofloxacin
,11967606,Peak concentrations (C(max)),"Peak concentrations (C(max)) for group A were D(0) 6.1+/-1.2 mg/l, D(2) 9.0+/-1.8 mg/l and D(7) 5.8+/-1.3 mg/l and, for group B, 7.4+/-1.3 mg/l, 7.8+/-1.6 mg/l and 6.4+/-1.3 mg/l, respectively, for the study periods.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [l],9.0,259172,DB00537,Ciprofloxacin
,11967606,Peak concentrations (C(max)),"Peak concentrations (C(max)) for group A were D(0) 6.1+/-1.2 mg/l, D(2) 9.0+/-1.8 mg/l and D(7) 5.8+/-1.3 mg/l and, for group B, 7.4+/-1.3 mg/l, 7.8+/-1.6 mg/l and 6.4+/-1.3 mg/l, respectively, for the study periods.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [l],5.8,259173,DB00537,Ciprofloxacin
,11967606,Peak concentrations (C(max)),"Peak concentrations (C(max)) for group A were D(0) 6.1+/-1.2 mg/l, D(2) 9.0+/-1.8 mg/l and D(7) 5.8+/-1.3 mg/l and, for group B, 7.4+/-1.3 mg/l, 7.8+/-1.6 mg/l and 6.4+/-1.3 mg/l, respectively, for the study periods.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [l],7.4,259174,DB00537,Ciprofloxacin
,11967606,Peak concentrations (C(max)),"Peak concentrations (C(max)) for group A were D(0) 6.1+/-1.2 mg/l, D(2) 9.0+/-1.8 mg/l and D(7) 5.8+/-1.3 mg/l and, for group B, 7.4+/-1.3 mg/l, 7.8+/-1.6 mg/l and 6.4+/-1.3 mg/l, respectively, for the study periods.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [l],7.8,259175,DB00537,Ciprofloxacin
,11967606,Peak concentrations (C(max)),"Peak concentrations (C(max)) for group A were D(0) 6.1+/-1.2 mg/l, D(2) 9.0+/-1.8 mg/l and D(7) 5.8+/-1.3 mg/l and, for group B, 7.4+/-1.3 mg/l, 7.8+/-1.6 mg/l and 6.4+/-1.3 mg/l, respectively, for the study periods.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [l],6.4,259176,DB00537,Ciprofloxacin
,11967606,Concentration 12 h after the start of infusion (C(min)),Concentration 12 h after the start of infusion (C(min)) for all periods were 0.2 mg/l or less.,Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [l],0.2,259177,DB00537,Ciprofloxacin
,11967606,"Areas under the curve (AUC, 12 h)","Areas under the curve (AUC, 12 h) were group A: 15.6+/-1.3, 19.2+/-1.63 and 14.1+/-1.4 mg/h per l, and group B: 15.9+/-1.3, 18.0+/-1.7 and 13.2+/-1.26 mg/h per l.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [h·l],15.6,259178,DB00537,Ciprofloxacin
,11967606,"Areas under the curve (AUC, 12 h)","Areas under the curve (AUC, 12 h) were group A: 15.6+/-1.3, 19.2+/-1.63 and 14.1+/-1.4 mg/h per l, and group B: 15.9+/-1.3, 18.0+/-1.7 and 13.2+/-1.26 mg/h per l.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [h·l],19.2,259179,DB00537,Ciprofloxacin
,11967606,"Areas under the curve (AUC, 12 h)","Areas under the curve (AUC, 12 h) were group A: 15.6+/-1.3, 19.2+/-1.63 and 14.1+/-1.4 mg/h per l, and group B: 15.9+/-1.3, 18.0+/-1.7 and 13.2+/-1.26 mg/h per l.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [h·l],14.1,259180,DB00537,Ciprofloxacin
,11967606,"Areas under the curve (AUC, 12 h)","Areas under the curve (AUC, 12 h) were group A: 15.6+/-1.3, 19.2+/-1.63 and 14.1+/-1.4 mg/h per l, and group B: 15.9+/-1.3, 18.0+/-1.7 and 13.2+/-1.26 mg/h per l.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [h·l],15.9,259181,DB00537,Ciprofloxacin
,11967606,"Areas under the curve (AUC, 12 h)","Areas under the curve (AUC, 12 h) were group A: 15.6+/-1.3, 19.2+/-1.63 and 14.1+/-1.4 mg/h per l, and group B: 15.9+/-1.3, 18.0+/-1.7 and 13.2+/-1.26 mg/h per l.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [h·l],18.0,259182,DB00537,Ciprofloxacin
,11967606,"Areas under the curve (AUC, 12 h)","Areas under the curve (AUC, 12 h) were group A: 15.6+/-1.3, 19.2+/-1.63 and 14.1+/-1.4 mg/h per l, and group B: 15.9+/-1.3, 18.0+/-1.7 and 13.2+/-1.26 mg/h per l.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [h·l],13.2,259183,DB00537,Ciprofloxacin
,11967606,area under the inhibitory curve (AUIC),"To achieve end points of area under the inhibitory curve (AUIC) of 100-150 mg/h per l, 10 mg/kg ciprofloxacin eight hourly would be required for some resistant ICU organisms.",Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967606/),[mg] / [h·l],100-150,259184,DB00537,Ciprofloxacin
,10702553,C(max),Serum ciprofloxacin concentrations were comparable to those of normal volunteers (C(max) = 4.0 +/- 1 mg/L and AUC = 11.4 +/- 2 mg.h/L) during the immediate post-burn period after dose 1 (C(max1) = 4.8 +/- 3 mg/L and AUC(0-12) = 12.5 +/- 7 mg.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[mg] / [l],4.0,259640,DB00537,Ciprofloxacin
,10702553,AUC,Serum ciprofloxacin concentrations were comparable to those of normal volunteers (C(max) = 4.0 +/- 1 mg/L and AUC = 11.4 +/- 2 mg.h/L) during the immediate post-burn period after dose 1 (C(max1) = 4.8 +/- 3 mg/L and AUC(0-12) = 12.5 +/- 7 mg.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[h·mg] / [l],11.4,259641,DB00537,Ciprofloxacin
,10702553,C(max1),Serum ciprofloxacin concentrations were comparable to those of normal volunteers (C(max) = 4.0 +/- 1 mg/L and AUC = 11.4 +/- 2 mg.h/L) during the immediate post-burn period after dose 1 (C(max1) = 4.8 +/- 3 mg/L and AUC(0-12) = 12.5 +/- 7 mg.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[mg] / [l],4.8,259642,DB00537,Ciprofloxacin
,10702553,AUC(0-12),Serum ciprofloxacin concentrations were comparable to those of normal volunteers (C(max) = 4.0 +/- 1 mg/L and AUC = 11.4 +/- 2 mg.h/L) during the immediate post-burn period after dose 1 (C(max1) = 4.8 +/- 3 mg/L and AUC(0-12) = 12.5 +/- 7 mg.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),mg,12.5,259643,DB00537,Ciprofloxacin
,10702553,C(max3),h/L) and dose 3 (C(max3) = 4.9 +/- 2 mg/L and AUC(24-36) = 17.5 +/- 11 mg.h/L).,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[mg] / [l],4.9,259644,DB00537,Ciprofloxacin
,10702553,AUC(24-36),h/L) and dose 3 (C(max3) = 4.9 +/- 2 mg/L and AUC(24-36) = 17.5 +/- 11 mg.h/L).,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[h·mg] / [l],17.5,259645,DB00537,Ciprofloxacin
,10702553,eschar concentration,Mean burn eschar concentration during the 72 h post-burn was significantly lower than that found during clinical sepsis (18 +/- 17 compared with 41.3 +/- 54 microg/g; P < 0.05 by t test).,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[μg] / [g],18,259646,DB00537,Ciprofloxacin
,10702553,eschar concentration,Mean burn eschar concentration during the 72 h post-burn was significantly lower than that found during clinical sepsis (18 +/- 17 compared with 41.3 +/- 54 microg/g; P < 0.05 by t test).,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[μg] / [g],41.3,259647,DB00537,Ciprofloxacin
,10702553,C(max1),Similar serum concentrations were achieved in patients with clinical sepsis (C(max1) = 4.2 +/- 0.2 mg/L and AUC(0-12) = 15.0 +/- 3 mg.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[mg] / [l],4.2,259648,DB00537,Ciprofloxacin
,10702553,AUC(0-12),Similar serum concentrations were achieved in patients with clinical sepsis (C(max1) = 4.2 +/- 0.2 mg/L and AUC(0-12) = 15.0 +/- 3 mg.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),mg,15.0,259649,DB00537,Ciprofloxacin
,10702553,C(max3),h/L; C(max3) = 5.0 +/- 1 mg/L and AUC(24-36) = 22.8 +/- 9 mg.h/L).,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[mg] / [l],5.0,259650,DB00537,Ciprofloxacin
,10702553,AUC(24-36),h/L; C(max3) = 5.0 +/- 1 mg/L and AUC(24-36) = 22.8 +/- 9 mg.h/L).,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[h·mg] / [l],22.8,259651,DB00537,Ciprofloxacin
>,10702553,C(max)/MIC ratio,A C(max)/MIC ratio > 10 (MIC = 0.5 mg/L) and an AUC/MIC ratio > 100 SIT(-1).h (serum inhibitory titre) (MIC = 0.125 mg/L) were achieved.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),,10,259652,DB00537,Ciprofloxacin
,10702553,MIC,A C(max)/MIC ratio > 10 (MIC = 0.5 mg/L) and an AUC/MIC ratio > 100 SIT(-1).h (serum inhibitory titre) (MIC = 0.125 mg/L) were achieved.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[mg] / [l],0.5,259653,DB00537,Ciprofloxacin
>,10702553,AUC/MIC ratio,A C(max)/MIC ratio > 10 (MIC = 0.5 mg/L) and an AUC/MIC ratio > 100 SIT(-1).h (serum inhibitory titre) (MIC = 0.125 mg/L) were achieved.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[h] / [sit],100,259654,DB00537,Ciprofloxacin
,10702553,MIC,A C(max)/MIC ratio > 10 (MIC = 0.5 mg/L) and an AUC/MIC ratio > 100 SIT(-1).h (serum inhibitory titre) (MIC = 0.125 mg/L) were achieved.,Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702553/),[mg] / [l],0.125,259655,DB00537,Ciprofloxacin
,2610503,peak concentration in serum,"The peak concentration in serum, total body clearance (CLs), steady-state volume of distribution (Vss), and terminal elimination half-life after intravenous dosing were 3.5 +/- 0.8 micrograms/ml, 4.38 +/- 1.80 ml/min per kg, 1.6 +/- 0.6 liters/kg, and 5.8 +/- 2.4 h, respectively.",Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610503/),[μg] / [ml],3.5,259934,DB00537,Ciprofloxacin
,2610503,steady-state volume of distribution (Vss),"The peak concentration in serum, total body clearance (CLs), steady-state volume of distribution (Vss), and terminal elimination half-life after intravenous dosing were 3.5 +/- 0.8 micrograms/ml, 4.38 +/- 1.80 ml/min per kg, 1.6 +/- 0.6 liters/kg, and 5.8 +/- 2.4 h, respectively.",Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610503/),[ml] / [kg·min],4.38,259935,DB00537,Ciprofloxacin
,2610503,steady-state volume of distribution (Vss),"The peak concentration in serum, total body clearance (CLs), steady-state volume of distribution (Vss), and terminal elimination half-life after intravenous dosing were 3.5 +/- 0.8 micrograms/ml, 4.38 +/- 1.80 ml/min per kg, 1.6 +/- 0.6 liters/kg, and 5.8 +/- 2.4 h, respectively.",Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610503/),[l] / [kg],1.6,259936,DB00537,Ciprofloxacin
,2610503,terminal elimination half-life,"The peak concentration in serum, total body clearance (CLs), steady-state volume of distribution (Vss), and terminal elimination half-life after intravenous dosing were 3.5 +/- 0.8 micrograms/ml, 4.38 +/- 1.80 ml/min per kg, 1.6 +/- 0.6 liters/kg, and 5.8 +/- 2.4 h, respectively.",Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610503/),h,5.8,259937,DB00537,Ciprofloxacin
,2610503,peak concentration,"The peak concentration in serum, time to peak concentration in serum, absorption lag time, and absolute bioavailability (F) after oral dosing were 7.6 +/- 2.2 micrograms/ml, 1.9 +/- 1.0 h, 0.4 +/- 0.5 h, and 7.7 +/- 24.2%, respectively.",Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610503/),[μg] / [ml],7.6,259938,DB00537,Ciprofloxacin
,2610503,time to peak concentration,"The peak concentration in serum, time to peak concentration in serum, absorption lag time, and absolute bioavailability (F) after oral dosing were 7.6 +/- 2.2 micrograms/ml, 1.9 +/- 1.0 h, 0.4 +/- 0.5 h, and 7.7 +/- 24.2%, respectively.",Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610503/),h,1.9,259939,DB00537,Ciprofloxacin
,2610503,absorption lag time,"The peak concentration in serum, time to peak concentration in serum, absorption lag time, and absolute bioavailability (F) after oral dosing were 7.6 +/- 2.2 micrograms/ml, 1.9 +/- 1.0 h, 0.4 +/- 0.5 h, and 7.7 +/- 24.2%, respectively.",Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610503/),h,1.9,259940,DB00537,Ciprofloxacin
,2610503,absolute bioavailability (F),"The peak concentration in serum, time to peak concentration in serum, absorption lag time, and absolute bioavailability (F) after oral dosing were 7.6 +/- 2.2 micrograms/ml, 1.9 +/- 1.0 h, 0.4 +/- 0.5 h, and 7.7 +/- 24.2%, respectively.",Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610503/),%,7.7,259941,DB00537,Ciprofloxacin
,2356443,absolute bioavailability,"Despite larger absolute bioavailability of the first dose in the elderly (77 vs. 63%; p less than 0.05), the effect of ciprofloxacin on the microflora was similar in the two groups of volunteers.",Influence of ciprofloxacin on the colonic microflora in young and elderly volunteers: no impact of the altered drug absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2356443/),%,77,260003,DB00537,Ciprofloxacin
,2356443,absolute bioavailability,"Despite larger absolute bioavailability of the first dose in the elderly (77 vs. 63%; p less than 0.05), the effect of ciprofloxacin on the microflora was similar in the two groups of volunteers.",Influence of ciprofloxacin on the colonic microflora in young and elderly volunteers: no impact of the altered drug absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2356443/),%,63,260004,DB00537,Ciprofloxacin
,15526888,plasma concentration,"Intravenous administration of enrofloxacin resulted in an extrapolated mean plasma concentration of 4.19 +/- 4.23 microg/ml at time zero, with average plasma drug levels remaining above 1.0 microg/ml for an average of 36 hr.",Pharmacokinetics of enrofloxacin after single-dose oral and intravenous administration in the American alligator (Alligator mississippiensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526888/),[μg] / [ml],4.19,260111,DB00537,Ciprofloxacin
,15526888,Plasma volume of distribution,"Plasma volume of distribution for i.v. enrofloxacin was 1.88 +/- 0.96 L/kg, with a harmonic mean elimination half-life of 21.05 hr and mean total body clearance rate of 0.047 +/- 0.021 L/hr/kg.",Pharmacokinetics of enrofloxacin after single-dose oral and intravenous administration in the American alligator (Alligator mississippiensis). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526888/),[l] / [kg],1.88,260112,DB00537,Ciprofloxacin
,15526888,elimination half-life,"Plasma volume of distribution for i.v. enrofloxacin was 1.88 +/- 0.96 L/kg, with a harmonic mean elimination half-life of 21.05 hr and mean total body clearance rate of 0.047 +/- 0.021 L/hr/kg.",Pharmacokinetics of enrofloxacin after single-dose oral and intravenous administration in the American alligator (Alligator mississippiensis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526888/),h,21.05,260113,DB00537,Ciprofloxacin
,15526888,total body clearance rate,"Plasma volume of distribution for i.v. enrofloxacin was 1.88 +/- 0.96 L/kg, with a harmonic mean elimination half-life of 21.05 hr and mean total body clearance rate of 0.047 +/- 0.021 L/hr/kg.",Pharmacokinetics of enrofloxacin after single-dose oral and intravenous administration in the American alligator (Alligator mississippiensis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526888/),[l] / [h·kg],0.047,260114,DB00537,Ciprofloxacin
,15526888,maximum plasma concentration,"Oral administration of enrofloxacin achieved a mean maximum plasma concentration of 0.50 +/- 0.27 microg/ml at 55 +/- 29 hr after administration, with a harmonic mean terminal elimination half-life of 77.73 hr.",Pharmacokinetics of enrofloxacin after single-dose oral and intravenous administration in the American alligator (Alligator mississippiensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526888/),[μg] / [ml],0.50,260115,DB00537,Ciprofloxacin
,15526888,terminal elimination half-life,"Oral administration of enrofloxacin achieved a mean maximum plasma concentration of 0.50 +/- 0.27 microg/ml at 55 +/- 29 hr after administration, with a harmonic mean terminal elimination half-life of 77.73 hr.",Pharmacokinetics of enrofloxacin after single-dose oral and intravenous administration in the American alligator (Alligator mississippiensis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526888/),h,77.73,260116,DB00537,Ciprofloxacin
,15526888,minimum inhibitory concentration,"On the basis of the results of this study, enrofloxacin administered to American alligators at 5 mg/kg i.v. q 36 hr is expected to maintain plasma concentrations that approximate the minimum inhibitory concentration for susceptible organisms (0.5 microg/ml).",Pharmacokinetics of enrofloxacin after single-dose oral and intravenous administration in the American alligator (Alligator mississippiensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526888/),[μg] / [ml],0.5,260117,DB00537,Ciprofloxacin
,21670178,peak (maximum) concentration (C(max)),"The mean peak (maximum) concentration (C(max)) and trough (minimum) concentration in plasma were 5.37 ± 1.57 and 1 ± 0.53 mg/liter, respectively.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),[mg] / [l],5.37,260738,DB00537,Ciprofloxacin
,21670178,trough (minimum) concentration,"The mean peak (maximum) concentration (C(max)) and trough (minimum) concentration in plasma were 5.37 ± 1.57 and 1 ± 0.53 mg/liter, respectively.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),[mg] / [l],1,260739,DB00537,Ciprofloxacin
,21670178,volume of distribution,"Mean values for volume of distribution, clearance, half-life, and area under the curve from 0 to 24 h (AUC(0-24)) were 169.87 ± 84.11 liters, 26.96 ± 8.86 liters/h, 5.35 ± 2.21 h, and 47.41 ± 17.02 mg · h/liter, respectively.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),l,169.87,260740,DB00537,Ciprofloxacin
,21670178,half-life,"Mean values for volume of distribution, clearance, half-life, and area under the curve from 0 to 24 h (AUC(0-24)) were 169.87 ± 84.11 liters, 26.96 ± 8.86 liters/h, 5.35 ± 2.21 h, and 47.41 ± 17.02 mg · h/liter, respectively.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),[l] / [h],26.96,260741,DB00537,Ciprofloxacin
,21670178,area under the curve from 0 to 24 h (AUC(0-24)),"Mean values for volume of distribution, clearance, half-life, and area under the curve from 0 to 24 h (AUC(0-24)) were 169.87 ± 84.11 liters, 26.96 ± 8.86 liters/h, 5.35 ± 2.21 h, and 47.41 ± 17.02 mg · h/liter, respectively.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),[h·mg] / [l],47.41,260742,DB00537,Ciprofloxacin
,21670178,C(max),"In bronchial secretions, a mean C(max) of 3.08 ± 1.21 mg/liter was achieved in 3.12 ± 1.01 h, and the penetration ratio was 1.16 ± 0.59.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),[mg] / [l],3.08,260743,DB00537,Ciprofloxacin
,21670178,penetration ratio,"In bronchial secretions, a mean C(max) of 3.08 ± 1.21 mg/liter was achieved in 3.12 ± 1.01 h, and the penetration ratio was 1.16 ± 0.59.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),,1.16,260744,DB00537,Ciprofloxacin
≥,21670178,AUC(0-24)/MIC,"The target of AUC(0-24)/MIC of ≥125 was attained in all patients, in the majority of them (76%), and in none at MICs of 0.125, 0.25, and 1 μg/ml, respectively.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),,125,260745,DB00537,Ciprofloxacin
,21670178,MICs,"The target of AUC(0-24)/MIC of ≥125 was attained in all patients, in the majority of them (76%), and in none at MICs of 0.125, 0.25, and 1 μg/ml, respectively.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),[μg] / [ml],0.125,260746,DB00537,Ciprofloxacin
,21670178,MICs,"The target of AUC(0-24)/MIC of ≥125 was attained in all patients, in the majority of them (76%), and in none at MICs of 0.125, 0.25, and 1 μg/ml, respectively.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),[μg] / [ml],0.25,260747,DB00537,Ciprofloxacin
,21670178,MICs,"The target of AUC(0-24)/MIC of ≥125 was attained in all patients, in the majority of them (76%), and in none at MICs of 0.125, 0.25, and 1 μg/ml, respectively.",Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),[μg] / [ml],1,260748,DB00537,Ciprofloxacin
≥,21670178,ratio C(max)/MIC,Slightly better results were obtained for the ratio C(max)/MIC of ≥10.,Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),,10,260749,DB00537,Ciprofloxacin
≥,21670178,MICs,There is wide interindividual variability in its pharmacokinetic parameters in critically ill COPD patients and inadequate pharmacodynamic exposure against bacteria with MICs of ≥0.5 μg/ml.,Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670178/),[μg] / [ml],0.5,260750,DB00537,Ciprofloxacin
,19635960,MIC [CIP MIC],The susceptible Escherichia coli strain CFT073 (ciprofloxacin MIC [CIP MIC] of 0.008 microg/ml) was compared to its transconjugants harboring qnrA1 or qnrS1 and to an S83L gyrA mutant.,Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635960/),[μg] / [ml],0.008,263156,DB00537,Ciprofloxacin
,19635960,MICs,"The three derivatives showed similar low-level resistance to fluoroquinolones (CIP MICs, 0.25 to 0.5 microg/ml).",Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635960/),[μg] / [ml],0.25 to 0.5,263157,DB00537,Ciprofloxacin
,19635960,viable bacterial counts,"In mice infected with the susceptible strain, ciprofloxacin significantly decreased viable bacterial counts (log10 CFU/g of tissue) in the bladder (4.2 +/- 0.5 versus 5.5 +/- 1.3; P = 0.001) and in the kidney (3.6 +/- 0.8 versus 5.0 +/- 1.1; P = 0.003) compared with those of untreated mice.",Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635960/),log,4.2,263158,DB00537,Ciprofloxacin
,19635960,viable bacterial counts,"In mice infected with the susceptible strain, ciprofloxacin significantly decreased viable bacterial counts (log10 CFU/g of tissue) in the bladder (4.2 +/- 0.5 versus 5.5 +/- 1.3; P = 0.001) and in the kidney (3.6 +/- 0.8 versus 5.0 +/- 1.1; P = 0.003) compared with those of untreated mice.",Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635960/),log,5.5,263159,DB00537,Ciprofloxacin
,19635960,viable bacterial counts,"In mice infected with the susceptible strain, ciprofloxacin significantly decreased viable bacterial counts (log10 CFU/g of tissue) in the bladder (4.2 +/- 0.5 versus 5.5 +/- 1.3; P = 0.001) and in the kidney (3.6 +/- 0.8 versus 5.0 +/- 1.1; P = 0.003) compared with those of untreated mice.",Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635960/),log,3.6,263160,DB00537,Ciprofloxacin
,19635960,viable bacterial counts,"In mice infected with the susceptible strain, ciprofloxacin significantly decreased viable bacterial counts (log10 CFU/g of tissue) in the bladder (4.2 +/- 0.5 versus 5.5 +/- 1.3; P = 0.001) and in the kidney (3.6 +/- 0.8 versus 5.0 +/- 1.1; P = 0.003) compared with those of untreated mice.",Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635960/),log,5.0,263161,DB00537,Ciprofloxacin
,19635960,area under the concentration-time curve from 0 to 24 h/MIC,"The area under the concentration-time curve from 0 to 24 h/MIC and the maximum concentration of drug in serum/MIC ratios measured in plasma were indeed equal to 827 and 147, respectively, for the parental strain, and only 12.4 to 24.8 and 2.2 to 4.4, respectively, for the derivative strains.",Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635960/),,827,263162,DB00537,Ciprofloxacin
,19635960,maximum concentration of drug in serum/MIC,"The area under the concentration-time curve from 0 to 24 h/MIC and the maximum concentration of drug in serum/MIC ratios measured in plasma were indeed equal to 827 and 147, respectively, for the parental strain, and only 12.4 to 24.8 and 2.2 to 4.4, respectively, for the derivative strains.",Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635960/),,2.2 to 4.4,263163,DB00537,Ciprofloxacin
,10049262,total amount of unchanged,"The total amount of unchanged ciprofloxacin excreted over 24 h under acidic conditions was 88.4 +/- 14.5 mg (mean +/- standard deviation) (44.2% of the oral dose) and 82.4 +/- 16.5 mg (41.2% of the oral dose) under alkaline conditions, while the total amount of unchanged drug excreted over 24 h in volunteers receiving neither sodium bicarbonate nor ammonium chloride was 90.53 +/- 9.8 mg (45.2% of the oral dose).",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),mg,88.4,263349,DB00537,Ciprofloxacin
,10049262,total amount of unchanged,"The total amount of unchanged ciprofloxacin excreted over 24 h under acidic conditions was 88.4 +/- 14.5 mg (mean +/- standard deviation) (44.2% of the oral dose) and 82.4 +/- 16.5 mg (41.2% of the oral dose) under alkaline conditions, while the total amount of unchanged drug excreted over 24 h in volunteers receiving neither sodium bicarbonate nor ammonium chloride was 90.53 +/- 9.8 mg (45.2% of the oral dose).",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),mg,82.4,263350,DB00537,Ciprofloxacin
,10049262,total amount of unchanged drug excreted,"The total amount of unchanged ciprofloxacin excreted over 24 h under acidic conditions was 88.4 +/- 14.5 mg (mean +/- standard deviation) (44.2% of the oral dose) and 82.4 +/- 16.5 mg (41.2% of the oral dose) under alkaline conditions, while the total amount of unchanged drug excreted over 24 h in volunteers receiving neither sodium bicarbonate nor ammonium chloride was 90.53 +/- 9.8 mg (45.2% of the oral dose).",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),mg,90.53,263351,DB00537,Ciprofloxacin
,10049262,renal clearance,"The mean renal clearance of ciprofloxacin was 16.78 +/- 2.67, 16.08 +/- 3.2, and 16.31 +/- 2.67 liters/h with acidification, alkalinization, and control, respectively.",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),[l] / [h],16.78,263352,DB00537,Ciprofloxacin
,10049262,renal clearance,"The mean renal clearance of ciprofloxacin was 16.78 +/- 2.67, 16.08 +/- 3.2, and 16.31 +/- 2.67 liters/h with acidification, alkalinization, and control, respectively.",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),[l] / [h],16.08,263353,DB00537,Ciprofloxacin
,10049262,renal clearance,"The mean renal clearance of ciprofloxacin was 16.78 +/- 2.67, 16.08 +/- 3.2, and 16.31 +/- 2.67 liters/h with acidification, alkalinization, and control, respectively.",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),[l] / [h],16.31,263354,DB00537,Ciprofloxacin
,15388445,half-lives [t(1/2)s],"The first compartment including the kidney, heart, and spleen, from which the radiotracer was washed out relatively quickly (half-lives [t(1/2)s], 68, 57, and 106 min, respectively).","[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388445/),min,68,263554,DB00537,Ciprofloxacin
,15388445,half-lives [t(1/2)s],"The first compartment including the kidney, heart, and spleen, from which the radiotracer was washed out relatively quickly (half-lives [t(1/2)s], 68, 57, and 106 min, respectively).","[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388445/),min,57,263555,DB00537,Ciprofloxacin
,15388445,half-lives [t(1/2)s],"The first compartment including the kidney, heart, and spleen, from which the radiotracer was washed out relatively quickly (half-lives [t(1/2)s], 68, 57, and 106 min, respectively).","[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388445/),min,106,263556,DB00537,Ciprofloxacin
>,15388445,t(1/2),"The second compartment comprised liver, muscle, and lung tissue, which displayed prolonged radiotracer retention (t(1/2), >130 min).","[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388445/),min,130,263557,DB00537,Ciprofloxacin
,15388445,standardized uptake values [SUVs],"The highest concentrations of radioactivity were measured in the liver and kidney, the main organs of excretion (standardized uptake values [SUVs], 4.9 +/- 1.0 and 9.9 +/- 4.4, respectively).","[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388445/),,4.9,263558,DB00537,Ciprofloxacin
,15388445,standardized uptake values [SUVs],"The highest concentrations of radioactivity were measured in the liver and kidney, the main organs of excretion (standardized uptake values [SUVs], 4.9 +/- 1.0 and 9.9 +/- 4.4, respectively).","[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388445/),,9.9,263559,DB00537,Ciprofloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],3.19 x 10(4),263673,DB00537,Ciprofloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],1.21 x 10(5),263674,DB00537,Ciprofloxacin
,17145798,MICs,"MICs for Mycobacterium tuberculosis H37Rv were 0.1 mg/liter (sparfloxacin [SPX]) and 0.5 mg/liter (moxifloxacin [MXF], ciprofloxacin [CIP], and ofloxacin [OFX]).","Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145798/),[mg] / [l],0.1,263778,DB00537,Ciprofloxacin
,17145798,MICs,"MICs for Mycobacterium tuberculosis H37Rv were 0.1 mg/liter (sparfloxacin [SPX]) and 0.5 mg/liter (moxifloxacin [MXF], ciprofloxacin [CIP], and ofloxacin [OFX]).","Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145798/),[mg] / [l],0.5,263779,DB00537,Ciprofloxacin
exceeding,3158275,volumes of distribution,High volumes of distribution (exceeding 200 liters/100 kg) suggested effective diffusions in the extravascular space.,Pharmacokinetics of ciprofloxacin after oral and parenteral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158275/),[l] / [100·kg],200,264161,DB00537,Ciprofloxacin
,3158275,terminal half-life,The terminal half-life of ciprofloxacin ranged between 3 and 4 h.,Pharmacokinetics of ciprofloxacin after oral and parenteral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158275/),h,3 and 4,264162,DB00537,Ciprofloxacin
,3158275,absolute bioavailability,"After oral administration, absorption was sufficient, and the absolute bioavailability varied between 0.77 and 0.63.",Pharmacokinetics of ciprofloxacin after oral and parenteral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158275/),,0.77 and 0.63,264163,DB00537,Ciprofloxacin
>,33165876,AUC0-24/MIC,"100% of patients achieved PK/PD target AUC0-24/MIC > 40, AUC0-24/MIC > 125, AUC0-24/MIC > 250 for MIC 1, 0.25, and 0.125 µg mL-1, respectively.",Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients - new assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33165876/),,40,264297,DB00537,Ciprofloxacin
>,33165876,AUC0-24/MIC,"100% of patients achieved PK/PD target AUC0-24/MIC > 40, AUC0-24/MIC > 125, AUC0-24/MIC > 250 for MIC 1, 0.25, and 0.125 µg mL-1, respectively.",Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients - new assessment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33165876/),,125,264298,DB00537,Ciprofloxacin
>,33165876,AUC0-24/MIC,"100% of patients achieved PK/PD target AUC0-24/MIC > 40, AUC0-24/MIC > 125, AUC0-24/MIC > 250 for MIC 1, 0.25, and 0.125 µg mL-1, respectively.",Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients - new assessment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33165876/),,250,264299,DB00537,Ciprofloxacin
,33165876,MIC,"100% of patients achieved PK/PD target AUC0-24/MIC > 40, AUC0-24/MIC > 125, AUC0-24/MIC > 250 for MIC 1, 0.25, and 0.125 µg mL-1, respectively.",Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients - new assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33165876/),[μg] / [ml],1,264300,DB00537,Ciprofloxacin
,33165876,MIC,"100% of patients achieved PK/PD target AUC0-24/MIC > 40, AUC0-24/MIC > 125, AUC0-24/MIC > 250 for MIC 1, 0.25, and 0.125 µg mL-1, respectively.",Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients - new assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33165876/),[μg] / [ml],0.25,264301,DB00537,Ciprofloxacin
,33165876,MIC,"100% of patients achieved PK/PD target AUC0-24/MIC > 40, AUC0-24/MIC > 125, AUC0-24/MIC > 250 for MIC 1, 0.25, and 0.125 µg mL-1, respectively.",Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients - new assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33165876/),[μg] / [ml],0.125,264302,DB00537,Ciprofloxacin
,7752310,plasma half-life,"Mean plasma half-life, based on the terminal phase, was 157.89 min (harmonic mean).",Pharmacokinetics of ciprofloxacin in ponies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752310/),min,157.89,264372,DB00537,Ciprofloxacin
,7752310,Total body clearance,Total body clearance of ciprofloxacin was 18.12 +/- 3.99 mL/min/kg.,Pharmacokinetics of ciprofloxacin in ponies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752310/),[ml] / [kg·min],18.12,264373,DB00537,Ciprofloxacin
,7752310,Volume of distribution at steady-state,Volume of distribution at steady-state was 3.45 +/- 0.72 L/kg.,Pharmacokinetics of ciprofloxacin in ponies. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752310/),[l] / [kg],3.45,264374,DB00537,Ciprofloxacin
,7752310,Bioavailability,Bioavailability of oral ciprofloxacin in ponies was 6.8 +/- 5.33%.,Pharmacokinetics of ciprofloxacin in ponies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752310/),%,6.8,264375,DB00537,Ciprofloxacin
,2720726,maximum serum concentrations,"The maximum serum concentrations were obtained 30 minutes after intraperitoneal administration (ciprofloxacin, 2.7 micrograms/ml; clindamycin, 9.0 micrograms/ml; ampicillin, 3.9 micrograms/ml).",Activity of ciprofloxacin in the treatment of experimental intra-abdominal abscesses in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720726/),[μg] / [ml],2.7,264415,DB00537,Ciprofloxacin
,2720726,maximum serum concentrations,"The maximum serum concentrations were obtained 30 minutes after intraperitoneal administration (ciprofloxacin, 2.7 micrograms/ml; clindamycin, 9.0 micrograms/ml; ampicillin, 3.9 micrograms/ml).",Activity of ciprofloxacin in the treatment of experimental intra-abdominal abscesses in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720726/),[μg] / [ml],9.0,264416,DB00537,Ciprofloxacin
,2720726,maximum serum concentrations,"The maximum serum concentrations were obtained 30 minutes after intraperitoneal administration (ciprofloxacin, 2.7 micrograms/ml; clindamycin, 9.0 micrograms/ml; ampicillin, 3.9 micrograms/ml).",Activity of ciprofloxacin in the treatment of experimental intra-abdominal abscesses in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720726/),[μg] / [ml],3.9,264417,DB00537,Ciprofloxacin
,11874520,peak serum concentrations,"All FQs were rapidly absorbed and achieved average peak serum concentrations of 1.41, 1.11, 1.47 and 1.37 mug/mL for enrofloxacin, difloxacin, marbofloxacin and orbifloxacin, respectively.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),[μg] / [ml],1.41,265697,DB00537,Ciprofloxacin
,11874520,peak serum concentrations,"All FQs were rapidly absorbed and achieved average peak serum concentrations of 1.41, 1.11, 1.47 and 1.37 mug/mL for enrofloxacin, difloxacin, marbofloxacin and orbifloxacin, respectively.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),[μg] / [ml],1.11,265698,DB00537,Ciprofloxacin
,11874520,peak serum concentrations,"All FQs were rapidly absorbed and achieved average peak serum concentrations of 1.41, 1.11, 1.47 and 1.37 mug/mL for enrofloxacin, difloxacin, marbofloxacin and orbifloxacin, respectively.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),[μg] / [ml],1.47,265699,DB00537,Ciprofloxacin
,11874520,peak serum concentrations,"All FQs were rapidly absorbed and achieved average peak serum concentrations of 1.41, 1.11, 1.47 and 1.37 mug/mL for enrofloxacin, difloxacin, marbofloxacin and orbifloxacin, respectively.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),[μg] / [ml],1.37,265700,DB00537,Ciprofloxacin
,11874520,terminal half-life (t(1/2)),"Enrofloxacin was eliminated at a terminal half-life (t(1/2)) of 4.1 h, difloxacin at 6.9 h, orbifloxacin at 7.1 h and marbofloxacin at 9.1 h.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),h,4.1,265701,DB00537,Ciprofloxacin
,11874520,terminal half-life (t(1/2)),"Enrofloxacin was eliminated at a terminal half-life (t(1/2)) of 4.1 h, difloxacin at 6.9 h, orbifloxacin at 7.1 h and marbofloxacin at 9.1 h.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),h,6.9,265702,DB00537,Ciprofloxacin
,11874520,terminal half-life (t(1/2)),"Enrofloxacin was eliminated at a terminal half-life (t(1/2)) of 4.1 h, difloxacin at 6.9 h, orbifloxacin at 7.1 h and marbofloxacin at 9.1 h.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),h,7.1,265703,DB00537,Ciprofloxacin
,11874520,terminal half-life (t(1/2)),"Enrofloxacin was eliminated at a terminal half-life (t(1/2)) of 4.1 h, difloxacin at 6.9 h, orbifloxacin at 7.1 h and marbofloxacin at 9.1 h.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),h,9.1,265704,DB00537,Ciprofloxacin
,11874520,area under the serum concentration-time curve of the 24-h dosing interval (AUC0--24),"While the area under the serum concentration-time curve of the 24-h dosing interval (AUC0--24) for marbofloxacin and orbifloxacin were similar (approximately 13 microg x h/mL), enrofloxacin attained an AUC(0-24) of 8.7 and difloxacin of 9.3 microg x h/mL.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),[h·μg] / [ml],13,265705,DB00537,Ciprofloxacin
,11874520,AUC(0-24),"While the area under the serum concentration-time curve of the 24-h dosing interval (AUC0--24) for marbofloxacin and orbifloxacin were similar (approximately 13 microg x h/mL), enrofloxacin attained an AUC(0-24) of 8.7 and difloxacin of 9.3 microg x h/mL.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),[h·μg] / [ml],8.7,265706,DB00537,Ciprofloxacin
,11874520,AUC(0-24),"While the area under the serum concentration-time curve of the 24-h dosing interval (AUC0--24) for marbofloxacin and orbifloxacin were similar (approximately 13 microg x h/mL), enrofloxacin attained an AUC(0-24) of 8.7 and difloxacin of 9.3 microg x h/mL.","Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874520/),[h·μg] / [ml],9.3,265707,DB00537,Ciprofloxacin
,16518708,MIC,Measured serum concentration profiles were linked to ciprofloxacin's effect against Escherichia coli (MIC 0.013 mg/l) from in vitro kill curve studies where the pharmacokinetics of ciprofloxacin were simulated and change in number of bacteria (CFU/ml) versus time was monitored.,Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518708/),[mg] / [l],0.013,265968,DB00537,Ciprofloxacin
,18520606,recoveries,"The recoveries at concentrations of 90, 1400, and 2800 ng/mL were 103.5%, 100.2%, and 100.2%, respectively.",Validation of a reversed-phase high-performance liquid chromatography method with fluorescence detection for the bioequivalence study of norfloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520606/),%,1400,266073,DB00537,Ciprofloxacin
,18520606,recoveries,"The recoveries at concentrations of 90, 1400, and 2800 ng/mL were 103.5%, 100.2%, and 100.2%, respectively.",Validation of a reversed-phase high-performance liquid chromatography method with fluorescence detection for the bioequivalence study of norfloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520606/),%,280,266074,DB00537,Ciprofloxacin
,18520606,recoveries,"The recoveries at concentrations of 90, 1400, and 2800 ng/mL were 103.5%, 100.2%, and 100.2%, respectively.",Validation of a reversed-phase high-performance liquid chromatography method with fluorescence detection for the bioequivalence study of norfloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520606/),%,103.5,266075,DB00537,Ciprofloxacin
,18520606,recoveries,"The recoveries at concentrations of 90, 1400, and 2800 ng/mL were 103.5%, 100.2%, and 100.2%, respectively.",Validation of a reversed-phase high-performance liquid chromatography method with fluorescence detection for the bioequivalence study of norfloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520606/),%,100.2,266076,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],3.54,266150,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],3.43,266151,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],2.93,266152,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],2.24,266153,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],1.79,266154,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],0.88,266155,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],2.41,266156,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],1.91,266157,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],1.25,266158,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],0.64,266159,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],0.29,266160,DB00537,Ciprofloxacin
,2589384,breast milk levels,"The mean breast milk levels of pefloxacin were 3.54, 3.43, 2.93, 2.24, 1.79, and 0.88 micrograms/ml, and of ofloxacin, 2.41, 1.91, 1.25, 0.64, 0.29, and 0.05 micrograms/ml.",Pharmacokinetics of three newer quinolones in pregnant and lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589384/),[μg] / [ml],0.05,266161,DB00537,Ciprofloxacin
,1664829,cumulative survival,A 79% cumulative survival rate was obtained in temafloxacin-treated mice (50 mg/kg); a figure not significantly different from those for erythromycin and amoxycillin but far higher than those for ofloxacin and ciprofloxacin (7% survivors).,Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664829/),%,79,266296,DB00537,Ciprofloxacin
,7785830,elimination half-life,"The elimination half-life and the mean +/- SEM residence time of enrofloxacin for plasma were 10.29 +/- 0.45 and 9.65 +/- 0.48 hours, respectively, after IV administration and 14.23 +/- 0.46 and 15.30 +/- 0.53 hours, respectively, after oral administration.",Pharmacokinetics and residues of enrofloxacin in chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785830/),h,10.29,266659,DB00537,Ciprofloxacin
,7785830,elimination half-life,"The elimination half-life and the mean +/- SEM residence time of enrofloxacin for plasma were 10.29 +/- 0.45 and 9.65 +/- 0.48 hours, respectively, after IV administration and 14.23 +/- 0.46 and 15.30 +/- 0.53 hours, respectively, after oral administration.",Pharmacokinetics and residues of enrofloxacin in chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785830/),h,14.23,266660,DB00537,Ciprofloxacin
,7785830,residence time,"The elimination half-life and the mean +/- SEM residence time of enrofloxacin for plasma were 10.29 +/- 0.45 and 9.65 +/- 0.48 hours, respectively, after IV administration and 14.23 +/- 0.46 and 15.30 +/- 0.53 hours, respectively, after oral administration.",Pharmacokinetics and residues of enrofloxacin in chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785830/),h,9.65,266661,DB00537,Ciprofloxacin
,7785830,residence time,"The elimination half-life and the mean +/- SEM residence time of enrofloxacin for plasma were 10.29 +/- 0.45 and 9.65 +/- 0.48 hours, respectively, after IV administration and 14.23 +/- 0.46 and 15.30 +/- 0.53 hours, respectively, after oral administration.",Pharmacokinetics and residues of enrofloxacin in chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785830/),h,15.30,266662,DB00537,Ciprofloxacin
,7785830,time to reach maximal plasma concentration,"After single oral administration, enrofloxacin was absorbed slowly, with time to reach maximal plasma concentration of 1.64 +/- 0.04 hours.",Pharmacokinetics and residues of enrofloxacin in chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785830/),h,1.64,266663,DB00537,Ciprofloxacin
,7785830,Maximal plasma concentration,Maximal plasma concentration was 2.44 +/- 0.06 micrograms/ml.,Pharmacokinetics and residues of enrofloxacin in chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785830/),[μg] / [ml],2.44,266664,DB00537,Ciprofloxacin
,7785830,Oral bioavailability,Oral bioavailability was found to be 64.0 +/- 0.2%.,Pharmacokinetics and residues of enrofloxacin in chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785830/),%,64.0,266665,DB00537,Ciprofloxacin
,3479419,peak,Mean serum concentrations of ofloxacin (peak 5.9 mg/l) were higher than for ciprofloxacin (peak 4.0 mg/l).,Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479419/),[mg] / [l],5.9,266717,DB00537,Ciprofloxacin
,3479419,peak,Mean serum concentrations of ofloxacin (peak 5.9 mg/l) were higher than for ciprofloxacin (peak 4.0 mg/l).,Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479419/),[mg] / [l],4.0,266718,DB00537,Ciprofloxacin
,3479419,serum elimination half-life,"Relative to ofloxacin ciprofloxacin had a significantly shorter serum elimination half-life (3.4 vs. 6.4 h), showed less penetration into sputum (18% vs. 79%) and a lesser amount was recovered in urine (21% vs. 71% up to 12 h after dosing).",Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479419/),h,3.4,266719,DB00537,Ciprofloxacin
,3479419,serum elimination half-life,"Relative to ofloxacin ciprofloxacin had a significantly shorter serum elimination half-life (3.4 vs. 6.4 h), showed less penetration into sputum (18% vs. 79%) and a lesser amount was recovered in urine (21% vs. 71% up to 12 h after dosing).",Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479419/),h,6.4,266720,DB00537,Ciprofloxacin
,2942101,peak serum concentrations,The peak serum concentrations determined from the individual data occurred at approximately 1.5 h after each dose and ranged from 0.42 to 4.2 micrograms/ml; the mean peak concentrations increased in proportion to the dose.,Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942101/),[μg] / [ml],0.42 to 4.2,266902,DB00537,Ciprofloxacin
,2942101,elimination half-lives,"The mean elimination half-lives calculated from pooled data were 4.1, 4.1, 6.9, and 6.3 h for doses of 250, 500, 750, and 1,000 mg, respectively.",Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942101/),h,4.1,266903,DB00537,Ciprofloxacin
,2942101,elimination half-lives,"The mean elimination half-lives calculated from pooled data were 4.1, 4.1, 6.9, and 6.3 h for doses of 250, 500, 750, and 1,000 mg, respectively.",Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942101/),h,6.9,266904,DB00537,Ciprofloxacin
,2942101,elimination half-lives,"The mean elimination half-lives calculated from pooled data were 4.1, 4.1, 6.9, and 6.3 h for doses of 250, 500, 750, and 1,000 mg, respectively.",Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942101/),h,6.3,266905,DB00537,Ciprofloxacin
greater,2942101,serum concentrations,"The mean serum concentrations 12 and 24 h following each dose were greater than or equal to 0.08 and 0.01 micrograms/ml, respectively.",Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942101/),[μg] / [ml],0.08,266906,DB00537,Ciprofloxacin
,2942101,serum concentrations,"The mean serum concentrations 12 and 24 h following each dose were greater than or equal to 0.08 and 0.01 micrograms/ml, respectively.",Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942101/),[μg] / [ml],0.01,266907,DB00537,Ciprofloxacin
,2942101,urinary recovery level,The urinary recovery level of unchanged ciprofloxacin over a 24-h period ranged from 28 to 44%.,Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942101/),%,28 to 44,266908,DB00537,Ciprofloxacin
,2942101,renal clearances,The mean renal clearances for each dose ranged from 300 to 500 ml/min.,Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2942101/),[ml] / [min],300 to 500,266909,DB00537,Ciprofloxacin
,21356290,zeta potential,"SE-CFn-SDC was characterized for globulet size (278±12 nm), zeta potential (-25.3±1 mV), viscosity (2.6±0.3 cP), transmission electron microscopy (TEM), drug entrapment and for in vitro release profile.",Ciprofloxacin surf-plexes in sub-micron emulsions: a novel approach to improve payload efficiency and antimicrobial efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356290/),m,-,269233,DB00537,Ciprofloxacin
,21356290,zeta potential,"SE-CFn-SDC was characterized for globulet size (278±12 nm), zeta potential (-25.3±1 mV), viscosity (2.6±0.3 cP), transmission electron microscopy (TEM), drug entrapment and for in vitro release profile.",Ciprofloxacin surf-plexes in sub-micron emulsions: a novel approach to improve payload efficiency and antimicrobial efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356290/),m,25.3,269234,DB00537,Ciprofloxacin
,21356290,viscosity,"SE-CFn-SDC was characterized for globulet size (278±12 nm), zeta potential (-25.3±1 mV), viscosity (2.6±0.3 cP), transmission electron microscopy (TEM), drug entrapment and for in vitro release profile.",Ciprofloxacin surf-plexes in sub-micron emulsions: a novel approach to improve payload efficiency and antimicrobial efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356290/),cp,2.6,269235,DB00537,Ciprofloxacin
,21356290,entrapment efficiency (EE),The entrapment efficiency (EE) was significantly improved (≥80%; p≤0.05) on ion-pairing while it was merely 27.2±3.1% for free CFn.,Ciprofloxacin surf-plexes in sub-micron emulsions: a novel approach to improve payload efficiency and antimicrobial efficacy. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356290/),%,27.2,269236,DB00537,Ciprofloxacin
,21356290,AUC(0-24h),"When tested in male Balb/c mice, the AUC(0-24h) of SE-CH-CFn-SDC (23.27±2.8 h μg/ml) was found to be 1.7-fold and 5-fold higher as compared to SE-CFn-SDC (13.17±0.88 h μg/ml) and CFn solution (4.70±0.77 h μg/ml), respectively.",Ciprofloxacin surf-plexes in sub-micron emulsions: a novel approach to improve payload efficiency and antimicrobial efficacy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356290/),[h·μg] / [ml],23.27,269237,DB00537,Ciprofloxacin
,21356290,AUC(0-24h),"When tested in male Balb/c mice, the AUC(0-24h) of SE-CH-CFn-SDC (23.27±2.8 h μg/ml) was found to be 1.7-fold and 5-fold higher as compared to SE-CFn-SDC (13.17±0.88 h μg/ml) and CFn solution (4.70±0.77 h μg/ml), respectively.",Ciprofloxacin surf-plexes in sub-micron emulsions: a novel approach to improve payload efficiency and antimicrobial efficacy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356290/),[h·μg] / [ml],13.17,269238,DB00537,Ciprofloxacin
,21356290,AUC(0-24h),"When tested in male Balb/c mice, the AUC(0-24h) of SE-CH-CFn-SDC (23.27±2.8 h μg/ml) was found to be 1.7-fold and 5-fold higher as compared to SE-CFn-SDC (13.17±0.88 h μg/ml) and CFn solution (4.70±0.77 h μg/ml), respectively.",Ciprofloxacin surf-plexes in sub-micron emulsions: a novel approach to improve payload efficiency and antimicrobial efficacy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356290/),[h·μg] / [ml],4.70,269239,DB00537,Ciprofloxacin
,3105446,peak level,"Absorption was rapid, with a mean peak level in serum of 6.1 micrograms/ml, which was attained 0.71 h after administration.","Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105446/),[μg] / [ml],6.1,269563,DB00537,Ciprofloxacin
,3105446,elimination half-life,The elimination half-life in serum was 11.95 h.,"Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105446/),h,11.95,269564,DB00537,Ciprofloxacin
,3105446,percent penetration,The agent penetrated the inflammatory fluid rapidly; the percent penetration was 89.7%.,"Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105446/),%,89.7,269565,DB00537,Ciprofloxacin
,3105446,Urinary recovery,Urinary recovery of Ro 23-6240 was 58.6% by 72 h.,"Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105446/),%,58.6,269566,DB00537,Ciprofloxacin
,2751742,plasma half-life,At the end of infusion the concentrations of ciprofloxacin in plasma reached 4.2 +/- 0.8 microgram/ml and decreased after a fast distribution period (plasma half-life 0.20 +/- 0.09 h) with a terminal half-life of 4.2 +/- 1.3 h to 0.2 +/- 0.09 microgram/ml after 10 h.,Pharmacokinetics of ciprofloxacin in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751742/),h,0.20,269728,DB00537,Ciprofloxacin
,2751742,terminal half-life,At the end of infusion the concentrations of ciprofloxacin in plasma reached 4.2 +/- 0.8 microgram/ml and decreased after a fast distribution period (plasma half-life 0.20 +/- 0.09 h) with a terminal half-life of 4.2 +/- 1.3 h to 0.2 +/- 0.09 microgram/ml after 10 h.,Pharmacokinetics of ciprofloxacin in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751742/),h,4.2,269729,DB00537,Ciprofloxacin
,2751742,terminal half-life,At the end of infusion the concentrations of ciprofloxacin in plasma reached 4.2 +/- 0.8 microgram/ml and decreased after a fast distribution period (plasma half-life 0.20 +/- 0.09 h) with a terminal half-life of 4.2 +/- 1.3 h to 0.2 +/- 0.09 microgram/ml after 10 h.,Pharmacokinetics of ciprofloxacin in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751742/),[μg] / [ml],0.2,269730,DB00537,Ciprofloxacin
,2751742,plasma clearance,"The apparent volume of distribution in steady state was 183 +/- 45% of body weight, the plasma clearance 457 +/- 146 ml/min/70 kg.",Pharmacokinetics of ciprofloxacin in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751742/),[ml] / [70·kg·min],457,269731,DB00537,Ciprofloxacin
,3144532,peak serum concentrations,"The peak serum concentrations of unchanged fleroxacin were about 1.5, 3 and 5 mg/l at 1-2 h after single oral doses of 100, 200 and 400 mg, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],1.5,269953,DB00537,Ciprofloxacin
,3144532,peak serum concentrations,"The peak serum concentrations of unchanged fleroxacin were about 1.5, 3 and 5 mg/l at 1-2 h after single oral doses of 100, 200 and 400 mg, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],3,269954,DB00537,Ciprofloxacin
,3144532,peak serum concentrations,"The peak serum concentrations of unchanged fleroxacin were about 1.5, 3 and 5 mg/l at 1-2 h after single oral doses of 100, 200 and 400 mg, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],5,269955,DB00537,Ciprofloxacin
,3144532,apparent serum elimination half-life,"The apparent serum elimination half-life was about 10 h, independent of the dose.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),h,10,269956,DB00537,Ciprofloxacin
,3144532,Steady state serum concentrations,"Steady state serum concentrations were achieved from day 3 onwards by repeated doses of twice-a-day dosage regimen and were 2-4 and 5-9 mg/l after 200 and 400 mg bid, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],2-4,269957,DB00537,Ciprofloxacin
,3144532,Steady state serum concentrations,"Steady state serum concentrations were achieved from day 3 onwards by repeated doses of twice-a-day dosage regimen and were 2-4 and 5-9 mg/l after 200 and 400 mg bid, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],5-9,269958,DB00537,Ciprofloxacin
,3144532,concentrations,The mean concentrations of unchanged drug in urine were about 200 and 300 mg/l at the respective dosages.,Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),,300,269959,DB00537,Ciprofloxacin
,3144532,serum protein binding,The serum protein binding of fleroxacin was 32%.,Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),%,32,269960,DB00537,Ciprofloxacin
,18647468,flow rate,"The method employs reversed-phase chromatography using an RP-C18 column with an isocratic mobile phase of acetonitrile-2% acetic acid aqueous solution (16:84, v/v), umbelliferone as an internal standard, and a flow rate of 1.0 mL/min.",Analysis of ciprofloxacin by a simple high-performance liquid chromatography method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647468/),[ml] / [min],1.0,270104,DB00537,Ciprofloxacin
,18647468,limit of detection,"The limit of detection is 0.25 microM (S/N = 3, injection volume = 10 microL).",Analysis of ciprofloxacin by a simple high-performance liquid chromatography method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647468/),μM,0.25,270105,DB00537,Ciprofloxacin
,18647468,S/N,"The limit of detection is 0.25 microM (S/N = 3, injection volume = 10 microL).",Analysis of ciprofloxacin by a simple high-performance liquid chromatography method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647468/),,3,270106,DB00537,Ciprofloxacin
,18647468,injection volume,"The limit of detection is 0.25 microM (S/N = 3, injection volume = 10 microL).",Analysis of ciprofloxacin by a simple high-performance liquid chromatography method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647468/),μl,10,270107,DB00537,Ciprofloxacin
greater,18647468,recoveries,All the recoveries are greater than 93.8%.,Analysis of ciprofloxacin by a simple high-performance liquid chromatography method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647468/),%,93.8,270108,DB00537,Ciprofloxacin
,9250569,area under the curve,"The mean +/- SD for area under the curve, mean peak concentration (C(max)), and time to C(max) (T(max)) were 18.7 +/- 5.03 mg/L x hour, 4.41 +/- 1.74 mg/L, and 1.81 +/- 0.843 hours, respectively.","A prospective, open-label study of single-dose ciprofloxacin absorption after chemotherapy in patients with malignancy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250569/),[mg] / [h·l],18.7,270149,DB00537,Ciprofloxacin
,9250569,peak concentration (C(max)),"The mean +/- SD for area under the curve, mean peak concentration (C(max)), and time to C(max) (T(max)) were 18.7 +/- 5.03 mg/L x hour, 4.41 +/- 1.74 mg/L, and 1.81 +/- 0.843 hours, respectively.","A prospective, open-label study of single-dose ciprofloxacin absorption after chemotherapy in patients with malignancy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250569/),[mg] / [l],4.41,270150,DB00537,Ciprofloxacin
,9250569,time to C(max) (T(max)),"The mean +/- SD for area under the curve, mean peak concentration (C(max)), and time to C(max) (T(max)) were 18.7 +/- 5.03 mg/L x hour, 4.41 +/- 1.74 mg/L, and 1.81 +/- 0.843 hours, respectively.","A prospective, open-label study of single-dose ciprofloxacin absorption after chemotherapy in patients with malignancy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250569/),h,1.81,270151,DB00537,Ciprofloxacin
,12213112,apparent elimination half-life,"The absorption of enrofloxacin was delayed after subcutaneous administration, the mean apparent elimination half-life being about 23 h, whereas after i.v. administration elimination t(1/2) was only 1.5 h.",Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213112/),h,23,270438,DB00537,Ciprofloxacin
,12213112,elimination t(1/2),"The absorption of enrofloxacin was delayed after subcutaneous administration, the mean apparent elimination half-life being about 23 h, whereas after i.v. administration elimination t(1/2) was only 1.5 h.",Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213112/),h,1.5,270439,DB00537,Ciprofloxacin
,12213112,elimination half-life,"No differences were present in the pharmacokinetic parameters of flunixin between treatment groups: mean elimination half-life was 5.7-6.2 h, volume of distribution 0.43-0.49 L/kg and clearance 0.13-0.14 L h/kg.",Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213112/),h,5.7-6.2,270440,DB00537,Ciprofloxacin
,12213112,volume of distribution,"No differences were present in the pharmacokinetic parameters of flunixin between treatment groups: mean elimination half-life was 5.7-6.2 h, volume of distribution 0.43-0.49 L/kg and clearance 0.13-0.14 L h/kg.",Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213112/),[l] / [kg],0.43-0.49,270441,DB00537,Ciprofloxacin
,12213112,clearance,"No differences were present in the pharmacokinetic parameters of flunixin between treatment groups: mean elimination half-life was 5.7-6.2 h, volume of distribution 0.43-0.49 L/kg and clearance 0.13-0.14 L h/kg.",Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213112/),[h·l] / [kg],0.13-0.14,270442,DB00537,Ciprofloxacin
,4015071,Blood radioactivity,Blood radioactivity peaked at 0.5 h after oral administration and was equivalent to 7.54 micrograms/ml for males and 6.73 micrograms/ml for females.,Metabolism and disposition of amifloxacin in laboratory animals. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015071/),[μg] / [ml],7.54,271269,DB00537,Ciprofloxacin
,4015071,Blood radioactivity,Blood radioactivity peaked at 0.5 h after oral administration and was equivalent to 7.54 micrograms/ml for males and 6.73 micrograms/ml for females.,Metabolism and disposition of amifloxacin in laboratory animals. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015071/),[μg] / [ml],6.73,271270,DB00537,Ciprofloxacin
,4015071,apparent first-order terminal elimination half-life,The apparent first-order terminal elimination half-life of intact amifloxacin in plasma was 2.3 h; radioactivity in plasma was eliminated more slowly.,Metabolism and disposition of amifloxacin in laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015071/),h,2.3,271271,DB00537,Ciprofloxacin
,3463542,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax 1.2 h) and enoxacin the least (Tmax 1.9 h).,The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,1.2,271330,DB00537,Ciprofloxacin
,3463542,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax 1.2 h) and enoxacin the least (Tmax 1.9 h).,The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,1.9,271331,DB00537,Ciprofloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,3.75,271332,DB00537,Ciprofloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,3.9,271333,DB00537,Ciprofloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,4.0,271334,DB00537,Ciprofloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,7.0,271335,DB00537,Ciprofloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,6.2,271336,DB00537,Ciprofloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,5.1,271337,DB00537,Ciprofloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,62,271338,DB00537,Ciprofloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,46.4,271339,DB00537,Ciprofloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,11.6,271340,DB00537,Ciprofloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,27,271341,DB00537,Ciprofloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,30.6,271342,DB00537,Ciprofloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,75.7,271343,DB00537,Ciprofloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,73,271344,DB00537,Ciprofloxacin
,14558441,AUC,"AUC was 12.11 mg h/l, Cmax 2.44 mg/l, tmax 0.79 h and half-life 3.8 h.",Pharmacokinetics of ciprofloxacin in healthy Mexican volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558441/),[h·mg] / [l],12.11,272985,DB00537,Ciprofloxacin
,14558441,Cmax,"AUC was 12.11 mg h/l, Cmax 2.44 mg/l, tmax 0.79 h and half-life 3.8 h.",Pharmacokinetics of ciprofloxacin in healthy Mexican volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558441/),[mg] / [l],2.44,272986,DB00537,Ciprofloxacin
,14558441,tmax,"AUC was 12.11 mg h/l, Cmax 2.44 mg/l, tmax 0.79 h and half-life 3.8 h.",Pharmacokinetics of ciprofloxacin in healthy Mexican volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558441/),h,0.79,272987,DB00537,Ciprofloxacin
,14558441,half-life,"AUC was 12.11 mg h/l, Cmax 2.44 mg/l, tmax 0.79 h and half-life 3.8 h.",Pharmacokinetics of ciprofloxacin in healthy Mexican volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558441/),h,3.8,272988,DB00537,Ciprofloxacin
,10609773,Cmax,Lomefloxacin showed a Cmax of 1.62 microg/ml at the Tmax of 1 hr whereas ciprofloxacin showed a Cmax of 102.8 ngs/ml at the Tmax of 1 hr.,Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609773/),[μg] / [ml],1.62,273443,DB00537,Ciprofloxacin
,10609773,Tmax,Lomefloxacin showed a Cmax of 1.62 microg/ml at the Tmax of 1 hr whereas ciprofloxacin showed a Cmax of 102.8 ngs/ml at the Tmax of 1 hr.,Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609773/),h,1,273444,DB00537,Ciprofloxacin
,10609773,Cmax,Lomefloxacin showed a Cmax of 1.62 microg/ml at the Tmax of 1 hr whereas ciprofloxacin showed a Cmax of 102.8 ngs/ml at the Tmax of 1 hr.,Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609773/),[ngs] / [ml],102.8,273445,DB00537,Ciprofloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],6.21,273557,DB00537,Ciprofloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],4.34,273558,DB00537,Ciprofloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],3.42,273559,DB00537,Ciprofloxacin
,10991830,Elimination half-lives,Elimination half-lives ranged from 12.12+/-3.93 h (grepafloxacin) to 5.37+/-0.82 h (ciprofloxacin).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),h,12.12,273560,DB00537,Ciprofloxacin
,10991830,Elimination half-lives,Elimination half-lives ranged from 12.12+/-3.93 h (grepafloxacin) to 5.37+/-0.82 h (ciprofloxacin).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),h,5.37,273561,DB00537,Ciprofloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],44.8,273562,DB00537,Ciprofloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],39.3,273563,DB00537,Ciprofloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],30,273564,DB00537,Ciprofloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],5.75,273565,DB00537,Ciprofloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.48,273566,DB00537,Ciprofloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.17,273567,DB00537,Ciprofloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.09,273568,DB00537,Ciprofloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],19.7,273569,DB00537,Ciprofloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],19.5,273570,DB00537,Ciprofloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],4.6,273571,DB00537,Ciprofloxacin
,8321920,blood clearance,"The following pharmacokinetic parameters (mean +/- SD) were calculated based on total blood radioactivity for the 14C-ddI alone and combination groups, respectively: blood clearance 13.5 +/- 2.0 vs.",Effect of ciprofloxacin on the disposition of 14C-dideoxyinosine-derived radioactivity in the rat. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321920/),,13.5,274078,DB00537,Ciprofloxacin
,8321920,terminal disposition half-life,"12.7 +/- 1.5 ml/min/kg, terminal disposition half-life 49.9 +/- 2.2 vs.",Effect of ciprofloxacin on the disposition of 14C-dideoxyinosine-derived radioactivity in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321920/),,49.9,274079,DB00537,Ciprofloxacin
,8321920,steady-state volume of distribution,"49.0 +/- 6.0 min, steady-state volume of distribution 891 +/- 134 vs. 825 +/- 126 ml/kg, mean residence time 66.2 +/- 3.1 vs.",Effect of ciprofloxacin on the disposition of 14C-dideoxyinosine-derived radioactivity in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321920/),[ml] / [kg],891,274080,DB00537,Ciprofloxacin
,8321920,steady-state volume of distribution,"49.0 +/- 6.0 min, steady-state volume of distribution 891 +/- 134 vs. 825 +/- 126 ml/kg, mean residence time 66.2 +/- 3.1 vs.",Effect of ciprofloxacin on the disposition of 14C-dideoxyinosine-derived radioactivity in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321920/),[ml] / [kg],825,274081,DB00537,Ciprofloxacin
,8321920,mean residence time,"49.0 +/- 6.0 min, steady-state volume of distribution 891 +/- 134 vs. 825 +/- 126 ml/kg, mean residence time 66.2 +/- 3.1 vs.",Effect of ciprofloxacin on the disposition of 14C-dideoxyinosine-derived radioactivity in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321920/),,66.2,274082,DB00537,Ciprofloxacin
